{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "45f3f7e3",
   "metadata": {},
   "source": [
    "## Extract text data from pdf"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "07efcc40",
   "metadata": {},
   "outputs": [],
   "source": [
    "# importing libraries to extract text data from pdf\n",
    "from pdfminer.pdfinterp import PDFResourceManager, PDFPageInterpreter\n",
    "from pdfminer.layout import LAParams\n",
    "from pdfminer.converter import TextConverter\n",
    "from io import StringIO\n",
    "from pdfminer.pdfpage import PDFPage"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "cd535506",
   "metadata": {},
   "outputs": [],
   "source": [
    "def path(path_to_pdf):\n",
    "    resource_manager = PDFResourceManager()\n",
    "    out_text = StringIO()\n",
    "    laParams = LAParams()\n",
    "    text_converter = TextConverter(resource_manager, out_text, laparams=laParams)\n",
    "    fp = open(path_to_pdf,'rb')\n",
    "    interpreter = PDFPageInterpreter(resource_manager, text_converter)\n",
    "    for page in PDFPage.get_pages(fp,pagenos=set(), maxpages=0, password=\"\", caching=True, check_extractable=True):\n",
    "        interpreter.process_page(page)\n",
    "    text = out_text.getvalue()\n",
    "    fp.close()\n",
    "    text_converter.close()\n",
    "    out_text.close()\n",
    "    return text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "287f91f4",
   "metadata": {},
   "outputs": [],
   "source": [
    "path_to_pdf = (r\"D:\\Live Project\\Data\\27-30.pdf\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "0468f100",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Haematologia, Vol. 30, No. 1, pp. 27–30 (2000)\n",
      "(cid:211) VSP 2000.\n",
      "\n",
      "Serum L-selectin and P-selectin levels in lymphomas\n",
      "\n",
      "Short communication\n",
      "\n",
      "I. C. HAZNEDARO ˇGLU, M. BENEKLI\n",
      "I. H. GÜLLÜ, S. V. DÜNDAR and ¸S. KIRAZLI\n",
      "Department of Internal Medicine, Hematology and Oncology Division, Hacettepe University\n",
      "Medical School, Ankara, Turkey\n",
      "\n",
      ", O. OZCEBE, M. C. SAVA ¸S,\n",
      "\n",
      "(cid:3)\n",
      "\n",
      "Abstract—The migration of normal and malignant lymphoid cells is governed by speciﬁc adhesion\n",
      "molecules. Selectins comprise a family of adhesion receptors expressed by leukocytes, platelets and\n",
      "endothelial cells. In this study, the serum levels of soluble L-selectin and P-selectin were measured in\n",
      "patients with non-Hodgkin’s lymphoma and Hodgkin’s disease and found to be signiﬁcantly elevated\n",
      "in both patient groups compared to healthy controls. This result provides evidence that alterations in\n",
      "the expression and function of adhesion molecules may play an important role in the progression of\n",
      "lymphomas. Further studies are awaited to establish the exact roles of these adhesion molecules in\n",
      "distinct patterns of growth and spread of lymphomas.\n",
      "\n",
      "Key words: L-selectin; P-selectin; Hodgkin’s disease; non-Hodgkin’s lymphoma.\n",
      "\n",
      "INTRODUCTION\n",
      "\n",
      "Adhesion of lymphocytes to endothelium is essential in lymphocyte trafﬁcking\n",
      "[1, 2]. Lymphocytes migrate from the circulation by selective attachment to spe-\n",
      "cialized endothelial cells lining the postcapillary high endothelial venules (HEV)\n",
      "in organized lymphoid tissues, lymph nodes and Peyer’s patches. Selectins com-\n",
      "prise a family of adhesion molecules which have been demonstrated to participate in\n",
      "the initial tetherting/ rolling of leukocytes on activated endothelium [3]. L-selectin\n",
      "(CD62L, LAM-1, LECAM-1) mediates the binding of lymphocytes to HEV of\n",
      "peripheral lymph nodes through interactions with corresponding endothelial lig-\n",
      "and and therefore also known as the lymphocyte homing receptor [4]. P-selectin\n",
      "(CD62P, PADGEM, GMP-140) is stored both in the alpha granules in platelets and\n",
      "Weibel-Palade bodies of endothelial cells [5] and involved in the stabilization of\n",
      "\n",
      "(cid:3)\n",
      "\n",
      "To whom correspondence should be addressed. M. Benekli, 14. Sokak, 43/ 8. Bahçelievler,\n",
      "\n",
      "Ankara, Turkey.\n",
      "\n",
      "\f",
      "28\n",
      "\n",
      "I. C. Haznedaroˇglu et al.\n",
      "\n",
      "platelet aggregates and in the interaction of leukocytes with activated platelets or\n",
      "endothelial cells [6].\n",
      "\n",
      "Lymphoma cells represent immortalized counterparts of normal lymphocytes. A\n",
      "similar adhesion mechanism is also utilized by malignant lymphoid cells during\n",
      "dissemination [7, 8]. Altered expression patterns of adhesion molecules appear\n",
      "to be involved in the spread of lymphoid malignancies and Hodgkin’s disease\n",
      "(HD) [7–10]. In this study, serum levels of soluble L-selectin and P-selectin were\n",
      "determined in patients with HD and non-Hodgkin’s lymphoma (NHL) and in normal\n",
      "healthy individuals.\n",
      "\n",
      "PATIENTS AND METHODS\n",
      "\n",
      "The study group consisted of 17 patients (10 NHL, 7 HD; 11 men, 6 women; median\n",
      "age 35 years, range 19– 70) and 15 healthy volunteers (11 men, 4 women; median\n",
      "age 49 years, range 36– 67). Out of 10 NHL patients, 5 were classiﬁed as low-\n",
      "grade, 1 intermediate, and 4 high-grade according to the Working Formulation.\n",
      "Four patients out of 7 with HD had mixed cellularity, 1 nodular sclerosis, and\n",
      "2 lymphocyte predominance type. Staging was performed according to the Ann\n",
      "Arbor system.\n",
      "In NHL, 2 patients had stage III and 8 patients had stage IV\n",
      "disease, and in HD 1 patient had stage II, 2 stage III, and the remaining 4 stage IV\n",
      "disease. All patients with HD and 3 out of 10 with NHL had B-symptoms. Serum\n",
      "L-selectin and P-selectin levels were determined using a commercially available\n",
      "ELISA kit (Bender MedSystems, Vienna, Austria) according to the manufacturer’s\n",
      "instructions. Data are presented as mean (cid:6) SD. Mann–Whitney U test was used\n",
      "for statistical analysis.\n",
      "\n",
      "RESULTS\n",
      "Adhesion molecule levels were signiﬁcantly higher in lymphoma patients compared\n",
      "to healthy controls (Table 1) (Fig. 1). Serum levels of sL-Selectin (1137 (cid:6)\n",
      "428 ng/ml vs 625 (cid:6) 159 ng/ml; p D 0:0023 and sP-Selectin (610 (cid:6) 211 ng/ml\n",
      "vs 178 (cid:6) 48 ng/ ml; p D 0:0001) were signiﬁcantly increased in patients with\n",
      "non-Hodgkin’s lymphoma compared to the control group. In HD, serum soluble\n",
      "L-selectin (1140 (cid:6) 498 ng/ml; p D 0:0082) and P-selectin (875 (cid:6) 370 ng/ ml;\n",
      "p D 0:0002) concentrations were signiﬁcantly elevated also compared to healthy\n",
      "controls (625 (cid:6) 159 ng/ ml and 178 (cid:6) 48 ng/ml for L-selectin and P-selectin,\n",
      "respectively).\n",
      "\n",
      "DISCUSSION\n",
      "\n",
      "Disseminating malignant lymphoma cells and lymphocytes share several character-\n",
      "istics, including migration and extravasation involving adhesive interactions [7, 8].\n",
      "\n",
      "\f",
      "Adhesion molecules in lymphomas\n",
      "\n",
      "29\n",
      "\n",
      "Table 1.\n",
      "Serum soluble P-selectin and L-selectin levels in the study group\n",
      "\n",
      "Patients\n",
      "\n",
      "HD\n",
      "HNL\n",
      "Controls\n",
      "\n",
      "P-selectin (ng/ml)\n",
      "875 (cid:6) 370\n",
      "610 (cid:6) 211\n",
      "178 (cid:6) 48\n",
      "\n",
      "* Compared with healthy controls.\n",
      "\n",
      "(cid:3)\n",
      "\n",
      "p\n",
      "\n",
      "0.0002\n",
      "0.0001\n",
      "\n",
      "L-selectin (ng/ml)\n",
      "1140 (cid:6) 498\n",
      "1137 (cid:6) 428\n",
      "625 (cid:6) 159\n",
      "\n",
      "(cid:3)\n",
      "\n",
      "p\n",
      "\n",
      "0.0082\n",
      "0.0023\n",
      "\n",
      "Figure 1. Circulating soluble P-selectin and L-selectin levels in the study group.\n",
      "\n",
      "Emerging evidence indicates that the adhesion molecules governing the homing\n",
      "of normal lymphocytes also mediate the dissemination of their neoplastic counter-\n",
      "parts. Adhesion molecules have also been demonstrated to function in the spread\n",
      "of HD [9, 10]. Therefore, we determined serum levels of soluble adhesion mole-\n",
      "cules, L-selectin and P-selectin as indicators of distinctive clinical and biological\n",
      "behaviour of lymphoid malignancies.\n",
      "In this report we demonstrated that serum\n",
      "concentrations of these adhesion receptors are increased in patients with HD and\n",
      "NHL. Our results conﬁrm and extend data published previously on the role of dis-\n",
      "tinct adhesion molecules in lymphomas. Elevated levels of circulating intercellular\n",
      "adhesion molecule-1 were reported in various hematologic malignancies including\n",
      "HD [9, 10], acute lymphoblastic leukemia [10], chronic lymphocytic leukemia [11]\n",
      "and NHL [12, 13], and non-hematologic malignancies [10, 13]. To our knowledge,\n",
      "\n",
      "\f",
      "30\n",
      "\n",
      "I. C. Haznedaroˇglu et al.\n",
      "\n",
      "this report is the ﬁrst investigating the levels of circulating L-selectin and P-selectin\n",
      "in NHL and HD.\n",
      "\n",
      "Differential expression of these adhesion molecules may account for diverse\n",
      "patterns of growth and dissemination of lymphomas. The study of adhesion\n",
      "molecule expression and function may allow a better understanding of the malignant\n",
      "behavior of lymphoid cells. Our data need to be validated and extended in a\n",
      "more homogenous patient series in order to elucidate the clinical and prognostic\n",
      "signiﬁcance of L-selectin and P-selectin in lymphomas.\n",
      "\n",
      "REFERENCES\n",
      "\n",
      "1. Shimizu, Y., Newman, W., Tanaka, Y., Shaw, S., Lymphocyte interactions with endothelial cells,\n",
      "\n",
      "Immunol. Today 13, 106 (1992).\n",
      "\n",
      "2. Stoolman, L. M., Adhesion molecules controlling lymphocyte migration, Cell 56, 907 (1989).\n",
      "3. Bevilacqua, M. P., Nelson, R. M., Selectins, J. Clin. Invest. 91, 379 (1993).\n",
      "4. Gallatin, W. M., Weissman, I. L., Butcher, E. C., A cell-surface molecule involved in organ-\n",
      "\n",
      "speciﬁc homing of lymphocytes, Nature 304, 30 (1983).\n",
      "\n",
      "5. Bonfanti, R., Furie, B. C., Furie, B., Wagner, D. D., PADGEM (GMP 140) is a component of\n",
      "\n",
      "Weibel-Palade bodies of human endothelial cells, Blood 73, 1109 (1989).\n",
      "\n",
      "6. De Bruijne-Admiraal, L. G., Modderman, P. W., Von dem Borne, A. E. G. Kr., Sonnenberg, A.,\n",
      "-dependent adhesion of activated platelet to many different types of\n",
      "\n",
      "C\n",
      "P-selectin mediates Ca2\n",
      "leukocytes: Detection by ﬂow cytometry, Blood 80, 134 (1992).\n",
      "\n",
      "7. Pals, S. T., Horst, E., Scheper, R. J., Meijer, C. J. L. M., Mechanisms of human lymphocyte\n",
      "\n",
      "migration and their role in the pathogenesis of disease, Immunol. Rev. 108, 111 (1989).\n",
      "\n",
      "8. Pals, S. T., Drillenburg, P., Radaszkiewicz, T., Manten-Horst, E., Adhesion molecules in the\n",
      "\n",
      "dissemination of non-Hodgkin’s lymphomas, Acta Haematol. 97, 73 (1997).\n",
      "\n",
      "9. Gruss, H.-J., Dölken, G., Brach, M. A., Mertelsmann, R., Herrmann, F., Serum levels of\n",
      "\n",
      "circulating ICAM-1 are increased in Hodgkin’s disease, Leukemia 8, 1245 (1993).\n",
      "\n",
      "10. Pui C.-H., Luo, X., Evans, W., Martin, S., Rugg, A., Wilimas, J., Crist, W. M., Hudson, M.,\n",
      "\n",
      "Serum intercellular adhesion molecule-1 in childhood malignancy, Blood 82, 895 (1993).\n",
      "\n",
      "11. Christiansen, I., Gidlöf, C., Wallgren, A. C., Simonsson, B., Tötterman, T. H., Serum levels of\n",
      "soluble intercellular adhesion molecule-1 are increased in chronic B-lymphocytic leukemia and\n",
      "correlate with clinical stage and prognostic markers, Blood 84, 3010 (1994).\n",
      "\n",
      "12. Christiansen, I., Gidlöf, C., Kalkner, K.-M., Hagberg, H., Bennmarker, H., Tötterman, T.,\n",
      "Elevated serum levels of soluble ICAM-1 in non-Hodgkin’s lymphomas correlate with tumour\n",
      "burden, disease activity and other prognostic markers, Br. J. Haematol. 92, 639 (1996).\n",
      "\n",
      "13. Benekli, M., Güllü, I. H., Tekuzman, G., Sava¸s, M. C., Hayran, M., Hasçelik, G., Fırat, D.,\n",
      "Circulating intercellular adhesion molecule-1 and E-selectin in gastric cancer, Br. J. Cancer 78,\n",
      "267 (1998).\n",
      "\n",
      "\f",
      "\f",
      "\n"
     ]
    }
   ],
   "source": [
    "# extracting the text\n",
    "output_text = path(path_to_pdf)\n",
    "print(output_text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "8ec13f23",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "4daf0de6",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Haematologia, \n",
       "<mark class=\"entity\" style=\"background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Vol\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DRUG</span>\n",
       "</mark>\n",
       ". 30, No. 1, pp. 27–30 (2000)</br>(cid:211) VSP 2000.</br></br>Serum L-selectin and P-selectin levels in lymphomas</br></br>Short communication</br></br>I. C. HAZNEDARO ˇGLU, M. \n",
       "<mark class=\"entity\" style=\"background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BENEKLI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DRUG</span>\n",
       "</mark>\n",
       "</br>I. H. GÜLLÜ, S. V. DÜNDAR and ¸S. KIRAZLI</br>Department of Internal Medicine, Hematology and Oncology Division, Hacettepe University</br>Medical School, Ankara, Turkey</br></br>, O. OZCEBE, M. C. SAVA ¸S,</br></br>(cid:3)</br></br>Abstract—The migration of normal and malignant lymphoid cells is governed by speciﬁc adhesion</br>molecules. Selectins comprise a family of adhesion receptors expressed by leukocytes, platelets and</br>endothelial cells. In this study, the serum levels of soluble L-selectin and P-selectin were measured in</br>patients with non-Hodgkin’s lymphoma and Hodgkin’s disease and found to be signiﬁcantly elevated</br>in both patient groups compared to healthy controls. This result provides evidence that alterations in</br>the expression and function of adhesion molecules may play an important role in the progression of</br>lymphomas. Further studies are awaited to establish the exact roles of these adhesion molecules in</br>distinct patterns of growth and spread of lymphomas.</br></br>Key words: L-selectin; P-selectin; Hodgkin’s disease; non-Hodgkin’s lymphoma.</br></br>INTRODUCTION</br></br>Adhesion of lymphocytes to endothelium is essential in lymphocyte trafﬁcking</br>[1, 2]. Lymphocytes migrate from the circulation by selective attachment to spe-</br>cialized endothelial cells lining the postcapillary high endothelial venules (HEV)</br>in organized lymphoid tissues, lymph nodes and Peyer’s patches. Selectins com-</br>prise a family of adhesion molecules which have been demonstrated to participate in</br>the initial tetherting/ rolling of leukocytes on activated endothelium [3]. L-selectin</br>(CD62L, LAM-1, LECAM-1) mediates the binding of lymphocytes to HEV of</br>peripheral lymph nodes through interactions with corresponding endothelial lig-</br>and and therefore also known as the lymphocyte homing receptor [4]. P-selectin</br>(CD62P, PADGEM, GMP-140) is stored both in the alpha granules in platelets and</br>\n",
       "<mark class=\"entity\" style=\"background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Weibel\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DRUG</span>\n",
       "</mark>\n",
       "-Palade bodies of endothelial cells [5] and involved in the stabilization of</br></br>(cid:3)</br></br>To whom correspondence should be addressed. M. Benekli, 14. Sokak, 43/ 8. Bahçelievler,</br></br>Ankara, Turkey.</br></br>\f",
       "28</br></br>I. C. Haznedaroˇglu et al.</br></br>platelet aggregates and in the interaction of leukocytes with activated platelets or</br>endothelial cells [6].</br></br>Lymphoma cells represent immortalized counterparts of normal lymphocytes. A</br>similar adhesion mechanism is also utilized by malignant lymphoid cells during</br>dissemination [7, 8]. Altered expression patterns of adhesion molecules appear</br>to be involved in the spread of lymphoid malignancies and Hodgkin’s disease</br>(HD) [7–10]. In this study, serum levels of soluble L-selectin and P-selectin were</br>determined in patients with HD and non-Hodgkin’s lymphoma (NHL) and in normal</br>healthy individuals.</br></br>PATIENTS AND METHODS</br></br>The study group consisted of 17 patients (10 NHL, 7 HD; 11 men, 6 women; median</br>age 35 years, range 19– 70) and 15 healthy volunteers (11 men, 4 women; median</br>age 49 years, range 36– 67). Out of 10 NHL patients, 5 were classiﬁed as low-</br>grade, 1 intermediate, and 4 high-grade according to the Working Formulation.</br>Four patients out of 7 with HD had mixed cellularity, 1 nodular sclerosis, and</br>2 lymphocyte predominance type. Staging was performed according to the Ann</br>Arbor system.</br>In NHL, 2 patients had stage III and 8 patients had stage IV</br>disease, and in HD 1 patient had stage II, 2 stage III, and the remaining 4 stage IV</br>disease. All patients with HD and 3 out of 10 with NHL had B-symptoms. Serum</br>L-selectin and P-selectin levels were determined using a commercially available</br>ELISA kit (Bender MedSystems, Vienna, Austria) according to the manufacturer’s</br>instructions. Data are presented as mean (cid:6) SD. Mann–Whitney U test was used</br>for statistical analysis.</br></br>RESULTS</br>Adhesion molecule levels were signiﬁcantly higher in lymphoma patients compared</br>to healthy controls (Table 1) (Fig. 1). Serum levels of sL-Selectin (1137 (cid:6)</br>428 ng/ml vs 625 (cid:6) 159 ng/ml; p D 0:0023 and sP-Selectin (610 (cid:6) 211 ng/ml</br>vs 178 (cid:6) 48 ng/ ml; p D 0:0001) were signiﬁcantly increased in patients with</br>non-Hodgkin’s lymphoma compared to the control group. In HD, serum soluble</br>L-selectin (1140 (cid:6) 498 ng/ml; p D 0:0082) and P-selectin (875 (cid:6) 370 ng/ ml;</br>p D 0:0002) concentrations were signiﬁcantly elevated also compared to healthy</br>controls (625 (cid:6) 159 ng/ ml and 178 (cid:6) 48 ng/ml for L-selectin and P-selectin,</br>respectively).</br></br>DISCUSSION</br></br>Disseminating malignant lymphoma cells and lymphocytes share several character-</br>istics, including migration and extravasation involving adhesive \n",
       "<mark class=\"entity\" style=\"background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    interactions\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DRUG</span>\n",
       "</mark>\n",
       " [7, 8].</br></br>\f",
       "Adhesion molecules in lymphomas</br></br>29</br></br>Table 1.</br>Serum soluble P-selectin and L-selectin levels in the study group</br></br>Patients</br></br>HD</br>HNL</br>Controls</br></br>P-selectin (ng/ml)</br>875 (cid:6) 370</br>610 (cid:6) 211</br>178 (cid:6) 48</br></br>* Compared with healthy controls.</br></br>(cid:3)</br></br>p</br></br>0.0002</br>0.0001</br></br>L-selectin (ng/ml)</br>1140 (cid:6) 498</br>1137 (cid:6) 428</br>625 (cid:6) 159</br></br>(cid:3)</br></br>p</br></br>0.0082</br>0.0023</br></br>Figure 1. Circulating soluble P-selectin and L-selectin levels in the study group.</br></br>Emerging evidence indicates that the adhesion molecules governing the homing</br>of normal lymphocytes also mediate the dissemination of their neoplastic counter-</br>parts. Adhesion molecules have also been demonstrated to function in the spread</br>of HD [9, 10]. Therefore, we determined serum levels of soluble adhesion mole-</br>cules, L-selectin and P-selectin as indicators of distinctive clinical and biological</br>behaviour of lymphoid malignancies.</br>In this report we demonstrated that serum</br>concentrations of these adhesion receptors are increased in patients with HD and</br>NHL. Our results conﬁrm and extend data published previously on the role of dis-</br>tinct adhesion molecules in lymphomas. Elevated levels of circulating intercellular</br>adhesion molecule-1 were reported in various hematologic malignancies including</br>HD [9, 10], acute lymphoblastic leukemia [10], chronic lymphocytic leukemia [11]</br>and NHL [12, 13], and non-hematologic malignancies [10, 13]. To our knowledge,</br></br>\f",
       "30</br></br>I. C. Haznedaroˇglu et al.</br></br>this report is the ﬁrst investigating the levels of circulating L-selectin and P-selectin</br>in NHL and HD.</br></br>Differential expression of these adhesion molecules may account for diverse</br>patterns of growth and dissemination of lymphomas. The study of adhesion</br>molecule expression and function may allow a better understanding of the malignant</br>behavior of lymphoid cells. Our data need to be validated and extended in a</br>more homogenous patient series in order to elucidate the clinical and prognostic</br>signiﬁcance of L-selectin and P-selectin in lymphomas.</br></br>REFERENCES</br></br>1. \n",
       "<mark class=\"entity\" style=\"background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Shimizu\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DRUG</span>\n",
       "</mark>\n",
       ", Y., Newman, W., Tanaka, Y., Shaw, S., Lymphocyte interactions with endothelial cells,</br></br>Immunol. Today 13, 106 (1992).</br></br>2. Stoolman, L. M., Adhesion molecules controlling lymphocyte migration, Cell 56, 907 (1989).</br>3. Bevilacqua, M. P., Nelson, R. M., Selectins, J. Clin. Invest. 91, 379 (1993).</br>4. Gallatin, W. M., Weissman, I. L., Butcher, E. C., A cell-surface molecule involved in organ-</br></br>speciﬁc homing of lymphocytes, Nature 304, 30 (1983).</br></br>5. Bonfanti, R., Furie, B. C., Furie, B., Wagner, D. D., PADGEM (GMP 140) is a component of</br></br>Weibel-Palade bodies of human endothelial cells, Blood 73, 1109 (1989).</br></br>6. De Bruijne-Admiraal, L. G., \n",
       "<mark class=\"entity\" style=\"background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Modderman\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DRUG</span>\n",
       "</mark>\n",
       ", P. W., Von dem Borne, A. E. G. Kr., Sonnenberg, A.,</br>-dependent adhesion of activated platelet to many different types of</br></br>C</br>P-selectin mediates Ca2</br>leukocytes: Detection by ﬂow cytometry, Blood 80, 134 (1992).</br></br>7. Pals, S. T., Horst, E., Scheper, R. J., Meijer, C. J. L. M., Mechanisms of human lymphocyte</br></br>migration and their role in the pathogenesis of disease, Immunol. Rev. 108, 111 (1989).</br></br>8. Pals, S. T., Drillenburg, P., Radaszkiewicz, T., Manten-Horst, E., Adhesion molecules in the</br></br>dissemination of non-Hodgkin’s lymphomas, Acta Haematol. 97, 73 (1997).</br></br>9. Gruss, H.-J., Dölken, G., Brach, M. A., Mertelsmann, R., Herrmann, F., Serum levels of</br></br>circulating ICAM-1 are increased in Hodgkin’s disease, Leukemia 8, 1245 (1993).</br></br>10. Pui C.-H., Luo, X., Evans, W., Martin, S., Rugg, A., Wilimas, J., Crist, W. M., Hudson, M.,</br></br>Serum intercellular adhesion molecule-1 in childhood malignancy, Blood 82, 895 (1993).</br></br>11. Christiansen, I., Gidlöf, C., Wallgren, A. C., Simonsson, B., Tötterman, T. H., Serum levels of</br>soluble intercellular adhesion molecule-1 are increased in chronic B-lymphocytic leukemia and</br>correlate with clinical stage and prognostic markers, Blood 84, 3010 (1994).</br></br>12. Christiansen, I., Gidlöf, C., Kalkner, K.-M., Hagberg, H., Bennmarker, H., \n",
       "<mark class=\"entity\" style=\"background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Tötterman\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DRUG</span>\n",
       "</mark>\n",
       ", T.,</br>Elevated serum levels of soluble ICAM-1 in non-Hodgkin’s lymphomas correlate with tumour</br>burden, disease activity and other prognostic markers, Br. J. Haematol. 92, 639 (1996).</br></br>13. Benekli, M., Güllü, I. H., Tekuzman, G., Sava¸s, M. C., Hayran, M., Hasçelik, G., Fırat, D.,</br>Circulating intercellular adhesion molecule-1 and E-selectin in gastric cancer, Br. J. Cancer 78,</br>267 (1998).</br></br>\f",
       "\f",
       "</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": [
       "[('Vol', 'DRUG'),\n",
       " ('BENEKLI', 'DRUG'),\n",
       " ('Weibel', 'DRUG'),\n",
       " ('interactions', 'DRUG'),\n",
       " ('Shimizu', 'DRUG'),\n",
       " ('Modderman', 'DRUG'),\n",
       " ('Tötterman', 'DRUG')]"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import spacy\n",
    "\n",
    "med7 = spacy.load(\"en_core_med7_lg\")\n",
    "\n",
    "# create distinct colours for labels\n",
    "col_dict = {}\n",
    "seven_colours = ['#e6194B', '#3cb44b', '#ffe119', '#ffd8b1', '#f58231', '#f032e6', '#42d4f4']\n",
    "for label, colour in zip(med7.pipe_labels['ner'], seven_colours):\n",
    "    col_dict[label] = colour\n",
    "\n",
    "options = {'ents': med7.pipe_labels['ner'], 'colors':col_dict}\n",
    "\n",
    "doc = med7(output_text)\n",
    "\n",
    "spacy.displacy.render(doc, style='ent', jupyter=True, options=options)\n",
    "\n",
    "[(ent.text, ent.label_) for ent in doc.ents]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "7d3d999d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[['Vol', 'DRUG'],\n",
       " ['BENEKLI', 'DRUG'],\n",
       " ['Weibel', 'DRUG'],\n",
       " ['interactions', 'DRUG'],\n",
       " ['Shimizu', 'DRUG'],\n",
       " ['Modderman', 'DRUG'],\n",
       " ['Tötterman', 'DRUG']]"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data1 = [[ent.text, ent.label_] for ent in doc.ents]\n",
    "data1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "bf198816",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Name</th>\n",
       "      <th>Category</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Vol</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>BENEKLI</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Weibel</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>interactions</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Shimizu</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Modderman</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Tötterman</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "           Name Category\n",
       "0           Vol     DRUG\n",
       "1       BENEKLI     DRUG\n",
       "2        Weibel     DRUG\n",
       "3  interactions     DRUG\n",
       "4       Shimizu     DRUG\n",
       "5     Modderman     DRUG\n",
       "6     Tötterman     DRUG"
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "df = pd.DataFrame(data1)\n",
    "df.columns = [\"Name\",\"Category\"]\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "2237de4f",
   "metadata": {},
   "outputs": [],
   "source": [
    "path_to_pdf_1 = (r\"D:\\Live Project\\Data\\888-97.pdf\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "2d195581",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "C(cid:2) 2008, the Authors\n",
      "Journal compilation C(cid:2) 2008, Wiley Periodicals, Inc.\n",
      "DOI: 10.1111/j.1540-8175.2008.00696.x\n",
      "\n",
      "Cell Therapy in Patients with Left Ventricular\n",
      "Dysfunction Due to Myocardial Infarction\n",
      "Roman Panovsky, M.D., Ph.D.,∗ Jaroslav Meluzin, M.D., Ph.D, F.E.S.C.,∗\n",
      "Stanislav Janousek, M.D., Ph.D.,† Jiˇr´ı Mayer, M.D., Ph.D.,‡ Milan Kaminek, M.D., Ph.D.,§\n",
      "Ladislav Groch, M.D.,∗ Jiˇr´ı Prasek, M.D., Ph.D.,¶ Jaroslav Stanicek, M.D.,(cid:4) Ladislav Dusek,\n",
      "M.D.,# Ota Hlinomaz, M.D., Ph.D.,∗ Petr Kala, M.D., Ph.D.,† Martin Klabusay, M.D., Ph.D.,‡\n",
      "Zdenek Koristek M.D.,‡ and Milan Navratil M.D.‡\n",
      "∗First Department of Internal Medicine/Cardioangiology, St. Anna Hospital, Masaryk University,\n",
      "Brno, Czech Republic, †Department of Internal Medicine/Cardiology, Brno University Hospital,\n",
      "Brno, Czech Republic, ‡Department of Internal Medicine/Hematooncology, Brno University\n",
      "Hospital, Brno, Czech Republic, §Department of Nuclear Medicine, UH Olomouc, Czech Republic,\n",
      "¶Department of Nuclear Medicine, Brno University Hospital, Brno, Czech Republic, (cid:4)Department\n",
      "of Nuclear Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic, and #Center of\n",
      "Biostatistics and Analyses, Brno University Hospital, Brno, Czech Republic\n",
      "\n",
      "Objectives: The purpose of this study was to determine the impact of autologous transplantation\n",
      "of mononuclear bone marrow cells on myocardial function in patients with left ventricular (LV)\n",
      "dysfunction due to an acute myocardial infarction. Methods: The randomized study included 82\n",
      "patients with a ﬁrst acute myocardial infarction treated with a stent implantation. This presentation\n",
      "is a subanalysis of 47 patients with left ventricular dysfunction–EF (ejection fraction) ≤ 40%. Group\n",
      "H patients (n = 17) received higher number (100,000,000) of cells; Group L patients (n = 13) received\n",
      "lower number (10,000,000) of cells. The patients of control Group C (n = 17) were not treated with\n",
      "cells. The Doppler tissue imaging and single photon emission computed tomography were performed\n",
      "before cell transplantation and 3 months later. Results: At 3 months of follow-up, the baseline EF\n",
      "of 35%, 36%, 35% in Groups H, L, and C increased by 6% (P < 0.01 vs. baseline), 5% (P < 0.01 vs.\n",
      "baseline), and 4% (P = NS vs. baseline), respectively, as assessed by single photon emission computed\n",
      "tomography (P = NS between groups). The baseline number of akinetic segments of 6.9, 7.0, and 6.2 in\n",
      "H, L, and C groups decreased by 1.7 (P < 0.01 vs. baseline), 1.5 (P < 0.01 vs. baseline), and 0.7 (P = NS\n",
      "vs. baseline, P = NS between groups), respectively, as demonstrated by echocardiography. Conclusion:\n",
      "In our study, the statistically important effect of transplantation of mononuclear bone marrow cells\n",
      "on myocardial function was not found. Only an insigniﬁcant trend toward the improvement of global\n",
      "LV EF fraction was found at 3-month follow-up. (ECHOCARDIOGRAPHY, Volume 25, September\n",
      "2008)\n",
      "\n",
      "stem cells, coronary artery disease, left ventricular dysfunction\n",
      "\n",
      "Postmyocardial infarction congestive heart\n",
      "failure remains to be a major clinical prob-\n",
      "lem, despite advances in the medical and sur-\n",
      "\n",
      "The work was supported in part by a grant of the Ministry\n",
      "of Health of the Czech Republic (IGA, No. 1 A/8676-3), and\n",
      "by grants of the Ministry of Education of the Czech Republic\n",
      "(MSM, No. 0021622402 and MSM, No. 0021622430). Oth-\n",
      "erwise, there is no conﬂict of interest.\n",
      "\n",
      "Address for correspondence and reprint requests: Ro-\n",
      "man Panovsk´y, Ph.D., First Department of Internal\n",
      "Medicine/Cardioangiology, St. Anna’s Hospital, Masaryk\n",
      "University, Pekaˇrsk´a 53 656 91 Brno, Czech Republic. Fax:\n",
      "+420-543182205; E-mail: panovsky@fnusa.cz\n",
      "\n",
      "gical treatment of acute coronary syndromes.\n",
      "Coronary artery disease accounts for approx-\n",
      "imately 50% of all cardiovascular deaths and\n",
      "is the leading cause of congestive heart fail-\n",
      "ure. The 1-year mortality rate for patients di-\n",
      "agnosed with congestive heart failure is about\n",
      "20%, and from 1994 to 2004, deaths from heart\n",
      "failure increased 28%.1,2 Development of heart\n",
      "failure in survivors of acute myocardial infarc-\n",
      "tion involves myocyte loss in the area supplied\n",
      "by the infarct-related artery and subsequent\n",
      "formation of noncontractile ﬁbrous tissue. To\n",
      "date, no therapeutic procedure like angio-\n",
      "plasty or thrombolytic agents could reverse the\n",
      "\n",
      "888\n",
      "\n",
      "ECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\n",
      "\n",
      "Vol. 25, No. 8, 2008\n",
      "\n",
      "\f",
      "CELL THERAPY IN AN ACUTE MYOCARDIAL INFARCTION\n",
      "\n",
      "irreversible myocardial injury completely. The\n",
      "recovery of contractile function after revascu-\n",
      "larization occurs only in the areas of hibernat-\n",
      "ing myocardium. Heart transplantation may be\n",
      "an option in selected patients, but the donor\n",
      "supply is strictly limited.\n",
      "\n",
      "Recent experimental and clinical studies sug-\n",
      "gest that cell transplantation into damaged my-\n",
      "ocardium may have the potential to restore\n",
      "myocardial viability and improve left ventric-\n",
      "ular function. Different cell types can be po-\n",
      "tentially used for transplantation. To avoid\n",
      "problems with donor availability, immunolog-\n",
      "ical rejection, arrhythmias, and ethical prob-\n",
      "lems, autologous bone marrow cells appear par-\n",
      "ticularly attractive. But in a majority of studies,\n",
      "only patients with almost normal function or\n",
      "only mild dysfunction of the left ventricle were\n",
      "studied.3–12\n",
      "\n",
      "So the purpose of this study was to determine\n",
      "the impact of autologous transplantation of\n",
      "mononuclear bone marrow cells on myocardial\n",
      "function in patients with moderate-to-severe\n",
      "left ventricular dysfunction.\n",
      "\n",
      "Materials and Methods\n",
      "\n",
      "Study Population\n",
      "\n",
      "The randomized study included patients with\n",
      "a ﬁrst acute myocardial infarction treated with\n",
      "coronary angioplasty with a stent implanta-\n",
      "tion. Only patients with successful recanaliza-\n",
      "tion of the infarct-related artery (TIMI ﬂow\n",
      "grade 3) and the evidence of an irreversible\n",
      "damage of at least two akinetic or dyskinetic\n",
      "myocardial segments identiﬁed by dobutamine\n",
      "echocardiography, gated technetium-99 m ses-\n",
      "tamibi single photon emission computed to-\n",
      "mography, and positron emission tomography\n",
      "(performed in only 73% of patients) were in-\n",
      "cluded. The exclusion criteria were: (1) age >\n",
      "70 years; (2) noncardiac disease adversely af-\n",
      "fecting prognosis; (3) another cardiac disease\n",
      "except coronary artery disease; (4) coagulopa-\n",
      "thy, thrombocytopenia, leucopenia; (5) absence\n",
      "of a signiﬁcant increase in cardiac enzymes (cre-\n",
      "atine kinase over 20 µkat/l or creatine kinase-\n",
      "MB over 3 µkat/l or troponin I over 20 µg/l-\n",
      "–normal upper limits in our laboratories are\n",
      "2.85 µkat/l, 0.42 µkat/l, and 2.0 µg/l, respec-\n",
      "tively); (6) patient instability on days 3–7 after\n",
      "MI; and (7) need for coronary revascularization\n",
      "in the future for multivessel disease.\n",
      "\n",
      "From a total number of 82 patients who com-\n",
      "pleted the baseline and 3-month follow-up ex-\n",
      "\n",
      "amination, 66 patients were analyzed in the\n",
      "previously published study.12 This ﬁrst 66 pa-\n",
      "tients were randomized into three arms: (1) a\n",
      "group treated with a higher number of mononu-\n",
      "clear bone marrow cells (deﬁned as a mean\n",
      "number of 1 × 108 cells); (2) a group treated\n",
      "with a lower number of cells (deﬁned as a\n",
      "mean number of 1 × 107 cells); and (3) a con-\n",
      "trol group not treated with cell transplanta-\n",
      "tion. Subsequent 16 patients were randomized\n",
      "into only two arms: higher-dose-treated group\n",
      "and control group. The reason for changing ran-\n",
      "domization schema was no signiﬁcant effect of\n",
      "a lower-dose cells in the previous study. This\n",
      "presentation is a subanalysis of 47 (from all\n",
      "the 82) patients with signiﬁcant left ventricu-\n",
      "lar dysfunction-–ejection fraction (EF) ≤ 40%.\n",
      "Forty-ﬁve patients underwent the primary an-\n",
      "gioplasty (within 12 hours of chest pain on-\n",
      "set)and two patients were treated with angio-\n",
      "plasty within the interval from 12 hours to\n",
      "3 days after symptom onset.\n",
      "\n",
      "Study Design\n",
      "\n",
      "On day 3–6 after myocardial infarction, rest\n",
      "and dobutamine echocardiography was per-\n",
      "formed to evaluate the presence of akinetic or\n",
      "dyskinetic left ventricular segments without\n",
      "any contractile reserve. At the same time color\n",
      "Doppler tissue imaging was performed. Within\n",
      "the next 2 days patients underwent the gated\n",
      "technetium-99 m sestamibi single photon emis-\n",
      "sion computed tomography and positron emis-\n",
      "sion tomography. Patients with an evidence of\n",
      "an irreversible damage of at least two akinetic\n",
      "or dyskinetic myocardial segments proved by\n",
      "all methods were then randomized. Patients\n",
      "of cell groups underwent subsequently a bone\n",
      "marrow aspiration. Autologous bone marrow\n",
      "mononuclear cells were transplanted into the\n",
      "infarct-related artery 20–21 hours after the\n",
      "bone marrow aspiration, 5–9 days after my-\n",
      "ocardial infarction. Immediately before and 10\n",
      "and 20 hours after the procedure, blood samples\n",
      "for cardiac enzymes (creatine kinase, creatine\n",
      "kinase–MB and troponin I) were acquired.\n",
      "\n",
      "Three months after randomization, rest\n",
      "echocardiography with Doppler tissue imaging,\n",
      "single photon emission computed tomography,\n",
      "and coronary angiography were repeated. Pa-\n",
      "tients of the control group underwent the same\n",
      "procedures and examinations, as did the trans-\n",
      "planted patients except for bone marrow aspi-\n",
      "ration and cell transplantation.\n",
      "\n",
      "Vol. 25, No. 8, 2008\n",
      "\n",
      "ECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\n",
      "\n",
      "889\n",
      "\n",
      "\f",
      "PANOVSKY, ET AL.\n",
      "\n",
      "In this subanalysis, the changes of following\n",
      "echocardiographic parameters were assessed:\n",
      "(1) the peak systolic velocity of the myocardium\n",
      "adjacent to mitral annulus of infarcted wall\n",
      "(Sinfarct) (as a parameter of the regional longi-\n",
      "tudinal left ventricular systolic function); (2)\n",
      "the mean six-site systolic velocity of the my-\n",
      "ocardium adjacent to mitral annulus (as a pa-\n",
      "rameter of the global longitudinal left ventric-\n",
      "ular systolic function), which was calculated as\n",
      "mean six-site S = (Slateral + Sseptal + Santerior +\n",
      "Sinferior + Santeroseptal + Sposterior)/6; and (3) num-\n",
      "ber of akinetic segments.\n",
      "The changes of following parameters derived\n",
      "from single photon emission computed tomog-\n",
      "raphy were assessed: (1) left ventricle end-\n",
      "diastolic volume; (2) left ventricle end-systolic\n",
      "volume; (3) left ventricle ejection fraction; and\n",
      "(4) perfusion defect size.\n",
      "\n",
      "The institutional ethics committee approved\n",
      "the study and written consent was obtained\n",
      "from each patient.\n",
      "\n",
      "Echocardiography\n",
      "\n",
      "Using commercially available equipment\n",
      "Vivid 7 (GE/Vingmed, Milwaukee, WI, USA)\n",
      "with an M3 S transducer, echocardiographic ex-\n",
      "aminations were performed in one center. Two-\n",
      "dimensional and color Doppler tissue images of\n",
      "apical views (apical 4- and 2-chamber and api-\n",
      "cal long-axis views) were obtained and stored\n",
      "digitally for the subsequent ofﬂine quantitative\n",
      "analysis using a software incorporated in Vivid\n",
      "7 (Echopac 7 version 1.3, GE/Vingmed). The\n",
      "wider-angle sector (60–70 degrees) was used to\n",
      "depict two-dimensional images for wall motion\n",
      "analysis. The narrow angle sector (30–45 de-\n",
      "grees) was used to obtain color Doppler tissue\n",
      "images of individual left ventricular walls (sep-\n",
      "tum, lateral, inferior, anterior, posterior, and\n",
      "anteroseptal walls) at the high frame rates of\n",
      "172–234 frames per second.\n",
      "\n",
      "Dobutamine\n",
      "\n",
      "echocardiography was per-\n",
      "formed in all patients with starting dose of\n",
      "5 µg/kg per min. The dose was increased at\n",
      "5-minute intervals to 10, and 20 µg/kg per\n",
      "min. The parasternal\n",
      "long-axis and three\n",
      "apical views were digitally stored at rest and\n",
      "at the last minute of all doses of dobutamine\n",
      "for a subsequent wall motion analysis. A\n",
      "16-segment model was used for regional wall\n",
      "motion analysis.13 The akinetic and dyskinetic\n",
      "segments with no improvement in thickening\n",
      "after any dose of dobutamine were regarded\n",
      "as irreversibly damaged. A good interobserver\n",
      "\n",
      "and intraobserver variability in scoring dys-\n",
      "functional segments (agreement 93% and 96%,\n",
      "respectively) and in determining the contractile\n",
      "reserve (agreement 92% and 95%, respectively)\n",
      "has already been described.14\n",
      "\n",
      "The regional longitudinal systolic function\n",
      "was evaluated from the color Doppler tis-\n",
      "sue imaging.15,16 Peak systolic velocities (S)\n",
      "were determined for the basal myocardium\n",
      "of each wall adjacent to the mitral annulus\n",
      "(Slateral, Sseptal, Santerior, Sinferior, Santeroseptal, and\n",
      "Sposterior). The results were obtained as a mean\n",
      "from three consecutive heart cycles. Two expe-\n",
      "rienced echocardiographers who were blinded\n",
      "to the patient treatment performed the analy-\n",
      "ses. The reproducibility of estimation of S val-\n",
      "ues of individual walls was evaluated in our\n",
      "initial 3-month project.12 For all S values, the\n",
      "estimated 95% conﬁdence limits for differences\n",
      "between intraobserver (JM) pairs of measure-\n",
      "ment revealed repeated results to vary in a\n",
      "range of ± 10.6% as based on the mean primary\n",
      "values and similarly ± 11.5% for the interob-\n",
      "server variability (JM and RP). The sufﬁcient\n",
      "interobserver reproducibility was also proved in\n",
      "applied pairwise ANOVA models: only 4.8% of\n",
      "overall variability could be attributed to the dif-\n",
      "ferences among observers and the interobserver\n",
      "effect was unambiguously not signiﬁcant (P =\n",
      "0.963).\n",
      "\n",
      "Gated Technetium-99 m Sestamibi Single\n",
      "Photon Emission Computed Tomography\n",
      "\n",
      "Seven hundred forty MBq technetium-99 m\n",
      "sestamibi was injected at rest. Gated single pho-\n",
      "ton emission computed tomography imaging\n",
      "acquisition (64 projections from the 45◦ right\n",
      "anterior oblique projection to the 45◦ left pos-\n",
      "terior oblique projection) began 1 hour after\n",
      "sestamibi injection using a 2-detector gamma\n",
      "camera (ecam, Siemens, Erlangen, Germany)\n",
      "equipped with a low-energy, high-resolution\n",
      "parallel-hole collimators. The MIBI uptake\n",
      "was analyzed visually and quantitatively on\n",
      "computer-generated polar maps by an experi-\n",
      "enced nuclear cardiologist who was unaware\n",
      "of the patients treatment. Pixels with a ses-\n",
      "tamibi activity > 2.5 SD below the correspond-\n",
      "ing normal mean values were considered ab-\n",
      "normal. The computer automatically expressed\n",
      "a perfusion defect as the number of abnormal\n",
      "pixels divided by the total number of left ven-\n",
      "tricle pixels × 100 project.17 In the viability\n",
      "analysis, the myocardial region with the maxi-\n",
      "mum sestamibi uptake was used as a reference\n",
      "\n",
      "890\n",
      "\n",
      "ECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\n",
      "\n",
      "Vol. 25, No. 8, 2008\n",
      "\n",
      "\f",
      "CELL THERAPY IN AN ACUTE MYOCARDIAL INFARCTION\n",
      "\n",
      "region. The tracer uptake in other myocardial\n",
      "regions was then expressed as a percentage\n",
      "of the activity measured in the reference re-\n",
      "gion. Nonviable myocardium was deﬁned as\n",
      "that having sestamibi uptake below the thresh-\n",
      "old of 50% of the maximum project.18 Gated\n",
      "single photon emission computed tomography\n",
      "rest left ventricular ejection fractions and left\n",
      "ventricular end-diastolic/end-systolic volumes\n",
      "were obtained using automated, commercially\n",
      "available software four-dimensional-MSPECT\n",
      "(University of Michigan, Ann Arbor, MI, USA).\n",
      "\n",
      "Positron Emission Tomography\n",
      "\n",
      "To\n",
      "\n",
      "emission\n",
      "\n",
      "viability, F-18-\n",
      "assess myocardial\n",
      "ﬂuorodeoxyglucose-positron\n",
      "to-\n",
      "mography was performed with a whole-body\n",
      "positron emission tomography scanner (ECAT\n",
      "ACCEL, Siemens, Knoxville, TN, USA). Ac-\n",
      "quisition was started 50 minutes after the\n",
      "administration of ﬂuorodeoxyglucose (200–250\n",
      "MBq intravenously) and images of glucose\n",
      "utilization were acquired for 15–20 minutes\n",
      "in a 3D mode. The metabolic defects were\n",
      "analyzed on computer-generated polar maps.\n",
      "The myocardial ﬂuorodeoxyglucose uptake for\n",
      "each part of the left ventricle was normalized\n",
      "to a myocardial region with the maximum\n",
      "ﬂuorodeoxyglucose uptake. A nonviable my-\n",
      "ocardium was deﬁned as that having less\n",
      "than 50% of the maximum ﬂuorodeoxyglucose\n",
      "uptake.18\n",
      "\n",
      "Bone Marrow Aspiration and Preparation\n",
      "\n",
      "The target volume of bone marrow blood\n",
      "(100 ml for the lower cell dose, 150 ml for\n",
      "the higher cell dose) was obtained from iliac\n",
      "crests under local anesthesia and moderate se-\n",
      "dation with midazolam, mixed with 4% human\n",
      "albumin and 5,000 IU of heparin, and cen-\n",
      "trifuged (15 minutes, 240 g) to receive buffy-\n",
      "coat. Mononuclear cells were collected using\n",
      "density gradient centrifugation of the buffy-\n",
      "coat (20 minutes, 1,200 g, Histopaque 1077,\n",
      "Sigma-Aldrich, St. Louis, MO, USA), washed,\n",
      "and resuspended. One hundred twenty-ﬁve per-\n",
      "cent of the target amount of mononuclear cells\n",
      "was added to the CellGro serum-free medium\n",
      "(CellGenix, Freiburg, Germany) to reach 0.3–\n",
      "1.0 × 106 cells/ml. After an overnight cultiva-\n",
      "tion (37 ◦C, 5% CO2) in a teﬂon bag (VueLife,\n",
      "CellGenix), 105% of the target number of\n",
      "mononuclear cells was withdrawn, washed, and\n",
      "resuspended in the Hank’s salt solution (Sigma-\n",
      "\n",
      "Aldrich) with 4% human albumin and 1,000 IU\n",
      "of heparin into a total volume of 22 ml.\n",
      "\n",
      "Cell Implantation\n",
      "\n",
      "Autologous mononuclear bone marrow cells\n",
      "were transplanted 5–9 days after the infarc-\n",
      "tion onset using a modiﬁcation of the method\n",
      "described previously by Strauer et al.19 Cells\n",
      "were implanted intracoronary via a percuta-\n",
      "neous transluminal catheter into the infarct-\n",
      "related coronary artery. A total of seven balloon\n",
      "inﬂations at the place of previous stent implan-\n",
      "tation lasting for 3 minutes were carried out\n",
      "with 3-minute intervals of balloon deﬂation. At\n",
      "the beginning of each balloon inﬂation, 3 ml\n",
      "of cell suspension was slowly injected into the\n",
      "artery. All patients were on daily doses of 75 mg\n",
      "of clopidogrel and 100 mg of aspirin and, in ad-\n",
      "dition, a bolus of 100 units/kg of body weight of\n",
      "heparin was administered immediately before\n",
      "the procedure to minimize the risk of throm-\n",
      "botic complications.\n",
      "\n",
      "Statistical Analysis\n",
      "\n",
      "Standard descriptive statistics were used\n",
      "to summarize the sample distribution of in-\n",
      "dividual variables (means, standard errors,\n",
      "conﬁdence limits). A univariate t-test for two\n",
      "independent samples was applied to compare\n",
      "values of parameters between the groups. A\n",
      "paired t-test was applied to compare changes\n",
      "in values prior and after the treatment. All\n",
      "parametric tests were performed with the ver-\n",
      "iﬁed assumption of normal distribution\n",
      "(Shapiro–Wilk’s W-test).\n",
      "indepen-\n",
      "dent samples were mutually compared on\n",
      "the basis of proved homogeneity of variance\n",
      "(Variance ratio F-test). The correlation analysis\n",
      "was based on Pearson’s correlation coefﬁcient.\n",
      "A P < 0.05 was considered statistically\n",
      "signiﬁcant.\n",
      "\n",
      "Repeated measures ANOVA model was used\n",
      "to test the results obtained by different ob-\n",
      "servers (measured in all patients included\n",
      "in the reproducibility test). The pairwise de-\n",
      "sign included overall F-test of the main ef-\n",
      "fects (i.e., differences among different ob-\n",
      "servers) and then estimation of within-observer\n",
      "variability.\n",
      "\n",
      "Two\n",
      "\n",
      "Results\n",
      "\n",
      "This subanalysis contains 47 patients. Thirty\n",
      "of them were treated with mononuclear bone\n",
      "\n",
      "Vol. 25, No. 8, 2008\n",
      "\n",
      "ECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\n",
      "\n",
      "891\n",
      "\n",
      "\f",
      "PANOVSKY, ET AL.\n",
      "\n",
      "TABLE I\n",
      "\n",
      "Characteristics of the Study Population\n",
      "\n",
      "Parameter\n",
      "\n",
      "Age (years)\n",
      "Men\n",
      "Hypertension\n",
      "Hyperlipidemia\n",
      "Diabetes mellitus\n",
      "Single-vessel disease\n",
      "Double-vessel disease\n",
      "Triple-vessel disease\n",
      "IRA: LAD\n",
      "IRA: LCX\n",
      "IRA: RCA\n",
      "Maximum CK (ukat/l)\n",
      "Maximum CK-MB (ukat/l)\n",
      "Time from infarct onset to\n",
      "\n",
      "reperfusion (min)\n",
      "\n",
      "Time from infarct onset to cell\n",
      "\n",
      "transplantation (days)\n",
      "\n",
      "Dobutamine echo\n",
      "No. of irreversibly damaged segments\n",
      "Medication on hospital discharge\n",
      "\n",
      "Aspirin\n",
      "Clopidogrel\n",
      "ACE inhibitor\n",
      "Beta blocker\n",
      "Statin\n",
      "\n",
      "Control (C)\n",
      "Group (n = 17)\n",
      "\n",
      "52 (2)\n",
      "15 (88%)\n",
      "9 (53%)\n",
      "6 (35%)\n",
      "4 (24%)\n",
      "11 (65%)\n",
      "6 (35%)\n",
      "\n",
      "0%\n",
      "16 (94%)\n",
      "0%\n",
      "\n",
      "1 (6%)\n",
      "80.2 (11.1)\n",
      "7.4 (0.6)\n",
      "507 (240)\n",
      "\n",
      "–\n",
      "\n",
      "Lower Cell Dose (L) Higher Cell Dose (H)\n",
      "\n",
      "Group (n = 13)\n",
      "\n",
      "Group (n = 17)\n",
      "\n",
      "55 (2)\n",
      "12 (92%)\n",
      "5 (39%)\n",
      "9 (69%)\n",
      "1 (8%)\n",
      "9 (69%)\n",
      "3 (23%)\n",
      "1 (8%)\n",
      "12 (92%)\n",
      "0%\n",
      "\n",
      "1 (8%)\n",
      "80.2 (9.4)\n",
      "7.6 (0.9)\n",
      "263 (53)\n",
      "\n",
      "7 (0.4)\n",
      "\n",
      "55 (5)\n",
      "15 (88%)\n",
      "5 (29%)\n",
      "7 (41%)\n",
      "3 (18%)\n",
      "13 (76%)\n",
      "4 (24%)\n",
      "\n",
      "0%\n",
      "16 (94%)\n",
      "0%\n",
      "\n",
      "1 (6%)\n",
      "68.9 (7.2)\n",
      "6.8 (0.7)\n",
      "484 (192)\n",
      "\n",
      "7 (0.3)\n",
      "\n",
      "6 (0.7)\n",
      "\n",
      "7 (0.4)\n",
      "\n",
      "7 (0.7)\n",
      "\n",
      "17 (100%)\n",
      "15 (88%)\n",
      "17 (100%)\n",
      "17 (100%)\n",
      "17 (100%)\n",
      "\n",
      "13 (100%)\n",
      "13 (100%)\n",
      "13 (100%)\n",
      "13 (100%)\n",
      "13 (100%)\n",
      "\n",
      "17 (100%)\n",
      "17 (100%)\n",
      "17 (100%)\n",
      "17 (100%)\n",
      "17 (100%)\n",
      "\n",
      "The values are expressed as the mean supplied by standard error (in parentheses) or number (%) of\n",
      "subjects. ACE = angiotensin-converting enzyme; CK = creatine kinase; echo = echocardiography; IRA =\n",
      "infarct-related artery; LAD = left anterior descending coronary artery; LCX = left circumﬂex artery;\n",
      "No = number; RCA = right coronary artery.\n",
      "\n",
      "marrow cell implantation–17 patients in the\n",
      "Group H with higher cell doses, while 13 in\n",
      "the Group L with lower cell doses, and 17 of\n",
      "them served as a control Group C. The base-\n",
      "line characteristics are presented in Table I.\n",
      "There were no signiﬁcant differences among the\n",
      "groups.\n",
      "\n",
      "The Effect of Cell Transplantation\n",
      "on Myocardial Function and Left\n",
      "Ventricle Remodeling\n",
      "\n",
      "The results of echocardiographic examina-\n",
      "tions and single photon emission computed to-\n",
      "mography data are demonstrated in Table II.\n",
      "\n",
      "There was a trend toward the prevention of\n",
      "the left ventricle dilatation (end-diastolic vol-\n",
      "ume) and the improvement of the left ventri-\n",
      "cle ejection fraction in transplanted patients.\n",
      "Patients of the high-doses group signiﬁcantly\n",
      "improved the regional systolic function (Sinfarct)\n",
      "after 3-month follow-up. We proved signiﬁcant\n",
      "\n",
      "improvement in these parameters (left ventri-\n",
      "cle ejection fraction, end-systolic volume, peak\n",
      "systolic velocity of infarcted myocardium and\n",
      "number of akinetic segments) in cell therapy\n",
      "patients, as it is documented through signiﬁ-\n",
      "cant results of within-group testing. However,\n",
      "there were no statistically differences among\n",
      "the groups.\n",
      "\n",
      "The side effects have already been pub-\n",
      "\n",
      "lished.12\n",
      "\n",
      "Phenotype of Transplanted Cells\n",
      "\n",
      "The samples were analyzed from 29 patients\n",
      "(in one patient a small sample size did not allow\n",
      "adequate analysis). The transplanted leuko-\n",
      "cytes contained in the mean 43.4% CD3+ cells,\n",
      "2.9% CD16+ cells, 11.0% CD19+ cells, 0.4%\n",
      "CD33+ cells, and 1.1% CD34+ cells, respec-\n",
      "tively. The viability of mononuclear cells was\n",
      "evaluated after the cultivation. In all cases, the\n",
      "viability exceeded 95%.\n",
      "\n",
      "892\n",
      "\n",
      "ECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\n",
      "\n",
      "Vol. 25, No. 8, 2008\n",
      "\n",
      "\f",
      "CELL THERAPY IN AN ACUTE MYOCARDIAL INFARCTION\n",
      "\n",
      "TABLE II\n",
      "\n",
      "Comparison of Baseline and 3-Month Follow-Up Echocardiographic and Single Photon Emission Computed Tomography\n",
      "\n",
      "Results for the Treatment and Control Groups\n",
      "\n",
      "Parameter\n",
      "\n",
      "Echocardiography\n",
      "\n",
      "Mean 6-site S (cm/s)\n",
      "Baseline\n",
      "Follow-up\n",
      "Change‡\n",
      "P-value‡\n",
      "\n",
      "Sinfarct (cm/s)\n",
      "\n",
      "Baseline\n",
      "Follow-up\n",
      "Change‡\n",
      "P-value‡\n",
      "\n",
      "No. of akinetic s∗\n",
      "\n",
      "Baseline\n",
      "Follow-up\n",
      "Change‡\n",
      "P-value‡\n",
      "\n",
      "SPECT\n",
      "\n",
      "EDV (ml)\n",
      "Baseline\n",
      "Follow-up\n",
      "Change‡\n",
      "P-value‡\n",
      "ESV (ml)\n",
      "\n",
      "Baseline\n",
      "Follow-up\n",
      "Change‡\n",
      "P-value‡\n",
      "LV EF (%)\n",
      "Baseline\n",
      "Follow-up\n",
      "Change‡\n",
      "P-value‡\n",
      "\n",
      "Perfusion defect (%)\n",
      "\n",
      "Baseline\n",
      "Follow-up\n",
      "Change‡\n",
      "P-value‡\n",
      "\n",
      "C Group\n",
      "(n = 17)\n",
      "\n",
      "L Group\n",
      "(n = 13)\n",
      "\n",
      "H Group\n",
      "(n = 17)\n",
      "\n",
      "Mutual Comparison (P-Values)†\n",
      "\n",
      "C vs. L\n",
      "\n",
      "C vs. H\n",
      "\n",
      "L vs. H\n",
      "\n",
      "4.9 (0.2)\n",
      "5.2 (0.3)\n",
      "0.3 (0.2)\n",
      "0.393\n",
      "\n",
      "4.5 (0.2)\n",
      "4.8 (0.3)\n",
      "0.3 (0.2)\n",
      "0.153\n",
      "\n",
      "6.2 (0.6)\n",
      "5.5 (0.7)\n",
      "−0.7 (0.4)\n",
      "0.062\n",
      "\n",
      "171 (9)\n",
      "183 (13)\n",
      "12 (8)\n",
      "0.153\n",
      "\n",
      "112 (7)\n",
      "115 (11)\n",
      "3 (8)\n",
      "0.713\n",
      "\n",
      "35 (1)\n",
      "39 (2)\n",
      "4 (2)\n",
      "0.062\n",
      "\n",
      "52 (4)\n",
      "41 (4)\n",
      "−11 (3)\n",
      "<0.001\n",
      "\n",
      "5.1 (0.3)\n",
      "4.9 (0.3)\n",
      "−0.2 (0.3)\n",
      "0.625\n",
      "\n",
      "4.2 (0.3)\n",
      "4.4 (0.3)\n",
      "0.2 (0.2)\n",
      "0.337\n",
      "\n",
      "7.0 (0.4)\n",
      "5.5 (0.6)\n",
      "−1.5 (0.5)\n",
      "<0.001\n",
      "\n",
      "176 (12)\n",
      "180 (12)\n",
      "4 (10)\n",
      "\n",
      "0.696\n",
      "\n",
      "112 (9)\n",
      "106 (9)\n",
      "−6 (7)\n",
      "0.408\n",
      "\n",
      "36 (1)\n",
      "41 (2)\n",
      "5 (1)\n",
      "<0.001\n",
      "\n",
      "51 (4)\n",
      "41 (5)\n",
      "−10 (2)\n",
      "<0.001\n",
      "\n",
      "5.2 (0.2)\n",
      "5.0 (0.2)\n",
      "−0.2 (0.2)\n",
      "0.193\n",
      "\n",
      "4.3 (0.2)\n",
      "4.7 (0.3)\n",
      "0.4 (0.1)\n",
      "0.013\n",
      "\n",
      "6.9 (0.6)\n",
      "5.2 (0.7)\n",
      "−1.7 (0.5)\n",
      "<0.001\n",
      "\n",
      "178 (13)\n",
      "181 (12)\n",
      "3 (8)\n",
      "0.713\n",
      "\n",
      "117 (10)\n",
      "107 (9)\n",
      "−10 (4)\n",
      "0.023\n",
      "\n",
      "35 (1)\n",
      "41 (2)\n",
      "6 (2)\n",
      "<0.001\n",
      "\n",
      "53 (4)\n",
      "43 (4)\n",
      "−10 (2)\n",
      "<0.001\n",
      "\n",
      "0.821\n",
      "0.485\n",
      "0.298\n",
      "\n",
      "0.691\n",
      "0.283\n",
      "0.261\n",
      "\n",
      "0.366\n",
      "0.995\n",
      "0.242\n",
      "\n",
      "0.786\n",
      "0.841\n",
      "0.509\n",
      "\n",
      "0.998\n",
      "0.555\n",
      "0.402\n",
      "\n",
      "0.343\n",
      "0.284\n",
      "0.609\n",
      "\n",
      "0.880\n",
      "0.872\n",
      "0.601\n",
      "\n",
      "0.416\n",
      "0.611\n",
      "0.153\n",
      "\n",
      "0.975\n",
      "0.432\n",
      "0.342\n",
      "\n",
      "0.411\n",
      "0.744\n",
      "0.128\n",
      "\n",
      "0.677\n",
      "0.876\n",
      "0.431\n",
      "\n",
      "0.674\n",
      "0.572\n",
      "0.094\n",
      "\n",
      "0.939\n",
      "0.324\n",
      "0.262\n",
      "\n",
      "0.911\n",
      "0.657\n",
      "0.537\n",
      "\n",
      "0.594\n",
      "0.822\n",
      "0.813\n",
      "\n",
      "0.704\n",
      "0.728\n",
      "0.215\n",
      "\n",
      "0.889\n",
      "0.768\n",
      "0.798\n",
      "\n",
      "0.907\n",
      "0.957\n",
      "0.941\n",
      "\n",
      "0.694\n",
      "0.949\n",
      "0.706\n",
      "\n",
      "0.308\n",
      "0.897\n",
      "0.589\n",
      "\n",
      "0.799\n",
      "0.800\n",
      "0.958\n",
      "\n",
      "The values are expressed as the mean supplied by standard error (in parentheses). ∗Identiﬁed as nonviable on pretransplant\n",
      "dobutamine echocardiography. †Mutual signiﬁcance “between groups” tested by t-test for two independent samples. ‡Pairwise\n",
      "calculated “within group” change of values tested by t-test for two-paired samples.\n",
      "EDV = end-diastolic volume; ESV = end-systolic volume; LV EF = left ventricular ejection fraction; m = myocardium; S =\n",
      "peak systolic velocity of basal myocardium adjacent to mitral annulus; Sinfarct = peak systolic velocity of the infarcted wall;\n",
      "Mean 6-site S = (Slateral + Sseptal + Santerior + Sinferior + Santeroseptal + Sposterior)/6; s = segments; SPECT = single photon\n",
      "emission computed tomography; other abbreviations as in Table I.\n",
      "\n",
      "Discussion\n",
      "\n",
      "Potential Effect of Cell Therapy\n",
      "\n",
      "Bone marrow contains a great number of\n",
      "primitive cells that are able to differentiate\n",
      "into specialized cells, for example into endothe-\n",
      "\n",
      "lial cells or myocytes.20–24 Some of these prim-\n",
      "itive cells produce different growth factors,21\n",
      "for example vascular endothelial growth fac-\n",
      "tor, basic ﬁbroblast growth factor, and cytokines\n",
      "with proangiogenetic effect. For these reasons,\n",
      "many experimental studies were performed and\n",
      "\n",
      "Vol. 25, No. 8, 2008\n",
      "\n",
      "ECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\n",
      "\n",
      "893\n",
      "\n",
      "\f",
      "PANOVSKY, ET AL.\n",
      "\n",
      "proved the possibility of cell therapy to improve\n",
      "perfusion or/and function of dysfunctional my-\n",
      "ocardium.20–26\n",
      "\n",
      "Despite numerous unresolved questions con-\n",
      "cerning the cell transplantation, these ﬁrst\n",
      "hopeful experimental studies were immediately\n",
      "followed by clinical trials, mostly in patients\n",
      "with acute myocardial infarction. The num-\n",
      "bers of patients included are relatively small.\n",
      "Many of these studies are not randomized. The\n",
      "type and amount of cells that are necessary\n",
      "to implant to really regenerate damaged my-\n",
      "ocardium are not known.\n",
      "\n",
      "At present, we do not know the mechanism\n",
      "of action of the implanted cells in studies that\n",
      "found improvement in myocardial function or\n",
      "perfusion following the cell therapy. Recently,\n",
      "several experimental projects described no or\n",
      "only negligible transdifferentiation of adult\n",
      "stem cells into the myocytes.27–30 The beneﬁt\n",
      "of cell transplantation may be induced by the\n",
      "paracrine stem cell effect.31,32\n",
      "\n",
      "Studies in Patients with Acute Myocardial\n",
      "Infarctions\n",
      "\n",
      "Transplantation of mononuclear bone mar-\n",
      "row cells into the region of\n",
      "infarcted my-\n",
      "ocardium has been previously suggested as a\n",
      "promising alternative treatment for left ven-\n",
      "tricle dysfunction. Nevertheless, the results\n",
      "of randomized studies are controversial.3,4,7–9\n",
      "Some of them indicated that patients with\n",
      "the most depressed left ventricular contrac-\n",
      "tile function had the greatest improvement in\n",
      "contractile function after intracoronary admin-\n",
      "istration of bone marrow cells. For example,\n",
      "REPAIR-AMI,33 so far the largest randomized\n",
      "multicenter “cell study,” showed signiﬁcantly\n",
      "greater increase in the global left ejection frac-\n",
      "tion in the bone marrow cell group (5.5% vs.\n",
      "3.0% in the control group) at 4 months follow-\n",
      "up. Higher impact of cells was found among pa-\n",
      "tients with a baseline left ventricle ejection frac-\n",
      "tion below the median value (48.9%). In these\n",
      "patients, the absolute increase in ejection frac-\n",
      "tion was three times higher that in the placebo\n",
      "group (7.5% as compared with 2.5%; absolute\n",
      "difference: 5.0%). Among patients with a base-\n",
      "line ejection fraction above median, the abso-\n",
      "lute difference between groups was only 0.3%\n",
      "(4.0% vs. 3.7%). Similar observations were pre-\n",
      "viously described in TOPCARE-AMI trial,34 in\n",
      "which baseline left ventricle ejection fraction\n",
      "was the only signiﬁcant predictor of improve-\n",
      "\n",
      "ment in ejection fraction during the 4-months\n",
      "follow-up.\n",
      "\n",
      "In the randomized, double-blind, placebo-\n",
      "controlled study of Janssens group,35 in 67 pa-\n",
      "tients with ST-elevation myocardial infarction\n",
      "treated with coronary intervention, no effect\n",
      "of autologous bone marrow-derived stem cell\n",
      "transfer on left ventricle ejection fraction was\n",
      "found. However, the treatment was associated\n",
      "with a signiﬁcant reduction in myocardial in-\n",
      "farct size and better recovery of regional sys-\n",
      "tolic function. The effect of treatment on the\n",
      "probability of improvement in regional function\n",
      "showed a predominant interaction in the most\n",
      "severely affected segments. In addition to that,\n",
      "on positron emission tomography examination,\n",
      "patients with larger myocardial infarction had\n",
      "a greater increase in metabolic activity after cell\n",
      "therapy than after placebo infusion.\n",
      "\n",
      "On the other hand, BOOST trial 36,37 did not\n",
      "describe the inverse relation between baseline\n",
      "left ventricular ejection fraction and absolute\n",
      "improvement of the left ventricle function af-\n",
      "ter implantation of the bone marrow cells into\n",
      "the infarcted myocardium. At 6-month follow-\n",
      "up, patients in a control group of this study im-\n",
      "proved their ejection fraction from 51.3% to 52%\n",
      "(0.7% absolute change), while the bone marrow\n",
      "cell group from 50.0% to 56.7% (6.7% absolute\n",
      "change). The bone marrow cell subgroup pa-\n",
      "tients with ejection fraction of the left ventri-\n",
      "cle > 52% increased their ejection by 8.0%, but\n",
      "patients with ejection fraction ≤ 52% only by\n",
      "4.5%.\n",
      "\n",
      "The main limitation of these studies is the\n",
      "fact, that patients with only mild left ventricu-\n",
      "lar dysfunction were included.\n",
      "\n",
      "Studies in Patients with Moderate-to-Severe\n",
      "Left Ventricular Dysfunction\n",
      "\n",
      "There are only few trials studying cell ther-\n",
      "apy in patients with moderate-to-severe left\n",
      "ventricular dysfunction and their results are\n",
      "controversial too. Bartunek et al.3 described\n",
      "improvement of the left ventricular perfor-\n",
      "mance and increased myocardial perfusion and\n",
      "viability among patients with acute myocar-\n",
      "dial infarction treated with stenting and intra-\n",
      "coronary administration of CD133+ progenitor\n",
      "cells. The left ventricular ejection fraction in-\n",
      "creased from 45.0% to 52.1%.\n",
      "\n",
      "Controversially, ASTAMI trial 11 did not ﬁnd\n",
      "any signiﬁcant difference between 47 patients\n",
      "treated with cell transplantations and 50 pa-\n",
      "tients in the control group. The left ventricular\n",
      "\n",
      "894\n",
      "\n",
      "ECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\n",
      "\n",
      "Vol. 25, No. 8, 2008\n",
      "\n",
      "\f",
      "CELL THERAPY IN AN ACUTE MYOCARDIAL INFARCTION\n",
      "\n",
      "ejection fraction and end-diastolic volume were\n",
      "assessed by single photon emission computed\n",
      "tomography, echocardiography, and magnetic\n",
      "resonance. Improvement versus baseline val-\n",
      "ues was found in both groups, but they did not\n",
      "signiﬁcantly differ. Results were consistent for\n",
      "all the three methods. No improvement in car-\n",
      "diac function was also found in Kuethe et al.38 in\n",
      "their study with ﬁve patients with a large acute\n",
      "anterior myocardial infarction and intracoro-\n",
      "nary mononuclear bone marrow cell implanta-\n",
      "tion.\n",
      "\n",
      "In our previous study,12 the signiﬁcant and\n",
      "dose-related improvement was found in the re-\n",
      "gional systolic function of the infarcted wall af-\n",
      "ter cell transplantation. As compared to con-\n",
      "trols, a higher cell dose signiﬁcantly improved\n",
      "global LV systolic function. Both cell doses pre-\n",
      "vented the left ventricle from the dilation, while\n",
      "the end-diastolic volume signiﬁcantly increased\n",
      "in the control group. Because patients with the\n",
      "greatest damage to their myocardium are the\n",
      "ones who need treatment most, the substudy\n",
      "of these patients was performed. In this sub-\n",
      "study the statistically important effect of au-\n",
      "tologous transplantation of mononuclear bone\n",
      "marrow cells on myocardial function was not\n",
      "found in patients with moderate-to-severe left\n",
      "ventricular dysfunction. Only an insigniﬁcant\n",
      "trend toward the prevention of the left ventric-\n",
      "ular dilatation and improvement of global left\n",
      "ventricle ejection fraction was found at 3-month\n",
      "follow-up.\n",
      "\n",
      "Study Limitations\n",
      "\n",
      "Except the fact that our study is subanalysis,\n",
      "the major limitations of our study are the small\n",
      "number of patients enrolled. However, to this\n",
      "moment it is one of the studies with the highest\n",
      "number of patients with more severe left ven-\n",
      "tricular dysfunction ever published. Compared\n",
      "to other studies, the very rigorous myocardial\n",
      "viability assessment was performed before in-\n",
      "clusion to this study.\n",
      "\n",
      "The groups differ slightly in time from on-\n",
      "set of infarction to reperfusion. The differences\n",
      "were not statistically signiﬁcant. The hetero-\n",
      "geneity was caused by the inclusion of two pa-\n",
      "tients with delayed coronary angioplasty (one\n",
      "patient in the Group H and one patient in the\n",
      "Group C ). In our previous study the biggest\n",
      "effect of cell transplantations was found be-\n",
      "tween higher dose and control groups. In this\n",
      "study, the difference in time from infarct on-\n",
      "set to reperfusion between Groups H and C was\n",
      "\n",
      "just 23 minutes. So this difference has not been\n",
      "supposed to affect the results.\n",
      "\n",
      "Because of ethical consideration, the patients\n",
      "included into the control group did not undergo\n",
      "the identical procedures, as did the bone mar-\n",
      "row cell patients, being excluded from the bone\n",
      "marrow aspiration and coronary angiography\n",
      "with the sham cell transplantation. For techni-\n",
      "cal reasons, the positron emission tomography\n",
      "(PET) was not performed in all our patients.\n",
      "\n",
      "In addition to the limited study population,\n",
      "another explanation of our results could be the\n",
      "very severe myocardial damage with almost no\n",
      "surviving myocytes. In these conditions, there is\n",
      "no suitable milieu for catching implanted cells\n",
      "and their differentiation into cardiomyocytes.\n",
      "Also the severe destruction of microcirculation\n",
      "could make the cell homing more difﬁcult com-\n",
      "pared to patients with less severe myocardial\n",
      "damage.\n",
      "\n",
      "Conclusion\n",
      "\n",
      "The important thing is the fact that the selec-\n",
      "tion of cells and the whole method of cell ther-\n",
      "apy are just at the beginning of the way. Prob-\n",
      "ably, it is not realistic to expect some greater\n",
      "changes of left ventricle function in this manner\n",
      "of treatment. It is necessary to look for the best\n",
      "cell type, an optimal way and time of cell deliv-\n",
      "ery, and the help of some cytokines. For solving\n",
      "these clinical questions, we must also better un-\n",
      "derstand the mechanisms of potential positive\n",
      "effect of the cell therapy.\n",
      "\n",
      "Taking together, the results of trials show\n",
      "that there is still work to be done to understand\n",
      "a lot of questions related to the cell therapy. Fur-\n",
      "ther studies, including larger numbers of pa-\n",
      "tients, are needed to resolve all these tasks.\n",
      "\n",
      "References\n",
      "\n",
      "1. Ho KK, Anderson KM, Kannel WB, et al: Survival af-\n",
      "ter the onset of congestive heart failure in Framing-\n",
      "ham Heart Study subjects. Circulation 1993;88:107–\n",
      "115.\n",
      "\n",
      "2. Rosamond W, Flegal K, Friday G, et al: Heart dis-\n",
      "ease and stroke statistics–2007 update. A report from\n",
      "the American Heart Association Statistics Commit-\n",
      "tee and Stroke Statistics Subcommittee. Circulation\n",
      "2007;115:e69–e171.\n",
      "\n",
      "3. Bartunek J, Vanderheyden M, Vandekerckhove B,\n",
      "et al: Intracoronary injection of CD133-positive en-\n",
      "riched bone marrow progenitor cells promotes cardiac\n",
      "recovery after recent myocardial infarction: Feasibil-\n",
      "ity and safety. Circulation 2005;112(Suppl.):I-178–\n",
      "I-183.\n",
      "\n",
      "4. Fern´andez-Avil´es F, San Rom´an JA, Garc´ıa-Frade\n",
      "J, et al: Experimental and clinical regenerative\n",
      "\n",
      "Vol. 25, No. 8, 2008\n",
      "\n",
      "ECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\n",
      "\n",
      "895\n",
      "\n",
      "\f",
      "PANOVSKY, ET AL.\n",
      "\n",
      "capability of human bone marrow cell after myocar-\n",
      "dial infarction. Circ Res 2004;95:742–748.\n",
      "\n",
      "5. Fuchs S, Satler LF, Kornowski R, et al: Catheter-\n",
      "based autologous bone marrow myocardial\n",
      "injec-\n",
      "tion in no-option patients with advanced coronary\n",
      "artery disease. A feasibility study. J Am Coll Cardiol\n",
      "2003;41(10):1721–1724.\n",
      "\n",
      "6. Gali ˜nanes M, Loubani M, Davies J, et al: Auto-\n",
      "transplantation of unmanipulated bone marrow into\n",
      "scarred myocardium is safe and enhances car-\n",
      "diac function in humans. Cell Transplant 2004;13:\n",
      "7–13.\n",
      "\n",
      "7. Hamano K, Nishida M, Hirata K, et al: Local implan-\n",
      "tation of autologous bone marrow cells for therapeu-\n",
      "tic angiogenesis in patients with ischemic heart dis-\n",
      "ease. Clinical trial and preliminary results. Jpn Circ\n",
      "J 2001;65:845–847.\n",
      "\n",
      "8. Chen SL, Fang WW, Ye F, et al: Effect on left ven-\n",
      "tricular function of intracoronary transplantation of\n",
      "autologous bone marrow mesenchymal stem cell in pa-\n",
      "tients with acute myocardial infarction. Am J Cardiol\n",
      "2004;94:82–95.\n",
      "\n",
      "9. Stamm C, Westphal B, Kleine HD, et al: Autologous\n",
      "bone-marrow stem-cell transplantation for myocar-\n",
      "dial regeneration. Lancet 2003;361:45–46.\n",
      "\n",
      "10. Tse HF, Kwong YL, Chan JKF, et al: Angiogenesis in\n",
      "ischaemic myocardium by intramyocardial autologous\n",
      "bone marrow mononuclear cell implantation. Lancet\n",
      "2003;361:47–49.\n",
      "\n",
      "11. Lunde K, Solheim S, Aakhus S, et al: Intracoronary\n",
      "injection of mononuclear bone marrow cells in acute\n",
      "myocardial infarction. N Engl J Med 2006;355:1199–\n",
      "1209.\n",
      "\n",
      "12. Meluzin J, Mayer J, Groch L, et al: Autologous trans-\n",
      "plantation of mononuclear bone marrow cells in pa-\n",
      "tients with acute myocardial infarction: The effect of\n",
      "the dose of transplanted cells on myocardial function.\n",
      "Am Heart J 2006;152:975.e9–975.e15.\n",
      "\n",
      "13. Schiller NB, Shah PM, Crawford M, et al: Recom-\n",
      "mendations for quantitation of the left ventricle by\n",
      "two-dimensional echocardiography. J Am Soc Echocar-\n",
      "diogr 1989;2:358–367.\n",
      "\n",
      "14. Meluz´ın J, Cigarroa CG, Brickner E, et al: Dobu-\n",
      "tamine echocardiography in predicting improvement\n",
      "in global left ventricular systolic function after coro-\n",
      "nary bypass or angioplasty in patients with healed\n",
      "myocardial\n",
      "infarcts. Am J Cardiol 1995;76:877–\n",
      "880.\n",
      "\n",
      "15. Wandt B, Fornander Y, Egerlid R: Maximal longitu-\n",
      "dinal contraction velocity in assessment of left ven-\n",
      "tricular systolic function: A pulsed tissue Doppler and\n",
      "M-mode study. Echocardiography 2004;21(7):587–\n",
      "592.\n",
      "\n",
      "16. Yuda S, Inaba Y, Fujii S, et al: Assessment of left\n",
      "ventricular ejection fraction using long-axis systolic\n",
      "function is independent of image quality: A study\n",
      "of tissue Doppler imaging and M-mode echocar-\n",
      "diography.\n",
      "2006;23(10):846–\n",
      "852.\n",
      "\n",
      "Echocardiography\n",
      "\n",
      "17. Dakik HA, Howell JF, Lawrie GM, et al: Assessment\n",
      "of myocardial viability with 99mTc-sestamibi tomog-\n",
      "raphy before coronary bypass graft surgery. Circula-\n",
      "tion 1997;96:2892–2898.\n",
      "\n",
      "18. Maes AF, Borgers M, Flameng W, et al: Assessment of\n",
      "myocardial viability in chronic coronary artery disease\n",
      "using technetium-99 m sestamibi SPECT. J Am Coll\n",
      "Cardiol 1997;29:62–68.\n",
      "\n",
      "19. Strauer BE, Brehm M, Zeus T, et al: Repair of\n",
      "infarcted myocardium by autologous intracoronary\n",
      "mononuclear bone marrow cell transplantation in hu-\n",
      "mans. Circulation 2002;106:1913–1918.\n",
      "\n",
      "20. Tomita S, Li RK, Weisel RD, et al: Autologous trans-\n",
      "plantation of bone marrow cells improves damaged\n",
      "heart\n",
      "function. Circulation 1999;100(Suppl.II):II-\n",
      "247–II-256.\n",
      "\n",
      "21. Fuchs S, Baffour R, Zhou YF, et al: Transendocar-\n",
      "dial delivery of autologous bone marrow enhances col-\n",
      "lateral perfusion and regional function in pigs with\n",
      "chronic experimental myocardial ischemia. J Am Coll\n",
      "Cardiol 2001;37:1726–1732.\n",
      "\n",
      "22. Makino S, Fukuda K, Miyoshi S, et al: Cardiomyocytes\n",
      "can be generated from marrow stromal cells in vitro.\n",
      "J Clin Invest 1999;103:697–705.\n",
      "\n",
      "23. Jackson KA, Majka SM, Wang H, et al: Regenera-\n",
      "tion of ischemic cardiac muscle and vascular endothe-\n",
      "lium by adult stem cells. J Clin Invest 2001;107:1395–\n",
      "1402.\n",
      "\n",
      "24. Hamano K, Li TS, Kobayashi T, et al: The induction of\n",
      "angiogenesis by the implantation of autologous bone\n",
      "marrow cells: A novel and simple therapeutic method.\n",
      "Surgery 2001;130:44–54.\n",
      "\n",
      "25. Orlic D, Kajstura J, Chimenti S, et al: Mobilized\n",
      "bone marrow cells repair the infarcted heart, improv-\n",
      "ing function and survival. Proc Natl Acad Sci (USA)\n",
      "2001;98:0344–0349.\n",
      "\n",
      "26. Orlic D, Kajstura J, Chimenti S, et al: Bone mar-\n",
      "row cells regenerate infarcted myocardium. Nature\n",
      "2001;410:701–705.\n",
      "\n",
      "27. Limbourg FP, Ringes-Lichtenberg S, Schaefer A, et al:\n",
      "Haematopoietic stem cells improve cardiac function\n",
      "after infarction without permanent cardiac engraft-\n",
      "ment. Eur J Heart Failure 2005;7:722–729.\n",
      "\n",
      "28. Balsam LB, Wagers AJ, Christensen JL, et al:\n",
      "Haematopoietic stem cells adopt mature haematopoi-\n",
      "etic\n",
      "in ischaemic myocardium. Nature\n",
      "2004;428:668–673.\n",
      "\n",
      "fates\n",
      "\n",
      "29. Murry ChE, Soonpaa MH, Reinecke H, et al:\n",
      "Haematopoietic stem cells do not transdifferentiate\n",
      "into cardiac myocytes in myocardial infarcts. Nature\n",
      "2004;428:664–668.\n",
      "\n",
      "30. Nygren JM, Jovinge S, Breitbach M, et al: Bone\n",
      "marrow-derived hematopoietic cells generate car-\n",
      "diomyocytes at a low frequency through fusion, but not\n",
      "transdifferentiation. Nature Medicine 2004;10:494–\n",
      "501.\n",
      "\n",
      "31. Kinnaird T, Stabile E, Burnett MS, et al: Local deliv-\n",
      "ery of marrow-derived stromal cells augments collat-\n",
      "eral perfusion through paracrine mechanisms. Circu-\n",
      "lation 2004;109:1543–1549.\n",
      "\n",
      "32. Misao Y, Takemura G, Arai M, et al: Bone marrow-\n",
      "derived myocyte-like cells and regulation of repair-\n",
      "related cytokines after bone marrow cell transplan-\n",
      "tation. Cardiovasc Res 2006;69:476–490.\n",
      "\n",
      "33. Schachinger V, Erbs S, Elsasser A, et al: The REPAIR-\n",
      "AMI\n",
      "Intracoronary bone marrow-\n",
      "derived progenitor cells in acute myocardial infarc-\n",
      "tion. N Engl J Med 2006;355:1210–1221.\n",
      "\n",
      "Investigators.\n",
      "\n",
      "34. Sch¨achinger V, Assmuss B, Britten MB, et al: Trans-\n",
      "plantation of progenitor cells and regeneration en-\n",
      "hancement in acute myocardial infarction. Final one-\n",
      "year results of the TOPCARE-AMI trial. J Am Coll\n",
      "Cardiol 2004;44:1690–1699.\n",
      "\n",
      "35. Janssens S, Dubois C, Bogaert J, et al: Autol-\n",
      "ogous bone marrow-derived stem-cell transfer in\n",
      "\n",
      "896\n",
      "\n",
      "ECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\n",
      "\n",
      "Vol. 25, No. 8, 2008\n",
      "\n",
      "\f",
      "CELL THERAPY IN AN ACUTE MYOCARDIAL INFARCTION\n",
      "\n",
      "patients with ST-segment elevation myocardial infarc-\n",
      "tion: Double-blind, randomised controlled trial. 2006;\n",
      "367(9505):113–121.\n",
      "\n",
      "36. Wollert KC, Meyer GP, Lotz J, et al: Intracoronary au-\n",
      "tologous bone-marrow cell transfer after myocardial\n",
      "infarction: The BOOST randomized controlled clinical\n",
      "trial. Lancet 2004;363:141–148.\n",
      "\n",
      "37. Meyer GP, Wollert KC, Lotz J, et al: Intracoronary\n",
      "bone marrow cell transfer after myocardial infarction.\n",
      "\n",
      "Eighteen months’ follow-up data from the randomized,\n",
      "controlled BOOST (bone marrow transfer to enhance\n",
      "ST-elevation infarct regeneration) Trial. Circulation\n",
      "2006;113:1287–1294.\n",
      "\n",
      "38. Kuethe F, Richartz BM, Sayer HG, et al: Lack of regen-\n",
      "eration of myocardium by autologous intracoronary\n",
      "mononuclear bone marrow cell transplantation in hu-\n",
      "mans with large anterior myocardial infarctions. Int\n",
      "J Cardiol 2004;97:123–127.\n",
      "\n",
      "Vol. 25, No. 8, 2008\n",
      "\n",
      "ECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\n",
      "\n",
      "897\n",
      "\n",
      "\f",
      "\n"
     ]
    }
   ],
   "source": [
    "# extracting the text\n",
    "output_text_1 = path(path_to_pdf_1)\n",
    "print(output_text_1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "9dfd4043",
   "metadata": {},
   "outputs": [],
   "source": [
    "path_to_pdf_2 = (r\"D:\\Live Project\\Data\\888-896.pdf\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "1a532666",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Articles                                                                                                  Chronic Lymphocytic Leukemia\n",
      "HLA-G is a component of the chronic lymphocytic leukemia escape\n",
      "repertoire to generate immune suppression: impact of the HLA-G 14\n",
      "base pair (rs66554220) polymorphism\n",
      "\n",
      "Roberta Rizzo,1 Valentina Audrito,2,5 Paola Vacca,3 Davide Rossi,4 Davide Brusa,5 Marina Stignani,1 Daria Bortolotti,1\n",
      "Giovanni D’Arena,6 Marta Coscia,7 Luca Laurenti,8 Francesco Forconi,9 Gianluca Gaidano,4 Maria Cristina Mingari,3,10\n",
      "Lorenzo Moretta,11 Fabio Malavasi,2,12 and Silvia Deaglio2,5\n",
      "1Department of Medical Sciences, Sections of Microbiology and Medical Genetics, University of Ferrara, Italy; 2Department of\n",
      "Medical Sciences, University of Turin, Italy; 3Department of Experimental Medicine, University of Genoa, Italy; 4Division of\n",
      "Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; 5Human\n",
      "Genetics Foundation (HuGeF), Turin, Italy; 6Department of Onco-Hematology, IRCCS ‘‘Centro di Riferimento Oncologico della\n",
      "Basilicata’’, Rionero in Vulture, Italy; 7Division of Hematology, University of Turin, Azienda Ospedaliera Città della Salute e della\n",
      "Scienza di Torino, Italy; 8Institute of Hematology, Catholic University of the Sacred Heart, Rome, Italy; 9Cancer Sciences Unit, CRUK\n",
      "Center, University of Southampton & Haematology Department, SUHT, Southampton, UK; 10AOU San Martino–Istituto Nazionale per\n",
      "la Ricerca sul Cancro, Genoa, Italy; 11Giannina Gaslini Institute, Genoa, Italy; and 12Research Center for Experimental Medicine, Città\n",
      "della Salute e della Scienza Hospital, Turin, Italy\n",
      "\n",
      "ABSTRACT\n",
      "\n",
      "This work investigates the possibility that HLA-G, a molecule modulating innate and adaptive immunity, is part of\n",
      "an immune escape strategy of chronic lymphocytic leukemia cells. A 14 base pair insertion/deletion polymorphism\n",
      "(rs66554220) in the 3'-untranslated region of HLA-G influences mRNA stability and protein expression. The analysis\n",
      "of a cohort of patients with chronic lymphocytic leukemia confirmed that del/del individuals are characterized by\n",
      "higher  levels  of  surface  and  soluble  HLA-G  than  subjects  with  the  other  two  genotypes.  In  line  with  its  role  in\n",
      "immunomodulation, the percentage of regulatory T lymphocytes is higher in del/del patients than in patients with\n",
      "the other genotypes and correlates with the amounts of surface or soluble HLA-G. Furthermore, addition of sHLA-\n",
      "G-rich plasma from patients with chronic lymphocytic leukemia induces natural killer cell apoptosis and impairs nat-\n",
      "ural killer cell lysis, with effects proportional to the amount of soluble HLA-G added. Lastly, the presence of an HLA-\n",
      "G 14 base pair polymorphism is of prognostic value, with del/del patients showing reduced overall survival, as com-\n",
      "pared to those with other genotypes. These results suggest that: (i) the HLA-G 14 base pair polymorphism influences\n",
      "the levels of surface and soluble HLA-G expression, and (ii) the over-expression of HLA-G molecules contributes to\n",
      "creating tolerogenic conditions. \n",
      "\n",
      "Introduction\n",
      "\n",
      "Chronic lymphocytic leukemia (CLL), the most common\n",
      "type of adult leukemia in Caucasian populations, is charac-\n",
      "terized  by  the  progressive  accumulation  of  mature\n",
      "CD5+/CD23+ B cells in the peripheral blood and lymphoid\n",
      "organs.1 Several observations point to immune escape being\n",
      "a relevant mechanism of tumor promotion. First, CLL cells\n",
      "express  high  levels  of  immunomodulatory  factors  (e.g.,\n",
      "transforming growth factor2 and interleukin-103), which sup-\n",
      "press responses to antigens and influence activation, expan-\n",
      "sion, and effector functions of T lymphocytes.4 Secondly, an\n",
      "increase  in  the  numbers  of  circulating  regulatory  T  cells\n",
      "(Treg) parallels disease progression.5,6 Lastly, adenosine pro-\n",
      "duction in the extracellular milieu by selected leukemic sub-\n",
      "populations  shields  the  CLL  clone  from  the  actions  of  the\n",
      "immune system.7\n",
      "\n",
      "The aim of this work was to investigate the role of human\n",
      "leukocyte antigen G (HLA-G) as a further strategy adopted by\n",
      "CLL cells to evade immune defenses and to create protected\n",
      "niches in which to grow and expand. HLA-G is a non-classical\n",
      "major histocompatibility complex (MHC) class I product with\n",
      "\n",
      "limited sequence variability. It is exclusively expressed in tis-\n",
      "sues where the immune system needs to be constantly sup-\n",
      "pressed,  including  cytotrophoblast  from  early  gestation  pla-\n",
      "centas, amniotic cells, endothelial cells of chorionic blood ves-\n",
      "sels, thymic epithelial cells and corneas.8 HLA-G is a tolero-\n",
      "genic molecule which inhibits cytolysis mediated by natural\n",
      "killer  (NK)  cells  or  T  lymphocytes,  induces  T-cell  apoptosis\n",
      "and  blocks  transendothelial  migration  of  NK  cells.9 These\n",
      "functions  are  exerted  upon  binding \n",
      "the  killer  cell\n",
      "immunoglobulin-like \n",
      "the\n",
      "immunoglobulin-like  transcript-2  and  -4  ligands.10,11 Hence,\n",
      "the immunosuppressive features of HLA-G are functional in\n",
      "pregnancy, organ transplantation, autoimmune diseases, and\n",
      "cancer immune escape.12\n",
      "\n",
      "(KIR)2DL4 \n",
      "\n",
      "receptor \n",
      "\n",
      "and \n",
      "\n",
      "The  HLA-G gene  encodes  seven  isoforms  generated\n",
      "through  alternative  splicing:  four  are  membrane-bound\n",
      "(namely, HLA-G1, -G2, -G3, and -G4), while three (HLA-G5,\n",
      "-G6, and -G7) are soluble and represent the counterparts of\n",
      "HLA-G1,  -G2  and  -G3,  respectively.  An  alternative  mecha-\n",
      "nism to generate soluble HLA-G (sHLA-G) forms is represent-\n",
      "ed by proteolytic cleavage of the membrane molecules.13\n",
      "\n",
      "HLA-G is characterized by different polymorphisms at the\n",
      "\n",
      "©2014 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2013.095281\n",
      "The online version of this article has a Supplementary Appendix.\n",
      "Manuscript received on July 23, 2013. Manuscript accepted on December 17, 2013.\n",
      "Correspondence:  silvia.deaglio@unito.it   or   roberta.rizzo@unife.it.\n",
      "\n",
      "888\n",
      "\n",
      "haematologica | 2014; 99(5)\n",
      "\n",
      "\f",
      "5’  upstream  regulatory  and  the  3’  untranslated  regions.14\n",
      "One  of  these,  characterized  by  the  deletion/insertion\n",
      "(del/ins) of 14 base pairs (14 bp) (rs66554220), is responsi-\n",
      "ble for mRNA stability and consequently protein produc-\n",
      "tion.15 The  presence  of  the  14  bp  sequence  is  associated\n",
      "with  unstable  mRNA  and  reduced  sHLA-G  protein  pro-\n",
      "duction.16 This  polymorphism  is  implicated  in  autoim-\n",
      "mune and chronic inflammatory conditions,8 while its role\n",
      "in cancer growth and progression is still controversial.\n",
      "\n",
      "The role of HLA-G products in CLL patients has been\n",
      "evaluated  in  previous  studies,  although  these  focused\n",
      "exclusively on the expression either of the membrane or\n",
      "of  the  secreted  isoform  of  the  molecule.  The  results\n",
      "obtained indicate that: (i) HLA-G expression at transcrip-\n",
      "tion  and  protein  levels  is  increased  in  CLL  cells  as  com-\n",
      "pared to normal B lymphocytes;17-19 and (ii) HLA-G expres-\n",
      "sion correlates with worse clinical outcome in CLL.20,21\n",
      "\n",
      "This work was undertaken with the aim of assessing the\n",
      "impact of the HLA-G 14 bp polymorphism on expression\n",
      "of the membrane and soluble forms of the HLA-G protein,\n",
      "and its role in promoting immune escape in a large, well-\n",
      "characterized cohort of CLL patients.\n",
      "\n",
      "Methods\n",
      "\n",
      "Patients and controls\n",
      "\n",
      "Five hundred and six individuals with a confirmed diagnosis of\n",
      "CLL  were  enrolled  at  diagnosis  into  a  retrospective  study  and\n",
      "typed for HLA-G rs66554220 polymorphism. The patients’ char-\n",
      "acteristics  are  reported  in  Online  Supplementary  Table  S1.  Blood\n",
      "samples from patients or non-leukemic individuals were obtained\n",
      "after  written  informed  consent  in  accordance  with  local  institu-\n",
      "tional guidelines and the Declaration of Helsinki. The study was\n",
      "approved by the Human Genetics Foundation Ethical Committee.\n",
      "Peripheral blood mononuclear cells and purified B lymphocytes\n",
      "\n",
      "were obtained as described elsewhere.22\n",
      "\n",
      "Flow cytometric analyses \n",
      "\n",
      "Antibodies used for flow cytometry are detailed in the Online\n",
      "Supplementary Materials and Methods. Data were acquired using a\n",
      "FACSCanto  II  (BD  Biosciences,  Buccinasco,  Italy)  or  Gallios\n",
      "(Beckman  Coulter)  flow  cytofluorimeter,  processed  with  DIVA\n",
      "v6.1.3  (BD  Biosciences),  and  analyzed  with  FlowJo  version  9.01\n",
      "software  (TreeStar,  Ashland,  OR,  USA).  At  least  10,000  events\n",
      "were analyzed for each sample.\n",
      "\n",
      "Typing the HLA-G 14 base pair polymorphism \n",
      "\n",
      "Genomic DNA was extracted from peripheral blood mononu-\n",
      "clear  cells  using  a  DNeasy  Blood  &  Tissue  Kit  (Qiagen,  Milan,\n",
      "Italy). The HLA-G 14 bp polymorphism was genotyped by poly-\n",
      "merase chain reaction.23,24\n",
      "\n",
      "Soluble HLA-G detection by enzyme-linked \n",
      "immunosorbent assay\n",
      "\n",
      "sHLA-G1 and HLA-G5 levels were measured as reported previ-\n",
      "ously.25 After both enzyme-linked immunosorbent assay (ELISA)\n",
      "measurements, the amount of sHLA-G1 was expressed as the dif-\n",
      "ference  between  sHLA-G1/HLA-G5  and  HLA-G5  concentra-\n",
      "tions.26\n",
      "\n",
      "Isolation and culture of natural killer cells \n",
      "\n",
      "NK cells were isolated from peripheral blood mononuclear cells\n",
      "or from decidua as described elsewhere.27,28 Purified NK cells were\n",
      "cultured  on  allogeneic  irradiated  feeder  cells  in  the  presence  of\n",
      "\n",
      "HLA-G polymorphism in CLL\n",
      "\n",
      "interleukin-2  (100  U/mL)  and  phytohemagglutinin  (1.5  ng/mL,\n",
      "Gibco, Life Technologies).27\n",
      "\n",
      "Natural killer cell apoptosis\n",
      "\n",
      "Freshly isolated or interleukin-2 activated NK cells were incu-\n",
      "bated with different serum samples from CLL patients representa-\n",
      "tive of the different 14 bp HLA-G polymorphism. After overnight\n",
      "incubation, NK cell apoptosis was measured using annexin V and\n",
      "propidium iodide (Invitrogen, Eugene, OR, USA).\n",
      "\n",
      "Natural killer cell cytolytic activity\n",
      "\n",
      "Interleukin-2-activated NK cells were tested for cytolytic activi-\n",
      "\n",
      "ty in a 4 h 51Cr-release assay against the K562 cell line.27\n",
      "\n",
      "Statistical analyses\n",
      "\n",
      "Overall survival was measured from date of sampling to date of\n",
      "death (event) or last follow-up (censoring). Survival analysis was\n",
      "performed  by  the  Kaplan-Meier  method.  The  crude  association\n",
      "between time-fixed exposure variables at diagnosis and survival\n",
      "was  estimated  by  log-rank  analysis.  Statistical  significance  was\n",
      "defined as a P value <0.05. Statistical tests were performed using\n",
      "GraphPad  Prism  6.0  software  (Graphpad  Software,  San  Diego,\n",
      "CA, USA) and SPSS software v20.0 (Chicago, IL, USA).\n",
      "\n",
      "Results\n",
      "\n",
      "Effects of the HLA-G 14 base pair polymorphism \n",
      "on membrane and soluble protein expression \n",
      "in patients with chronic lymphocytic leukemia\n",
      "\n",
      "The  hypothesis  underlying  this  study  is  that  patients\n",
      "with a del/del genotype of the 14 bp polymorphism have\n",
      "more  stable  HLA-G mRNA,  resulting  in  higher  levels  of\n",
      "the molecule on the cell surface and in biological fluids.16\n",
      "This hypothesis was tested by determining the effects\n",
      "of the 14 bp polymorphism on the expression of HLA-G\n",
      "protein  at  the  surface  of  CLL  B  cells  obtained  from  126\n",
      "patients.  The  observed  levels  of  HLA-G  expression  on\n",
      "CD19+/CD5+ CLL  B  lymphocytes  were  highly  variable\n",
      "[mean ± standard error of mean (SEM) 7.35±1.13%, Figure\n",
      "1A,B].  Patients  with  a  del/del  genotype  had  a  trend\n",
      "towards  increased  levels  (n=51,  mean  8.97±1.85)  of  sur-\n",
      "face  HLA-G,  even  if  a  comparison  with  levels  in  ins/del\n",
      "(n=48,  mean  6.38±2)  or  ins/ins  (n=27,  mean  6.03±1.77)\n",
      "patients  was  not  statistically  significant  (Figure  1C).\n",
      "However, when divided into quartiles, 25.4% of the 126\n",
      "patients had a surface HLA-G expression by leukemic cells\n",
      "above  the  third  quartile  (third  quartile  value:  9.5%).  Of\n",
      "these,  58%  had  a  del/del,  23%  an  ins/del  and  19%  an\n",
      "ins/ins genotype (P<0.0001, χ\n",
      "Attention  was  next  focused  on  HLA-G  plasma  levels\n",
      "assayed by ELISA in a cohort of 60 patients and 60 sex-\n",
      "and age-matched controls. Results indicate a marked vari-\n",
      "ability  in  concentration  in  both  CLL  patients  (mean  ±\n",
      "SEM,  19.71±2.83  ng/mL)  and  controls  (mean  ±  SEM,\n",
      "17.28±23.64  ng/mL),  without  statistically  significant  dif-\n",
      "ferences between the two groups (Figure 2A). When CLL\n",
      "patients and controls were divided according to genotype,\n",
      "del/del  patients  (n=27)  had  significantly  higher  levels  of\n",
      "sHLA-G (mean 30.82±4.8 ng/mL) than had either ins/del\n",
      "(n=18, mean 13.68±3.67 ng/mL, P=0.015, Mann-Whitney\n",
      "test)  or  ins/ins  patients  (n=15,  mean  6.95±2.74  ng/mL,\n",
      "P=0.003, Mann-Whitney test, Figure 2B). Del/del controls\n",
      "showed a tendency towards a higher production of sHLA-\n",
      "\n",
      "2 test, Figure 1D). \n",
      "\n",
      "haematologica | 2014; 99(5)\n",
      "\n",
      "889\n",
      "\n",
      "\f",
      "R. Rizzo et al.\n",
      "\n",
      "G  (n=22,  mean  22.06±27.32  ng/mL)  when  compared  to\n",
      "ins/del (n=25, mean 16.93±24.87 ng/mL) or ins/ins (n=13,\n",
      "mean 9.88 ± 11.90 ng/mL) individuals, without the differ-\n",
      "ence reaching statistical significance (Online Supplementary\n",
      "Figure  S1A).  After  dividing  sHLA-G  levels  into  quartiles,\n",
      "25% of CLL patients and of controls had sHLA-G expres-\n",
      "sion above the third quartile (third quartile value in CLL\n",
      "patients:  31.75  ng/mL;  third  quartile  value  in  controls:\n",
      "24.40  ng/mL).  Of  these,  in  the  CLL  cohort  80%  had  a\n",
      "del/del genotype, while 13% had an ins/del genotype and\n",
      "the  remaining  7%  had  an  ins/ins  genotype  (P<0.0001,\n",
      "Fisher exact test, Figure 2C). When considering controls,\n",
      "46%  presented  a  del/del,  46%  an  ins/del  and  8%  an\n",
      "ins/ins  genotype  (P<0.0001,  Fisher  exact  test,  Online\n",
      "Supplementary Figure S1B).\n",
      "\n",
      "We  then  asked  whether  sHLA-G  levels  correlate  with\n",
      "HLA-G  expressed  on  the  membrane  of  CLL  cells.  As\n",
      "expected, the levels of expression of sHLA-G and mem-\n",
      "brane  HLA-G  were  positively  correlated  (n=60,  rho=0.4,\n",
      "P=0.003,  Spearman  correlation  test),  in  line  with  a  rela-\n",
      "tionship  between  surface  HLA-G  expression  and  release\n",
      "(Figure 2D). The analysis of covariance showed an inde-\n",
      "pendent effect of 14 bp polymorphism (P=0.003) and sur-\n",
      "face HLA-G expression (P=0.02) on sHLA-G plasma levels.\n",
      "Using an isoform-sensitive ELISA, sHLA-G1 was predom-\n",
      "inant in the plasma of CLL patients, indicating a derivation\n",
      "from  shedding  of  the  membrane  form  rather  than  from\n",
      "alternative  splicing  (sHLA-G1  versus HLA-G5  isoforms,\n",
      "P=0.001; Mann-Whitney test, Figure 2E). \n",
      "\n",
      "The conclusion is that patients with a del/del genotype\n",
      "\n",
      "A\n",
      "\n",
      "C\n",
      "S\n",
      "S\n",
      "\n",
      "250k\n",
      "\n",
      "200k\n",
      "\n",
      "150k\n",
      "\n",
      "100k\n",
      "\n",
      "50k\n",
      "\n",
      "0\n",
      "\n",
      "5\n",
      "D\n",
      "C\n",
      "\n",
      "105\n",
      "\n",
      "104\n",
      "\n",
      "103\n",
      "\n",
      "102\n",
      "\n",
      "101\n",
      "\n",
      "100\n",
      "\n",
      "B\n",
      "\n",
      "C\n",
      "\n",
      ")\n",
      "\n",
      "%\n",
      "\n",
      "(\n",
      " \n",
      "G\n",
      "-\n",
      "A\n",
      "L\n",
      "H\n",
      " \n",
      "e\n",
      "c\n",
      "a\n",
      "f\n",
      "r\n",
      "u\n",
      "S\n",
      "\n",
      "0\n",
      "\n",
      "50k\n",
      "\n",
      "100k\n",
      "\n",
      "150k\n",
      "FSC\n",
      "\n",
      "200k\n",
      "\n",
      "250k\n",
      "\n",
      "100\n",
      "\n",
      "101\n",
      "\n",
      "102\n",
      "103\n",
      "CD19\n",
      "\n",
      "104\n",
      "\n",
      "105\n",
      "\n",
      "# 1 low\n",
      "\n",
      "# 2 intermediate\n",
      "\n",
      "100\n",
      "\n",
      "1 %\n",
      "\n",
      "19%\n",
      "\n",
      "80\n",
      "\n",
      "60\n",
      "\n",
      "40\n",
      "\n",
      "20\n",
      "\n",
      "0\n",
      "\n",
      "# 3 high\n",
      "\n",
      "54%\n",
      "\n",
      "100\n",
      "\n",
      "80\n",
      "\n",
      "60\n",
      "\n",
      "40\n",
      "\n",
      "20\n",
      "\n",
      "0\n",
      "\n",
      "100\n",
      "\n",
      "101\n",
      "\n",
      "102\n",
      "\n",
      "103\n",
      "\n",
      "104\n",
      "\n",
      "105\n",
      "\n",
      "100\n",
      "\n",
      "101\n",
      "\n",
      "102\n",
      "\n",
      "103\n",
      "\n",
      "104\n",
      "\n",
      "105\n",
      "\n",
      "100\n",
      "\n",
      "101\n",
      "\n",
      "102\n",
      "\n",
      "103\n",
      "\n",
      "104\n",
      "\n",
      "105\n",
      "\n",
      "HLA-G\n",
      "\n",
      "D\n",
      "\n",
      "100\n",
      "\n",
      "s\n",
      "t\n",
      "n\n",
      "e\n",
      "i\n",
      "t\n",
      "a\n",
      "p\n",
      "\n",
      " \n",
      "f\n",
      "o\n",
      "%\n",
      "\n",
      " \n",
      "\n",
      "75\n",
      "\n",
      "50\n",
      "\n",
      "25\n",
      "\n",
      "0\n",
      "\n",
      "n=48\n",
      "\n",
      "n=51\n",
      "\n",
      "n=27\n",
      "\n",
      "del/del\n",
      "\n",
      "ins/del\n",
      "\n",
      "ins/ins\n",
      "\n",
      "HLA-G genotype\n",
      "\n",
      "P<0.0001\n",
      "\n",
      ">9.5%\n",
      "\n",
      "<9.5%\n",
      "\n",
      "del/del\n",
      "\n",
      "ins/del\n",
      "\n",
      "ins/ins\n",
      "\n",
      "HLA-G genotype\n",
      "\n",
      "100\n",
      "\n",
      "80\n",
      "\n",
      "60\n",
      "\n",
      "40\n",
      "\n",
      "20\n",
      "\n",
      "0\n",
      "\n",
      "80\n",
      "\n",
      "60\n",
      "\n",
      "40\n",
      "\n",
      "20\n",
      "\n",
      "0\n",
      "\n",
      "HLA-G \n",
      "\n",
      "expression \n",
      "\n",
      "Figure  1.  Distribution  of  membrane\n",
      "HLA-G in a cohort of 126 CLL patients\n",
      "typed  for  the  14  bp  polymorphism.\n",
      "(A) Density plots represent the gating\n",
      "strategy.  Left  panel  indicates  the\n",
      "morphological  gate, \n",
      "right  panel\n",
      "shows  the  staining  for  CD19  and\n",
      "CD5.  (B)  Histograms  represent  sur-\n",
      "face \n",
      "in\n",
      "CD19+/CD5+ CLL B lymphocytes from\n",
      "three  representative  patients.  (C)\n",
      "Patients were then divided according\n",
      "to  the  14  bp  polymorphism  into\n",
      "groups  with  del/del, \n",
      "ins/del  or\n",
      "ins/ins genotype. Box plots represent\n",
      "the distribution of mHLA-G in the dif-\n",
      "ferent  categories.  (D)  Graph  repre-\n",
      "senting  the  percentages  of  patients\n",
      "expressing  mHLA-G  above  (black\n",
      "bars)  or  below  (open  bars)  the  third\n",
      "quartile (9.5%).\n",
      "\n",
      "890\n",
      "\n",
      "haematologica | 2014; 99(5)\n",
      "\n",
      "\f",
      "have  significantly  higher  sHLA-G  levels  and  tend  to\n",
      "express more membrane HLA-G on leukemic cells than do\n",
      "patients with the other genotypes.\n",
      "Effects of the HLA-G 14 base pair polymorphism on \n",
      "the number of circulating T lymphocytes in patients\n",
      "with chronic lymphocytic leukemia \n",
      "\n",
      "CLL  development  and  progression  are  paralleled  by  a\n",
      "progressive  impairment  of  host  immune  defenses,  with\n",
      "clinically manifest immune defects of the T-cell compart-\n",
      "ment.  The  next  step  of  the  study  was  to  determine\n",
      "whether high levels of surface and sHLA-G would reflect\n",
      "the immune defects characterizing CLL. To this aim, the\n",
      "composition  of  T-cell  subsets  was  assessed  in  52  CLL\n",
      "patients  divided  according  to  HLA-G 14  bp  polymor-\n",
      "phism.\n",
      "\n",
      "CD4+ and CD8+ and T-cell percentages were not signifi-\n",
      "cantly different among the groups with the three HLA-G\n",
      "14 bp genotypes (Figure 3A,B). In contrast, the number of\n",
      "Treg, defined as CD4+/CD25high/CD127low), was significant-\n",
      "ly  higher  in  patients  with  the  del/del  genotype  (mean\n",
      "6.97% ± 0.88) than in the group with the ins/ins genotype\n",
      "(mean 3.23% ± 0.69, P=0.006, Mann-Whitney test, Figure\n",
      "3C). Heterozygous patients displayed intermediate values,\n",
      "not significantly different from those in either the ins/ins\n",
      "or del/del homozygous patients (mean 5.77% ± 0.78). The\n",
      "percentage of Treg correlated positively with the levels of\n",
      "expression of surface HLA-G on CLL cells (n=33, rho=0.4,\n",
      "P=0.04,  Spearman  correlation  test),  suggesting  that  the\n",
      "amount of HLA-G expressed by leukemic cells could influ-\n",
      "ence the frequency of Treg (Figure 3D). In line with this\n",
      "observation was the finding that the percentage of circu-\n",
      "lating Treg was higher in cases of CLL with surface HLA-\n",
      "G expression >9.5% (third quartile) than in CLL in which\n",
      "\n",
      "HLA-G polymorphism in CLL\n",
      "\n",
      "surface  HLA-G  expression  was  <9.5%  (mean  6.95%  ±\n",
      "0.98 versus mean 4.31% ± 0.52, P=0.03, Mann-Whitney U\n",
      "test; Figure 3E).\n",
      "\n",
      "No statistically significant correlation could be detected\n",
      "between sHLA-G levels and the frequency of Treg, likely\n",
      "due to the limited sample analyzed (n=13, data not shown).\n",
      "However,  CLL  patients  in  whom  sHLA-G  levels  were\n",
      ">31.75 ng/mL (third quartile) tended to have a higher per-\n",
      "centage  of  Treg  than  patients  in  whom  sHLA-G  levels\n",
      "were <31.75 ng/mL (mean 5.1% ± 1.44 versus mean 3.37%\n",
      "±  0.52,  P=0.30,  Mann-Whitney  test,  Figure  3F).Together,\n",
      "these data suggest that HLA-G expression is linked to an\n",
      "expansion of Treg, as partly observed in other models.29\n",
      "Effects of the HLA-G polymorphism on natural\n",
      "killer cell function\n",
      "\n",
      "An alternative mechanism through which HLA-G mole-\n",
      "cules  suppress  the  immune  response  is  their  inhibitory\n",
      "effect on NK cell activation and cytotoxic functions, medi-\n",
      "ated  through  the  KIR2DL4  ligand.11 We,  therefore,  ana-\n",
      "lyzed  the  possible  implication  of  sHLA-G  molecules  in\n",
      "plasma samples on composition, activation and functional\n",
      "activities of NK cells in CLL samples. The reference con-\n",
      "trol was represented by healthy individuals matched for\n",
      "gender and age. \n",
      "\n",
      "The  number  of  circulating  NK  cells \n",
      "\n",
      "(gated  as\n",
      "CD56+/CD3-) was sharply decreased in CLL patients (n=9,\n",
      "mean 2.53% ± 0.88) as compared to controls (n=11, mean\n",
      "11.52% ± 1.22, P<0.0001, Mann-Whitney test, Figure 4A). \n",
      "The  cytolytic  activity  of  NK  cells  isolated  from  CLL\n",
      "patients (n=9) was tested after culture for 2-4 weeks in the\n",
      "presence  of  interleukin-2.  Cells  were  then  assessed  for\n",
      "their ability to lyse the K562 target cell line in a 51Cr-release\n",
      "cytolytic  assay  at  different  effector:target  (E:T)  ratios\n",
      "\n",
      "A\n",
      "\n",
      "100\n",
      "\n",
      "n=60\n",
      "\n",
      "B\n",
      "\n",
      "P=0.003\n",
      "\n",
      "C\n",
      "\n",
      "100\n",
      "\n",
      "P=0.015\n",
      "\n",
      "n=27\n",
      "\n",
      "P<0.0001\n",
      "\n",
      "100\n",
      "\n",
      "<31.75 ng/mL\n",
      ">31.75 ng/mL\n",
      "\n",
      ")\n",
      "L\n",
      "m\n",
      "/\n",
      "g\n",
      "n\n",
      "(\n",
      " \n",
      "G\n",
      "-\n",
      "A\n",
      "L\n",
      "H\n",
      " \n",
      "e\n",
      "b\n",
      "u\n",
      "o\n",
      "S\n",
      "\n",
      "l\n",
      "\n",
      "l\n",
      "\n",
      "80\n",
      "\n",
      "60\n",
      "\n",
      "40\n",
      "\n",
      "20\n",
      "\n",
      "0\n",
      "\n",
      "75\n",
      "\n",
      "50\n",
      "\n",
      "25\n",
      "\n",
      "0\n",
      "\n",
      "CLL \n",
      "\n",
      "controls\n",
      "\n",
      ")\n",
      "L\n",
      "m\n",
      "/\n",
      "g\n",
      "n\n",
      "(\n",
      " \n",
      "G\n",
      "-\n",
      "A\n",
      "L\n",
      "H\n",
      " \n",
      "e\n",
      "b\n",
      "u\n",
      "o\n",
      "S\n",
      "\n",
      "l\n",
      "\n",
      "l\n",
      "\n",
      "D\n",
      "\n",
      "n=18\n",
      "\n",
      "n=15\n",
      "\n",
      "del/del\n",
      "\n",
      "ins/del\n",
      "\n",
      "ins/ins\n",
      "\n",
      "HLA-G genotype\n",
      "\n",
      ")\n",
      "L\n",
      "m\n",
      "/\n",
      "g\n",
      "n\n",
      "(\n",
      " \n",
      "G\n",
      "-\n",
      "A\n",
      "L\n",
      "H\n",
      " \n",
      "e\n",
      "b\n",
      "u\n",
      "o\n",
      "S\n",
      "\n",
      "l\n",
      "\n",
      "l\n",
      "\n",
      "100\n",
      "\n",
      "80\n",
      "\n",
      "60\n",
      "\n",
      "40\n",
      "\n",
      "20\n",
      "\n",
      "0\n",
      "\n",
      "n=60\n",
      "rho=0.4\n",
      "P=0.003\n",
      "80\n",
      "\n",
      "0\n",
      "\n",
      "20\n",
      "\n",
      "40\n",
      "\n",
      "HLA-G (%)\n",
      "\n",
      "60\n",
      "\n",
      "s\n",
      "t\n",
      "n\n",
      "e\n",
      "i\n",
      "t\n",
      "a\n",
      "p\n",
      "\n",
      " \n",
      "f\n",
      "o\n",
      "%\n",
      "\n",
      " \n",
      "\n",
      "E\n",
      "\n",
      ")\n",
      "L\n",
      "m\n",
      "/\n",
      "g\n",
      "n\n",
      "(\n",
      " \n",
      "G\n",
      "-\n",
      "A\n",
      "L\n",
      "H\n",
      " \n",
      "e\n",
      "b\n",
      "u\n",
      "o\n",
      "S\n",
      "\n",
      "l\n",
      "\n",
      "l\n",
      "\n",
      "75\n",
      "\n",
      "50\n",
      "\n",
      "25\n",
      "\n",
      "0\n",
      "\n",
      "80\n",
      "\n",
      "60\n",
      "\n",
      "40\n",
      "\n",
      "20\n",
      "\n",
      "0\n",
      "\n",
      "del/del\n",
      "\n",
      "ins/del\n",
      "\n",
      "ins/ins\n",
      "\n",
      "HLA-G genotype\n",
      "\n",
      "P=0.001\n",
      "\n",
      "n=60\n",
      "\n",
      "n=60\n",
      "\n",
      "sHLA-G1 sHLA-G5\n",
      "\n",
      "Figure 2. Quantification of soluble HLA-G\n",
      "levels  in  a  cohort  of  60  CLL  patients\n",
      "typed  for  the  14  bp  polymorphism.  (A)\n",
      "Box  plot  analysis  summarizing  data\n",
      "obtained  with  a  quantitative  ELISA  per-\n",
      "formed on 60 plasma samples from CLL\n",
      "patients  and  60  plasma  samples  from\n",
      "control subjects (controls). The lower and\n",
      "upper  limits  of  the  box  define  the  first\n",
      "and  third  quartiles,  respectively,  while\n",
      "the  line  inside  the  box  represents  the\n",
      "median. Whiskers identify minimum and\n",
      "maximum values. (B) Graph showing sol-\n",
      "uble HLA-G levels in CLL patients divided\n",
      "according  to  the  14  bp  polymorphism\n",
      "into  del/del,  ins/del  and  ins/ins  cate-\n",
      "gories.  (C)  Graph  representing  the  per-\n",
      "centages of CLL patients expressing sol-\n",
      "uble HLA-G above (black bars) or below\n",
      "(open  bars)  the  third  quartile  (31.75\n",
      "ng/mL)  in  the  three  genotypes.  (D)\n",
      "Regression lines showing a positive cor-\n",
      "relation between the percentage of CLL\n",
      "cells  expressing  HLA-G  on  the  cell  sur-\n",
      "face and the amount of soluble HLA-G in\n",
      "the  plasma.  Spearman  coefficient  (rho)\n",
      "and  the  corresponding  P value  are  pro-\n",
      "vided. (E) Box plot showing the results of\n",
      "an ELISA using isoform-specific antibod-\n",
      "ies to discriminate between soluble HLA-\n",
      "G1 (derived from shedding of the mem-\n",
      "brane form) and soluble HLA-G5 (derived\n",
      "from alternative splicing).\n",
      "\n",
      "haematologica | 2014; 99(5)\n",
      "\n",
      "891\n",
      "\n",
      "\f",
      "R. Rizzo et al.\n",
      "\n",
      "A\n",
      "\n",
      "s\n",
      "l\n",
      "l\n",
      "e\n",
      "c\n",
      " \n",
      "\n",
      "T\n",
      "\n",
      "+\n",
      "\n",
      "4\n",
      "D\n",
      "C\n",
      "\n",
      " \n",
      "f\n",
      "o\n",
      "%\n",
      "\n",
      " \n",
      "\n",
      "D\n",
      "\n",
      "s\n",
      "\n",
      "l\n",
      "l\n",
      "\n",
      "e\n",
      "c\n",
      " \n",
      "\n",
      "g\n",
      "e\n",
      "r\n",
      "T\n",
      "%\n",
      "\n",
      " \n",
      "\n",
      "20\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "0\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "0\n",
      "\n",
      "0\n",
      "\n",
      "B\n",
      "\n",
      "10\n",
      "\n",
      "s\n",
      "l\n",
      "l\n",
      "e\n",
      "c\n",
      " \n",
      "\n",
      "T\n",
      "\n",
      "+\n",
      "\n",
      "8\n",
      "D\n",
      "C\n",
      "\n",
      " \n",
      "f\n",
      "o\n",
      "%\n",
      "\n",
      " \n",
      "\n",
      "8\n",
      "\n",
      "6\n",
      "\n",
      "4\n",
      "\n",
      "2\n",
      "\n",
      "0\n",
      "\n",
      "E\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "s\n",
      "\n",
      "l\n",
      "l\n",
      "\n",
      "e\n",
      "c\n",
      " \n",
      "\n",
      "g\n",
      "e\n",
      "r\n",
      "T\n",
      "%\n",
      "\n",
      " \n",
      "\n",
      "n=16\n",
      "\n",
      "n=24\n",
      "\n",
      "n=12\n",
      "\n",
      "del/del\n",
      "\n",
      "ins/del\n",
      "\n",
      "ins/ins\n",
      "\n",
      "HLA-G genotype\n",
      "\n",
      "P=0.032\n",
      "\n",
      "n=8\n",
      "\n",
      "n=21\n",
      "\n",
      "0\n",
      "membrane HLA-G (%)\n",
      "\n",
      ">9.5\n",
      "\n",
      "<9.5\n",
      "\n",
      "C\n",
      "\n",
      "s\n",
      "l\n",
      "l\n",
      "e\n",
      "c\n",
      " \n",
      "\n",
      "g\n",
      "e\n",
      "r\n",
      "T\n",
      "%\n",
      "\n",
      " \n",
      "\n",
      "F\n",
      "\n",
      "s\n",
      "\n",
      "l\n",
      "l\n",
      "\n",
      "e\n",
      "c\n",
      " \n",
      "\n",
      "g\n",
      "e\n",
      "r\n",
      "T\n",
      "%\n",
      "\n",
      " \n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "0\n",
      "\n",
      "8\n",
      "\n",
      "6\n",
      "\n",
      "4\n",
      "\n",
      "2\n",
      "\n",
      "0\n",
      "\n",
      "P=0.006\n",
      "\n",
      "P=0.45\n",
      "\n",
      "n=13\n",
      "\n",
      "n=9\n",
      "\n",
      "n=6\n",
      "\n",
      "del/del\n",
      "\n",
      "ins/del\n",
      "\n",
      "ins/ins\n",
      "\n",
      "HLA-G genotype\n",
      "\n",
      "P=0.30\n",
      "\n",
      "n=4\n",
      "\n",
      "n=9\n",
      "\n",
      ">31.75\n",
      "\n",
      "<31.75\n",
      "\n",
      "soluble HLA-G (ng/mL)\n",
      "\n",
      "n=16\n",
      "\n",
      "n=24\n",
      "\n",
      "n=12\n",
      "\n",
      "del/del\n",
      "\n",
      "ins/del\n",
      "\n",
      "ins/ins\n",
      "\n",
      "HLA-G genotype\n",
      "\n",
      "n=33\n",
      "rho=0.4\n",
      "P=0.04\n",
      "5\n",
      "20\n",
      "membrane HLA-G (%)\n",
      "\n",
      "10\n",
      "\n",
      "15\n",
      "\n",
      "25\n",
      "\n",
      "Figure 3. Evaluation of the T-cell compartment in CLL patients typed for the 14 bp polymorphism. Percentage of total CD4+ (A) and CD8+ (B)\n",
      "circulating  T  lymphocytes  and  Treg  (C)  in  CLL  patients  divided  according  to  the  14  bp  polymorphism.  Treg  were  defined  as\n",
      "CD4+/CD25high/CD127low. (D) Regression line showing a positive correlation between membrane HLA-G and the percentage of circulating Treg.\n",
      "Spearman coefficient (rho) and the corresponding P values are provided. (E) Percentage of Treg in CLL patients expressing membrane HLA-G\n",
      "above or below the third quartile (9.5%). (F) Percentage of Treg in CLL patients expressing soluble HLA-G above or below the third quartile\n",
      "(31.75 mg/mL).\n",
      "\n",
      "(from 40:1 to 0.25:1). Controls were interleukin-2-activat-\n",
      "ed NK cells from healthy donors. As shown in Figure 4B,\n",
      "the  NK-cell-mediated  cytolytic  activity  in  CLL  patients\n",
      "was lower than that in healthy donors. Thus, for example,\n",
      "40% target cell lysis was obtained at an E:T ratio of 2.5:1\n",
      "from  healthy  donors  and  at  20:1  for  NK  cells  from  CLL\n",
      "patients (Figure 4B). \n",
      "\n",
      "We next asked whether KIR2DL4, the main HLA-G lig-\n",
      "and,30 was expressed by NK cells. While resting NK cells\n",
      "from  normal  donors  and  from  CLL  patients  lacked\n",
      "KIR2DL4,  the  ligand  was  induced  upon  interleukin-2-\n",
      "mediated NK cell activation, in agreement with published\n",
      "data30 (Figure  4C).  Representative  expression  plots  are\n",
      "reported in Online Supplementary Figure S2, showing results\n",
      "from an experiment in which decidual NK cells were used\n",
      "as  a  positive  control.  No  differential  expression  in\n",
      "KIR2DL4  was  noted  in  HLA-G  typed  patients  (data  not\n",
      "shown). The next step was to test whether sHLA-G present\n",
      "in plasma could induce apoptosis or inhibit the cytolytic\n",
      "function  of  NK  cells  obtained  from  normal  donors.  To\n",
      "answer this question, we used plasma from CLL patients\n",
      "containing different levels of sHLA-G to interfere with the\n",
      "\n",
      "viability  and  cytotoxic  activity  of  NK  cells.  Plasma  from\n",
      "CLL  patients  significantly  compromised  the  viability  of\n",
      "NK cells from normal donors, by inducing apoptosis. The\n",
      "effect was directly correlated to sHLA-G levels in plasma,\n",
      "with  significantly  lower  survival  of  the  NK  cells  when\n",
      "exposed  to  plasma  from  patients  with  sHLA-G  >31.75\n",
      "ng/mL as compared to plasma from patients with unde-\n",
      "tectable sHLA-G (Figure 4D).\n",
      "\n",
      "Similarly, NK cell function was significantly impaired in\n",
      "the  presence  of  CLL  plasma  samples  with  detectable\n",
      "sHLA-G (P<0.0001, Mann-Whitney test, Figure 4E). At an\n",
      "E:T  ratio  of  10:1  donor  NK  cells  in  the  absence  of  CLL\n",
      "plasma  efficiently  killed  target  cells  (mean  85%  ±  1.63),\n",
      "while  in  the  presence  of  CLL  plasma  samples  with\n",
      "detectable  sHLA-G,  the  cytolytic  activity  was  sharply\n",
      "reduced (mean 27.38% ± 4.72). CLL plasma samples with\n",
      "no sHLA-G were used as the control. The presence of NK\n",
      "cell inhibition also in the presence of CLL plasma samples\n",
      "with undetectable sHLA-G suggests the presence of other\n",
      "factors implicated in NK cell activation control. However,\n",
      "the degree of inhibition correlated with the concentrations\n",
      "of sHLA-G (Figure 4F). There was an inverse correlation\n",
      "\n",
      "892\n",
      "\n",
      "haematologica | 2014; 99(5)\n",
      "\n",
      "\f",
      "P<0.0001\n",
      "\n",
      "n=11\n",
      "\n",
      "n=9\n",
      "\n",
      "CLL\n",
      "\n",
      "controls\n",
      "\n",
      "20\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "0\n",
      "\n",
      "B\n",
      "\n",
      "s\n",
      "i\n",
      "s\n",
      "y\n",
      "l\n",
      " \n",
      "l\n",
      "l\n",
      "e\n",
      "c\n",
      " \n",
      "f\n",
      "o\n",
      "%\n",
      "\n",
      " \n",
      "\n",
      "100\n",
      "\n",
      "80\n",
      "\n",
      "60\n",
      "\n",
      "40\n",
      "\n",
      "20\n",
      "\n",
      "0\n",
      "\n",
      "controls\n",
      "CLL\n",
      "\n",
      "C\n",
      "\n",
      "s\n",
      "l\n",
      "l\n",
      "e\n",
      "c\n",
      " \n",
      "K\n",
      "N\n",
      "n\n",
      "o\n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      "o\n",
      "i\n",
      "t\n",
      "a\n",
      "r\n",
      " \n",
      "I\n",
      "F\n",
      "M\n",
      "4\n",
      "L\n",
      "D\n",
      "2\n",
      "R\n",
      "K\n",
      "\n",
      "I\n",
      "\n",
      " \n",
      "\n",
      "1\n",
      "\n",
      ":\n",
      "\n",
      "0\n",
      "4\n",
      "\n",
      "1\n",
      "\n",
      ":\n",
      "\n",
      "0\n",
      "2\n",
      "\n",
      "1\n",
      "\n",
      ":\n",
      "\n",
      "0\n",
      "1\n",
      "\n",
      "1\n",
      "\n",
      ":\n",
      "\n",
      "5\n",
      "\n",
      "1\n",
      "\n",
      ":\n",
      "\n",
      "5\n",
      "2\n",
      "\n",
      "1\n",
      "\n",
      ":\n",
      "\n",
      "5\n",
      "2\n",
      "\n",
      ".\n",
      "\n",
      "1\n",
      "\n",
      "1\n",
      "\n",
      ":\n",
      "\n",
      "5\n",
      "\n",
      ".\n",
      "\n",
      "0\n",
      "\n",
      "1\n",
      "\n",
      ":\n",
      "\n",
      "5\n",
      "2\n",
      "\n",
      ".\n",
      "\n",
      "0\n",
      "\n",
      "E:T ratio\n",
      "\n",
      "HLA-G polymorphism in CLL\n",
      "\n",
      "3\n",
      "\n",
      "2\n",
      "\n",
      "1\n",
      "\n",
      "0\n",
      "\n",
      "P=0.01\n",
      "\n",
      "n=10\n",
      "\n",
      "n=10\n",
      "\n",
      "day 0\n",
      "\n",
      "day 7\n",
      "+ IL-2\n",
      "\n",
      "P<0.0001\n",
      "\n",
      "100\n",
      "\n",
      "P<0.0001\n",
      "\n",
      "P=0.009\n",
      "\n",
      "n=7\n",
      "<0 ng/mL >25 ng/mL\n",
      "\n",
      "sHLA-G\n",
      "\n",
      "no\n",
      "\n",
      "plasma\n",
      "\n",
      "E\n",
      "\n",
      "s\n",
      "\n",
      "i\n",
      "\n",
      "s\n",
      "y\n",
      "\n",
      "l\n",
      " \n",
      "l\n",
      "l\n",
      "\n",
      "e\n",
      "c\n",
      " \n",
      "f\n",
      "o\n",
      "%\n",
      "\n",
      " \n",
      "\n",
      "P<0.0001\n",
      "\n",
      "100\n",
      "\n",
      "n=7\n",
      "\n",
      "F\n",
      "\n",
      "100\n",
      "\n",
      "P=0.001\n",
      "\n",
      "P=0.001\n",
      "\n",
      "n=7\n",
      "\n",
      "80\n",
      "\n",
      "60\n",
      "\n",
      "40\n",
      "\n",
      "20\n",
      "\n",
      "0\n",
      "\n",
      "n=12\n",
      "\n",
      "no\n",
      "\n",
      "plasma\n",
      "\n",
      "sHLA-G\n",
      "\n",
      "s\n",
      "\n",
      "i\n",
      "\n",
      "s\n",
      "y\n",
      "\n",
      "l\n",
      " \n",
      "l\n",
      "l\n",
      "\n",
      "e\n",
      "c\n",
      " \n",
      "f\n",
      "o\n",
      "%\n",
      "\n",
      " \n",
      "\n",
      "80\n",
      "\n",
      "60\n",
      "\n",
      "40\n",
      "\n",
      "20\n",
      "\n",
      "0\n",
      "\n",
      "P=0.002\n",
      "\n",
      "n=6\n",
      "\n",
      "n=6\n",
      "\n",
      "no\n",
      "\n",
      "plasma\n",
      "\n",
      "<0 ng/mL >25 ng/mL\n",
      "\n",
      "sHLA-G\n",
      "\n",
      "100\n",
      "\n",
      "P<0.0001\n",
      "\n",
      "80\n",
      "\n",
      "60\n",
      "\n",
      "40\n",
      "\n",
      "20\n",
      "\n",
      "0\n",
      "\n",
      "del/del\n",
      "\n",
      "ins/del\n",
      "\n",
      "ins/ins\n",
      "\n",
      "H\n",
      "\n",
      "n\n",
      "o\n",
      "i\n",
      "t\n",
      "i\n",
      "b\n",
      "h\n",
      "n\n",
      "\n",
      "i\n",
      "\n",
      "i\n",
      " \n",
      "s\n",
      "s\n",
      "y\n",
      "\n",
      "i\n",
      "\n",
      "l\n",
      " \n",
      "\n",
      "%\n",
      "\n",
      "A\n",
      "\n",
      "s\n",
      "l\n",
      "l\n",
      "e\n",
      "c\n",
      " \n",
      "K\n",
      "N\n",
      "\n",
      "-\n",
      "\n",
      "3\n",
      "D\n",
      "C\n",
      "\n",
      "/\n",
      "\n",
      "+\n",
      "\n",
      "6\n",
      "5\n",
      "D\n",
      "C\n",
      "\n",
      " \n",
      "f\n",
      "o\n",
      "%\n",
      "\n",
      " \n",
      "\n",
      "D\n",
      "\n",
      "80\n",
      "\n",
      "60\n",
      "\n",
      "40\n",
      "\n",
      "20\n",
      "\n",
      "0\n",
      "\n",
      "y\n",
      "t\n",
      "i\n",
      "l\n",
      "i\n",
      "\n",
      "b\n",
      "a\n",
      "\n",
      "i\n",
      "\n",
      "v\n",
      " \n",
      "%\n",
      "\n",
      "G\n",
      "\n",
      "n=22\n",
      "rho=-0.49\n",
      "P=0.02\n",
      "\n",
      "60\n",
      "\n",
      "40\n",
      "\n",
      "20\n",
      "\n",
      ")\n",
      "L\n",
      "m\n",
      "/\n",
      "g\n",
      "n\n",
      "(\n",
      " \n",
      "G\n",
      "-\n",
      "A\n",
      "L\n",
      "H\n",
      " \n",
      "e\n",
      "b\n",
      "u\n",
      "o\n",
      "S\n",
      "\n",
      "l\n",
      "\n",
      "l\n",
      "\n",
      "0\n",
      "\n",
      "0\n",
      "\n",
      "20\n",
      "\n",
      "40\n",
      "\n",
      "60\n",
      "\n",
      "80\n",
      "\n",
      "100\n",
      "\n",
      "Figure 4. Evaluation of the NK cell compartment in CLL patients typed for the 14 bp polymorphism. (A) Percentage of circulating CD56+/CD3-\n",
      "NK cells in seven CLL patients and in 11 healthy donors (controls) with a comparable age and male:female ratio. (B)  51Cr cytotoxicity assay\n",
      "comparing the lytic potential of in vitro interleukin-2-activated NK cells from controls (circles) or CLL patients (squares) against the K562 target\n",
      "cell line. (C) Expression of KIR2DL4 in resting and interleukin-2-activated NK cells from CLL patients. Data are expressed as mean fluorescence\n",
      "intensity (MFI) ratio. (D) Percentage of NK cell viability in the presence of sHLA-G-high and sHLA-G-low plasma from CLL patients. (E) Inhibition\n",
      "of cytolytic activity of interleukin-2-activated HD-NK cells against K562 target cells in the presence or absence of plasma obtained from CLL\n",
      "patients. (F) The inhibitory effect of CLL plasma on NK cell lysis was studied in patients with high levels of soluble HLA-G and compared to that\n",
      "in patients with undetectable soluble HLA-G. (G) Regression line showing a negative correlation between the amount of soluble HLA-G and the\n",
      "percentage of cell lysis. Spearman coefficient (rho) and the corresponding P value are provided. (H) Graph representing the percentage of NK\n",
      "cell lysis inhibition obtained using plasma derived from patients categorized on the basis of HLA-G genotype. \n",
      "\n",
      "haematologica | 2014; 99(5)\n",
      "\n",
      "893\n",
      "\n",
      "\f",
      "R. Rizzo et al.\n",
      "\n",
      "between sHLA-G levels in CLL plasma samples (n=22) and\n",
      "the cytolytic activity of NK cells expressed as percentage\n",
      "cell  lysis  (rho=  –0.49,  P=0.02,  Spearman  correlation  test,\n",
      "Figure 4G). Consistent with the notion that CLL patients\n",
      "with del/del polymorphism have higher levels of sHLA-G\n",
      "compared  to  the  levels  in  patients  with  the  other  geno-\n",
      "types, plasma from del/del patients showed greater inhibi-\n",
      "tion than plasma from patients with the other genotypes.\n",
      "Thus, at an E:T ratio of 10:1, del/del plasma inhibited NK\n",
      "cell  lysis  by  57.9%,  while  the  effects  exerted  by  ins/del\n",
      "and  ins/ins  plasma  were  35.8%  and  5.3%,  respectively\n",
      "(P<0.0001, Fisher exact test, Figure 4H). \n",
      "Proof-of-principle: the HLA-G 14 bp polymorphism\n",
      "influences survival of patients with chronic \n",
      "lymphocytic leukemia\n",
      "\n",
      "The results obtained so far indicate that the HLA-G 14\n",
      "bp polymorphism dictates the amount of HLA-G protein\n",
      "present  on  the  cell  surface  and  in  the  plasma  of  CLL\n",
      "patients and that the molecule quantitatively and qualita-\n",
      "tively modulates T and NK immunocompetence. In con-\n",
      "sideration of the immunosuppressive features of HLA-G,\n",
      "patients characterized by a del/del genotype would have\n",
      "higher  levels  of  HLA-G,  would  be  more  immunosup-\n",
      "pressed  and  ultimately  have  a  worse  clinical  outcome.\n",
      "This issue was approached by testing the frequency of the\n",
      "HLA-G 14 bp polymorphism in 506 CLL patients (Online\n",
      "Supplementary Table S1). The genotype frequencies were in\n",
      "Hardy-Weinberg  equilibrium:  176/506  patients  (34.8%)\n",
      "were  del/del  homozygous,  81/506  (16%)  were  ins/ins\n",
      "homozygous  and  the  remaining  249/506  (49.2%)  were\n",
      "ins/del heterozygous. None of the demographic (age and\n",
      "sex),  clinical  (disease  stage,  splenomegaly,  lymph  node\n",
      "size), laboratory (lactate dehydrogenase or β2-microglobu-\n",
      "lin  levels),  or  molecular  variables  (CD38,  ZAP-70,  IGHV\n",
      "mutational  status,  chromosomal  aberrations)  showed  a\n",
      "preferential  association  with  the  HLA-G polymorphism\n",
      "(Online Supplementary Table S1). According to the survival\n",
      "analysis,  patients  harboring  the  del/del  genotype  had  a\n",
      "shorter  survival  than  patients  harboring  the  ins/del  or\n",
      "ins/ins  genotype  (P=0.027,  log-rank  test,  Figure  5A).\n",
      "Consistently, CLL patients with sHLA-G levels above the\n",
      "third quartile had a shorter survival (median, 63.9 months)\n",
      "than patients with sHLA-G levels below the third quartile\n",
      "(median, 71.5 months, P=0.0215, log-rank test; Figure 5B),\n",
      "and CLL patients with plasma samples showing inhibitory\n",
      "effects  on  NK  cells  showed  a  trend  towards  having  a\n",
      "shorter  survival  than  patients  whose  plasma  lacked\n",
      "inhibitory effects (P=0.147, log-rank test, data not shown). \n",
      "\n",
      "Discussion\n",
      "\n",
      "HLA-G  is  a  non-classical  HLA  protein  that  works  by\n",
      "modulating the main functions of NK cells and Treg. HLA-\n",
      "G-mediated signals are critical in mediating tolerance dur-\n",
      "ing specific ontogenetic moments (e.g., pregnancy). HLA-\n",
      "G may be expressed by tumor cells as part of a strategy to\n",
      "evade the action of the innate and adaptive immune sys-\n",
      "tem.\n",
      "\n",
      "To test whether this may happen in CLL cells, HLA-G\n",
      "expression was assessed in a large cohort of CLL patients\n",
      "with well-defined molecular and clinical characteristics for\n",
      "whom survival data available. The originality of this work\n",
      "is that the analyses of surface or sHLA-G expression were\n",
      "\n",
      "A\n",
      "\n",
      "100\n",
      "\n",
      ")\n",
      "\n",
      "%\n",
      "\n",
      "(\n",
      " \n",
      "\n",
      "i\n",
      "\n",
      "i\n",
      "\n",
      "g\n",
      "n\n",
      "v\n",
      "v\n",
      "r\n",
      "u\n",
      "s\n",
      " \n",
      "\n",
      "n\n",
      "o\n",
      "i\n",
      "t\n",
      "r\n",
      "o\n",
      "p\n",
      "o\n",
      "r\n",
      "P\n",
      "\n",
      "HLA-G ins/del ins/ins\n",
      "\n",
      "HLA-G del/del\n",
      "\n",
      "80\n",
      "\n",
      "60\n",
      "\n",
      "40\n",
      "\n",
      "20\n",
      "\n",
      "0\n",
      "\n",
      "n=506\n",
      "P=0.027\n",
      "\n",
      "0 24 48 72 96 120 144 168 192 216 240 264 288 312\n",
      "\n",
      "Months\n",
      "\n",
      "B\n",
      "\n",
      "100\n",
      "\n",
      ")\n",
      "\n",
      "%\n",
      "\n",
      "(\n",
      " \n",
      "\n",
      "g\n",
      "n\n",
      "v\n",
      "\n",
      "i\n",
      "\n",
      "i\n",
      "\n",
      "v\n",
      "r\n",
      "u\n",
      "s\n",
      " \n",
      "\n",
      "n\n",
      "o\n",
      "i\n",
      "t\n",
      "r\n",
      "o\n",
      "p\n",
      "o\n",
      "r\n",
      "P\n",
      "\n",
      "80\n",
      "\n",
      "60\n",
      "\n",
      "40\n",
      "\n",
      "20\n",
      "\n",
      "0\n",
      "\n",
      "sHLA-G >31.75 ng/mL\n",
      "\n",
      "sHLA-G >31.75 ng/mL\n",
      "\n",
      "n=109\n",
      "P=0.021\n",
      "\n",
      "0 24 48 72 96 120144 168 192 216 240 264 288 312 336\n",
      "\n",
      "Months\n",
      "\n",
      "Figure  5.  Kaplan-Meier  curves  showing  overall  survival  in  506  CLL\n",
      "patients. (A) Kaplan-Meier estimates of overall survival according to\n",
      "HLA-G 14 bp genotype. (B) Kaplan-Meier estimates of overall survival\n",
      "according to soluble HLA-G levels. \n",
      "\n",
      "accompanied  by  characterization  of  the  14  bp  polymor-\n",
      "phism in the 3’ untranslated region. This choice was dic-\n",
      "tated by evidence derived from different models indicat-\n",
      "ing  that  this  polymorphism  accurately  predicts  the\n",
      "amount of transcribed protein, either bound to the mem-\n",
      "brane or released into biological fluids.\n",
      "\n",
      "Our results indicate an association between the del/del\n",
      "genotype  and  increased  levels  of  plasma  HLA-G  mole-\n",
      "cules. This association is apparent only in CLL patients, as\n",
      "plasma from age- and sex-matched controls failed to show\n",
      "a  statistically  significant  association  between  the  del/del\n",
      "genotype and the amount of plasma HLA-G. \n",
      "\n",
      "The  situation  on  the  cell  membrane  is  less  defined:\n",
      "del/del patients more frequently expressed higher levels of\n",
      "the  molecule,  although  statistical  significance  was  not\n",
      "reached. A potential explanation for this finding lies in the\n",
      "relative  instability  of  HLA-G  molecules  on  the  CLL  cell\n",
      "membrane. Results showing a correlation between mem-\n",
      "brane and sHLA-G levels support the view that the main\n",
      "mechanism  of  generation  of  sHLA-G  is  shedding  rather\n",
      "than alternative splicing. This was confirmed by an analy-\n",
      "sis of HLA-G isoforms, which demonstrated a dominance\n",
      "of sHLA-G1, generated by proteolytic cleavage of mem-\n",
      "\n",
      "894\n",
      "\n",
      "haematologica | 2014; 99(5)\n",
      "\n",
      "\f",
      "brane HLA-G1. No preference of isoform according to the\n",
      "14 bp polymorphism was noted, in agreement with previ-\n",
      "ously published data.31,32\n",
      "\n",
      "A reasonable hypothesis to explain this result is that the\n",
      "membrane  form  represents  a  transitory  step.  A  conse-\n",
      "quence is that quantification of soluble rather than surface\n",
      "HLA-G  may  be  more  accurate.  This  is  also  in  line  with\n",
      "previous studies, which found that sHLA-G levels in plas-\n",
      "ma  were  higher  in  CLL  patients  than  in  healthy  con-\n",
      "trols.17,18 A second issue favoring the view that quantifica-\n",
      "tion of soluble rather than membrane HLA-G is an inform-\n",
      "ative and dependable assay derives from old and new facts\n",
      "linked  to  the  unique  lipid  structure  of  the  CLL  cell  sur-\n",
      "face,33,34 potentially increasing the instability of the mem-\n",
      "brane  form.  In  agreement  with  this,  in  myeloma  cells\n",
      "mHLA-G  is  also  released  from  the  cell  membrane  in\n",
      "microparticles.35 These findings suggest that quantification\n",
      "of sHLA-G may be clinically useful and more informative\n",
      "than analysis of the surface of tumor cells. \n",
      "\n",
      "The second set of results obtained in this study may be\n",
      "considered as tiles creating a tolerogenic mosaic, in which\n",
      "HLA-G  molecules  represent  a  link  between  innate  and\n",
      "adaptive immunity. Accordingly, the presence of a del/del\n",
      "genotype (i.e., with high sHLA-G levels) is paralleled by an\n",
      "expansion of Treg in the circulation. Supportive data come\n",
      "from other models, in which HLA-G is reported to induce\n",
      "Treg. As an example, peripheral blood mononuclear cells\n",
      "exposed to sHLA-G5 acquire regulatory features, inhibit-\n",
      "ing  allo-proliferative  responses  exerted  by  other  T  lym-\n",
      "phocytes.  It  is  also  known  that  patients  receiving  com-\n",
      "bined liver/kidney transplants show high levels of sHLA-\n",
      "G5,  which  correlate  with  increased  percentages  of  sup-\n",
      "pressor T cells.36 Similarly, stem-cell transplanted patients\n",
      "have high levels of sHLA-G5 in the peripheral blood, with\n",
      "a simultaneous expansion of CD4+/CD25+/CD152+ T lym-\n",
      "phocytes with suppressive activity. Indirect confirmation\n",
      "in the CLL model may be deduced from data showing that\n",
      "an increase in Treg positively correlates with the presence\n",
      "of clinical and biological features of aggressive disease.37\n",
      "\n",
      "NK cells obtained from CLL patients have less cytotoxic\n",
      "activity  than  NK  cell  populations  obtained  from  healthy\n",
      "donors of a comparable age. This suggests that leukemic\n",
      "cells directly affect NK cell viability and/or activity. This\n",
      "would  be  achieved  through  binding  HLA-G  to  the\n",
      "KIR2DL4 ligand, which becomes expressed once NK cells\n",
      "are activated in the presence of interleukin-2. Our working\n",
      "hypothesis  is  that  ectopic  expression  of  HLA-G  con-\n",
      "tributes to block NK cell functions. With the aim of repro-\n",
      "ducing physiological conditions the experiments were per-\n",
      "formed  using  whole  plasma  instead  of  purified  HLA-G.\n",
      "The  assumption  was  confirmed  by  incubating  NK  cells\n",
      "obtained  from  normal  donors  with  plasma  from  CLL\n",
      "\n",
      "HLA-G polymorphism in CLL\n",
      "\n",
      "patients  containing  variable  amounts  of  sHLA-G.  This\n",
      "was followed by a marked induction of NK cell apoptosis,\n",
      "which was proportional to the amount of sHLA-G present\n",
      "in plasma. Furthermore, lysis inhibition was also propor-\n",
      "tional to the amount of sHLA-G. It is worth noting that\n",
      "CLL plasma samples with undetectable sHLA-G were able\n",
      "to induce moderate NK cell apoptosis and to reduce NK\n",
      "cell cytotoxicity. These results suggest the presence of fac-\n",
      "tors  other  than  sHLA-G  that  are  able  to  control  NK  cell\n",
      "activation in CLL. As expected, NK cell function of del/del\n",
      "patients was more impaired than that of ins/del or ins/ins\n",
      "patients. \n",
      "\n",
      "In  conclusion,  the  data  obtained  in  this  study  provide\n",
      "two different sets of information. The first one indicates\n",
      "that  the  14  bp  polymorphism  influences  quantitative\n",
      "analyses  of  sHLA-G.  The  amount  of  sHLA-G  in  plasma\n",
      "has a prognostic value, suggesting that this specific assay\n",
      "may  be  relevant  in  the  management  of  CLL  patients,\n",
      "rather than the mere measurement of membrane HLA-G.\n",
      "The  second  set  of  results  indicates  that  the  presence  of\n",
      "HLA-G molecules in the neoplastic environment, in either\n",
      "a soluble form or bound to the membrane, creates a favor-\n",
      "able setting for CLL expansion. As proof of this, evalua-\n",
      "tion of the impact of the 14 bp polymorphism on the clin-\n",
      "ical outcome of the disease showed that del/del patients\n",
      "have  a  poorer  overall  survival  than  do  either    ins/del  or\n",
      "ins/ins patients. \n",
      "\n",
      "Taken together, our results support the view that HLA-\n",
      "G molecules are part of the escape strategies designed by\n",
      "CLL  cells  and  indicate  that  a  quantitative  analysis  of\n",
      "sHLA-G levels may be of clinical relevance in the manage-\n",
      "ment of CLL patients.\n",
      "\n",
      "Funding\n",
      "Work  supported  by  grants  from  the  Italian  Ministries  of\n",
      "Education,  University  and  Research  (Futuro  in  Ricerca  2008  #\n",
      "RBFR08ATLH,  PRIN  2009  #  2009LMEEEH_002  e  #\n",
      "NANLST_001,  FIRB  2010  #  RBAP11FXBC-005),  Italian\n",
      "Ministry of Health (Bando Giovani Ricercatori 2008 # GR-2008-\n",
      "1138053),  Associazione  Italiana  per  la  Ricerca  sul  Cancro\n",
      "Foundation  (Special  Program  Molecular  Clinical  Oncology  5  x\n",
      "1000 N. 10007; My First AIRC Grant N. 13470 and IG 12754),\n",
      "Fondazione  Cariplo,  Compagnia  di  San  Paolo \n",
      "(N.\n",
      "PMN_call_2012_0071) and local funds of the University of Turin\n",
      "(ex-60%). \n",
      "\n",
      "The Fondazione Ricerca Molinette provided valuable assistance\n",
      "\n",
      "and support.\n",
      "\n",
      "Authorship and Disclosures\n",
      "Information on authorship, contributions, and financial & other\n",
      "disclosures was provided by the authors and is available with the\n",
      "online version of this article at www.haematologica.org.\n",
      "\n",
      "References\n",
      "\n",
      "1. Chiorazzi  N,  Rai  KR,  Ferrarini  M.  Chronic\n",
      "lymphocytic leukemia. N Engl J Med. 2005;\n",
      "352(8):804-15.\n",
      "\n",
      "2. Lotz M, Ranheim E, Kipps TJ. Transforming\n",
      "growth  factor  beta  as  endogenous  growth\n",
      "inhibitor of chronic lymphocytic leukemia B\n",
      "cells. J Exp Med. 1994;179(3):999-1004.\n",
      "\n",
      "3. Benjamin D, Park CD, Sharma V. Human B\n",
      "\n",
      "interleukin  10.  Leuk  Lymphoma.\n",
      "\n",
      "cell \n",
      "1994;12(3-4):205-10.\n",
      "\n",
      "4. Ramsay AG, Johnson AJ, Lee AM, Gorgun\n",
      "G, Le Dieu R, Blum W, et al. Chronic lym-\n",
      "phocytic  leukemia  T  cells  show  impaired\n",
      "immunological  synapse  formation  that  can\n",
      "be  reversed  with  an  immunomodulating\n",
      "drug. J Clin Invest. 2008;118(7):2427-37.\n",
      "\n",
      "5. Giannopoulos  K,  Schmitt  M,  Wlasiuk  P,\n",
      "Chen  J,  Bojarska-Junak  A,  Kowal  M,  et  al.\n",
      "The high frequency of T regulatory cells in\n",
      "\n",
      "patients  with  B-cell  chronic  lymphocytic\n",
      "leukemia  is  diminished  through  treatment\n",
      "with  thalidomide.  Leukemia.  2008;22(1):\n",
      "222-4.\n",
      "\n",
      "6. D'Arena G, D'Auria F, Simeon V, Laurenti L,\n",
      "Deaglio S, Mansueto G, et al. A shorter time\n",
      "to the first treatment may be predicted by\n",
      "the absolute number of regulatory T-cells in\n",
      "patients  with  Rai  stage  0  chronic  lympho-\n",
      "cytic \n",
      "J  Hematol.\n",
      "2012;87(6):628-31.\n",
      "\n",
      "leukemia.  Am \n",
      "\n",
      "haematologica | 2014; 99(5)\n",
      "\n",
      "895\n",
      "\n",
      "\f",
      "R. Rizzo et al.\n",
      "\n",
      "7. Serra S, Horenstein AL, Vaisitti T, Brusa D,\n",
      "Rossi  D,  Laurenti  L,  et  al.  CD73-generated\n",
      "extracellular  adenosine  in  chronic  lympho-\n",
      "cytic leukemia creates local conditions coun-\n",
      "teracting  drug-induced  cell  death.  Blood.\n",
      "2011;118(23):6141-52.\n",
      "\n",
      "8. Rizzo R, Bortolotti D, Baricordi OR, Fainardi\n",
      "E. New insights into HLA-G and inflamma-\n",
      "tory diseases. Inflamm Allergy Drug Targets.\n",
      "2012;11(6):448-63.\n",
      "\n",
      "9. Carosella  ED.  The  tolerogenic  molecule\n",
      "\n",
      "HLA-G. Immunol Lett. 2011;138(1):22-4.\n",
      "\n",
      "10. Shiroishi  M,  Tsumoto  K,  Amano  K,\n",
      "Shirakihara Y, Colonna M, Braud VM, et al.\n",
      "Human  inhibitory  receptors  Ig-like  tran-\n",
      "script 2 (ILT2) and ILT4 compete with CD8\n",
      "for MHC class I binding and bind preferen-\n",
      "tially  to  HLA-G.  Proc  Natl  Acad  Sci  USA.\n",
      "2003;100(15):8856-61.\n",
      "\n",
      "11. Rajagopalan  S,  Long  EO.  A  human  histo-\n",
      "compatibility  leukocyte  antigen  (HLA)-G-\n",
      "specific  receptor  expressed  on  all  natural\n",
      "killer cells. J Exp Med. 1999;189(7):1093-100.\n",
      "12. Du L, Xiao X, Wang C, Zhang X, Zheng N,\n",
      "Wang L, et al. Human leukocyte antigen-G is\n",
      "closely  associated  with  tumor  immune\n",
      "escape  in  gastric  cancer  by  increasing  local\n",
      "regulatory  T  cells.  Cancer  Sci.  2011;102(7):\n",
      "1272-80.\n",
      "\n",
      "13. Diaz-Lagares  A,  Alegre  E,  LeMaoult  J,\n",
      "Carosella ED, Gonzalez A. Nitric oxide pro-\n",
      "duces HLA-G nitration and induces metallo-\n",
      "protease-dependent  shedding  creating  a\n",
      "tolerogenic  milieu.  Immunology.  2009;126\n",
      "(3):436-45.\n",
      "\n",
      "14. Rizzo R, Rubini M, Govoni M, Padovan M,\n",
      "Melchiorri L, Stignani M, et al. HLA-G 14-bp\n",
      "polymorphism  regulates  the  methotrexate\n",
      "response \n",
      "arthritis.\n",
      "Pharmacogenet  Genomics.  2006;16(9):615-\n",
      "23.\n",
      "\n",
      "rheumatoid \n",
      "\n",
      "15. Hviid  TV,  Rizzo  R,  Christiansen  OB,\n",
      "Melchiorri  L,  Lindhard  A,  Baricordi  OR.\n",
      "HLA-G  and  IL-10  in  serum  in  relation  to\n",
      "HLA-G  genotype  and  polymorphisms.\n",
      "Immunogenetics. 2004;56(3):135-41.\n",
      "\n",
      "16. Rizzo R, Hviid TV, Stignani M, Balboni A,\n",
      "Grappa MT, Melchiorri L, et al. The HLA-G\n",
      "genotype  is  associated  with  IL-10  levels  in\n",
      "activated PBMCs. Immunogenetics. 2005;57\n",
      "(3-4):172-81.\n",
      "\n",
      "17. Amiot  L,  Le  Friec  G,  Sebti  Y,  Drenou  B,\n",
      "Pangault  C,  Guilloux  V,  et  al.  HLA-G  and\n",
      "lymphoproliferative \n",
      "Semin\n",
      "Cancer Biol. 2003;13(5):379-85.\n",
      "\n",
      "disorders. \n",
      "\n",
      "18. Sebti  Y,  Le  Friec  G,  Pangault  C,  Gros  F,\n",
      "\n",
      "in \n",
      "\n",
      "Drenou B, Guilloux V, et al. Soluble HLA-G\n",
      "molecules are increased in lymphoprolifera-\n",
      "tive disorders. Hum Immunol. 2003; 64(11):\n",
      "1093-101.\n",
      "\n",
      "19. Rezvany  MR,  Kazemi  A,  Hajifathali  A,\n",
      "Kaviani S, Mellstedt H. Analysis of HLA-G\n",
      "gene  expression  in  B-lymphocytes  from\n",
      "chronic lymphocytic leukemia patients. Iran\n",
      "Biomed J. 2007;11(2):125-9.\n",
      "\n",
      "20. Nuckel H, Rebmann V, Durig J, Duhrsen U,\n",
      "Grosse-Wilde H. HLA-G expression is asso-\n",
      "ciated  with  an  unfavorable  outcome  and\n",
      "immunodeficiency  in  chronic  lymphocytic\n",
      "leukemia. Blood. 2005;105(4):1694-8.\n",
      "\n",
      "21. Erikci AA, Karagoz B, Ozyurt M, Ozturk A,\n",
      "Kilic  S,  Bilgi  O.  HLA-G  expression  in  B\n",
      "chronic lymphocytic leukemia: a new prog-\n",
      "nostic  marker?  Hematology.  2009;14(2):\n",
      "101-5.\n",
      "\n",
      "22. Deaglio  S,  Vaisitti  T,  Bergui  L,  Bonello  L,\n",
      "Horenstein  AL,  Tamagnone  L,  et  al.  CD38\n",
      "and CD100 lead a network of surface recep-\n",
      "tors  relaying  positive  signals  for  B-CLL\n",
      "growth  and  survival.  Blood.  2005;105\n",
      "(8):3042-50.\n",
      "\n",
      "23. Hviid TV, Rizzo R, Melchiorri L, Stignani M,\n",
      "Baricordi  OR.  Polymorphism  in  the  5'\n",
      "upstream  regulatory  and  3'  untranslated\n",
      "regions of the HLA-G gene in relation to sol-\n",
      "uble  HLA-G  and  IL-10  expression.  Hum\n",
      "Immunol. 2006;67(1-2):53-62.\n",
      "\n",
      "24. Rizzo  R,  Bortolotti  D,  Fredj  NB,  Rotola  A,\n",
      "Cura F, Castellazzi M, et al. Role of HLA-G\n",
      "14bp deletion/insertion and +3142C>G poly-\n",
      "morphisms  in  the  production  of  sHLA-G\n",
      "molecules  in  relapsing-remitting  multiple\n",
      "sclerosis. Hum Immunol. 2012;73(11):1140-6.\n",
      "25. Rebmann  V,  LeMaoult  J,  Rouas-Freiss  N,\n",
      "Carosella \n",
      "H.\n",
      "Quantification and identification of soluble\n",
      "HLA-G  isoforms.  Tissue  Antigens.  2007;69\n",
      "(Suppl 1):143-9.\n",
      "\n",
      "Grosse-Wilde \n",
      "\n",
      "ED, \n",
      "\n",
      "26. Fainardi  E,  Rizzo  R,  Melchiorri  L,  Stignani\n",
      "M, Castellazzi M, Caniatti ML, et al. Soluble\n",
      "HLA-G  molecules  are  released  as  HLA-G5\n",
      "and not as soluble HLA-G1 isoforms in CSF\n",
      "of patients with relapsing-remitting multiple\n",
      "sclerosis.  J  Neuroimmunol.  2007;192(1-\n",
      "2):219-25.\n",
      "\n",
      "27. Vacca P, Martini S, Garelli V, Passalacqua G,\n",
      "Moretta  L,  Mingari  MC.  NK  cells  from\n",
      "malignant  pleural  effusions  are  not  anergic\n",
      "but  produce  cytokines  and  display  strong\n",
      "antitumor activity on short-term IL-2 activa-\n",
      "tion. Eur J Immunol. 2013;43(2):550-61.\n",
      "\n",
      "28. Vacca  P,  Cantoni  C,  Vitale  M,  Prato  C,\n",
      "\n",
      "Canegallo  F,  Fenoglio  D,  et  al.  Crosstalk\n",
      "between  decidual  NK  and  CD14+\n",
      "myelomonocytic cells results in induction of\n",
      "Tregs  and  immunosuppression.  Proc  Natl\n",
      "Acad Sci USA. 2010;107(26):11918-23.\n",
      "\n",
      "29. Castellaneta A, Mazariegos GV, Nayyar N,\n",
      "Zeevi  A,  Thomson  AW.  HLA-G  level  on\n",
      "monocytoid  dendritic  cells  correlates  with\n",
      "regulatory  T-cell  Foxp3  expression  in  liver\n",
      "transplant \n",
      "tolerance.  Transplantation.\n",
      "2011;91(10):1132-40.\n",
      "\n",
      "30. Rajagopalan S, Bryceson YT, Kuppusamy SP,\n",
      "Geraghty DE, van der Meer A, Joosten I, et\n",
      "al. Activation of NK cells by an endocytosed\n",
      "receptor  for  soluble  HLA-G.  PLoS  Biol.\n",
      "2006;4(1):e9.\n",
      "\n",
      "31. Hviid TV, Hylenius S, Rorbye C, Nielsen LG.\n",
      "HLA-G  allelic  variants  are  associated  with\n",
      "differences  in  the  HLA-G  mRNA  isoform\n",
      "profile \n",
      "and  HLA-G  mRNA \n",
      "levels.\n",
      "Immunogenetics. 2003;55(2):63-79.\n",
      "\n",
      "32. Svendsen SG, Hantash BM, Zhao L, Faber C,\n",
      "Bzorek M, Nissen MH, et al. The expression\n",
      "and functional activity of membrane-bound\n",
      "human leukocyte antigen-G1 are influenced\n",
      "by \n",
      "region.  Hum\n",
      "Immunol. 2013;74(7):818-27.\n",
      "\n",
      "the  3'-untranslated \n",
      "\n",
      "33. Daefler S, Krueger GR. Expression of prolif-\n",
      "eration  and  differentiation  antigens  in\n",
      "response to modulation of membrane fluid-\n",
      "ity  in  chronic  lymphocytic  leukemia  lym-\n",
      "phocytes. Anticancer Res. 1989;9(2):501-6.\n",
      "\n",
      "34. Herishanu Y, Kay S, Dezorella N, Baron S,\n",
      "Hazan-Halevy I, Porat Z, et al. Divergence in\n",
      "CD19-mediated signaling unfolds intraclon-\n",
      "al  diversity \n",
      "lymphocytic\n",
      "leukemia, which correlates with disease pro-\n",
      "gression. J Immunol. 2013;190(2):784-93.\n",
      "\n",
      "in  chronic \n",
      "\n",
      "T,  Gilliam  M, \n",
      "\n",
      "35. Kshirsagar SK, Alam SM, Jasti S, Hodes H,\n",
      "Nauser \n",
      "al.\n",
      "Immunomodulatory molecules are released\n",
      "from the first trimester and term placenta via\n",
      "exosomes. Placenta. 2012;33(12):982-90.\n",
      "\n",
      "36. Naji  A,  Le  Rond  S,  Durrbach  A,  Krawice-\n",
      "Radanne  I,  Creput  C,  Daouya  M,  et  al.\n",
      "CD3+CD4low  and  CD3+CD8low  are\n",
      "induced by HLA-G: novel human peripheral\n",
      "blood suppressor T-cell subsets involved in\n",
      "transplant  acceptance.  Blood.  2007;110(12):\n",
      "3936-48.\n",
      "\n",
      "37. D'Arena  G,  Laurenti  L,  Minervini  MM,\n",
      "Deaglio  S,  Bonello  L,  De  Martino  L,  et  al.\n",
      "Regulatory  T-cell  number  is  increased  in\n",
      "chronic lymphocytic leukemia patients and\n",
      "correlates  with  progressive  disease.  Leuk\n",
      "Res. 2011;35(3):363-8.\n",
      "\n",
      "et \n",
      "\n",
      "896\n",
      "\n",
      "haematologica | 2014; 99(5)\n",
      "\n",
      "\f",
      "\n"
     ]
    }
   ],
   "source": [
    "# extracting the text\n",
    "output_text_2 = path(path_to_pdf_2)\n",
    "print(output_text_2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "382528ed",
   "metadata": {},
   "outputs": [],
   "source": [
    "path_to_pdf_3 = (r\"D:\\Live Project\\Data\\603913.pdf\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "c1134bc3",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Hindawi Publishing Corporation\n",
      "Cardiology Research and Practice\n",
      "Volume 2013, Article ID 603913, 5 pages\n",
      "http://dx.doi.org/10.1155/2013/603913\n",
      "\n",
      "Research Article\n",
      "Effect of Ivabradine on Endothelial Function in Diastolic and\n",
      "Right Heart Failure Patients\n",
      "\n",
      "Arturo Orea-Tejeda,1 Karla Balderas-Muñoz,1 Lilia Castillo-Martínez,1\n",
      "Oscar Infante-Vázquez,2 Raúl Martínez Memije,2 Candace Keirns-Davis,3\n",
      "Joel Dorantes-García,4 René Narváez-David,4 and Zuilma Vázquez-Ortíz4\n",
      "1 Heart Failure Clinic, Instituto Nacional de Ciencias M´edicas y Nutrici´on Salvador Zubir´an, Mexico\n",
      "2 Instrumentation Department, Instituto Nacional de Cardiolog´ıa “ICh”, Mexico\n",
      "3 Massachusetts General Hospital, Boston, MA, USA\n",
      "4 Cardiology Department, Instituto Nacional de Ciencias M´edicas y Nutrici´on Salvador Zubir´an, Mexico\n",
      "\n",
      "Correspondence should be addressed to Lilia Castillo-Mart´ınez; caml1225@yahoo.com\n",
      "\n",
      "Received 18 June 2013; Revised 12 August 2013; Accepted 28 August 2013\n",
      "\n",
      "Academic Editor: Gregory Giamouzis\n",
      "\n",
      "Copyright © 2013 Arturo Orea-Tejeda et al. This is an open access article distributed under the Creative Commons Attribution\n",
      "License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly\n",
      "cited.\n",
      "\n",
      "Background. Ivabradine is an If ion current inhibitor that has proved to reduce mortality in patients with systolic heart failure by\n",
      "slowing heart rate without decreasing myocardial contractility. Photoplethysmography is a simple, low-cost optical technique that\n",
      "can evaluate vascular function and detect changes in blood flow, pulse, and swelling of tissular microvascular space. Objective.\n",
      "To evaluate the effect of ivabradine on endothelial function by photoplethysmography in diastolic and right heart failure patients.\n",
      "Methodology. 15 patients were included (mean age of 78.1 ± 9.2 years) with optimally treated diastolic and right heart failure. They\n",
      "underwent photoplethysmography before and after induced ischemia to evaluate the wave blood flow on the finger, using the\n",
      "maximum amplitude time/total time (MAT/TT) index. Two measurements were made before and after oral Ivabradine (mean\n",
      "12.5 mg a day during 6 months of followup). Results. In the study group, the MAT/TT index was 29.1 ± 2.2 versus 24.3 ± 3.2 (𝑃 = 0.05)\n",
      "in basal recording and 30.4 ± 2.1 versus 23.3 ± 2.9 (𝑃 = 0.002), before versus after ischemia and before versus after Ivabradine\n",
      "intervention, respectively. Conclusions. Ivabradine administration improves endothelial function (shear stress) in diastolic and right\n",
      "heart failure patients.\n",
      "\n",
      "1. Background\n",
      "Diastolic dysfunction has been associated with symptoms\n",
      "of congestive heart failure in patients with preserved left\n",
      "ventricular ejection fraction [1]. In the largest single-center\n",
      "study with approximately 36, 000 outpatients with normal\n",
      "LVEF, some authors have shown that diastolic dysfunction is\n",
      "an independent predictor of all-cause mortality [2].\n",
      "\n",
      "In outpatients with heart failure with preserved ejection\n",
      "fraction (HFpEF) at the baseline echocardiogram, worsening\n",
      "of diastolic function in a follow-up study is also an inde-\n",
      "pendent predictor of all-cause mortality [3]. In addition,\n",
      "Achong showed that improvement in diastolic function was\n",
      "associated with increased survival (𝑃 = 0.05) in a mixed\n",
      "cohort of inpatients and outpatients with normal or mild\n",
      "\n",
      "systolic dysfunction [4], while the more advanced the stage\n",
      "is, the higher the filling pressures and the worse the outcomes\n",
      "are [5].\n",
      "\n",
      "In patients with atrial fibrillation, if diastolic function was\n",
      "assessed, it was based on deceleration time of mitral E-wave\n",
      "velocity and tissue Doppler imaging (i.e., peak early mitral\n",
      "inflow velocity/diastolic early tissue velocity [E/e󸀠]) [6].\n",
      "\n",
      "Ivabradine added to recommended treatment, improved\n",
      "the outcome of heart failure patients reducing cardiovascular\n",
      "death and hospitalizations rate [7]. In patients with coronary\n",
      "disease and left ventricular dysfunction also the benefit was\n",
      "observed [8]. In experimental studies, ivabradine have been\n",
      "demonstrated that reduces fibrosis and improve endothelial\n",
      "function [9–12].\n",
      "\n",
      "\f",
      "2\n",
      "\n",
      "Cardiology Research and Practice\n",
      "\n",
      "Ivabradine also has demonstrated a favorable effect on\n",
      "LV remodeling after 8 months of followup as well as and\n",
      "antianginal effect [13].\n",
      "\n",
      "Hyperemic coronary blood flow velocity also increases\n",
      "after ivabradine treatment, probably because the diastolic\n",
      "period is prolonged (per cardiac beat and per minute). It has\n",
      "been speculated that the most probable explanation of the\n",
      "improvement of ventricular relaxation caused by ivabradine\n",
      "treatment could be its effect on coronary blood flow velocity\n",
      "during hyperemia [14].\n",
      "\n",
      "To evaluate the effect of ivabradine on endothelial func-\n",
      "tion by photoplethysmography in patients with right heart\n",
      "failure and preserved ejection fraction, we performed this\n",
      "open-label clinical trial.\n",
      "\n",
      "2. Methods\n",
      "2.1. Study Population. This open-label clinical trial included\n",
      "ambulatory patients who came to the Heart Failure Clinic\n",
      "of the Instituto Nacional de Ciencias M´edicas y Nutrici´on\n",
      "“Salvador Zubir´an.” Patients were recruited if they were\n",
      "men or nongravid women with more than 18 years of age\n",
      "with a confirmed diagnosis of stable heart failure with\n",
      "preserved ejection fraction in New York Heart Association\n",
      "functional classes II to III. Candidates were excluded if they\n",
      "had had myocardial infarction, unstable angina or a history\n",
      "of myocardial revascularization (percutaneous transluminal\n",
      "coronary angioplasty or aortocoronary bypass grafts), cere-\n",
      "brovascular events during the previous 3 months, dysfunc-\n",
      "tional prosthetic heart valve, obstructive or nonobstructive\n",
      "cardiomyopathy, uncorrected congenital heart disease, active\n",
      "myocarditis, a history of resuscitation from sudden death, or\n",
      "severe arrhythmias.\n",
      "\n",
      "Heart failure was established by signs and symptoms as\n",
      "well as echocardiographic and radioisotopic ventriculogra-\n",
      "phy findings. Preserved ejection fraction was defined as a left\n",
      "ventricular ejection fraction ≥ 50%, LVEDVI < 97 mL/m2,\n",
      "left atrial diameter > 40 mL/m2, tissue doppler E/E󸀠\n",
      "> 15\n",
      "echo-blood flow Doppler E/A in >50 years <0.5, and DT in\n",
      ">50 years >280 ms [15]. Right ventricular dysfunction was\n",
      "defined as ejection fraction ≤ 35% measured by radioisotopic\n",
      "ventriculography [16, 17].\n",
      "\n",
      "All patients received standard heart\n",
      "\n",
      "failure therapy\n",
      "and their comorbidities (diuretics, angiotensin-converting\n",
      "enzyme inhibitors, angiotensin II antagonists, aldosterone\n",
      "receptor blockers, digitalis, and beta-adrenoreceptor block-\n",
      "ers), at their maximum doses tolerated. Some patients that\n",
      "developed atrial fibrillation also received digital.\n",
      "\n",
      "2.2. Study Design. This was an investigator-initiated, single\n",
      "center, single-arm, open-label clinical trial.\n",
      "\n",
      "After baseline measurements, in addition to conventional\n",
      "therapy, patients received an average of ivabradine 12.5 mg\n",
      "(10–15 mg) a day, according their tolerance during 6 months\n",
      "of follow-up [18, 19]. Patients underwent 2D and Doppler\n",
      "echocardiograms and radioisotopic (rest/effort) left and right\n",
      "ventriculography before and after oral ivabradine.\n",
      "\n",
      "Table 1: Demographic and clinical characteristics of the CHF\n",
      "patients.\n",
      "\n",
      "Variables\n",
      "Age (years)\n",
      "Female (%)\n",
      "Arterial hypertension (%)\n",
      "Hypothyroidism (%)\n",
      "Diabetes mellitus (%)\n",
      "COPD (%)\n",
      "Dyslipidemia (%)\n",
      "End Stage Kidney disease (%)\n",
      "Functional class (NYHA):\n",
      "\n",
      "II\n",
      "III\n",
      "\n",
      "𝑁 = 15\n",
      "\n",
      "78.1 ± 9.2\n",
      "\n",
      "73.3\n",
      "73.3\n",
      "53.3\n",
      "33.3\n",
      "33.3\n",
      "26.6\n",
      "26.6\n",
      "\n",
      "60\n",
      "40\n",
      "\n",
      "2.2.1. Photoplethysmography. A baseline digital photoplethys-\n",
      "mographic wave was recorded for 30 seconds. The forearm\n",
      "was then compressed with a sphygmomanometer cuff for\n",
      "5 minutes using a pressure of 30 mmHg above the systolic\n",
      "arterial pressure recorded (ischemic phase). The compression\n",
      "was then released and the digital photoplethysmographic\n",
      "wave was recorded for 120 seconds. The wave was analyzed\n",
      "at 30-second intervals for comparison with the baseline\n",
      "values. The most representative waves were selected from\n",
      "the recording of each interval, and the maximum amplitude\n",
      "time (MAT) and total time (TT) were measured in order to\n",
      "calculate the MAT/TT index. A MAT/TT index of less than 30\n",
      "was considered normal, as proposed in other studies [20, 21].\n",
      "Cardiologists who performed the echocardiograms and\n",
      "radioventriculography did not have access to patients’ infor-\n",
      "mation.\n",
      "\n",
      "2.3. Statistical Analysis. Continuous variables were expressed\n",
      "as mean ± standard deviation (SD) and categorical variables\n",
      "as percentages. To compare the changes from baseline to\n",
      "6 months, a paired t-test was used. A 𝑃 value of <0.05\n",
      "was considered statistically significant. All analyses were\n",
      "performed using a commercially available package (SPSS for\n",
      "Windows, version 17.0 SPSS Inc.).\n",
      "\n",
      "3. Results\n",
      "Fifteen patients (73.6% female) were studied. Arterial hyper-\n",
      "tension and hypothyroidism (under treatment and well\n",
      "controlled) were the most common comorbidities with\n",
      "patients in functional classes (NYHA) II and III (Table 1).\n",
      "It is important to note that COPD and ESKD patients\n",
      "were not excluded from the study. Concomitant medica-\n",
      "tion was as follows: diuretic (73%) and adrenergic beta\n",
      "blocker receptor (BB, 73%) agents were the most commonly\n",
      "employed; 46.6% also received mineralocorticoid receptor\n",
      "antagonists (MRAmedications) and angiotensin-converting-\n",
      "enzyme inhibitors (ACEIs)/angiotensin receptors blockers\n",
      "(ARB).\n",
      "\n",
      "\f",
      "Cardiology Research and Practice\n",
      "\n",
      "3\n",
      "\n",
      "Maximum amplitude time/total time (MAT/TT) index\n",
      "\n",
      "Preischemic\n",
      "\n",
      "period\n",
      "\n",
      "Postischemic\n",
      "\n",
      "period\n",
      "\n",
      "29.1 ± 2.2\n",
      "\n",
      "30.4 ± 2.1\n",
      "\n",
      "Before\n",
      "\n",
      "Ivabradine\n",
      "\n",
      "After\n",
      "\n",
      "24.3 ± 3.2\n",
      "\n",
      "23.3 ± 2.9\n",
      "\n",
      "P = 0.05\n",
      "\n",
      "P = 0.002\n",
      "\n",
      "Figure 1: Pre and after ischemic period, before and after 6 months\n",
      "of follow-up of oral ivabradine.\n",
      "\n",
      "Patients received an average of 12.5 (range 10–15) mg/day\n",
      "during the 6 months of followup. It was particularly interest-\n",
      "ing that heart rate did not decrease in any patients below the\n",
      "10% recommended (88 versus 82 beats/min) in the literature\n",
      "in spite of the top doses received.\n",
      "\n",
      "Figure 1 shows the maximum amplitude time/total time\n",
      "(MAT/TT) index before and after the followup. A significant\n",
      "increase in pre- and post-ischemic periods after ivabradine\n",
      "administration is evident when basal values are compared\n",
      "with those at the end of followup.\n",
      "\n",
      "Improvement of the endothelial-dependent vasodilata-\n",
      "tion expressed by significant changes observed in the photo-\n",
      "plethysmographic curves occurred concurrently. All patients\n",
      "had some degree of clinical improvement, 8/9 (88.8%) from\n",
      "NYHA III to II and 4/6 (66.6%) from II to I, respectively,\n",
      "although this did not achieve statistical significance (𝑃 =\n",
      "0.08).\n",
      "\n",
      "With respect to cardiac structural changes, in the echo-\n",
      "cardiographic study, only right ventricular diastolic diameter\n",
      "(40.5 ± 7.8 versus 36.4 ± 5.3; 𝑃 = 0.05) was significantly\n",
      "different after the followup. There was also a reduction of\n",
      "8.15% in the systolic pulmonary arterial pressure (59.6 ± 8.4\n",
      "versus 54.9 ± 10.2; 𝑃 = 0.05).\n",
      "\n",
      "4. Discussion\n",
      "Approximately 50% of patients with heart failure (HF)\n",
      "have normal or preserved left ventricular ejection fraction\n",
      "(HFPEF) [22], and their prognosis is similar to that of\n",
      "patients with HF with reduced LVEF (HFREF) [22, 23]. Left\n",
      "ventricular diastolic dysfunction (LVDD) plays an important\n",
      "role in patients with HFPEF [24] and could be due to\n",
      "structural and molecular abnormalities of the cardiovascular\n",
      "system. These abnormalities include myocardial ischemia,\n",
      "cardiac hypertrophy, cardiac inflammation [25], and ventric-\n",
      "ular vascular stiffening, in part due to the reduced effects of\n",
      "nitric oxide and impaired endothelial function [26]. Borlaug\n",
      "et al. recently demonstrated that global cardiovascular reserve\n",
      "functions, including endothelial function, are impaired in\n",
      "subjects with HFNEF who have hypertension, a very frequent\n",
      "\n",
      "cause of HF [27]. In HFREF, coronary endothelial function is\n",
      "also impaired [28], and it has been reported that peripheral\n",
      "endothelial dysfunction is associated with the severity of HF\n",
      "symptoms and clinical outcome in patients with HFREF [29,\n",
      "30]. Moreover, vascular stiffness and resistance with elevated\n",
      "blood pressure has been proposed as a potential important\n",
      "noncardiac factor in patients with HFpEF [31].\n",
      "\n",
      "Endothelial dysfunction has been shown to be involved in\n",
      "the pathogenesis of HF, mainly HFREF. Several studies have\n",
      "reported that peripheral endothelial dysfunction is associated\n",
      "with the clinical outcome in patients with HFREF [30].\n",
      "Borlaug et al. recently reported that subjects with HFpEF had\n",
      "limited arterial vasodilator response to exercise, which might\n",
      "impair cardiac output reserve under stress [32].\n",
      "\n",
      "Peripheral endothelial function is impaired in patients\n",
      "with HFpEF, and when it is evaluated as a reactive hyper-\n",
      "emia by peripheral arterial tonometry (RH-PAT), it signifi-\n",
      "cantly correlates with future cardiovascular events. Peripheral\n",
      "endothelial function is thus an independent predictor after\n",
      "adjusting various clinical parameters [33]. Indeed, the prog-\n",
      "nostic impact of the reactive hyperemia index in patients with\n",
      "HFpEF suggests that endothelial dysfunction may not be a\n",
      "passive finding, but may rather play an active and important\n",
      "pathophysiologic role in HFpEF [32]. When matched in\n",
      "patients and controls for diabetes and hypertension, more\n",
      "endothelial dysfunction was found in patients with HFPEF,\n",
      "who were notably more obese than controls [34].\n",
      "\n",
      "The results of the systolic heart failure treatment with the\n",
      "If inhibitor ivabradine trial (SHIFT) showed that treatment\n",
      "with ivabradine added to conventional therapy for HF was\n",
      "associated with an 18% reduction in the relative risk for\n",
      "the primary composite endpoint of cardiovascular death or\n",
      "hospitalization for worsening HF (𝑃 < 0.0001) [7]. It also had\n",
      "a positive effect on LV remodelling in the echocardiographic\n",
      "substudy of the BEAUTIFUL (morBidity-mortality EvAlUa-\n",
      "Tion of the If inhibitor ivabradine in patients with coronary\n",
      "disease and left ventricULar dysfunction) study [8].\n",
      "\n",
      "In experimental studies, ivabradine has been demon-\n",
      "strated to reduces fibrosis and improve endothelial function\n",
      "[9–12], together with its antiischemic and antianginal effects\n",
      "[13] which could explain why all our patients improved\n",
      "their functional class, possibly associated with increased\n",
      "hyperemic coronary blood flow velocity. It may also be\n",
      "explained by the prolonged diastolic period (per cardiac\n",
      "beat and per minute). Moreover, we can speculate that\n",
      "the endothelial-dependent vasodilatation expressed by the\n",
      "significant changes observed in the photoplethysmographic\n",
      "curves in peripheral and coronary territories plays an impor-\n",
      "tant role in improving coronary blood reserve as has already\n",
      "been described [35, 36], and flow velocity may have a\n",
      "direct effect on coronary vessels and reduced ventricular\n",
      "wall tension, with improvement of ventricular relaxation [14],\n",
      "added to diminished right ventricular diastolic diameter with\n",
      "significant reduction of arterial pulmonary pressure, which\n",
      "probably reflects improved coronary perfusion pressure (aor-\n",
      "tic mean pressure/coronary sinus ratio).\n",
      "\n",
      "In experimental postinfarction settings, both cardiac [37]\n",
      "and pulmonary vascular [38] endothelial dysfunction may\n",
      "\n",
      "\f",
      "4\n",
      "\n",
      "Cardiology Research and Practice\n",
      "\n",
      "contribute to the development of heart failure through endo-\n",
      "cardial and myocardial capillary endothelial abnormalities\n",
      "[39] and could explain the impaired left ventricular relaxation\n",
      "in pressure-overload hypertrophy [40].\n",
      "\n",
      "Preserved ejection fraction is present in almost 50%\n",
      "of heart failure patients and is cause of half of HF hos-\n",
      "pitalizations, and traditional HF treatment is not effective.\n",
      "A recently published pathophysiology-based novel phar-\n",
      "macotherapy for these patients considers spironolactone,\n",
      "aliskiren, and neprilisyn as therapeutic options for HFPEF\n",
      "because of their anti-hypertrophic and anti-fibrotic effects\n",
      "[41]. Combined ventricular and vascular stiffening involving\n",
      "both the systemic and pulmonary circulations, plays a role\n",
      "in the pathophysiology of HFpEF [42, 43]. Thus, the effects\n",
      "of ivabradine on endothelial function, that we observed,\n",
      "may represent a major advantage when it is used to treat\n",
      "left diastolic dysfunction because of its secondary impact\n",
      "on pulmonary arterial hypertension and damaged right\n",
      "ventricular function.\n",
      "\n",
      "5. Limitations\n",
      "The number of patients studied was small, and the interven-\n",
      "tion period was short. It is probable that a longer followup\n",
      "would show changes in variables such as left ventricular\n",
      "diastolic diameter and other structural characteristics. In\n",
      "addition, the lack of direct quantification of pulmonary\n",
      "pressures is a drawback.\n",
      "\n",
      "Our findings support continued investigation into the\n",
      "effects of ivabradine on right ventricular function, systemic\n",
      "arterial pressure, and systolic pulmonary arterial pressure in\n",
      "heart failure patients with preserved ejection fraction. More\n",
      "studies are required to evaluate the effects observed on a\n",
      "larger number of patients for a longer period.\n",
      "\n",
      "References\n",
      "[1] W. Aljaroudi, M. C. Alraies, C. Halley et al., “Impact of\n",
      "progression of diastolic dysfunction on mortality in patients\n",
      "with normal ejection fraction,” Circulation, vol. 125, no. 6, pp.\n",
      "782–788, 2012.\n",
      "\n",
      "[2] M. Senni, C. M. Tribouilloy, R. J. Rodeheffer et al., “Congestive\n",
      "heart failure in the community: a study of all incident cases in\n",
      "Olmsted County, Minnesota, in 1991,” Circulation, vol. 98, no.\n",
      "21, pp. 2282–2289, 1998.\n",
      "\n",
      "[3] B. G. Angeja and W. Grossman, “Evaluation and management of\n",
      "diastolic heart failure,” Circulation, vol. 107, no. 5, pp. 659–663,\n",
      "2003.\n",
      "\n",
      "[4] P. M. Mottram and T. H. Marwick, “Assessment of diastolic\n",
      "function: what the general cardiologist needs to know,” Heart,\n",
      "vol. 91, no. 5, pp. 681–695, 2005.\n",
      "\n",
      "[5] C. M. Halley, P. L. Houghtaling, M. K. Khalil, J. D. Thomas,\n",
      "and W. A. Jaber, “Mortality rate in patients with diastolic\n",
      "dysfunction and normal systolic function,” Archives of Internal\n",
      "Medicine, vol. 171, no. 12, pp. 1082–1087, 2011.\n",
      "\n",
      "[6] H. Okura, Y. Takada, T. Kubo et al., “Tissue Doppler-derived\n",
      "index of left ventricular filling pressure, E/E󸀠, predicts survival\n",
      "of patients with non-valvular atrial fibrillation,” Heart, vol. 92,\n",
      "no. 9, pp. 1248–1252, 2006.\n",
      "\n",
      "[7] K. Swedberg, M. Komajda, M. B¨ohm et al., “Ivabradine and\n",
      "outcomes in chronic heart failure (SHIFT): a randomised\n",
      "placebo-controlled study,” The Lancet, vol. 376, no. 9744, pp.\n",
      "875–885, 2010, Erratum in The Lancet, vol. 376, p. 1988, 2010.\n",
      "\n",
      "[8] C. Ceconi, S. B. Freedman, J. C. Tardif et al., “Effect of heart\n",
      "rate reduction by ivabradine on left ventricular remodeling in\n",
      "the echocardiographic substudy of BEAUTIFUL,” International\n",
      "Journal of Cardiology, vol. 146, no. 3, pp. 408–414, 2011.\n",
      "\n",
      "[9] P. Mulder, S. Barbier, A. Chagraoui et al., “Long-term heart\n",
      "rate reduction induced by the selective If current inhibitor\n",
      "ivabradine improves left ventricular function and intrinsic\n",
      "myocardial structure in congestive heart failure,” Circulation,\n",
      "vol. 109, no. 13, pp. 1674–1679, 2004.\n",
      "\n",
      "[10] E. I. Dedkov, W. Zheng, L. P. Christensen, R. M. Weiss, F.\n",
      "Mahlberg-Gaudin, and R. J. Tomanek, “Preservation of coro-\n",
      "nary reserve by ivabradine-induced reduction in heart rate in\n",
      "infarcted rats is associated with decrease in perivascular col-\n",
      "lagen,” American Journal of Physiology—Heart and Circulatory\n",
      "Physiology, vol. 293, no. 1, pp. H590–H598, 2007.\n",
      "\n",
      "[11] P. Milliez, S. Messaoudi, J. Nehme, C. Rodriguez, J.-L. Samuel,\n",
      "and C. Delcayre, “Beneficial effects of delayed ivabradine treat-\n",
      "ment on cardiac anatomical and electrical remodeling in rat\n",
      "severe chronic heart failure,” American Journal of Physiology—\n",
      "Heart and Circulatory Physiology, vol. 296, no. 2, pp. H435–\n",
      "H441, 2009.\n",
      "\n",
      "[12] M. Vercauteren, J. Favre, P. Mulder, F. Mahlberg-Gaudin, C.\n",
      "Thuillez, and V. Richard, “Protection of endothelial function by\n",
      "long-term heart rate reduction induced by ivabradine in a rat\n",
      "model of chronic heart failure,” European Heart Journal, vol. 28,\n",
      "supplement, p. 48, 2007.\n",
      "\n",
      "[13] G. Riccioni, N. Vitulano, and N. D’Orazio, “Ivabradine: beyond\n",
      "heart rate control,” Advances in Therapy, vol. 26, no. 1, pp. 12–24,\n",
      "2009.\n",
      "\n",
      "[14] E. I. Skalidis, M. I. Hamilos, G. Chlouverakis, E. A. Zacharis,\n",
      "and P. E. Vardas, “Ivabradine improves coronary flow reserve\n",
      "in patients with stable coronary artery disease,” Atherosclerosis,\n",
      "vol. 215, no. 1, pp. 160–165, 2011.\n",
      "\n",
      "[15] W. J. Paulus, C. Tsch¨ope, J. E. Sanderson et al., “How to diagnose\n",
      "diastolic heart failure: a consensus statement on the diagnosis\n",
      "of heart failure with normal left ventricular ejection fraction\n",
      "by the Heart Failure and Echocardiography Associations of the\n",
      "European Society of Cardiology,” European Heart Journal, vol.\n",
      "28, no. 20, pp. 2539–2550, 2007.\n",
      "\n",
      "[16] N. F. Voelkel, R. A. Quaife, L. A. Leinwand et al., “Right\n",
      "ventricular function and failure: report of a National Heart,\n",
      "Lung, and Blood Institute working group on cellular and\n",
      "molecular mechanisms of right heart failure,” Circulation, vol.\n",
      "114, no. 17, pp. 1883–1891, 2006.\n",
      "\n",
      "[17] J. F. Setaro, M. W. Cleman, and M. S. Remetz, “The right\n",
      "ventricle in disorders causing pulmonary venous hypertension,”\n",
      "Cardiology Clinics, vol. 10, no. 1, pp. 165–183, 1992.\n",
      "\n",
      "[18] F. M. Sarullo, G. Fazio, D. Puccio et al., “Impact of “off-label”\n",
      "use of ivabradine on exercise capacity, gas exchange, functional\n",
      "class, quality of life, and neurohormonal modulation in patients\n",
      "with ischemic chronic heart failure,” Journal of Cardiovascular\n",
      "Pharmacology and Therapeutics, vol. 15, no. 4, pp. 349–355, 2010.\n",
      "[19] A. Schuster and W. H. W. Tang, “Ivabradine in heart failure: to\n",
      "SHIFT or not to SHIFT,” Current Heart Failure Reports, vol. 8,\n",
      "no. 1, pp. 1–3, 2011.\n",
      "\n",
      "[20] J. T. Kuvin, A. R. Patel, K. A. Sliney et al., “Assessment of\n",
      "peripheral vascular endothelial function with finger arterial\n",
      "\n",
      "\f",
      "Cardiology Research and Practice\n",
      "\n",
      "5\n",
      "\n",
      "[35] M. B. Britten, A. M. Zeiher, and V. Sch¨achinger, “Microvascular\n",
      "dysfunction in angiographically normal or mildly diseased\n",
      "coronary arteries predicts adverse cardiovascular long-term\n",
      "outcome,” Coronary Artery Disease, vol. 15, no. 5, pp. 259–264,\n",
      "2004.\n",
      "\n",
      "[36] B. A. Herzog, L. Husmann, I. Valenta et al., “Long-term prog-\n",
      "nostic value of 13N-ammonia myocardial perfusion positron\n",
      "emission tomography added value of coronary flow reserve,”\n",
      "Journal of the American College of Cardiology, vol. 54, no. 2, pp.\n",
      "150–156, 2009.\n",
      "\n",
      "[37] X.-L. Qi, D. J. Stewart, H. Gosselin et al., “Improvement of\n",
      "endocardial and vascular endothelial function on myocardial\n",
      "performance by captopril treatment in postinfarct rat hearts,”\n",
      "Circulation, vol. 100, no. 12, pp. 1338–1345, 1999.\n",
      "\n",
      "[38] A. Ben Driss, C. Devaux, D. Henrion et al., “Hemodynamic\n",
      "stresses induce endothelial dysfunction and remodeling of\n",
      "pulmonary artery in experimental compensated heart failure,”\n",
      "Circulation, vol. 101, no. 23, pp. 2764–2770, 2000.\n",
      "\n",
      "[39] D. Popov, A. Sima, D. Stern, and M. Simionescu, “The patho-\n",
      "morphological alterations of endocardial endothelium in exper-\n",
      "imental diabetes and diabetes associated with hyperlipidemia,”\n",
      "Acta Diabetologica, vol. 33, no. 1, pp. 41–47, 1996.\n",
      "\n",
      "[40] P. A. MacCarthy and A. M. Shah, “Impaired endothelium-\n",
      "dependent regulation of ventricular relaxation in pressure-\n",
      "overload cardiac hypertrophy,” Circulation, vol. 101, no. 15, pp.\n",
      "1854–1860, 2000.\n",
      "\n",
      "[41] D. M. Konstantinou, Y. S. Chatzizisis, and G. D. Giannoglou,\n",
      "“Pathophysiology-based novel pharmacotherapy for heart fail-\n",
      "ure with preserved ejection fraction,” Pharmacology & Thera-\n",
      "peutics, 2013.\n",
      "\n",
      "[42] C. S. P. Lam, V. L. Roger, R. J. Rodeheffer et al., “Cardiac\n",
      "structure and ventricular-vascular function in persons with\n",
      "heart failure and preserved ejection fraction from Olmsted\n",
      "County, Minnesota,” Circulation, vol. 115, no. 15, pp. 1982–1990,\n",
      "2007.\n",
      "\n",
      "[43] C. S. P. Lam, V. L. Roger, R. J. Rodeheffer, B. A. Borlaug, F.\n",
      "T. Enders, and M. M. Redfield, “Pulmonary hypertension in\n",
      "heart failure with preserved ejection fraction: a community-\n",
      "based study,” Journal of the American College of Cardiology, vol.\n",
      "53, no. 13, pp. 1119–1126, 2009.\n",
      "\n",
      "pulse wave amplitude,” American Heart Journal, vol. 146, no. 1,\n",
      "pp. 168–174, 2003.\n",
      "\n",
      "[21] A. Aldama, H. ´Alvarez, A. Rodr´ıguez, and B. Reyes, “Evaluaci´on\n",
      "cualitativa de la morfolog´ıa de la se˜nal fotopletismogr´afica en\n",
      "el diagn´ostico de la insuficiencia arterial,” Revista Cubana de\n",
      "Investigaciones Biom´edicas, vol. 27, no. 1, 2008.\n",
      "\n",
      "[22] R. S. Bhatia, J. V. Tu, D. S. Lee et al., “Outcome of heart failure\n",
      "with preserved ejection fraction in a population-based study,”\n",
      "The New England Journal of Medicine, vol. 355, no. 3, pp. 260–\n",
      "269, 2006.\n",
      "\n",
      "[23] T. E. Owan, D. O. Hodge, R. M. Herges, S. J. Jacobsen, V. L.\n",
      "Roger, and M. M. Redfield, “Trends in prevalence and outcome\n",
      "of heart failure with preserved ejection fraction,” The New\n",
      "England Journal of Medicine, vol. 355, no. 3, pp. 251–259, 2006.\n",
      "[24] M. R. Zile, C. F. Baicu, and W. H. Gaasch, “Diastolic heart\n",
      "failure: abnormalities in active relaxation and passive stiffness\n",
      "of the left ventricle,” The New England Journal of Medicine, vol.\n",
      "350, no. 19, pp. 1953–1959, 2004.\n",
      "\n",
      "[25] J. Matsubara, S. Sugiyama, T. Nozaki et al., “Pentraxin 3 is a new\n",
      "inflammatory marker correlated with left ventricular diastolic\n",
      "dysfunction and heart failure with normal ejection fraction,”\n",
      "Journal of the American College of Cardiology, vol. 57, no. 7, pp.\n",
      "861–869, 2011.\n",
      "\n",
      "[26] M. Ouzounian, D. S. Lee, and P. P. Liu, “Diastolic heart failure:\n",
      "mechanisms and controversies,” Nature Reviews Cardiology, vol.\n",
      "5, pp. 375–386, 2008.\n",
      "\n",
      "[27] B. A. Borlaug, T. P. Olson, C. S. P. Lam et al., “Global car-\n",
      "diovascular reserve dysfunction in heart failure with preserved\n",
      "ejection fraction,” Journal of the American College of Cardiology,\n",
      "vol. 56, no. 11, pp. 845–854, 2010.\n",
      "\n",
      "[28] S. H. Kubo, T. S. Rector, A. J. Bank, R. E. Williams, and S. M.\n",
      "Heifetz, “Endothelium-dependent vasodilation is attenuated in\n",
      "patients with heart failure,” Circulation, vol. 84, no. 4, pp. 1589–\n",
      "1596, 1991.\n",
      "\n",
      "[29] M. A. AlZadjali, V. Godfrey, F. Khan et al., “Insulin resistance\n",
      "is highly prevalent and is associated with reduced exercise\n",
      "tolerance in non-diabetic patients with heart failure,” Journal of\n",
      "the American College of Cardiology, vol. 53, no. 9, pp. 747–753,\n",
      "2009.\n",
      "\n",
      "[30] D. Fischer, S. Rossa, U. Landmesser et al., “Endothelial dys-\n",
      "function in patients with chronic heart failure is independently\n",
      "associated with increased incidence of hospitalization, cardiac\n",
      "transplantation, or death,” European Heart Journal, vol. 26, no.\n",
      "1, pp. 65–69, 2005.\n",
      "\n",
      "[31] G. Cotter, M. Metra, O. Milo-Cotter, H. C. Dittrich, and M. Ghe-\n",
      "orghiade, “Fluid overload in acute heart failure—re-distribution\n",
      "and other mechanisms beyond fluid accumulation,” European\n",
      "Journal of Heart Failure, vol. 10, no. 2, pp. 165–169, 2008.\n",
      "\n",
      "[32] B. A. Borlaug, V. Melenovsky, S. D. Russell et al., “Impaired\n",
      "chronotropic and vasodilator reserves limit exercise capacity in\n",
      "patients with heart failure and a preserved ejection fraction,”\n",
      "Circulation, vol. 114, no. 20, pp. 2138–2147, 2006.\n",
      "\n",
      "[33] E. Akiyama, S. Sugiyama, Y. Matsuzawa et al., “Incremental\n",
      "prognostic significance of peripheral endothelial dysfunction in\n",
      "patients with heart failure with normal left ventricular ejection\n",
      "fraction,” Journal of the American College of Cardiology, vol. 60,\n",
      "no. 18, pp. 1778–1786, 2012.\n",
      "\n",
      "[34] C. S. Lam and D. L. Brutsaert, “Endothelial dysfunction: a\n",
      "pathophysiologic factor in heart failure with preserved ejection\n",
      "fraction,” Journal of the American College of Cardiology, vol. 60,\n",
      "no. 18, pp. 1787–1789, 2012.\n",
      "\n",
      "\f",
      "Submit your manuscripts at\n",
      "\n",
      "http://www.hindawi.com\n",
      "\n",
      "Hindawi Publishing Corporationhttp://www.hindawi.comVolume 2013Oxidative Medicine and Cellular LongevityHindawi Publishing Corporation http://www.hindawi.comVolume 2013Hindawi Publishing Corporation http://www.hindawi.comVolume 2013The Scientific World JournalInternational Journal ofEndocrinologyHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013ISRN AnesthesiologyHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013OncologyJournal ofHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013PPARResearchHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013OphthalmologyJournal ofHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013ISRN AllergyHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013BioMed Research InternationalHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013ObesityJournal ofHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013ISRN AddictionHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013Hindawi Publishing Corporationhttp://www.hindawi.comVolume 2013 Computational and  Mathematical Methods in MedicineISRN AIDSHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013Clinical &DevelopmentalImmunologyHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013Diabetes ResearchJournal ofHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013Evidence-Based Complementary and Alternative MedicineVolume 2013Hindawi Publishing Corporationhttp://www.hindawi.comHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013Gastroenterology Research and PracticeHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013ISRN BiomarkersHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013MEDIATORSINFLAMMATIONof\f",
      "\n"
     ]
    }
   ],
   "source": [
    "# extracting the text\n",
    "output_text_3 = path(path_to_pdf_3)\n",
    "print(output_text_3)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "d7c542cb",
   "metadata": {},
   "outputs": [],
   "source": [
    "merged_text = output_text + output_text_1 + output_text_2 + output_text_3"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "00a04f65",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"Haematologia, Vol. 30, No. 1, pp. 27–30 (2000)\\n(cid:211) VSP 2000.\\n\\nSerum L-selectin and P-selectin levels in lymphomas\\n\\nShort communication\\n\\nI. C. HAZNEDARO ˇGLU, M. BENEKLI\\nI. H. GÜLLÜ, S. V. DÜNDAR and ¸S. KIRAZLI\\nDepartment of Internal Medicine, Hematology and Oncology Division, Hacettepe University\\nMedical School, Ankara, Turkey\\n\\n, O. OZCEBE, M. C. SAVA ¸S,\\n\\n(cid:3)\\n\\nAbstract—The migration of normal and malignant lymphoid cells is governed by speciﬁc adhesion\\nmolecules. Selectins comprise a family of adhesion receptors expressed by leukocytes, platelets and\\nendothelial cells. In this study, the serum levels of soluble L-selectin and P-selectin were measured in\\npatients with non-Hodgkin’s lymphoma and Hodgkin’s disease and found to be signiﬁcantly elevated\\nin both patient groups compared to healthy controls. This result provides evidence that alterations in\\nthe expression and function of adhesion molecules may play an important role in the progression of\\nlymphomas. Further studies are awaited to establish the exact roles of these adhesion molecules in\\ndistinct patterns of growth and spread of lymphomas.\\n\\nKey words: L-selectin; P-selectin; Hodgkin’s disease; non-Hodgkin’s lymphoma.\\n\\nINTRODUCTION\\n\\nAdhesion of lymphocytes to endothelium is essential in lymphocyte trafﬁcking\\n[1, 2]. Lymphocytes migrate from the circulation by selective attachment to spe-\\ncialized endothelial cells lining the postcapillary high endothelial venules (HEV)\\nin organized lymphoid tissues, lymph nodes and Peyer’s patches. Selectins com-\\nprise a family of adhesion molecules which have been demonstrated to participate in\\nthe initial tetherting/ rolling of leukocytes on activated endothelium [3]. L-selectin\\n(CD62L, LAM-1, LECAM-1) mediates the binding of lymphocytes to HEV of\\nperipheral lymph nodes through interactions with corresponding endothelial lig-\\nand and therefore also known as the lymphocyte homing receptor [4]. P-selectin\\n(CD62P, PADGEM, GMP-140) is stored both in the alpha granules in platelets and\\nWeibel-Palade bodies of endothelial cells [5] and involved in the stabilization of\\n\\n(cid:3)\\n\\nTo whom correspondence should be addressed. M. Benekli, 14. Sokak, 43/ 8. Bahçelievler,\\n\\nAnkara, Turkey.\\n\\n\\x0c28\\n\\nI. C. Haznedaroˇglu et al.\\n\\nplatelet aggregates and in the interaction of leukocytes with activated platelets or\\nendothelial cells [6].\\n\\nLymphoma cells represent immortalized counterparts of normal lymphocytes. A\\nsimilar adhesion mechanism is also utilized by malignant lymphoid cells during\\ndissemination [7, 8]. Altered expression patterns of adhesion molecules appear\\nto be involved in the spread of lymphoid malignancies and Hodgkin’s disease\\n(HD) [7–10]. In this study, serum levels of soluble L-selectin and P-selectin were\\ndetermined in patients with HD and non-Hodgkin’s lymphoma (NHL) and in normal\\nhealthy individuals.\\n\\nPATIENTS AND METHODS\\n\\nThe study group consisted of 17 patients (10 NHL, 7 HD; 11 men, 6 women; median\\nage 35 years, range 19– 70) and 15 healthy volunteers (11 men, 4 women; median\\nage 49 years, range 36– 67). Out of 10 NHL patients, 5 were classiﬁed as low-\\ngrade, 1 intermediate, and 4 high-grade according to the Working Formulation.\\nFour patients out of 7 with HD had mixed cellularity, 1 nodular sclerosis, and\\n2 lymphocyte predominance type. Staging was performed according to the Ann\\nArbor system.\\nIn NHL, 2 patients had stage III and 8 patients had stage IV\\ndisease, and in HD 1 patient had stage II, 2 stage III, and the remaining 4 stage IV\\ndisease. All patients with HD and 3 out of 10 with NHL had B-symptoms. Serum\\nL-selectin and P-selectin levels were determined using a commercially available\\nELISA kit (Bender MedSystems, Vienna, Austria) according to the manufacturer’s\\ninstructions. Data are presented as mean (cid:6) SD. Mann–Whitney U test was used\\nfor statistical analysis.\\n\\nRESULTS\\nAdhesion molecule levels were signiﬁcantly higher in lymphoma patients compared\\nto healthy controls (Table 1) (Fig. 1). Serum levels of sL-Selectin (1137 (cid:6)\\n428 ng/ml vs 625 (cid:6) 159 ng/ml; p D 0:0023 and sP-Selectin (610 (cid:6) 211 ng/ml\\nvs 178 (cid:6) 48 ng/ ml; p D 0:0001) were signiﬁcantly increased in patients with\\nnon-Hodgkin’s lymphoma compared to the control group. In HD, serum soluble\\nL-selectin (1140 (cid:6) 498 ng/ml; p D 0:0082) and P-selectin (875 (cid:6) 370 ng/ ml;\\np D 0:0002) concentrations were signiﬁcantly elevated also compared to healthy\\ncontrols (625 (cid:6) 159 ng/ ml and 178 (cid:6) 48 ng/ml for L-selectin and P-selectin,\\nrespectively).\\n\\nDISCUSSION\\n\\nDisseminating malignant lymphoma cells and lymphocytes share several character-\\nistics, including migration and extravasation involving adhesive interactions [7, 8].\\n\\n\\x0cAdhesion molecules in lymphomas\\n\\n29\\n\\nTable 1.\\nSerum soluble P-selectin and L-selectin levels in the study group\\n\\nPatients\\n\\nHD\\nHNL\\nControls\\n\\nP-selectin (ng/ml)\\n875 (cid:6) 370\\n610 (cid:6) 211\\n178 (cid:6) 48\\n\\n* Compared with healthy controls.\\n\\n(cid:3)\\n\\np\\n\\n0.0002\\n0.0001\\n\\nL-selectin (ng/ml)\\n1140 (cid:6) 498\\n1137 (cid:6) 428\\n625 (cid:6) 159\\n\\n(cid:3)\\n\\np\\n\\n0.0082\\n0.0023\\n\\nFigure 1. Circulating soluble P-selectin and L-selectin levels in the study group.\\n\\nEmerging evidence indicates that the adhesion molecules governing the homing\\nof normal lymphocytes also mediate the dissemination of their neoplastic counter-\\nparts. Adhesion molecules have also been demonstrated to function in the spread\\nof HD [9, 10]. Therefore, we determined serum levels of soluble adhesion mole-\\ncules, L-selectin and P-selectin as indicators of distinctive clinical and biological\\nbehaviour of lymphoid malignancies.\\nIn this report we demonstrated that serum\\nconcentrations of these adhesion receptors are increased in patients with HD and\\nNHL. Our results conﬁrm and extend data published previously on the role of dis-\\ntinct adhesion molecules in lymphomas. Elevated levels of circulating intercellular\\nadhesion molecule-1 were reported in various hematologic malignancies including\\nHD [9, 10], acute lymphoblastic leukemia [10], chronic lymphocytic leukemia [11]\\nand NHL [12, 13], and non-hematologic malignancies [10, 13]. To our knowledge,\\n\\n\\x0c30\\n\\nI. C. Haznedaroˇglu et al.\\n\\nthis report is the ﬁrst investigating the levels of circulating L-selectin and P-selectin\\nin NHL and HD.\\n\\nDifferential expression of these adhesion molecules may account for diverse\\npatterns of growth and dissemination of lymphomas. The study of adhesion\\nmolecule expression and function may allow a better understanding of the malignant\\nbehavior of lymphoid cells. Our data need to be validated and extended in a\\nmore homogenous patient series in order to elucidate the clinical and prognostic\\nsigniﬁcance of L-selectin and P-selectin in lymphomas.\\n\\nREFERENCES\\n\\n1. Shimizu, Y., Newman, W., Tanaka, Y., Shaw, S., Lymphocyte interactions with endothelial cells,\\n\\nImmunol. Today 13, 106 (1992).\\n\\n2. Stoolman, L. M., Adhesion molecules controlling lymphocyte migration, Cell 56, 907 (1989).\\n3. Bevilacqua, M. P., Nelson, R. M., Selectins, J. Clin. Invest. 91, 379 (1993).\\n4. Gallatin, W. M., Weissman, I. L., Butcher, E. C., A cell-surface molecule involved in organ-\\n\\nspeciﬁc homing of lymphocytes, Nature 304, 30 (1983).\\n\\n5. Bonfanti, R., Furie, B. C., Furie, B., Wagner, D. D., PADGEM (GMP 140) is a component of\\n\\nWeibel-Palade bodies of human endothelial cells, Blood 73, 1109 (1989).\\n\\n6. De Bruijne-Admiraal, L. G., Modderman, P. W., Von dem Borne, A. E. G. Kr., Sonnenberg, A.,\\n-dependent adhesion of activated platelet to many different types of\\n\\nC\\nP-selectin mediates Ca2\\nleukocytes: Detection by ﬂow cytometry, Blood 80, 134 (1992).\\n\\n7. Pals, S. T., Horst, E., Scheper, R. J., Meijer, C. J. L. M., Mechanisms of human lymphocyte\\n\\nmigration and their role in the pathogenesis of disease, Immunol. Rev. 108, 111 (1989).\\n\\n8. Pals, S. T., Drillenburg, P., Radaszkiewicz, T., Manten-Horst, E., Adhesion molecules in the\\n\\ndissemination of non-Hodgkin’s lymphomas, Acta Haematol. 97, 73 (1997).\\n\\n9. Gruss, H.-J., Dölken, G., Brach, M. A., Mertelsmann, R., Herrmann, F., Serum levels of\\n\\ncirculating ICAM-1 are increased in Hodgkin’s disease, Leukemia 8, 1245 (1993).\\n\\n10. Pui C.-H., Luo, X., Evans, W., Martin, S., Rugg, A., Wilimas, J., Crist, W. M., Hudson, M.,\\n\\nSerum intercellular adhesion molecule-1 in childhood malignancy, Blood 82, 895 (1993).\\n\\n11. Christiansen, I., Gidlöf, C., Wallgren, A. C., Simonsson, B., Tötterman, T. H., Serum levels of\\nsoluble intercellular adhesion molecule-1 are increased in chronic B-lymphocytic leukemia and\\ncorrelate with clinical stage and prognostic markers, Blood 84, 3010 (1994).\\n\\n12. Christiansen, I., Gidlöf, C., Kalkner, K.-M., Hagberg, H., Bennmarker, H., Tötterman, T.,\\nElevated serum levels of soluble ICAM-1 in non-Hodgkin’s lymphomas correlate with tumour\\nburden, disease activity and other prognostic markers, Br. J. Haematol. 92, 639 (1996).\\n\\n13. Benekli, M., Güllü, I. H., Tekuzman, G., Sava¸s, M. C., Hayran, M., Hasçelik, G., Fırat, D.,\\nCirculating intercellular adhesion molecule-1 and E-selectin in gastric cancer, Br. J. Cancer 78,\\n267 (1998).\\n\\n\\x0c\\x0cC(cid:2) 2008, the Authors\\nJournal compilation C(cid:2) 2008, Wiley Periodicals, Inc.\\nDOI: 10.1111/j.1540-8175.2008.00696.x\\n\\nCell Therapy in Patients with Left Ventricular\\nDysfunction Due to Myocardial Infarction\\nRoman Panovsky, M.D., Ph.D.,∗ Jaroslav Meluzin, M.D., Ph.D, F.E.S.C.,∗\\nStanislav Janousek, M.D., Ph.D.,† Jiˇr´ı Mayer, M.D., Ph.D.,‡ Milan Kaminek, M.D., Ph.D.,§\\nLadislav Groch, M.D.,∗ Jiˇr´ı Prasek, M.D., Ph.D.,¶ Jaroslav Stanicek, M.D.,(cid:4) Ladislav Dusek,\\nM.D.,# Ota Hlinomaz, M.D., Ph.D.,∗ Petr Kala, M.D., Ph.D.,† Martin Klabusay, M.D., Ph.D.,‡\\nZdenek Koristek M.D.,‡ and Milan Navratil M.D.‡\\n∗First Department of Internal Medicine/Cardioangiology, St. Anna Hospital, Masaryk University,\\nBrno, Czech Republic, †Department of Internal Medicine/Cardiology, Brno University Hospital,\\nBrno, Czech Republic, ‡Department of Internal Medicine/Hematooncology, Brno University\\nHospital, Brno, Czech Republic, §Department of Nuclear Medicine, UH Olomouc, Czech Republic,\\n¶Department of Nuclear Medicine, Brno University Hospital, Brno, Czech Republic, (cid:4)Department\\nof Nuclear Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic, and #Center of\\nBiostatistics and Analyses, Brno University Hospital, Brno, Czech Republic\\n\\nObjectives: The purpose of this study was to determine the impact of autologous transplantation\\nof mononuclear bone marrow cells on myocardial function in patients with left ventricular (LV)\\ndysfunction due to an acute myocardial infarction. Methods: The randomized study included 82\\npatients with a ﬁrst acute myocardial infarction treated with a stent implantation. This presentation\\nis a subanalysis of 47 patients with left ventricular dysfunction–EF (ejection fraction) ≤ 40%. Group\\nH patients (n = 17) received higher number (100,000,000) of cells; Group L patients (n = 13) received\\nlower number (10,000,000) of cells. The patients of control Group C (n = 17) were not treated with\\ncells. The Doppler tissue imaging and single photon emission computed tomography were performed\\nbefore cell transplantation and 3 months later. Results: At 3 months of follow-up, the baseline EF\\nof 35%, 36%, 35% in Groups H, L, and C increased by 6% (P < 0.01 vs. baseline), 5% (P < 0.01 vs.\\nbaseline), and 4% (P = NS vs. baseline), respectively, as assessed by single photon emission computed\\ntomography (P = NS between groups). The baseline number of akinetic segments of 6.9, 7.0, and 6.2 in\\nH, L, and C groups decreased by 1.7 (P < 0.01 vs. baseline), 1.5 (P < 0.01 vs. baseline), and 0.7 (P = NS\\nvs. baseline, P = NS between groups), respectively, as demonstrated by echocardiography. Conclusion:\\nIn our study, the statistically important effect of transplantation of mononuclear bone marrow cells\\non myocardial function was not found. Only an insigniﬁcant trend toward the improvement of global\\nLV EF fraction was found at 3-month follow-up. (ECHOCARDIOGRAPHY, Volume 25, September\\n2008)\\n\\nstem cells, coronary artery disease, left ventricular dysfunction\\n\\nPostmyocardial infarction congestive heart\\nfailure remains to be a major clinical prob-\\nlem, despite advances in the medical and sur-\\n\\nThe work was supported in part by a grant of the Ministry\\nof Health of the Czech Republic (IGA, No. 1 A/8676-3), and\\nby grants of the Ministry of Education of the Czech Republic\\n(MSM, No. 0021622402 and MSM, No. 0021622430). Oth-\\nerwise, there is no conﬂict of interest.\\n\\nAddress for correspondence and reprint requests: Ro-\\nman Panovsk´y, Ph.D., First Department of Internal\\nMedicine/Cardioangiology, St. Anna’s Hospital, Masaryk\\nUniversity, Pekaˇrsk´a 53 656 91 Brno, Czech Republic. Fax:\\n+420-543182205; E-mail: panovsky@fnusa.cz\\n\\ngical treatment of acute coronary syndromes.\\nCoronary artery disease accounts for approx-\\nimately 50% of all cardiovascular deaths and\\nis the leading cause of congestive heart fail-\\nure. The 1-year mortality rate for patients di-\\nagnosed with congestive heart failure is about\\n20%, and from 1994 to 2004, deaths from heart\\nfailure increased 28%.1,2 Development of heart\\nfailure in survivors of acute myocardial infarc-\\ntion involves myocyte loss in the area supplied\\nby the infarct-related artery and subsequent\\nformation of noncontractile ﬁbrous tissue. To\\ndate, no therapeutic procedure like angio-\\nplasty or thrombolytic agents could reverse the\\n\\n888\\n\\nECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\\n\\nVol. 25, No. 8, 2008\\n\\n\\x0cCELL THERAPY IN AN ACUTE MYOCARDIAL INFARCTION\\n\\nirreversible myocardial injury completely. The\\nrecovery of contractile function after revascu-\\nlarization occurs only in the areas of hibernat-\\ning myocardium. Heart transplantation may be\\nan option in selected patients, but the donor\\nsupply is strictly limited.\\n\\nRecent experimental and clinical studies sug-\\ngest that cell transplantation into damaged my-\\nocardium may have the potential to restore\\nmyocardial viability and improve left ventric-\\nular function. Different cell types can be po-\\ntentially used for transplantation. To avoid\\nproblems with donor availability, immunolog-\\nical rejection, arrhythmias, and ethical prob-\\nlems, autologous bone marrow cells appear par-\\nticularly attractive. But in a majority of studies,\\nonly patients with almost normal function or\\nonly mild dysfunction of the left ventricle were\\nstudied.3–12\\n\\nSo the purpose of this study was to determine\\nthe impact of autologous transplantation of\\nmononuclear bone marrow cells on myocardial\\nfunction in patients with moderate-to-severe\\nleft ventricular dysfunction.\\n\\nMaterials and Methods\\n\\nStudy Population\\n\\nThe randomized study included patients with\\na ﬁrst acute myocardial infarction treated with\\ncoronary angioplasty with a stent implanta-\\ntion. Only patients with successful recanaliza-\\ntion of the infarct-related artery (TIMI ﬂow\\ngrade 3) and the evidence of an irreversible\\ndamage of at least two akinetic or dyskinetic\\nmyocardial segments identiﬁed by dobutamine\\nechocardiography, gated technetium-99 m ses-\\ntamibi single photon emission computed to-\\nmography, and positron emission tomography\\n(performed in only 73% of patients) were in-\\ncluded. The exclusion criteria were: (1) age >\\n70 years; (2) noncardiac disease adversely af-\\nfecting prognosis; (3) another cardiac disease\\nexcept coronary artery disease; (4) coagulopa-\\nthy, thrombocytopenia, leucopenia; (5) absence\\nof a signiﬁcant increase in cardiac enzymes (cre-\\natine kinase over 20 µkat/l or creatine kinase-\\nMB over 3 µkat/l or troponin I over 20 µg/l-\\n–normal upper limits in our laboratories are\\n2.85 µkat/l, 0.42 µkat/l, and 2.0 µg/l, respec-\\ntively); (6) patient instability on days 3–7 after\\nMI; and (7) need for coronary revascularization\\nin the future for multivessel disease.\\n\\nFrom a total number of 82 patients who com-\\npleted the baseline and 3-month follow-up ex-\\n\\namination, 66 patients were analyzed in the\\npreviously published study.12 This ﬁrst 66 pa-\\ntients were randomized into three arms: (1) a\\ngroup treated with a higher number of mononu-\\nclear bone marrow cells (deﬁned as a mean\\nnumber of 1 × 108 cells); (2) a group treated\\nwith a lower number of cells (deﬁned as a\\nmean number of 1 × 107 cells); and (3) a con-\\ntrol group not treated with cell transplanta-\\ntion. Subsequent 16 patients were randomized\\ninto only two arms: higher-dose-treated group\\nand control group. The reason for changing ran-\\ndomization schema was no signiﬁcant effect of\\na lower-dose cells in the previous study. This\\npresentation is a subanalysis of 47 (from all\\nthe 82) patients with signiﬁcant left ventricu-\\nlar dysfunction-–ejection fraction (EF) ≤ 40%.\\nForty-ﬁve patients underwent the primary an-\\ngioplasty (within 12 hours of chest pain on-\\nset)and two patients were treated with angio-\\nplasty within the interval from 12 hours to\\n3 days after symptom onset.\\n\\nStudy Design\\n\\nOn day 3–6 after myocardial infarction, rest\\nand dobutamine echocardiography was per-\\nformed to evaluate the presence of akinetic or\\ndyskinetic left ventricular segments without\\nany contractile reserve. At the same time color\\nDoppler tissue imaging was performed. Within\\nthe next 2 days patients underwent the gated\\ntechnetium-99 m sestamibi single photon emis-\\nsion computed tomography and positron emis-\\nsion tomography. Patients with an evidence of\\nan irreversible damage of at least two akinetic\\nor dyskinetic myocardial segments proved by\\nall methods were then randomized. Patients\\nof cell groups underwent subsequently a bone\\nmarrow aspiration. Autologous bone marrow\\nmononuclear cells were transplanted into the\\ninfarct-related artery 20–21 hours after the\\nbone marrow aspiration, 5–9 days after my-\\nocardial infarction. Immediately before and 10\\nand 20 hours after the procedure, blood samples\\nfor cardiac enzymes (creatine kinase, creatine\\nkinase–MB and troponin I) were acquired.\\n\\nThree months after randomization, rest\\nechocardiography with Doppler tissue imaging,\\nsingle photon emission computed tomography,\\nand coronary angiography were repeated. Pa-\\ntients of the control group underwent the same\\nprocedures and examinations, as did the trans-\\nplanted patients except for bone marrow aspi-\\nration and cell transplantation.\\n\\nVol. 25, No. 8, 2008\\n\\nECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\\n\\n889\\n\\n\\x0cPANOVSKY, ET AL.\\n\\nIn this subanalysis, the changes of following\\nechocardiographic parameters were assessed:\\n(1) the peak systolic velocity of the myocardium\\nadjacent to mitral annulus of infarcted wall\\n(Sinfarct) (as a parameter of the regional longi-\\ntudinal left ventricular systolic function); (2)\\nthe mean six-site systolic velocity of the my-\\nocardium adjacent to mitral annulus (as a pa-\\nrameter of the global longitudinal left ventric-\\nular systolic function), which was calculated as\\nmean six-site S = (Slateral + Sseptal + Santerior +\\nSinferior + Santeroseptal + Sposterior)/6; and (3) num-\\nber of akinetic segments.\\nThe changes of following parameters derived\\nfrom single photon emission computed tomog-\\nraphy were assessed: (1) left ventricle end-\\ndiastolic volume; (2) left ventricle end-systolic\\nvolume; (3) left ventricle ejection fraction; and\\n(4) perfusion defect size.\\n\\nThe institutional ethics committee approved\\nthe study and written consent was obtained\\nfrom each patient.\\n\\nEchocardiography\\n\\nUsing commercially available equipment\\nVivid 7 (GE/Vingmed, Milwaukee, WI, USA)\\nwith an M3 S transducer, echocardiographic ex-\\naminations were performed in one center. Two-\\ndimensional and color Doppler tissue images of\\napical views (apical 4- and 2-chamber and api-\\ncal long-axis views) were obtained and stored\\ndigitally for the subsequent ofﬂine quantitative\\nanalysis using a software incorporated in Vivid\\n7 (Echopac 7 version 1.3, GE/Vingmed). The\\nwider-angle sector (60–70 degrees) was used to\\ndepict two-dimensional images for wall motion\\nanalysis. The narrow angle sector (30–45 de-\\ngrees) was used to obtain color Doppler tissue\\nimages of individual left ventricular walls (sep-\\ntum, lateral, inferior, anterior, posterior, and\\nanteroseptal walls) at the high frame rates of\\n172–234 frames per second.\\n\\nDobutamine\\n\\nechocardiography was per-\\nformed in all patients with starting dose of\\n5 µg/kg per min. The dose was increased at\\n5-minute intervals to 10, and 20 µg/kg per\\nmin. The parasternal\\nlong-axis and three\\napical views were digitally stored at rest and\\nat the last minute of all doses of dobutamine\\nfor a subsequent wall motion analysis. A\\n16-segment model was used for regional wall\\nmotion analysis.13 The akinetic and dyskinetic\\nsegments with no improvement in thickening\\nafter any dose of dobutamine were regarded\\nas irreversibly damaged. A good interobserver\\n\\nand intraobserver variability in scoring dys-\\nfunctional segments (agreement 93% and 96%,\\nrespectively) and in determining the contractile\\nreserve (agreement 92% and 95%, respectively)\\nhas already been described.14\\n\\nThe regional longitudinal systolic function\\nwas evaluated from the color Doppler tis-\\nsue imaging.15,16 Peak systolic velocities (S)\\nwere determined for the basal myocardium\\nof each wall adjacent to the mitral annulus\\n(Slateral, Sseptal, Santerior, Sinferior, Santeroseptal, and\\nSposterior). The results were obtained as a mean\\nfrom three consecutive heart cycles. Two expe-\\nrienced echocardiographers who were blinded\\nto the patient treatment performed the analy-\\nses. The reproducibility of estimation of S val-\\nues of individual walls was evaluated in our\\ninitial 3-month project.12 For all S values, the\\nestimated 95% conﬁdence limits for differences\\nbetween intraobserver (JM) pairs of measure-\\nment revealed repeated results to vary in a\\nrange of ± 10.6% as based on the mean primary\\nvalues and similarly ± 11.5% for the interob-\\nserver variability (JM and RP). The sufﬁcient\\ninterobserver reproducibility was also proved in\\napplied pairwise ANOVA models: only 4.8% of\\noverall variability could be attributed to the dif-\\nferences among observers and the interobserver\\neffect was unambiguously not signiﬁcant (P =\\n0.963).\\n\\nGated Technetium-99 m Sestamibi Single\\nPhoton Emission Computed Tomography\\n\\nSeven hundred forty MBq technetium-99 m\\nsestamibi was injected at rest. Gated single pho-\\nton emission computed tomography imaging\\nacquisition (64 projections from the 45◦ right\\nanterior oblique projection to the 45◦ left pos-\\nterior oblique projection) began 1 hour after\\nsestamibi injection using a 2-detector gamma\\ncamera (ecam, Siemens, Erlangen, Germany)\\nequipped with a low-energy, high-resolution\\nparallel-hole collimators. The MIBI uptake\\nwas analyzed visually and quantitatively on\\ncomputer-generated polar maps by an experi-\\nenced nuclear cardiologist who was unaware\\nof the patients treatment. Pixels with a ses-\\ntamibi activity > 2.5 SD below the correspond-\\ning normal mean values were considered ab-\\nnormal. The computer automatically expressed\\na perfusion defect as the number of abnormal\\npixels divided by the total number of left ven-\\ntricle pixels × 100 project.17 In the viability\\nanalysis, the myocardial region with the maxi-\\nmum sestamibi uptake was used as a reference\\n\\n890\\n\\nECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\\n\\nVol. 25, No. 8, 2008\\n\\n\\x0cCELL THERAPY IN AN ACUTE MYOCARDIAL INFARCTION\\n\\nregion. The tracer uptake in other myocardial\\nregions was then expressed as a percentage\\nof the activity measured in the reference re-\\ngion. Nonviable myocardium was deﬁned as\\nthat having sestamibi uptake below the thresh-\\nold of 50% of the maximum project.18 Gated\\nsingle photon emission computed tomography\\nrest left ventricular ejection fractions and left\\nventricular end-diastolic/end-systolic volumes\\nwere obtained using automated, commercially\\navailable software four-dimensional-MSPECT\\n(University of Michigan, Ann Arbor, MI, USA).\\n\\nPositron Emission Tomography\\n\\nTo\\n\\nemission\\n\\nviability, F-18-\\nassess myocardial\\nﬂuorodeoxyglucose-positron\\nto-\\nmography was performed with a whole-body\\npositron emission tomography scanner (ECAT\\nACCEL, Siemens, Knoxville, TN, USA). Ac-\\nquisition was started 50 minutes after the\\nadministration of ﬂuorodeoxyglucose (200–250\\nMBq intravenously) and images of glucose\\nutilization were acquired for 15–20 minutes\\nin a 3D mode. The metabolic defects were\\nanalyzed on computer-generated polar maps.\\nThe myocardial ﬂuorodeoxyglucose uptake for\\neach part of the left ventricle was normalized\\nto a myocardial region with the maximum\\nﬂuorodeoxyglucose uptake. A nonviable my-\\nocardium was deﬁned as that having less\\nthan 50% of the maximum ﬂuorodeoxyglucose\\nuptake.18\\n\\nBone Marrow Aspiration and Preparation\\n\\nThe target volume of bone marrow blood\\n(100 ml for the lower cell dose, 150 ml for\\nthe higher cell dose) was obtained from iliac\\ncrests under local anesthesia and moderate se-\\ndation with midazolam, mixed with 4% human\\nalbumin and 5,000 IU of heparin, and cen-\\ntrifuged (15 minutes, 240 g) to receive buffy-\\ncoat. Mononuclear cells were collected using\\ndensity gradient centrifugation of the buffy-\\ncoat (20 minutes, 1,200 g, Histopaque 1077,\\nSigma-Aldrich, St. Louis, MO, USA), washed,\\nand resuspended. One hundred twenty-ﬁve per-\\ncent of the target amount of mononuclear cells\\nwas added to the CellGro serum-free medium\\n(CellGenix, Freiburg, Germany) to reach 0.3–\\n1.0 × 106 cells/ml. After an overnight cultiva-\\ntion (37 ◦C, 5% CO2) in a teﬂon bag (VueLife,\\nCellGenix), 105% of the target number of\\nmononuclear cells was withdrawn, washed, and\\nresuspended in the Hank’s salt solution (Sigma-\\n\\nAldrich) with 4% human albumin and 1,000 IU\\nof heparin into a total volume of 22 ml.\\n\\nCell Implantation\\n\\nAutologous mononuclear bone marrow cells\\nwere transplanted 5–9 days after the infarc-\\ntion onset using a modiﬁcation of the method\\ndescribed previously by Strauer et al.19 Cells\\nwere implanted intracoronary via a percuta-\\nneous transluminal catheter into the infarct-\\nrelated coronary artery. A total of seven balloon\\ninﬂations at the place of previous stent implan-\\ntation lasting for 3 minutes were carried out\\nwith 3-minute intervals of balloon deﬂation. At\\nthe beginning of each balloon inﬂation, 3 ml\\nof cell suspension was slowly injected into the\\nartery. All patients were on daily doses of 75 mg\\nof clopidogrel and 100 mg of aspirin and, in ad-\\ndition, a bolus of 100 units/kg of body weight of\\nheparin was administered immediately before\\nthe procedure to minimize the risk of throm-\\nbotic complications.\\n\\nStatistical Analysis\\n\\nStandard descriptive statistics were used\\nto summarize the sample distribution of in-\\ndividual variables (means, standard errors,\\nconﬁdence limits). A univariate t-test for two\\nindependent samples was applied to compare\\nvalues of parameters between the groups. A\\npaired t-test was applied to compare changes\\nin values prior and after the treatment. All\\nparametric tests were performed with the ver-\\niﬁed assumption of normal distribution\\n(Shapiro–Wilk’s W-test).\\nindepen-\\ndent samples were mutually compared on\\nthe basis of proved homogeneity of variance\\n(Variance ratio F-test). The correlation analysis\\nwas based on Pearson’s correlation coefﬁcient.\\nA P < 0.05 was considered statistically\\nsigniﬁcant.\\n\\nRepeated measures ANOVA model was used\\nto test the results obtained by different ob-\\nservers (measured in all patients included\\nin the reproducibility test). The pairwise de-\\nsign included overall F-test of the main ef-\\nfects (i.e., differences among different ob-\\nservers) and then estimation of within-observer\\nvariability.\\n\\nTwo\\n\\nResults\\n\\nThis subanalysis contains 47 patients. Thirty\\nof them were treated with mononuclear bone\\n\\nVol. 25, No. 8, 2008\\n\\nECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\\n\\n891\\n\\n\\x0cPANOVSKY, ET AL.\\n\\nTABLE I\\n\\nCharacteristics of the Study Population\\n\\nParameter\\n\\nAge (years)\\nMen\\nHypertension\\nHyperlipidemia\\nDiabetes mellitus\\nSingle-vessel disease\\nDouble-vessel disease\\nTriple-vessel disease\\nIRA: LAD\\nIRA: LCX\\nIRA: RCA\\nMaximum CK (ukat/l)\\nMaximum CK-MB (ukat/l)\\nTime from infarct onset to\\n\\nreperfusion (min)\\n\\nTime from infarct onset to cell\\n\\ntransplantation (days)\\n\\nDobutamine echo\\nNo. of irreversibly damaged segments\\nMedication on hospital discharge\\n\\nAspirin\\nClopidogrel\\nACE inhibitor\\nBeta blocker\\nStatin\\n\\nControl (C)\\nGroup (n = 17)\\n\\n52 (2)\\n15 (88%)\\n9 (53%)\\n6 (35%)\\n4 (24%)\\n11 (65%)\\n6 (35%)\\n\\n0%\\n16 (94%)\\n0%\\n\\n1 (6%)\\n80.2 (11.1)\\n7.4 (0.6)\\n507 (240)\\n\\n–\\n\\nLower Cell Dose (L) Higher Cell Dose (H)\\n\\nGroup (n = 13)\\n\\nGroup (n = 17)\\n\\n55 (2)\\n12 (92%)\\n5 (39%)\\n9 (69%)\\n1 (8%)\\n9 (69%)\\n3 (23%)\\n1 (8%)\\n12 (92%)\\n0%\\n\\n1 (8%)\\n80.2 (9.4)\\n7.6 (0.9)\\n263 (53)\\n\\n7 (0.4)\\n\\n55 (5)\\n15 (88%)\\n5 (29%)\\n7 (41%)\\n3 (18%)\\n13 (76%)\\n4 (24%)\\n\\n0%\\n16 (94%)\\n0%\\n\\n1 (6%)\\n68.9 (7.2)\\n6.8 (0.7)\\n484 (192)\\n\\n7 (0.3)\\n\\n6 (0.7)\\n\\n7 (0.4)\\n\\n7 (0.7)\\n\\n17 (100%)\\n15 (88%)\\n17 (100%)\\n17 (100%)\\n17 (100%)\\n\\n13 (100%)\\n13 (100%)\\n13 (100%)\\n13 (100%)\\n13 (100%)\\n\\n17 (100%)\\n17 (100%)\\n17 (100%)\\n17 (100%)\\n17 (100%)\\n\\nThe values are expressed as the mean supplied by standard error (in parentheses) or number (%) of\\nsubjects. ACE = angiotensin-converting enzyme; CK = creatine kinase; echo = echocardiography; IRA =\\ninfarct-related artery; LAD = left anterior descending coronary artery; LCX = left circumﬂex artery;\\nNo = number; RCA = right coronary artery.\\n\\nmarrow cell implantation–17 patients in the\\nGroup H with higher cell doses, while 13 in\\nthe Group L with lower cell doses, and 17 of\\nthem served as a control Group C. The base-\\nline characteristics are presented in Table I.\\nThere were no signiﬁcant differences among the\\ngroups.\\n\\nThe Effect of Cell Transplantation\\non Myocardial Function and Left\\nVentricle Remodeling\\n\\nThe results of echocardiographic examina-\\ntions and single photon emission computed to-\\nmography data are demonstrated in Table II.\\n\\nThere was a trend toward the prevention of\\nthe left ventricle dilatation (end-diastolic vol-\\nume) and the improvement of the left ventri-\\ncle ejection fraction in transplanted patients.\\nPatients of the high-doses group signiﬁcantly\\nimproved the regional systolic function (Sinfarct)\\nafter 3-month follow-up. We proved signiﬁcant\\n\\nimprovement in these parameters (left ventri-\\ncle ejection fraction, end-systolic volume, peak\\nsystolic velocity of infarcted myocardium and\\nnumber of akinetic segments) in cell therapy\\npatients, as it is documented through signiﬁ-\\ncant results of within-group testing. However,\\nthere were no statistically differences among\\nthe groups.\\n\\nThe side effects have already been pub-\\n\\nlished.12\\n\\nPhenotype of Transplanted Cells\\n\\nThe samples were analyzed from 29 patients\\n(in one patient a small sample size did not allow\\nadequate analysis). The transplanted leuko-\\ncytes contained in the mean 43.4% CD3+ cells,\\n2.9% CD16+ cells, 11.0% CD19+ cells, 0.4%\\nCD33+ cells, and 1.1% CD34+ cells, respec-\\ntively. The viability of mononuclear cells was\\nevaluated after the cultivation. In all cases, the\\nviability exceeded 95%.\\n\\n892\\n\\nECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\\n\\nVol. 25, No. 8, 2008\\n\\n\\x0cCELL THERAPY IN AN ACUTE MYOCARDIAL INFARCTION\\n\\nTABLE II\\n\\nComparison of Baseline and 3-Month Follow-Up Echocardiographic and Single Photon Emission Computed Tomography\\n\\nResults for the Treatment and Control Groups\\n\\nParameter\\n\\nEchocardiography\\n\\nMean 6-site S (cm/s)\\nBaseline\\nFollow-up\\nChange‡\\nP-value‡\\n\\nSinfarct (cm/s)\\n\\nBaseline\\nFollow-up\\nChange‡\\nP-value‡\\n\\nNo. of akinetic s∗\\n\\nBaseline\\nFollow-up\\nChange‡\\nP-value‡\\n\\nSPECT\\n\\nEDV (ml)\\nBaseline\\nFollow-up\\nChange‡\\nP-value‡\\nESV (ml)\\n\\nBaseline\\nFollow-up\\nChange‡\\nP-value‡\\nLV EF (%)\\nBaseline\\nFollow-up\\nChange‡\\nP-value‡\\n\\nPerfusion defect (%)\\n\\nBaseline\\nFollow-up\\nChange‡\\nP-value‡\\n\\nC Group\\n(n = 17)\\n\\nL Group\\n(n = 13)\\n\\nH Group\\n(n = 17)\\n\\nMutual Comparison (P-Values)†\\n\\nC vs. L\\n\\nC vs. H\\n\\nL vs. H\\n\\n4.9 (0.2)\\n5.2 (0.3)\\n0.3 (0.2)\\n0.393\\n\\n4.5 (0.2)\\n4.8 (0.3)\\n0.3 (0.2)\\n0.153\\n\\n6.2 (0.6)\\n5.5 (0.7)\\n−0.7 (0.4)\\n0.062\\n\\n171 (9)\\n183 (13)\\n12 (8)\\n0.153\\n\\n112 (7)\\n115 (11)\\n3 (8)\\n0.713\\n\\n35 (1)\\n39 (2)\\n4 (2)\\n0.062\\n\\n52 (4)\\n41 (4)\\n−11 (3)\\n<0.001\\n\\n5.1 (0.3)\\n4.9 (0.3)\\n−0.2 (0.3)\\n0.625\\n\\n4.2 (0.3)\\n4.4 (0.3)\\n0.2 (0.2)\\n0.337\\n\\n7.0 (0.4)\\n5.5 (0.6)\\n−1.5 (0.5)\\n<0.001\\n\\n176 (12)\\n180 (12)\\n4 (10)\\n\\n0.696\\n\\n112 (9)\\n106 (9)\\n−6 (7)\\n0.408\\n\\n36 (1)\\n41 (2)\\n5 (1)\\n<0.001\\n\\n51 (4)\\n41 (5)\\n−10 (2)\\n<0.001\\n\\n5.2 (0.2)\\n5.0 (0.2)\\n−0.2 (0.2)\\n0.193\\n\\n4.3 (0.2)\\n4.7 (0.3)\\n0.4 (0.1)\\n0.013\\n\\n6.9 (0.6)\\n5.2 (0.7)\\n−1.7 (0.5)\\n<0.001\\n\\n178 (13)\\n181 (12)\\n3 (8)\\n0.713\\n\\n117 (10)\\n107 (9)\\n−10 (4)\\n0.023\\n\\n35 (1)\\n41 (2)\\n6 (2)\\n<0.001\\n\\n53 (4)\\n43 (4)\\n−10 (2)\\n<0.001\\n\\n0.821\\n0.485\\n0.298\\n\\n0.691\\n0.283\\n0.261\\n\\n0.366\\n0.995\\n0.242\\n\\n0.786\\n0.841\\n0.509\\n\\n0.998\\n0.555\\n0.402\\n\\n0.343\\n0.284\\n0.609\\n\\n0.880\\n0.872\\n0.601\\n\\n0.416\\n0.611\\n0.153\\n\\n0.975\\n0.432\\n0.342\\n\\n0.411\\n0.744\\n0.128\\n\\n0.677\\n0.876\\n0.431\\n\\n0.674\\n0.572\\n0.094\\n\\n0.939\\n0.324\\n0.262\\n\\n0.911\\n0.657\\n0.537\\n\\n0.594\\n0.822\\n0.813\\n\\n0.704\\n0.728\\n0.215\\n\\n0.889\\n0.768\\n0.798\\n\\n0.907\\n0.957\\n0.941\\n\\n0.694\\n0.949\\n0.706\\n\\n0.308\\n0.897\\n0.589\\n\\n0.799\\n0.800\\n0.958\\n\\nThe values are expressed as the mean supplied by standard error (in parentheses). ∗Identiﬁed as nonviable on pretransplant\\ndobutamine echocardiography. †Mutual signiﬁcance “between groups” tested by t-test for two independent samples. ‡Pairwise\\ncalculated “within group” change of values tested by t-test for two-paired samples.\\nEDV = end-diastolic volume; ESV = end-systolic volume; LV EF = left ventricular ejection fraction; m = myocardium; S =\\npeak systolic velocity of basal myocardium adjacent to mitral annulus; Sinfarct = peak systolic velocity of the infarcted wall;\\nMean 6-site S = (Slateral + Sseptal + Santerior + Sinferior + Santeroseptal + Sposterior)/6; s = segments; SPECT = single photon\\nemission computed tomography; other abbreviations as in Table I.\\n\\nDiscussion\\n\\nPotential Effect of Cell Therapy\\n\\nBone marrow contains a great number of\\nprimitive cells that are able to differentiate\\ninto specialized cells, for example into endothe-\\n\\nlial cells or myocytes.20–24 Some of these prim-\\nitive cells produce different growth factors,21\\nfor example vascular endothelial growth fac-\\ntor, basic ﬁbroblast growth factor, and cytokines\\nwith proangiogenetic effect. For these reasons,\\nmany experimental studies were performed and\\n\\nVol. 25, No. 8, 2008\\n\\nECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\\n\\n893\\n\\n\\x0cPANOVSKY, ET AL.\\n\\nproved the possibility of cell therapy to improve\\nperfusion or/and function of dysfunctional my-\\nocardium.20–26\\n\\nDespite numerous unresolved questions con-\\ncerning the cell transplantation, these ﬁrst\\nhopeful experimental studies were immediately\\nfollowed by clinical trials, mostly in patients\\nwith acute myocardial infarction. The num-\\nbers of patients included are relatively small.\\nMany of these studies are not randomized. The\\ntype and amount of cells that are necessary\\nto implant to really regenerate damaged my-\\nocardium are not known.\\n\\nAt present, we do not know the mechanism\\nof action of the implanted cells in studies that\\nfound improvement in myocardial function or\\nperfusion following the cell therapy. Recently,\\nseveral experimental projects described no or\\nonly negligible transdifferentiation of adult\\nstem cells into the myocytes.27–30 The beneﬁt\\nof cell transplantation may be induced by the\\nparacrine stem cell effect.31,32\\n\\nStudies in Patients with Acute Myocardial\\nInfarctions\\n\\nTransplantation of mononuclear bone mar-\\nrow cells into the region of\\ninfarcted my-\\nocardium has been previously suggested as a\\npromising alternative treatment for left ven-\\ntricle dysfunction. Nevertheless, the results\\nof randomized studies are controversial.3,4,7–9\\nSome of them indicated that patients with\\nthe most depressed left ventricular contrac-\\ntile function had the greatest improvement in\\ncontractile function after intracoronary admin-\\nistration of bone marrow cells. For example,\\nREPAIR-AMI,33 so far the largest randomized\\nmulticenter “cell study,” showed signiﬁcantly\\ngreater increase in the global left ejection frac-\\ntion in the bone marrow cell group (5.5% vs.\\n3.0% in the control group) at 4 months follow-\\nup. Higher impact of cells was found among pa-\\ntients with a baseline left ventricle ejection frac-\\ntion below the median value (48.9%). In these\\npatients, the absolute increase in ejection frac-\\ntion was three times higher that in the placebo\\ngroup (7.5% as compared with 2.5%; absolute\\ndifference: 5.0%). Among patients with a base-\\nline ejection fraction above median, the abso-\\nlute difference between groups was only 0.3%\\n(4.0% vs. 3.7%). Similar observations were pre-\\nviously described in TOPCARE-AMI trial,34 in\\nwhich baseline left ventricle ejection fraction\\nwas the only signiﬁcant predictor of improve-\\n\\nment in ejection fraction during the 4-months\\nfollow-up.\\n\\nIn the randomized, double-blind, placebo-\\ncontrolled study of Janssens group,35 in 67 pa-\\ntients with ST-elevation myocardial infarction\\ntreated with coronary intervention, no effect\\nof autologous bone marrow-derived stem cell\\ntransfer on left ventricle ejection fraction was\\nfound. However, the treatment was associated\\nwith a signiﬁcant reduction in myocardial in-\\nfarct size and better recovery of regional sys-\\ntolic function. The effect of treatment on the\\nprobability of improvement in regional function\\nshowed a predominant interaction in the most\\nseverely affected segments. In addition to that,\\non positron emission tomography examination,\\npatients with larger myocardial infarction had\\na greater increase in metabolic activity after cell\\ntherapy than after placebo infusion.\\n\\nOn the other hand, BOOST trial 36,37 did not\\ndescribe the inverse relation between baseline\\nleft ventricular ejection fraction and absolute\\nimprovement of the left ventricle function af-\\nter implantation of the bone marrow cells into\\nthe infarcted myocardium. At 6-month follow-\\nup, patients in a control group of this study im-\\nproved their ejection fraction from 51.3% to 52%\\n(0.7% absolute change), while the bone marrow\\ncell group from 50.0% to 56.7% (6.7% absolute\\nchange). The bone marrow cell subgroup pa-\\ntients with ejection fraction of the left ventri-\\ncle > 52% increased their ejection by 8.0%, but\\npatients with ejection fraction ≤ 52% only by\\n4.5%.\\n\\nThe main limitation of these studies is the\\nfact, that patients with only mild left ventricu-\\nlar dysfunction were included.\\n\\nStudies in Patients with Moderate-to-Severe\\nLeft Ventricular Dysfunction\\n\\nThere are only few trials studying cell ther-\\napy in patients with moderate-to-severe left\\nventricular dysfunction and their results are\\ncontroversial too. Bartunek et al.3 described\\nimprovement of the left ventricular perfor-\\nmance and increased myocardial perfusion and\\nviability among patients with acute myocar-\\ndial infarction treated with stenting and intra-\\ncoronary administration of CD133+ progenitor\\ncells. The left ventricular ejection fraction in-\\ncreased from 45.0% to 52.1%.\\n\\nControversially, ASTAMI trial 11 did not ﬁnd\\nany signiﬁcant difference between 47 patients\\ntreated with cell transplantations and 50 pa-\\ntients in the control group. The left ventricular\\n\\n894\\n\\nECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\\n\\nVol. 25, No. 8, 2008\\n\\n\\x0cCELL THERAPY IN AN ACUTE MYOCARDIAL INFARCTION\\n\\nejection fraction and end-diastolic volume were\\nassessed by single photon emission computed\\ntomography, echocardiography, and magnetic\\nresonance. Improvement versus baseline val-\\nues was found in both groups, but they did not\\nsigniﬁcantly differ. Results were consistent for\\nall the three methods. No improvement in car-\\ndiac function was also found in Kuethe et al.38 in\\ntheir study with ﬁve patients with a large acute\\nanterior myocardial infarction and intracoro-\\nnary mononuclear bone marrow cell implanta-\\ntion.\\n\\nIn our previous study,12 the signiﬁcant and\\ndose-related improvement was found in the re-\\ngional systolic function of the infarcted wall af-\\nter cell transplantation. As compared to con-\\ntrols, a higher cell dose signiﬁcantly improved\\nglobal LV systolic function. Both cell doses pre-\\nvented the left ventricle from the dilation, while\\nthe end-diastolic volume signiﬁcantly increased\\nin the control group. Because patients with the\\ngreatest damage to their myocardium are the\\nones who need treatment most, the substudy\\nof these patients was performed. In this sub-\\nstudy the statistically important effect of au-\\ntologous transplantation of mononuclear bone\\nmarrow cells on myocardial function was not\\nfound in patients with moderate-to-severe left\\nventricular dysfunction. Only an insigniﬁcant\\ntrend toward the prevention of the left ventric-\\nular dilatation and improvement of global left\\nventricle ejection fraction was found at 3-month\\nfollow-up.\\n\\nStudy Limitations\\n\\nExcept the fact that our study is subanalysis,\\nthe major limitations of our study are the small\\nnumber of patients enrolled. However, to this\\nmoment it is one of the studies with the highest\\nnumber of patients with more severe left ven-\\ntricular dysfunction ever published. Compared\\nto other studies, the very rigorous myocardial\\nviability assessment was performed before in-\\nclusion to this study.\\n\\nThe groups differ slightly in time from on-\\nset of infarction to reperfusion. The differences\\nwere not statistically signiﬁcant. The hetero-\\ngeneity was caused by the inclusion of two pa-\\ntients with delayed coronary angioplasty (one\\npatient in the Group H and one patient in the\\nGroup C ). In our previous study the biggest\\neffect of cell transplantations was found be-\\ntween higher dose and control groups. In this\\nstudy, the difference in time from infarct on-\\nset to reperfusion between Groups H and C was\\n\\njust 23 minutes. So this difference has not been\\nsupposed to affect the results.\\n\\nBecause of ethical consideration, the patients\\nincluded into the control group did not undergo\\nthe identical procedures, as did the bone mar-\\nrow cell patients, being excluded from the bone\\nmarrow aspiration and coronary angiography\\nwith the sham cell transplantation. For techni-\\ncal reasons, the positron emission tomography\\n(PET) was not performed in all our patients.\\n\\nIn addition to the limited study population,\\nanother explanation of our results could be the\\nvery severe myocardial damage with almost no\\nsurviving myocytes. In these conditions, there is\\nno suitable milieu for catching implanted cells\\nand their differentiation into cardiomyocytes.\\nAlso the severe destruction of microcirculation\\ncould make the cell homing more difﬁcult com-\\npared to patients with less severe myocardial\\ndamage.\\n\\nConclusion\\n\\nThe important thing is the fact that the selec-\\ntion of cells and the whole method of cell ther-\\napy are just at the beginning of the way. Prob-\\nably, it is not realistic to expect some greater\\nchanges of left ventricle function in this manner\\nof treatment. It is necessary to look for the best\\ncell type, an optimal way and time of cell deliv-\\nery, and the help of some cytokines. For solving\\nthese clinical questions, we must also better un-\\nderstand the mechanisms of potential positive\\neffect of the cell therapy.\\n\\nTaking together, the results of trials show\\nthat there is still work to be done to understand\\na lot of questions related to the cell therapy. Fur-\\nther studies, including larger numbers of pa-\\ntients, are needed to resolve all these tasks.\\n\\nReferences\\n\\n1. Ho KK, Anderson KM, Kannel WB, et al: Survival af-\\nter the onset of congestive heart failure in Framing-\\nham Heart Study subjects. Circulation 1993;88:107–\\n115.\\n\\n2. Rosamond W, Flegal K, Friday G, et al: Heart dis-\\nease and stroke statistics–2007 update. A report from\\nthe American Heart Association Statistics Commit-\\ntee and Stroke Statistics Subcommittee. Circulation\\n2007;115:e69–e171.\\n\\n3. Bartunek J, Vanderheyden M, Vandekerckhove B,\\net al: Intracoronary injection of CD133-positive en-\\nriched bone marrow progenitor cells promotes cardiac\\nrecovery after recent myocardial infarction: Feasibil-\\nity and safety. Circulation 2005;112(Suppl.):I-178–\\nI-183.\\n\\n4. Fern´andez-Avil´es F, San Rom´an JA, Garc´ıa-Frade\\nJ, et al: Experimental and clinical regenerative\\n\\nVol. 25, No. 8, 2008\\n\\nECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\\n\\n895\\n\\n\\x0cPANOVSKY, ET AL.\\n\\ncapability of human bone marrow cell after myocar-\\ndial infarction. Circ Res 2004;95:742–748.\\n\\n5. Fuchs S, Satler LF, Kornowski R, et al: Catheter-\\nbased autologous bone marrow myocardial\\ninjec-\\ntion in no-option patients with advanced coronary\\nartery disease. A feasibility study. J Am Coll Cardiol\\n2003;41(10):1721–1724.\\n\\n6. Gali ˜nanes M, Loubani M, Davies J, et al: Auto-\\ntransplantation of unmanipulated bone marrow into\\nscarred myocardium is safe and enhances car-\\ndiac function in humans. Cell Transplant 2004;13:\\n7–13.\\n\\n7. Hamano K, Nishida M, Hirata K, et al: Local implan-\\ntation of autologous bone marrow cells for therapeu-\\ntic angiogenesis in patients with ischemic heart dis-\\nease. Clinical trial and preliminary results. Jpn Circ\\nJ 2001;65:845–847.\\n\\n8. Chen SL, Fang WW, Ye F, et al: Effect on left ven-\\ntricular function of intracoronary transplantation of\\nautologous bone marrow mesenchymal stem cell in pa-\\ntients with acute myocardial infarction. Am J Cardiol\\n2004;94:82–95.\\n\\n9. Stamm C, Westphal B, Kleine HD, et al: Autologous\\nbone-marrow stem-cell transplantation for myocar-\\ndial regeneration. Lancet 2003;361:45–46.\\n\\n10. Tse HF, Kwong YL, Chan JKF, et al: Angiogenesis in\\nischaemic myocardium by intramyocardial autologous\\nbone marrow mononuclear cell implantation. Lancet\\n2003;361:47–49.\\n\\n11. Lunde K, Solheim S, Aakhus S, et al: Intracoronary\\ninjection of mononuclear bone marrow cells in acute\\nmyocardial infarction. N Engl J Med 2006;355:1199–\\n1209.\\n\\n12. Meluzin J, Mayer J, Groch L, et al: Autologous trans-\\nplantation of mononuclear bone marrow cells in pa-\\ntients with acute myocardial infarction: The effect of\\nthe dose of transplanted cells on myocardial function.\\nAm Heart J 2006;152:975.e9–975.e15.\\n\\n13. Schiller NB, Shah PM, Crawford M, et al: Recom-\\nmendations for quantitation of the left ventricle by\\ntwo-dimensional echocardiography. J Am Soc Echocar-\\ndiogr 1989;2:358–367.\\n\\n14. Meluz´ın J, Cigarroa CG, Brickner E, et al: Dobu-\\ntamine echocardiography in predicting improvement\\nin global left ventricular systolic function after coro-\\nnary bypass or angioplasty in patients with healed\\nmyocardial\\ninfarcts. Am J Cardiol 1995;76:877–\\n880.\\n\\n15. Wandt B, Fornander Y, Egerlid R: Maximal longitu-\\ndinal contraction velocity in assessment of left ven-\\ntricular systolic function: A pulsed tissue Doppler and\\nM-mode study. Echocardiography 2004;21(7):587–\\n592.\\n\\n16. Yuda S, Inaba Y, Fujii S, et al: Assessment of left\\nventricular ejection fraction using long-axis systolic\\nfunction is independent of image quality: A study\\nof tissue Doppler imaging and M-mode echocar-\\ndiography.\\n2006;23(10):846–\\n852.\\n\\nEchocardiography\\n\\n17. Dakik HA, Howell JF, Lawrie GM, et al: Assessment\\nof myocardial viability with 99mTc-sestamibi tomog-\\nraphy before coronary bypass graft surgery. Circula-\\ntion 1997;96:2892–2898.\\n\\n18. Maes AF, Borgers M, Flameng W, et al: Assessment of\\nmyocardial viability in chronic coronary artery disease\\nusing technetium-99 m sestamibi SPECT. J Am Coll\\nCardiol 1997;29:62–68.\\n\\n19. Strauer BE, Brehm M, Zeus T, et al: Repair of\\ninfarcted myocardium by autologous intracoronary\\nmononuclear bone marrow cell transplantation in hu-\\nmans. Circulation 2002;106:1913–1918.\\n\\n20. Tomita S, Li RK, Weisel RD, et al: Autologous trans-\\nplantation of bone marrow cells improves damaged\\nheart\\nfunction. Circulation 1999;100(Suppl.II):II-\\n247–II-256.\\n\\n21. Fuchs S, Baffour R, Zhou YF, et al: Transendocar-\\ndial delivery of autologous bone marrow enhances col-\\nlateral perfusion and regional function in pigs with\\nchronic experimental myocardial ischemia. J Am Coll\\nCardiol 2001;37:1726–1732.\\n\\n22. Makino S, Fukuda K, Miyoshi S, et al: Cardiomyocytes\\ncan be generated from marrow stromal cells in vitro.\\nJ Clin Invest 1999;103:697–705.\\n\\n23. Jackson KA, Majka SM, Wang H, et al: Regenera-\\ntion of ischemic cardiac muscle and vascular endothe-\\nlium by adult stem cells. J Clin Invest 2001;107:1395–\\n1402.\\n\\n24. Hamano K, Li TS, Kobayashi T, et al: The induction of\\nangiogenesis by the implantation of autologous bone\\nmarrow cells: A novel and simple therapeutic method.\\nSurgery 2001;130:44–54.\\n\\n25. Orlic D, Kajstura J, Chimenti S, et al: Mobilized\\nbone marrow cells repair the infarcted heart, improv-\\ning function and survival. Proc Natl Acad Sci (USA)\\n2001;98:0344–0349.\\n\\n26. Orlic D, Kajstura J, Chimenti S, et al: Bone mar-\\nrow cells regenerate infarcted myocardium. Nature\\n2001;410:701–705.\\n\\n27. Limbourg FP, Ringes-Lichtenberg S, Schaefer A, et al:\\nHaematopoietic stem cells improve cardiac function\\nafter infarction without permanent cardiac engraft-\\nment. Eur J Heart Failure 2005;7:722–729.\\n\\n28. Balsam LB, Wagers AJ, Christensen JL, et al:\\nHaematopoietic stem cells adopt mature haematopoi-\\netic\\nin ischaemic myocardium. Nature\\n2004;428:668–673.\\n\\nfates\\n\\n29. Murry ChE, Soonpaa MH, Reinecke H, et al:\\nHaematopoietic stem cells do not transdifferentiate\\ninto cardiac myocytes in myocardial infarcts. Nature\\n2004;428:664–668.\\n\\n30. Nygren JM, Jovinge S, Breitbach M, et al: Bone\\nmarrow-derived hematopoietic cells generate car-\\ndiomyocytes at a low frequency through fusion, but not\\ntransdifferentiation. Nature Medicine 2004;10:494–\\n501.\\n\\n31. Kinnaird T, Stabile E, Burnett MS, et al: Local deliv-\\nery of marrow-derived stromal cells augments collat-\\neral perfusion through paracrine mechanisms. Circu-\\nlation 2004;109:1543–1549.\\n\\n32. Misao Y, Takemura G, Arai M, et al: Bone marrow-\\nderived myocyte-like cells and regulation of repair-\\nrelated cytokines after bone marrow cell transplan-\\ntation. Cardiovasc Res 2006;69:476–490.\\n\\n33. Schachinger V, Erbs S, Elsasser A, et al: The REPAIR-\\nAMI\\nIntracoronary bone marrow-\\nderived progenitor cells in acute myocardial infarc-\\ntion. N Engl J Med 2006;355:1210–1221.\\n\\nInvestigators.\\n\\n34. Sch¨achinger V, Assmuss B, Britten MB, et al: Trans-\\nplantation of progenitor cells and regeneration en-\\nhancement in acute myocardial infarction. Final one-\\nyear results of the TOPCARE-AMI trial. J Am Coll\\nCardiol 2004;44:1690–1699.\\n\\n35. Janssens S, Dubois C, Bogaert J, et al: Autol-\\nogous bone marrow-derived stem-cell transfer in\\n\\n896\\n\\nECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\\n\\nVol. 25, No. 8, 2008\\n\\n\\x0cCELL THERAPY IN AN ACUTE MYOCARDIAL INFARCTION\\n\\npatients with ST-segment elevation myocardial infarc-\\ntion: Double-blind, randomised controlled trial. 2006;\\n367(9505):113–121.\\n\\n36. Wollert KC, Meyer GP, Lotz J, et al: Intracoronary au-\\ntologous bone-marrow cell transfer after myocardial\\ninfarction: The BOOST randomized controlled clinical\\ntrial. Lancet 2004;363:141–148.\\n\\n37. Meyer GP, Wollert KC, Lotz J, et al: Intracoronary\\nbone marrow cell transfer after myocardial infarction.\\n\\nEighteen months’ follow-up data from the randomized,\\ncontrolled BOOST (bone marrow transfer to enhance\\nST-elevation infarct regeneration) Trial. Circulation\\n2006;113:1287–1294.\\n\\n38. Kuethe F, Richartz BM, Sayer HG, et al: Lack of regen-\\neration of myocardium by autologous intracoronary\\nmononuclear bone marrow cell transplantation in hu-\\nmans with large anterior myocardial infarctions. Int\\nJ Cardiol 2004;97:123–127.\\n\\nVol. 25, No. 8, 2008\\n\\nECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\\n\\n897\\n\\n\\x0cArticles                                                                                                  Chronic Lymphocytic Leukemia\\nHLA-G is a component of the chronic lymphocytic leukemia escape\\nrepertoire to generate immune suppression: impact of the HLA-G 14\\nbase pair (rs66554220) polymorphism\\n\\nRoberta Rizzo,1 Valentina Audrito,2,5 Paola Vacca,3 Davide Rossi,4 Davide Brusa,5 Marina Stignani,1 Daria Bortolotti,1\\nGiovanni D’Arena,6 Marta Coscia,7 Luca Laurenti,8 Francesco Forconi,9 Gianluca Gaidano,4 Maria Cristina Mingari,3,10\\nLorenzo Moretta,11 Fabio Malavasi,2,12 and Silvia Deaglio2,5\\n1Department of Medical Sciences, Sections of Microbiology and Medical Genetics, University of Ferrara, Italy; 2Department of\\nMedical Sciences, University of Turin, Italy; 3Department of Experimental Medicine, University of Genoa, Italy; 4Division of\\nHematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; 5Human\\nGenetics Foundation (HuGeF), Turin, Italy; 6Department of Onco-Hematology, IRCCS ‘‘Centro di Riferimento Oncologico della\\nBasilicata’’, Rionero in Vulture, Italy; 7Division of Hematology, University of Turin, Azienda Ospedaliera Città della Salute e della\\nScienza di Torino, Italy; 8Institute of Hematology, Catholic University of the Sacred Heart, Rome, Italy; 9Cancer Sciences Unit, CRUK\\nCenter, University of Southampton & Haematology Department, SUHT, Southampton, UK; 10AOU San Martino–Istituto Nazionale per\\nla Ricerca sul Cancro, Genoa, Italy; 11Giannina Gaslini Institute, Genoa, Italy; and 12Research Center for Experimental Medicine, Città\\ndella Salute e della Scienza Hospital, Turin, Italy\\n\\nABSTRACT\\n\\nThis work investigates the possibility that HLA-G, a molecule modulating innate and adaptive immunity, is part of\\nan immune escape strategy of chronic lymphocytic leukemia cells. A 14 base pair insertion/deletion polymorphism\\n(rs66554220) in the 3'-untranslated region of HLA-G influences mRNA stability and protein expression. The analysis\\nof a cohort of patients with chronic lymphocytic leukemia confirmed that del/del individuals are characterized by\\nhigher  levels  of  surface  and  soluble  HLA-G  than  subjects  with  the  other  two  genotypes.  In  line  with  its  role  in\\nimmunomodulation, the percentage of regulatory T lymphocytes is higher in del/del patients than in patients with\\nthe other genotypes and correlates with the amounts of surface or soluble HLA-G. Furthermore, addition of sHLA-\\nG-rich plasma from patients with chronic lymphocytic leukemia induces natural killer cell apoptosis and impairs nat-\\nural killer cell lysis, with effects proportional to the amount of soluble HLA-G added. Lastly, the presence of an HLA-\\nG 14 base pair polymorphism is of prognostic value, with del/del patients showing reduced overall survival, as com-\\npared to those with other genotypes. These results suggest that: (i) the HLA-G 14 base pair polymorphism influences\\nthe levels of surface and soluble HLA-G expression, and (ii) the over-expression of HLA-G molecules contributes to\\ncreating tolerogenic conditions. \\n\\nIntroduction\\n\\nChronic lymphocytic leukemia (CLL), the most common\\ntype of adult leukemia in Caucasian populations, is charac-\\nterized  by  the  progressive  accumulation  of  mature\\nCD5+/CD23+ B cells in the peripheral blood and lymphoid\\norgans.1 Several observations point to immune escape being\\na relevant mechanism of tumor promotion. First, CLL cells\\nexpress  high  levels  of  immunomodulatory  factors  (e.g.,\\ntransforming growth factor2 and interleukin-103), which sup-\\npress responses to antigens and influence activation, expan-\\nsion, and effector functions of T lymphocytes.4 Secondly, an\\nincrease  in  the  numbers  of  circulating  regulatory  T  cells\\n(Treg) parallels disease progression.5,6 Lastly, adenosine pro-\\nduction in the extracellular milieu by selected leukemic sub-\\npopulations  shields  the  CLL  clone  from  the  actions  of  the\\nimmune system.7\\n\\nThe aim of this work was to investigate the role of human\\nleukocyte antigen G (HLA-G) as a further strategy adopted by\\nCLL cells to evade immune defenses and to create protected\\nniches in which to grow and expand. HLA-G is a non-classical\\nmajor histocompatibility complex (MHC) class I product with\\n\\nlimited sequence variability. It is exclusively expressed in tis-\\nsues where the immune system needs to be constantly sup-\\npressed,  including  cytotrophoblast  from  early  gestation  pla-\\ncentas, amniotic cells, endothelial cells of chorionic blood ves-\\nsels, thymic epithelial cells and corneas.8 HLA-G is a tolero-\\ngenic molecule which inhibits cytolysis mediated by natural\\nkiller  (NK)  cells  or  T  lymphocytes,  induces  T-cell  apoptosis\\nand  blocks  transendothelial  migration  of  NK  cells.9 These\\nfunctions  are  exerted  upon  binding \\nthe  killer  cell\\nimmunoglobulin-like \\nthe\\nimmunoglobulin-like  transcript-2  and  -4  ligands.10,11 Hence,\\nthe immunosuppressive features of HLA-G are functional in\\npregnancy, organ transplantation, autoimmune diseases, and\\ncancer immune escape.12\\n\\n(KIR)2DL4 \\n\\nreceptor \\n\\nand \\n\\nThe  HLA-G gene  encodes  seven  isoforms  generated\\nthrough  alternative  splicing:  four  are  membrane-bound\\n(namely, HLA-G1, -G2, -G3, and -G4), while three (HLA-G5,\\n-G6, and -G7) are soluble and represent the counterparts of\\nHLA-G1,  -G2  and  -G3,  respectively.  An  alternative  mecha-\\nnism to generate soluble HLA-G (sHLA-G) forms is represent-\\ned by proteolytic cleavage of the membrane molecules.13\\n\\nHLA-G is characterized by different polymorphisms at the\\n\\n©2014 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2013.095281\\nThe online version of this article has a Supplementary Appendix.\\nManuscript received on July 23, 2013. Manuscript accepted on December 17, 2013.\\nCorrespondence:  silvia.deaglio@unito.it   or   roberta.rizzo@unife.it.\\n\\n888\\n\\nhaematologica | 2014; 99(5)\\n\\n\\x0c5’  upstream  regulatory  and  the  3’  untranslated  regions.14\\nOne  of  these,  characterized  by  the  deletion/insertion\\n(del/ins) of 14 base pairs (14 bp) (rs66554220), is responsi-\\nble for mRNA stability and consequently protein produc-\\ntion.15 The  presence  of  the  14  bp  sequence  is  associated\\nwith  unstable  mRNA  and  reduced  sHLA-G  protein  pro-\\nduction.16 This  polymorphism  is  implicated  in  autoim-\\nmune and chronic inflammatory conditions,8 while its role\\nin cancer growth and progression is still controversial.\\n\\nThe role of HLA-G products in CLL patients has been\\nevaluated  in  previous  studies,  although  these  focused\\nexclusively on the expression either of the membrane or\\nof  the  secreted  isoform  of  the  molecule.  The  results\\nobtained indicate that: (i) HLA-G expression at transcrip-\\ntion  and  protein  levels  is  increased  in  CLL  cells  as  com-\\npared to normal B lymphocytes;17-19 and (ii) HLA-G expres-\\nsion correlates with worse clinical outcome in CLL.20,21\\n\\nThis work was undertaken with the aim of assessing the\\nimpact of the HLA-G 14 bp polymorphism on expression\\nof the membrane and soluble forms of the HLA-G protein,\\nand its role in promoting immune escape in a large, well-\\ncharacterized cohort of CLL patients.\\n\\nMethods\\n\\nPatients and controls\\n\\nFive hundred and six individuals with a confirmed diagnosis of\\nCLL  were  enrolled  at  diagnosis  into  a  retrospective  study  and\\ntyped for HLA-G rs66554220 polymorphism. The patients’ char-\\nacteristics  are  reported  in  Online  Supplementary  Table  S1.  Blood\\nsamples from patients or non-leukemic individuals were obtained\\nafter  written  informed  consent  in  accordance  with  local  institu-\\ntional guidelines and the Declaration of Helsinki. The study was\\napproved by the Human Genetics Foundation Ethical Committee.\\nPeripheral blood mononuclear cells and purified B lymphocytes\\n\\nwere obtained as described elsewhere.22\\n\\nFlow cytometric analyses \\n\\nAntibodies used for flow cytometry are detailed in the Online\\nSupplementary Materials and Methods. Data were acquired using a\\nFACSCanto  II  (BD  Biosciences,  Buccinasco,  Italy)  or  Gallios\\n(Beckman  Coulter)  flow  cytofluorimeter,  processed  with  DIVA\\nv6.1.3  (BD  Biosciences),  and  analyzed  with  FlowJo  version  9.01\\nsoftware  (TreeStar,  Ashland,  OR,  USA).  At  least  10,000  events\\nwere analyzed for each sample.\\n\\nTyping the HLA-G 14 base pair polymorphism \\n\\nGenomic DNA was extracted from peripheral blood mononu-\\nclear  cells  using  a  DNeasy  Blood  &  Tissue  Kit  (Qiagen,  Milan,\\nItaly). The HLA-G 14 bp polymorphism was genotyped by poly-\\nmerase chain reaction.23,24\\n\\nSoluble HLA-G detection by enzyme-linked \\nimmunosorbent assay\\n\\nsHLA-G1 and HLA-G5 levels were measured as reported previ-\\nously.25 After both enzyme-linked immunosorbent assay (ELISA)\\nmeasurements, the amount of sHLA-G1 was expressed as the dif-\\nference  between  sHLA-G1/HLA-G5  and  HLA-G5  concentra-\\ntions.26\\n\\nIsolation and culture of natural killer cells \\n\\nNK cells were isolated from peripheral blood mononuclear cells\\nor from decidua as described elsewhere.27,28 Purified NK cells were\\ncultured  on  allogeneic  irradiated  feeder  cells  in  the  presence  of\\n\\nHLA-G polymorphism in CLL\\n\\ninterleukin-2  (100  U/mL)  and  phytohemagglutinin  (1.5  ng/mL,\\nGibco, Life Technologies).27\\n\\nNatural killer cell apoptosis\\n\\nFreshly isolated or interleukin-2 activated NK cells were incu-\\nbated with different serum samples from CLL patients representa-\\ntive of the different 14 bp HLA-G polymorphism. After overnight\\nincubation, NK cell apoptosis was measured using annexin V and\\npropidium iodide (Invitrogen, Eugene, OR, USA).\\n\\nNatural killer cell cytolytic activity\\n\\nInterleukin-2-activated NK cells were tested for cytolytic activi-\\n\\nty in a 4 h 51Cr-release assay against the K562 cell line.27\\n\\nStatistical analyses\\n\\nOverall survival was measured from date of sampling to date of\\ndeath (event) or last follow-up (censoring). Survival analysis was\\nperformed  by  the  Kaplan-Meier  method.  The  crude  association\\nbetween time-fixed exposure variables at diagnosis and survival\\nwas  estimated  by  log-rank  analysis.  Statistical  significance  was\\ndefined as a P value <0.05. Statistical tests were performed using\\nGraphPad  Prism  6.0  software  (Graphpad  Software,  San  Diego,\\nCA, USA) and SPSS software v20.0 (Chicago, IL, USA).\\n\\nResults\\n\\nEffects of the HLA-G 14 base pair polymorphism \\non membrane and soluble protein expression \\nin patients with chronic lymphocytic leukemia\\n\\nThe  hypothesis  underlying  this  study  is  that  patients\\nwith a del/del genotype of the 14 bp polymorphism have\\nmore  stable  HLA-G mRNA,  resulting  in  higher  levels  of\\nthe molecule on the cell surface and in biological fluids.16\\nThis hypothesis was tested by determining the effects\\nof the 14 bp polymorphism on the expression of HLA-G\\nprotein  at  the  surface  of  CLL  B  cells  obtained  from  126\\npatients.  The  observed  levels  of  HLA-G  expression  on\\nCD19+/CD5+ CLL  B  lymphocytes  were  highly  variable\\n[mean ± standard error of mean (SEM) 7.35±1.13%, Figure\\n1A,B].  Patients  with  a  del/del  genotype  had  a  trend\\ntowards  increased  levels  (n=51,  mean  8.97±1.85)  of  sur-\\nface  HLA-G,  even  if  a  comparison  with  levels  in  ins/del\\n(n=48,  mean  6.38±2)  or  ins/ins  (n=27,  mean  6.03±1.77)\\npatients  was  not  statistically  significant  (Figure  1C).\\nHowever, when divided into quartiles, 25.4% of the 126\\npatients had a surface HLA-G expression by leukemic cells\\nabove  the  third  quartile  (third  quartile  value:  9.5%).  Of\\nthese,  58%  had  a  del/del,  23%  an  ins/del  and  19%  an\\nins/ins genotype (P<0.0001, χ\\nAttention  was  next  focused  on  HLA-G  plasma  levels\\nassayed by ELISA in a cohort of 60 patients and 60 sex-\\nand age-matched controls. Results indicate a marked vari-\\nability  in  concentration  in  both  CLL  patients  (mean  ±\\nSEM,  19.71±2.83  ng/mL)  and  controls  (mean  ±  SEM,\\n17.28±23.64  ng/mL),  without  statistically  significant  dif-\\nferences between the two groups (Figure 2A). When CLL\\npatients and controls were divided according to genotype,\\ndel/del  patients  (n=27)  had  significantly  higher  levels  of\\nsHLA-G (mean 30.82±4.8 ng/mL) than had either ins/del\\n(n=18, mean 13.68±3.67 ng/mL, P=0.015, Mann-Whitney\\ntest)  or  ins/ins  patients  (n=15,  mean  6.95±2.74  ng/mL,\\nP=0.003, Mann-Whitney test, Figure 2B). Del/del controls\\nshowed a tendency towards a higher production of sHLA-\\n\\n2 test, Figure 1D). \\n\\nhaematologica | 2014; 99(5)\\n\\n889\\n\\n\\x0cR. Rizzo et al.\\n\\nG  (n=22,  mean  22.06±27.32  ng/mL)  when  compared  to\\nins/del (n=25, mean 16.93±24.87 ng/mL) or ins/ins (n=13,\\nmean 9.88 ± 11.90 ng/mL) individuals, without the differ-\\nence reaching statistical significance (Online Supplementary\\nFigure  S1A).  After  dividing  sHLA-G  levels  into  quartiles,\\n25% of CLL patients and of controls had sHLA-G expres-\\nsion above the third quartile (third quartile value in CLL\\npatients:  31.75  ng/mL;  third  quartile  value  in  controls:\\n24.40  ng/mL).  Of  these,  in  the  CLL  cohort  80%  had  a\\ndel/del genotype, while 13% had an ins/del genotype and\\nthe  remaining  7%  had  an  ins/ins  genotype  (P<0.0001,\\nFisher exact test, Figure 2C). When considering controls,\\n46%  presented  a  del/del,  46%  an  ins/del  and  8%  an\\nins/ins  genotype  (P<0.0001,  Fisher  exact  test,  Online\\nSupplementary Figure S1B).\\n\\nWe  then  asked  whether  sHLA-G  levels  correlate  with\\nHLA-G  expressed  on  the  membrane  of  CLL  cells.  As\\nexpected, the levels of expression of sHLA-G and mem-\\nbrane  HLA-G  were  positively  correlated  (n=60,  rho=0.4,\\nP=0.003,  Spearman  correlation  test),  in  line  with  a  rela-\\ntionship  between  surface  HLA-G  expression  and  release\\n(Figure 2D). The analysis of covariance showed an inde-\\npendent effect of 14 bp polymorphism (P=0.003) and sur-\\nface HLA-G expression (P=0.02) on sHLA-G plasma levels.\\nUsing an isoform-sensitive ELISA, sHLA-G1 was predom-\\ninant in the plasma of CLL patients, indicating a derivation\\nfrom  shedding  of  the  membrane  form  rather  than  from\\nalternative  splicing  (sHLA-G1  versus HLA-G5  isoforms,\\nP=0.001; Mann-Whitney test, Figure 2E). \\n\\nThe conclusion is that patients with a del/del genotype\\n\\nA\\n\\nC\\nS\\nS\\n\\n250k\\n\\n200k\\n\\n150k\\n\\n100k\\n\\n50k\\n\\n0\\n\\n5\\nD\\nC\\n\\n105\\n\\n104\\n\\n103\\n\\n102\\n\\n101\\n\\n100\\n\\nB\\n\\nC\\n\\n)\\n\\n%\\n\\n(\\n \\nG\\n-\\nA\\nL\\nH\\n \\ne\\nc\\na\\nf\\nr\\nu\\nS\\n\\n0\\n\\n50k\\n\\n100k\\n\\n150k\\nFSC\\n\\n200k\\n\\n250k\\n\\n100\\n\\n101\\n\\n102\\n103\\nCD19\\n\\n104\\n\\n105\\n\\n# 1 low\\n\\n# 2 intermediate\\n\\n100\\n\\n1 %\\n\\n19%\\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\n# 3 high\\n\\n54%\\n\\n100\\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\n100\\n\\n101\\n\\n102\\n\\n103\\n\\n104\\n\\n105\\n\\n100\\n\\n101\\n\\n102\\n\\n103\\n\\n104\\n\\n105\\n\\n100\\n\\n101\\n\\n102\\n\\n103\\n\\n104\\n\\n105\\n\\nHLA-G\\n\\nD\\n\\n100\\n\\ns\\nt\\nn\\ne\\ni\\nt\\na\\np\\n\\n \\nf\\no\\n%\\n\\n \\n\\n75\\n\\n50\\n\\n25\\n\\n0\\n\\nn=48\\n\\nn=51\\n\\nn=27\\n\\ndel/del\\n\\nins/del\\n\\nins/ins\\n\\nHLA-G genotype\\n\\nP<0.0001\\n\\n>9.5%\\n\\n<9.5%\\n\\ndel/del\\n\\nins/del\\n\\nins/ins\\n\\nHLA-G genotype\\n\\n100\\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\nHLA-G \\n\\nexpression \\n\\nFigure  1.  Distribution  of  membrane\\nHLA-G in a cohort of 126 CLL patients\\ntyped  for  the  14  bp  polymorphism.\\n(A) Density plots represent the gating\\nstrategy.  Left  panel  indicates  the\\nmorphological  gate, \\nright  panel\\nshows  the  staining  for  CD19  and\\nCD5.  (B)  Histograms  represent  sur-\\nface \\nin\\nCD19+/CD5+ CLL B lymphocytes from\\nthree  representative  patients.  (C)\\nPatients were then divided according\\nto  the  14  bp  polymorphism  into\\ngroups  with  del/del, \\nins/del  or\\nins/ins genotype. Box plots represent\\nthe distribution of mHLA-G in the dif-\\nferent  categories.  (D)  Graph  repre-\\nsenting  the  percentages  of  patients\\nexpressing  mHLA-G  above  (black\\nbars)  or  below  (open  bars)  the  third\\nquartile (9.5%).\\n\\n890\\n\\nhaematologica | 2014; 99(5)\\n\\n\\x0chave  significantly  higher  sHLA-G  levels  and  tend  to\\nexpress more membrane HLA-G on leukemic cells than do\\npatients with the other genotypes.\\nEffects of the HLA-G 14 base pair polymorphism on \\nthe number of circulating T lymphocytes in patients\\nwith chronic lymphocytic leukemia \\n\\nCLL  development  and  progression  are  paralleled  by  a\\nprogressive  impairment  of  host  immune  defenses,  with\\nclinically manifest immune defects of the T-cell compart-\\nment.  The  next  step  of  the  study  was  to  determine\\nwhether high levels of surface and sHLA-G would reflect\\nthe immune defects characterizing CLL. To this aim, the\\ncomposition  of  T-cell  subsets  was  assessed  in  52  CLL\\npatients  divided  according  to  HLA-G 14  bp  polymor-\\nphism.\\n\\nCD4+ and CD8+ and T-cell percentages were not signifi-\\ncantly different among the groups with the three HLA-G\\n14 bp genotypes (Figure 3A,B). In contrast, the number of\\nTreg, defined as CD4+/CD25high/CD127low), was significant-\\nly  higher  in  patients  with  the  del/del  genotype  (mean\\n6.97% ± 0.88) than in the group with the ins/ins genotype\\n(mean 3.23% ± 0.69, P=0.006, Mann-Whitney test, Figure\\n3C). Heterozygous patients displayed intermediate values,\\nnot significantly different from those in either the ins/ins\\nor del/del homozygous patients (mean 5.77% ± 0.78). The\\npercentage of Treg correlated positively with the levels of\\nexpression of surface HLA-G on CLL cells (n=33, rho=0.4,\\nP=0.04,  Spearman  correlation  test),  suggesting  that  the\\namount of HLA-G expressed by leukemic cells could influ-\\nence the frequency of Treg (Figure 3D). In line with this\\nobservation was the finding that the percentage of circu-\\nlating Treg was higher in cases of CLL with surface HLA-\\nG expression >9.5% (third quartile) than in CLL in which\\n\\nHLA-G polymorphism in CLL\\n\\nsurface  HLA-G  expression  was  <9.5%  (mean  6.95%  ±\\n0.98 versus mean 4.31% ± 0.52, P=0.03, Mann-Whitney U\\ntest; Figure 3E).\\n\\nNo statistically significant correlation could be detected\\nbetween sHLA-G levels and the frequency of Treg, likely\\ndue to the limited sample analyzed (n=13, data not shown).\\nHowever,  CLL  patients  in  whom  sHLA-G  levels  were\\n>31.75 ng/mL (third quartile) tended to have a higher per-\\ncentage  of  Treg  than  patients  in  whom  sHLA-G  levels\\nwere <31.75 ng/mL (mean 5.1% ± 1.44 versus mean 3.37%\\n±  0.52,  P=0.30,  Mann-Whitney  test,  Figure  3F).Together,\\nthese data suggest that HLA-G expression is linked to an\\nexpansion of Treg, as partly observed in other models.29\\nEffects of the HLA-G polymorphism on natural\\nkiller cell function\\n\\nAn alternative mechanism through which HLA-G mole-\\ncules  suppress  the  immune  response  is  their  inhibitory\\neffect on NK cell activation and cytotoxic functions, medi-\\nated  through  the  KIR2DL4  ligand.11 We,  therefore,  ana-\\nlyzed  the  possible  implication  of  sHLA-G  molecules  in\\nplasma samples on composition, activation and functional\\nactivities of NK cells in CLL samples. The reference con-\\ntrol was represented by healthy individuals matched for\\ngender and age. \\n\\nThe  number  of  circulating  NK  cells \\n\\n(gated  as\\nCD56+/CD3-) was sharply decreased in CLL patients (n=9,\\nmean 2.53% ± 0.88) as compared to controls (n=11, mean\\n11.52% ± 1.22, P<0.0001, Mann-Whitney test, Figure 4A). \\nThe  cytolytic  activity  of  NK  cells  isolated  from  CLL\\npatients (n=9) was tested after culture for 2-4 weeks in the\\npresence  of  interleukin-2.  Cells  were  then  assessed  for\\ntheir ability to lyse the K562 target cell line in a 51Cr-release\\ncytolytic  assay  at  different  effector:target  (E:T)  ratios\\n\\nA\\n\\n100\\n\\nn=60\\n\\nB\\n\\nP=0.003\\n\\nC\\n\\n100\\n\\nP=0.015\\n\\nn=27\\n\\nP<0.0001\\n\\n100\\n\\n<31.75 ng/mL\\n>31.75 ng/mL\\n\\n)\\nL\\nm\\n/\\ng\\nn\\n(\\n \\nG\\n-\\nA\\nL\\nH\\n \\ne\\nb\\nu\\no\\nS\\n\\nl\\n\\nl\\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\n75\\n\\n50\\n\\n25\\n\\n0\\n\\nCLL \\n\\ncontrols\\n\\n)\\nL\\nm\\n/\\ng\\nn\\n(\\n \\nG\\n-\\nA\\nL\\nH\\n \\ne\\nb\\nu\\no\\nS\\n\\nl\\n\\nl\\n\\nD\\n\\nn=18\\n\\nn=15\\n\\ndel/del\\n\\nins/del\\n\\nins/ins\\n\\nHLA-G genotype\\n\\n)\\nL\\nm\\n/\\ng\\nn\\n(\\n \\nG\\n-\\nA\\nL\\nH\\n \\ne\\nb\\nu\\no\\nS\\n\\nl\\n\\nl\\n\\n100\\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\nn=60\\nrho=0.4\\nP=0.003\\n80\\n\\n0\\n\\n20\\n\\n40\\n\\nHLA-G (%)\\n\\n60\\n\\ns\\nt\\nn\\ne\\ni\\nt\\na\\np\\n\\n \\nf\\no\\n%\\n\\n \\n\\nE\\n\\n)\\nL\\nm\\n/\\ng\\nn\\n(\\n \\nG\\n-\\nA\\nL\\nH\\n \\ne\\nb\\nu\\no\\nS\\n\\nl\\n\\nl\\n\\n75\\n\\n50\\n\\n25\\n\\n0\\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\ndel/del\\n\\nins/del\\n\\nins/ins\\n\\nHLA-G genotype\\n\\nP=0.001\\n\\nn=60\\n\\nn=60\\n\\nsHLA-G1 sHLA-G5\\n\\nFigure 2. Quantification of soluble HLA-G\\nlevels  in  a  cohort  of  60  CLL  patients\\ntyped  for  the  14  bp  polymorphism.  (A)\\nBox  plot  analysis  summarizing  data\\nobtained  with  a  quantitative  ELISA  per-\\nformed on 60 plasma samples from CLL\\npatients  and  60  plasma  samples  from\\ncontrol subjects (controls). The lower and\\nupper  limits  of  the  box  define  the  first\\nand  third  quartiles,  respectively,  while\\nthe  line  inside  the  box  represents  the\\nmedian. Whiskers identify minimum and\\nmaximum values. (B) Graph showing sol-\\nuble HLA-G levels in CLL patients divided\\naccording  to  the  14  bp  polymorphism\\ninto  del/del,  ins/del  and  ins/ins  cate-\\ngories.  (C)  Graph  representing  the  per-\\ncentages of CLL patients expressing sol-\\nuble HLA-G above (black bars) or below\\n(open  bars)  the  third  quartile  (31.75\\nng/mL)  in  the  three  genotypes.  (D)\\nRegression lines showing a positive cor-\\nrelation between the percentage of CLL\\ncells  expressing  HLA-G  on  the  cell  sur-\\nface and the amount of soluble HLA-G in\\nthe  plasma.  Spearman  coefficient  (rho)\\nand  the  corresponding  P value  are  pro-\\nvided. (E) Box plot showing the results of\\nan ELISA using isoform-specific antibod-\\nies to discriminate between soluble HLA-\\nG1 (derived from shedding of the mem-\\nbrane form) and soluble HLA-G5 (derived\\nfrom alternative splicing).\\n\\nhaematologica | 2014; 99(5)\\n\\n891\\n\\n\\x0cR. Rizzo et al.\\n\\nA\\n\\ns\\nl\\nl\\ne\\nc\\n \\n\\nT\\n\\n+\\n\\n4\\nD\\nC\\n\\n \\nf\\no\\n%\\n\\n \\n\\nD\\n\\ns\\n\\nl\\nl\\n\\ne\\nc\\n \\n\\ng\\ne\\nr\\nT\\n%\\n\\n \\n\\n20\\n\\n15\\n\\n10\\n\\n5\\n\\n0\\n\\n15\\n\\n10\\n\\n5\\n\\n0\\n\\n0\\n\\nB\\n\\n10\\n\\ns\\nl\\nl\\ne\\nc\\n \\n\\nT\\n\\n+\\n\\n8\\nD\\nC\\n\\n \\nf\\no\\n%\\n\\n \\n\\n8\\n\\n6\\n\\n4\\n\\n2\\n\\n0\\n\\nE\\n\\n15\\n\\n10\\n\\n5\\n\\ns\\n\\nl\\nl\\n\\ne\\nc\\n \\n\\ng\\ne\\nr\\nT\\n%\\n\\n \\n\\nn=16\\n\\nn=24\\n\\nn=12\\n\\ndel/del\\n\\nins/del\\n\\nins/ins\\n\\nHLA-G genotype\\n\\nP=0.032\\n\\nn=8\\n\\nn=21\\n\\n0\\nmembrane HLA-G (%)\\n\\n>9.5\\n\\n<9.5\\n\\nC\\n\\ns\\nl\\nl\\ne\\nc\\n \\n\\ng\\ne\\nr\\nT\\n%\\n\\n \\n\\nF\\n\\ns\\n\\nl\\nl\\n\\ne\\nc\\n \\n\\ng\\ne\\nr\\nT\\n%\\n\\n \\n\\n15\\n\\n10\\n\\n5\\n\\n0\\n\\n8\\n\\n6\\n\\n4\\n\\n2\\n\\n0\\n\\nP=0.006\\n\\nP=0.45\\n\\nn=13\\n\\nn=9\\n\\nn=6\\n\\ndel/del\\n\\nins/del\\n\\nins/ins\\n\\nHLA-G genotype\\n\\nP=0.30\\n\\nn=4\\n\\nn=9\\n\\n>31.75\\n\\n<31.75\\n\\nsoluble HLA-G (ng/mL)\\n\\nn=16\\n\\nn=24\\n\\nn=12\\n\\ndel/del\\n\\nins/del\\n\\nins/ins\\n\\nHLA-G genotype\\n\\nn=33\\nrho=0.4\\nP=0.04\\n5\\n20\\nmembrane HLA-G (%)\\n\\n10\\n\\n15\\n\\n25\\n\\nFigure 3. Evaluation of the T-cell compartment in CLL patients typed for the 14 bp polymorphism. Percentage of total CD4+ (A) and CD8+ (B)\\ncirculating  T  lymphocytes  and  Treg  (C)  in  CLL  patients  divided  according  to  the  14  bp  polymorphism.  Treg  were  defined  as\\nCD4+/CD25high/CD127low. (D) Regression line showing a positive correlation between membrane HLA-G and the percentage of circulating Treg.\\nSpearman coefficient (rho) and the corresponding P values are provided. (E) Percentage of Treg in CLL patients expressing membrane HLA-G\\nabove or below the third quartile (9.5%). (F) Percentage of Treg in CLL patients expressing soluble HLA-G above or below the third quartile\\n(31.75 mg/mL).\\n\\n(from 40:1 to 0.25:1). Controls were interleukin-2-activat-\\ned NK cells from healthy donors. As shown in Figure 4B,\\nthe  NK-cell-mediated  cytolytic  activity  in  CLL  patients\\nwas lower than that in healthy donors. Thus, for example,\\n40% target cell lysis was obtained at an E:T ratio of 2.5:1\\nfrom  healthy  donors  and  at  20:1  for  NK  cells  from  CLL\\npatients (Figure 4B). \\n\\nWe next asked whether KIR2DL4, the main HLA-G lig-\\nand,30 was expressed by NK cells. While resting NK cells\\nfrom  normal  donors  and  from  CLL  patients  lacked\\nKIR2DL4,  the  ligand  was  induced  upon  interleukin-2-\\nmediated NK cell activation, in agreement with published\\ndata30 (Figure  4C).  Representative  expression  plots  are\\nreported in Online Supplementary Figure S2, showing results\\nfrom an experiment in which decidual NK cells were used\\nas  a  positive  control.  No  differential  expression  in\\nKIR2DL4  was  noted  in  HLA-G  typed  patients  (data  not\\nshown). The next step was to test whether sHLA-G present\\nin plasma could induce apoptosis or inhibit the cytolytic\\nfunction  of  NK  cells  obtained  from  normal  donors.  To\\nanswer this question, we used plasma from CLL patients\\ncontaining different levels of sHLA-G to interfere with the\\n\\nviability  and  cytotoxic  activity  of  NK  cells.  Plasma  from\\nCLL  patients  significantly  compromised  the  viability  of\\nNK cells from normal donors, by inducing apoptosis. The\\neffect was directly correlated to sHLA-G levels in plasma,\\nwith  significantly  lower  survival  of  the  NK  cells  when\\nexposed  to  plasma  from  patients  with  sHLA-G  >31.75\\nng/mL as compared to plasma from patients with unde-\\ntectable sHLA-G (Figure 4D).\\n\\nSimilarly, NK cell function was significantly impaired in\\nthe  presence  of  CLL  plasma  samples  with  detectable\\nsHLA-G (P<0.0001, Mann-Whitney test, Figure 4E). At an\\nE:T  ratio  of  10:1  donor  NK  cells  in  the  absence  of  CLL\\nplasma  efficiently  killed  target  cells  (mean  85%  ±  1.63),\\nwhile  in  the  presence  of  CLL  plasma  samples  with\\ndetectable  sHLA-G,  the  cytolytic  activity  was  sharply\\nreduced (mean 27.38% ± 4.72). CLL plasma samples with\\nno sHLA-G were used as the control. The presence of NK\\ncell inhibition also in the presence of CLL plasma samples\\nwith undetectable sHLA-G suggests the presence of other\\nfactors implicated in NK cell activation control. However,\\nthe degree of inhibition correlated with the concentrations\\nof sHLA-G (Figure 4F). There was an inverse correlation\\n\\n892\\n\\nhaematologica | 2014; 99(5)\\n\\n\\x0cP<0.0001\\n\\nn=11\\n\\nn=9\\n\\nCLL\\n\\ncontrols\\n\\n20\\n\\n15\\n\\n10\\n\\n5\\n\\n0\\n\\nB\\n\\ns\\ni\\ns\\ny\\nl\\n \\nl\\nl\\ne\\nc\\n \\nf\\no\\n%\\n\\n \\n\\n100\\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\ncontrols\\nCLL\\n\\nC\\n\\ns\\nl\\nl\\ne\\nc\\n \\nK\\nN\\nn\\no\\n\\n \\n\\n \\n\\no\\ni\\nt\\na\\nr\\n \\nI\\nF\\nM\\n4\\nL\\nD\\n2\\nR\\nK\\n\\nI\\n\\n \\n\\n1\\n\\n:\\n\\n0\\n4\\n\\n1\\n\\n:\\n\\n0\\n2\\n\\n1\\n\\n:\\n\\n0\\n1\\n\\n1\\n\\n:\\n\\n5\\n\\n1\\n\\n:\\n\\n5\\n2\\n\\n1\\n\\n:\\n\\n5\\n2\\n\\n.\\n\\n1\\n\\n1\\n\\n:\\n\\n5\\n\\n.\\n\\n0\\n\\n1\\n\\n:\\n\\n5\\n2\\n\\n.\\n\\n0\\n\\nE:T ratio\\n\\nHLA-G polymorphism in CLL\\n\\n3\\n\\n2\\n\\n1\\n\\n0\\n\\nP=0.01\\n\\nn=10\\n\\nn=10\\n\\nday 0\\n\\nday 7\\n+ IL-2\\n\\nP<0.0001\\n\\n100\\n\\nP<0.0001\\n\\nP=0.009\\n\\nn=7\\n<0 ng/mL >25 ng/mL\\n\\nsHLA-G\\n\\nno\\n\\nplasma\\n\\nE\\n\\ns\\n\\ni\\n\\ns\\ny\\n\\nl\\n \\nl\\nl\\n\\ne\\nc\\n \\nf\\no\\n%\\n\\n \\n\\nP<0.0001\\n\\n100\\n\\nn=7\\n\\nF\\n\\n100\\n\\nP=0.001\\n\\nP=0.001\\n\\nn=7\\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\nn=12\\n\\nno\\n\\nplasma\\n\\nsHLA-G\\n\\ns\\n\\ni\\n\\ns\\ny\\n\\nl\\n \\nl\\nl\\n\\ne\\nc\\n \\nf\\no\\n%\\n\\n \\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\nP=0.002\\n\\nn=6\\n\\nn=6\\n\\nno\\n\\nplasma\\n\\n<0 ng/mL >25 ng/mL\\n\\nsHLA-G\\n\\n100\\n\\nP<0.0001\\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\ndel/del\\n\\nins/del\\n\\nins/ins\\n\\nH\\n\\nn\\no\\ni\\nt\\ni\\nb\\nh\\nn\\n\\ni\\n\\ni\\n \\ns\\ns\\ny\\n\\ni\\n\\nl\\n \\n\\n%\\n\\nA\\n\\ns\\nl\\nl\\ne\\nc\\n \\nK\\nN\\n\\n-\\n\\n3\\nD\\nC\\n\\n/\\n\\n+\\n\\n6\\n5\\nD\\nC\\n\\n \\nf\\no\\n%\\n\\n \\n\\nD\\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\ny\\nt\\ni\\nl\\ni\\n\\nb\\na\\n\\ni\\n\\nv\\n \\n%\\n\\nG\\n\\nn=22\\nrho=-0.49\\nP=0.02\\n\\n60\\n\\n40\\n\\n20\\n\\n)\\nL\\nm\\n/\\ng\\nn\\n(\\n \\nG\\n-\\nA\\nL\\nH\\n \\ne\\nb\\nu\\no\\nS\\n\\nl\\n\\nl\\n\\n0\\n\\n0\\n\\n20\\n\\n40\\n\\n60\\n\\n80\\n\\n100\\n\\nFigure 4. Evaluation of the NK cell compartment in CLL patients typed for the 14 bp polymorphism. (A) Percentage of circulating CD56+/CD3-\\nNK cells in seven CLL patients and in 11 healthy donors (controls) with a comparable age and male:female ratio. (B)  51Cr cytotoxicity assay\\ncomparing the lytic potential of in vitro interleukin-2-activated NK cells from controls (circles) or CLL patients (squares) against the K562 target\\ncell line. (C) Expression of KIR2DL4 in resting and interleukin-2-activated NK cells from CLL patients. Data are expressed as mean fluorescence\\nintensity (MFI) ratio. (D) Percentage of NK cell viability in the presence of sHLA-G-high and sHLA-G-low plasma from CLL patients. (E) Inhibition\\nof cytolytic activity of interleukin-2-activated HD-NK cells against K562 target cells in the presence or absence of plasma obtained from CLL\\npatients. (F) The inhibitory effect of CLL plasma on NK cell lysis was studied in patients with high levels of soluble HLA-G and compared to that\\nin patients with undetectable soluble HLA-G. (G) Regression line showing a negative correlation between the amount of soluble HLA-G and the\\npercentage of cell lysis. Spearman coefficient (rho) and the corresponding P value are provided. (H) Graph representing the percentage of NK\\ncell lysis inhibition obtained using plasma derived from patients categorized on the basis of HLA-G genotype. \\n\\nhaematologica | 2014; 99(5)\\n\\n893\\n\\n\\x0cR. Rizzo et al.\\n\\nbetween sHLA-G levels in CLL plasma samples (n=22) and\\nthe cytolytic activity of NK cells expressed as percentage\\ncell  lysis  (rho=  –0.49,  P=0.02,  Spearman  correlation  test,\\nFigure 4G). Consistent with the notion that CLL patients\\nwith del/del polymorphism have higher levels of sHLA-G\\ncompared  to  the  levels  in  patients  with  the  other  geno-\\ntypes, plasma from del/del patients showed greater inhibi-\\ntion than plasma from patients with the other genotypes.\\nThus, at an E:T ratio of 10:1, del/del plasma inhibited NK\\ncell  lysis  by  57.9%,  while  the  effects  exerted  by  ins/del\\nand  ins/ins  plasma  were  35.8%  and  5.3%,  respectively\\n(P<0.0001, Fisher exact test, Figure 4H). \\nProof-of-principle: the HLA-G 14 bp polymorphism\\ninfluences survival of patients with chronic \\nlymphocytic leukemia\\n\\nThe results obtained so far indicate that the HLA-G 14\\nbp polymorphism dictates the amount of HLA-G protein\\npresent  on  the  cell  surface  and  in  the  plasma  of  CLL\\npatients and that the molecule quantitatively and qualita-\\ntively modulates T and NK immunocompetence. In con-\\nsideration of the immunosuppressive features of HLA-G,\\npatients characterized by a del/del genotype would have\\nhigher  levels  of  HLA-G,  would  be  more  immunosup-\\npressed  and  ultimately  have  a  worse  clinical  outcome.\\nThis issue was approached by testing the frequency of the\\nHLA-G 14 bp polymorphism in 506 CLL patients (Online\\nSupplementary Table S1). The genotype frequencies were in\\nHardy-Weinberg  equilibrium:  176/506  patients  (34.8%)\\nwere  del/del  homozygous,  81/506  (16%)  were  ins/ins\\nhomozygous  and  the  remaining  249/506  (49.2%)  were\\nins/del heterozygous. None of the demographic (age and\\nsex),  clinical  (disease  stage,  splenomegaly,  lymph  node\\nsize), laboratory (lactate dehydrogenase or β2-microglobu-\\nlin  levels),  or  molecular  variables  (CD38,  ZAP-70,  IGHV\\nmutational  status,  chromosomal  aberrations)  showed  a\\npreferential  association  with  the  HLA-G polymorphism\\n(Online Supplementary Table S1). According to the survival\\nanalysis,  patients  harboring  the  del/del  genotype  had  a\\nshorter  survival  than  patients  harboring  the  ins/del  or\\nins/ins  genotype  (P=0.027,  log-rank  test,  Figure  5A).\\nConsistently, CLL patients with sHLA-G levels above the\\nthird quartile had a shorter survival (median, 63.9 months)\\nthan patients with sHLA-G levels below the third quartile\\n(median, 71.5 months, P=0.0215, log-rank test; Figure 5B),\\nand CLL patients with plasma samples showing inhibitory\\neffects  on  NK  cells  showed  a  trend  towards  having  a\\nshorter  survival  than  patients  whose  plasma  lacked\\ninhibitory effects (P=0.147, log-rank test, data not shown). \\n\\nDiscussion\\n\\nHLA-G  is  a  non-classical  HLA  protein  that  works  by\\nmodulating the main functions of NK cells and Treg. HLA-\\nG-mediated signals are critical in mediating tolerance dur-\\ning specific ontogenetic moments (e.g., pregnancy). HLA-\\nG may be expressed by tumor cells as part of a strategy to\\nevade the action of the innate and adaptive immune sys-\\ntem.\\n\\nTo test whether this may happen in CLL cells, HLA-G\\nexpression was assessed in a large cohort of CLL patients\\nwith well-defined molecular and clinical characteristics for\\nwhom survival data available. The originality of this work\\nis that the analyses of surface or sHLA-G expression were\\n\\nA\\n\\n100\\n\\n)\\n\\n%\\n\\n(\\n \\n\\ni\\n\\ni\\n\\ng\\nn\\nv\\nv\\nr\\nu\\ns\\n \\n\\nn\\no\\ni\\nt\\nr\\no\\np\\no\\nr\\nP\\n\\nHLA-G ins/del ins/ins\\n\\nHLA-G del/del\\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\nn=506\\nP=0.027\\n\\n0 24 48 72 96 120 144 168 192 216 240 264 288 312\\n\\nMonths\\n\\nB\\n\\n100\\n\\n)\\n\\n%\\n\\n(\\n \\n\\ng\\nn\\nv\\n\\ni\\n\\ni\\n\\nv\\nr\\nu\\ns\\n \\n\\nn\\no\\ni\\nt\\nr\\no\\np\\no\\nr\\nP\\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\nsHLA-G >31.75 ng/mL\\n\\nsHLA-G >31.75 ng/mL\\n\\nn=109\\nP=0.021\\n\\n0 24 48 72 96 120144 168 192 216 240 264 288 312 336\\n\\nMonths\\n\\nFigure  5.  Kaplan-Meier  curves  showing  overall  survival  in  506  CLL\\npatients. (A) Kaplan-Meier estimates of overall survival according to\\nHLA-G 14 bp genotype. (B) Kaplan-Meier estimates of overall survival\\naccording to soluble HLA-G levels. \\n\\naccompanied  by  characterization  of  the  14  bp  polymor-\\nphism in the 3’ untranslated region. This choice was dic-\\ntated by evidence derived from different models indicat-\\ning  that  this  polymorphism  accurately  predicts  the\\namount of transcribed protein, either bound to the mem-\\nbrane or released into biological fluids.\\n\\nOur results indicate an association between the del/del\\ngenotype  and  increased  levels  of  plasma  HLA-G  mole-\\ncules. This association is apparent only in CLL patients, as\\nplasma from age- and sex-matched controls failed to show\\na  statistically  significant  association  between  the  del/del\\ngenotype and the amount of plasma HLA-G. \\n\\nThe  situation  on  the  cell  membrane  is  less  defined:\\ndel/del patients more frequently expressed higher levels of\\nthe  molecule,  although  statistical  significance  was  not\\nreached. A potential explanation for this finding lies in the\\nrelative  instability  of  HLA-G  molecules  on  the  CLL  cell\\nmembrane. Results showing a correlation between mem-\\nbrane and sHLA-G levels support the view that the main\\nmechanism  of  generation  of  sHLA-G  is  shedding  rather\\nthan alternative splicing. This was confirmed by an analy-\\nsis of HLA-G isoforms, which demonstrated a dominance\\nof sHLA-G1, generated by proteolytic cleavage of mem-\\n\\n894\\n\\nhaematologica | 2014; 99(5)\\n\\n\\x0cbrane HLA-G1. No preference of isoform according to the\\n14 bp polymorphism was noted, in agreement with previ-\\nously published data.31,32\\n\\nA reasonable hypothesis to explain this result is that the\\nmembrane  form  represents  a  transitory  step.  A  conse-\\nquence is that quantification of soluble rather than surface\\nHLA-G  may  be  more  accurate.  This  is  also  in  line  with\\nprevious studies, which found that sHLA-G levels in plas-\\nma  were  higher  in  CLL  patients  than  in  healthy  con-\\ntrols.17,18 A second issue favoring the view that quantifica-\\ntion of soluble rather than membrane HLA-G is an inform-\\native and dependable assay derives from old and new facts\\nlinked  to  the  unique  lipid  structure  of  the  CLL  cell  sur-\\nface,33,34 potentially increasing the instability of the mem-\\nbrane  form.  In  agreement  with  this,  in  myeloma  cells\\nmHLA-G  is  also  released  from  the  cell  membrane  in\\nmicroparticles.35 These findings suggest that quantification\\nof sHLA-G may be clinically useful and more informative\\nthan analysis of the surface of tumor cells. \\n\\nThe second set of results obtained in this study may be\\nconsidered as tiles creating a tolerogenic mosaic, in which\\nHLA-G  molecules  represent  a  link  between  innate  and\\nadaptive immunity. Accordingly, the presence of a del/del\\ngenotype (i.e., with high sHLA-G levels) is paralleled by an\\nexpansion of Treg in the circulation. Supportive data come\\nfrom other models, in which HLA-G is reported to induce\\nTreg. As an example, peripheral blood mononuclear cells\\nexposed to sHLA-G5 acquire regulatory features, inhibit-\\ning  allo-proliferative  responses  exerted  by  other  T  lym-\\nphocytes.  It  is  also  known  that  patients  receiving  com-\\nbined liver/kidney transplants show high levels of sHLA-\\nG5,  which  correlate  with  increased  percentages  of  sup-\\npressor T cells.36 Similarly, stem-cell transplanted patients\\nhave high levels of sHLA-G5 in the peripheral blood, with\\na simultaneous expansion of CD4+/CD25+/CD152+ T lym-\\nphocytes with suppressive activity. Indirect confirmation\\nin the CLL model may be deduced from data showing that\\nan increase in Treg positively correlates with the presence\\nof clinical and biological features of aggressive disease.37\\n\\nNK cells obtained from CLL patients have less cytotoxic\\nactivity  than  NK  cell  populations  obtained  from  healthy\\ndonors of a comparable age. This suggests that leukemic\\ncells directly affect NK cell viability and/or activity. This\\nwould  be  achieved  through  binding  HLA-G  to  the\\nKIR2DL4 ligand, which becomes expressed once NK cells\\nare activated in the presence of interleukin-2. Our working\\nhypothesis  is  that  ectopic  expression  of  HLA-G  con-\\ntributes to block NK cell functions. With the aim of repro-\\nducing physiological conditions the experiments were per-\\nformed  using  whole  plasma  instead  of  purified  HLA-G.\\nThe  assumption  was  confirmed  by  incubating  NK  cells\\nobtained  from  normal  donors  with  plasma  from  CLL\\n\\nHLA-G polymorphism in CLL\\n\\npatients  containing  variable  amounts  of  sHLA-G.  This\\nwas followed by a marked induction of NK cell apoptosis,\\nwhich was proportional to the amount of sHLA-G present\\nin plasma. Furthermore, lysis inhibition was also propor-\\ntional to the amount of sHLA-G. It is worth noting that\\nCLL plasma samples with undetectable sHLA-G were able\\nto induce moderate NK cell apoptosis and to reduce NK\\ncell cytotoxicity. These results suggest the presence of fac-\\ntors  other  than  sHLA-G  that  are  able  to  control  NK  cell\\nactivation in CLL. As expected, NK cell function of del/del\\npatients was more impaired than that of ins/del or ins/ins\\npatients. \\n\\nIn  conclusion,  the  data  obtained  in  this  study  provide\\ntwo different sets of information. The first one indicates\\nthat  the  14  bp  polymorphism  influences  quantitative\\nanalyses  of  sHLA-G.  The  amount  of  sHLA-G  in  plasma\\nhas a prognostic value, suggesting that this specific assay\\nmay  be  relevant  in  the  management  of  CLL  patients,\\nrather than the mere measurement of membrane HLA-G.\\nThe  second  set  of  results  indicates  that  the  presence  of\\nHLA-G molecules in the neoplastic environment, in either\\na soluble form or bound to the membrane, creates a favor-\\nable setting for CLL expansion. As proof of this, evalua-\\ntion of the impact of the 14 bp polymorphism on the clin-\\nical outcome of the disease showed that del/del patients\\nhave  a  poorer  overall  survival  than  do  either    ins/del  or\\nins/ins patients. \\n\\nTaken together, our results support the view that HLA-\\nG molecules are part of the escape strategies designed by\\nCLL  cells  and  indicate  that  a  quantitative  analysis  of\\nsHLA-G levels may be of clinical relevance in the manage-\\nment of CLL patients.\\n\\nFunding\\nWork  supported  by  grants  from  the  Italian  Ministries  of\\nEducation,  University  and  Research  (Futuro  in  Ricerca  2008  #\\nRBFR08ATLH,  PRIN  2009  #  2009LMEEEH_002  e  #\\nNANLST_001,  FIRB  2010  #  RBAP11FXBC-005),  Italian\\nMinistry of Health (Bando Giovani Ricercatori 2008 # GR-2008-\\n1138053),  Associazione  Italiana  per  la  Ricerca  sul  Cancro\\nFoundation  (Special  Program  Molecular  Clinical  Oncology  5  x\\n1000 N. 10007; My First AIRC Grant N. 13470 and IG 12754),\\nFondazione  Cariplo,  Compagnia  di  San  Paolo \\n(N.\\nPMN_call_2012_0071) and local funds of the University of Turin\\n(ex-60%). \\n\\nThe Fondazione Ricerca Molinette provided valuable assistance\\n\\nand support.\\n\\nAuthorship and Disclosures\\nInformation on authorship, contributions, and financial & other\\ndisclosures was provided by the authors and is available with the\\nonline version of this article at www.haematologica.org.\\n\\nReferences\\n\\n1. Chiorazzi  N,  Rai  KR,  Ferrarini  M.  Chronic\\nlymphocytic leukemia. N Engl J Med. 2005;\\n352(8):804-15.\\n\\n2. Lotz M, Ranheim E, Kipps TJ. Transforming\\ngrowth  factor  beta  as  endogenous  growth\\ninhibitor of chronic lymphocytic leukemia B\\ncells. J Exp Med. 1994;179(3):999-1004.\\n\\n3. Benjamin D, Park CD, Sharma V. Human B\\n\\ninterleukin  10.  Leuk  Lymphoma.\\n\\ncell \\n1994;12(3-4):205-10.\\n\\n4. Ramsay AG, Johnson AJ, Lee AM, Gorgun\\nG, Le Dieu R, Blum W, et al. Chronic lym-\\nphocytic  leukemia  T  cells  show  impaired\\nimmunological  synapse  formation  that  can\\nbe  reversed  with  an  immunomodulating\\ndrug. J Clin Invest. 2008;118(7):2427-37.\\n\\n5. Giannopoulos  K,  Schmitt  M,  Wlasiuk  P,\\nChen  J,  Bojarska-Junak  A,  Kowal  M,  et  al.\\nThe high frequency of T regulatory cells in\\n\\npatients  with  B-cell  chronic  lymphocytic\\nleukemia  is  diminished  through  treatment\\nwith  thalidomide.  Leukemia.  2008;22(1):\\n222-4.\\n\\n6. D'Arena G, D'Auria F, Simeon V, Laurenti L,\\nDeaglio S, Mansueto G, et al. A shorter time\\nto the first treatment may be predicted by\\nthe absolute number of regulatory T-cells in\\npatients  with  Rai  stage  0  chronic  lympho-\\ncytic \\nJ  Hematol.\\n2012;87(6):628-31.\\n\\nleukemia.  Am \\n\\nhaematologica | 2014; 99(5)\\n\\n895\\n\\n\\x0cR. Rizzo et al.\\n\\n7. Serra S, Horenstein AL, Vaisitti T, Brusa D,\\nRossi  D,  Laurenti  L,  et  al.  CD73-generated\\nextracellular  adenosine  in  chronic  lympho-\\ncytic leukemia creates local conditions coun-\\nteracting  drug-induced  cell  death.  Blood.\\n2011;118(23):6141-52.\\n\\n8. Rizzo R, Bortolotti D, Baricordi OR, Fainardi\\nE. New insights into HLA-G and inflamma-\\ntory diseases. Inflamm Allergy Drug Targets.\\n2012;11(6):448-63.\\n\\n9. Carosella  ED.  The  tolerogenic  molecule\\n\\nHLA-G. Immunol Lett. 2011;138(1):22-4.\\n\\n10. Shiroishi  M,  Tsumoto  K,  Amano  K,\\nShirakihara Y, Colonna M, Braud VM, et al.\\nHuman  inhibitory  receptors  Ig-like  tran-\\nscript 2 (ILT2) and ILT4 compete with CD8\\nfor MHC class I binding and bind preferen-\\ntially  to  HLA-G.  Proc  Natl  Acad  Sci  USA.\\n2003;100(15):8856-61.\\n\\n11. Rajagopalan  S,  Long  EO.  A  human  histo-\\ncompatibility  leukocyte  antigen  (HLA)-G-\\nspecific  receptor  expressed  on  all  natural\\nkiller cells. J Exp Med. 1999;189(7):1093-100.\\n12. Du L, Xiao X, Wang C, Zhang X, Zheng N,\\nWang L, et al. Human leukocyte antigen-G is\\nclosely  associated  with  tumor  immune\\nescape  in  gastric  cancer  by  increasing  local\\nregulatory  T  cells.  Cancer  Sci.  2011;102(7):\\n1272-80.\\n\\n13. Diaz-Lagares  A,  Alegre  E,  LeMaoult  J,\\nCarosella ED, Gonzalez A. Nitric oxide pro-\\nduces HLA-G nitration and induces metallo-\\nprotease-dependent  shedding  creating  a\\ntolerogenic  milieu.  Immunology.  2009;126\\n(3):436-45.\\n\\n14. Rizzo R, Rubini M, Govoni M, Padovan M,\\nMelchiorri L, Stignani M, et al. HLA-G 14-bp\\npolymorphism  regulates  the  methotrexate\\nresponse \\narthritis.\\nPharmacogenet  Genomics.  2006;16(9):615-\\n23.\\n\\nrheumatoid \\n\\n15. Hviid  TV,  Rizzo  R,  Christiansen  OB,\\nMelchiorri  L,  Lindhard  A,  Baricordi  OR.\\nHLA-G  and  IL-10  in  serum  in  relation  to\\nHLA-G  genotype  and  polymorphisms.\\nImmunogenetics. 2004;56(3):135-41.\\n\\n16. Rizzo R, Hviid TV, Stignani M, Balboni A,\\nGrappa MT, Melchiorri L, et al. The HLA-G\\ngenotype  is  associated  with  IL-10  levels  in\\nactivated PBMCs. Immunogenetics. 2005;57\\n(3-4):172-81.\\n\\n17. Amiot  L,  Le  Friec  G,  Sebti  Y,  Drenou  B,\\nPangault  C,  Guilloux  V,  et  al.  HLA-G  and\\nlymphoproliferative \\nSemin\\nCancer Biol. 2003;13(5):379-85.\\n\\ndisorders. \\n\\n18. Sebti  Y,  Le  Friec  G,  Pangault  C,  Gros  F,\\n\\nin \\n\\nDrenou B, Guilloux V, et al. Soluble HLA-G\\nmolecules are increased in lymphoprolifera-\\ntive disorders. Hum Immunol. 2003; 64(11):\\n1093-101.\\n\\n19. Rezvany  MR,  Kazemi  A,  Hajifathali  A,\\nKaviani S, Mellstedt H. Analysis of HLA-G\\ngene  expression  in  B-lymphocytes  from\\nchronic lymphocytic leukemia patients. Iran\\nBiomed J. 2007;11(2):125-9.\\n\\n20. Nuckel H, Rebmann V, Durig J, Duhrsen U,\\nGrosse-Wilde H. HLA-G expression is asso-\\nciated  with  an  unfavorable  outcome  and\\nimmunodeficiency  in  chronic  lymphocytic\\nleukemia. Blood. 2005;105(4):1694-8.\\n\\n21. Erikci AA, Karagoz B, Ozyurt M, Ozturk A,\\nKilic  S,  Bilgi  O.  HLA-G  expression  in  B\\nchronic lymphocytic leukemia: a new prog-\\nnostic  marker?  Hematology.  2009;14(2):\\n101-5.\\n\\n22. Deaglio  S,  Vaisitti  T,  Bergui  L,  Bonello  L,\\nHorenstein  AL,  Tamagnone  L,  et  al.  CD38\\nand CD100 lead a network of surface recep-\\ntors  relaying  positive  signals  for  B-CLL\\ngrowth  and  survival.  Blood.  2005;105\\n(8):3042-50.\\n\\n23. Hviid TV, Rizzo R, Melchiorri L, Stignani M,\\nBaricordi  OR.  Polymorphism  in  the  5'\\nupstream  regulatory  and  3'  untranslated\\nregions of the HLA-G gene in relation to sol-\\nuble  HLA-G  and  IL-10  expression.  Hum\\nImmunol. 2006;67(1-2):53-62.\\n\\n24. Rizzo  R,  Bortolotti  D,  Fredj  NB,  Rotola  A,\\nCura F, Castellazzi M, et al. Role of HLA-G\\n14bp deletion/insertion and +3142C>G poly-\\nmorphisms  in  the  production  of  sHLA-G\\nmolecules  in  relapsing-remitting  multiple\\nsclerosis. Hum Immunol. 2012;73(11):1140-6.\\n25. Rebmann  V,  LeMaoult  J,  Rouas-Freiss  N,\\nCarosella \\nH.\\nQuantification and identification of soluble\\nHLA-G  isoforms.  Tissue  Antigens.  2007;69\\n(Suppl 1):143-9.\\n\\nGrosse-Wilde \\n\\nED, \\n\\n26. Fainardi  E,  Rizzo  R,  Melchiorri  L,  Stignani\\nM, Castellazzi M, Caniatti ML, et al. Soluble\\nHLA-G  molecules  are  released  as  HLA-G5\\nand not as soluble HLA-G1 isoforms in CSF\\nof patients with relapsing-remitting multiple\\nsclerosis.  J  Neuroimmunol.  2007;192(1-\\n2):219-25.\\n\\n27. Vacca P, Martini S, Garelli V, Passalacqua G,\\nMoretta  L,  Mingari  MC.  NK  cells  from\\nmalignant  pleural  effusions  are  not  anergic\\nbut  produce  cytokines  and  display  strong\\nantitumor activity on short-term IL-2 activa-\\ntion. Eur J Immunol. 2013;43(2):550-61.\\n\\n28. Vacca  P,  Cantoni  C,  Vitale  M,  Prato  C,\\n\\nCanegallo  F,  Fenoglio  D,  et  al.  Crosstalk\\nbetween  decidual  NK  and  CD14+\\nmyelomonocytic cells results in induction of\\nTregs  and  immunosuppression.  Proc  Natl\\nAcad Sci USA. 2010;107(26):11918-23.\\n\\n29. Castellaneta A, Mazariegos GV, Nayyar N,\\nZeevi  A,  Thomson  AW.  HLA-G  level  on\\nmonocytoid  dendritic  cells  correlates  with\\nregulatory  T-cell  Foxp3  expression  in  liver\\ntransplant \\ntolerance.  Transplantation.\\n2011;91(10):1132-40.\\n\\n30. Rajagopalan S, Bryceson YT, Kuppusamy SP,\\nGeraghty DE, van der Meer A, Joosten I, et\\nal. Activation of NK cells by an endocytosed\\nreceptor  for  soluble  HLA-G.  PLoS  Biol.\\n2006;4(1):e9.\\n\\n31. Hviid TV, Hylenius S, Rorbye C, Nielsen LG.\\nHLA-G  allelic  variants  are  associated  with\\ndifferences  in  the  HLA-G  mRNA  isoform\\nprofile \\nand  HLA-G  mRNA \\nlevels.\\nImmunogenetics. 2003;55(2):63-79.\\n\\n32. Svendsen SG, Hantash BM, Zhao L, Faber C,\\nBzorek M, Nissen MH, et al. The expression\\nand functional activity of membrane-bound\\nhuman leukocyte antigen-G1 are influenced\\nby \\nregion.  Hum\\nImmunol. 2013;74(7):818-27.\\n\\nthe  3'-untranslated \\n\\n33. Daefler S, Krueger GR. Expression of prolif-\\neration  and  differentiation  antigens  in\\nresponse to modulation of membrane fluid-\\nity  in  chronic  lymphocytic  leukemia  lym-\\nphocytes. Anticancer Res. 1989;9(2):501-6.\\n\\n34. Herishanu Y, Kay S, Dezorella N, Baron S,\\nHazan-Halevy I, Porat Z, et al. Divergence in\\nCD19-mediated signaling unfolds intraclon-\\nal  diversity \\nlymphocytic\\nleukemia, which correlates with disease pro-\\ngression. J Immunol. 2013;190(2):784-93.\\n\\nin  chronic \\n\\nT,  Gilliam  M, \\n\\n35. Kshirsagar SK, Alam SM, Jasti S, Hodes H,\\nNauser \\nal.\\nImmunomodulatory molecules are released\\nfrom the first trimester and term placenta via\\nexosomes. Placenta. 2012;33(12):982-90.\\n\\n36. Naji  A,  Le  Rond  S,  Durrbach  A,  Krawice-\\nRadanne  I,  Creput  C,  Daouya  M,  et  al.\\nCD3+CD4low  and  CD3+CD8low  are\\ninduced by HLA-G: novel human peripheral\\nblood suppressor T-cell subsets involved in\\ntransplant  acceptance.  Blood.  2007;110(12):\\n3936-48.\\n\\n37. D'Arena  G,  Laurenti  L,  Minervini  MM,\\nDeaglio  S,  Bonello  L,  De  Martino  L,  et  al.\\nRegulatory  T-cell  number  is  increased  in\\nchronic lymphocytic leukemia patients and\\ncorrelates  with  progressive  disease.  Leuk\\nRes. 2011;35(3):363-8.\\n\\net \\n\\n896\\n\\nhaematologica | 2014; 99(5)\\n\\n\\x0cHindawi Publishing Corporation\\nCardiology Research and Practice\\nVolume 2013, Article ID 603913, 5 pages\\nhttp://dx.doi.org/10.1155/2013/603913\\n\\nResearch Article\\nEffect of Ivabradine on Endothelial Function in Diastolic and\\nRight Heart Failure Patients\\n\\nArturo Orea-Tejeda,1 Karla Balderas-Muñoz,1 Lilia Castillo-Martínez,1\\nOscar Infante-Vázquez,2 Raúl Martínez Memije,2 Candace Keirns-Davis,3\\nJoel Dorantes-García,4 René Narváez-David,4 and Zuilma Vázquez-Ortíz4\\n1 Heart Failure Clinic, Instituto Nacional de Ciencias M´edicas y Nutrici´on Salvador Zubir´an, Mexico\\n2 Instrumentation Department, Instituto Nacional de Cardiolog´ıa “ICh”, Mexico\\n3 Massachusetts General Hospital, Boston, MA, USA\\n4 Cardiology Department, Instituto Nacional de Ciencias M´edicas y Nutrici´on Salvador Zubir´an, Mexico\\n\\nCorrespondence should be addressed to Lilia Castillo-Mart´ınez; caml1225@yahoo.com\\n\\nReceived 18 June 2013; Revised 12 August 2013; Accepted 28 August 2013\\n\\nAcademic Editor: Gregory Giamouzis\\n\\nCopyright © 2013 Arturo Orea-Tejeda et al. This is an open access article distributed under the Creative Commons Attribution\\nLicense, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly\\ncited.\\n\\nBackground. Ivabradine is an If ion current inhibitor that has proved to reduce mortality in patients with systolic heart failure by\\nslowing heart rate without decreasing myocardial contractility. Photoplethysmography is a simple, low-cost optical technique that\\ncan evaluate vascular function and detect changes in blood flow, pulse, and swelling of tissular microvascular space. Objective.\\nTo evaluate the effect of ivabradine on endothelial function by photoplethysmography in diastolic and right heart failure patients.\\nMethodology. 15 patients were included (mean age of 78.1 ± 9.2 years) with optimally treated diastolic and right heart failure. They\\nunderwent photoplethysmography before and after induced ischemia to evaluate the wave blood flow on the finger, using the\\nmaximum amplitude time/total time (MAT/TT) index. Two measurements were made before and after oral Ivabradine (mean\\n12.5 mg a day during 6 months of followup). Results. In the study group, the MAT/TT index was 29.1 ± 2.2 versus 24.3 ± 3.2 (𝑃 = 0.05)\\nin basal recording and 30.4 ± 2.1 versus 23.3 ± 2.9 (𝑃 = 0.002), before versus after ischemia and before versus after Ivabradine\\nintervention, respectively. Conclusions. Ivabradine administration improves endothelial function (shear stress) in diastolic and right\\nheart failure patients.\\n\\n1. Background\\nDiastolic dysfunction has been associated with symptoms\\nof congestive heart failure in patients with preserved left\\nventricular ejection fraction [1]. In the largest single-center\\nstudy with approximately 36, 000 outpatients with normal\\nLVEF, some authors have shown that diastolic dysfunction is\\nan independent predictor of all-cause mortality [2].\\n\\nIn outpatients with heart failure with preserved ejection\\nfraction (HFpEF) at the baseline echocardiogram, worsening\\nof diastolic function in a follow-up study is also an inde-\\npendent predictor of all-cause mortality [3]. In addition,\\nAchong showed that improvement in diastolic function was\\nassociated with increased survival (𝑃 = 0.05) in a mixed\\ncohort of inpatients and outpatients with normal or mild\\n\\nsystolic dysfunction [4], while the more advanced the stage\\nis, the higher the filling pressures and the worse the outcomes\\nare [5].\\n\\nIn patients with atrial fibrillation, if diastolic function was\\nassessed, it was based on deceleration time of mitral E-wave\\nvelocity and tissue Doppler imaging (i.e., peak early mitral\\ninflow velocity/diastolic early tissue velocity [E/e\\U000f8020]) [6].\\n\\nIvabradine added to recommended treatment, improved\\nthe outcome of heart failure patients reducing cardiovascular\\ndeath and hospitalizations rate [7]. In patients with coronary\\ndisease and left ventricular dysfunction also the benefit was\\nobserved [8]. In experimental studies, ivabradine have been\\ndemonstrated that reduces fibrosis and improve endothelial\\nfunction [9–12].\\n\\n\\x0c2\\n\\nCardiology Research and Practice\\n\\nIvabradine also has demonstrated a favorable effect on\\nLV remodeling after 8 months of followup as well as and\\nantianginal effect [13].\\n\\nHyperemic coronary blood flow velocity also increases\\nafter ivabradine treatment, probably because the diastolic\\nperiod is prolonged (per cardiac beat and per minute). It has\\nbeen speculated that the most probable explanation of the\\nimprovement of ventricular relaxation caused by ivabradine\\ntreatment could be its effect on coronary blood flow velocity\\nduring hyperemia [14].\\n\\nTo evaluate the effect of ivabradine on endothelial func-\\ntion by photoplethysmography in patients with right heart\\nfailure and preserved ejection fraction, we performed this\\nopen-label clinical trial.\\n\\n2. Methods\\n2.1. Study Population. This open-label clinical trial included\\nambulatory patients who came to the Heart Failure Clinic\\nof the Instituto Nacional de Ciencias M´edicas y Nutrici´on\\n“Salvador Zubir´an.” Patients were recruited if they were\\nmen or nongravid women with more than 18 years of age\\nwith a confirmed diagnosis of stable heart failure with\\npreserved ejection fraction in New York Heart Association\\nfunctional classes II to III. Candidates were excluded if they\\nhad had myocardial infarction, unstable angina or a history\\nof myocardial revascularization (percutaneous transluminal\\ncoronary angioplasty or aortocoronary bypass grafts), cere-\\nbrovascular events during the previous 3 months, dysfunc-\\ntional prosthetic heart valve, obstructive or nonobstructive\\ncardiomyopathy, uncorrected congenital heart disease, active\\nmyocarditis, a history of resuscitation from sudden death, or\\nsevere arrhythmias.\\n\\nHeart failure was established by signs and symptoms as\\nwell as echocardiographic and radioisotopic ventriculogra-\\nphy findings. Preserved ejection fraction was defined as a left\\nventricular ejection fraction ≥ 50%, LVEDVI < 97 mL/m2,\\nleft atrial diameter > 40 mL/m2, tissue doppler E/E\\U000f8020\\n> 15\\necho-blood flow Doppler E/A in >50 years <0.5, and DT in\\n>50 years >280 ms [15]. Right ventricular dysfunction was\\ndefined as ejection fraction ≤ 35% measured by radioisotopic\\nventriculography [16, 17].\\n\\nAll patients received standard heart\\n\\nfailure therapy\\nand their comorbidities (diuretics, angiotensin-converting\\nenzyme inhibitors, angiotensin II antagonists, aldosterone\\nreceptor blockers, digitalis, and beta-adrenoreceptor block-\\ners), at their maximum doses tolerated. Some patients that\\ndeveloped atrial fibrillation also received digital.\\n\\n2.2. Study Design. This was an investigator-initiated, single\\ncenter, single-arm, open-label clinical trial.\\n\\nAfter baseline measurements, in addition to conventional\\ntherapy, patients received an average of ivabradine 12.5 mg\\n(10–15 mg) a day, according their tolerance during 6 months\\nof follow-up [18, 19]. Patients underwent 2D and Doppler\\nechocardiograms and radioisotopic (rest/effort) left and right\\nventriculography before and after oral ivabradine.\\n\\nTable 1: Demographic and clinical characteristics of the CHF\\npatients.\\n\\nVariables\\nAge (years)\\nFemale (%)\\nArterial hypertension (%)\\nHypothyroidism (%)\\nDiabetes mellitus (%)\\nCOPD (%)\\nDyslipidemia (%)\\nEnd Stage Kidney disease (%)\\nFunctional class (NYHA):\\n\\nII\\nIII\\n\\n𝑁 = 15\\n\\n78.1 ± 9.2\\n\\n73.3\\n73.3\\n53.3\\n33.3\\n33.3\\n26.6\\n26.6\\n\\n60\\n40\\n\\n2.2.1. Photoplethysmography. A baseline digital photoplethys-\\nmographic wave was recorded for 30 seconds. The forearm\\nwas then compressed with a sphygmomanometer cuff for\\n5 minutes using a pressure of 30 mmHg above the systolic\\narterial pressure recorded (ischemic phase). The compression\\nwas then released and the digital photoplethysmographic\\nwave was recorded for 120 seconds. The wave was analyzed\\nat 30-second intervals for comparison with the baseline\\nvalues. The most representative waves were selected from\\nthe recording of each interval, and the maximum amplitude\\ntime (MAT) and total time (TT) were measured in order to\\ncalculate the MAT/TT index. A MAT/TT index of less than 30\\nwas considered normal, as proposed in other studies [20, 21].\\nCardiologists who performed the echocardiograms and\\nradioventriculography did not have access to patients’ infor-\\nmation.\\n\\n2.3. Statistical Analysis. Continuous variables were expressed\\nas mean ± standard deviation (SD) and categorical variables\\nas percentages. To compare the changes from baseline to\\n6 months, a paired t-test was used. A 𝑃 value of <0.05\\nwas considered statistically significant. All analyses were\\nperformed using a commercially available package (SPSS for\\nWindows, version 17.0 SPSS Inc.).\\n\\n3. Results\\nFifteen patients (73.6% female) were studied. Arterial hyper-\\ntension and hypothyroidism (under treatment and well\\ncontrolled) were the most common comorbidities with\\npatients in functional classes (NYHA) II and III (Table 1).\\nIt is important to note that COPD and ESKD patients\\nwere not excluded from the study. Concomitant medica-\\ntion was as follows: diuretic (73%) and adrenergic beta\\nblocker receptor (BB, 73%) agents were the most commonly\\nemployed; 46.6% also received mineralocorticoid receptor\\nantagonists (MRAmedications) and angiotensin-converting-\\nenzyme inhibitors (ACEIs)/angiotensin receptors blockers\\n(ARB).\\n\\n\\x0cCardiology Research and Practice\\n\\n3\\n\\nMaximum amplitude time/total time (MAT/TT) index\\n\\nPreischemic\\n\\nperiod\\n\\nPostischemic\\n\\nperiod\\n\\n29.1 ± 2.2\\n\\n30.4 ± 2.1\\n\\nBefore\\n\\nIvabradine\\n\\nAfter\\n\\n24.3 ± 3.2\\n\\n23.3 ± 2.9\\n\\nP = 0.05\\n\\nP = 0.002\\n\\nFigure 1: Pre and after ischemic period, before and after 6 months\\nof follow-up of oral ivabradine.\\n\\nPatients received an average of 12.5 (range 10–15) mg/day\\nduring the 6 months of followup. It was particularly interest-\\ning that heart rate did not decrease in any patients below the\\n10% recommended (88 versus 82 beats/min) in the literature\\nin spite of the top doses received.\\n\\nFigure 1 shows the maximum amplitude time/total time\\n(MAT/TT) index before and after the followup. A significant\\nincrease in pre- and post-ischemic periods after ivabradine\\nadministration is evident when basal values are compared\\nwith those at the end of followup.\\n\\nImprovement of the endothelial-dependent vasodilata-\\ntion expressed by significant changes observed in the photo-\\nplethysmographic curves occurred concurrently. All patients\\nhad some degree of clinical improvement, 8/9 (88.8%) from\\nNYHA III to II and 4/6 (66.6%) from II to I, respectively,\\nalthough this did not achieve statistical significance (𝑃 =\\n0.08).\\n\\nWith respect to cardiac structural changes, in the echo-\\ncardiographic study, only right ventricular diastolic diameter\\n(40.5 ± 7.8 versus 36.4 ± 5.3; 𝑃 = 0.05) was significantly\\ndifferent after the followup. There was also a reduction of\\n8.15% in the systolic pulmonary arterial pressure (59.6 ± 8.4\\nversus 54.9 ± 10.2; 𝑃 = 0.05).\\n\\n4. Discussion\\nApproximately 50% of patients with heart failure (HF)\\nhave normal or preserved left ventricular ejection fraction\\n(HFPEF) [22], and their prognosis is similar to that of\\npatients with HF with reduced LVEF (HFREF) [22, 23]. Left\\nventricular diastolic dysfunction (LVDD) plays an important\\nrole in patients with HFPEF [24] and could be due to\\nstructural and molecular abnormalities of the cardiovascular\\nsystem. These abnormalities include myocardial ischemia,\\ncardiac hypertrophy, cardiac inflammation [25], and ventric-\\nular vascular stiffening, in part due to the reduced effects of\\nnitric oxide and impaired endothelial function [26]. Borlaug\\net al. recently demonstrated that global cardiovascular reserve\\nfunctions, including endothelial function, are impaired in\\nsubjects with HFNEF who have hypertension, a very frequent\\n\\ncause of HF [27]. In HFREF, coronary endothelial function is\\nalso impaired [28], and it has been reported that peripheral\\nendothelial dysfunction is associated with the severity of HF\\nsymptoms and clinical outcome in patients with HFREF [29,\\n30]. Moreover, vascular stiffness and resistance with elevated\\nblood pressure has been proposed as a potential important\\nnoncardiac factor in patients with HFpEF [31].\\n\\nEndothelial dysfunction has been shown to be involved in\\nthe pathogenesis of HF, mainly HFREF. Several studies have\\nreported that peripheral endothelial dysfunction is associated\\nwith the clinical outcome in patients with HFREF [30].\\nBorlaug et al. recently reported that subjects with HFpEF had\\nlimited arterial vasodilator response to exercise, which might\\nimpair cardiac output reserve under stress [32].\\n\\nPeripheral endothelial function is impaired in patients\\nwith HFpEF, and when it is evaluated as a reactive hyper-\\nemia by peripheral arterial tonometry (RH-PAT), it signifi-\\ncantly correlates with future cardiovascular events. Peripheral\\nendothelial function is thus an independent predictor after\\nadjusting various clinical parameters [33]. Indeed, the prog-\\nnostic impact of the reactive hyperemia index in patients with\\nHFpEF suggests that endothelial dysfunction may not be a\\npassive finding, but may rather play an active and important\\npathophysiologic role in HFpEF [32]. When matched in\\npatients and controls for diabetes and hypertension, more\\nendothelial dysfunction was found in patients with HFPEF,\\nwho were notably more obese than controls [34].\\n\\nThe results of the systolic heart failure treatment with the\\nIf inhibitor ivabradine trial (SHIFT) showed that treatment\\nwith ivabradine added to conventional therapy for HF was\\nassociated with an 18% reduction in the relative risk for\\nthe primary composite endpoint of cardiovascular death or\\nhospitalization for worsening HF (𝑃 < 0.0001) [7]. It also had\\na positive effect on LV remodelling in the echocardiographic\\nsubstudy of the BEAUTIFUL (morBidity-mortality EvAlUa-\\nTion of the If inhibitor ivabradine in patients with coronary\\ndisease and left ventricULar dysfunction) study [8].\\n\\nIn experimental studies, ivabradine has been demon-\\nstrated to reduces fibrosis and improve endothelial function\\n[9–12], together with its antiischemic and antianginal effects\\n[13] which could explain why all our patients improved\\ntheir functional class, possibly associated with increased\\nhyperemic coronary blood flow velocity. It may also be\\nexplained by the prolonged diastolic period (per cardiac\\nbeat and per minute). Moreover, we can speculate that\\nthe endothelial-dependent vasodilatation expressed by the\\nsignificant changes observed in the photoplethysmographic\\ncurves in peripheral and coronary territories plays an impor-\\ntant role in improving coronary blood reserve as has already\\nbeen described [35, 36], and flow velocity may have a\\ndirect effect on coronary vessels and reduced ventricular\\nwall tension, with improvement of ventricular relaxation [14],\\nadded to diminished right ventricular diastolic diameter with\\nsignificant reduction of arterial pulmonary pressure, which\\nprobably reflects improved coronary perfusion pressure (aor-\\ntic mean pressure/coronary sinus ratio).\\n\\nIn experimental postinfarction settings, both cardiac [37]\\nand pulmonary vascular [38] endothelial dysfunction may\\n\\n\\x0c4\\n\\nCardiology Research and Practice\\n\\ncontribute to the development of heart failure through endo-\\ncardial and myocardial capillary endothelial abnormalities\\n[39] and could explain the impaired left ventricular relaxation\\nin pressure-overload hypertrophy [40].\\n\\nPreserved ejection fraction is present in almost 50%\\nof heart failure patients and is cause of half of HF hos-\\npitalizations, and traditional HF treatment is not effective.\\nA recently published pathophysiology-based novel phar-\\nmacotherapy for these patients considers spironolactone,\\naliskiren, and neprilisyn as therapeutic options for HFPEF\\nbecause of their anti-hypertrophic and anti-fibrotic effects\\n[41]. Combined ventricular and vascular stiffening involving\\nboth the systemic and pulmonary circulations, plays a role\\nin the pathophysiology of HFpEF [42, 43]. Thus, the effects\\nof ivabradine on endothelial function, that we observed,\\nmay represent a major advantage when it is used to treat\\nleft diastolic dysfunction because of its secondary impact\\non pulmonary arterial hypertension and damaged right\\nventricular function.\\n\\n5. Limitations\\nThe number of patients studied was small, and the interven-\\ntion period was short. It is probable that a longer followup\\nwould show changes in variables such as left ventricular\\ndiastolic diameter and other structural characteristics. In\\naddition, the lack of direct quantification of pulmonary\\npressures is a drawback.\\n\\nOur findings support continued investigation into the\\neffects of ivabradine on right ventricular function, systemic\\narterial pressure, and systolic pulmonary arterial pressure in\\nheart failure patients with preserved ejection fraction. More\\nstudies are required to evaluate the effects observed on a\\nlarger number of patients for a longer period.\\n\\nReferences\\n[1] W. Aljaroudi, M. C. Alraies, C. Halley et al., “Impact of\\nprogression of diastolic dysfunction on mortality in patients\\nwith normal ejection fraction,” Circulation, vol. 125, no. 6, pp.\\n782–788, 2012.\\n\\n[2] M. Senni, C. M. Tribouilloy, R. J. Rodeheffer et al., “Congestive\\nheart failure in the community: a study of all incident cases in\\nOlmsted County, Minnesota, in 1991,” Circulation, vol. 98, no.\\n21, pp. 2282–2289, 1998.\\n\\n[3] B. G. Angeja and W. Grossman, “Evaluation and management of\\ndiastolic heart failure,” Circulation, vol. 107, no. 5, pp. 659–663,\\n2003.\\n\\n[4] P. M. Mottram and T. H. Marwick, “Assessment of diastolic\\nfunction: what the general cardiologist needs to know,” Heart,\\nvol. 91, no. 5, pp. 681–695, 2005.\\n\\n[5] C. M. Halley, P. L. Houghtaling, M. K. Khalil, J. D. Thomas,\\nand W. A. Jaber, “Mortality rate in patients with diastolic\\ndysfunction and normal systolic function,” Archives of Internal\\nMedicine, vol. 171, no. 12, pp. 1082–1087, 2011.\\n\\n[6] H. Okura, Y. Takada, T. Kubo et al., “Tissue Doppler-derived\\nindex of left ventricular filling pressure, E/E\\U000f8020, predicts survival\\nof patients with non-valvular atrial fibrillation,” Heart, vol. 92,\\nno. 9, pp. 1248–1252, 2006.\\n\\n[7] K. Swedberg, M. Komajda, M. B¨ohm et al., “Ivabradine and\\noutcomes in chronic heart failure (SHIFT): a randomised\\nplacebo-controlled study,” The Lancet, vol. 376, no. 9744, pp.\\n875–885, 2010, Erratum in The Lancet, vol. 376, p. 1988, 2010.\\n\\n[8] C. Ceconi, S. B. Freedman, J. C. Tardif et al., “Effect of heart\\nrate reduction by ivabradine on left ventricular remodeling in\\nthe echocardiographic substudy of BEAUTIFUL,” International\\nJournal of Cardiology, vol. 146, no. 3, pp. 408–414, 2011.\\n\\n[9] P. Mulder, S. Barbier, A. Chagraoui et al., “Long-term heart\\nrate reduction induced by the selective If current inhibitor\\nivabradine improves left ventricular function and intrinsic\\nmyocardial structure in congestive heart failure,” Circulation,\\nvol. 109, no. 13, pp. 1674–1679, 2004.\\n\\n[10] E. I. Dedkov, W. Zheng, L. P. Christensen, R. M. Weiss, F.\\nMahlberg-Gaudin, and R. J. Tomanek, “Preservation of coro-\\nnary reserve by ivabradine-induced reduction in heart rate in\\ninfarcted rats is associated with decrease in perivascular col-\\nlagen,” American Journal of Physiology—Heart and Circulatory\\nPhysiology, vol. 293, no. 1, pp. H590–H598, 2007.\\n\\n[11] P. Milliez, S. Messaoudi, J. Nehme, C. Rodriguez, J.-L. Samuel,\\nand C. Delcayre, “Beneficial effects of delayed ivabradine treat-\\nment on cardiac anatomical and electrical remodeling in rat\\nsevere chronic heart failure,” American Journal of Physiology—\\nHeart and Circulatory Physiology, vol. 296, no. 2, pp. H435–\\nH441, 2009.\\n\\n[12] M. Vercauteren, J. Favre, P. Mulder, F. Mahlberg-Gaudin, C.\\nThuillez, and V. Richard, “Protection of endothelial function by\\nlong-term heart rate reduction induced by ivabradine in a rat\\nmodel of chronic heart failure,” European Heart Journal, vol. 28,\\nsupplement, p. 48, 2007.\\n\\n[13] G. Riccioni, N. Vitulano, and N. D’Orazio, “Ivabradine: beyond\\nheart rate control,” Advances in Therapy, vol. 26, no. 1, pp. 12–24,\\n2009.\\n\\n[14] E. I. Skalidis, M. I. Hamilos, G. Chlouverakis, E. A. Zacharis,\\nand P. E. Vardas, “Ivabradine improves coronary flow reserve\\nin patients with stable coronary artery disease,” Atherosclerosis,\\nvol. 215, no. 1, pp. 160–165, 2011.\\n\\n[15] W. J. Paulus, C. Tsch¨ope, J. E. Sanderson et al., “How to diagnose\\ndiastolic heart failure: a consensus statement on the diagnosis\\nof heart failure with normal left ventricular ejection fraction\\nby the Heart Failure and Echocardiography Associations of the\\nEuropean Society of Cardiology,” European Heart Journal, vol.\\n28, no. 20, pp. 2539–2550, 2007.\\n\\n[16] N. F. Voelkel, R. A. Quaife, L. A. Leinwand et al., “Right\\nventricular function and failure: report of a National Heart,\\nLung, and Blood Institute working group on cellular and\\nmolecular mechanisms of right heart failure,” Circulation, vol.\\n114, no. 17, pp. 1883–1891, 2006.\\n\\n[17] J. F. Setaro, M. W. Cleman, and M. S. Remetz, “The right\\nventricle in disorders causing pulmonary venous hypertension,”\\nCardiology Clinics, vol. 10, no. 1, pp. 165–183, 1992.\\n\\n[18] F. M. Sarullo, G. Fazio, D. Puccio et al., “Impact of “off-label”\\nuse of ivabradine on exercise capacity, gas exchange, functional\\nclass, quality of life, and neurohormonal modulation in patients\\nwith ischemic chronic heart failure,” Journal of Cardiovascular\\nPharmacology and Therapeutics, vol. 15, no. 4, pp. 349–355, 2010.\\n[19] A. Schuster and W. H. W. Tang, “Ivabradine in heart failure: to\\nSHIFT or not to SHIFT,” Current Heart Failure Reports, vol. 8,\\nno. 1, pp. 1–3, 2011.\\n\\n[20] J. T. Kuvin, A. R. Patel, K. A. Sliney et al., “Assessment of\\nperipheral vascular endothelial function with finger arterial\\n\\n\\x0cCardiology Research and Practice\\n\\n5\\n\\n[35] M. B. Britten, A. M. Zeiher, and V. Sch¨achinger, “Microvascular\\ndysfunction in angiographically normal or mildly diseased\\ncoronary arteries predicts adverse cardiovascular long-term\\noutcome,” Coronary Artery Disease, vol. 15, no. 5, pp. 259–264,\\n2004.\\n\\n[36] B. A. Herzog, L. Husmann, I. Valenta et al., “Long-term prog-\\nnostic value of 13N-ammonia myocardial perfusion positron\\nemission tomography added value of coronary flow reserve,”\\nJournal of the American College of Cardiology, vol. 54, no. 2, pp.\\n150–156, 2009.\\n\\n[37] X.-L. Qi, D. J. Stewart, H. Gosselin et al., “Improvement of\\nendocardial and vascular endothelial function on myocardial\\nperformance by captopril treatment in postinfarct rat hearts,”\\nCirculation, vol. 100, no. 12, pp. 1338–1345, 1999.\\n\\n[38] A. Ben Driss, C. Devaux, D. Henrion et al., “Hemodynamic\\nstresses induce endothelial dysfunction and remodeling of\\npulmonary artery in experimental compensated heart failure,”\\nCirculation, vol. 101, no. 23, pp. 2764–2770, 2000.\\n\\n[39] D. Popov, A. Sima, D. Stern, and M. Simionescu, “The patho-\\nmorphological alterations of endocardial endothelium in exper-\\nimental diabetes and diabetes associated with hyperlipidemia,”\\nActa Diabetologica, vol. 33, no. 1, pp. 41–47, 1996.\\n\\n[40] P. A. MacCarthy and A. M. Shah, “Impaired endothelium-\\ndependent regulation of ventricular relaxation in pressure-\\noverload cardiac hypertrophy,” Circulation, vol. 101, no. 15, pp.\\n1854–1860, 2000.\\n\\n[41] D. M. Konstantinou, Y. S. Chatzizisis, and G. D. Giannoglou,\\n“Pathophysiology-based novel pharmacotherapy for heart fail-\\nure with preserved ejection fraction,” Pharmacology & Thera-\\npeutics, 2013.\\n\\n[42] C. S. P. Lam, V. L. Roger, R. J. Rodeheffer et al., “Cardiac\\nstructure and ventricular-vascular function in persons with\\nheart failure and preserved ejection fraction from Olmsted\\nCounty, Minnesota,” Circulation, vol. 115, no. 15, pp. 1982–1990,\\n2007.\\n\\n[43] C. S. P. Lam, V. L. Roger, R. J. Rodeheffer, B. A. Borlaug, F.\\nT. Enders, and M. M. Redfield, “Pulmonary hypertension in\\nheart failure with preserved ejection fraction: a community-\\nbased study,” Journal of the American College of Cardiology, vol.\\n53, no. 13, pp. 1119–1126, 2009.\\n\\npulse wave amplitude,” American Heart Journal, vol. 146, no. 1,\\npp. 168–174, 2003.\\n\\n[21] A. Aldama, H. ´Alvarez, A. Rodr´ıguez, and B. Reyes, “Evaluaci´on\\ncualitativa de la morfolog´ıa de la se˜nal fotopletismogr´afica en\\nel diagn´ostico de la insuficiencia arterial,” Revista Cubana de\\nInvestigaciones Biom´edicas, vol. 27, no. 1, 2008.\\n\\n[22] R. S. Bhatia, J. V. Tu, D. S. Lee et al., “Outcome of heart failure\\nwith preserved ejection fraction in a population-based study,”\\nThe New England Journal of Medicine, vol. 355, no. 3, pp. 260–\\n269, 2006.\\n\\n[23] T. E. Owan, D. O. Hodge, R. M. Herges, S. J. Jacobsen, V. L.\\nRoger, and M. M. Redfield, “Trends in prevalence and outcome\\nof heart failure with preserved ejection fraction,” The New\\nEngland Journal of Medicine, vol. 355, no. 3, pp. 251–259, 2006.\\n[24] M. R. Zile, C. F. Baicu, and W. H. Gaasch, “Diastolic heart\\nfailure: abnormalities in active relaxation and passive stiffness\\nof the left ventricle,” The New England Journal of Medicine, vol.\\n350, no. 19, pp. 1953–1959, 2004.\\n\\n[25] J. Matsubara, S. Sugiyama, T. Nozaki et al., “Pentraxin 3 is a new\\ninflammatory marker correlated with left ventricular diastolic\\ndysfunction and heart failure with normal ejection fraction,”\\nJournal of the American College of Cardiology, vol. 57, no. 7, pp.\\n861–869, 2011.\\n\\n[26] M. Ouzounian, D. S. Lee, and P. P. Liu, “Diastolic heart failure:\\nmechanisms and controversies,” Nature Reviews Cardiology, vol.\\n5, pp. 375–386, 2008.\\n\\n[27] B. A. Borlaug, T. P. Olson, C. S. P. Lam et al., “Global car-\\ndiovascular reserve dysfunction in heart failure with preserved\\nejection fraction,” Journal of the American College of Cardiology,\\nvol. 56, no. 11, pp. 845–854, 2010.\\n\\n[28] S. H. Kubo, T. S. Rector, A. J. Bank, R. E. Williams, and S. M.\\nHeifetz, “Endothelium-dependent vasodilation is attenuated in\\npatients with heart failure,” Circulation, vol. 84, no. 4, pp. 1589–\\n1596, 1991.\\n\\n[29] M. A. AlZadjali, V. Godfrey, F. Khan et al., “Insulin resistance\\nis highly prevalent and is associated with reduced exercise\\ntolerance in non-diabetic patients with heart failure,” Journal of\\nthe American College of Cardiology, vol. 53, no. 9, pp. 747–753,\\n2009.\\n\\n[30] D. Fischer, S. Rossa, U. Landmesser et al., “Endothelial dys-\\nfunction in patients with chronic heart failure is independently\\nassociated with increased incidence of hospitalization, cardiac\\ntransplantation, or death,” European Heart Journal, vol. 26, no.\\n1, pp. 65–69, 2005.\\n\\n[31] G. Cotter, M. Metra, O. Milo-Cotter, H. C. Dittrich, and M. Ghe-\\norghiade, “Fluid overload in acute heart failure—re-distribution\\nand other mechanisms beyond fluid accumulation,” European\\nJournal of Heart Failure, vol. 10, no. 2, pp. 165–169, 2008.\\n\\n[32] B. A. Borlaug, V. Melenovsky, S. D. Russell et al., “Impaired\\nchronotropic and vasodilator reserves limit exercise capacity in\\npatients with heart failure and a preserved ejection fraction,”\\nCirculation, vol. 114, no. 20, pp. 2138–2147, 2006.\\n\\n[33] E. Akiyama, S. Sugiyama, Y. Matsuzawa et al., “Incremental\\nprognostic significance of peripheral endothelial dysfunction in\\npatients with heart failure with normal left ventricular ejection\\nfraction,” Journal of the American College of Cardiology, vol. 60,\\nno. 18, pp. 1778–1786, 2012.\\n\\n[34] C. S. Lam and D. L. Brutsaert, “Endothelial dysfunction: a\\npathophysiologic factor in heart failure with preserved ejection\\nfraction,” Journal of the American College of Cardiology, vol. 60,\\nno. 18, pp. 1787–1789, 2012.\\n\\n\\x0cSubmit your manuscripts at\\n\\nhttp://www.hindawi.com\\n\\nHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013Oxidative Medicine and Cellular LongevityHindawi Publishing Corporation http://www.hindawi.comVolume 2013Hindawi Publishing Corporation http://www.hindawi.comVolume 2013The Scientific World JournalInternational Journal ofEndocrinologyHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013ISRN AnesthesiologyHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013OncologyJournal ofHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013PPARResearchHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013OphthalmologyJournal ofHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013ISRN AllergyHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013BioMed Research InternationalHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013ObesityJournal ofHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013ISRN AddictionHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013Hindawi Publishing Corporationhttp://www.hindawi.comVolume 2013 Computational and  Mathematical Methods in MedicineISRN AIDSHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013Clinical &DevelopmentalImmunologyHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013Diabetes ResearchJournal ofHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013Evidence-Based Complementary and Alternative MedicineVolume 2013Hindawi Publishing Corporationhttp://www.hindawi.comHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013Gastroenterology Research and PracticeHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013ISRN BiomarkersHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013MEDIATORSINFLAMMATIONof\\x0c\""
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "merged_text"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "9f238bf7",
   "metadata": {},
   "source": [
    "#### Data Preparation and EDA"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "5e8cd8fa",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[nltk_data] Downloading package wordnet to\n",
      "[nltk_data]     C:\\Users\\Zaid\\AppData\\Roaming\\nltk_data...\n",
      "[nltk_data]   Package wordnet is already up-to-date!\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "\"Haematologia, Vol. 30, No. 1, pp. 27–30 (2000)\\n(cid:211) VSP 2000.\\n\\nSerum L-selectin and P-selectin levels in lymphomas\\n\\nShort communication\\n\\nI. C. HAZNEDARO ˇGLU, M. BENEKLI\\nI. H. GÜLLÜ, S. V. DÜNDAR and ¸S. KIRAZLI\\nDepartment of Internal Medicine, Hematology and Oncology Division, Hacettepe University\\nMedical School, Ankara, Turkey\\n\\n, O. OZCEBE, M. C. SAVA ¸S,\\n\\n(cid:3)\\n\\nAbstract—The migration of normal and malignant lymphoid cells is governed by speciﬁc adhesion\\nmolecules. Selectins comprise a family of adhesion receptors expressed by leukocytes, platelets and\\nendothelial cells. In this study, the serum levels of soluble L-selectin and P-selectin were measured in\\npatients with non-Hodgkin’s lymphoma and Hodgkin’s disease and found to be signiﬁcantly elevated\\nin both patient groups compared to healthy controls. This result provides evidence that alterations in\\nthe expression and function of adhesion molecules may play an important role in the progression of\\nlymphomas. Further studies are awaited to establish the exact roles of these adhesion molecules in\\ndistinct patterns of growth and spread of lymphomas.\\n\\nKey words: L-selectin; P-selectin; Hodgkin’s disease; non-Hodgkin’s lymphoma.\\n\\nINTRODUCTION\\n\\nAdhesion of lymphocytes to endothelium is essential in lymphocyte trafﬁcking\\n[1, 2]. Lymphocytes migrate from the circulation by selective attachment to spe-\\ncialized endothelial cells lining the postcapillary high endothelial venules (HEV)\\nin organized lymphoid tissues, lymph nodes and Peyer’s patches. Selectins com-\\nprise a family of adhesion molecules which have been demonstrated to participate in\\nthe initial tetherting/ rolling of leukocytes on activated endothelium [3]. L-selectin\\n(CD62L, LAM-1, LECAM-1) mediates the binding of lymphocytes to HEV of\\nperipheral lymph nodes through interactions with corresponding endothelial lig-\\nand and therefore also known as the lymphocyte homing receptor [4]. P-selectin\\n(CD62P, PADGEM, GMP-140) is stored both in the alpha granules in platelets and\\nWeibel-Palade bodies of endothelial cells [5] and involved in the stabilization of\\n\\n(cid:3)\\n\\nTo whom correspondence should be addressed. M. Benekli, 14. Sokak, 43/ 8. Bahçelievler,\\n\\nAnkara, Turkey.\\n\\n\\x0c28\\n\\nI. C. Haznedaroˇglu et al.\\n\\nplatelet aggregates and in the interaction of leukocytes with activated platelets or\\nendothelial cells [6].\\n\\nLymphoma cells represent immortalized counterparts of normal lymphocytes. A\\nsimilar adhesion mechanism is also utilized by malignant lymphoid cells during\\ndissemination [7, 8]. Altered expression patterns of adhesion molecules appear\\nto be involved in the spread of lymphoid malignancies and Hodgkin’s disease\\n(HD) [7–10]. In this study, serum levels of soluble L-selectin and P-selectin were\\ndetermined in patients with HD and non-Hodgkin’s lymphoma (NHL) and in normal\\nhealthy individuals.\\n\\nPATIENTS AND METHODS\\n\\nThe study group consisted of 17 patients (10 NHL, 7 HD; 11 men, 6 women; median\\nage 35 years, range 19– 70) and 15 healthy volunteers (11 men, 4 women; median\\nage 49 years, range 36– 67). Out of 10 NHL patients, 5 were classiﬁed as low-\\ngrade, 1 intermediate, and 4 high-grade according to the Working Formulation.\\nFour patients out of 7 with HD had mixed cellularity, 1 nodular sclerosis, and\\n2 lymphocyte predominance type. Staging was performed according to the Ann\\nArbor system.\\nIn NHL, 2 patients had stage III and 8 patients had stage IV\\ndisease, and in HD 1 patient had stage II, 2 stage III, and the remaining 4 stage IV\\ndisease. All patients with HD and 3 out of 10 with NHL had B-symptoms. Serum\\nL-selectin and P-selectin levels were determined using a commercially available\\nELISA kit (Bender MedSystems, Vienna, Austria) according to the manufacturer’s\\ninstructions. Data are presented as mean (cid:6) SD. Mann–Whitney U test was used\\nfor statistical analysis.\\n\\nRESULTS\\nAdhesion molecule levels were signiﬁcantly higher in lymphoma patients compared\\nto healthy controls (Table 1) (Fig. 1). Serum levels of sL-Selectin (1137 (cid:6)\\n428 ng/ml vs 625 (cid:6) 159 ng/ml; p D 0:0023 and sP-Selectin (610 (cid:6) 211 ng/ml\\nvs 178 (cid:6) 48 ng/ ml; p D 0:0001) were signiﬁcantly increased in patients with\\nnon-Hodgkin’s lymphoma compared to the control group. In HD, serum soluble\\nL-selectin (1140 (cid:6) 498 ng/ml; p D 0:0082) and P-selectin (875 (cid:6) 370 ng/ ml;\\np D 0:0002) concentrations were signiﬁcantly elevated also compared to healthy\\ncontrols (625 (cid:6) 159 ng/ ml and 178 (cid:6) 48 ng/ml for L-selectin and P-selectin,\\nrespectively).\\n\\nDISCUSSION\\n\\nDisseminating malignant lymphoma cells and lymphocytes share several character-\\nistics, including migration and extravasation involving adhesive interactions [7, 8].\\n\\n\\x0cAdhesion molecules in lymphomas\\n\\n29\\n\\nTable 1.\\nSerum soluble P-selectin and L-selectin levels in the study group\\n\\nPatients\\n\\nHD\\nHNL\\nControls\\n\\nP-selectin (ng/ml)\\n875 (cid:6) 370\\n610 (cid:6) 211\\n178 (cid:6) 48\\n\\n* Compared with healthy controls.\\n\\n(cid:3)\\n\\np\\n\\n0.0002\\n0.0001\\n\\nL-selectin (ng/ml)\\n1140 (cid:6) 498\\n1137 (cid:6) 428\\n625 (cid:6) 159\\n\\n(cid:3)\\n\\np\\n\\n0.0082\\n0.0023\\n\\nFigure 1. Circulating soluble P-selectin and L-selectin levels in the study group.\\n\\nEmerging evidence indicates that the adhesion molecules governing the homing\\nof normal lymphocytes also mediate the dissemination of their neoplastic counter-\\nparts. Adhesion molecules have also been demonstrated to function in the spread\\nof HD [9, 10]. Therefore, we determined serum levels of soluble adhesion mole-\\ncules, L-selectin and P-selectin as indicators of distinctive clinical and biological\\nbehaviour of lymphoid malignancies.\\nIn this report we demonstrated that serum\\nconcentrations of these adhesion receptors are increased in patients with HD and\\nNHL. Our results conﬁrm and extend data published previously on the role of dis-\\ntinct adhesion molecules in lymphomas. Elevated levels of circulating intercellular\\nadhesion molecule-1 were reported in various hematologic malignancies including\\nHD [9, 10], acute lymphoblastic leukemia [10], chronic lymphocytic leukemia [11]\\nand NHL [12, 13], and non-hematologic malignancies [10, 13]. To our knowledge,\\n\\n\\x0c30\\n\\nI. C. Haznedaroˇglu et al.\\n\\nthis report is the ﬁrst investigating the levels of circulating L-selectin and P-selectin\\nin NHL and HD.\\n\\nDifferential expression of these adhesion molecules may account for diverse\\npatterns of growth and dissemination of lymphomas. The study of adhesion\\nmolecule expression and function may allow a better understanding of the malignant\\nbehavior of lymphoid cells. Our data need to be validated and extended in a\\nmore homogenous patient series in order to elucidate the clinical and prognostic\\nsigniﬁcance of L-selectin and P-selectin in lymphomas.\\n\\nREFERENCES\\n\\n1. Shimizu, Y., Newman, W., Tanaka, Y., Shaw, S., Lymphocyte interactions with endothelial cells,\\n\\nImmunol. Today 13, 106 (1992).\\n\\n2. Stoolman, L. M., Adhesion molecules controlling lymphocyte migration, Cell 56, 907 (1989).\\n3. Bevilacqua, M. P., Nelson, R. M., Selectins, J. Clin. Invest. 91, 379 (1993).\\n4. Gallatin, W. M., Weissman, I. L., Butcher, E. C., A cell-surface molecule involved in organ-\\n\\nspeciﬁc homing of lymphocytes, Nature 304, 30 (1983).\\n\\n5. Bonfanti, R., Furie, B. C., Furie, B., Wagner, D. D., PADGEM (GMP 140) is a component of\\n\\nWeibel-Palade bodies of human endothelial cells, Blood 73, 1109 (1989).\\n\\n6. De Bruijne-Admiraal, L. G., Modderman, P. W., Von dem Borne, A. E. G. Kr., Sonnenberg, A.,\\n-dependent adhesion of activated platelet to many different types of\\n\\nC\\nP-selectin mediates Ca2\\nleukocytes: Detection by ﬂow cytometry, Blood 80, 134 (1992).\\n\\n7. Pals, S. T., Horst, E., Scheper, R. J., Meijer, C. J. L. M., Mechanisms of human lymphocyte\\n\\nmigration and their role in the pathogenesis of disease, Immunol. Rev. 108, 111 (1989).\\n\\n8. Pals, S. T., Drillenburg, P., Radaszkiewicz, T., Manten-Horst, E., Adhesion molecules in the\\n\\ndissemination of non-Hodgkin’s lymphomas, Acta Haematol. 97, 73 (1997).\\n\\n9. Gruss, H.-J., Dölken, G., Brach, M. A., Mertelsmann, R., Herrmann, F., Serum levels of\\n\\ncirculating ICAM-1 are increased in Hodgkin’s disease, Leukemia 8, 1245 (1993).\\n\\n10. Pui C.-H., Luo, X., Evans, W., Martin, S., Rugg, A., Wilimas, J., Crist, W. M., Hudson, M.,\\n\\nSerum intercellular adhesion molecule-1 in childhood malignancy, Blood 82, 895 (1993).\\n\\n11. Christiansen, I., Gidlöf, C., Wallgren, A. C., Simonsson, B., Tötterman, T. H., Serum levels of\\nsoluble intercellular adhesion molecule-1 are increased in chronic B-lymphocytic leukemia and\\ncorrelate with clinical stage and prognostic markers, Blood 84, 3010 (1994).\\n\\n12. Christiansen, I., Gidlöf, C., Kalkner, K.-M., Hagberg, H., Bennmarker, H., Tötterman, T.,\\nElevated serum levels of soluble ICAM-1 in non-Hodgkin’s lymphomas correlate with tumour\\nburden, disease activity and other prognostic markers, Br. J. Haematol. 92, 639 (1996).\\n\\n13. Benekli, M., Güllü, I. H., Tekuzman, G., Sava¸s, M. C., Hayran, M., Hasçelik, G., Fırat, D.,\\nCirculating intercellular adhesion molecule-1 and E-selectin in gastric cancer, Br. J. Cancer 78,\\n267 (1998).\\n\\n\\x0c\\x0cC(cid:2) 2008, the Authors\\nJournal compilation C(cid:2) 2008, Wiley Periodicals, Inc.\\nDOI: 10.1111/j.1540-8175.2008.00696.x\\n\\nCell Therapy in Patients with Left Ventricular\\nDysfunction Due to Myocardial Infarction\\nRoman Panovsky, M.D., Ph.D.,∗ Jaroslav Meluzin, M.D., Ph.D, F.E.S.C.,∗\\nStanislav Janousek, M.D., Ph.D.,† Jiˇr´ı Mayer, M.D., Ph.D.,‡ Milan Kaminek, M.D., Ph.D.,§\\nLadislav Groch, M.D.,∗ Jiˇr´ı Prasek, M.D., Ph.D.,¶ Jaroslav Stanicek, M.D.,(cid:4) Ladislav Dusek,\\nM.D.,# Ota Hlinomaz, M.D., Ph.D.,∗ Petr Kala, M.D., Ph.D.,† Martin Klabusay, M.D., Ph.D.,‡\\nZdenek Koristek M.D.,‡ and Milan Navratil M.D.‡\\n∗First Department of Internal Medicine/Cardioangiology, St. Anna Hospital, Masaryk University,\\nBrno, Czech Republic, †Department of Internal Medicine/Cardiology, Brno University Hospital,\\nBrno, Czech Republic, ‡Department of Internal Medicine/Hematooncology, Brno University\\nHospital, Brno, Czech Republic, §Department of Nuclear Medicine, UH Olomouc, Czech Republic,\\n¶Department of Nuclear Medicine, Brno University Hospital, Brno, Czech Republic, (cid:4)Department\\nof Nuclear Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic, and #Center of\\nBiostatistics and Analyses, Brno University Hospital, Brno, Czech Republic\\n\\nObjectives: The purpose of this study was to determine the impact of autologous transplantation\\nof mononuclear bone marrow cells on myocardial function in patients with left ventricular (LV)\\ndysfunction due to an acute myocardial infarction. Methods: The randomized study included 82\\npatients with a ﬁrst acute myocardial infarction treated with a stent implantation. This presentation\\nis a subanalysis of 47 patients with left ventricular dysfunction–EF (ejection fraction) ≤ 40%. Group\\nH patients (n = 17) received higher number (100,000,000) of cells; Group L patients (n = 13) received\\nlower number (10,000,000) of cells. The patients of control Group C (n = 17) were not treated with\\ncells. The Doppler tissue imaging and single photon emission computed tomography were performed\\nbefore cell transplantation and 3 months later. Results: At 3 months of follow-up, the baseline EF\\nof 35%, 36%, 35% in Groups H, L, and C increased by 6% (P < 0.01 vs. baseline), 5% (P < 0.01 vs.\\nbaseline), and 4% (P = NS vs. baseline), respectively, as assessed by single photon emission computed\\ntomography (P = NS between groups). The baseline number of akinetic segments of 6.9, 7.0, and 6.2 in\\nH, L, and C groups decreased by 1.7 (P < 0.01 vs. baseline), 1.5 (P < 0.01 vs. baseline), and 0.7 (P = NS\\nvs. baseline, P = NS between groups), respectively, as demonstrated by echocardiography. Conclusion:\\nIn our study, the statistically important effect of transplantation of mononuclear bone marrow cells\\non myocardial function was not found. Only an insigniﬁcant trend toward the improvement of global\\nLV EF fraction was found at 3-month follow-up. (ECHOCARDIOGRAPHY, Volume 25, September\\n2008)\\n\\nstem cells, coronary artery disease, left ventricular dysfunction\\n\\nPostmyocardial infarction congestive heart\\nfailure remains to be a major clinical prob-\\nlem, despite advances in the medical and sur-\\n\\nThe work was supported in part by a grant of the Ministry\\nof Health of the Czech Republic (IGA, No. 1 A/8676-3), and\\nby grants of the Ministry of Education of the Czech Republic\\n(MSM, No. 0021622402 and MSM, No. 0021622430). Oth-\\nerwise, there is no conﬂict of interest.\\n\\nAddress for correspondence and reprint requests: Ro-\\nman Panovsk´y, Ph.D., First Department of Internal\\nMedicine/Cardioangiology, St. Anna’s Hospital, Masaryk\\nUniversity, Pekaˇrsk´a 53 656 91 Brno, Czech Republic. Fax:\\n+420-543182205; E-mail: panovsky@fnusa.cz\\n\\ngical treatment of acute coronary syndromes.\\nCoronary artery disease accounts for approx-\\nimately 50% of all cardiovascular deaths and\\nis the leading cause of congestive heart fail-\\nure. The 1-year mortality rate for patients di-\\nagnosed with congestive heart failure is about\\n20%, and from 1994 to 2004, deaths from heart\\nfailure increased 28%.1,2 Development of heart\\nfailure in survivors of acute myocardial infarc-\\ntion involves myocyte loss in the area supplied\\nby the infarct-related artery and subsequent\\nformation of noncontractile ﬁbrous tissue. To\\ndate, no therapeutic procedure like angio-\\nplasty or thrombolytic agents could reverse the\\n\\n888\\n\\nECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\\n\\nVol. 25, No. 8, 2008\\n\\n\\x0cCELL THERAPY IN AN ACUTE MYOCARDIAL INFARCTION\\n\\nirreversible myocardial injury completely. The\\nrecovery of contractile function after revascu-\\nlarization occurs only in the areas of hibernat-\\ning myocardium. Heart transplantation may be\\nan option in selected patients, but the donor\\nsupply is strictly limited.\\n\\nRecent experimental and clinical studies sug-\\ngest that cell transplantation into damaged my-\\nocardium may have the potential to restore\\nmyocardial viability and improve left ventric-\\nular function. Different cell types can be po-\\ntentially used for transplantation. To avoid\\nproblems with donor availability, immunolog-\\nical rejection, arrhythmias, and ethical prob-\\nlems, autologous bone marrow cells appear par-\\nticularly attractive. But in a majority of studies,\\nonly patients with almost normal function or\\nonly mild dysfunction of the left ventricle were\\nstudied.3–12\\n\\nSo the purpose of this study was to determine\\nthe impact of autologous transplantation of\\nmononuclear bone marrow cells on myocardial\\nfunction in patients with moderate-to-severe\\nleft ventricular dysfunction.\\n\\nMaterials and Methods\\n\\nStudy Population\\n\\nThe randomized study included patients with\\na ﬁrst acute myocardial infarction treated with\\ncoronary angioplasty with a stent implanta-\\ntion. Only patients with successful recanaliza-\\ntion of the infarct-related artery (TIMI ﬂow\\ngrade 3) and the evidence of an irreversible\\ndamage of at least two akinetic or dyskinetic\\nmyocardial segments identiﬁed by dobutamine\\nechocardiography, gated technetium-99 m ses-\\ntamibi single photon emission computed to-\\nmography, and positron emission tomography\\n(performed in only 73% of patients) were in-\\ncluded. The exclusion criteria were: (1) age >\\n70 years; (2) noncardiac disease adversely af-\\nfecting prognosis; (3) another cardiac disease\\nexcept coronary artery disease; (4) coagulopa-\\nthy, thrombocytopenia, leucopenia; (5) absence\\nof a signiﬁcant increase in cardiac enzymes (cre-\\natine kinase over 20 µkat/l or creatine kinase-\\nMB over 3 µkat/l or troponin I over 20 µg/l-\\n–normal upper limits in our laboratories are\\n2.85 µkat/l, 0.42 µkat/l, and 2.0 µg/l, respec-\\ntively); (6) patient instability on days 3–7 after\\nMI; and (7) need for coronary revascularization\\nin the future for multivessel disease.\\n\\nFrom a total number of 82 patients who com-\\npleted the baseline and 3-month follow-up ex-\\n\\namination, 66 patients were analyzed in the\\npreviously published study.12 This ﬁrst 66 pa-\\ntients were randomized into three arms: (1) a\\ngroup treated with a higher number of mononu-\\nclear bone marrow cells (deﬁned as a mean\\nnumber of 1 × 108 cells); (2) a group treated\\nwith a lower number of cells (deﬁned as a\\nmean number of 1 × 107 cells); and (3) a con-\\ntrol group not treated with cell transplanta-\\ntion. Subsequent 16 patients were randomized\\ninto only two arms: higher-dose-treated group\\nand control group. The reason for changing ran-\\ndomization schema was no signiﬁcant effect of\\na lower-dose cells in the previous study. This\\npresentation is a subanalysis of 47 (from all\\nthe 82) patients with signiﬁcant left ventricu-\\nlar dysfunction-–ejection fraction (EF) ≤ 40%.\\nForty-ﬁve patients underwent the primary an-\\ngioplasty (within 12 hours of chest pain on-\\nset)and two patients were treated with angio-\\nplasty within the interval from 12 hours to\\n3 days after symptom onset.\\n\\nStudy Design\\n\\nOn day 3–6 after myocardial infarction, rest\\nand dobutamine echocardiography was per-\\nformed to evaluate the presence of akinetic or\\ndyskinetic left ventricular segments without\\nany contractile reserve. At the same time color\\nDoppler tissue imaging was performed. Within\\nthe next 2 days patients underwent the gated\\ntechnetium-99 m sestamibi single photon emis-\\nsion computed tomography and positron emis-\\nsion tomography. Patients with an evidence of\\nan irreversible damage of at least two akinetic\\nor dyskinetic myocardial segments proved by\\nall methods were then randomized. Patients\\nof cell groups underwent subsequently a bone\\nmarrow aspiration. Autologous bone marrow\\nmononuclear cells were transplanted into the\\ninfarct-related artery 20–21 hours after the\\nbone marrow aspiration, 5–9 days after my-\\nocardial infarction. Immediately before and 10\\nand 20 hours after the procedure, blood samples\\nfor cardiac enzymes (creatine kinase, creatine\\nkinase–MB and troponin I) were acquired.\\n\\nThree months after randomization, rest\\nechocardiography with Doppler tissue imaging,\\nsingle photon emission computed tomography,\\nand coronary angiography were repeated. Pa-\\ntients of the control group underwent the same\\nprocedures and examinations, as did the trans-\\nplanted patients except for bone marrow aspi-\\nration and cell transplantation.\\n\\nVol. 25, No. 8, 2008\\n\\nECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\\n\\n889\\n\\n\\x0cPANOVSKY, ET AL.\\n\\nIn this subanalysis, the changes of following\\nechocardiographic parameters were assessed:\\n(1) the peak systolic velocity of the myocardium\\nadjacent to mitral annulus of infarcted wall\\n(Sinfarct) (as a parameter of the regional longi-\\ntudinal left ventricular systolic function); (2)\\nthe mean six-site systolic velocity of the my-\\nocardium adjacent to mitral annulus (as a pa-\\nrameter of the global longitudinal left ventric-\\nular systolic function), which was calculated as\\nmean six-site S = (Slateral + Sseptal + Santerior +\\nSinferior + Santeroseptal + Sposterior)/6; and (3) num-\\nber of akinetic segments.\\nThe changes of following parameters derived\\nfrom single photon emission computed tomog-\\nraphy were assessed: (1) left ventricle end-\\ndiastolic volume; (2) left ventricle end-systolic\\nvolume; (3) left ventricle ejection fraction; and\\n(4) perfusion defect size.\\n\\nThe institutional ethics committee approved\\nthe study and written consent was obtained\\nfrom each patient.\\n\\nEchocardiography\\n\\nUsing commercially available equipment\\nVivid 7 (GE/Vingmed, Milwaukee, WI, USA)\\nwith an M3 S transducer, echocardiographic ex-\\naminations were performed in one center. Two-\\ndimensional and color Doppler tissue images of\\napical views (apical 4- and 2-chamber and api-\\ncal long-axis views) were obtained and stored\\ndigitally for the subsequent ofﬂine quantitative\\nanalysis using a software incorporated in Vivid\\n7 (Echopac 7 version 1.3, GE/Vingmed). The\\nwider-angle sector (60–70 degrees) was used to\\ndepict two-dimensional images for wall motion\\nanalysis. The narrow angle sector (30–45 de-\\ngrees) was used to obtain color Doppler tissue\\nimages of individual left ventricular walls (sep-\\ntum, lateral, inferior, anterior, posterior, and\\nanteroseptal walls) at the high frame rates of\\n172–234 frames per second.\\n\\nDobutamine\\n\\nechocardiography was per-\\nformed in all patients with starting dose of\\n5 µg/kg per min. The dose was increased at\\n5-minute intervals to 10, and 20 µg/kg per\\nmin. The parasternal\\nlong-axis and three\\napical views were digitally stored at rest and\\nat the last minute of all doses of dobutamine\\nfor a subsequent wall motion analysis. A\\n16-segment model was used for regional wall\\nmotion analysis.13 The akinetic and dyskinetic\\nsegments with no improvement in thickening\\nafter any dose of dobutamine were regarded\\nas irreversibly damaged. A good interobserver\\n\\nand intraobserver variability in scoring dys-\\nfunctional segments (agreement 93% and 96%,\\nrespectively) and in determining the contractile\\nreserve (agreement 92% and 95%, respectively)\\nhas already been described.14\\n\\nThe regional longitudinal systolic function\\nwas evaluated from the color Doppler tis-\\nsue imaging.15,16 Peak systolic velocities (S)\\nwere determined for the basal myocardium\\nof each wall adjacent to the mitral annulus\\n(Slateral, Sseptal, Santerior, Sinferior, Santeroseptal, and\\nSposterior). The results were obtained as a mean\\nfrom three consecutive heart cycles. Two expe-\\nrienced echocardiographers who were blinded\\nto the patient treatment performed the analy-\\nses. The reproducibility of estimation of S val-\\nues of individual walls was evaluated in our\\ninitial 3-month project.12 For all S values, the\\nestimated 95% conﬁdence limits for differences\\nbetween intraobserver (JM) pairs of measure-\\nment revealed repeated results to vary in a\\nrange of ± 10.6% as based on the mean primary\\nvalues and similarly ± 11.5% for the interob-\\nserver variability (JM and RP). The sufﬁcient\\ninterobserver reproducibility was also proved in\\napplied pairwise ANOVA models: only 4.8% of\\noverall variability could be attributed to the dif-\\nferences among observers and the interobserver\\neffect was unambiguously not signiﬁcant (P =\\n0.963).\\n\\nGated Technetium-99 m Sestamibi Single\\nPhoton Emission Computed Tomography\\n\\nSeven hundred forty MBq technetium-99 m\\nsestamibi was injected at rest. Gated single pho-\\nton emission computed tomography imaging\\nacquisition (64 projections from the 45◦ right\\nanterior oblique projection to the 45◦ left pos-\\nterior oblique projection) began 1 hour after\\nsestamibi injection using a 2-detector gamma\\ncamera (ecam, Siemens, Erlangen, Germany)\\nequipped with a low-energy, high-resolution\\nparallel-hole collimators. The MIBI uptake\\nwas analyzed visually and quantitatively on\\ncomputer-generated polar maps by an experi-\\nenced nuclear cardiologist who was unaware\\nof the patients treatment. Pixels with a ses-\\ntamibi activity > 2.5 SD below the correspond-\\ning normal mean values were considered ab-\\nnormal. The computer automatically expressed\\na perfusion defect as the number of abnormal\\npixels divided by the total number of left ven-\\ntricle pixels × 100 project.17 In the viability\\nanalysis, the myocardial region with the maxi-\\nmum sestamibi uptake was used as a reference\\n\\n890\\n\\nECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\\n\\nVol. 25, No. 8, 2008\\n\\n\\x0cCELL THERAPY IN AN ACUTE MYOCARDIAL INFARCTION\\n\\nregion. The tracer uptake in other myocardial\\nregions was then expressed as a percentage\\nof the activity measured in the reference re-\\ngion. Nonviable myocardium was deﬁned as\\nthat having sestamibi uptake below the thresh-\\nold of 50% of the maximum project.18 Gated\\nsingle photon emission computed tomography\\nrest left ventricular ejection fractions and left\\nventricular end-diastolic/end-systolic volumes\\nwere obtained using automated, commercially\\navailable software four-dimensional-MSPECT\\n(University of Michigan, Ann Arbor, MI, USA).\\n\\nPositron Emission Tomography\\n\\nTo\\n\\nemission\\n\\nviability, F-18-\\nassess myocardial\\nﬂuorodeoxyglucose-positron\\nto-\\nmography was performed with a whole-body\\npositron emission tomography scanner (ECAT\\nACCEL, Siemens, Knoxville, TN, USA). Ac-\\nquisition was started 50 minutes after the\\nadministration of ﬂuorodeoxyglucose (200–250\\nMBq intravenously) and images of glucose\\nutilization were acquired for 15–20 minutes\\nin a 3D mode. The metabolic defects were\\nanalyzed on computer-generated polar maps.\\nThe myocardial ﬂuorodeoxyglucose uptake for\\neach part of the left ventricle was normalized\\nto a myocardial region with the maximum\\nﬂuorodeoxyglucose uptake. A nonviable my-\\nocardium was deﬁned as that having less\\nthan 50% of the maximum ﬂuorodeoxyglucose\\nuptake.18\\n\\nBone Marrow Aspiration and Preparation\\n\\nThe target volume of bone marrow blood\\n(100 ml for the lower cell dose, 150 ml for\\nthe higher cell dose) was obtained from iliac\\ncrests under local anesthesia and moderate se-\\ndation with midazolam, mixed with 4% human\\nalbumin and 5,000 IU of heparin, and cen-\\ntrifuged (15 minutes, 240 g) to receive buffy-\\ncoat. Mononuclear cells were collected using\\ndensity gradient centrifugation of the buffy-\\ncoat (20 minutes, 1,200 g, Histopaque 1077,\\nSigma-Aldrich, St. Louis, MO, USA), washed,\\nand resuspended. One hundred twenty-ﬁve per-\\ncent of the target amount of mononuclear cells\\nwas added to the CellGro serum-free medium\\n(CellGenix, Freiburg, Germany) to reach 0.3–\\n1.0 × 106 cells/ml. After an overnight cultiva-\\ntion (37 ◦C, 5% CO2) in a teﬂon bag (VueLife,\\nCellGenix), 105% of the target number of\\nmononuclear cells was withdrawn, washed, and\\nresuspended in the Hank’s salt solution (Sigma-\\n\\nAldrich) with 4% human albumin and 1,000 IU\\nof heparin into a total volume of 22 ml.\\n\\nCell Implantation\\n\\nAutologous mononuclear bone marrow cells\\nwere transplanted 5–9 days after the infarc-\\ntion onset using a modiﬁcation of the method\\ndescribed previously by Strauer et al.19 Cells\\nwere implanted intracoronary via a percuta-\\nneous transluminal catheter into the infarct-\\nrelated coronary artery. A total of seven balloon\\ninﬂations at the place of previous stent implan-\\ntation lasting for 3 minutes were carried out\\nwith 3-minute intervals of balloon deﬂation. At\\nthe beginning of each balloon inﬂation, 3 ml\\nof cell suspension was slowly injected into the\\nartery. All patients were on daily doses of 75 mg\\nof clopidogrel and 100 mg of aspirin and, in ad-\\ndition, a bolus of 100 units/kg of body weight of\\nheparin was administered immediately before\\nthe procedure to minimize the risk of throm-\\nbotic complications.\\n\\nStatistical Analysis\\n\\nStandard descriptive statistics were used\\nto summarize the sample distribution of in-\\ndividual variables (means, standard errors,\\nconﬁdence limits). A univariate t-test for two\\nindependent samples was applied to compare\\nvalues of parameters between the groups. A\\npaired t-test was applied to compare changes\\nin values prior and after the treatment. All\\nparametric tests were performed with the ver-\\niﬁed assumption of normal distribution\\n(Shapiro–Wilk’s W-test).\\nindepen-\\ndent samples were mutually compared on\\nthe basis of proved homogeneity of variance\\n(Variance ratio F-test). The correlation analysis\\nwas based on Pearson’s correlation coefﬁcient.\\nA P < 0.05 was considered statistically\\nsigniﬁcant.\\n\\nRepeated measures ANOVA model was used\\nto test the results obtained by different ob-\\nservers (measured in all patients included\\nin the reproducibility test). The pairwise de-\\nsign included overall F-test of the main ef-\\nfects (i.e., differences among different ob-\\nservers) and then estimation of within-observer\\nvariability.\\n\\nTwo\\n\\nResults\\n\\nThis subanalysis contains 47 patients. Thirty\\nof them were treated with mononuclear bone\\n\\nVol. 25, No. 8, 2008\\n\\nECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\\n\\n891\\n\\n\\x0cPANOVSKY, ET AL.\\n\\nTABLE I\\n\\nCharacteristics of the Study Population\\n\\nParameter\\n\\nAge (years)\\nMen\\nHypertension\\nHyperlipidemia\\nDiabetes mellitus\\nSingle-vessel disease\\nDouble-vessel disease\\nTriple-vessel disease\\nIRA: LAD\\nIRA: LCX\\nIRA: RCA\\nMaximum CK (ukat/l)\\nMaximum CK-MB (ukat/l)\\nTime from infarct onset to\\n\\nreperfusion (min)\\n\\nTime from infarct onset to cell\\n\\ntransplantation (days)\\n\\nDobutamine echo\\nNo. of irreversibly damaged segments\\nMedication on hospital discharge\\n\\nAspirin\\nClopidogrel\\nACE inhibitor\\nBeta blocker\\nStatin\\n\\nControl (C)\\nGroup (n = 17)\\n\\n52 (2)\\n15 (88%)\\n9 (53%)\\n6 (35%)\\n4 (24%)\\n11 (65%)\\n6 (35%)\\n\\n0%\\n16 (94%)\\n0%\\n\\n1 (6%)\\n80.2 (11.1)\\n7.4 (0.6)\\n507 (240)\\n\\n–\\n\\nLower Cell Dose (L) Higher Cell Dose (H)\\n\\nGroup (n = 13)\\n\\nGroup (n = 17)\\n\\n55 (2)\\n12 (92%)\\n5 (39%)\\n9 (69%)\\n1 (8%)\\n9 (69%)\\n3 (23%)\\n1 (8%)\\n12 (92%)\\n0%\\n\\n1 (8%)\\n80.2 (9.4)\\n7.6 (0.9)\\n263 (53)\\n\\n7 (0.4)\\n\\n55 (5)\\n15 (88%)\\n5 (29%)\\n7 (41%)\\n3 (18%)\\n13 (76%)\\n4 (24%)\\n\\n0%\\n16 (94%)\\n0%\\n\\n1 (6%)\\n68.9 (7.2)\\n6.8 (0.7)\\n484 (192)\\n\\n7 (0.3)\\n\\n6 (0.7)\\n\\n7 (0.4)\\n\\n7 (0.7)\\n\\n17 (100%)\\n15 (88%)\\n17 (100%)\\n17 (100%)\\n17 (100%)\\n\\n13 (100%)\\n13 (100%)\\n13 (100%)\\n13 (100%)\\n13 (100%)\\n\\n17 (100%)\\n17 (100%)\\n17 (100%)\\n17 (100%)\\n17 (100%)\\n\\nThe values are expressed as the mean supplied by standard error (in parentheses) or number (%) of\\nsubjects. ACE = angiotensin-converting enzyme; CK = creatine kinase; echo = echocardiography; IRA =\\ninfarct-related artery; LAD = left anterior descending coronary artery; LCX = left circumﬂex artery;\\nNo = number; RCA = right coronary artery.\\n\\nmarrow cell implantation–17 patients in the\\nGroup H with higher cell doses, while 13 in\\nthe Group L with lower cell doses, and 17 of\\nthem served as a control Group C. The base-\\nline characteristics are presented in Table I.\\nThere were no signiﬁcant differences among the\\ngroups.\\n\\nThe Effect of Cell Transplantation\\non Myocardial Function and Left\\nVentricle Remodeling\\n\\nThe results of echocardiographic examina-\\ntions and single photon emission computed to-\\nmography data are demonstrated in Table II.\\n\\nThere was a trend toward the prevention of\\nthe left ventricle dilatation (end-diastolic vol-\\nume) and the improvement of the left ventri-\\ncle ejection fraction in transplanted patients.\\nPatients of the high-doses group signiﬁcantly\\nimproved the regional systolic function (Sinfarct)\\nafter 3-month follow-up. We proved signiﬁcant\\n\\nimprovement in these parameters (left ventri-\\ncle ejection fraction, end-systolic volume, peak\\nsystolic velocity of infarcted myocardium and\\nnumber of akinetic segments) in cell therapy\\npatients, as it is documented through signiﬁ-\\ncant results of within-group testing. However,\\nthere were no statistically differences among\\nthe groups.\\n\\nThe side effects have already been pub-\\n\\nlished.12\\n\\nPhenotype of Transplanted Cells\\n\\nThe samples were analyzed from 29 patients\\n(in one patient a small sample size did not allow\\nadequate analysis). The transplanted leuko-\\ncytes contained in the mean 43.4% CD3+ cells,\\n2.9% CD16+ cells, 11.0% CD19+ cells, 0.4%\\nCD33+ cells, and 1.1% CD34+ cells, respec-\\ntively. The viability of mononuclear cells was\\nevaluated after the cultivation. In all cases, the\\nviability exceeded 95%.\\n\\n892\\n\\nECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\\n\\nVol. 25, No. 8, 2008\\n\\n\\x0cCELL THERAPY IN AN ACUTE MYOCARDIAL INFARCTION\\n\\nTABLE II\\n\\nComparison of Baseline and 3-Month Follow-Up Echocardiographic and Single Photon Emission Computed Tomography\\n\\nResults for the Treatment and Control Groups\\n\\nParameter\\n\\nEchocardiography\\n\\nMean 6-site S (cm/s)\\nBaseline\\nFollow-up\\nChange‡\\nP-value‡\\n\\nSinfarct (cm/s)\\n\\nBaseline\\nFollow-up\\nChange‡\\nP-value‡\\n\\nNo. of akinetic s∗\\n\\nBaseline\\nFollow-up\\nChange‡\\nP-value‡\\n\\nSPECT\\n\\nEDV (ml)\\nBaseline\\nFollow-up\\nChange‡\\nP-value‡\\nESV (ml)\\n\\nBaseline\\nFollow-up\\nChange‡\\nP-value‡\\nLV EF (%)\\nBaseline\\nFollow-up\\nChange‡\\nP-value‡\\n\\nPerfusion defect (%)\\n\\nBaseline\\nFollow-up\\nChange‡\\nP-value‡\\n\\nC Group\\n(n = 17)\\n\\nL Group\\n(n = 13)\\n\\nH Group\\n(n = 17)\\n\\nMutual Comparison (P-Values)†\\n\\nC vs. L\\n\\nC vs. H\\n\\nL vs. H\\n\\n4.9 (0.2)\\n5.2 (0.3)\\n0.3 (0.2)\\n0.393\\n\\n4.5 (0.2)\\n4.8 (0.3)\\n0.3 (0.2)\\n0.153\\n\\n6.2 (0.6)\\n5.5 (0.7)\\n−0.7 (0.4)\\n0.062\\n\\n171 (9)\\n183 (13)\\n12 (8)\\n0.153\\n\\n112 (7)\\n115 (11)\\n3 (8)\\n0.713\\n\\n35 (1)\\n39 (2)\\n4 (2)\\n0.062\\n\\n52 (4)\\n41 (4)\\n−11 (3)\\n<0.001\\n\\n5.1 (0.3)\\n4.9 (0.3)\\n−0.2 (0.3)\\n0.625\\n\\n4.2 (0.3)\\n4.4 (0.3)\\n0.2 (0.2)\\n0.337\\n\\n7.0 (0.4)\\n5.5 (0.6)\\n−1.5 (0.5)\\n<0.001\\n\\n176 (12)\\n180 (12)\\n4 (10)\\n\\n0.696\\n\\n112 (9)\\n106 (9)\\n−6 (7)\\n0.408\\n\\n36 (1)\\n41 (2)\\n5 (1)\\n<0.001\\n\\n51 (4)\\n41 (5)\\n−10 (2)\\n<0.001\\n\\n5.2 (0.2)\\n5.0 (0.2)\\n−0.2 (0.2)\\n0.193\\n\\n4.3 (0.2)\\n4.7 (0.3)\\n0.4 (0.1)\\n0.013\\n\\n6.9 (0.6)\\n5.2 (0.7)\\n−1.7 (0.5)\\n<0.001\\n\\n178 (13)\\n181 (12)\\n3 (8)\\n0.713\\n\\n117 (10)\\n107 (9)\\n−10 (4)\\n0.023\\n\\n35 (1)\\n41 (2)\\n6 (2)\\n<0.001\\n\\n53 (4)\\n43 (4)\\n−10 (2)\\n<0.001\\n\\n0.821\\n0.485\\n0.298\\n\\n0.691\\n0.283\\n0.261\\n\\n0.366\\n0.995\\n0.242\\n\\n0.786\\n0.841\\n0.509\\n\\n0.998\\n0.555\\n0.402\\n\\n0.343\\n0.284\\n0.609\\n\\n0.880\\n0.872\\n0.601\\n\\n0.416\\n0.611\\n0.153\\n\\n0.975\\n0.432\\n0.342\\n\\n0.411\\n0.744\\n0.128\\n\\n0.677\\n0.876\\n0.431\\n\\n0.674\\n0.572\\n0.094\\n\\n0.939\\n0.324\\n0.262\\n\\n0.911\\n0.657\\n0.537\\n\\n0.594\\n0.822\\n0.813\\n\\n0.704\\n0.728\\n0.215\\n\\n0.889\\n0.768\\n0.798\\n\\n0.907\\n0.957\\n0.941\\n\\n0.694\\n0.949\\n0.706\\n\\n0.308\\n0.897\\n0.589\\n\\n0.799\\n0.800\\n0.958\\n\\nThe values are expressed as the mean supplied by standard error (in parentheses). ∗Identiﬁed as nonviable on pretransplant\\ndobutamine echocardiography. †Mutual signiﬁcance “between groups” tested by t-test for two independent samples. ‡Pairwise\\ncalculated “within group” change of values tested by t-test for two-paired samples.\\nEDV = end-diastolic volume; ESV = end-systolic volume; LV EF = left ventricular ejection fraction; m = myocardium; S =\\npeak systolic velocity of basal myocardium adjacent to mitral annulus; Sinfarct = peak systolic velocity of the infarcted wall;\\nMean 6-site S = (Slateral + Sseptal + Santerior + Sinferior + Santeroseptal + Sposterior)/6; s = segments; SPECT = single photon\\nemission computed tomography; other abbreviations as in Table I.\\n\\nDiscussion\\n\\nPotential Effect of Cell Therapy\\n\\nBone marrow contains a great number of\\nprimitive cells that are able to differentiate\\ninto specialized cells, for example into endothe-\\n\\nlial cells or myocytes.20–24 Some of these prim-\\nitive cells produce different growth factors,21\\nfor example vascular endothelial growth fac-\\ntor, basic ﬁbroblast growth factor, and cytokines\\nwith proangiogenetic effect. For these reasons,\\nmany experimental studies were performed and\\n\\nVol. 25, No. 8, 2008\\n\\nECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\\n\\n893\\n\\n\\x0cPANOVSKY, ET AL.\\n\\nproved the possibility of cell therapy to improve\\nperfusion or/and function of dysfunctional my-\\nocardium.20–26\\n\\nDespite numerous unresolved questions con-\\ncerning the cell transplantation, these ﬁrst\\nhopeful experimental studies were immediately\\nfollowed by clinical trials, mostly in patients\\nwith acute myocardial infarction. The num-\\nbers of patients included are relatively small.\\nMany of these studies are not randomized. The\\ntype and amount of cells that are necessary\\nto implant to really regenerate damaged my-\\nocardium are not known.\\n\\nAt present, we do not know the mechanism\\nof action of the implanted cells in studies that\\nfound improvement in myocardial function or\\nperfusion following the cell therapy. Recently,\\nseveral experimental projects described no or\\nonly negligible transdifferentiation of adult\\nstem cells into the myocytes.27–30 The beneﬁt\\nof cell transplantation may be induced by the\\nparacrine stem cell effect.31,32\\n\\nStudies in Patients with Acute Myocardial\\nInfarctions\\n\\nTransplantation of mononuclear bone mar-\\nrow cells into the region of\\ninfarcted my-\\nocardium has been previously suggested as a\\npromising alternative treatment for left ven-\\ntricle dysfunction. Nevertheless, the results\\nof randomized studies are controversial.3,4,7–9\\nSome of them indicated that patients with\\nthe most depressed left ventricular contrac-\\ntile function had the greatest improvement in\\ncontractile function after intracoronary admin-\\nistration of bone marrow cells. For example,\\nREPAIR-AMI,33 so far the largest randomized\\nmulticenter “cell study,” showed signiﬁcantly\\ngreater increase in the global left ejection frac-\\ntion in the bone marrow cell group (5.5% vs.\\n3.0% in the control group) at 4 months follow-\\nup. Higher impact of cells was found among pa-\\ntients with a baseline left ventricle ejection frac-\\ntion below the median value (48.9%). In these\\npatients, the absolute increase in ejection frac-\\ntion was three times higher that in the placebo\\ngroup (7.5% as compared with 2.5%; absolute\\ndifference: 5.0%). Among patients with a base-\\nline ejection fraction above median, the abso-\\nlute difference between groups was only 0.3%\\n(4.0% vs. 3.7%). Similar observations were pre-\\nviously described in TOPCARE-AMI trial,34 in\\nwhich baseline left ventricle ejection fraction\\nwas the only signiﬁcant predictor of improve-\\n\\nment in ejection fraction during the 4-months\\nfollow-up.\\n\\nIn the randomized, double-blind, placebo-\\ncontrolled study of Janssens group,35 in 67 pa-\\ntients with ST-elevation myocardial infarction\\ntreated with coronary intervention, no effect\\nof autologous bone marrow-derived stem cell\\ntransfer on left ventricle ejection fraction was\\nfound. However, the treatment was associated\\nwith a signiﬁcant reduction in myocardial in-\\nfarct size and better recovery of regional sys-\\ntolic function. The effect of treatment on the\\nprobability of improvement in regional function\\nshowed a predominant interaction in the most\\nseverely affected segments. In addition to that,\\non positron emission tomography examination,\\npatients with larger myocardial infarction had\\na greater increase in metabolic activity after cell\\ntherapy than after placebo infusion.\\n\\nOn the other hand, BOOST trial 36,37 did not\\ndescribe the inverse relation between baseline\\nleft ventricular ejection fraction and absolute\\nimprovement of the left ventricle function af-\\nter implantation of the bone marrow cells into\\nthe infarcted myocardium. At 6-month follow-\\nup, patients in a control group of this study im-\\nproved their ejection fraction from 51.3% to 52%\\n(0.7% absolute change), while the bone marrow\\ncell group from 50.0% to 56.7% (6.7% absolute\\nchange). The bone marrow cell subgroup pa-\\ntients with ejection fraction of the left ventri-\\ncle > 52% increased their ejection by 8.0%, but\\npatients with ejection fraction ≤ 52% only by\\n4.5%.\\n\\nThe main limitation of these studies is the\\nfact, that patients with only mild left ventricu-\\nlar dysfunction were included.\\n\\nStudies in Patients with Moderate-to-Severe\\nLeft Ventricular Dysfunction\\n\\nThere are only few trials studying cell ther-\\napy in patients with moderate-to-severe left\\nventricular dysfunction and their results are\\ncontroversial too. Bartunek et al.3 described\\nimprovement of the left ventricular perfor-\\nmance and increased myocardial perfusion and\\nviability among patients with acute myocar-\\ndial infarction treated with stenting and intra-\\ncoronary administration of CD133+ progenitor\\ncells. The left ventricular ejection fraction in-\\ncreased from 45.0% to 52.1%.\\n\\nControversially, ASTAMI trial 11 did not ﬁnd\\nany signiﬁcant difference between 47 patients\\ntreated with cell transplantations and 50 pa-\\ntients in the control group. The left ventricular\\n\\n894\\n\\nECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\\n\\nVol. 25, No. 8, 2008\\n\\n\\x0cCELL THERAPY IN AN ACUTE MYOCARDIAL INFARCTION\\n\\nejection fraction and end-diastolic volume were\\nassessed by single photon emission computed\\ntomography, echocardiography, and magnetic\\nresonance. Improvement versus baseline val-\\nues was found in both groups, but they did not\\nsigniﬁcantly differ. Results were consistent for\\nall the three methods. No improvement in car-\\ndiac function was also found in Kuethe et al.38 in\\ntheir study with ﬁve patients with a large acute\\nanterior myocardial infarction and intracoro-\\nnary mononuclear bone marrow cell implanta-\\ntion.\\n\\nIn our previous study,12 the signiﬁcant and\\ndose-related improvement was found in the re-\\ngional systolic function of the infarcted wall af-\\nter cell transplantation. As compared to con-\\ntrols, a higher cell dose signiﬁcantly improved\\nglobal LV systolic function. Both cell doses pre-\\nvented the left ventricle from the dilation, while\\nthe end-diastolic volume signiﬁcantly increased\\nin the control group. Because patients with the\\ngreatest damage to their myocardium are the\\nones who need treatment most, the substudy\\nof these patients was performed. In this sub-\\nstudy the statistically important effect of au-\\ntologous transplantation of mononuclear bone\\nmarrow cells on myocardial function was not\\nfound in patients with moderate-to-severe left\\nventricular dysfunction. Only an insigniﬁcant\\ntrend toward the prevention of the left ventric-\\nular dilatation and improvement of global left\\nventricle ejection fraction was found at 3-month\\nfollow-up.\\n\\nStudy Limitations\\n\\nExcept the fact that our study is subanalysis,\\nthe major limitations of our study are the small\\nnumber of patients enrolled. However, to this\\nmoment it is one of the studies with the highest\\nnumber of patients with more severe left ven-\\ntricular dysfunction ever published. Compared\\nto other studies, the very rigorous myocardial\\nviability assessment was performed before in-\\nclusion to this study.\\n\\nThe groups differ slightly in time from on-\\nset of infarction to reperfusion. The differences\\nwere not statistically signiﬁcant. The hetero-\\ngeneity was caused by the inclusion of two pa-\\ntients with delayed coronary angioplasty (one\\npatient in the Group H and one patient in the\\nGroup C ). In our previous study the biggest\\neffect of cell transplantations was found be-\\ntween higher dose and control groups. In this\\nstudy, the difference in time from infarct on-\\nset to reperfusion between Groups H and C was\\n\\njust 23 minutes. So this difference has not been\\nsupposed to affect the results.\\n\\nBecause of ethical consideration, the patients\\nincluded into the control group did not undergo\\nthe identical procedures, as did the bone mar-\\nrow cell patients, being excluded from the bone\\nmarrow aspiration and coronary angiography\\nwith the sham cell transplantation. For techni-\\ncal reasons, the positron emission tomography\\n(PET) was not performed in all our patients.\\n\\nIn addition to the limited study population,\\nanother explanation of our results could be the\\nvery severe myocardial damage with almost no\\nsurviving myocytes. In these conditions, there is\\nno suitable milieu for catching implanted cells\\nand their differentiation into cardiomyocytes.\\nAlso the severe destruction of microcirculation\\ncould make the cell homing more difﬁcult com-\\npared to patients with less severe myocardial\\ndamage.\\n\\nConclusion\\n\\nThe important thing is the fact that the selec-\\ntion of cells and the whole method of cell ther-\\napy are just at the beginning of the way. Prob-\\nably, it is not realistic to expect some greater\\nchanges of left ventricle function in this manner\\nof treatment. It is necessary to look for the best\\ncell type, an optimal way and time of cell deliv-\\nery, and the help of some cytokines. For solving\\nthese clinical questions, we must also better un-\\nderstand the mechanisms of potential positive\\neffect of the cell therapy.\\n\\nTaking together, the results of trials show\\nthat there is still work to be done to understand\\na lot of questions related to the cell therapy. Fur-\\nther studies, including larger numbers of pa-\\ntients, are needed to resolve all these tasks.\\n\\nReferences\\n\\n1. Ho KK, Anderson KM, Kannel WB, et al: Survival af-\\nter the onset of congestive heart failure in Framing-\\nham Heart Study subjects. Circulation 1993;88:107–\\n115.\\n\\n2. Rosamond W, Flegal K, Friday G, et al: Heart dis-\\nease and stroke statistics–2007 update. A report from\\nthe American Heart Association Statistics Commit-\\ntee and Stroke Statistics Subcommittee. Circulation\\n2007;115:e69–e171.\\n\\n3. Bartunek J, Vanderheyden M, Vandekerckhove B,\\net al: Intracoronary injection of CD133-positive en-\\nriched bone marrow progenitor cells promotes cardiac\\nrecovery after recent myocardial infarction: Feasibil-\\nity and safety. Circulation 2005;112(Suppl.):I-178–\\nI-183.\\n\\n4. Fern´andez-Avil´es F, San Rom´an JA, Garc´ıa-Frade\\nJ, et al: Experimental and clinical regenerative\\n\\nVol. 25, No. 8, 2008\\n\\nECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\\n\\n895\\n\\n\\x0cPANOVSKY, ET AL.\\n\\ncapability of human bone marrow cell after myocar-\\ndial infarction. Circ Res 2004;95:742–748.\\n\\n5. Fuchs S, Satler LF, Kornowski R, et al: Catheter-\\nbased autologous bone marrow myocardial\\ninjec-\\ntion in no-option patients with advanced coronary\\nartery disease. A feasibility study. J Am Coll Cardiol\\n2003;41(10):1721–1724.\\n\\n6. Gali ˜nanes M, Loubani M, Davies J, et al: Auto-\\ntransplantation of unmanipulated bone marrow into\\nscarred myocardium is safe and enhances car-\\ndiac function in humans. Cell Transplant 2004;13:\\n7–13.\\n\\n7. Hamano K, Nishida M, Hirata K, et al: Local implan-\\ntation of autologous bone marrow cells for therapeu-\\ntic angiogenesis in patients with ischemic heart dis-\\nease. Clinical trial and preliminary results. Jpn Circ\\nJ 2001;65:845–847.\\n\\n8. Chen SL, Fang WW, Ye F, et al: Effect on left ven-\\ntricular function of intracoronary transplantation of\\nautologous bone marrow mesenchymal stem cell in pa-\\ntients with acute myocardial infarction. Am J Cardiol\\n2004;94:82–95.\\n\\n9. Stamm C, Westphal B, Kleine HD, et al: Autologous\\nbone-marrow stem-cell transplantation for myocar-\\ndial regeneration. Lancet 2003;361:45–46.\\n\\n10. Tse HF, Kwong YL, Chan JKF, et al: Angiogenesis in\\nischaemic myocardium by intramyocardial autologous\\nbone marrow mononuclear cell implantation. Lancet\\n2003;361:47–49.\\n\\n11. Lunde K, Solheim S, Aakhus S, et al: Intracoronary\\ninjection of mononuclear bone marrow cells in acute\\nmyocardial infarction. N Engl J Med 2006;355:1199–\\n1209.\\n\\n12. Meluzin J, Mayer J, Groch L, et al: Autologous trans-\\nplantation of mononuclear bone marrow cells in pa-\\ntients with acute myocardial infarction: The effect of\\nthe dose of transplanted cells on myocardial function.\\nAm Heart J 2006;152:975.e9–975.e15.\\n\\n13. Schiller NB, Shah PM, Crawford M, et al: Recom-\\nmendations for quantitation of the left ventricle by\\ntwo-dimensional echocardiography. J Am Soc Echocar-\\ndiogr 1989;2:358–367.\\n\\n14. Meluz´ın J, Cigarroa CG, Brickner E, et al: Dobu-\\ntamine echocardiography in predicting improvement\\nin global left ventricular systolic function after coro-\\nnary bypass or angioplasty in patients with healed\\nmyocardial\\ninfarcts. Am J Cardiol 1995;76:877–\\n880.\\n\\n15. Wandt B, Fornander Y, Egerlid R: Maximal longitu-\\ndinal contraction velocity in assessment of left ven-\\ntricular systolic function: A pulsed tissue Doppler and\\nM-mode study. Echocardiography 2004;21(7):587–\\n592.\\n\\n16. Yuda S, Inaba Y, Fujii S, et al: Assessment of left\\nventricular ejection fraction using long-axis systolic\\nfunction is independent of image quality: A study\\nof tissue Doppler imaging and M-mode echocar-\\ndiography.\\n2006;23(10):846–\\n852.\\n\\nEchocardiography\\n\\n17. Dakik HA, Howell JF, Lawrie GM, et al: Assessment\\nof myocardial viability with 99mTc-sestamibi tomog-\\nraphy before coronary bypass graft surgery. Circula-\\ntion 1997;96:2892–2898.\\n\\n18. Maes AF, Borgers M, Flameng W, et al: Assessment of\\nmyocardial viability in chronic coronary artery disease\\nusing technetium-99 m sestamibi SPECT. J Am Coll\\nCardiol 1997;29:62–68.\\n\\n19. Strauer BE, Brehm M, Zeus T, et al: Repair of\\ninfarcted myocardium by autologous intracoronary\\nmononuclear bone marrow cell transplantation in hu-\\nmans. Circulation 2002;106:1913–1918.\\n\\n20. Tomita S, Li RK, Weisel RD, et al: Autologous trans-\\nplantation of bone marrow cells improves damaged\\nheart\\nfunction. Circulation 1999;100(Suppl.II):II-\\n247–II-256.\\n\\n21. Fuchs S, Baffour R, Zhou YF, et al: Transendocar-\\ndial delivery of autologous bone marrow enhances col-\\nlateral perfusion and regional function in pigs with\\nchronic experimental myocardial ischemia. J Am Coll\\nCardiol 2001;37:1726–1732.\\n\\n22. Makino S, Fukuda K, Miyoshi S, et al: Cardiomyocytes\\ncan be generated from marrow stromal cells in vitro.\\nJ Clin Invest 1999;103:697–705.\\n\\n23. Jackson KA, Majka SM, Wang H, et al: Regenera-\\ntion of ischemic cardiac muscle and vascular endothe-\\nlium by adult stem cells. J Clin Invest 2001;107:1395–\\n1402.\\n\\n24. Hamano K, Li TS, Kobayashi T, et al: The induction of\\nangiogenesis by the implantation of autologous bone\\nmarrow cells: A novel and simple therapeutic method.\\nSurgery 2001;130:44–54.\\n\\n25. Orlic D, Kajstura J, Chimenti S, et al: Mobilized\\nbone marrow cells repair the infarcted heart, improv-\\ning function and survival. Proc Natl Acad Sci (USA)\\n2001;98:0344–0349.\\n\\n26. Orlic D, Kajstura J, Chimenti S, et al: Bone mar-\\nrow cells regenerate infarcted myocardium. Nature\\n2001;410:701–705.\\n\\n27. Limbourg FP, Ringes-Lichtenberg S, Schaefer A, et al:\\nHaematopoietic stem cells improve cardiac function\\nafter infarction without permanent cardiac engraft-\\nment. Eur J Heart Failure 2005;7:722–729.\\n\\n28. Balsam LB, Wagers AJ, Christensen JL, et al:\\nHaematopoietic stem cells adopt mature haematopoi-\\netic\\nin ischaemic myocardium. Nature\\n2004;428:668–673.\\n\\nfates\\n\\n29. Murry ChE, Soonpaa MH, Reinecke H, et al:\\nHaematopoietic stem cells do not transdifferentiate\\ninto cardiac myocytes in myocardial infarcts. Nature\\n2004;428:664–668.\\n\\n30. Nygren JM, Jovinge S, Breitbach M, et al: Bone\\nmarrow-derived hematopoietic cells generate car-\\ndiomyocytes at a low frequency through fusion, but not\\ntransdifferentiation. Nature Medicine 2004;10:494–\\n501.\\n\\n31. Kinnaird T, Stabile E, Burnett MS, et al: Local deliv-\\nery of marrow-derived stromal cells augments collat-\\neral perfusion through paracrine mechanisms. Circu-\\nlation 2004;109:1543–1549.\\n\\n32. Misao Y, Takemura G, Arai M, et al: Bone marrow-\\nderived myocyte-like cells and regulation of repair-\\nrelated cytokines after bone marrow cell transplan-\\ntation. Cardiovasc Res 2006;69:476–490.\\n\\n33. Schachinger V, Erbs S, Elsasser A, et al: The REPAIR-\\nAMI\\nIntracoronary bone marrow-\\nderived progenitor cells in acute myocardial infarc-\\ntion. N Engl J Med 2006;355:1210–1221.\\n\\nInvestigators.\\n\\n34. Sch¨achinger V, Assmuss B, Britten MB, et al: Trans-\\nplantation of progenitor cells and regeneration en-\\nhancement in acute myocardial infarction. Final one-\\nyear results of the TOPCARE-AMI trial. J Am Coll\\nCardiol 2004;44:1690–1699.\\n\\n35. Janssens S, Dubois C, Bogaert J, et al: Autol-\\nogous bone marrow-derived stem-cell transfer in\\n\\n896\\n\\nECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\\n\\nVol. 25, No. 8, 2008\\n\\n\\x0cCELL THERAPY IN AN ACUTE MYOCARDIAL INFARCTION\\n\\npatients with ST-segment elevation myocardial infarc-\\ntion: Double-blind, randomised controlled trial. 2006;\\n367(9505):113–121.\\n\\n36. Wollert KC, Meyer GP, Lotz J, et al: Intracoronary au-\\ntologous bone-marrow cell transfer after myocardial\\ninfarction: The BOOST randomized controlled clinical\\ntrial. Lancet 2004;363:141–148.\\n\\n37. Meyer GP, Wollert KC, Lotz J, et al: Intracoronary\\nbone marrow cell transfer after myocardial infarction.\\n\\nEighteen months’ follow-up data from the randomized,\\ncontrolled BOOST (bone marrow transfer to enhance\\nST-elevation infarct regeneration) Trial. Circulation\\n2006;113:1287–1294.\\n\\n38. Kuethe F, Richartz BM, Sayer HG, et al: Lack of regen-\\neration of myocardium by autologous intracoronary\\nmononuclear bone marrow cell transplantation in hu-\\nmans with large anterior myocardial infarctions. Int\\nJ Cardiol 2004;97:123–127.\\n\\nVol. 25, No. 8, 2008\\n\\nECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech.\\n\\n897\\n\\n\\x0cArticles                                                                                                  Chronic Lymphocytic Leukemia\\nHLA-G is a component of the chronic lymphocytic leukemia escape\\nrepertoire to generate immune suppression: impact of the HLA-G 14\\nbase pair (rs66554220) polymorphism\\n\\nRoberta Rizzo,1 Valentina Audrito,2,5 Paola Vacca,3 Davide Rossi,4 Davide Brusa,5 Marina Stignani,1 Daria Bortolotti,1\\nGiovanni D’Arena,6 Marta Coscia,7 Luca Laurenti,8 Francesco Forconi,9 Gianluca Gaidano,4 Maria Cristina Mingari,3,10\\nLorenzo Moretta,11 Fabio Malavasi,2,12 and Silvia Deaglio2,5\\n1Department of Medical Sciences, Sections of Microbiology and Medical Genetics, University of Ferrara, Italy; 2Department of\\nMedical Sciences, University of Turin, Italy; 3Department of Experimental Medicine, University of Genoa, Italy; 4Division of\\nHematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; 5Human\\nGenetics Foundation (HuGeF), Turin, Italy; 6Department of Onco-Hematology, IRCCS ‘‘Centro di Riferimento Oncologico della\\nBasilicata’’, Rionero in Vulture, Italy; 7Division of Hematology, University of Turin, Azienda Ospedaliera Città della Salute e della\\nScienza di Torino, Italy; 8Institute of Hematology, Catholic University of the Sacred Heart, Rome, Italy; 9Cancer Sciences Unit, CRUK\\nCenter, University of Southampton & Haematology Department, SUHT, Southampton, UK; 10AOU San Martino–Istituto Nazionale per\\nla Ricerca sul Cancro, Genoa, Italy; 11Giannina Gaslini Institute, Genoa, Italy; and 12Research Center for Experimental Medicine, Città\\ndella Salute e della Scienza Hospital, Turin, Italy\\n\\nABSTRACT\\n\\nThis work investigates the possibility that HLA-G, a molecule modulating innate and adaptive immunity, is part of\\nan immune escape strategy of chronic lymphocytic leukemia cells. A 14 base pair insertion/deletion polymorphism\\n(rs66554220) in the 3'-untranslated region of HLA-G influences mRNA stability and protein expression. The analysis\\nof a cohort of patients with chronic lymphocytic leukemia confirmed that del/del individuals are characterized by\\nhigher  levels  of  surface  and  soluble  HLA-G  than  subjects  with  the  other  two  genotypes.  In  line  with  its  role  in\\nimmunomodulation, the percentage of regulatory T lymphocytes is higher in del/del patients than in patients with\\nthe other genotypes and correlates with the amounts of surface or soluble HLA-G. Furthermore, addition of sHLA-\\nG-rich plasma from patients with chronic lymphocytic leukemia induces natural killer cell apoptosis and impairs nat-\\nural killer cell lysis, with effects proportional to the amount of soluble HLA-G added. Lastly, the presence of an HLA-\\nG 14 base pair polymorphism is of prognostic value, with del/del patients showing reduced overall survival, as com-\\npared to those with other genotypes. These results suggest that: (i) the HLA-G 14 base pair polymorphism influences\\nthe levels of surface and soluble HLA-G expression, and (ii) the over-expression of HLA-G molecules contributes to\\ncreating tolerogenic conditions. \\n\\nIntroduction\\n\\nChronic lymphocytic leukemia (CLL), the most common\\ntype of adult leukemia in Caucasian populations, is charac-\\nterized  by  the  progressive  accumulation  of  mature\\nCD5+/CD23+ B cells in the peripheral blood and lymphoid\\norgans.1 Several observations point to immune escape being\\na relevant mechanism of tumor promotion. First, CLL cells\\nexpress  high  levels  of  immunomodulatory  factors  (e.g.,\\ntransforming growth factor2 and interleukin-103), which sup-\\npress responses to antigens and influence activation, expan-\\nsion, and effector functions of T lymphocytes.4 Secondly, an\\nincrease  in  the  numbers  of  circulating  regulatory  T  cells\\n(Treg) parallels disease progression.5,6 Lastly, adenosine pro-\\nduction in the extracellular milieu by selected leukemic sub-\\npopulations  shields  the  CLL  clone  from  the  actions  of  the\\nimmune system.7\\n\\nThe aim of this work was to investigate the role of human\\nleukocyte antigen G (HLA-G) as a further strategy adopted by\\nCLL cells to evade immune defenses and to create protected\\nniches in which to grow and expand. HLA-G is a non-classical\\nmajor histocompatibility complex (MHC) class I product with\\n\\nlimited sequence variability. It is exclusively expressed in tis-\\nsues where the immune system needs to be constantly sup-\\npressed,  including  cytotrophoblast  from  early  gestation  pla-\\ncentas, amniotic cells, endothelial cells of chorionic blood ves-\\nsels, thymic epithelial cells and corneas.8 HLA-G is a tolero-\\ngenic molecule which inhibits cytolysis mediated by natural\\nkiller  (NK)  cells  or  T  lymphocytes,  induces  T-cell  apoptosis\\nand  blocks  transendothelial  migration  of  NK  cells.9 These\\nfunctions  are  exerted  upon  binding \\nthe  killer  cell\\nimmunoglobulin-like \\nthe\\nimmunoglobulin-like  transcript-2  and  -4  ligands.10,11 Hence,\\nthe immunosuppressive features of HLA-G are functional in\\npregnancy, organ transplantation, autoimmune diseases, and\\ncancer immune escape.12\\n\\n(KIR)2DL4 \\n\\nreceptor \\n\\nand \\n\\nThe  HLA-G gene  encodes  seven  isoforms  generated\\nthrough  alternative  splicing:  four  are  membrane-bound\\n(namely, HLA-G1, -G2, -G3, and -G4), while three (HLA-G5,\\n-G6, and -G7) are soluble and represent the counterparts of\\nHLA-G1,  -G2  and  -G3,  respectively.  An  alternative  mecha-\\nnism to generate soluble HLA-G (sHLA-G) forms is represent-\\ned by proteolytic cleavage of the membrane molecules.13\\n\\nHLA-G is characterized by different polymorphisms at the\\n\\n©2014 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2013.095281\\nThe online version of this article has a Supplementary Appendix.\\nManuscript received on July 23, 2013. Manuscript accepted on December 17, 2013.\\nCorrespondence:  silvia.deaglio@unito.it   or   roberta.rizzo@unife.it.\\n\\n888\\n\\nhaematologica | 2014; 99(5)\\n\\n\\x0c5’  upstream  regulatory  and  the  3’  untranslated  regions.14\\nOne  of  these,  characterized  by  the  deletion/insertion\\n(del/ins) of 14 base pairs (14 bp) (rs66554220), is responsi-\\nble for mRNA stability and consequently protein produc-\\ntion.15 The  presence  of  the  14  bp  sequence  is  associated\\nwith  unstable  mRNA  and  reduced  sHLA-G  protein  pro-\\nduction.16 This  polymorphism  is  implicated  in  autoim-\\nmune and chronic inflammatory conditions,8 while its role\\nin cancer growth and progression is still controversial.\\n\\nThe role of HLA-G products in CLL patients has been\\nevaluated  in  previous  studies,  although  these  focused\\nexclusively on the expression either of the membrane or\\nof  the  secreted  isoform  of  the  molecule.  The  results\\nobtained indicate that: (i) HLA-G expression at transcrip-\\ntion  and  protein  levels  is  increased  in  CLL  cells  as  com-\\npared to normal B lymphocytes;17-19 and (ii) HLA-G expres-\\nsion correlates with worse clinical outcome in CLL.20,21\\n\\nThis work was undertaken with the aim of assessing the\\nimpact of the HLA-G 14 bp polymorphism on expression\\nof the membrane and soluble forms of the HLA-G protein,\\nand its role in promoting immune escape in a large, well-\\ncharacterized cohort of CLL patients.\\n\\nMethods\\n\\nPatients and controls\\n\\nFive hundred and six individuals with a confirmed diagnosis of\\nCLL  were  enrolled  at  diagnosis  into  a  retrospective  study  and\\ntyped for HLA-G rs66554220 polymorphism. The patients’ char-\\nacteristics  are  reported  in  Online  Supplementary  Table  S1.  Blood\\nsamples from patients or non-leukemic individuals were obtained\\nafter  written  informed  consent  in  accordance  with  local  institu-\\ntional guidelines and the Declaration of Helsinki. The study was\\napproved by the Human Genetics Foundation Ethical Committee.\\nPeripheral blood mononuclear cells and purified B lymphocytes\\n\\nwere obtained as described elsewhere.22\\n\\nFlow cytometric analyses \\n\\nAntibodies used for flow cytometry are detailed in the Online\\nSupplementary Materials and Methods. Data were acquired using a\\nFACSCanto  II  (BD  Biosciences,  Buccinasco,  Italy)  or  Gallios\\n(Beckman  Coulter)  flow  cytofluorimeter,  processed  with  DIVA\\nv6.1.3  (BD  Biosciences),  and  analyzed  with  FlowJo  version  9.01\\nsoftware  (TreeStar,  Ashland,  OR,  USA).  At  least  10,000  events\\nwere analyzed for each sample.\\n\\nTyping the HLA-G 14 base pair polymorphism \\n\\nGenomic DNA was extracted from peripheral blood mononu-\\nclear  cells  using  a  DNeasy  Blood  &  Tissue  Kit  (Qiagen,  Milan,\\nItaly). The HLA-G 14 bp polymorphism was genotyped by poly-\\nmerase chain reaction.23,24\\n\\nSoluble HLA-G detection by enzyme-linked \\nimmunosorbent assay\\n\\nsHLA-G1 and HLA-G5 levels were measured as reported previ-\\nously.25 After both enzyme-linked immunosorbent assay (ELISA)\\nmeasurements, the amount of sHLA-G1 was expressed as the dif-\\nference  between  sHLA-G1/HLA-G5  and  HLA-G5  concentra-\\ntions.26\\n\\nIsolation and culture of natural killer cells \\n\\nNK cells were isolated from peripheral blood mononuclear cells\\nor from decidua as described elsewhere.27,28 Purified NK cells were\\ncultured  on  allogeneic  irradiated  feeder  cells  in  the  presence  of\\n\\nHLA-G polymorphism in CLL\\n\\ninterleukin-2  (100  U/mL)  and  phytohemagglutinin  (1.5  ng/mL,\\nGibco, Life Technologies).27\\n\\nNatural killer cell apoptosis\\n\\nFreshly isolated or interleukin-2 activated NK cells were incu-\\nbated with different serum samples from CLL patients representa-\\ntive of the different 14 bp HLA-G polymorphism. After overnight\\nincubation, NK cell apoptosis was measured using annexin V and\\npropidium iodide (Invitrogen, Eugene, OR, USA).\\n\\nNatural killer cell cytolytic activity\\n\\nInterleukin-2-activated NK cells were tested for cytolytic activi-\\n\\nty in a 4 h 51Cr-release assay against the K562 cell line.27\\n\\nStatistical analyses\\n\\nOverall survival was measured from date of sampling to date of\\ndeath (event) or last follow-up (censoring). Survival analysis was\\nperformed  by  the  Kaplan-Meier  method.  The  crude  association\\nbetween time-fixed exposure variables at diagnosis and survival\\nwas  estimated  by  log-rank  analysis.  Statistical  significance  was\\ndefined as a P value <0.05. Statistical tests were performed using\\nGraphPad  Prism  6.0  software  (Graphpad  Software,  San  Diego,\\nCA, USA) and SPSS software v20.0 (Chicago, IL, USA).\\n\\nResults\\n\\nEffects of the HLA-G 14 base pair polymorphism \\non membrane and soluble protein expression \\nin patients with chronic lymphocytic leukemia\\n\\nThe  hypothesis  underlying  this  study  is  that  patients\\nwith a del/del genotype of the 14 bp polymorphism have\\nmore  stable  HLA-G mRNA,  resulting  in  higher  levels  of\\nthe molecule on the cell surface and in biological fluids.16\\nThis hypothesis was tested by determining the effects\\nof the 14 bp polymorphism on the expression of HLA-G\\nprotein  at  the  surface  of  CLL  B  cells  obtained  from  126\\npatients.  The  observed  levels  of  HLA-G  expression  on\\nCD19+/CD5+ CLL  B  lymphocytes  were  highly  variable\\n[mean ± standard error of mean (SEM) 7.35±1.13%, Figure\\n1A,B].  Patients  with  a  del/del  genotype  had  a  trend\\ntowards  increased  levels  (n=51,  mean  8.97±1.85)  of  sur-\\nface  HLA-G,  even  if  a  comparison  with  levels  in  ins/del\\n(n=48,  mean  6.38±2)  or  ins/ins  (n=27,  mean  6.03±1.77)\\npatients  was  not  statistically  significant  (Figure  1C).\\nHowever, when divided into quartiles, 25.4% of the 126\\npatients had a surface HLA-G expression by leukemic cells\\nabove  the  third  quartile  (third  quartile  value:  9.5%).  Of\\nthese,  58%  had  a  del/del,  23%  an  ins/del  and  19%  an\\nins/ins genotype (P<0.0001, χ\\nAttention  was  next  focused  on  HLA-G  plasma  levels\\nassayed by ELISA in a cohort of 60 patients and 60 sex-\\nand age-matched controls. Results indicate a marked vari-\\nability  in  concentration  in  both  CLL  patients  (mean  ±\\nSEM,  19.71±2.83  ng/mL)  and  controls  (mean  ±  SEM,\\n17.28±23.64  ng/mL),  without  statistically  significant  dif-\\nferences between the two groups (Figure 2A). When CLL\\npatients and controls were divided according to genotype,\\ndel/del  patients  (n=27)  had  significantly  higher  levels  of\\nsHLA-G (mean 30.82±4.8 ng/mL) than had either ins/del\\n(n=18, mean 13.68±3.67 ng/mL, P=0.015, Mann-Whitney\\ntest)  or  ins/ins  patients  (n=15,  mean  6.95±2.74  ng/mL,\\nP=0.003, Mann-Whitney test, Figure 2B). Del/del controls\\nshowed a tendency towards a higher production of sHLA-\\n\\n2 test, Figure 1D). \\n\\nhaematologica | 2014; 99(5)\\n\\n889\\n\\n\\x0cR. Rizzo et al.\\n\\nG  (n=22,  mean  22.06±27.32  ng/mL)  when  compared  to\\nins/del (n=25, mean 16.93±24.87 ng/mL) or ins/ins (n=13,\\nmean 9.88 ± 11.90 ng/mL) individuals, without the differ-\\nence reaching statistical significance (Online Supplementary\\nFigure  S1A).  After  dividing  sHLA-G  levels  into  quartiles,\\n25% of CLL patients and of controls had sHLA-G expres-\\nsion above the third quartile (third quartile value in CLL\\npatients:  31.75  ng/mL;  third  quartile  value  in  controls:\\n24.40  ng/mL).  Of  these,  in  the  CLL  cohort  80%  had  a\\ndel/del genotype, while 13% had an ins/del genotype and\\nthe  remaining  7%  had  an  ins/ins  genotype  (P<0.0001,\\nFisher exact test, Figure 2C). When considering controls,\\n46%  presented  a  del/del,  46%  an  ins/del  and  8%  an\\nins/ins  genotype  (P<0.0001,  Fisher  exact  test,  Online\\nSupplementary Figure S1B).\\n\\nWe  then  asked  whether  sHLA-G  levels  correlate  with\\nHLA-G  expressed  on  the  membrane  of  CLL  cells.  As\\nexpected, the levels of expression of sHLA-G and mem-\\nbrane  HLA-G  were  positively  correlated  (n=60,  rho=0.4,\\nP=0.003,  Spearman  correlation  test),  in  line  with  a  rela-\\ntionship  between  surface  HLA-G  expression  and  release\\n(Figure 2D). The analysis of covariance showed an inde-\\npendent effect of 14 bp polymorphism (P=0.003) and sur-\\nface HLA-G expression (P=0.02) on sHLA-G plasma levels.\\nUsing an isoform-sensitive ELISA, sHLA-G1 was predom-\\ninant in the plasma of CLL patients, indicating a derivation\\nfrom  shedding  of  the  membrane  form  rather  than  from\\nalternative  splicing  (sHLA-G1  versus HLA-G5  isoforms,\\nP=0.001; Mann-Whitney test, Figure 2E). \\n\\nThe conclusion is that patients with a del/del genotype\\n\\nA\\n\\nC\\nS\\nS\\n\\n250k\\n\\n200k\\n\\n150k\\n\\n100k\\n\\n50k\\n\\n0\\n\\n5\\nD\\nC\\n\\n105\\n\\n104\\n\\n103\\n\\n102\\n\\n101\\n\\n100\\n\\nB\\n\\nC\\n\\n)\\n\\n%\\n\\n(\\n \\nG\\n-\\nA\\nL\\nH\\n \\ne\\nc\\na\\nf\\nr\\nu\\nS\\n\\n0\\n\\n50k\\n\\n100k\\n\\n150k\\nFSC\\n\\n200k\\n\\n250k\\n\\n100\\n\\n101\\n\\n102\\n103\\nCD19\\n\\n104\\n\\n105\\n\\n# 1 low\\n\\n# 2 intermediate\\n\\n100\\n\\n1 %\\n\\n19%\\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\n# 3 high\\n\\n54%\\n\\n100\\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\n100\\n\\n101\\n\\n102\\n\\n103\\n\\n104\\n\\n105\\n\\n100\\n\\n101\\n\\n102\\n\\n103\\n\\n104\\n\\n105\\n\\n100\\n\\n101\\n\\n102\\n\\n103\\n\\n104\\n\\n105\\n\\nHLA-G\\n\\nD\\n\\n100\\n\\ns\\nt\\nn\\ne\\ni\\nt\\na\\np\\n\\n \\nf\\no\\n%\\n\\n \\n\\n75\\n\\n50\\n\\n25\\n\\n0\\n\\nn=48\\n\\nn=51\\n\\nn=27\\n\\ndel/del\\n\\nins/del\\n\\nins/ins\\n\\nHLA-G genotype\\n\\nP<0.0001\\n\\n>9.5%\\n\\n<9.5%\\n\\ndel/del\\n\\nins/del\\n\\nins/ins\\n\\nHLA-G genotype\\n\\n100\\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\nHLA-G \\n\\nexpression \\n\\nFigure  1.  Distribution  of  membrane\\nHLA-G in a cohort of 126 CLL patients\\ntyped  for  the  14  bp  polymorphism.\\n(A) Density plots represent the gating\\nstrategy.  Left  panel  indicates  the\\nmorphological  gate, \\nright  panel\\nshows  the  staining  for  CD19  and\\nCD5.  (B)  Histograms  represent  sur-\\nface \\nin\\nCD19+/CD5+ CLL B lymphocytes from\\nthree  representative  patients.  (C)\\nPatients were then divided according\\nto  the  14  bp  polymorphism  into\\ngroups  with  del/del, \\nins/del  or\\nins/ins genotype. Box plots represent\\nthe distribution of mHLA-G in the dif-\\nferent  categories.  (D)  Graph  repre-\\nsenting  the  percentages  of  patients\\nexpressing  mHLA-G  above  (black\\nbars)  or  below  (open  bars)  the  third\\nquartile (9.5%).\\n\\n890\\n\\nhaematologica | 2014; 99(5)\\n\\n\\x0chave  significantly  higher  sHLA-G  levels  and  tend  to\\nexpress more membrane HLA-G on leukemic cells than do\\npatients with the other genotypes.\\nEffects of the HLA-G 14 base pair polymorphism on \\nthe number of circulating T lymphocytes in patients\\nwith chronic lymphocytic leukemia \\n\\nCLL  development  and  progression  are  paralleled  by  a\\nprogressive  impairment  of  host  immune  defenses,  with\\nclinically manifest immune defects of the T-cell compart-\\nment.  The  next  step  of  the  study  was  to  determine\\nwhether high levels of surface and sHLA-G would reflect\\nthe immune defects characterizing CLL. To this aim, the\\ncomposition  of  T-cell  subsets  was  assessed  in  52  CLL\\npatients  divided  according  to  HLA-G 14  bp  polymor-\\nphism.\\n\\nCD4+ and CD8+ and T-cell percentages were not signifi-\\ncantly different among the groups with the three HLA-G\\n14 bp genotypes (Figure 3A,B). In contrast, the number of\\nTreg, defined as CD4+/CD25high/CD127low), was significant-\\nly  higher  in  patients  with  the  del/del  genotype  (mean\\n6.97% ± 0.88) than in the group with the ins/ins genotype\\n(mean 3.23% ± 0.69, P=0.006, Mann-Whitney test, Figure\\n3C). Heterozygous patients displayed intermediate values,\\nnot significantly different from those in either the ins/ins\\nor del/del homozygous patients (mean 5.77% ± 0.78). The\\npercentage of Treg correlated positively with the levels of\\nexpression of surface HLA-G on CLL cells (n=33, rho=0.4,\\nP=0.04,  Spearman  correlation  test),  suggesting  that  the\\namount of HLA-G expressed by leukemic cells could influ-\\nence the frequency of Treg (Figure 3D). In line with this\\nobservation was the finding that the percentage of circu-\\nlating Treg was higher in cases of CLL with surface HLA-\\nG expression >9.5% (third quartile) than in CLL in which\\n\\nHLA-G polymorphism in CLL\\n\\nsurface  HLA-G  expression  was  <9.5%  (mean  6.95%  ±\\n0.98 versus mean 4.31% ± 0.52, P=0.03, Mann-Whitney U\\ntest; Figure 3E).\\n\\nNo statistically significant correlation could be detected\\nbetween sHLA-G levels and the frequency of Treg, likely\\ndue to the limited sample analyzed (n=13, data not shown).\\nHowever,  CLL  patients  in  whom  sHLA-G  levels  were\\n>31.75 ng/mL (third quartile) tended to have a higher per-\\ncentage  of  Treg  than  patients  in  whom  sHLA-G  levels\\nwere <31.75 ng/mL (mean 5.1% ± 1.44 versus mean 3.37%\\n±  0.52,  P=0.30,  Mann-Whitney  test,  Figure  3F).Together,\\nthese data suggest that HLA-G expression is linked to an\\nexpansion of Treg, as partly observed in other models.29\\nEffects of the HLA-G polymorphism on natural\\nkiller cell function\\n\\nAn alternative mechanism through which HLA-G mole-\\ncules  suppress  the  immune  response  is  their  inhibitory\\neffect on NK cell activation and cytotoxic functions, medi-\\nated  through  the  KIR2DL4  ligand.11 We,  therefore,  ana-\\nlyzed  the  possible  implication  of  sHLA-G  molecules  in\\nplasma samples on composition, activation and functional\\nactivities of NK cells in CLL samples. The reference con-\\ntrol was represented by healthy individuals matched for\\ngender and age. \\n\\nThe  number  of  circulating  NK  cells \\n\\n(gated  as\\nCD56+/CD3-) was sharply decreased in CLL patients (n=9,\\nmean 2.53% ± 0.88) as compared to controls (n=11, mean\\n11.52% ± 1.22, P<0.0001, Mann-Whitney test, Figure 4A). \\nThe  cytolytic  activity  of  NK  cells  isolated  from  CLL\\npatients (n=9) was tested after culture for 2-4 weeks in the\\npresence  of  interleukin-2.  Cells  were  then  assessed  for\\ntheir ability to lyse the K562 target cell line in a 51Cr-release\\ncytolytic  assay  at  different  effector:target  (E:T)  ratios\\n\\nA\\n\\n100\\n\\nn=60\\n\\nB\\n\\nP=0.003\\n\\nC\\n\\n100\\n\\nP=0.015\\n\\nn=27\\n\\nP<0.0001\\n\\n100\\n\\n<31.75 ng/mL\\n>31.75 ng/mL\\n\\n)\\nL\\nm\\n/\\ng\\nn\\n(\\n \\nG\\n-\\nA\\nL\\nH\\n \\ne\\nb\\nu\\no\\nS\\n\\nl\\n\\nl\\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\n75\\n\\n50\\n\\n25\\n\\n0\\n\\nCLL \\n\\ncontrols\\n\\n)\\nL\\nm\\n/\\ng\\nn\\n(\\n \\nG\\n-\\nA\\nL\\nH\\n \\ne\\nb\\nu\\no\\nS\\n\\nl\\n\\nl\\n\\nD\\n\\nn=18\\n\\nn=15\\n\\ndel/del\\n\\nins/del\\n\\nins/ins\\n\\nHLA-G genotype\\n\\n)\\nL\\nm\\n/\\ng\\nn\\n(\\n \\nG\\n-\\nA\\nL\\nH\\n \\ne\\nb\\nu\\no\\nS\\n\\nl\\n\\nl\\n\\n100\\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\nn=60\\nrho=0.4\\nP=0.003\\n80\\n\\n0\\n\\n20\\n\\n40\\n\\nHLA-G (%)\\n\\n60\\n\\ns\\nt\\nn\\ne\\ni\\nt\\na\\np\\n\\n \\nf\\no\\n%\\n\\n \\n\\nE\\n\\n)\\nL\\nm\\n/\\ng\\nn\\n(\\n \\nG\\n-\\nA\\nL\\nH\\n \\ne\\nb\\nu\\no\\nS\\n\\nl\\n\\nl\\n\\n75\\n\\n50\\n\\n25\\n\\n0\\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\ndel/del\\n\\nins/del\\n\\nins/ins\\n\\nHLA-G genotype\\n\\nP=0.001\\n\\nn=60\\n\\nn=60\\n\\nsHLA-G1 sHLA-G5\\n\\nFigure 2. Quantification of soluble HLA-G\\nlevels  in  a  cohort  of  60  CLL  patients\\ntyped  for  the  14  bp  polymorphism.  (A)\\nBox  plot  analysis  summarizing  data\\nobtained  with  a  quantitative  ELISA  per-\\nformed on 60 plasma samples from CLL\\npatients  and  60  plasma  samples  from\\ncontrol subjects (controls). The lower and\\nupper  limits  of  the  box  define  the  first\\nand  third  quartiles,  respectively,  while\\nthe  line  inside  the  box  represents  the\\nmedian. Whiskers identify minimum and\\nmaximum values. (B) Graph showing sol-\\nuble HLA-G levels in CLL patients divided\\naccording  to  the  14  bp  polymorphism\\ninto  del/del,  ins/del  and  ins/ins  cate-\\ngories.  (C)  Graph  representing  the  per-\\ncentages of CLL patients expressing sol-\\nuble HLA-G above (black bars) or below\\n(open  bars)  the  third  quartile  (31.75\\nng/mL)  in  the  three  genotypes.  (D)\\nRegression lines showing a positive cor-\\nrelation between the percentage of CLL\\ncells  expressing  HLA-G  on  the  cell  sur-\\nface and the amount of soluble HLA-G in\\nthe  plasma.  Spearman  coefficient  (rho)\\nand  the  corresponding  P value  are  pro-\\nvided. (E) Box plot showing the results of\\nan ELISA using isoform-specific antibod-\\nies to discriminate between soluble HLA-\\nG1 (derived from shedding of the mem-\\nbrane form) and soluble HLA-G5 (derived\\nfrom alternative splicing).\\n\\nhaematologica | 2014; 99(5)\\n\\n891\\n\\n\\x0cR. Rizzo et al.\\n\\nA\\n\\ns\\nl\\nl\\ne\\nc\\n \\n\\nT\\n\\n+\\n\\n4\\nD\\nC\\n\\n \\nf\\no\\n%\\n\\n \\n\\nD\\n\\ns\\n\\nl\\nl\\n\\ne\\nc\\n \\n\\ng\\ne\\nr\\nT\\n%\\n\\n \\n\\n20\\n\\n15\\n\\n10\\n\\n5\\n\\n0\\n\\n15\\n\\n10\\n\\n5\\n\\n0\\n\\n0\\n\\nB\\n\\n10\\n\\ns\\nl\\nl\\ne\\nc\\n \\n\\nT\\n\\n+\\n\\n8\\nD\\nC\\n\\n \\nf\\no\\n%\\n\\n \\n\\n8\\n\\n6\\n\\n4\\n\\n2\\n\\n0\\n\\nE\\n\\n15\\n\\n10\\n\\n5\\n\\ns\\n\\nl\\nl\\n\\ne\\nc\\n \\n\\ng\\ne\\nr\\nT\\n%\\n\\n \\n\\nn=16\\n\\nn=24\\n\\nn=12\\n\\ndel/del\\n\\nins/del\\n\\nins/ins\\n\\nHLA-G genotype\\n\\nP=0.032\\n\\nn=8\\n\\nn=21\\n\\n0\\nmembrane HLA-G (%)\\n\\n>9.5\\n\\n<9.5\\n\\nC\\n\\ns\\nl\\nl\\ne\\nc\\n \\n\\ng\\ne\\nr\\nT\\n%\\n\\n \\n\\nF\\n\\ns\\n\\nl\\nl\\n\\ne\\nc\\n \\n\\ng\\ne\\nr\\nT\\n%\\n\\n \\n\\n15\\n\\n10\\n\\n5\\n\\n0\\n\\n8\\n\\n6\\n\\n4\\n\\n2\\n\\n0\\n\\nP=0.006\\n\\nP=0.45\\n\\nn=13\\n\\nn=9\\n\\nn=6\\n\\ndel/del\\n\\nins/del\\n\\nins/ins\\n\\nHLA-G genotype\\n\\nP=0.30\\n\\nn=4\\n\\nn=9\\n\\n>31.75\\n\\n<31.75\\n\\nsoluble HLA-G (ng/mL)\\n\\nn=16\\n\\nn=24\\n\\nn=12\\n\\ndel/del\\n\\nins/del\\n\\nins/ins\\n\\nHLA-G genotype\\n\\nn=33\\nrho=0.4\\nP=0.04\\n5\\n20\\nmembrane HLA-G (%)\\n\\n10\\n\\n15\\n\\n25\\n\\nFigure 3. Evaluation of the T-cell compartment in CLL patients typed for the 14 bp polymorphism. Percentage of total CD4+ (A) and CD8+ (B)\\ncirculating  T  lymphocytes  and  Treg  (C)  in  CLL  patients  divided  according  to  the  14  bp  polymorphism.  Treg  were  defined  as\\nCD4+/CD25high/CD127low. (D) Regression line showing a positive correlation between membrane HLA-G and the percentage of circulating Treg.\\nSpearman coefficient (rho) and the corresponding P values are provided. (E) Percentage of Treg in CLL patients expressing membrane HLA-G\\nabove or below the third quartile (9.5%). (F) Percentage of Treg in CLL patients expressing soluble HLA-G above or below the third quartile\\n(31.75 mg/mL).\\n\\n(from 40:1 to 0.25:1). Controls were interleukin-2-activat-\\ned NK cells from healthy donors. As shown in Figure 4B,\\nthe  NK-cell-mediated  cytolytic  activity  in  CLL  patients\\nwas lower than that in healthy donors. Thus, for example,\\n40% target cell lysis was obtained at an E:T ratio of 2.5:1\\nfrom  healthy  donors  and  at  20:1  for  NK  cells  from  CLL\\npatients (Figure 4B). \\n\\nWe next asked whether KIR2DL4, the main HLA-G lig-\\nand,30 was expressed by NK cells. While resting NK cells\\nfrom  normal  donors  and  from  CLL  patients  lacked\\nKIR2DL4,  the  ligand  was  induced  upon  interleukin-2-\\nmediated NK cell activation, in agreement with published\\ndata30 (Figure  4C).  Representative  expression  plots  are\\nreported in Online Supplementary Figure S2, showing results\\nfrom an experiment in which decidual NK cells were used\\nas  a  positive  control.  No  differential  expression  in\\nKIR2DL4  was  noted  in  HLA-G  typed  patients  (data  not\\nshown). The next step was to test whether sHLA-G present\\nin plasma could induce apoptosis or inhibit the cytolytic\\nfunction  of  NK  cells  obtained  from  normal  donors.  To\\nanswer this question, we used plasma from CLL patients\\ncontaining different levels of sHLA-G to interfere with the\\n\\nviability  and  cytotoxic  activity  of  NK  cells.  Plasma  from\\nCLL  patients  significantly  compromised  the  viability  of\\nNK cells from normal donors, by inducing apoptosis. The\\neffect was directly correlated to sHLA-G levels in plasma,\\nwith  significantly  lower  survival  of  the  NK  cells  when\\nexposed  to  plasma  from  patients  with  sHLA-G  >31.75\\nng/mL as compared to plasma from patients with unde-\\ntectable sHLA-G (Figure 4D).\\n\\nSimilarly, NK cell function was significantly impaired in\\nthe  presence  of  CLL  plasma  samples  with  detectable\\nsHLA-G (P<0.0001, Mann-Whitney test, Figure 4E). At an\\nE:T  ratio  of  10:1  donor  NK  cells  in  the  absence  of  CLL\\nplasma  efficiently  killed  target  cells  (mean  85%  ±  1.63),\\nwhile  in  the  presence  of  CLL  plasma  samples  with\\ndetectable  sHLA-G,  the  cytolytic  activity  was  sharply\\nreduced (mean 27.38% ± 4.72). CLL plasma samples with\\nno sHLA-G were used as the control. The presence of NK\\ncell inhibition also in the presence of CLL plasma samples\\nwith undetectable sHLA-G suggests the presence of other\\nfactors implicated in NK cell activation control. However,\\nthe degree of inhibition correlated with the concentrations\\nof sHLA-G (Figure 4F). There was an inverse correlation\\n\\n892\\n\\nhaematologica | 2014; 99(5)\\n\\n\\x0cP<0.0001\\n\\nn=11\\n\\nn=9\\n\\nCLL\\n\\ncontrols\\n\\n20\\n\\n15\\n\\n10\\n\\n5\\n\\n0\\n\\nB\\n\\ns\\ni\\ns\\ny\\nl\\n \\nl\\nl\\ne\\nc\\n \\nf\\no\\n%\\n\\n \\n\\n100\\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\ncontrols\\nCLL\\n\\nC\\n\\ns\\nl\\nl\\ne\\nc\\n \\nK\\nN\\nn\\no\\n\\n \\n\\n \\n\\no\\ni\\nt\\na\\nr\\n \\nI\\nF\\nM\\n4\\nL\\nD\\n2\\nR\\nK\\n\\nI\\n\\n \\n\\n1\\n\\n:\\n\\n0\\n4\\n\\n1\\n\\n:\\n\\n0\\n2\\n\\n1\\n\\n:\\n\\n0\\n1\\n\\n1\\n\\n:\\n\\n5\\n\\n1\\n\\n:\\n\\n5\\n2\\n\\n1\\n\\n:\\n\\n5\\n2\\n\\n.\\n\\n1\\n\\n1\\n\\n:\\n\\n5\\n\\n.\\n\\n0\\n\\n1\\n\\n:\\n\\n5\\n2\\n\\n.\\n\\n0\\n\\nE:T ratio\\n\\nHLA-G polymorphism in CLL\\n\\n3\\n\\n2\\n\\n1\\n\\n0\\n\\nP=0.01\\n\\nn=10\\n\\nn=10\\n\\nday 0\\n\\nday 7\\n+ IL-2\\n\\nP<0.0001\\n\\n100\\n\\nP<0.0001\\n\\nP=0.009\\n\\nn=7\\n<0 ng/mL >25 ng/mL\\n\\nsHLA-G\\n\\nno\\n\\nplasma\\n\\nE\\n\\ns\\n\\ni\\n\\ns\\ny\\n\\nl\\n \\nl\\nl\\n\\ne\\nc\\n \\nf\\no\\n%\\n\\n \\n\\nP<0.0001\\n\\n100\\n\\nn=7\\n\\nF\\n\\n100\\n\\nP=0.001\\n\\nP=0.001\\n\\nn=7\\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\nn=12\\n\\nno\\n\\nplasma\\n\\nsHLA-G\\n\\ns\\n\\ni\\n\\ns\\ny\\n\\nl\\n \\nl\\nl\\n\\ne\\nc\\n \\nf\\no\\n%\\n\\n \\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\nP=0.002\\n\\nn=6\\n\\nn=6\\n\\nno\\n\\nplasma\\n\\n<0 ng/mL >25 ng/mL\\n\\nsHLA-G\\n\\n100\\n\\nP<0.0001\\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\ndel/del\\n\\nins/del\\n\\nins/ins\\n\\nH\\n\\nn\\no\\ni\\nt\\ni\\nb\\nh\\nn\\n\\ni\\n\\ni\\n \\ns\\ns\\ny\\n\\ni\\n\\nl\\n \\n\\n%\\n\\nA\\n\\ns\\nl\\nl\\ne\\nc\\n \\nK\\nN\\n\\n-\\n\\n3\\nD\\nC\\n\\n/\\n\\n+\\n\\n6\\n5\\nD\\nC\\n\\n \\nf\\no\\n%\\n\\n \\n\\nD\\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\ny\\nt\\ni\\nl\\ni\\n\\nb\\na\\n\\ni\\n\\nv\\n \\n%\\n\\nG\\n\\nn=22\\nrho=-0.49\\nP=0.02\\n\\n60\\n\\n40\\n\\n20\\n\\n)\\nL\\nm\\n/\\ng\\nn\\n(\\n \\nG\\n-\\nA\\nL\\nH\\n \\ne\\nb\\nu\\no\\nS\\n\\nl\\n\\nl\\n\\n0\\n\\n0\\n\\n20\\n\\n40\\n\\n60\\n\\n80\\n\\n100\\n\\nFigure 4. Evaluation of the NK cell compartment in CLL patients typed for the 14 bp polymorphism. (A) Percentage of circulating CD56+/CD3-\\nNK cells in seven CLL patients and in 11 healthy donors (controls) with a comparable age and male:female ratio. (B)  51Cr cytotoxicity assay\\ncomparing the lytic potential of in vitro interleukin-2-activated NK cells from controls (circles) or CLL patients (squares) against the K562 target\\ncell line. (C) Expression of KIR2DL4 in resting and interleukin-2-activated NK cells from CLL patients. Data are expressed as mean fluorescence\\nintensity (MFI) ratio. (D) Percentage of NK cell viability in the presence of sHLA-G-high and sHLA-G-low plasma from CLL patients. (E) Inhibition\\nof cytolytic activity of interleukin-2-activated HD-NK cells against K562 target cells in the presence or absence of plasma obtained from CLL\\npatients. (F) The inhibitory effect of CLL plasma on NK cell lysis was studied in patients with high levels of soluble HLA-G and compared to that\\nin patients with undetectable soluble HLA-G. (G) Regression line showing a negative correlation between the amount of soluble HLA-G and the\\npercentage of cell lysis. Spearman coefficient (rho) and the corresponding P value are provided. (H) Graph representing the percentage of NK\\ncell lysis inhibition obtained using plasma derived from patients categorized on the basis of HLA-G genotype. \\n\\nhaematologica | 2014; 99(5)\\n\\n893\\n\\n\\x0cR. Rizzo et al.\\n\\nbetween sHLA-G levels in CLL plasma samples (n=22) and\\nthe cytolytic activity of NK cells expressed as percentage\\ncell  lysis  (rho=  –0.49,  P=0.02,  Spearman  correlation  test,\\nFigure 4G). Consistent with the notion that CLL patients\\nwith del/del polymorphism have higher levels of sHLA-G\\ncompared  to  the  levels  in  patients  with  the  other  geno-\\ntypes, plasma from del/del patients showed greater inhibi-\\ntion than plasma from patients with the other genotypes.\\nThus, at an E:T ratio of 10:1, del/del plasma inhibited NK\\ncell  lysis  by  57.9%,  while  the  effects  exerted  by  ins/del\\nand  ins/ins  plasma  were  35.8%  and  5.3%,  respectively\\n(P<0.0001, Fisher exact test, Figure 4H). \\nProof-of-principle: the HLA-G 14 bp polymorphism\\ninfluences survival of patients with chronic \\nlymphocytic leukemia\\n\\nThe results obtained so far indicate that the HLA-G 14\\nbp polymorphism dictates the amount of HLA-G protein\\npresent  on  the  cell  surface  and  in  the  plasma  of  CLL\\npatients and that the molecule quantitatively and qualita-\\ntively modulates T and NK immunocompetence. In con-\\nsideration of the immunosuppressive features of HLA-G,\\npatients characterized by a del/del genotype would have\\nhigher  levels  of  HLA-G,  would  be  more  immunosup-\\npressed  and  ultimately  have  a  worse  clinical  outcome.\\nThis issue was approached by testing the frequency of the\\nHLA-G 14 bp polymorphism in 506 CLL patients (Online\\nSupplementary Table S1). The genotype frequencies were in\\nHardy-Weinberg  equilibrium:  176/506  patients  (34.8%)\\nwere  del/del  homozygous,  81/506  (16%)  were  ins/ins\\nhomozygous  and  the  remaining  249/506  (49.2%)  were\\nins/del heterozygous. None of the demographic (age and\\nsex),  clinical  (disease  stage,  splenomegaly,  lymph  node\\nsize), laboratory (lactate dehydrogenase or β2-microglobu-\\nlin  levels),  or  molecular  variables  (CD38,  ZAP-70,  IGHV\\nmutational  status,  chromosomal  aberrations)  showed  a\\npreferential  association  with  the  HLA-G polymorphism\\n(Online Supplementary Table S1). According to the survival\\nanalysis,  patients  harboring  the  del/del  genotype  had  a\\nshorter  survival  than  patients  harboring  the  ins/del  or\\nins/ins  genotype  (P=0.027,  log-rank  test,  Figure  5A).\\nConsistently, CLL patients with sHLA-G levels above the\\nthird quartile had a shorter survival (median, 63.9 months)\\nthan patients with sHLA-G levels below the third quartile\\n(median, 71.5 months, P=0.0215, log-rank test; Figure 5B),\\nand CLL patients with plasma samples showing inhibitory\\neffects  on  NK  cells  showed  a  trend  towards  having  a\\nshorter  survival  than  patients  whose  plasma  lacked\\ninhibitory effects (P=0.147, log-rank test, data not shown). \\n\\nDiscussion\\n\\nHLA-G  is  a  non-classical  HLA  protein  that  works  by\\nmodulating the main functions of NK cells and Treg. HLA-\\nG-mediated signals are critical in mediating tolerance dur-\\ning specific ontogenetic moments (e.g., pregnancy). HLA-\\nG may be expressed by tumor cells as part of a strategy to\\nevade the action of the innate and adaptive immune sys-\\ntem.\\n\\nTo test whether this may happen in CLL cells, HLA-G\\nexpression was assessed in a large cohort of CLL patients\\nwith well-defined molecular and clinical characteristics for\\nwhom survival data available. The originality of this work\\nis that the analyses of surface or sHLA-G expression were\\n\\nA\\n\\n100\\n\\n)\\n\\n%\\n\\n(\\n \\n\\ni\\n\\ni\\n\\ng\\nn\\nv\\nv\\nr\\nu\\ns\\n \\n\\nn\\no\\ni\\nt\\nr\\no\\np\\no\\nr\\nP\\n\\nHLA-G ins/del ins/ins\\n\\nHLA-G del/del\\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\nn=506\\nP=0.027\\n\\n0 24 48 72 96 120 144 168 192 216 240 264 288 312\\n\\nMonths\\n\\nB\\n\\n100\\n\\n)\\n\\n%\\n\\n(\\n \\n\\ng\\nn\\nv\\n\\ni\\n\\ni\\n\\nv\\nr\\nu\\ns\\n \\n\\nn\\no\\ni\\nt\\nr\\no\\np\\no\\nr\\nP\\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\nsHLA-G >31.75 ng/mL\\n\\nsHLA-G >31.75 ng/mL\\n\\nn=109\\nP=0.021\\n\\n0 24 48 72 96 120144 168 192 216 240 264 288 312 336\\n\\nMonths\\n\\nFigure  5.  Kaplan-Meier  curves  showing  overall  survival  in  506  CLL\\npatients. (A) Kaplan-Meier estimates of overall survival according to\\nHLA-G 14 bp genotype. (B) Kaplan-Meier estimates of overall survival\\naccording to soluble HLA-G levels. \\n\\naccompanied  by  characterization  of  the  14  bp  polymor-\\nphism in the 3’ untranslated region. This choice was dic-\\ntated by evidence derived from different models indicat-\\ning  that  this  polymorphism  accurately  predicts  the\\namount of transcribed protein, either bound to the mem-\\nbrane or released into biological fluids.\\n\\nOur results indicate an association between the del/del\\ngenotype  and  increased  levels  of  plasma  HLA-G  mole-\\ncules. This association is apparent only in CLL patients, as\\nplasma from age- and sex-matched controls failed to show\\na  statistically  significant  association  between  the  del/del\\ngenotype and the amount of plasma HLA-G. \\n\\nThe  situation  on  the  cell  membrane  is  less  defined:\\ndel/del patients more frequently expressed higher levels of\\nthe  molecule,  although  statistical  significance  was  not\\nreached. A potential explanation for this finding lies in the\\nrelative  instability  of  HLA-G  molecules  on  the  CLL  cell\\nmembrane. Results showing a correlation between mem-\\nbrane and sHLA-G levels support the view that the main\\nmechanism  of  generation  of  sHLA-G  is  shedding  rather\\nthan alternative splicing. This was confirmed by an analy-\\nsis of HLA-G isoforms, which demonstrated a dominance\\nof sHLA-G1, generated by proteolytic cleavage of mem-\\n\\n894\\n\\nhaematologica | 2014; 99(5)\\n\\n\\x0cbrane HLA-G1. No preference of isoform according to the\\n14 bp polymorphism was noted, in agreement with previ-\\nously published data.31,32\\n\\nA reasonable hypothesis to explain this result is that the\\nmembrane  form  represents  a  transitory  step.  A  conse-\\nquence is that quantification of soluble rather than surface\\nHLA-G  may  be  more  accurate.  This  is  also  in  line  with\\nprevious studies, which found that sHLA-G levels in plas-\\nma  were  higher  in  CLL  patients  than  in  healthy  con-\\ntrols.17,18 A second issue favoring the view that quantifica-\\ntion of soluble rather than membrane HLA-G is an inform-\\native and dependable assay derives from old and new facts\\nlinked  to  the  unique  lipid  structure  of  the  CLL  cell  sur-\\nface,33,34 potentially increasing the instability of the mem-\\nbrane  form.  In  agreement  with  this,  in  myeloma  cells\\nmHLA-G  is  also  released  from  the  cell  membrane  in\\nmicroparticles.35 These findings suggest that quantification\\nof sHLA-G may be clinically useful and more informative\\nthan analysis of the surface of tumor cells. \\n\\nThe second set of results obtained in this study may be\\nconsidered as tiles creating a tolerogenic mosaic, in which\\nHLA-G  molecules  represent  a  link  between  innate  and\\nadaptive immunity. Accordingly, the presence of a del/del\\ngenotype (i.e., with high sHLA-G levels) is paralleled by an\\nexpansion of Treg in the circulation. Supportive data come\\nfrom other models, in which HLA-G is reported to induce\\nTreg. As an example, peripheral blood mononuclear cells\\nexposed to sHLA-G5 acquire regulatory features, inhibit-\\ning  allo-proliferative  responses  exerted  by  other  T  lym-\\nphocytes.  It  is  also  known  that  patients  receiving  com-\\nbined liver/kidney transplants show high levels of sHLA-\\nG5,  which  correlate  with  increased  percentages  of  sup-\\npressor T cells.36 Similarly, stem-cell transplanted patients\\nhave high levels of sHLA-G5 in the peripheral blood, with\\na simultaneous expansion of CD4+/CD25+/CD152+ T lym-\\nphocytes with suppressive activity. Indirect confirmation\\nin the CLL model may be deduced from data showing that\\nan increase in Treg positively correlates with the presence\\nof clinical and biological features of aggressive disease.37\\n\\nNK cells obtained from CLL patients have less cytotoxic\\nactivity  than  NK  cell  populations  obtained  from  healthy\\ndonors of a comparable age. This suggests that leukemic\\ncells directly affect NK cell viability and/or activity. This\\nwould  be  achieved  through  binding  HLA-G  to  the\\nKIR2DL4 ligand, which becomes expressed once NK cells\\nare activated in the presence of interleukin-2. Our working\\nhypothesis  is  that  ectopic  expression  of  HLA-G  con-\\ntributes to block NK cell functions. With the aim of repro-\\nducing physiological conditions the experiments were per-\\nformed  using  whole  plasma  instead  of  purified  HLA-G.\\nThe  assumption  was  confirmed  by  incubating  NK  cells\\nobtained  from  normal  donors  with  plasma  from  CLL\\n\\nHLA-G polymorphism in CLL\\n\\npatients  containing  variable  amounts  of  sHLA-G.  This\\nwas followed by a marked induction of NK cell apoptosis,\\nwhich was proportional to the amount of sHLA-G present\\nin plasma. Furthermore, lysis inhibition was also propor-\\ntional to the amount of sHLA-G. It is worth noting that\\nCLL plasma samples with undetectable sHLA-G were able\\nto induce moderate NK cell apoptosis and to reduce NK\\ncell cytotoxicity. These results suggest the presence of fac-\\ntors  other  than  sHLA-G  that  are  able  to  control  NK  cell\\nactivation in CLL. As expected, NK cell function of del/del\\npatients was more impaired than that of ins/del or ins/ins\\npatients. \\n\\nIn  conclusion,  the  data  obtained  in  this  study  provide\\ntwo different sets of information. The first one indicates\\nthat  the  14  bp  polymorphism  influences  quantitative\\nanalyses  of  sHLA-G.  The  amount  of  sHLA-G  in  plasma\\nhas a prognostic value, suggesting that this specific assay\\nmay  be  relevant  in  the  management  of  CLL  patients,\\nrather than the mere measurement of membrane HLA-G.\\nThe  second  set  of  results  indicates  that  the  presence  of\\nHLA-G molecules in the neoplastic environment, in either\\na soluble form or bound to the membrane, creates a favor-\\nable setting for CLL expansion. As proof of this, evalua-\\ntion of the impact of the 14 bp polymorphism on the clin-\\nical outcome of the disease showed that del/del patients\\nhave  a  poorer  overall  survival  than  do  either    ins/del  or\\nins/ins patients. \\n\\nTaken together, our results support the view that HLA-\\nG molecules are part of the escape strategies designed by\\nCLL  cells  and  indicate  that  a  quantitative  analysis  of\\nsHLA-G levels may be of clinical relevance in the manage-\\nment of CLL patients.\\n\\nFunding\\nWork  supported  by  grants  from  the  Italian  Ministries  of\\nEducation,  University  and  Research  (Futuro  in  Ricerca  2008  #\\nRBFR08ATLH,  PRIN  2009  #  2009LMEEEH_002  e  #\\nNANLST_001,  FIRB  2010  #  RBAP11FXBC-005),  Italian\\nMinistry of Health (Bando Giovani Ricercatori 2008 # GR-2008-\\n1138053),  Associazione  Italiana  per  la  Ricerca  sul  Cancro\\nFoundation  (Special  Program  Molecular  Clinical  Oncology  5  x\\n1000 N. 10007; My First AIRC Grant N. 13470 and IG 12754),\\nFondazione  Cariplo,  Compagnia  di  San  Paolo \\n(N.\\nPMN_call_2012_0071) and local funds of the University of Turin\\n(ex-60%). \\n\\nThe Fondazione Ricerca Molinette provided valuable assistance\\n\\nand support.\\n\\nAuthorship and Disclosures\\nInformation on authorship, contributions, and financial & other\\ndisclosures was provided by the authors and is available with the\\nonline version of this article at www.haematologica.org.\\n\\nReferences\\n\\n1. Chiorazzi  N,  Rai  KR,  Ferrarini  M.  Chronic\\nlymphocytic leukemia. N Engl J Med. 2005;\\n352(8):804-15.\\n\\n2. Lotz M, Ranheim E, Kipps TJ. Transforming\\ngrowth  factor  beta  as  endogenous  growth\\ninhibitor of chronic lymphocytic leukemia B\\ncells. J Exp Med. 1994;179(3):999-1004.\\n\\n3. Benjamin D, Park CD, Sharma V. Human B\\n\\ninterleukin  10.  Leuk  Lymphoma.\\n\\ncell \\n1994;12(3-4):205-10.\\n\\n4. Ramsay AG, Johnson AJ, Lee AM, Gorgun\\nG, Le Dieu R, Blum W, et al. Chronic lym-\\nphocytic  leukemia  T  cells  show  impaired\\nimmunological  synapse  formation  that  can\\nbe  reversed  with  an  immunomodulating\\ndrug. J Clin Invest. 2008;118(7):2427-37.\\n\\n5. Giannopoulos  K,  Schmitt  M,  Wlasiuk  P,\\nChen  J,  Bojarska-Junak  A,  Kowal  M,  et  al.\\nThe high frequency of T regulatory cells in\\n\\npatients  with  B-cell  chronic  lymphocytic\\nleukemia  is  diminished  through  treatment\\nwith  thalidomide.  Leukemia.  2008;22(1):\\n222-4.\\n\\n6. D'Arena G, D'Auria F, Simeon V, Laurenti L,\\nDeaglio S, Mansueto G, et al. A shorter time\\nto the first treatment may be predicted by\\nthe absolute number of regulatory T-cells in\\npatients  with  Rai  stage  0  chronic  lympho-\\ncytic \\nJ  Hematol.\\n2012;87(6):628-31.\\n\\nleukemia.  Am \\n\\nhaematologica | 2014; 99(5)\\n\\n895\\n\\n\\x0cR. Rizzo et al.\\n\\n7. Serra S, Horenstein AL, Vaisitti T, Brusa D,\\nRossi  D,  Laurenti  L,  et  al.  CD73-generated\\nextracellular  adenosine  in  chronic  lympho-\\ncytic leukemia creates local conditions coun-\\nteracting  drug-induced  cell  death.  Blood.\\n2011;118(23):6141-52.\\n\\n8. Rizzo R, Bortolotti D, Baricordi OR, Fainardi\\nE. New insights into HLA-G and inflamma-\\ntory diseases. Inflamm Allergy Drug Targets.\\n2012;11(6):448-63.\\n\\n9. Carosella  ED.  The  tolerogenic  molecule\\n\\nHLA-G. Immunol Lett. 2011;138(1):22-4.\\n\\n10. Shiroishi  M,  Tsumoto  K,  Amano  K,\\nShirakihara Y, Colonna M, Braud VM, et al.\\nHuman  inhibitory  receptors  Ig-like  tran-\\nscript 2 (ILT2) and ILT4 compete with CD8\\nfor MHC class I binding and bind preferen-\\ntially  to  HLA-G.  Proc  Natl  Acad  Sci  USA.\\n2003;100(15):8856-61.\\n\\n11. Rajagopalan  S,  Long  EO.  A  human  histo-\\ncompatibility  leukocyte  antigen  (HLA)-G-\\nspecific  receptor  expressed  on  all  natural\\nkiller cells. J Exp Med. 1999;189(7):1093-100.\\n12. Du L, Xiao X, Wang C, Zhang X, Zheng N,\\nWang L, et al. Human leukocyte antigen-G is\\nclosely  associated  with  tumor  immune\\nescape  in  gastric  cancer  by  increasing  local\\nregulatory  T  cells.  Cancer  Sci.  2011;102(7):\\n1272-80.\\n\\n13. Diaz-Lagares  A,  Alegre  E,  LeMaoult  J,\\nCarosella ED, Gonzalez A. Nitric oxide pro-\\nduces HLA-G nitration and induces metallo-\\nprotease-dependent  shedding  creating  a\\ntolerogenic  milieu.  Immunology.  2009;126\\n(3):436-45.\\n\\n14. Rizzo R, Rubini M, Govoni M, Padovan M,\\nMelchiorri L, Stignani M, et al. HLA-G 14-bp\\npolymorphism  regulates  the  methotrexate\\nresponse \\narthritis.\\nPharmacogenet  Genomics.  2006;16(9):615-\\n23.\\n\\nrheumatoid \\n\\n15. Hviid  TV,  Rizzo  R,  Christiansen  OB,\\nMelchiorri  L,  Lindhard  A,  Baricordi  OR.\\nHLA-G  and  IL-10  in  serum  in  relation  to\\nHLA-G  genotype  and  polymorphisms.\\nImmunogenetics. 2004;56(3):135-41.\\n\\n16. Rizzo R, Hviid TV, Stignani M, Balboni A,\\nGrappa MT, Melchiorri L, et al. The HLA-G\\ngenotype  is  associated  with  IL-10  levels  in\\nactivated PBMCs. Immunogenetics. 2005;57\\n(3-4):172-81.\\n\\n17. Amiot  L,  Le  Friec  G,  Sebti  Y,  Drenou  B,\\nPangault  C,  Guilloux  V,  et  al.  HLA-G  and\\nlymphoproliferative \\nSemin\\nCancer Biol. 2003;13(5):379-85.\\n\\ndisorders. \\n\\n18. Sebti  Y,  Le  Friec  G,  Pangault  C,  Gros  F,\\n\\nin \\n\\nDrenou B, Guilloux V, et al. Soluble HLA-G\\nmolecules are increased in lymphoprolifera-\\ntive disorders. Hum Immunol. 2003; 64(11):\\n1093-101.\\n\\n19. Rezvany  MR,  Kazemi  A,  Hajifathali  A,\\nKaviani S, Mellstedt H. Analysis of HLA-G\\ngene  expression  in  B-lymphocytes  from\\nchronic lymphocytic leukemia patients. Iran\\nBiomed J. 2007;11(2):125-9.\\n\\n20. Nuckel H, Rebmann V, Durig J, Duhrsen U,\\nGrosse-Wilde H. HLA-G expression is asso-\\nciated  with  an  unfavorable  outcome  and\\nimmunodeficiency  in  chronic  lymphocytic\\nleukemia. Blood. 2005;105(4):1694-8.\\n\\n21. Erikci AA, Karagoz B, Ozyurt M, Ozturk A,\\nKilic  S,  Bilgi  O.  HLA-G  expression  in  B\\nchronic lymphocytic leukemia: a new prog-\\nnostic  marker?  Hematology.  2009;14(2):\\n101-5.\\n\\n22. Deaglio  S,  Vaisitti  T,  Bergui  L,  Bonello  L,\\nHorenstein  AL,  Tamagnone  L,  et  al.  CD38\\nand CD100 lead a network of surface recep-\\ntors  relaying  positive  signals  for  B-CLL\\ngrowth  and  survival.  Blood.  2005;105\\n(8):3042-50.\\n\\n23. Hviid TV, Rizzo R, Melchiorri L, Stignani M,\\nBaricordi  OR.  Polymorphism  in  the  5'\\nupstream  regulatory  and  3'  untranslated\\nregions of the HLA-G gene in relation to sol-\\nuble  HLA-G  and  IL-10  expression.  Hum\\nImmunol. 2006;67(1-2):53-62.\\n\\n24. Rizzo  R,  Bortolotti  D,  Fredj  NB,  Rotola  A,\\nCura F, Castellazzi M, et al. Role of HLA-G\\n14bp deletion/insertion and +3142C>G poly-\\nmorphisms  in  the  production  of  sHLA-G\\nmolecules  in  relapsing-remitting  multiple\\nsclerosis. Hum Immunol. 2012;73(11):1140-6.\\n25. Rebmann  V,  LeMaoult  J,  Rouas-Freiss  N,\\nCarosella \\nH.\\nQuantification and identification of soluble\\nHLA-G  isoforms.  Tissue  Antigens.  2007;69\\n(Suppl 1):143-9.\\n\\nGrosse-Wilde \\n\\nED, \\n\\n26. Fainardi  E,  Rizzo  R,  Melchiorri  L,  Stignani\\nM, Castellazzi M, Caniatti ML, et al. Soluble\\nHLA-G  molecules  are  released  as  HLA-G5\\nand not as soluble HLA-G1 isoforms in CSF\\nof patients with relapsing-remitting multiple\\nsclerosis.  J  Neuroimmunol.  2007;192(1-\\n2):219-25.\\n\\n27. Vacca P, Martini S, Garelli V, Passalacqua G,\\nMoretta  L,  Mingari  MC.  NK  cells  from\\nmalignant  pleural  effusions  are  not  anergic\\nbut  produce  cytokines  and  display  strong\\nantitumor activity on short-term IL-2 activa-\\ntion. Eur J Immunol. 2013;43(2):550-61.\\n\\n28. Vacca  P,  Cantoni  C,  Vitale  M,  Prato  C,\\n\\nCanegallo  F,  Fenoglio  D,  et  al.  Crosstalk\\nbetween  decidual  NK  and  CD14+\\nmyelomonocytic cells results in induction of\\nTregs  and  immunosuppression.  Proc  Natl\\nAcad Sci USA. 2010;107(26):11918-23.\\n\\n29. Castellaneta A, Mazariegos GV, Nayyar N,\\nZeevi  A,  Thomson  AW.  HLA-G  level  on\\nmonocytoid  dendritic  cells  correlates  with\\nregulatory  T-cell  Foxp3  expression  in  liver\\ntransplant \\ntolerance.  Transplantation.\\n2011;91(10):1132-40.\\n\\n30. Rajagopalan S, Bryceson YT, Kuppusamy SP,\\nGeraghty DE, van der Meer A, Joosten I, et\\nal. Activation of NK cells by an endocytosed\\nreceptor  for  soluble  HLA-G.  PLoS  Biol.\\n2006;4(1):e9.\\n\\n31. Hviid TV, Hylenius S, Rorbye C, Nielsen LG.\\nHLA-G  allelic  variants  are  associated  with\\ndifferences  in  the  HLA-G  mRNA  isoform\\nprofile \\nand  HLA-G  mRNA \\nlevels.\\nImmunogenetics. 2003;55(2):63-79.\\n\\n32. Svendsen SG, Hantash BM, Zhao L, Faber C,\\nBzorek M, Nissen MH, et al. The expression\\nand functional activity of membrane-bound\\nhuman leukocyte antigen-G1 are influenced\\nby \\nregion.  Hum\\nImmunol. 2013;74(7):818-27.\\n\\nthe  3'-untranslated \\n\\n33. Daefler S, Krueger GR. Expression of prolif-\\neration  and  differentiation  antigens  in\\nresponse to modulation of membrane fluid-\\nity  in  chronic  lymphocytic  leukemia  lym-\\nphocytes. Anticancer Res. 1989;9(2):501-6.\\n\\n34. Herishanu Y, Kay S, Dezorella N, Baron S,\\nHazan-Halevy I, Porat Z, et al. Divergence in\\nCD19-mediated signaling unfolds intraclon-\\nal  diversity \\nlymphocytic\\nleukemia, which correlates with disease pro-\\ngression. J Immunol. 2013;190(2):784-93.\\n\\nin  chronic \\n\\nT,  Gilliam  M, \\n\\n35. Kshirsagar SK, Alam SM, Jasti S, Hodes H,\\nNauser \\nal.\\nImmunomodulatory molecules are released\\nfrom the first trimester and term placenta via\\nexosomes. Placenta. 2012;33(12):982-90.\\n\\n36. Naji  A,  Le  Rond  S,  Durrbach  A,  Krawice-\\nRadanne  I,  Creput  C,  Daouya  M,  et  al.\\nCD3+CD4low  and  CD3+CD8low  are\\ninduced by HLA-G: novel human peripheral\\nblood suppressor T-cell subsets involved in\\ntransplant  acceptance.  Blood.  2007;110(12):\\n3936-48.\\n\\n37. D'Arena  G,  Laurenti  L,  Minervini  MM,\\nDeaglio  S,  Bonello  L,  De  Martino  L,  et  al.\\nRegulatory  T-cell  number  is  increased  in\\nchronic lymphocytic leukemia patients and\\ncorrelates  with  progressive  disease.  Leuk\\nRes. 2011;35(3):363-8.\\n\\net \\n\\n896\\n\\nhaematologica | 2014; 99(5)\\n\\n\\x0cHindawi Publishing Corporation\\nCardiology Research and Practice\\nVolume 2013, Article ID 603913, 5 pages\\nhttp://dx.doi.org/10.1155/2013/603913\\n\\nResearch Article\\nEffect of Ivabradine on Endothelial Function in Diastolic and\\nRight Heart Failure Patients\\n\\nArturo Orea-Tejeda,1 Karla Balderas-Muñoz,1 Lilia Castillo-Martínez,1\\nOscar Infante-Vázquez,2 Raúl Martínez Memije,2 Candace Keirns-Davis,3\\nJoel Dorantes-García,4 René Narváez-David,4 and Zuilma Vázquez-Ortíz4\\n1 Heart Failure Clinic, Instituto Nacional de Ciencias M´edicas y Nutrici´on Salvador Zubir´an, Mexico\\n2 Instrumentation Department, Instituto Nacional de Cardiolog´ıa “ICh”, Mexico\\n3 Massachusetts General Hospital, Boston, MA, USA\\n4 Cardiology Department, Instituto Nacional de Ciencias M´edicas y Nutrici´on Salvador Zubir´an, Mexico\\n\\nCorrespondence should be addressed to Lilia Castillo-Mart´ınez; caml1225@yahoo.com\\n\\nReceived 18 June 2013; Revised 12 August 2013; Accepted 28 August 2013\\n\\nAcademic Editor: Gregory Giamouzis\\n\\nCopyright © 2013 Arturo Orea-Tejeda et al. This is an open access article distributed under the Creative Commons Attribution\\nLicense, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly\\ncited.\\n\\nBackground. Ivabradine is an If ion current inhibitor that has proved to reduce mortality in patients with systolic heart failure by\\nslowing heart rate without decreasing myocardial contractility. Photoplethysmography is a simple, low-cost optical technique that\\ncan evaluate vascular function and detect changes in blood flow, pulse, and swelling of tissular microvascular space. Objective.\\nTo evaluate the effect of ivabradine on endothelial function by photoplethysmography in diastolic and right heart failure patients.\\nMethodology. 15 patients were included (mean age of 78.1 ± 9.2 years) with optimally treated diastolic and right heart failure. They\\nunderwent photoplethysmography before and after induced ischemia to evaluate the wave blood flow on the finger, using the\\nmaximum amplitude time/total time (MAT/TT) index. Two measurements were made before and after oral Ivabradine (mean\\n12.5 mg a day during 6 months of followup). Results. In the study group, the MAT/TT index was 29.1 ± 2.2 versus 24.3 ± 3.2 (𝑃 = 0.05)\\nin basal recording and 30.4 ± 2.1 versus 23.3 ± 2.9 (𝑃 = 0.002), before versus after ischemia and before versus after Ivabradine\\nintervention, respectively. Conclusions. Ivabradine administration improves endothelial function (shear stress) in diastolic and right\\nheart failure patients.\\n\\n1. Background\\nDiastolic dysfunction has been associated with symptoms\\nof congestive heart failure in patients with preserved left\\nventricular ejection fraction [1]. In the largest single-center\\nstudy with approximately 36, 000 outpatients with normal\\nLVEF, some authors have shown that diastolic dysfunction is\\nan independent predictor of all-cause mortality [2].\\n\\nIn outpatients with heart failure with preserved ejection\\nfraction (HFpEF) at the baseline echocardiogram, worsening\\nof diastolic function in a follow-up study is also an inde-\\npendent predictor of all-cause mortality [3]. In addition,\\nAchong showed that improvement in diastolic function was\\nassociated with increased survival (𝑃 = 0.05) in a mixed\\ncohort of inpatients and outpatients with normal or mild\\n\\nsystolic dysfunction [4], while the more advanced the stage\\nis, the higher the filling pressures and the worse the outcomes\\nare [5].\\n\\nIn patients with atrial fibrillation, if diastolic function was\\nassessed, it was based on deceleration time of mitral E-wave\\nvelocity and tissue Doppler imaging (i.e., peak early mitral\\ninflow velocity/diastolic early tissue velocity [E/e\\U000f8020]) [6].\\n\\nIvabradine added to recommended treatment, improved\\nthe outcome of heart failure patients reducing cardiovascular\\ndeath and hospitalizations rate [7]. In patients with coronary\\ndisease and left ventricular dysfunction also the benefit was\\nobserved [8]. In experimental studies, ivabradine have been\\ndemonstrated that reduces fibrosis and improve endothelial\\nfunction [9–12].\\n\\n\\x0c2\\n\\nCardiology Research and Practice\\n\\nIvabradine also has demonstrated a favorable effect on\\nLV remodeling after 8 months of followup as well as and\\nantianginal effect [13].\\n\\nHyperemic coronary blood flow velocity also increases\\nafter ivabradine treatment, probably because the diastolic\\nperiod is prolonged (per cardiac beat and per minute). It has\\nbeen speculated that the most probable explanation of the\\nimprovement of ventricular relaxation caused by ivabradine\\ntreatment could be its effect on coronary blood flow velocity\\nduring hyperemia [14].\\n\\nTo evaluate the effect of ivabradine on endothelial func-\\ntion by photoplethysmography in patients with right heart\\nfailure and preserved ejection fraction, we performed this\\nopen-label clinical trial.\\n\\n2. Methods\\n2.1. Study Population. This open-label clinical trial included\\nambulatory patients who came to the Heart Failure Clinic\\nof the Instituto Nacional de Ciencias M´edicas y Nutrici´on\\n“Salvador Zubir´an.” Patients were recruited if they were\\nmen or nongravid women with more than 18 years of age\\nwith a confirmed diagnosis of stable heart failure with\\npreserved ejection fraction in New York Heart Association\\nfunctional classes II to III. Candidates were excluded if they\\nhad had myocardial infarction, unstable angina or a history\\nof myocardial revascularization (percutaneous transluminal\\ncoronary angioplasty or aortocoronary bypass grafts), cere-\\nbrovascular events during the previous 3 months, dysfunc-\\ntional prosthetic heart valve, obstructive or nonobstructive\\ncardiomyopathy, uncorrected congenital heart disease, active\\nmyocarditis, a history of resuscitation from sudden death, or\\nsevere arrhythmias.\\n\\nHeart failure was established by signs and symptoms as\\nwell as echocardiographic and radioisotopic ventriculogra-\\nphy findings. Preserved ejection fraction was defined as a left\\nventricular ejection fraction ≥ 50%, LVEDVI < 97 mL/m2,\\nleft atrial diameter > 40 mL/m2, tissue doppler E/E\\U000f8020\\n> 15\\necho-blood flow Doppler E/A in >50 years <0.5, and DT in\\n>50 years >280 ms [15]. Right ventricular dysfunction was\\ndefined as ejection fraction ≤ 35% measured by radioisotopic\\nventriculography [16, 17].\\n\\nAll patients received standard heart\\n\\nfailure therapy\\nand their comorbidities (diuretics, angiotensin-converting\\nenzyme inhibitors, angiotensin II antagonists, aldosterone\\nreceptor blockers, digitalis, and beta-adrenoreceptor block-\\ners), at their maximum doses tolerated. Some patients that\\ndeveloped atrial fibrillation also received digital.\\n\\n2.2. Study Design. This was an investigator-initiated, single\\ncenter, single-arm, open-label clinical trial.\\n\\nAfter baseline measurements, in addition to conventional\\ntherapy, patients received an average of ivabradine 12.5 mg\\n(10–15 mg) a day, according their tolerance during 6 months\\nof follow-up [18, 19]. Patients underwent 2D and Doppler\\nechocardiograms and radioisotopic (rest/effort) left and right\\nventriculography before and after oral ivabradine.\\n\\nTable 1: Demographic and clinical characteristics of the CHF\\npatients.\\n\\nVariables\\nAge (years)\\nFemale (%)\\nArterial hypertension (%)\\nHypothyroidism (%)\\nDiabetes mellitus (%)\\nCOPD (%)\\nDyslipidemia (%)\\nEnd Stage Kidney disease (%)\\nFunctional class (NYHA):\\n\\nII\\nIII\\n\\n𝑁 = 15\\n\\n78.1 ± 9.2\\n\\n73.3\\n73.3\\n53.3\\n33.3\\n33.3\\n26.6\\n26.6\\n\\n60\\n40\\n\\n2.2.1. Photoplethysmography. A baseline digital photoplethys-\\nmographic wave was recorded for 30 seconds. The forearm\\nwas then compressed with a sphygmomanometer cuff for\\n5 minutes using a pressure of 30 mmHg above the systolic\\narterial pressure recorded (ischemic phase). The compression\\nwas then released and the digital photoplethysmographic\\nwave was recorded for 120 seconds. The wave was analyzed\\nat 30-second intervals for comparison with the baseline\\nvalues. The most representative waves were selected from\\nthe recording of each interval, and the maximum amplitude\\ntime (MAT) and total time (TT) were measured in order to\\ncalculate the MAT/TT index. A MAT/TT index of less than 30\\nwas considered normal, as proposed in other studies [20, 21].\\nCardiologists who performed the echocardiograms and\\nradioventriculography did not have access to patients’ infor-\\nmation.\\n\\n2.3. Statistical Analysis. Continuous variables were expressed\\nas mean ± standard deviation (SD) and categorical variables\\nas percentages. To compare the changes from baseline to\\n6 months, a paired t-test was used. A 𝑃 value of <0.05\\nwas considered statistically significant. All analyses were\\nperformed using a commercially available package (SPSS for\\nWindows, version 17.0 SPSS Inc.).\\n\\n3. Results\\nFifteen patients (73.6% female) were studied. Arterial hyper-\\ntension and hypothyroidism (under treatment and well\\ncontrolled) were the most common comorbidities with\\npatients in functional classes (NYHA) II and III (Table 1).\\nIt is important to note that COPD and ESKD patients\\nwere not excluded from the study. Concomitant medica-\\ntion was as follows: diuretic (73%) and adrenergic beta\\nblocker receptor (BB, 73%) agents were the most commonly\\nemployed; 46.6% also received mineralocorticoid receptor\\nantagonists (MRAmedications) and angiotensin-converting-\\nenzyme inhibitors (ACEIs)/angiotensin receptors blockers\\n(ARB).\\n\\n\\x0cCardiology Research and Practice\\n\\n3\\n\\nMaximum amplitude time/total time (MAT/TT) index\\n\\nPreischemic\\n\\nperiod\\n\\nPostischemic\\n\\nperiod\\n\\n29.1 ± 2.2\\n\\n30.4 ± 2.1\\n\\nBefore\\n\\nIvabradine\\n\\nAfter\\n\\n24.3 ± 3.2\\n\\n23.3 ± 2.9\\n\\nP = 0.05\\n\\nP = 0.002\\n\\nFigure 1: Pre and after ischemic period, before and after 6 months\\nof follow-up of oral ivabradine.\\n\\nPatients received an average of 12.5 (range 10–15) mg/day\\nduring the 6 months of followup. It was particularly interest-\\ning that heart rate did not decrease in any patients below the\\n10% recommended (88 versus 82 beats/min) in the literature\\nin spite of the top doses received.\\n\\nFigure 1 shows the maximum amplitude time/total time\\n(MAT/TT) index before and after the followup. A significant\\nincrease in pre- and post-ischemic periods after ivabradine\\nadministration is evident when basal values are compared\\nwith those at the end of followup.\\n\\nImprovement of the endothelial-dependent vasodilata-\\ntion expressed by significant changes observed in the photo-\\nplethysmographic curves occurred concurrently. All patients\\nhad some degree of clinical improvement, 8/9 (88.8%) from\\nNYHA III to II and 4/6 (66.6%) from II to I, respectively,\\nalthough this did not achieve statistical significance (𝑃 =\\n0.08).\\n\\nWith respect to cardiac structural changes, in the echo-\\ncardiographic study, only right ventricular diastolic diameter\\n(40.5 ± 7.8 versus 36.4 ± 5.3; 𝑃 = 0.05) was significantly\\ndifferent after the followup. There was also a reduction of\\n8.15% in the systolic pulmonary arterial pressure (59.6 ± 8.4\\nversus 54.9 ± 10.2; 𝑃 = 0.05).\\n\\n4. Discussion\\nApproximately 50% of patients with heart failure (HF)\\nhave normal or preserved left ventricular ejection fraction\\n(HFPEF) [22], and their prognosis is similar to that of\\npatients with HF with reduced LVEF (HFREF) [22, 23]. Left\\nventricular diastolic dysfunction (LVDD) plays an important\\nrole in patients with HFPEF [24] and could be due to\\nstructural and molecular abnormalities of the cardiovascular\\nsystem. These abnormalities include myocardial ischemia,\\ncardiac hypertrophy, cardiac inflammation [25], and ventric-\\nular vascular stiffening, in part due to the reduced effects of\\nnitric oxide and impaired endothelial function [26]. Borlaug\\net al. recently demonstrated that global cardiovascular reserve\\nfunctions, including endothelial function, are impaired in\\nsubjects with HFNEF who have hypertension, a very frequent\\n\\ncause of HF [27]. In HFREF, coronary endothelial function is\\nalso impaired [28], and it has been reported that peripheral\\nendothelial dysfunction is associated with the severity of HF\\nsymptoms and clinical outcome in patients with HFREF [29,\\n30]. Moreover, vascular stiffness and resistance with elevated\\nblood pressure has been proposed as a potential important\\nnoncardiac factor in patients with HFpEF [31].\\n\\nEndothelial dysfunction has been shown to be involved in\\nthe pathogenesis of HF, mainly HFREF. Several studies have\\nreported that peripheral endothelial dysfunction is associated\\nwith the clinical outcome in patients with HFREF [30].\\nBorlaug et al. recently reported that subjects with HFpEF had\\nlimited arterial vasodilator response to exercise, which might\\nimpair cardiac output reserve under stress [32].\\n\\nPeripheral endothelial function is impaired in patients\\nwith HFpEF, and when it is evaluated as a reactive hyper-\\nemia by peripheral arterial tonometry (RH-PAT), it signifi-\\ncantly correlates with future cardiovascular events. Peripheral\\nendothelial function is thus an independent predictor after\\nadjusting various clinical parameters [33]. Indeed, the prog-\\nnostic impact of the reactive hyperemia index in patients with\\nHFpEF suggests that endothelial dysfunction may not be a\\npassive finding, but may rather play an active and important\\npathophysiologic role in HFpEF [32]. When matched in\\npatients and controls for diabetes and hypertension, more\\nendothelial dysfunction was found in patients with HFPEF,\\nwho were notably more obese than controls [34].\\n\\nThe results of the systolic heart failure treatment with the\\nIf inhibitor ivabradine trial (SHIFT) showed that treatment\\nwith ivabradine added to conventional therapy for HF was\\nassociated with an 18% reduction in the relative risk for\\nthe primary composite endpoint of cardiovascular death or\\nhospitalization for worsening HF (𝑃 < 0.0001) [7]. It also had\\na positive effect on LV remodelling in the echocardiographic\\nsubstudy of the BEAUTIFUL (morBidity-mortality EvAlUa-\\nTion of the If inhibitor ivabradine in patients with coronary\\ndisease and left ventricULar dysfunction) study [8].\\n\\nIn experimental studies, ivabradine has been demon-\\nstrated to reduces fibrosis and improve endothelial function\\n[9–12], together with its antiischemic and antianginal effects\\n[13] which could explain why all our patients improved\\ntheir functional class, possibly associated with increased\\nhyperemic coronary blood flow velocity. It may also be\\nexplained by the prolonged diastolic period (per cardiac\\nbeat and per minute). Moreover, we can speculate that\\nthe endothelial-dependent vasodilatation expressed by the\\nsignificant changes observed in the photoplethysmographic\\ncurves in peripheral and coronary territories plays an impor-\\ntant role in improving coronary blood reserve as has already\\nbeen described [35, 36], and flow velocity may have a\\ndirect effect on coronary vessels and reduced ventricular\\nwall tension, with improvement of ventricular relaxation [14],\\nadded to diminished right ventricular diastolic diameter with\\nsignificant reduction of arterial pulmonary pressure, which\\nprobably reflects improved coronary perfusion pressure (aor-\\ntic mean pressure/coronary sinus ratio).\\n\\nIn experimental postinfarction settings, both cardiac [37]\\nand pulmonary vascular [38] endothelial dysfunction may\\n\\n\\x0c4\\n\\nCardiology Research and Practice\\n\\ncontribute to the development of heart failure through endo-\\ncardial and myocardial capillary endothelial abnormalities\\n[39] and could explain the impaired left ventricular relaxation\\nin pressure-overload hypertrophy [40].\\n\\nPreserved ejection fraction is present in almost 50%\\nof heart failure patients and is cause of half of HF hos-\\npitalizations, and traditional HF treatment is not effective.\\nA recently published pathophysiology-based novel phar-\\nmacotherapy for these patients considers spironolactone,\\naliskiren, and neprilisyn as therapeutic options for HFPEF\\nbecause of their anti-hypertrophic and anti-fibrotic effects\\n[41]. Combined ventricular and vascular stiffening involving\\nboth the systemic and pulmonary circulations, plays a role\\nin the pathophysiology of HFpEF [42, 43]. Thus, the effects\\nof ivabradine on endothelial function, that we observed,\\nmay represent a major advantage when it is used to treat\\nleft diastolic dysfunction because of its secondary impact\\non pulmonary arterial hypertension and damaged right\\nventricular function.\\n\\n5. Limitations\\nThe number of patients studied was small, and the interven-\\ntion period was short. It is probable that a longer followup\\nwould show changes in variables such as left ventricular\\ndiastolic diameter and other structural characteristics. In\\naddition, the lack of direct quantification of pulmonary\\npressures is a drawback.\\n\\nOur findings support continued investigation into the\\neffects of ivabradine on right ventricular function, systemic\\narterial pressure, and systolic pulmonary arterial pressure in\\nheart failure patients with preserved ejection fraction. More\\nstudies are required to evaluate the effects observed on a\\nlarger number of patients for a longer period.\\n\\nReferences\\n[1] W. Aljaroudi, M. C. Alraies, C. Halley et al., “Impact of\\nprogression of diastolic dysfunction on mortality in patients\\nwith normal ejection fraction,” Circulation, vol. 125, no. 6, pp.\\n782–788, 2012.\\n\\n[2] M. Senni, C. M. Tribouilloy, R. J. Rodeheffer et al., “Congestive\\nheart failure in the community: a study of all incident cases in\\nOlmsted County, Minnesota, in 1991,” Circulation, vol. 98, no.\\n21, pp. 2282–2289, 1998.\\n\\n[3] B. G. Angeja and W. Grossman, “Evaluation and management of\\ndiastolic heart failure,” Circulation, vol. 107, no. 5, pp. 659–663,\\n2003.\\n\\n[4] P. M. Mottram and T. H. Marwick, “Assessment of diastolic\\nfunction: what the general cardiologist needs to know,” Heart,\\nvol. 91, no. 5, pp. 681–695, 2005.\\n\\n[5] C. M. Halley, P. L. Houghtaling, M. K. Khalil, J. D. Thomas,\\nand W. A. Jaber, “Mortality rate in patients with diastolic\\ndysfunction and normal systolic function,” Archives of Internal\\nMedicine, vol. 171, no. 12, pp. 1082–1087, 2011.\\n\\n[6] H. Okura, Y. Takada, T. Kubo et al., “Tissue Doppler-derived\\nindex of left ventricular filling pressure, E/E\\U000f8020, predicts survival\\nof patients with non-valvular atrial fibrillation,” Heart, vol. 92,\\nno. 9, pp. 1248–1252, 2006.\\n\\n[7] K. Swedberg, M. Komajda, M. B¨ohm et al., “Ivabradine and\\noutcomes in chronic heart failure (SHIFT): a randomised\\nplacebo-controlled study,” The Lancet, vol. 376, no. 9744, pp.\\n875–885, 2010, Erratum in The Lancet, vol. 376, p. 1988, 2010.\\n\\n[8] C. Ceconi, S. B. Freedman, J. C. Tardif et al., “Effect of heart\\nrate reduction by ivabradine on left ventricular remodeling in\\nthe echocardiographic substudy of BEAUTIFUL,” International\\nJournal of Cardiology, vol. 146, no. 3, pp. 408–414, 2011.\\n\\n[9] P. Mulder, S. Barbier, A. Chagraoui et al., “Long-term heart\\nrate reduction induced by the selective If current inhibitor\\nivabradine improves left ventricular function and intrinsic\\nmyocardial structure in congestive heart failure,” Circulation,\\nvol. 109, no. 13, pp. 1674–1679, 2004.\\n\\n[10] E. I. Dedkov, W. Zheng, L. P. Christensen, R. M. Weiss, F.\\nMahlberg-Gaudin, and R. J. Tomanek, “Preservation of coro-\\nnary reserve by ivabradine-induced reduction in heart rate in\\ninfarcted rats is associated with decrease in perivascular col-\\nlagen,” American Journal of Physiology—Heart and Circulatory\\nPhysiology, vol. 293, no. 1, pp. H590–H598, 2007.\\n\\n[11] P. Milliez, S. Messaoudi, J. Nehme, C. Rodriguez, J.-L. Samuel,\\nand C. Delcayre, “Beneficial effects of delayed ivabradine treat-\\nment on cardiac anatomical and electrical remodeling in rat\\nsevere chronic heart failure,” American Journal of Physiology—\\nHeart and Circulatory Physiology, vol. 296, no. 2, pp. H435–\\nH441, 2009.\\n\\n[12] M. Vercauteren, J. Favre, P. Mulder, F. Mahlberg-Gaudin, C.\\nThuillez, and V. Richard, “Protection of endothelial function by\\nlong-term heart rate reduction induced by ivabradine in a rat\\nmodel of chronic heart failure,” European Heart Journal, vol. 28,\\nsupplement, p. 48, 2007.\\n\\n[13] G. Riccioni, N. Vitulano, and N. D’Orazio, “Ivabradine: beyond\\nheart rate control,” Advances in Therapy, vol. 26, no. 1, pp. 12–24,\\n2009.\\n\\n[14] E. I. Skalidis, M. I. Hamilos, G. Chlouverakis, E. A. Zacharis,\\nand P. E. Vardas, “Ivabradine improves coronary flow reserve\\nin patients with stable coronary artery disease,” Atherosclerosis,\\nvol. 215, no. 1, pp. 160–165, 2011.\\n\\n[15] W. J. Paulus, C. Tsch¨ope, J. E. Sanderson et al., “How to diagnose\\ndiastolic heart failure: a consensus statement on the diagnosis\\nof heart failure with normal left ventricular ejection fraction\\nby the Heart Failure and Echocardiography Associations of the\\nEuropean Society of Cardiology,” European Heart Journal, vol.\\n28, no. 20, pp. 2539–2550, 2007.\\n\\n[16] N. F. Voelkel, R. A. Quaife, L. A. Leinwand et al., “Right\\nventricular function and failure: report of a National Heart,\\nLung, and Blood Institute working group on cellular and\\nmolecular mechanisms of right heart failure,” Circulation, vol.\\n114, no. 17, pp. 1883–1891, 2006.\\n\\n[17] J. F. Setaro, M. W. Cleman, and M. S. Remetz, “The right\\nventricle in disorders causing pulmonary venous hypertension,”\\nCardiology Clinics, vol. 10, no. 1, pp. 165–183, 1992.\\n\\n[18] F. M. Sarullo, G. Fazio, D. Puccio et al., “Impact of “off-label”\\nuse of ivabradine on exercise capacity, gas exchange, functional\\nclass, quality of life, and neurohormonal modulation in patients\\nwith ischemic chronic heart failure,” Journal of Cardiovascular\\nPharmacology and Therapeutics, vol. 15, no. 4, pp. 349–355, 2010.\\n[19] A. Schuster and W. H. W. Tang, “Ivabradine in heart failure: to\\nSHIFT or not to SHIFT,” Current Heart Failure Reports, vol. 8,\\nno. 1, pp. 1–3, 2011.\\n\\n[20] J. T. Kuvin, A. R. Patel, K. A. Sliney et al., “Assessment of\\nperipheral vascular endothelial function with finger arterial\\n\\n\\x0cCardiology Research and Practice\\n\\n5\\n\\n[35] M. B. Britten, A. M. Zeiher, and V. Sch¨achinger, “Microvascular\\ndysfunction in angiographically normal or mildly diseased\\ncoronary arteries predicts adverse cardiovascular long-term\\noutcome,” Coronary Artery Disease, vol. 15, no. 5, pp. 259–264,\\n2004.\\n\\n[36] B. A. Herzog, L. Husmann, I. Valenta et al., “Long-term prog-\\nnostic value of 13N-ammonia myocardial perfusion positron\\nemission tomography added value of coronary flow reserve,”\\nJournal of the American College of Cardiology, vol. 54, no. 2, pp.\\n150–156, 2009.\\n\\n[37] X.-L. Qi, D. J. Stewart, H. Gosselin et al., “Improvement of\\nendocardial and vascular endothelial function on myocardial\\nperformance by captopril treatment in postinfarct rat hearts,”\\nCirculation, vol. 100, no. 12, pp. 1338–1345, 1999.\\n\\n[38] A. Ben Driss, C. Devaux, D. Henrion et al., “Hemodynamic\\nstresses induce endothelial dysfunction and remodeling of\\npulmonary artery in experimental compensated heart failure,”\\nCirculation, vol. 101, no. 23, pp. 2764–2770, 2000.\\n\\n[39] D. Popov, A. Sima, D. Stern, and M. Simionescu, “The patho-\\nmorphological alterations of endocardial endothelium in exper-\\nimental diabetes and diabetes associated with hyperlipidemia,”\\nActa Diabetologica, vol. 33, no. 1, pp. 41–47, 1996.\\n\\n[40] P. A. MacCarthy and A. M. Shah, “Impaired endothelium-\\ndependent regulation of ventricular relaxation in pressure-\\noverload cardiac hypertrophy,” Circulation, vol. 101, no. 15, pp.\\n1854–1860, 2000.\\n\\n[41] D. M. Konstantinou, Y. S. Chatzizisis, and G. D. Giannoglou,\\n“Pathophysiology-based novel pharmacotherapy for heart fail-\\nure with preserved ejection fraction,” Pharmacology & Thera-\\npeutics, 2013.\\n\\n[42] C. S. P. Lam, V. L. Roger, R. J. Rodeheffer et al., “Cardiac\\nstructure and ventricular-vascular function in persons with\\nheart failure and preserved ejection fraction from Olmsted\\nCounty, Minnesota,” Circulation, vol. 115, no. 15, pp. 1982–1990,\\n2007.\\n\\n[43] C. S. P. Lam, V. L. Roger, R. J. Rodeheffer, B. A. Borlaug, F.\\nT. Enders, and M. M. Redfield, “Pulmonary hypertension in\\nheart failure with preserved ejection fraction: a community-\\nbased study,” Journal of the American College of Cardiology, vol.\\n53, no. 13, pp. 1119–1126, 2009.\\n\\npulse wave amplitude,” American Heart Journal, vol. 146, no. 1,\\npp. 168–174, 2003.\\n\\n[21] A. Aldama, H. ´Alvarez, A. Rodr´ıguez, and B. Reyes, “Evaluaci´on\\ncualitativa de la morfolog´ıa de la se˜nal fotopletismogr´afica en\\nel diagn´ostico de la insuficiencia arterial,” Revista Cubana de\\nInvestigaciones Biom´edicas, vol. 27, no. 1, 2008.\\n\\n[22] R. S. Bhatia, J. V. Tu, D. S. Lee et al., “Outcome of heart failure\\nwith preserved ejection fraction in a population-based study,”\\nThe New England Journal of Medicine, vol. 355, no. 3, pp. 260–\\n269, 2006.\\n\\n[23] T. E. Owan, D. O. Hodge, R. M. Herges, S. J. Jacobsen, V. L.\\nRoger, and M. M. Redfield, “Trends in prevalence and outcome\\nof heart failure with preserved ejection fraction,” The New\\nEngland Journal of Medicine, vol. 355, no. 3, pp. 251–259, 2006.\\n[24] M. R. Zile, C. F. Baicu, and W. H. Gaasch, “Diastolic heart\\nfailure: abnormalities in active relaxation and passive stiffness\\nof the left ventricle,” The New England Journal of Medicine, vol.\\n350, no. 19, pp. 1953–1959, 2004.\\n\\n[25] J. Matsubara, S. Sugiyama, T. Nozaki et al., “Pentraxin 3 is a new\\ninflammatory marker correlated with left ventricular diastolic\\ndysfunction and heart failure with normal ejection fraction,”\\nJournal of the American College of Cardiology, vol. 57, no. 7, pp.\\n861–869, 2011.\\n\\n[26] M. Ouzounian, D. S. Lee, and P. P. Liu, “Diastolic heart failure:\\nmechanisms and controversies,” Nature Reviews Cardiology, vol.\\n5, pp. 375–386, 2008.\\n\\n[27] B. A. Borlaug, T. P. Olson, C. S. P. Lam et al., “Global car-\\ndiovascular reserve dysfunction in heart failure with preserved\\nejection fraction,” Journal of the American College of Cardiology,\\nvol. 56, no. 11, pp. 845–854, 2010.\\n\\n[28] S. H. Kubo, T. S. Rector, A. J. Bank, R. E. Williams, and S. M.\\nHeifetz, “Endothelium-dependent vasodilation is attenuated in\\npatients with heart failure,” Circulation, vol. 84, no. 4, pp. 1589–\\n1596, 1991.\\n\\n[29] M. A. AlZadjali, V. Godfrey, F. Khan et al., “Insulin resistance\\nis highly prevalent and is associated with reduced exercise\\ntolerance in non-diabetic patients with heart failure,” Journal of\\nthe American College of Cardiology, vol. 53, no. 9, pp. 747–753,\\n2009.\\n\\n[30] D. Fischer, S. Rossa, U. Landmesser et al., “Endothelial dys-\\nfunction in patients with chronic heart failure is independently\\nassociated with increased incidence of hospitalization, cardiac\\ntransplantation, or death,” European Heart Journal, vol. 26, no.\\n1, pp. 65–69, 2005.\\n\\n[31] G. Cotter, M. Metra, O. Milo-Cotter, H. C. Dittrich, and M. Ghe-\\norghiade, “Fluid overload in acute heart failure—re-distribution\\nand other mechanisms beyond fluid accumulation,” European\\nJournal of Heart Failure, vol. 10, no. 2, pp. 165–169, 2008.\\n\\n[32] B. A. Borlaug, V. Melenovsky, S. D. Russell et al., “Impaired\\nchronotropic and vasodilator reserves limit exercise capacity in\\npatients with heart failure and a preserved ejection fraction,”\\nCirculation, vol. 114, no. 20, pp. 2138–2147, 2006.\\n\\n[33] E. Akiyama, S. Sugiyama, Y. Matsuzawa et al., “Incremental\\nprognostic significance of peripheral endothelial dysfunction in\\npatients with heart failure with normal left ventricular ejection\\nfraction,” Journal of the American College of Cardiology, vol. 60,\\nno. 18, pp. 1778–1786, 2012.\\n\\n[34] C. S. Lam and D. L. Brutsaert, “Endothelial dysfunction: a\\npathophysiologic factor in heart failure with preserved ejection\\nfraction,” Journal of the American College of Cardiology, vol. 60,\\nno. 18, pp. 1787–1789, 2012.\\n\\n\\x0cSubmit your manuscripts at\\n\\nhttp://www.hindawi.com\\n\\nHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013Oxidative Medicine and Cellular LongevityHindawi Publishing Corporation http://www.hindawi.comVolume 2013Hindawi Publishing Corporation http://www.hindawi.comVolume 2013The Scientific World JournalInternational Journal ofEndocrinologyHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013ISRN AnesthesiologyHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013OncologyJournal ofHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013PPARResearchHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013OphthalmologyJournal ofHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013ISRN AllergyHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013BioMed Research InternationalHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013ObesityJournal ofHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013ISRN AddictionHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013Hindawi Publishing Corporationhttp://www.hindawi.comVolume 2013 Computational and  Mathematical Methods in MedicineISRN AIDSHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013Clinical &DevelopmentalImmunologyHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013Diabetes ResearchJournal ofHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013Evidence-Based Complementary and Alternative MedicineVolume 2013Hindawi Publishing Corporationhttp://www.hindawi.comHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013Gastroenterology Research and PracticeHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013ISRN BiomarkersHindawi Publishing Corporationhttp://www.hindawi.comVolume 2013MEDIATORSINFLAMMATIONof\\x0c\""
      ]
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Lemmatization\n",
    "import nltk\n",
    "nltk.download('wordnet')\n",
    "from nltk.stem.wordnet import WordNetLemmatizer\n",
    "\n",
    "lemmatizer = WordNetLemmatizer()\n",
    "lemmatizer.lemmatize(merged_text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "da831d40",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAhwAAAGiCAYAAACs1h/kAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjQuMiwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy8rg+JYAAAACXBIWXMAAA9hAAAPYQGoP6dpAAEAAElEQVR4nOydZ3jdxpmo3wFwcHojDw97F9V7lyxLtuReY8dxmpN4k02cupu6u9nc3SS7ufEm21vabnridDuO417lItuS1bsoVom9n14AzP1xKEoUSYnq8jXf59EjApgZDHAAzDfffEVIKSVTTDHFFFNMMcUUFxDlUndgiimmmGKKKab4/58pgWOKKaaYYoopprjgTAkcU0wxxRRTTDHFBWdK4JhiiimmmGKKKS44UwLHFFNMMcUUU0xxwZkSOKaYYooppphiigvOlMAxxRRTTDHFFFNccKYEjimmmGKKKaaY4oIzJXBMMcUUU0wxxRQXnCmBY4oppphiiimmuOBc9gLHt771Laqrq3E4HCxZsoSXXnrpUndpiimmmGKKKaY4Qy5rgeNXv/oVn/70p/nSl77E9u3bufLKK7nxxhtpbW291F2bYooppphiiinOAHE5J29bsWIFixcv5tvf/vbIvlmzZvG2t72N+++//xL2bIoppphiiimmOBO0S92BichkMmzdupW/+qu/GrX/uuuuY9OmTWPKp9Np0un0yLZlWfT395Ofn48Q4oL3d4oppphiiineakgpiUajlJSUoCinXjS5bAWO3t5eTNOksLBw1P7CwkI6OzvHlL///vv56le/erG6N8UUU0wxxRRTDHPkyBHKyspOWeayFTiOcbJ2Qko5rsbii1/8Ip/97GdHtoeGhqioqODIkSP4fL4L3k8pJfu2NrHxjzt548UDLL96Frrdxk3vXkVReR77tjbxyM9fxRdwEY+lcHscfOgvbkbTVZ76zRa2vXwIl8dOPJLins9cT0VtmJ6OQX70z09gt2sMDcQpqQxx7+duJJ3K8OgDr/HyE7soKPJTVJHPtDmlrLt5Id/66kNoNo2W+k5qZpXS2zlISWWI9336ejpb+/jJvz+Jw2EjHk0xZ2k1t77vCjpb+/jvrzxEUVkQCXS09nHXh69myZXTeWPjAV56fBf7d7SwdO1MHE6d2z9wBYF87wW/p+eClJKfNj2LTVF5V+VV503LJaXkN60vMWQk+FDN9SgXSXt2JN7Lfxz6PX8x6y4KHIGR/fuHWnmg5QU+P+vt+G3ui9KXE5HSAsRlpUX8wY6tpAyDjGny/vkLyXO6Ro5ZUiKlxJISTVHOqt/JTJZfbdrJu69YiCIELx9sprlngBnFIQ6093Dr4lls3N9I1jS5fv50/rB1P26HztqZ1bx0sBkpJXZNQ1MUSvJ8+F0OWnoGWDe7hkgyzfN7G1g/p5bvP7+F8vwAEollSTbMncYft+3nPWsWoWvqOd+nY/dBIlFFbmZqSAtVKKd8ruVwHUVc1iaAbwqklPzo4BsMZZI4VBsLQ8U0Rfu5q2YBv2/aw5qiap5uO4QlJfPyiqn25vFg027cmo31pXX0puJs6z0KwLunLeZn9VtxaTZK3X7q/CEebNyNIS2KnT7WldTw00Nbeee0hRS7fLzc2cThoT7CTg83VczkaHyQTZ3N3F278Izei0gkQnl5OV7v6ceEy1bgCIVCqKo6RpvR3d09RusBYLfbsdvtY/b7fL6LInAArLx6AZW1ZXS1RvjUV9+Jw6kDOaHJ7fLQ0TTIfd+9g9KqAizLQrOptLf08drTB/niv99DMOTlsV+8yjO/3s6ff/0uPB4vX/yXD+Bw2ujrivC1T/wEaaoUlYT50OdvY7A7yfKrZ3HljfOB3MOLqXH125bR3TZA/Z6jfOord/Ptv/s9TruTJ3+1jTXXLOTau5Yx0BPlax//CRtuXY7H4yXSl+bTX7uemlklPPPgVrY+f5irblrC+luXU1pRxE/+9Uk+87V3o2rKyDVdzkgpqSwowabY8Pl851XgSDsk8bSBz+e9aB9dhxKnV03g9LrxOY8/z4VqAXXJCvL9ebi0sc//+URKAyPxCxAqqr4aoVYijUMINYxQghf03GeC6nDwoTnzeba5gR7ToOqE939vTzdPHD6EpqosLS5ldVn5GT8btkyWgvw88vOCRBIpuuIZCkP5uD1eQnkmofw83J4eVEXhaDQNNjsVRWHaoilU3UHA7cSmKqiKgsvtImGaJCwFze7kpd1N1JYV4/F6qS0rYUZxiMKAh21N7bRFU1iajs/nO28Cx96BTl7saOS+WatImlkeqN/KNaV11PkKxpTtSEQodvnoSETZP9jNhtK6c+7DWx0pJZrLwdxQAXkOF4PpFF6vj6NmkoyukrQJykNhNpTW8f0DmzHsGssqallTVA1AdrCbUpnh9e5WdLeTpCa4d85yvDY7z7TVc0X1DHw2B/sHu6kOF1MXKcXp8eD1+MhPBUlogkNDPXh8XryqhTPmOevv5WTqXLYCh67rLFmyhKeffpo77rhjZP/TTz/N7bfffgl7NjEn3/CTt4vL8ymtLkBVFdRhB6H2ll46j/Tzra88hBCCWCSJw6UjLUkskuKZB9+go7WPbNYgFkliGiZCCE609T12HikliiIIhDzEIknywl7sDh1pQSZt0Li/naNNPbyx8WBu3W0owdBAHK/fRV6Bl7LqMIqiECryk0pkkBIU5dTXdDly7N7cUrICGN3nie7byVhIUmYGS1rYVR2bUEe1IwBTWsSNNJqi4lBs47YnkSTNDFJKnJodZVgbIKUkKw3SZhZFKDhVHXGCpkBKiYUkOdw+J3Xx2DkqXWE+UXfruMeOXUfSSCOEwKnaESddtyktkmYGTSg41OMC8viYSKsLzXknRupRbK73YmZ3o6lXI2UWM/0i0upBsc1HCBtWdi9IC9V5E2b6VZBJVPtahOKZoP3zQ9Iw+O3+vSSyGa6tmTbqWCyTocznZ11lFb87sI/VZeVn3L6uqWyYOw0B+F0Orl84HWlJ8rwuppcU4LbrXD23Frddp61/iLevmEeBz01LzwBzyovQFAU5/IMqQtA1FMPrtGNKiyU1pRiWBcDbls3haN8gHoed6+ZP52jfIO9YOQ9NPTMhtzcVZ1NXM0HdyfJwBa90NpGxTNYV1zLdH+aFjgYk4NZ0arz5JA1jVH0pJQeHuvnBwS1cU1pHjTef7b1tRDIpVhVWAoLXu1uo8ASYFSxiS3crkWyaxaFShjIp9g50MidYiE3ROBzpBQnLwuW0RAeYn1/MGz1HWBoqRz3F+r9EksnsIpF8atzjmlqEx/1uhJjckCalSTT+c0yza9zjLuf12PX5k2rrXFGFgqaoI1qmFeEK/vfA69xcMRuvzc5QJkVvKo5d1fBoOp3JKJFsCpui8kjLXu6omjei5dBVDV3VcpNcTacvnSBrWSPvesYySZsGsWya59oOc0f1XA4N9SAlpE2DjGViSgtNnLtAOx6XrcAB8NnPfpb3ve99LF26lFWrVvG9732P1tZWPvrRj17qrp2Sifx+FFXh5E+506VTUhnio39zO5qe+zk0m4qiKPz2f17AyJq8+xMbyGYMGva2j6orAORJy0xieNASowcORVVwex3c+K6VzF5SNVLfG3DReaQfVVU41WT9snVlGodtA4f5/dFXyUqDFfkzuaNs9cix/ZFW/ti+mU/U3YpbcwCQlSbfPfwYS/PqWJk/k7ZkH//T8ARHEz2YWPhtbu6tvpaFgZqRdmJGkn8+8CD10TY0ReXu8rVcXTgfRShI4FetGylzhTgQOcKrvQcwpMF7KtdzfdFipJQ82bmVx9q3EDWSAMzxV/KR2hvx2VxIKRnIxPhuw2McjBzFZ3OxJK8OccLTEzNSfPvwHxnMxHFpdj47485RGo7HOraQMNI0x7s4ED2CJSVXFszhnsr16KoNKSUNsQ5+1PQ07cl+bIrKhsKFvK1sNfopPtrS7MJIPoZimwPCS04IGUCoeaj6EozEbxCKH6EUIMwupNWPld0HcgihlmGmn0Zz3jFh++cDu6pxTU0tFT4/ujr2w+m329FOY9wGYFqDGEYLuadfwabVoihuVEUh7D8uNFWGctodKS2c2lFMM0bAoWGzzWB68XFNwbSifEyrc2SQ09QSFKWAgNs5UsbndIz8LaVkWpGJaR4CoKrAhU2bdkZCv5SS3zfvZl1xLQUOD9v72jg41INNUXi9u4UrhmfKwMh3YzxKXH5KXD5WhivpSyWwKQq1vnyeb2+gJxVjur+AP7Tso8DpYWNHA/fNWoVPd2BYFoVOD39s2c+cvEIUBGnL5NBgDzv72wnYHTRE+lheUHHaa8lkdjEU/Zdxj+m2hbjd70BMekgzicV/Sia7Z9yjmlZ80QSO+fnF+HUHTs1G0O6k3BNAEQrz8orw6HbaEhG2dB/hbVVzybM7eb69gaeOHOLq0mmsL6ljT38Ha4qqsSkqi0OlaMPPx6JQKU8dPUg0m2Z2sJDGSD+WlOzu7yDs9LA8XE79UC9riqpJGll293UikRwe6mNmMHxBrvWyFjje+c530tfXx9/93d/R0dHB3Llzeeyxx6isrLzUXZsQp9uOkTXZ+WoDBcV+SipDON0Tq7qrZ5bg9jp46fFdzFlSxdBAHH+eB9/CCjLpLJqmEhtKsvWlgyRiqVF184v87Hr9MGU1BTjddgrLJlZra5rCulsW8tzD2/D4HGg2jb6uIVZfN/e01+Txu4j0x9nzRhO+gIuymgJ0u23yN+UiM8Nbxj1V6/lB41M0xUbPYAodQXYMNLJ3qJVleTmVcEu8ixd79nBraU4j4lLtrCmYw3RvKZpQ+HnL8/xPw+P866L70JXcK7NnqIVPTr+ND1Rfwxv99Xz78KNUeQqp9RQDksOxdp7o2MrNJcv48tz3kjDTBE+wsQjbA7y/egNlzgK604Pcv+9XPOcp4fbSlUgkP2l+lo5kP38z9z0AfPfwY6StzEh9l2bn7oq1bO2v55etGzGkOeo6W+Ld/LF9Mx+suY57qtbTGOvgHw/8jvmBGpbm1TGYjfPNA79lTWgOH6+7la7UAP984HcEdA/XFi6acFATSj5CLUQIByByH3hpAhIz/SqKvhChFCOtTiyjEc15F5axB4QbIbxYMj1uu+eTueEwRR4Pdm3s563A5cJts2HXNGaHCsapfZxU+lV6+j4KWIBCnv//4PX86SkGfIO+wS+SSr+GquRTXPgkmjp6+Tca+ylD0f8EIOj/P/g8H5nw/KbZSXffB8lk9yCEjaDvr7F5pk1YfiIylolveEDLmDntxXR/AdN8oVE2Lcf+t7BGTWKEENhVDZuiDs+eodQdoMDpwezvIG0aCCHYUFqHU7VR4PQQcrgxpMXvm3czL6+YjGUAApemo1oGEslMf5jfNu7itso5kxKidH0Rfu+fYVoDWNYgptlJOrOV3O9zpqh4PfeSzdaPtJfJ7sU0205Z65j28HxpeoUQrC6qGtnOmCbPttUzP68Yn+5ACMHa4ppRda4vnzHyd8jhZln4uJZuXUntyN9OzcbtVaO/79MDx5/5a8qmjzp2Z828c7qWyXDZW/18/OMfp7m5mXQ6zdatW1m7du1ZtyWlxLQsDNPEHFYznUx/IsGRgcFRdQ529fBSQzMZwxzZd3RwiIFEckx9f56HGz+8ht///nWeeWjriJDgy3Njq/BgnHROl8fOp/7+7ZiGyeO/ep09W5qwO3Pq+bd/aB2KqvDHn28iXBrk1ntWY7NrIyrXW+9Zjcfn4g8/eYWGfbkXZebCCjw+J+HiAJV1hegOjbnLqlFUhQ1vW8K1dy7llSf38NzD20insiiKgtNtZ8GqaSMuTYGQh1mLKzn2ThVX5POOj1zFC3/YzsY/7iAeT3Owu3fc+zceh7p7SWaykyp7PvDYnEz3lpKnj1XdB3UvS/PqeL5rx4ha+8WePdR5SihzhhBCkGf3ck3hQspdIYqcQTYULqQ/EyVpHh8sq9yFbChcSLEzj+uKFhN2+Nncd/D4PZFQ7MzjzrIrqHSHmeUrp8iZhxjWQC3Om8aSYB0FDj+zfRXM9ldyNNEL5LQXr/cd4G1lq6lxF1HjLuK20pWjNByqUKhyF1LtLhq1/0QqXAXcWrKCYmceK/JnUuLMpyWeE8C2DRwmbWa5vXQlYbufuf4qluVN57munVgT6rMUFNs8NMdNSKsbaTZjWZ2Y2W1IqxfLqMcyDiONQ1jZPSDTmOkXULRZSCuCmdmCal9/pj/nGbOhuhavPr6QXxPMY264EK9u5+qqmtMMHBLIAgaQIRr/OZY1cMpzS2kCBhJjghLmcHsGEw2UUkosK07/0FfIZHcAJm7X2/F47kGchc3QDWUzefLIQTZ2NLA4VEbY6aEtHsGmqmzubiVjmWzpaaU9EaE1NsCe/k4GM6MnNzZFpcaXz1NHD6IrGmUePw7VRpU3yB1V8+hJxohl0zhUG7W+fCD3jNb4QvSm4szLK0YA2/va6E7GmJdXzNy8IhJGlmpv/mmvQSCw63MJ+r9IfuAbFOR9m/zgNxDCedq647YnVLzu9xL0f5lQ8N8I538ft/OW09bb09rFrzftor1/aMIx5FxQhWBuXhFvq577pli+PlMuaw3HheB/X91KfyKBAO5aNJfa/LxRP2xDbz+Nvf28MxgY2RdwOfnR5u3MLS5E13IPeCKTHVddqygC98w8rqxZzU2zj0uQ5dMKueHeK8aoLIUQ5Bf6uPujYz/EBSUBPvgXN41sv9p8hO9t345A8Lb5s6gL5/OBz90wqs7tH1gDMErb8c6PrR8516pr57Dq2jmj6uQX+njfp68f2a6eUUz1jGIg9/E71NPLiuvnsu6WhUBOCo+0D47p70Q8uvcgdy+eR6l+XCvS3D+A124n353zIBhMpuiLJ6gN5U263bNBABsKF/KN/b+hLxPFqeps6tnHe6vWowoFKSUJM82zXTvYPdhMwkwzmInlPi4ntBOy+9CGP/42RSPsCNCZGj0YlTnzR9ZlT0RKSVO8i6c7t9Ge7CNjmdRH21gbzs1GotkkSTNDsfP4s1noCKCe4bpqoSOATcnVEUJgU9QRTciReA/dqUH+etePRgSW3swQIbsfc9hTYSwaqiP3PKqO23LX7v74yFGb51Mjf6vaDDhhzNecd55R3y9HskY9ieTjeNzvucCDgclQ9Fskko8C4LCvIej7IoIzNwoWQlDtzaPae/y9urPq+Ex2TVH1iAEiwEdmrhy3HUUIbig7PrMuduU8Eq4ozNU9JmQAbCipywnWwE3lM0f2v9jRyDWl05kVCJM0szzTVs/1ZTOwTWJ56+RrApXzMXwd/x214TZPTdDjoL6jl0fe2EdlQZDrF05nYVUJXqf9pPbODlVRKPcEzqmNy5m3nMAxlErx/uWL6BiK8uT+etbWVlHg8RB0OdjSchRd0zg6GOE32/cwr6SQGeEQYY8bj10faePI4BBbWttYX5dTdcUzGV6obyKRyXJFTW65p6lvgF9v38Oc4jCzi8JsaT3KkYEhFpQWYVoWLze2EM9kMS2La2bUkjZMXmpopjeeoCovwLpp1aNc07qiMf645wCfX78Gl25DVRSa+gd4o7WNsoCfFZVlHBkYojsWp6V/gCXlpSSyWfriCXpica6srSLkdrGltY3WgUGWlJdQk5/H1iPtZEyTjqEo182aRl88weaWo3jsdtbX1dDY189/vfQaS8pLWVFRxozCEM/XN6Eqxw0P93R0sa+zh5mFBcwpKuCVplYSmSyGZXHN9FosJK81H8G0LK6qqyGVzfLtlzdT6vexrKKUWUVhfrplO13RGKurK7lqWhWvtxwlls7gtdtZU1s5qTX3ySCEYLqvjIDu5o3+ekK6j6w0WRysRQiBJS3+p+EJ6qNt3Ft9LcXOIA2xTv67/pFR7RjyxNmpxLDMMYZWE318OlMD/O3un3JlwRzeW3k1XpuLbx9+dOS4IgQCgXnCOSwpOVNLmpzQMH4fNEWl1JXPR6fdNMrTxqnaJzQYu5CD7KlU1eMZ+p5NO2ePQKAjSRON/wS361aEuDCeb1JKEsk/Eol9BzDRtFryA/ejKMGzvqbzqf4/lzqrCqtyz7YQOFSNm8pn4bbpb6qZfGmen79++3oGYgm2HD7Ko1sP8MPn3mBxTSnXLqhjWlEIVbm83MQvJy77JZXzjWlZNPT2s7uji7KAn51tnXRGoqQNkxcONyGRRNNpFpYV88DWnSTGWQoo9HpIZrO0RyIA7O3o5kBXD7OLCnBoKhY5wWZhaRG/2LqLrGkyq7CAnW2dZAwTw7L41bbdlPi8dESivNHaxhP7D+HWbcc/mCed88jAEDWhPIIuJw6bjbRh8NMtO1hUVsKeji52tHVwqKePjYebWFxeQtDl5I3WNtqGIlTlBfnJ5u3sbu/ijdY2lpSX8outuxhKpXjyQD2DySSLyorRVRVdVZlfUsTB7h72DN+jArebK2sqqc4PoikKswoLeL35CFJCRyTKI3sOsLyyjKcO1NPUP8ivtu+myOelMxLljSNtpLIGdk0l3+3i97v2EXK7KfJ5WF5ZxuziMG7dRlVekNmFYVZUlmFKyW937GF6OMTO9g72doxvSX62OBQb68Lz2di9m409u1ieN2MkhkXayrJzsJHri5ewNK+OUmeISDYxRnV6NNFD3MgtscSMFK2JHmo8RZM6f0u8m5SZ4R3lVzLdV0ZQ99CfiY4c99vcBHQ39dG2XMwDKWmOd50k5JwbM7xlxIwkIXtuSWeOv5LZvgqq3OGLFlvkGFJKfrx/G7v6xgb0O8bPD+5gd9/pn4NXOlp4sGHveVZ1a7hctwAKmew+EqlnzrsqHXL3IZPdQf/gV5AygaLkkR/4BzTtdEs/bw50VR2ZOChCwavbL/qzdq4c09z4XQ6mFeVTWRAkbRgc7uzjm7/fyD/9YSOJ9NktHxuWRSKbJWOaI+99LJOmcaCfA309tEejZIePjYc5XD9tGCP1E9kszYMDHOjt4WhkiLRpXJBnd7K85TQcpmXR3DfArMICFpeV8Osdu3OBdaSFOfxD1IbyqA3l4bDZSGSzuPTRBpJ2TcOtH9d4zC8ppCcW57F9h7hx9nQEsKCkiJpQHnZNxbIkbl0f5Tsf9rqZVVRAXzxBLJOhKi/IMwcb8DnsTC8IjfnAeOw6Q8kUkpwwEk1ncNpsTAvl0RGJ0jowhFvXWVBaRG0op95UhGB6QYhZhQU8sucALQODTA+HqMkP4rbrDCXT6KrK0vJSwl4PlpRsamolms7QG0uQyGbx2HWcuo2Q24V7WMvjd9hHZsU9sQTFfi9VeQHKAn66ojHCHjeziwroTySIDfdzYWkxUsKeji6cNg2PrpPncuJ35Kzy/cPW+XkuJ4lMlny3i5r8IHWhfLqisUn/voZl8kL3LrpSgxyKtqEKhQeanyfsCHBVeD6aknNvvSI0m4eObqIp1sGX57535H7rikaVu5AXuneRp3vpTg3yfPeunGvqCaTMLN85/CiLgrVs7j+ETaisyJ85xmV5PIqdueWuR9pfZ5qnmC399Qxmjl+jU9W5qXgZv2nNZUZWEDzXvXNE8yCl5FC0jZ2DjTTEOogZSX7V+iJ5upc1BbMJ2wOnvU/zAlXM81fz9X2/5OrwAmyKRku8m4XBGtYUzDlt/fPN3r4uyjz+CY/PCxVR5Dq9O217LEJj5NR2FmeOidOxnnRmJ4ZxmGjsR7gc1yPE+Qu0JqXENDvoG/grTKsLgZ2g769x2FdfMmFDSgspoxjGEQyzDUvGESgI4UNTi1C1YhThA04dQC33PpiYZgdZoxHT6kcgUNVCNK0WVQmdlW3KpSCezrDpQDNP7DhEfzTBFTOr+Pp7bqQs308yk+X+B59n8+EjXD239vSNncRzzY3c/8pGrq6q4Qsr1/DbA3t5YM9OjkYiZC0Lr66zpLiETyxdwdyCwjH3fHdPF59/5glmhwr4xvrreaa5gR/s2ErjwABp08BlszGnoJCPLl7GqrKKSyLsveUEDofNxnUz6yjy5T5eJT4fz9c3caCrl0Qmi0Cwu72LP+45AFLisevs7uiiMxJj+9F2VlSV0x2N09Q3QNY0KQv4iaRyM12fw05z/yAeuz5igCmEwLAsDrT3jLSxoLR4ZI0854kmUBWBpirMKipAU5UxEVWr84MYlsWPXt9GwOlkaUUJmqLwyN4D7O/s4R0L59LQ1z/KgNCUkufrGznY3UNlXoBFZcU8sHUXacMga1oUeNwoJ0RbtCzJno5ullWU0jY4NKzaz13XM4caWFZRRtjrZntbB53RKLs7OikP+nls30Ee23eIpr4BrppWzfPHrg2BEIyoUUGOPOT5bhcvNjSTNU1mF4UJOp283NhCgcfNrMIC2oYiPL7vEDvaOnj/8kVn9BtLJE5V5+aS5SP7rBET0RzFzjw+WnsTaSvLNG/pyH4FhY9Nu5nfH32VZ7t2UOYM8Rez7qIh1oFzOE7F2oJ5bChcREu8i9f6DhCwufnbue8lX/eOXPcNxUtxqON78pS7wvzFrLt4tmsnbYleluVP5+aS5SNGqUIIbi9bicfm5I3+QwRtHj5Vdxst8e4RTYxFzld+hreMGd6ykXrWsLAzxyyjrcuGGJYdBIK7ytdQ5MgJO3bFxmdm3MEL3bvYPtCAIU0q3eFJa2mklLTEe2mOd0+q/HioQmFxXg0uVQcESSPLqx2tSCmZHyrCbdPJWiavdh4hbRgjdgPHzt8ej3BooJeMZSIQzM7PufKZlsWu3k4G0klm5YUJO3P3LG5k2dPXSda0mJtfSMCeE3L3DAs7DUN9JA2DRQXFeEYZnVoI4cDrfg8DQ39POrODZPpFXI4bzmNAuWNGorsABa/ng3jcd1+SgVhKiWEeJRb/KYnk4xhmG1KmyRm5CnICho6qhLHbV5Dn/xtUNTRBWxaZ7C6Got8mlX4FyxoiZzArAA1VDeFy3Ijf+1FUteyy1+TsbG7nqZ313LJkFktry/A4ji8JeRw6i2pKsKyz0yDEMmmahwZ5re0I//jay/x8z078dgcVfj8pw6QtOsSTjYfZ2dXJf1x/M0uLS0fdr5Rh0Dw4QCKb4bvbtvC97VtwajZKvT4MadEWjfDykRZ2d3dy/9XXcUNt3UW/35d1tthzIRKJ4Pf7GRoaGok0KqWkfShKgcc9om0wTIuGvn7smopNUfE57URTaQYSScoCfjx2ncO9/SQyGVRFYVoon754gt54HIGgLODDYbPR1NePrmnU5AeJZzIkslmKvF7aBiMU+jw09vaTzGbRFIXaUD698fiIsGJYFr/Zvpu6gnyypsWeji4+t37NKAlUSknaMGnqH0BKSU0oD9O0aOofIOR2Uej1MJRMgYCAM2fY+tMtOyjxeyn2eanJz2lbemJxumNxKvMCeHSd9qEoYa8bm6oipaQ/kaQjEiXkduHSdbx2nXgmQ1PfAMU+L25dp763D9OycNps1BXkE02nOTIwRKnfR8Dl5Ojg0Mi1SSlJZrMjxqF98QTFPi8Z0+RwTx8Bp5MSvxdLShr7cjPTIq+Hf37+Zd65aB5eh51S//mLFDoZxnslTmdbMFGZyZ7jfLf/2qPb2PTwG3zmOx9GKKebfY5mMueRUvKDxuf5bv0zk+7TybhUOz9c9TGq3AV84eXHaY9HWF6YCwjl1Gz83cprMaXFC0cb+d+9b/DRucvZUJFzC22JDPC3rz3DtRXT2NLVxlA6yddWX8em9hZ+sG8ra0ursaRkX38X/33V7WiKwldff5Z8hwtVCOoH+7j/iuvJd7j41MZH8Nh0AnYnhmVyz8xFVPmCxJOP0dP3p4AkFPwPHI41dHbfjmEewWG/knDoxygneElImaGz512kM6+iKPmUFD47yi1WSslg5B8Yiv4HAEH/3+LzfBQwGYz8y/B+E6fjBgry/gNF8TBhYIwLhJQWydQL9A9+CcNsPuGIAGzk7IgMjtkT6ba5FBU8iKKMDWstpUU8+RD9g1/GsvqG99pRhB2JRMoEOa8dsGnTCeX9O7ptwaSf80y2no7uG5Eyjm5bSFH4IRThOH3FCegf/HsisW8BkB/8R7zue8aUyQ4HXlQneKeyZu64bRyHgtPx4IG9fO6ZJ1CH3ZA/vHgp75o9D7/dgSEt3mhv4283PsvRaIQF4SJ+fPvb8duPX+9rbUe45/e/wZISXVV5x6y5fHjRUkIuN1JK9vf18OWNz7Kvt4dyn59f3HE3JR7vOX9bxxtrJ+Ito+E49mEt8XtHbauKYHrBaLcsj65T7Dv+Ap18vCzgoyww+sbOLT7B314IHm+s54MLFlMezKmJZxaO9vmv0AMABJwOLCkp8nk50NWLELCmpnLMZ0YIgcOmMevEdrTR5w24RruIhdwuKoJ+6gqOzz7CXg9h73HVdOkJ1yGEIN/tGhEORu6H3c68kuMz3/klo2fBAadzRMgBqAgevzaAIMePlfhz57NrGnNO6LsqBHXD9zmZzVIeDDA9HDpl9MHziZQSaUnSyQyqpmKz516NTCqbiwxry31AUok0doeei/iqKJhGbk3VPhzGXkpJJpnB5tDJpHJxM+xOfWSpJZPMDJe3jwgCUkrSiTSmaaE7bKja8aimmVQW0zCx2W1oNnWkHSNjYGRNdIctF1DuWPup7Mj67WRmEuf0sTmPUxUpJevLavnQnKV0JWJ84oU/EM9m8NsdXFdRxzNHGkaVbxjqp9Dl4T0zFjI9EOJH+7dR4s49W9W+IH+xZC2WlHz42Qc5EhuiJxmjP5Xg3TMWIIC9/d1s6mjl1uqZZEyT+cVFvHv6glP0L4mqFOF23c1Q9J9JpzeTTr+Ow77unD/Y8eQjI0aium0u+YG/R4hLIWxI0pnN9A78OZaVc9FW1TLczltx2JejKCFySyOdpDPbSaU34XbdMdzXsW2l0i/SP/AlLDmEogTxut+H03EtqloA0iBrNBCN/5Rk6jmyxiF6Bz5HYehnqErRZavpUFWF3S2d7GhuJ2scj31Tlu/n+oXT0ceJ/XKmmFKyvrqGjy9ZMcoT8qrKav5q9Vo+/fRj7Onp4uXWFm6aNn3MvZLA/HARf7l6LW7b8QjIS4pK+OraDdz7yO84Ghni0fqDfHjR0nPu75nwlhA4LCl5sbWZ+v4+ZocKmJ4f4tHDh1CF4JrqWp5paiBtmghgVVk5m9uPYliSeQVh5hQU8vtD+4lnMtw2fSYDqST7e3uIZjLcXjeTg/297O7uojaYx6rSch46tI9E1mAwNTZGx0QoQvC2ebMwpcwpLMX5sXK+flbdRf5knR8cmsa9yxdd1DXG2GCCX37zYdobuhBCcNOHrmbJNfPZ9PAbNOxq4d6vvoPmvUf57b88yif+/V5e+PWrdDV30981RKQvytXvXM3V77oCM2vwH5/6ITOX1bL9+T0IReGT/34vvnwvz/zsJTY/vh3TsJi1Yhp3/tmNqDaVp378Iq8/vh1pWuQVB/nwP7wHh9vOi797nY2/fhXLsvAEPNz3zffiCbrZ88pBHvnu02RTWfJL8rjn/9yJP+Rlx/N7eeg/n8DhtuPyOt9Uv70iBJW+wEiQKQEjy0PjMSe/kB/t38Y/bXuJjniUGyqnj1xvuTeAKnLLeXZVw7BM2mIRelMJnmjORe2cFsin2J2bVKiKoNqXd8p3TspceHiP+x3E4j/DtLqIxH6Iw74KzsJd9RhZ4yADQ19DyiSKUkB+8BuoauklGXCljDIw9LURYcNpv5q84P1oasVJ/ZG4nLcNayjGt9+w5BADQ/fnhA3hJxT8D5yO9aOWiDStBod9Nb0DnyWRfIRsdj/R2I8I+P6Siy1sTZaW7gH+7++eZVF1KTua2llSW8YbDUe59+ol5+0cihDcPG2su7AQgjUVlVT4/DQODrCxtZkbp00f905dX1s3Stg4Vn9+YRHzwoW81naUF1ub+ZMFi89KG3O2vCUEjr5kgq2d7Xxs8XIUIfjtgT0sLirGsCweO3yIWDaDAKYF89nd3UV7NMrHliznO9s2MzNUQLU/wK6eLt7oaMOj6xiWxbtmzyVtmvxm/x7WVlTx6OGDKEKgCMGGqhp+s390yNyeSJz2wQjzy8eX3oUQIyFpzweWlOxq7aA8P0C+x3X6CpcRQgjUi7yE8tj/PovL6+Rz3/0IRw938N2/+Dkzltay6tYlbHlqJ8/87CVef3wHt330WjwBF/GhBG0NXXz2ux9hoGuQf/7w95i/dhb+kJfmvUeYtrCKz373IxhZE2/QTeOuFjY9vIVP/ucHUVWFf7nvf6hbXMPslXU88/OX+ND/fRdVc8qJDyWwu3SMrMlTP3mROz91A7NXTyc+mMDlcxIbjPPA/b/ng3//Toqrw/zqnx7hsf99ljs+dSMP3P977vk/d1K3uJof/s2vSMUvbFRPRQhUoYxkHD1XJgpgNh4uzYbXprO+rIZit5fCE+w7xhNUK7wBilxePrt4DQ5Vw5TWiOGzmMSZ5bDqX1PLcbvuJBL7Nqn0S6Qz23DYV3I2A6RlRekf/AqmmUtZoCgeVLX4jNs5P0iSqZdIZ3YAoKlVw8LPeHYVOWFuIqNZKSXJ1HMjYcPdrjtxOq4eY4+Sa9eN3/txkqlnkTJBPPkIPu9HUcXEUZMvJY3d/ayeUcmHNiznHx/eyGduXcOOpg42HWzmxkUzTt/AJLCrGjWB8d2gPTadurx8GgcHqO/vxbCsMfGgVCGYnpc/bn2bojA7lBM4WoYGSWSz+KcEjvOLaUk0IdDVXJ4L05LYVQ1VWGQtE5dmQ1UEHl1nKJ1CVZSRH3HT0VYGUykKXG5MK2c0Vej24NBspE0Th2ZjWjCfGfkhBlKp4fC/6piP3p6jnTy1p545ZYXnVbCY+JotfrZpB3csmcMV0y/fUPCXA5ZpseeVgyQiSRp2NGNZFplEhkQ0STjo5j1ffBtfuvUbrLtrJQvWzR55kWcurcUTcOHyOvAG3XS19uIPedGdOkuvn48ncPyDfHhbE60H2vn2Z34MwGD3EP2dA+hOG9fccyU//fsHmb64mg33XJkTPm0q179/Lb/798fY9uxuNrz3SvKLg3S39tGy7yg///pDKIogOhCjak45Q71Rsuks0xZV4fQ4mL92Fpuf2HlB79vNpYuZ7S8jkk0ylE0wlEkwmE0wmIkTySaJGSli2RSdqUGSZuaUbYlhjcSJ2wDNkQE2tjVxaKAXBehPJ7mxagbxbIb2eJR/37EJm6JS6Qvw6YVX5HIJjWo39//yonKePdLAF15+nJDDRdzI8plFV1Ds8o5KaHd6BF73e4glfo1l9RGJ/Qi7vhQhzjzUfzzxWwyzjVx0AgvDaGYo+t/k+b/Cxf4054SEpzlmU+Fx33UORpwWyeRT5IxMNVzOGxGniO1i02pR1SIMoxHTaMcwmlH1y1PgsGsaGcPEpqmksgaDsST5XidtfUMjHoTnik1RJoyUqwhBgSv3XYmk06RNY4zAoQhBwDFxBNZC97ARdTabW7Z0nL3dy5nylhA4ClwuqgJB/nfHVmaHwlxbXcsjhw8CcH1NHXt6ulCFgt/uIJ7NsKWjjZ/u3sHykjIqfAGebKzHodmYHSrAqdlGPmJe3c76qmpeOtJCscfD+soadnd38mRjPWW+nO3GMVuRK2dUsXJaxaiZ+0T2uqfKYjpZgz5NUfi7t187yhX3dOc703OmzCzNse6RUNgu1U6le6xL7/nkTIJATRYhBA63nfXvvoJl1w2v4wtweXMv7eHtzYTLQxyt7yARTeL25zRGqUROg2BZEiNrYBtOvqcoCtpJ6cN1p87slXV89J/ed9wF15Wz7bj+A+tYcdMiNj+2nX+973t86YE/I68owJVvX8HCq+ew7dnd/Mcnf8AXvv9RbLpGQXk+n/i3D+B05z4Umq4SG8zFCjGzuVgd2fRxw74LgRCCsMNP2DH6OT+GRGJYFoY0uX/v73my49TCz33zlpNnz91Xj67zlRUbctpEaTEjGOKLS9cBoCkKqhB8d89m/mT2Eq4oqcS0LL6+5QW297RzVWk1K4tyuSUUBJ9dtIYStw+nqvE3y9fTFOknkkkTdnooHHaz/fOFV1DknlwGWyEEmlaN23kL0fiPR2byum3hpO/dMQzzCKpajM9zH5HodzCtTmLxX+BybMBhv+riGkqTIZPdN7xlw2G/4qzPL2WSTHY/AELomFYfqfRrpyifQQxH+ZRkMM2J47FcaqaXhHij4SiqIphdFubzP3kUy5JcPbf2vC0CnSx8n8yxWCamlON6xAgEp7ATH1lCyWWQvbg+I28JgUNVFG6rm4klj7tlfnhhzlhGAJX+wMjfhW4PLUODfGTRspEHqHbJipHjJ6IIwfrKGq6qrB5Ry/7pwtFGOFnT4r+e3sSR/iFqwnl84ppVI+28fKiZjsEoGdNkV2snIa+L965eREkgpx4+3NXHg1v30h2J4XPYuXHBDJZVn37Wsbeti5+8sp1kJstHrlrOvPKi4b6YfOvZ11heU84L+xsZTKRYNa2CWxbNxKaqZAyTJ3Yd5LWGI2RNk+qCPN67aiF+11gJWErJtv4mvrjjgZGImPMDlfzH0ntPmdrYsiSWaeUMJO0ahpHLR2Cz5bxkMuncwC0EZDImuq5hWbnyNk3FtCS7d7Yye24ZdrtGNmvmVPuagmlamIaFTVdH3JIng1AE6+5ayRM/fAFvngfNphEbjLPq1iUc2d/Gkz96gc9898Ns/PWr/PZfH+V9f/N2ALY+s4v562bTe7QPy5KUTpvYpXT+2lk88cMXePWPWymdVkz3kV4WrZ+L3anz+uPbKa4OU1CeM5o1sybZtMGrf9xKYUWI/OIgmk3FyBgU14QpqirgiR+9wOIN8xjsHqKktoiy6cWEK0I8+eMXmLN6Oq88vAWX7+ItpZ38TApyGkUd7bSproUQ1PqPG2bbFJU5+TmD4gKnmwLnaNW9JSVJI0tfKkFfMkF3MkZvKk6Ry0v4pFgdM4LHjax1VR21fYzpwfFdOidGwet+H/HE77HkENHYj8kPzs9d9Rm4sdpsswkF/xXdNhchNPoHv4yUCQaG7qcwNA9Vzedi2TJIK4E5nCdGEU40tfQ0NSbGkrGRtqRM0Nv/icnUOqH+5O3fLjYFPjefvHE1qiJ415qFzCjJPU+LqkvO2zlMaZExzXGPSSBp5AKL2RRl3AjMFjmPxolIZHPaxhM1+ReLt4TAAWPtAkapXU/42++ws6GqdtSSyKleeSEEKhOXtakK91yxiKf31LPxQFMud/1w2+2DUb7z7Gu8f81i3rlyPg++sYd/f/Jl7r/7BgzT4v5HXmDdrGqun1dHx0B0gvwWY5lWmM8nNqzkr379BH2xxMh+05Jsqm9l95EuPrBmMVnT5F+feJmSoI8VteVsbW7jgVd38ufXX4GmCJp7B1FOISpv7W8YpSo/OWPpeAz0x3jq8V2Uleczd34ZG5/bTzZrsmbdTHbvaEUImLewggP72hkcjFNUHKCjfRC7rmF32Jg+s5jnnt6LogjChX5ef/UwihCsXT+LJ/64g8KiAEuWVeMPTH6wFUKw6tYlOD0Otj6zG2lJ5q+bBVJyaFsT7/jcrRRXh7nt49fxh289xWB3LsLsvDWz2P/aIVLxNJ/4tw/g9rswDZPlNyzA6T3JY6g0jz//7w/ywm9eo35bE6V1xej2nEdKtD/Gvk2H0J069/7d3bgKvRjSIhVP89wvN6HZVN71l7dTPqMEoQg+/i8f4IVfbeK5X76C6ndQu6AKzabykW+8lyd/tJHNj+/ghj+5mqHeyOVqe3dOCHJaiYcb9/Gr+l14bXY+u2jNWQgOZ3l+IbDZZuB0Xkc88RsSySfxee/DptVxJp9Uj+tOdNu8nDGq650kkk+TSm8kk91DJPZdAr6/mnAp4nwjyYIcjpAp9Ny/s27MgFFZgSdzDcfKTByO/3Iga1q8dqiFxq5+sqbFMS3iQDx53mw4MqZJXzJBxfBE+EQsKWmL5qISh1zucQUGS0o647ExsZyOcWQ4QnbA7sBtO4ff+Sx4ywgck8Wp2ajLO332wskihCDs8xDyjm9gVREK8J7VC7FrOcv8bzy6kbRhoikKLruN9oEoa+qqmDO3EE05dUS/YzhsNkqDfhy28deV71g6hytnVCGBp/bUc7irjxW15ThsGmnDYDCRZGVtBUtPoU3JWAY7BlomextGME2LvDwPa9bN4PChTrq7I5SWBolGkkSjSe68eznZjMmeXUeom1GEZUpMw+LK62by2CM7uGLtDCqrQixYWMmmlw+xYFElXR2DdLQNoGkqV62fhTgLV1pVU1ly7XyWXDt/1P5r77ly5G+3z8W7/+ptI9vBIj93ffrmUeU1m8Y7v3DbmPaFEJRNL+GeL41NYnbrfddiWhYDySR2TWNbRwdOm42V71zBde9fSySdRgJpy0SRAtVn55oPX41hWRzu76ewOEQ8m0XkObnrL2/Fpqr0J5OY0sKS8qIa4F4MhBAUu718dN6KS9gLFZ/7AySSj2PJQaKxn5EX+ApCnInHyvHnVAg3Qf9f0tW7C8saIBL7CU7HBuz6iouytCJQYGRCY8IkJg+nag2hggRFySeU95+oSmDStTX18rU5297Yxg+fe4Nr5teNRF4GRv19rmRMk13dXSwsLB7z2/cm4tT352KazAsXjq/hkJLtne3cWFs35lg8m2VXd27Janp+COd5cOM9E6YEjktMgdczktHzWPAtKSU2VeFv37aB327ezZcfeoZCn4ePX7OSmoJTu++dDlURFPo8uTakRNfUYWNYmF9exF/evI7fvbGHn768nWvnTuM9qxZit419TLpTEZpjPWd8fkVRcLntCCEoLAoQCnnxBVwUFvk5sF9j43P7mTW7lOkzi7HZVIpLAhw+1MnLLx7EH3Bhs6moqsKuna1UVIXYtqUJ07Som1FMc2NPzmjwIoyvDrcdzXb+Zp+7urrY0dnB4uIS0qbBvp5utra3cXV1DZtaW1EVBY+u47RptA4OEfa4WVRUzJa2oywqLubH27dT6vMRy6SZGSqgeXCAhv4BPr1q1UWLZfJWQgiBrs/H6biKRPKPxJN/wOf54BkKHCe1Z1uAz/NhBiP/hJQRBoa+Tjj0ExT8F1zoEMKJItyY5GwwTKsfjbNbJhDChSK8WAwgZQabVo1Nqzqv/b1UhP0eppcUsLC6JBdldFgb49DP71D62/17uGnadEJO10iMHUtKfndgL93xGA5N45qqWib62D3eUM+7586n2n/c28WSkqca66nv70MVghtqp1308OZTAsclRhFMqEEs8Lr52IaV3HPFIn7w4la+9exrfPOdN57zjHWi6ooQrKgtZ2lNGY3d/Xzx108wqyTMymkVo8pJKdk3dJSYkTrjc+flu1mxOhct0utzcPNti8hmTVxuOzfdupBEIoPLpbPhurkk4mnsDhten5PlK2vxB1woiuDm2xdhGBYul05+yIOiKNjtGhuun3tRhA2AG/7kqvOq+K0OBmkc6OdoZAinZuPKyirq+/o41NvLjFAIh6ZxoLeXxoF+PLqOIgTFXu+IStVps7G+pobf7t2DIgT9ySRLS0ou+hrt+SaWTmNKSUNfPzMKQqNyGF16NLyePyGZehbL6iWa+AXiHCJdCqGMtJfObCWd2Uo09iP83j/jQi8zCOFA06rJGoeRMk0muxPdNuesBB1F8aBpVRhmK1ImyGYPoqmVl20wrzNBCMHO5nYOtHXjPCHH1qyyMJ+66Yrz8ivpisrhgX7+7MlH+eCCxVQFgqRNg6caD/ODHVuRwLXVtSwoKhr3fKoQDKSSfOqJR7lv8VJm5hdgSskrR1r49tbNGJbF8pIyrq68+EkBpwSOC0w8naFzMEpbf4RYKsOhzl78LgdF/rGhgE8kkkzzmy27qQ4F0TWVrqEo+R7XaR8QKSWdQzEGE0ni6QxH+gdp6OqjKOA9rTS7qb6F1v4hKvL89MUSSMDrHH/G9kZ/41nFXlAUBV0/nmfG7rBhd9iGj6n4fMdtH7w+J1JKVqyeRiDoRlVz9ex2G/bhbrlcx/tnt5+5a+LZ4nCdfbCn8ehLJDAtK5fjxpXTZPgddsp9fl47egRLSq6qrubJ+sNUB4N47Tp7urvoisU51NtLvisXsjvodJEazpXTn0qSMU3sk1CbSmlypkaPF4P63n6ODA0RTedSACwvL7vUXRpBCIFDX4LDvppk6lniiQfRbbPPqU1F+An4/oruvj9ByhiR2P/gdKxDty28wIODitN+5bBrrCQW/x1u5+3jRhE9PRpOx3pS6ZcAk3jiIZyO9eRCo7+56YnEWVRTyiduWDXKA/BYFtnzQYHbzT1zF/DtbZv52ON/wKHZMKVFyjAQwMrScv5q9Vp0ZfzJhFvX+fNlq/juti185unHcWgaUkLKyCKBWfkF/N269XgugfA+JXCcQNSI0ZHsRBMaJc4iOlJdGJZJuauE5sQRfJqHoB6gOd5KUA/g0Ty0Jo4QtheQtbIU2EP0pHtRhUrEiBKw+dnb1sV3Xn6BEnsZlQUBfvHaTmrC+dyzeiGVoUDOsGf4/AGXgytnVKMNWx/7nHY21bdgScm88iJuWjDztEKDJSVP76mnobuP2nAeBzt6aeoZ4O3L5lJXGOLK6VWjAoEtrCih0J/7qBQFvLzR1MaB9m7cdp2/vHkds4rHWvUnzAy7B1vP230/FUIISkovT5/880l1MEi53z9qTbbSH0ARgqpg7vpVIfiTxYtHngHTspgbLkRVFOry81GE4LYZM3ho/37mFRZyqK93QoHDkgYZcwghVAQqkWwjCjbyHOc2YJ5vSv0+Dvf1cUVVxbCR3uWGjtf9JyRTL2GaHaSsc8tUK4TAYV+F1/1eIrHvYVn9DAzdTzj/B2c5+E/+vC7nDQzFvoNptpPObGYo+i38vk8hcIwr7ORcoQ1AGxPR0u28hWjsBxhmK4nUk8QSv8HjunvYCHb8tqRMAeZwDpnLE49DZ2dzB1/4yWN4T0jcNq04nz/dsPw0tSdHyjB424zZLCsp49f7drO3p5uUaRB2udlQXcudM2YTcIz/m0DOBmR1WQWryyv45d7dbO/sIJZJk+d0saa8knfOnkuh23NJNE5TAscJdKd66Ep1k7YySCQHoodYlb+cvZEDdCQ7iRkJFgcX0BRvIWDzczTRztFkByE9xJ7Iflbnr2BP5ACaUClzlqArOh22A7z/2unk6QGW5x0PfyuEYEVNOStqykd++LI8P5+8ZtXI9juWzRvVv8k8IKqi8L4rFo17TAjBxzasHLV959LjqchrCvL4s+tWn/acRxN9tCf7T9uXyxE5HBVTIE74P8exAFDHYkpYw8dPDAx1LEdJru6xjLjipHZzxxUmH6JeEWLs8sdw3RMDxZ34tzLOcokqBDdNr6MjGmNOODzhLCZhdNIceRgLE4eaj0+vRj2H5YALhUPTyJomyaxB0DlxMKNLRU5AWI3DvpRUetPwoHmuKPi8HyOZ2kjWOEAqvYlo/Of4PB++oBooVS3D7/0U/YN/C2QZiv4n2ex+PO73ottmIoQLsLBkHMNoJZ3ZSjZbT37wm2OijqpqCQHf5+gb/EukTNE/+DdkMjtxu96OplUisA23FR1u6w2SqRfwut+Hx333qLaOx3g5JnCaSJlFyhjHY80YSCuKJazhIGzHvF3GvoO59o7/kxggs6N+O8tKYllREDYE2khbxUEvf3XHVWPuncdx/jSex2zqFhcVs6iomIxpYkk54gZ7um+KNRxfY3Z+AV++8moypok5HJvJNknHgwvFlMBxEhkriylz6a7z9DyCtgBHRTtO1Um1p4qwPUTUiLInsp8lwYUMZYc4ED2EQHAkcZSkmSSoByh0hHGpTuyKTtgRosyZ82s/eSZwIqfbniynqneqc0w2qNiugRZSZvas+nYumIZJIprEsiSapuLyOc/qHv2g4SX8Niev9TZwU8l8dg0eYSib5M9nXEdAd9GdjvLLptdoiveQb/fwrsqVTPPmUp/vHGjl4aPb6UvHcGt27ihfwrL8arKWyb8eeJKl+dVs7DrAUCbBslAN76hYjl29uK+Zy6ZTm5d32nJevQpTZrBk5ryEJr8QNPT3Y0lJ6+AgkVSKIu/lN/vNpa6/l1R6M7kZ/7m2J1CVMAH/F+jt+wSSFJHot3Dar8Rmm3XBBgwhBF73uzHNbiKxbyNlikTqCRKpZ1AUT06okCaWTAznUTGGPUrGap6EELhdd2JaA8NGsDGi8Z8Qjf8SRfHlbF1kdritJMdS1ntcd49pCyAW/3nOVkZGsaxcHUtGh+tCJnuIjp7bh41fnTnDVcWLx/UuXM5rR7WV0xp9HdPqxLJiSJlEyiSG2T1SZij678TiP0UIZ67N4bDzQf9fM7/y4oSfP7ZM4zhLT5Jjz8lkllQvFpdPTy4DBAJd0ZnpmU6BPZ/gcEbX2b4ZHE160RUdVaj4NC+17mqEyAklRY4wFhZ96X5W5i1FUzRcqhNVqKwPr6Un3YtHc5/yQ3Fshpwys0SzSWJGmoyVixapKSou1Y7P5sSp6iPxOC62pCqlxELyRn/jRT3vsXNv/O3rtDd2oTt08osDXP3OVWd1Dw5Hu8jT3awKTeOf9j/BF2bfyB+ObmdzXyPrCmdy/55HmOkr5uPTN7C9v4W/3/0w/770vQT03FLUusIZlDqDbOlr4p/3P87/rPwguqKxc6CV5lgvH6m7iqxl8g97/0iNp4DVBWPd0yZ7zTAcyMfMEjfSxI00GSuLIS0UBJqi4lBtuDUHLlXHpmiTCtWd08xoKEiktBAo9KV2YlhJwq7lqGcRqvtCUB0MsLn1KLH+Ad4xf+6l7s64CCFwOq5G1+eTyWw7b226HNfgdt1OLPErTKubgcg3KMj79rCm4UKhE/B9Bl2fSyT6bTLZPUiZwrIGgcETe4gQHnTbHCYaRoTQ8Hn+FN02k6Hof5HObM0JCsPJ4U5sSxF+dH0Buj5v3LbSmW0kUk+cot8ZDKNpzF67vhg4SeCQCRKpx7FOsfxlWX1YVt+ofYqST8D7aVD+/1/ivVBMCRwn4LV5mKbWUOzMRTnUh9XRmtCocleMKncMv8037t8n7htvPxwLLWtxJNHHlr4GtvU30hjrZjCbIG1mMSwTCahCwa5qeDQH5a58FgQrWRGqo85bhF2xXTDBQ0qJIU1iRpqeVISWeA+HIh1s6x/7YgP0paM8fPSNs3a18moOriqcgzaBMVQiluKGe6/Cl+dBKGefUVcgWBisZLqviN8f3cby/Br2DrbRn4nTFOuhKdbDB2rWoAqFOYFSftH8GgejnawM1TI/WEHMSBHJJJnhKyZjmcSyKfLsHgSCt5UvZmGwAgnM9pfSHOs9I4Hj2DPRl4lxMNLO3sEjHIp20J7oZyibJGVmMaSJJS0EueRpNkXDodrIs3uocIWYGyhnUbCKKk8Yu6KNe5+cWiElanBYryERqHhtVQihokwqUNOFx7Qs3LrOvUsXEc9kGEimyHddvOipdn0RBXnfATitMagQbkKBb5I1Goa3dRTFP6ac2/W24UH69G2CjYD/r3E6NgAShMb50KCcityzYsPluBGn/SqyxgHSmV0YRitSxkHYUJU8NK0K3TZneHlk4uUEIVQc9rXY7SvIZg+SzuzAMFqwZAwhdFSlAJs2Dd02C00rBcZfAvR63o/TcdUZX49tnHusKvmEgv+ClKfO7zP2WnQU5fSawykmZkrgOIEC+8WJVJgbyC12Dbbwm5bX2NLXQNSYOJyvIU3SVpZINkl7coDX+w7zk8YXmeUv466KFawJz8RxjoKHlJK0lWUgE6c9MUBTvJvD0U6aYt20JwcYzCTIWMYpVe9HEn18Y9/DZ92HSneI1QUzJhQ4nB47v/m3x3D7nBSU5nH9+9ci1DO/ZkEuBboiBLqiogoFZdgOI5JNMpCJ84OGF1HJJfsrcQWxK7k0579ofo1XexsIO7xICUkjM3JHVCHItx+PcaIpykjY99NhSYueVJTNffW80LWPfUNHGcwmTls/K01SVpaokaQnHeFgpJ2nO3fhVHVm+Eq4o3wZ68Kzcar6qOdDERqKGP36a8qlylQ6Pn/Yd4BIOo0AYpkMs8NhavMv3gdfU4vRXGODuI1HLi7HHHR9zqnL2Gah22ZNuk1NDaO5bp1U+fNJLp+HC7u+eFhLcI5t4cCuL8CuLzir+nZ9IXZ94Tn14xiK4sLlvOG8tDXFmTElcFxkpJR0pYb434bneKpj51nbQqSsLNsHmtg92MKKUB2fmH49tZ7CsxY6LCT/uO8RXuzeT9xIYUxyoLxYCCFYdfNiXF4n2bTB/CtnIk6VoegsCdm9FNh9fHHOrYQdOdflY1qmjuQgv27ZzD8veTfTvIW0xvvY3n9itNUzc407ps04GGnnkbatvNR9gN509LzYUyTNDDsGmtk92MqSvO18euZN5/R8XApWVZYT9nhymUyzWQZT6dNXOgXHjQWPcXot2fE6pzI+nHx7lzvHAg/mOJaG/twmMrn/h1sUx/5/c9+n88XopIcCRYizdrEV5IzPlZPqW1Ie/wHOw296LkwJHBcRKSU7Bpr5xr6HaYx1n77CJDCkxSs9B6mPdvL5WbewNjwL5Sws2XOC0CBD2cTpC18CpJS8/Pst5BUF8PhdPPfLTbzt49edlYbjVFS681lZUMs/7P0jV4anY0qLrlSED9WuxaHacKg2NvXU0xrv45WeeqxxDObOhGe79vAPe35P3Dy3wXQiTGmxue8wX9j2M/5+wd3M8Ze/aT72RV4vXbEYf9x/ECnhxhlnZwtzIgcjT9ESfw2H4mdN4SdRTxMbImPF2dTzbVYV3IdDHb00KrHY0f8rulL7KbDXsST/fWfdLyklg9kj2BUvLi1nIxDLdmNJA6+tmJjRBYDXNjZBoJSSuNFH2oqQp1ef0+/7wosHePzJ3RiGSXVVAR/7yNVjMh+fyTV1dUd46OGtNLX0YtNUrt0wh3VXnp+cI292pJQ89sQuOjoH+ZP3X8mV5ZX87PZ3oCnKWXlkzQoV8JPb7xqVkFRKyR8e2c4rr9VjGhYL5lfwvvesvmgBEk/m8ory8/8xUko29R7iSzt/ed6EjRPpTg3x97t/x1Mdu3IS7f+HZNIG/pCPQNiHZZ39QL+6YBqlriBezcE1RXPQFIX5wXJm+IpRhcKnZlzLHeVL6EgO0ZeOsyhYmbOR0N18Zf4dxI00DdFu7q5czgdr1+LW7KhC4briuYQdxwelFfm1zPSfIjy0gNm+MuzqhTfQbEv287U9D9GZGrrg5zqfdMfizCkMs6ikiMN9/cQzmZNmhWdGrfcq5vhvoy/diJyEFs+SBt2pg5hyrCZSoDA3cDuV7pX0Z1rgnDRTkm19P+dIfPPInvrIs+wZ/AMAB4aeYP/QREaTkq39P+Wp9q+SMiPn0AdYML+C9793NX6/i/qGLs7lU2KaFt/5n+fZsesI666cweqV0ygoGB3wMJXK8sqmeszLMsbK+CSSGTa9Wn9O36BjpNJZUqmcXU6B282qsnKWlZSeVYRgn93BytJyVpSWj4rIu3rVNO5592ok0NxyssHuxWVKw3EROKbZ+L97HqQ3HZ2wnFdzMs1bSJ23mBJXEI+Wi4sQzSZpS/ZzMNJOQ7SbxASz4aiR4p/3/5GA7mZF/rQzmukIBMXOIDWe8CnLWVJyNNE/bmZYh2Kj2Bk8a+m5xDlxnhghBGtuX8prj27DMCyuvGP5WS2pCCG4pWzhyPZ7qlcBcGX4+KzLodq4umgWVxeNXWufEyhlTuB46u5ZJwgU99Qcj2EihODG0tGJ4Mb0BUGpK8j6ojn8tvX1ccuoQsFnc1LqzKPcnU+JM4883YNDtWFhMZRJ0Jro48BQG83xnmHPpvFpjHXx48aNfGHWrW+a/CoBh4MXGpowLIs8lxO7qrKioiy3zGIO0pXcS1am8NmKKXBMRxU2pLTozzTTn27CpeVT6JiFpuTy99iEA7vqHRV7SkpJd+oAuuImoJcD0Jncg0vLR1dcCARxo5eO5G6caoAix2xUJWcTo6tudGVsYsacPVAHPamD2BQXxc652JRTRwrO+YDJE7blyPapltlSVpT+dBNurYDu1H4qPSsnLHs68oJuggEXr7x6mL7+2Fm3A5BMZTlwsIP3v/cKbrx+3rjX3tzSyy9+/TrLllaPRBK+3Dl8uItfP7iF5ctqOJfXSAjBHbctQUp5yqzc54IQgnCBj1C+l/w8N6Z5aSejUwLHBUZKSUdykH/Y9/CEwkZQd3N72VJuLFlEqSsPm1DHXS/OWAaNsW4ePPI6T05g/zGUTfDP+//Ifyy9lyJH4IwCT31h9m2n1Y7Eskk+/Pr3aBsn8Nd0XzH/vvRe1LNMqS0AXRn7SB6b0fpDXq7/wDoA9m8+TEFp3nlfUrnYCAS3ly3jifadI7lpbEKlzJ3P8vxprMifxjRvEUHdjT6Bx0lu8M2wd+goP2t6kdf7Dk/4Oz7dsYt3VKyg1jtWNX85kshm8dh1gk4nS8tKKPPnPD/SZoznOv+BPL0aXXXTkdiF31aKQ/VzOPoC+4YepdS1kObYazRpL7MqdB+qMrEm6VDkGQJ6+YjAsW/oUcpci6lwLydrpdjR/yvy7TXsTzxKiWshi/PePWEQLiklnam9bOn9McXOecSNHg5GnuSqos+jn8alVSKxhoX5ydrydCcP4NZCVLiX0xx/jQr38gsaIMw0LQ4c7GDzG42k0wazZpawYlkNdnvu+Ywn0jQ199LRMUg8kaGltZeXX6lHUQUL5pXj8ThIJDO0HunjyWf20D8Q45VX69FUFZtNZfGiSvRJJEOzLMne/W3Y7Rp1tcftk6SUHG7oJpnKMHd2GYoiME2Lvfva2LK1iaxhMnd2KcuWVKPruT739cc4crSfkuIAL718iI6uIUqKAqy7cgZ5eTmBMpE4oc/9cV7eVI+qKOh2jcULK7ENJ3NsbOoGIQj4nDz/4gE6OgYpKgpww3Xz8LhzHj3NLb0cOZL7hvoDTubNGRuyX0pJZ9cQr21uoK1tAF3XqKkOc8XqaTgdOj09EZqae1m4oGLkfiWTGXbsOsKsGcUEApPz6JJScuRoP9t3ttLW1o+mqcyeVcKyJdUj6SKklNQ3dOGw23A6dZ7feIDu7ghlpUFWrag4zRmOMyVwXGCy0uQ79U/TNMEyyhx/GX85+3am+0pOGT9BCIFdtTHTV8Jfzr6dlaE6/nHfI/Rnxs5CWuI9/KDhef5y9u1okxz8hRDo4vSPQ8YyJuyjIhTsim1CL5OzxcgYvPHMbtKJDN1HcirB3rYBpi+u4Tyf6qIjhKDWU8jqgum80dfI6oLpXF+8gDn+ctyafaTM6dpwaXaW5tUwx1/G9xue54Hml8f1cIkaSZ7v2kfNm8SA1LBMktksAYdjlHrfkCmSxgBVee+h0DFr2ONGYMgUuwcfYnXBRyl0zCZrJXi07a/pTddT6Dz7sO0Lgu8g7JhJlecKnu34OnMCt46x6TiGxGLXwO+o862nyr0SQ2Z4sv0r9KQOUuoaPwow5Oz6dvb/hsOR5wGIZDuo8qyesHyujkVL/FXK3UspcS1g39CjpK0oDnWsS+75QErJk8/s4acPbGLxgkqcLp3v/+hFtmxt4s8+fg26rtHePshvfreFRDJNOp1l+85WWo/0Y7OpVFcV4PE4OHCgnYf/uJ2m5l6GIkmeeGo3iqLgduvMmV06KYFDCHh9cyPbdjTzL994N47hnEzptMG//ddTzJ9bzrw5ZViW5JHHdvDr325myaIqdF3jO//zAtt2tPKxD1+NzaZy8FAn//xvT1BaGqQw7CcYdPH7R7bxyqv1/P2X78TptLF771Eee3IXjY09DEUSPP7UbhQh8PlyAsMxgePxp3bT3j6IEGCzaXg8dnbsbOWaq48/fx2dg7y06RB797VRWOjnm1+/G+2EyZOUkt17jvKNf34Mj8fB9LpChiJJGpt6WL60GqcDdu9t47v/+zzf/s8PkDd8v/r743zjnx7ly1+6nUULKyf1m5qmxU8f2EQkkqS6qoCBwQT/+K9P8Pa3LRm298j16+FHtpNIpEkms7jddpxOne07W1m+dPL5jaYEjguIlJLXeup5rmvPuMdn+0v5+sJ3n5EmQgiBJlTWF84FBH+3+7ckzbH+5E937OLW0iXMC1S8KQaWU6HZNOZfOZOdL+7nmveuQVEUNj+585IZPp0pUkri2UYMK4auBnFqow03VaHwienXY0qLYmfwjEKin8gxwePD09bTkRzgmc7d45bb3HeY99esnZSAeanx2R147faR8M7HcKl5LMl/P1v7fo4qbMwK3ESleyVpM0bWSuK1FeWWUBQnbi2foWz7GQocx8+lKTpurWD4/ubcctNmdEKBw5RZhjJH2W/00hDdCOTckC156hgaQsB03zVUe9cAsG/w0dP2Mm3FaEtspz/dTGP0ZYYybXQnD1LuXnZB3vve3ig/e+BV3vee1dxw7TyEgLVrpvM3X3mQq9fNZMmiKqbVhvnyl24nEknypx/7Ie+6ewVXXTlz5BoBFi2sZOGCSh741atsfPEgf/e3d2CzaaPKnA4hBGvXTOfRJ3ZS39DF3NmlCCFoaOymvX2QT33sGgA6u4b45a9f5yMfuoqr1s5ECFi1spa///ofWL9uJnOHtQtDkSRvv2Mp77xrOYoiWLViGn/z1Qdpae1l5oxiViyrYfnSGn7w4xfZvqOVr335DtRhW4uT+7xjVyt//Re3sHJ5LYoiMAwLTTuudVq5vJYVy2r51nefo7G5Z8y1pdMG//vDF6mtCfOFz9yIx2NHSshmTXR94lnWyX5Tk0FVFT79yeuw2zVUVcGSku99fyMvvnyId961fFRSzK3bW/jbL97G4kW57L+GYZFITH7p7fL/4ryJSZlZftb80rjr6n6bi8/Puu2MhI0TEUKwLjyLm0sW8dsjY9f/E2aGB49sZk6gHPUCp7a+0AhF4Pa5WHHDQpThdd61dywf+fvyRxLNHKQr/iSa6mNO/lc50YhAiJz9zPnCrti4t+YqXu+tJ2qMze1xNNFHJJMg5Bh/wLycsKSkN57AsCzmFx9fBhJCodpzBeXupXQm9/Jqz3dwayF8tmIUoZGxErjJx8IkY8WxK6fOziyEMiIQSCxS5vHlT0saZGXOe8uw0lhYaMrEeWcUoWJXvSwIvoNy19JR+0+HS8sjqOdU1E7VT9I8tZFvd+oAHq2QFQUfQqDQEn+d5vgmyt3LTnuus+FgfSexeIpwyDtigCgQ2O029h/oYMmiquEYHsODsMgdP9lG4ViZ4QIIMbbMZKiqDFFTVcDGlw4yd3YpUkpefPkglZX51FTnEk/u299OOm2QF3SP9FlTVVQtp9k4JnA4nTZWragdsSUpKfZj01Qi0eTIN3qyfS4pDrBkUdVIW8e0HydeP8gJhavOriGaWnr4m3ffhsdjH7lfdvv5H7KFELhcOqlUlr6+GOmMgXt4+2Sbj8qKfObPK0dRjl/XmYxfUwLHBUJKyfaBJvYOHhn3+O1lS5ntLzunWYimqNxVuZKnOncRyY4NHPZq7yE6k4OUut780fGklLzx9C6WXDMfVVPY/sJeVtyw8LQ2HDlPhFwcBYmJQB1Z3z4WRyG3XwFyiY1y+y1yQoFEYiFQT2jj2DmVE9o8Xi9X/nh7QigUe24CJH3JVy/E7RmFEIIaT5h5gQo29R4aczySTdKfib0pBI6hVIrZ4QKimQyxzHFNXtzooyO5m4CtDFVoqEIHJHbFQ6V7Obv6f8PswC30pA5hSoNC50yktEiagySMPkwrS8zowaH6sCte8vRKGqIvUuycx1D2KP3pRvBeBYApDfYPPkadbz0N0Y3k69U4VD+mNEiZg6TMQQwrRczoxa64sSkupvuuYffgQ6jChqY4iGW7qHSvRFfHGphOlpjRQ1dyHwCKsJFnr6I59iqVnpUU2KcPa3QcPNPx9eFllfP/+/b1x0kkMvzbfz01MuhIKVFVBfUS2FPZbCpXXzWLX/3mdd737lyqg9c2N/L2ty0ZGeT7+mPEYin+6d+eGBEQpJTYdW2U4blu03C5jkdNFcMxK84mJJHHbR+l0ThTIsM5o0Ih7wXXUGcyBn94dAfPvbAPIQQOh42Bgfi43mBej+OcjHvfsgJHMpPlpb1NLKwpwbIkRcFTz4DOFAvJ4+07yI7jzeG3ubildMl50TtUuELMD1Tycs+BMccGM3G2DzRT4gy+qZdVpJS07G9j4+82032kHyEgNphgxQ0LT1u3J/ki0fR+MtYAyexR3HoNtYGPogo3GauP5qEfkcg2Y1MCVPjuwavnvFWah36EUyuhP7WFpNFOiedWwq711A/8B4qwkTEH8Nvn0Zt8kSr/BwnYF9Gfep226IMYMoZNCVIT+Agu7dIsaalCYWFe1bgChykt+jPxi96ns2F6QYiqYIBtbR1MD+WP7FdQ6U3V0xR9BU3RWZh3NyF7HUIoLMp7NweGnmTXwO9waXmsK/wMdsVHxoqzvf+XJIwBPLYCtvb9jAJHHfMCdzDNt56UGWHX4G/J02tYlP8ePLYCFGFjhu868uyV7B78PU7Vz6qC+1BQiWY72d7/C9JWHEWobOn9ERXuZUzzXc1033Xoipv66HNY0iBkrxsT2XU0gpC9Do923EvMr5fitAIABPRy+tKN7Oj/NQAOzc/y/D9BE/ZhI9HcM+a1FVHqWkjSGLggAofTYcPndfD1v7uLYHC08KTbLr5BlRCC5Uur+dkDm9i15yiappBKZVmxrGZkEuBy6gSCbr759bvxekdrpkbZioixSyPn0LNzqm3Xc8sYyWTODXyib8jJIoFhmGfkYiyl5LXNDfzsgU18+lPXsXRxzsblsSd28ZsHt4xb51zu0VtW4DhwtJv2gQglQz5auge4eelxF0gpJR39UQzTJOBx4nXaz3jQ6E/HJsw5Mi9QTplrYhfQM0EVCkvza8YVOCSwtb+Rm0oWvckXVaC4Osyiq+cwY0kNmk0lWOiflFts1hykPfYwcwu+jkMtZG/fV+hNvkyh61oOD/wXDrWQWfl/SySzl4P9/8CC8L9hU/wkjTb6U68zLfhn2BQfinAgsRhMb6Mu+BlaIw+QMjoIuzbQGX+CgH0RDq2I6sCfoitBWiI/pzXyADPz/uoi3J2xCCGodBUgEGO8HaSUpMax+7kcaR0YJJbJsL+7hxKfF78jN2A4VD8rQn86quyx98mmOJkbuB24fdQxXXGzuuBj457HpjhZlPfucY8tzX8/ADWedaPa89qKWFv4mXHrqEKjxrOWGs/ayV0oOcPUEzmxbp13A3XeDWPqrCq4b9S2gsbK0Ecmfc4zZVptIVJC65E+ysvyTtDsnR2apmCa1khK9rMhlO9h0cJKXnz5ILqusXBB+Ui8DyEEdXWFZDMGbe0DLF1cdX76bFhY1oVzMS0M+wgGXLy2pYFZM8emHBBC4HTayGZMEok0wWGPlIbGbjKZM8u309jUQzDoZuXyWhwOG5Zl0XSB4nW8ZQWOsN/DQCzJ87sbWD1ztDVvJmvy3PbDeBw6dl3jhmVnFhlPSsnBSDt9mfHdYJflTxvJ+HquCCGY5i1CFePn7aiPdJCxDBwXIbjUhUIIgd2ps/aOZQz2RrEsi0Q0icM9cdKoE/Hb5xOwLwQEPn02KaMTw4oRSe+lOvynOLQwuhqkdehnxLKHCdqXAJKQax0+fc7IQGZYcVThxKtPx6mV4bXPwq7mM5B6AwBdzWcotYshczeGFSFrRTi2nHMp8OnO4UWh0Ugga43VvF2OmFLySksrK8rLGEwdt0eZjOfOZPaNLnBmfTubPpxJ2bO17Tpb0hmDbduaGYokOdzQRV9fjCee2o3X62DunFJC+V4qKvK5/tq5fPt7z9PeMUhpSZBIJElDYzd3v3054fCZaVVqqgvo7Y3xx0d3UjetkKxhsnB++YgB6WQQQrDhqll8818eB+Bzn75h1H2orQlz9VWz+M9vPcPtty6iqNDP0FCCxqZe3v3OFeTneSZqelxqa8I8+PBWHn18J9VVBRimxcL55ZOOyJpKZ9m2vWXkvvX2xXjiyV14PA7mzy0jL8+D3+/kztuX8JMHNpFJG8ydU0YmY3C0bYDbbllIMOCmpqoAu13jxz99heuvnUtvf4w//HH7qKWceCLNtu0tRKMpjrYNYFmSJ57ajcdjZ+H8CrxeB9WVIR56eCvPvrCP6qoCtm9vYeeu1guimX3LChyFAQ9XzKoilkwzs3R0sCtFEeiawuH2XhbUnCJS5CnYNdg6biwETajM8JWc1x8zZPeiK9q43ip96SjRbPJNLXBAToh74bev07i7FbtTx+lx8M7P3zKp+6gpbo6NJjnbipxdRs5o64SPhFCRJyyBacI9TvvDthm5XK25vgGWTLG3529x2coIOpZi1wrJZs4t6uO5ogmVcSWO85Cr5WIxPZRPkceDS7ed06x0itOTyRhs39lKIpkhHPYRDvs4WN+JEFBcFCCU70VTFe593xpKigNsfOkgQ5EkHredObNLcblGZ3q16RobrppFcfHELroLh0Ntb3z5IM88v4/KinzmzC7FdgafKyEEs2eVsmH9bKQlmTundNR7a9NUPvzBdZSVBnl5Uz3RaAqvx868ueU4Hbk+hwt8XHP17BHXWgCH08aG9bMJh0cvty9fWs273rGCZ57fh2FYTKsJM29O6YjAMXtmCaE8z4QGpem0wY7h+1xcHKC4OMCBQ50oiqCsNEheXi4B5K03L8Lvd/H0s3vZur0FXdeYUVeIbfg84bCPz336Bn730Bt87/sbKSz08af3rmXHriPk5+eEqEQiw7YdLWSzJrU1uXFu34F2VFWhtiaMz+dk5Ypa3vmOFTz2+C4kMGdWCV/8wi28+vrhUcLL/LllxBMZzmUC9ZYVOPYf7aZrMEq+183GvY3ctGTmyDFNVZhXXYwiBHOqCs+4bQtJfbRj3GNOVafIETjbbo+LR3NMGG8jbqSJGSkKuLwMBC1LYpkW2hms+6YTaVbctAjLtGjedxRpybMOzq8pXty2GvqSr1DsvplYthHDiuK2VZ1Ve1krSjzbRF3ep7GrBfSntnBsYD/RmFQeE3bkMav3C6f9eLMvowGoikLQdeZ5JaY4c7weBx+/b/1pyzkcNm69eSE33TAf07RQFAVNU8Y8yy6nzsc+cur2dF3jrjuXcvtti5Ay56KpnoW3isulc9+Hrpr4uFPnztuXcNvNi7CsXGTPE/s8rTbMtNrRffV5nXzivrHLWHa7jXffvYK77liKJDdenChcXL3u1NmA/T7npO6zzaay/qpZrLtyJqZpIQRomjpiQyGEYOniKhYtqMA0JaqWu3eLF1WNtFEQ8vLnn7j2lOc58Xogdw5FEcyYfqJXmOD6a+edts+n4y0rcChCoT+aIGuYdAxEefVgC8vrylEVhXTWYFdjBwtqS9i0r4W3XznvlIY7J5M2s3QkB8Y9pikKe4eO0Bwf63t9tkSzyQmTiJnSIjqOB8ulIDqUpL2ll6LyPNqae2k93M3K9bPIpLMM9sWpml7IYF+c7vYBisvzyWQMkvE0ldPCKKrCqluXYHfqbPzta1TPKZuUW6wqHKjKcZWpqrhQhROByrTgpzg8+F90x58FIagNfBS7mpsFaIoHVZzs+iiwKb6cbkNxowgdIWxoigddDRJ2Xc3+vq+hK0Fctkp0NQRA2uyicfB/iGebyFqD7Ov9MoXuGwg510z63h2b3VvDEWez0sSUJoZlkbVMstLI/W+ZZK3c34eiHW8mZcYlwbIkjz++k6NHxkbOPYbX6+DOty8bNfs9U6SUvLjxAAcOjD8RgZz79y23LKSk5Py5SF8ohBBomnrWid1Obks/gyWUcznPye6p59LWZIKTnY/zaJqY0OPl+O9w7ue5GNfzlhU48rxO5lQUEfQ4WVQj0NTj0q4iBNFEmp0N7XT0R3h88wGuXjgNp31yH5ykmWEoM37W1YFMnC/t/OV5u47TIZGnzK9xMdm9pZHIYIJQkR9rWCLX7RqdR/vZu62FeCxF6+EuFEVBStj68iF0u4ZlWtTOLiGdzJBfFOCWD2+gvaFrUuYRBe6rCbnWjhiKVfru4VgacadWxtzQ1zCtBIrQUYRjpFxN4GOjl1sAVTiZU/D3aMJNlf/eYa8DBU+wFoHGtOAnMawYQmiowoEp04BAV0NMC37ypLYmjuNwTLhIW1m6UkM0xXpojHVxJN5LV2qIoWyShJEmZWYwpIUlLSyZ05+c/PebXd4wLYvOaIyMaRL2uEclpTo/SF588QBvbBnfwBtys+c1V86goiJ/wjKnwzQtHn54Gzt3tk5YRlEEy5fXvCkEjimmOBvesgKHTVVp7RngcEcv00sKmF0eHomvIISgPBygIhzguqUz0FQF+xlI4AkjM649xaUgZ19w6YcdKSV1c8vY9XoDh/e2UVpdQHfHAKZpsfP1Rjw+J9mMgWFY5IfdhIr8KIqgdlYJoSI/8aEELz24mSvftgyhCl56aAvv+MxNqKeJba4K+4hQIoRAFcfV80IIBDaUk8JA56K5js1DkEv+lVvPPfH4cXdHFdsJbR0rI9DQ1dMPIsfy5RyMdPBi9z629DVwJNFHwkjz5hcdzo4DPb08XX8YTVFZV1PFvKIzX+I8V5LJLK2tfeckcESjKdraxtd6XmqkNECe9L0S9hGBW0oDK/0Cir4coVxeS7NTvLl4ywocTt1GyOemobOPI72D1Hf0cuequdhUFU1VmFtdxPPbD9MXSbB2Qc0ZGY8mzQzmZTDIH+Ny6Uk2Y5Af9lE9oxiXx85gb5RM2mDJmjqyGRNfwEVLfReJWJq+7gjrblrA0GAch0unv32ArtZetj67B1VTWLBu1iWPNGpZkh2b6mlr7mX+8hoq6o7nJ7EsyfZXDtHR2s+85TVUTAufwpdekjVNXuur51ctm9g90ErKGpuY762IrqosLS1lX3c3xnlIB342SCmpP9TBFVfUnbXNTUfHIEND42s9LzVm6lGM2HcQw8I0QsHm/SJCX5DblhnM5MMIrWZK4DhPSJlzVlcm+iZIiWFZaMpY25g3M29ZgSOaTFMY8LJyRiU2VaG1Z3BEw2GYFjsb2inO93HNkjr2NHUSTaTweyZnvJa1jElnenyrIISgpCKfkhNmiXOXVgOQP+xKl0pmyCvwIoH8Ai/FJ5Qtrgnz/r95O768Yc+Ry+AljA7GeeWpPcxdVs3GR3fyvj+/bkSbEh2MU7+njbfdu2bY0GviD0t7coBvHXqKjd17yZwnd9VjZ3uzP4V5TicHunuwqSp5zktnPFpf34VlybOKpimlpLGxm2z2MnVFtqIoWi023/8Z3iFACQDDkXqFji3wTWC0G/qxSL2Msh87pnG0GBu5Vxl17HjmD2UkZPjxsozU//+FRDYzvJRrI5rN0J9KUOUbX/OZNg1+Xb+bayumUeyeWMgzpcnLPY8wmO3Frji5KnwHDnVyWWIvBedd4Lj//vt58MEHOXDgAE6nk9WrV/ONb3yDGTOOx7KQUvLVr36V733vewwMDLBixQr++7//mzlz5oyUSafTfP7zn+cXv/gFyWSSDRs28K1vfYuysslnppsIKSUDsQQFfk8u0tqhVlZOH51id05VERXhAG29EdYtqEVVzt9s+mK+QuKEQNznp70Lh91hY/1tE2fTbNrdys6X9qMoCgVledx471WXND29UAR2h42C4gDVM4pH3RwhBJZpkUnn7GfUcaz4pZTsj7Txd7t/S+ME2YRHnQ9wqDpem5M83UNAd+GzufBodpyqjlPVcag6TtWGQ9Vpjnfzs6aX3tRCR1csRlskQpHXe1beC+eLI0f6SCTSeL1nJ/QcOth5nnt0nhFOhFI4RpC3slsx4z9GWhFs/v+L0MqB4Rm6sQcj/gBSDoHVi1AK0byfBiuGkXwYm+9LgIo0DmAkfjW8DUb0H1HsV2EmH0Fa3WjOO1EcNwEmVvoFzOQfkGRQ9StQXe9AiMnF27lQ9Cbj7O7txKHZqPXn8UZ3GxVeP0G7i5097czMC9MRjxLJpJidFyZtmtQP9rIkXMpQJsXhwT7mh4p57mgDCoKbq2dyaLAHv+6gMx4lY5kj72jDYB+aorC6uJJCl4eMabGvv5sKj5+GoX5mBAtwnGAhKqXFrqFNtCUb8WoBrgjd9NYSODZu3MgnPvEJli1bhmEYfOlLX+K6665j3759uN25ULjf/OY3+Zd/+Rd+9KMfMX36dL72ta9x7bXXcvDgQbzenFrv05/+NI888gi//OUvyc/P53Of+xy33HILW7duHcnQd7YkMwbP7W4AwG3XqSsJjQwGUkoOt/fx4q5GZleG6R6IceeV884sQY0ycbq0ancBn5xx43kL/HU6BDDdNzZS3dlyIQev093jo/Wd3PVnN+EOuBAwqUijFxKv38W6mxfQeribaXNKRx8LuFiwahqvPbuX2YurKK0KjToupaQl3suXd/2alvjEUf1UoVDmymNpXi2L86qp9oQJ2b04VR2bksvvcvJdOHYfX+4+wM+aXubNrOewpEQRCqo436LzxGiagqoqpNPHja37++N0d0fPSuDIZk0aGkYLlELk3B4zmctD6yGtfqzszuEtFWGbgRA6im0BwvtFMgMfAXmit1uabOQf0NzvR7EtJBP5Coq+BKFWYZmvIo16jruFR5HGoZFtK7sTabajut+PEE4QvuH92zDi38fm/QIIB9noN0E4UJ1vv2iajlx+nAS64sCm5AyU+1IJBjMpri+q4HcNezAsi0MDvVxRUkl/OommKOzu6+TGyuk8e6SBzkSUMo+fjW1NDGVSvGPaPNw2nRK3jxK3l4DdQdjpoX6wl2K3lxdbm0FKQk4323rakVIyM1gw0icBvNrZSmc8xtz8i2/DdD457wLHE088MWr7hz/8IeFwmK1bt7J27VqklPzbv/0bX/rSl7jzzjsB+PGPf0xhYSEPPPAA9913H0NDQ3z/+9/npz/9Kddck0sx/LOf/Yzy8nKeeeYZrr/++nPqo1PXePuqedg0FZfdNsYgtMDvpq40REm+/6wCfzlVfUKBQldtrAhNQ1fesqtZZ42mq/zs/ocIFPgIlQS55r1rLqnKVQjBjAUVzFhQMe6xOUuqmLOkaty6KTPLvx987JTCRp23iPdVr2VVaDpeWy5q6P9PKubJUOzzckVVBUcGh7Cfq+/fJAkG3ZSV5bF9e8vIvnQ6S3NzD7W14VPUHJ+hwQSdnYNjzlFRGWLHCee4lEjjINnYtwEQwoXN/zcg8hBCzy2vnJwHRmaRVgSh1YESRlErkTI1xrNrIlTnrSi2ZaMmelbqKRAurOz+4X64sdIbUZ1vP2/XeSokkgORbfyh/ftcU3g3y/JyMTgEggKnG5fNRqnbR38qyfz8IvKdLtpiEbZ1t5M0suzr78Zvd6ApCgVON9MDITZ1tLK3v4sZwQICdgcNQ/2Ue/20xyO0xSLoijoS1r3KF6QpMkCtPw+botIej+Ky6SwLl/GHxv2sKama0ObjzcIFf4OHhoYAyMvLZSxtamqis7OT6667bqSM3W5n3bp1bNq0ifvuu4+tW7eSzWZHlSkpKWHu3Lls2rRpXIEjnU6TTqdHtiORiaM8CiGwaQqPbT2AYZqsnFHJrLLwyLE8rwubqrD5QCvzqovPOPiXS7PjUHUS43iqJIw0aTM7rsCRMKJYWHi0iSPzTcQxV8oTByQpJf2ZLrJWmkLHxEnE0mYSQ2Zxa6c3CLtUj7sQgqvvXk2kLxfaXLfb3rSDr5SSl3sO8Hpv/bjHBXBN0Xw+M+tm8nXPm/Y6zwdHBofoiEbpisZoHhgg5L7w6uJM1mTatMJRAoeUcOhQJ+vXzz7j36OtbYBYLDVqX1lZHs5ziOtxvlH0ldj8/zC8JThtRD3hRnVcSzbyNRRtOpZxAJv3/4xfVpqM1rKpoIxNKCmtIRAaktx3XOhLUNSxwvwFQ0J9bCdD2T7S5vHfq9IXoMyT+zauLa2mOxHDqdmwKQpLwiXkO9z88tBOZucVUuT2YElJbzJBvtPFXXVz6U3G8dh0FhYUU+L2oisqVb4gZR4/ilC4pToXdNJj0/HWzMK0LByaxtVlNWiKgiFNQk438/IL3/TfggsqcEgp+exnP8uaNWuYO3cuAJ2dubXMwsLRg3hhYSEtLS0jZXRdJxgMjilzrP7J3H///Xz1q1+ddN+auwZYVFNCSdDHy/ubRwQOgHTWoD+a5JaVs3lm26EzFzhUnYDupj8TG3Mskk0SM1J4bWNVs/2ZbuJGhEr3DHTFQcqMowobumInacbRFBsgMWUuRbpN0UmZCeyKk6QZoyPVQqVrJqpQSVspnKobXXFwKLqDQkcFGSuNYWVxqm6yVpq0lcKuOklbSVShDbtlpjFkFqfqImUmRs5/qR90KSWvP76dPZsOYdNV/CHfpEObX24Y0uSRtq0YE+S9XhSs5i9m34bP5jyn6zPGyVT8ZqPQ42FPZxdrqivJnkEWzHMhmzGorAyhaQqGcfycDYe7ME3rjIJdSQmHG7pGtQNQV1dEa2vfeevzuTMcqn/Sz5tAKF4U21xUx3Vo6kdADH+vhQMp4yDTSBSkcQDkybGAxp5Hsc3GymxHc72bnIGqCVgX7R3PWGla4gfH7Ler2ogtrKYolHiOT8w8uh0pJSuLyin3+lCGNdvl3uOTxnJvYOTvUk9uf5nn+HHHCcNwgfN4Bt4qXxApJQ1D/awursCrX1pblvPBBRU4PvnJT7Jr1y5efvnlMcfGM6A73YN1qjJf/OIX+exnPzuyHYlEKC8vn7CtacX5PLr1AFsPH2XtnJpRx+w2DY9T56GX9zCvpmiCFibGrtoodQZpjHWNORY30nQkByl2jmedLDmSrKcrfYT5/lW0Jg4xkOmh2j2b1mQ9ppVFU2zEjAhO1cV0z0KOJA+jCRsBPURz/AD5ehGN8b1owoZL9VDlnoUiFLIywxv9z2JT7ITtZXSkmolmB1kYvJLedDs2xU6Jo4ptAxsJO8ooddbQENvNQKaHNQW3oA4/KpfSGmCoN8rqWxdjd+jU72geCW0upSQrMxjDrqS5eBl2VDGxd8ilpDsVYf9Q27jH7IrGh6atP2dhA3LP2pvZfgPA77BT4vdxsKeXxaVnl9foTDFNi7x8D16vk4GB+Mj+o8OaikDAfYrao5FSjjEYFUIwY2Yxhw5d3oakUlpY6aexsvVIsxsj+WuU7DRUx80g3EizDzP9LFZ2D2BDdVyN6rwLRZuGEE6yQ38JSh7S6gFx6oBtQghU5+1YmTfIDHwSoYaRVj+a6z2o9lNn3D1Vjp3JvkNSSgYyXfRlzvw3EUIw+wLZVgghqPXnjWyfeK2X47ftdFwwgeNTn/oUf/jDH3jxxRdHeZYUFeUG8M7OToqLjxszdnd3j2g9ioqKyGQyDAwMjNJydHd3s3r16nHPZ7fbsdsnLwFaMidYqIpgIJagunD0j5rKZFEVwdBJqtDJoCCY5S/jpXFSxhvSZO/gERYFq8Z5YATV7tnEjQjtqRYyVpqEGaUrfQQBBPUCkmaCfL0IIQQtiYPoipOhbB81njkU2Evx2fJImQkWBtawL7JlOHeHJGOlUIVGuauOrtQRUmaCPD2MT8vDsDJEjAHiZhSPLUCNew5d6SMj5zeliXryGu4lYOl183F5HDz1s5conVY0Kg7HM10Ps7n/eVShoaAQ0EMsCV7B4uAV2IR+Wb2cLfEeYsb4z1W1J8xcf/k591dKSWdq8E0ubsDBnj6ODg7h0nW6ojGKvd7TVzpHLEti1zVKSoKjBI6cLUbkjASOdDpLU9PoNAZOp42qqhDp9OURa0WxX4WiL57gYAjFZkP3fy23LWyAipXZjGU2ofv/AYQTafWTjfxfFH0FQq1CD/4nVvYACDuKVoM0Wjk23Ni8n0doNWPPJQLYAv+IzB5CWoMINYTQpo3brVwcC0lvuoPG+B46ki3EjCEsTOyKk4CtgGJnJaXOWoJ6CIWxkw9TmqTMOJFsPz3pdvZFtpCxcu9lY3wv4wnrQgjm+lfit40OAhfLDrFraBOWNAnZi5nhXTzhO2xKg+0DL5Ey4zhUFwsDVw5rr8e7Rov2ZDMHo9voSh3FlFn8tnxqPfOo9cxDG/7ejUc0O8juoU1Y0iKgFzDHtwxxGmcFU5rsGnyFuBFBVWwsDKzBqU7+eT8d530UkVLyqU99ioceeogXXniB6urqUcerq6spKiri6aefZtGinAtkJpNh48aNfOMb3wBgyZIl2Gw2nn76ae6++24AOjo62LNnD9/85jfPSz+buvqpDgepKcofY4yWNU2ypsXNK2eNZOY7E4QQLAxWogl1XLX2a331vLNqNfpJg7hb82KXTnTFkVsWMROUOmuodM+iKbYXp+rBa8sbcXXNCQQxSpxVuNTch7g/002lawaHYjup9cyjPdlM1sqSNpME9AI6ks1UumfSm27HlAZD2T66022krSRlzlpUoXEguo1CRzmq0Ch11o56oC+lDUfZtCKklNz92ZvpbOoZpfHKLS25eEf5h8haaeqje3m045ccTTRxe+n7sYnLY71cSkl3KoI5wXJKnbf4vGT2lUgORSbO2/FmocjrQddKebm5hQXFZ65tPBssy8IwLabVFbJ379GR/ZmMQVNjNzNmFE1aIOzvj9PTM9qerCDsIxj0XDZxORRt/FADQiio+pJxj0mzFSEcCK0K0EAmQCjDEUoFiDxU+/HJodCDJ/w9vnCTu6fO4wHHJkBKScpK8FzXb9k68AIJMzp+ewicqptFwbXcVPwBVEZ/y1/ve4oXex4mbkQxZGZU7KR9kc3si2we06aCQomzeozAMZTt4/GOn5KVGeb7VzPDO4EAR07geKH7QXozHeTphczxLR9X4EhbKZ7r/g2v9z1D2hodNO61vqeocs/ilpIPYJ/ADVYVGq/3PU1X+gg+Wx5lzloCemjcssfoS3fwh/bvkzTjlDvrWBJcd8ryZ8p5Fzg+8YlP8MADD/Dwww/j9XpHbC78fj9OZ05N/OlPf5qvf/3r1NXVUVdXx9e//nVcLhfvec97Rsp+6EMf4nOf+xz5+fnk5eXx+c9/nnnz5o14rZwrHqfOH9/Yz74j3UwvLWB53fHlF1VRMEyLJ984SFnIz+o5VWfc/nRfMSXOIK2JsV4I+waP0hjtGpOmPqiPtoAvcR4X1hYGrzztORedUKbCPR2AkL2YGs9sAPLtuQ92NDuAU/UMh+wxWRC4YqTePP/Kkb8L7OOrsJUJxA5rgkH0XMlmDLY/t4fssJuiBBp2tvDeL76NE8Oj2BUH1a7pqIrGDO8CSpyV/PboD5jhW8Bc35LLRsuRW+oYn3y7Z8JjZ8JAJj7hss2bBUtKwh43YY+bUp+XodTE9+18YpqSdCrLzJnFPHzSsUOHOrnhxvmTakdKyZEjfcTjo/tdUxPGZlPJGpeHwHE2qPYNWNmdZAY/A4hccDDPxxHKhRcKLUwe7/gZW/qfQSJxqz4KHeV4tAAAMWOI/kwnUWOQhBnDrfnH1QJoQiOoh0e+u1FjkN50O/+PvfOOk+Qo7/63Ok3Osznv7d7t5RylO510pxxAEkhkI8AGg21sY8Dg1zbGGDC2gReMjfGLjYgiI4FyTqfT5ZzThtu8O7szO3m66/1jZtPt7t1elED8PtLndrqrq6uru6qeesLvAQgZpXj14IRrFKFgVy7djn8q5KwcT3T+kFf6HkMi0YVBmaOOgB4mI9N0pVo5Gd/Pj1u+NhK+eyYcqosF/qt4susBYtkIh2LbWRm84awkhAej20maea3eAv8a9EvMgXLJBY7//M98aNX69evHHf/f//1f3vve9wLwiU98gmQyyYc//OER4q8nnnhihIMD4Ctf+QqapnHPPfeMEH995zvfuWgOjmFUhnzMqSxhQW3ZhOVTEQJVETgM23nlUBkLj+ZgXclsvn/yxQnn4maan7Zs5lNz3zxlWvnLCbfmZ1kwnx5ZP4dt9UyoQkGbIn9JIpchJ000Lu0zpZMZ2k90M3NpQQCTcNplO6t/myIU5vuW83zPI+waeIW53iVXjMfhXNAuIYncZJBSsqnnCN2pwct6n8uN3xw8TH8igRCCoUyGucXF1AT8V+TeqVSW+vpibDZ9nOnj+PEusllz2pk1jx7txLLGq+ZnN5XlqatfJxqOC4ISRPd+FmQKkCBsgHZFhPru1Gl2D7yERFLjnMXdlR8mZCtBKcw7FiYpM0FHqpmjsd0s9E0ePr8suIGlwWtHfm/rf5Zfnv4vAFaFbmRN+OZJ769c4vntTEgpOTq0iy39TyOReLQAd1b+EY3uhWhCRyJJmDE29T7K8z2/wpzgkDuKBf41vNz7MAkzxs7IiywJrMeYQojIyjT7BjcD4FK9zPYuu+Tv87KYVM4FIQSf+cxn+MxnPjNlGbvdzte//nW+/vWvX8LWjeLw6R46IlGqwj5OdUe4NTjqeZw1TbI5i2wuw+neQZbOvDB201vKF/NQ2zaik6SHf6pzL+tL5nJ10awrvvMWQkz50Z0LhqLh1ibPdNqfiTGYSWB3XNqMnk6Pg1vefy26kY+kQeapzs+VS8VQbJTaK+lKncaUOZTzFK4uF6bqP4Ce9OTq4elCSslANsGPmzf91id8W1xeRpnXgwDi2Sz9iYnj6HIhmcpQUuIlFHLR3j4wcryjY4BoNEk4fG5fEinlBMdQTVNpnFmKaVoTIld+m5Cfs1QQl3+3fyYimW7SVv5bWOi/miLbeE2xioZL8zLDNY8ZrnlT1pOPKFHO+J2HQHnN/NYsTDb3PUFOZlBQuL7kXmZ7Rhd/gcClermu+G560x3sGXx50nqEEISMEho9C9k98BKnkyc4nThOrWv2pGtOR/IUnal8pOgM9zyCxvlzzpwLr232q9cQYa+LSDzJc/tOUOwbr8Y2NI2GijBSShbMKCeVyU1LkBoLIQR17mKuL51c/Zo0M3z54G84HOs477qnAynlZalXEQrlk0bYwEA2wd7B1kt+X0UR6IbGib2tfP/zv+K7n/sFLQenZy6wqw6yZ9hnX0sIISi1+9GmcN46Eu24qEzDWWnyP8ef5Wjst99/o8rvYzCV4vs7d/OLvftxXCHiL4B0KovTaaOmZrzNOxpN0tExMK06kokMLc3jQ199PgcVFcGCwPFbrOF4DWGo9hETSXvyBKacfH4WQoz8/9uEwWwfrYk8R0/AKGaub8WEZ8hnvtZYFrz2rBoXgcLSwHpUoZGTGXYOvDjpXCilZO/gq2RlBgWVhf6rEZdBPHjDChwOQ+eO5XN461ULcNkNmnsiIx9tKpNly6EWQl4nJ9r7+MWLe0legEe5guBddWunXKBPJ/v5m10/YkvfsSmdCM8HUkoSuTS7Iqf4jyNPEMnEz33ReUIATb7JfTssKfl5y2biZvqyCDv7Xj7MbR+4jrf+xa0c3nESaxq8DPHcEHbVOaUn92uBSmcIrz65o9epeDfb+k+cd/9JKUmbWe4/8Ty/aHn1dSJeXTxOD0aZU1zMwvIyjvX1kc6dv/B/IUhnciiKYOas8WkBcjmLY8e6ptWGnp4YfX3juXgqK4N4vQ5M08K8Qrwiv2sotVcTsuXfy86BF/lZ23/QmjhK1spckW/jcqMn3T7iR1HmqMWpTu7XJYSg2FaJU5va70sIQY1zFmX2GgAORbcTzfZPKJcwhzgU3QZA2FZKnev8Ce6mg9c+1vE1wqHTPRw53U1NUYDeWAIBlPk9GLqGogiK/W56BuPEEmmqi/0kMzmc9vNTyQshKHcE+OPGG/jcvl+QniTleGuij7/e9UNuq1jKXVUrqHKGUMW5syQODyxTWkSzSU7Gu9nad5xXeo5wYqgLm6pzd/XK82rvdJ9pSaAOh2pMuhPf2X+K/z76NB9s3IhDvbThqKqu8uA3n0Q3NDqbe3nwm0+ydMM8qpsqJi2fMOOcTp6i0T33dRHWO4yQzc0cXwUv9UwkGcpaJv955AlqXGGqneFp9d9wxtn/PvY0T3TsnpJQ7LcRAYeDJ44eAwm6qiCBq2ouP/tkNmPm+TJmlqIoYpwfxtFp8GdIKTnV3EsqNX7Mz5xZiqYpWJb8vcBxgXCpXm4qfSe/PP1fDOUG2TXwIgeiW6hyzmSBbw0zPYvw6aF8NN9vmXYDYCDTiyxkzA0ZpZwtNtChunCoLoZyU/trGYqdxYF1tCWPE81FOBjbzqoxzqP5vE6H6M/k8/3M9a28pKGwY/H6mYWvMIq9Lpq7dQ62deN22HAY+siu0KZrLJtZSTpngpR09MfwuS7M50EIwYbSeZyMd3P/iecn1WTEc2l+3LyJR9t3ssBfzdLgDGZ6SwkaHpyagSpULGmRsXIkzAyDmTidyQFOxXs4FuvkVLyH/vQQ2TEhuLZLEFo5FYa5Irb2H59wzkLy4+ZNnBjq4t6aNczxVeLW7SMmBEtKLCnJSZOsZRI300QzCfozQxiKztJg3ZSTxDV3rSCdymLmTBRFIBQFt3+ipkBKiSlzvNz7BLHcIEsCV01S22sHVSjcXL6YV3qPTvo9HB/q4uM7vs8fNmxgVbgRl2afdMpJW1la43083bWPh0/voOsMJ9ESu4+0mWUgm5jk6gvDmTtIST46yRzzf9YySVlZUmaGlJklMgnjLoXrjsQ6yFomdlXHruoYioYmVFShoCoK5T4P9y1bcsXdfYfNHdU1YVwuG7HYKG/KiZM9pNM57OegJj9ypPMMoiZomp3XDl6IyfNCzLqX+pqLXcCzmRybnj9MXWMJ1bVnD9E8WxvmeJfj10M82/NLjsR2kbFSHB/ay/GhfXg0P3O8y1kVuoESe/U434zfBqTM0fF6roVfFRraNEjV5nhX8Fz3r4jlIuyKvMjSwKjzqETmOUQKHCbzfasv+hmmwhtW4GgoCxPyunDadHqjcSxLYhQ4N4QQVJfkzSBSShoqprfTnAqaovLe+vUkcxl+0vLKlOaTaDbJSz2HeannMKpQsCkamqKiIJAwMplnrdxr6hBoKBpvq13D7oFmMtZED2kLyat9x9jef4KgzUOJ3YdTNRAIstIkbWZJmGmGcilSZpa0mSVjmVxXMpelwbpJ7pjH/s1HaVxcyxPffYGS2iKuf8fVCGV0gkyacfZGt5HIDXEwtosTQ4fYUPwmal2Nr6udjhCCq4pmsThQy7b+E5OWORXv4e/3/IRKZ4gmbwVVrhAuLU+jHMul6EhGODHUTWu8j4Q5MVy0yOblswvu5cG2rTzSvvOStb010cevT29nKJtiKJcinkuTNNMkzbyAkTQzpM0cOWmSs0xyhW92MqSsLP+w56doijoiZOiKil01cKj6yL8O1YZbs+HS7ARtbt5SvQrvJKkBLiWGNRqBgIvSUt84gaOrc5DBgQT20qlzHpmmxdGj4zUhDodBXV1RflG3JOcjC0gpeab7JXIyS9JMcV3xWkxpsaV/BykzTb2rmtnemWzq20pvuo9Gdz3zfLPZMbCH5ngrYVuQq8KraE92sC2yG5uis77oavZFD9KXjhDLDbEyuIRKZzmb+7bTnuykylnBiuBidkT20JJoo8xRwsrgUhSh5J2TIwkGI3FKyvwAdLZH8Adc6DaNwf44mq7icBhksyaJeBp/wIXba8frd9JxOkJVTYhkIkN35yAlZX7sjunnR8prj+t5W9Wf05E6yc7ICxyMbWcg00ssF+HV/ifYO/gKV4dvZW3R7ejK64cWfJi07Cwlxvx97v6YjkDl00PM9i5jS/+TE5xHo9l+jg/tBaDK2UixrfKyzZdvWIFDUQQhT353XBX2T1nuUnW8TdX48Mwb8BoOvnvihXM6BprSyid/ex36lQkhWBVu5NaKJfyqdcuUQycnLbpTg9MOzzzX/NvV0ku0f4j5a5s4tqsZy7JQCyG6Xt2Ppmg80fmLkeiU99b+BfXuJpTXIPT4XHCoBn866yb+asf36UlPnmgwJy1OxXs4Fe+Z9PxUCNs8/J95d7EoUENLopdH23deMvG0Od7Dd0+8cMmccHMyT7IF0/OR8uoObihbeNkFjmEh1jA06meUcPToaJqCeDxNW1s/JWcROIbLjEVRkZeionx0y4X0XmuijRtKr6Ur1c3Ogb00eRo5nezg7dV3oQmV1sRpmuOtrAot48mu52jw1HF86BT1rhoa3HWA5Kmu51kWXMypeAt7BvfTneql2lXJHH0WOwf2oAqV08kO7ii/CQEMZKPsiOxmQ8k6nup6gUb3DMK2ILmcxUM/3UJjUzker4Ns1qSzfYBnHt9HY1MZzSd6ME0Ln99JV8cAC5bU8sLTB7jnPVdhGCqZTA7TtHjoZ9soLfOx5eWjvOWdqxHq9OdbIQSa0Kh0NlDpmMF15ls4GtvD1v6naU4cImHGeKrrpwihsr7oza+bTYcpc5hnyXM0lsgrZZ1dO2lhjaR0OBsEgiWBa9gZeZ5swXm0xtUEEo4M7WIoN4hAsMh/9WU1P/926ZquAPK05jliiRSnOvvpi8YviSOSQGBTdd5bv57PLriHOlfxZVUTT8cP5GKgCZUPN97A+pK5V4zfYsHVTaiaQtOyGdTPr0KM4bO4tvg2/nLm5/mLmZ/jTxr+jnur/pAG9xzU16GwAfnJsslbwafn3UnYdunoumtdRXxu4dtYFc5rdeb6KrGrr49w4N9GCAFNZziOmqbF0WOdZ50XOjsHGYiMXyzq6ouwn6cf2FioQsWu2nCqTjKFRSZoBHCodnRFJ21lSJoputO9LAksQBMat5RtxJIWD3c8SdbKa0d6030EdB9VjgpURSVkBHBqdiwpyVgZnKoDm2JgKAY5K0vSStOZ6maurwmnmg/p1jSFZasbaG3uZXAgwYmjXcQGk0QHk3mt8KxSqgoRPg6njSUr6xGKIDPG+T6TztFysoehoRQuj/28ND5jkffVUHBrPhb5r+a9dZ/iTeXvx1DsWJhs6XvirD4OlwRjpkCLs/vmJM34BObQsfDr4ZEIkf70xHxcY5E2kyStcwcHCCGocNRT5WwE4HBsB7FcBFOa7B3YjETi1YPM9Cy6rOvGG17gkFJiWqMfSDyV4eV9J9l3qov9pzp5fOtEx76LgSoU1hXP5t+Xv4/31q+nyOa9ZMu1IL8DXFc8m0/PvZOgcWlYKye9lxB4dQf/Z95dvKvualza5VVZCiEIVwQIlfrZt+kwDveoX8NwiJiuGOiKgaboiILAJaWclvf6cKbcycpFsxGOxvZyYuggWStDykzSmWq9JM+0JjyTf178Tub7q6dkcJ0ODEXj+tIFfHnpe8bl6SlzBKaMkvo9zg0hBA2NJej6eMH16JGpI1WklJw80U0mM97cOLupfPrJWCdBRmZ5rvtltkZ2Mtc7q8B6OTrualxVhG1BetN9ZK0cAsG2/l10p3swlLwv2OrQcvrS/fRnBrCpBrbCcQUFu2qj3FFG0kzyYPujvNq/nYDhp9FdT0+6j0QuiV6g4M7lLLo7B9E0hVg0yUB/HEtK3G4bhqGhGxo2u4bNrhMdTPDkw7txOAzMnMXhA+0cP9JJMplhwZIaVFWloiqIch7ajakghMBQbCwNXsdMd54iPZYbIJYbOPe1Y8afPIfQcCY0oY+YNhK5GNYUqmkpJR2pU6TMqTllimxl2NW8Bq8jdZKUObVA0ZfpJJGbHnePJnSWBNYjyJtRjsX2Esl00ZbMh+DO8izBU2BrvVx4Q5pUMjmTVCYvaZuWxf7WLq6enfcd0DWVzkiMGWUhvC47OevS+0oIIQjbPHyw8XrurFrBc10HeLZrP8dinQzlUuelrrYpOiGbm1neclaGGlkWqqfcEbjsGg7IP4dbs/PhmTdybck8ftH6Kpt7j9KfHpq2j4lAYFd1QjYPjZ6paZGllDz1w5cprgrj8jlQp5HjRkrJ6eRJjg3tZ65vGSGjhL5MfqEI20pJmnEimR4CRhhLSjb3PUmTdzHljppxasXmxFGSZpwKey2Q9yIfzn2QMpP0pjuQSAJGGFVoCBRMmcOSJulCMqigUUxvugNFqISMklESHyGY56viK0v/gCc6dvPrtu2cGOoiPYlvzGR959MdLArUcmfVCpaG6tHPyJDrUA0WBWrpTkUZVuQLIaZkiz0XNKHi1R1Y59yODp+/tN+gW7OjXGHVeFmZH7/fSU/P6MR+6lQPqVQOp3NyjcXhCYRfCjNnTj8Hy2RwqHbWFa3BrbmwKQYSyXUlV4+ctys27ii/mbSVGidgZGUWu5LPnrzIP48mbyNSykJ9qwvfLGwoXoeh6NxZcRspK4Wh6GhC46bS60iaKTShoRXGhaYprLy6EWlJHE4bcxdWkU5l0XQ1/36EACnJmRYD/XHWbZiDy5XPs7LxloVA/rrrb11IMpHBsE1vKRpOaDasAZiqP0X+JJD3cZiOptOuOgtXSvoL88R035dL82JXXaStFN3pNiKZnpEkm2PbnpVptvY/c1aBxqeHqXDM4NjQHvrSXRyMbWexf92EtljSZFfkBXJyeuZIIQSzPIsJGMX0Z7pGktUlzTia0AspLi7v2HpDChxbj7ZyoqsPm67lw9Msa0TgMDSV21fN4Vh7L26HwfJZlycET4i8PF3q8HNvzWruqlpBV2qAo7FOjsU6OZ3spy89RDyXJidNVCEwFB23ZidguChx+KhxFlHtClPuCODW7SivQRiYEAKVvOp+tq+CvnSMw9F2DkVP0xLvoz89RMJMk5MWqlBwqDoe3UnIcFPmCFDtClHpDFFs9+E+h5bEsOvYXQb+Ii82hzGtsZG2UqStJALB6eRJTgwdxCRHo3s+R2N7CdvKcKguNEUnlhtk0kqlZCDTh1N1U2yvIGEO0RlvI2wrZUfkJXx6kJPxQzR65qGgYlPtxLKD9GY68OlBSmyVnIofpj15iqSVYIFvFSX20VDeYW3R3VUruaV8MSeGutk70MKxWCfdqShDuVSeMl4oODUbQcNNhTPILE8Zs7zlFNt9UwqYAskHG5Zz34z1445eqA/EkmAdP7zqz6YUinPWAJri5XIpTxUEgcuouZsMHo+dyqrgOIGjpydGf/8QTufEfBvZrMnxY+NV4V6vk4rKiWXPB7PcDbg1F3Y1P04EAmNMhELep0FFG5Prw6Ya2BgvFDnUUabbsdfbCqY3Tai4x9QhELi08dFgQgicztHxqigqmnvioq5JybqNc/B4HShK/vv0+sZ/e27P1My7k2Fz3+OkzCSzvIsJGaUYim1EABnOjL1/8FWOxvYAEDLKJiRbmwxFtgpsip20lWT/4BYW+ddS5WwYU7eFJS1UoU7IuupU3VQ7Z7J38BWGcoM83vlDbit/Lx4tgEAgsYjlBni++1ccje0+aztUobEydAMn4wcwZY7HO3+IW/NR7xoN709bSXZEnmPHwAsMC0nTgVvzMc+3ihd6HqQteXxEe1Jqr6HS0XDZ1483pMCxoLaMlTOrR9SbnZHRiUQIgddlZ0njhdGZXwiEEBiqRpUrTJUrzLUlc0fCDfOfUWFnWhAohrPFvl6coGBU8Ci2+yi2+7i6qAlJPgR29BlG2z1sPjifZ6hpqqD1aAf9HQP4wl5KaorOqqIWQuDXw/j1MCGjhF0Dm0iYMbx6EFVozPUt43BsN3bVyQz3HLx6gDJ79QSnqbxHfA1VzgZUoREwwnSn80ynNsVGf6abamc+064lTUwrh8RCQaXeNRuvHmBz39MkzDhOzX2WHbrEruaFt7m+skL/CayCg1l+krNQCirw/ERjIbGIZw7gNJoQaEhyiOG8EjJBOvMsJZ535u8gJTmrD9PqRypVhbtaCFQkZuEN5e+ThwqYhXMahqIQsjnG3EcZV0dv/An8to1oiof8Ox+u6/Jr3C4XVFVhZmMpO3c0jxxLJjO0tPRROYkQMRkbaWVlAK/3wh1dhRAsDZ49i+rrEUIIKqvPvdifD3rSHbzS9yjP9fwCnx4iaJTi0rwoKCTNOL3pdnozHZgyh6HYWV98Jzbl3H0fMkqZ5VnMnsFNRHP93H/qi9S4ZuFSfZgyW/C9SHJ35R8Tto336xEorAndzLGhPfloucFXaEsco8IxA7vqJG5GaU+eIprto8bVlOe+SByatB1CCGZ7lrDEfw3bIs8wmO3j+83/SqVjBgGjmJyVoSvdSnfqNKWOapyqh2NDe6bdf4v8V/Nq35NEs/0MFUxNC/yrMa5AJM8bUuDwOGz0ROP84pW9XL+wkXg6S0Voco/zjuZ8ttfS6tAVmzCHtR+XMroilcxwdHcLc5bVTcsccbEYFoyUS9hlwTI/LYfbSSXSuLLnNjkAODUX0Ww/J+IHqHHNZDDbj64YeDQ/pxKHUYRK2kyiFFJZ7xnczHzfinEZGHXFhkv14tMDZK0MJ+KH6E530JPuwMIiZSZwaR68mp9dA5tQhEKlYwZ21THyDme457B/cBs2xY5bm/itSZmjN/4gQqi4jcUMpl7K31stIpk5jBAGhlpCzhpECBWbVo1Dn8FQehd2vZaeoR8Tdt8FCBKZA2hKAFVxkM51kDPHRktYDCSfJ2N2EHa9iWhqM5bMYtPKiWf2I1Bw6LPImHlqdJ99LdHUJtK5VsLuOxlIPo9dq8ZlW8Rg8iXARBVuctYAirCRswboTzxc0HKo+OxXMZh6iaDzFi63uvZyYlZT2TiOCsuSHD3SyerVE3eF7e0RotHUuGPDhF+/x8UjYISxKQ7SVpKedDs9hQyvYyFQKLJVsLHkrcz3rZrW3K0KjZvL3kXCHOLE0H4SZoyDBfbNYRiKfVIThhCCGlcTd5S/n8c6f8Bgto9ItodIdjTCTBUqMz2LeFP5B3i1/8kpBQ4ATTG4pezdqEJjx8BzZKwUJ+L7Ib4fAAWFWtds3lzxhxyMbp+2wCGEoMRWRb1rDgdj2zClhVP1MMe7/Iqsb29IgQOgpSeC12knEk/SEYkxv2Zy/4Fje1pQVIXSSyylX2lE+4b47j//mn/8/oeviMBxObD54Z3Y3TbC5UG6WnrIu7WffZDYFSfri+8A8k5TV4VvxJIWhmKjybMIU5oFyV6wKrSRnJVBE+MJnRrco5E4mtCY613KHO9SFAQDmV5muOdybGgfs72LWV98R0HQUpHSGtGWhI3Scfc+E6ZMYFpxSjzvIpk9gqGWoiouYqmt2PRqQJLOtuG1ryaZPUbG7MCmVZA1e/Da1+A0mnAbi+iIfgtV8WDJOJnsacKuu+mN/3LMnRQc+kxsWiWKcCFlDp99Db3xB7HrtUhpEs/swWXMR1WcJLNHMOVQobwDTQngd2wkmT2MAJLZE9i0GnyOq+lPPIbAIOi8mb74QziNefQlHsau1Z7zPb2eIYSgtrYIh0MnkRgNZx/OBKuOcXaUUnL8WPe4PClCCJqaJk8H8HucP64K38pMz2Ja4kfoSrcSzfaTtvLRMTbVQdAopto5kzrXHJyq57y4Pfx6Ee+u+ThHh/ZwfGgfkUw3ljSxqQ58eogyey0BvWjS6xWhsMi/lhpXE4ejO2hNHmUoF0VFIWiU0OBZyAz3XHRhY4F/DXbVWTDnTu4HZFdd3F5xH4sDazkY3U53ug1T5vDpYRrc85npWZTX3HjzkTGGYpuWJkcRKvP9qzkU245EUu+eS8AomVYfXSzekAKHlJLGsjD7mjvZfqyNG5fMmrRMKpFhyTWz0W2jaZdzWRNpSRB51jybw8izXhZ2P2bOJJPKoWoKhj1PZDPsTGVmTUzTxGY3UNQ8eU42kyOXNUfqGUYmlcU0LQy7jqqORlzksibZdA5VVzEK7ZIyT5OcSWXRDQ1NV8eVz2VyWNa5va5lwfzxejPXDCNY5qekOsyu5w5Me/0SQqCPsVOf+fdY0UJFRVUnDtixJhYhlIJzWb6/lgXXM5jtZ3lwPXbFOb7fxmiozmzHxHu40FQfffEHcduXkTV7yZrduGwLC2YLSVbpJ5rejK4EcRuLiaY2YckMirChCIOh9HZ89quIZw5g1+qwZIpI4omCtmG0HYZaTCT5BDatAkVxMpjahMe2jLwF3EJTvIX7W3jtqxlK78IwSgGJoeYzSFoygyUzGFo5khyRxNMYaimKsCGEga4W4zLm0Bd/iJDz1tfl93Q+KCryUFTkoXlMMraWlj6Sicw4HwQp4ciR8Ynz7Haduvri35o+sCxJMpPFYejj5qSLxXAk2LnCRs+EUXB4hWHTrUapvZoSW9XY2gv/jrb3QvpbCIFNdTDXu4K53hXnXa8QgqBRzKrQjazixgnXD19b4ainwlF/zraoaFQ7Z1HtHF6jRjdZw3UV2ysptp+fC0BfwdFdQWGR/+orlmvqDSlwnOqOsOVoKyBw2W10DQxRUzQ+dNAyLR6+/wW2PXOAdW9ayi3vznuD79l0hJd+sxPTtBjoiVFWG+a9n7oDm8Pg0I5T/OKbT5NOZFB1lff/7ZupnFHCj77yKOEyP/u3HGdoMMk7P3YzsxbXsveVYzzy3RfJZnIES3y882O34Au5ee6X23j54V2YpoXb5+D9f3sn/rCHY3tb+dk3niSXNUHAOz92C3WzK+hq7eOB//s4sYE4uqFzz59cT92cCjpO9XL/Fx/CNC2KygPj8kGcCSklmazJqztPsmJRLZqW9zY3LQu1MOlYBXZETbvy9nghBGtuX4qqKngCLtx+F+JS2msusE0BI0zAuDCK5vF1qYSct5P3d1Apcr+VUR+I4egSA1W4cBpzAIFDb6QgHhJ2vWWk/PD5YR+PM6UzXS2m2P0OQCHkLJ9wn1FIEpmD2LQKMmY+z4LXvgYAlzEflzEXEPQnHsZjW4GuDu/8BEHnTcQze/DYlqAqeRPSsGA8LEBPBSklliVHBPnzwcVcezbY7Qa1dUXjBI6+/iF6emPjBI5MJseJE+OJ2oaFld8W9ESH+NT3HuXz77qZ0sCla7cpc9x/6j9oS5ya9jVCKLy37iPUuRonOTf2/V7auWC07gur92Kvn7yuS1Nf3sdkMwBBWyl1rrlXbD5/QwocFSEfVZEouqpS4vewv2ViMiZFVbjrgxvIZU2SQ6P22HQqy4GtJ/j7+z+E2+vgCx/6H07sP03NrDL+959+xd1/vJEFqxtJJTO4ffmd8EBPjEhPlA9+9i2oqoLNYTA0kODHX3uc9/3NmyipDvGTf3+Sx77/Mvd+9EYWXT2LJdc0oWoq3/r7n7P75SNc86alvPSbnTQsqOa2964jFU/j9NqxLMmPvvoYS66ZzbJr57Dj+YP84N8e4a+/+T5+/s2nmLNiBje+fQ0v/WYH+149dtZ+2XvoNI8/f4BszsTtsuF22nhxyzFWLKpFEYL9RzsQwMrFddRXXxzd+/lCSskrv9nBqlsWU9lYdu4LzlHXsLNlHqKgRXhtkz3lnUKHdxoTJxmXsaDALzJcRp1QZuLxieaz/DMOHz/7ZOY0mtDUIIrQ0ZQz33m+Dr9jPYpwjPPcl1LB0CpxGqNZJ2NDKV7YfJRbN86fcJ8z8fLW4yxdUI3LeXZHtngizVA8TUlRXovT2z9Ey+l+lsy/tNFleQKwcp5/btTunk7lOHWqh9ra0X6JROJ0d49njq2ry5tjfltgWpKewfg4fqJLAQnEcoNEsn3nLDsMgUJuGiHiv8f0IKXkcGwHvem8Fm6Bb82k2WgtS5JKpMlmx5gGAZfXgapeuDbkDSNwdMefoT/1KgBhx1pqixfw+M7D7GvpZEHNxAVMCIFQBYoysXNnzKuitCoEAkKlPuLRJL0dEZCweG0Thl3H4R7d9QgFFq+djS/kHpmYWo520nKkgx98+RGEIhgaSFA3pwIpJScOtPHqE3uREpoPdzBneV71tu6OJfzg3x6h7VgX17x5KQuumkkqnubIzmb6Ogd54aHtZNN5E00qnub08W5u/YO12J0Gc5bX89gPNk3ZP0IIZjeUsr++mGvXzOJkSy+v7jqFaUkOH+/C47Yzq76EmoogT710iPrqi9/Vny8s0+LU/jZCZX40Q8MXnr59FkBKk1jmKD2JZ4lmDpA2+5Ayi6o4sKlFuPUGSlw34tKnTiB3OZGzhmgfeoh0rpti1/V4jfEpotWz2GellPQknh35xs+Epnio9ryPV7a2kUhmKCvxsWB2BZu3nySZylJS7KWhpoiXth4jl7NYt6qRgWiC7XtaCAVcrFpSyoEjHRw71cP8pnLKS/1s2XmKRDLNnJnldHT1snh+FW3tEQxdI5XJsv9wB411WRrrS3hpyzFisRSD0eSEdp/uGGDHvhYqywIsnFPJjr0tdHYPYklJKp3l5a3HyWZzrF3ZSM602LT1OJqqsHrZDB59Zh+nOwe49qpZzJ1Zxu79bYSC+ZDOvv4hNu84id/nZNmCal7eepxEKkNpkY+lC6rP+x03zixB0xRyOWuk7UeOdLJ+/eyR362t/cTj43PbNM0unxBGeSmQyeVIZXI4bQbRZAqBwOu0oSp5c20knsRtMzD0/DSfSGfyZjKHjWgihd3QSaQzeJ12kpksliXxOAoCnsg/z0A8iZTgddpQxKjpWAKxZJqcaeJx2NDVUf6XWDKNXtCQxhIpNFXB4xgf+qoKjUX+5SMEV1MhzzXjP+++GTZjT7Y4Djv+TvX+pZSkkhlsdn3S+f9MJBMZ9u1uwcxZVFQFqbrApHSXG1Lm+UWe7f4FFiZePcjSwPoJ/WDmTH7xvZd57pE94zIaG4bGp/7lbZRVXXh49xtG4IikttMc/R4AmuJjRuAq3nXNEiw5mrRtutBt2hmbQYmma5imRS5rYtj1Mz5qga6PJ2TSbRpFFUE+/IV7sTsK8e+6ykBPjO/9y8P8yRffRkV9Mfd/4aH8HaSkfm4ln/jGezmyq5kff+0J0skMi9Y24fTaeffHb6WiPm9fVxQF3aahairZVG7El+NcbJtCCDJZk0QyQ8jvorW9n5WL6ti+r4Vr6ooZiCbwuOw4zpEl83LBF/aw56VDaLpKoMTHurtWTHvRsGSWU4Pf4eTgt8lZk+cuAQW30YBLr7t0jT4PdAw9zMG+zwMWvcmXWF52P5qYfproSHrbyDd+JmxqMRWud7BzbwvvuGslDz62ixk1RWzecYJ33rUSr8fBll2n6O6NYVkW23Y3k8nk0FSFhtoihuJpHn9uP0vm1/DQE3t47z2r2b6nmfvetgan3eDAkQ5a2vrZtruZdasa+fUTe1i6oIaHn9rHbdcL+iNx5s4qZ/P28cnqLEvy4OO7mDurnKdePMiM2iIWza3i2MluUqkse06cpqNrEEUItuw8RWQwwezGUirLAjjsOvU1YYJ+J7MbS1FVhbrqMAePdrBobhVPvXiQlUvq2Xf4NEdOdrNjbwt/cM9qfvHwThbMqRhZiKcDIQSVlUHcbjsDA6O01MePdWGaFlphDjl2rHPcJD1K+DXtW00be051cv8z26gI+Tjc3kM8lWHtnDo+eOMqLEvyyfsf4Q9vWMmKxryvwyPbD7HnVCefesu1/N2PnqQ86GXbsVY2LmzkYFs33QND/MM7bsBlM5BS8oMXdnK0vY+hVJqrZtfyRzesxKZrpHMm9z+zjU2HmpFSEnA7+LPbrqa+JIgQgm898SpFXheH23s40dmPpip88d03UxwY5fIwFINby95K2FY8rWc93/QS+3e1UDOjmGB44u791LFuAiE3vsDETNPDeOyXO1h/03wCoXNzvuRyJq3NvTz/9AEWL6vjvR+89rzaermQtTKcjB9AVwykhO50K5v7nqA73YaCwtrw7QQncRZtb+3n2Yd38/6/uImistGIOiEE4RLvhPLngzeMwHEmhBDoZxE0spkc/V2DDPYPoaoKXa19BIun7uyiigDFlUEe+NpjrNg4j1gkQePCasKFTIpnoqw6TElVkMd/8DKL1jYR6YlSWV+CN+hCWpJo/xADvTEObDtBbSGl9bZn9mNzGNgcBt6gi3Qyg91hsPL6+fz6f1/g+ntXkU1nUVSFxeuaWHj1TB75/ktIKdn8+B6ymbOrJu02nbkzy9my6xRrltazfEEt82dXoCgivxvecZKTrb1ct2bUyTa/2zEBiUC7rJqBpuUzWHztXACS8fS075Xf/T/H8YH/wJJpQGBXS3DqdWiKA9NKkjZ7scjhtc17zcwqKbOTYf6LjBkptHX6AkfIcTVIyFiDZK0B0rkeopkDMMZJz7Bp+LwONE3N+wi57ISDblRVIZ5I43HZqK0KU1biw+U02L2/jYef2sfNG/L9Egq4uHXjfIQiCAXc+DwOhMh/H89uOpznsfHkTX1+r4Pbb1hALmficdsJ+JwTdpyWlfcd8nkd3LpxPg67jqYpqIUQ0uE21dcUUVrs5YnnDxAOunG78jtxw9DQNHVkLI8NPU1nTAI+Bx6XnWQyQ8DvJBRwoenqBeXt8PmclJcHxgkcbW15jYbP58xrPA6PN896vY5JuTouBXKmxfbjbayfN4MP37yaU90RPvndR7h+USO1RQHiqQw5c1Qlns6aJDMZkHnuoQ0LGlhQW8ZXH3qRr//hm3jgpd28eqSF6+Y3EE9lCLqd/Nt9q+iOxvnk/Y8wv6aUa+bW89j2Q+w4cZrPv+sm3HYbP3pxJ19+8AW+8v7bMTSNRDrLg1v288m7rqWxLEw8naHY54YznUXFqJYhmzV59pE99PXEWHZVA6EiL88+ugdVU9hw60LaTvWyb2cL4WIvV103mxef2k9/7xBzFlbR0FTGM4/uYSiaZPlVM3G6DPbtbKaqLq9pePXFI5w61k1tQzENs8r42Xc3UVLuY821s/H6HLz49AEURWHjbQs5tLeN5uPdNJ/o4Zob5wFTCzvDbfd4Hdx570p6u2OTlj3z2Jnso5PVezYBa6rzZ85bKTPOT1r/nUQuv8EadtYVKCwOXMPK0PWTznWJoTRVdUUsWjXjoswnk+ENK3CcC5GeKI9+/2Wy6SxZ4NHvv8xN71xDcUWQuStnjJSbv7qRcHkA3dD40D++lecf3M6LD+3AF3LTtLQWgLkrZ1BcNT6sVrdpfOhzb+WFB7fzwkPbCRR5aVxQTaDIy3s+eRvbnztIUbmfd3/8Nhzu/OSq6RpbntqPaZosu24Oq29aiFAEb/7AtWx+Yg+bH9+DzWGw6oa8jfz2+9bx9E+38PIju1iwZibBUv9ZQ2IVRbBm6ajn9HVX5QWLdSsbx/07FpIsB/v+iXSuh3lFn8NQL/3kKqVEWpIXfrGF9W9ZhaopPPPAJm5+7zXTozgnR2vsJ4UFHEpdNzMr+HEMNVRgAZRYMoNpDWGor506NOS4ivbYQ+SsGCWuG8ZFl5wLQgjCjjWE7KvJW8sl8Wwzr3a8nZw1SmwXG0rz4GO7CPiduFw2Ar7RXd6yhTU88fwBjp7spqTIy6GjnbSc7sfjthP0OZnVUMqhY53UVAYpK/bhH0NkVVLkJZHIsHxRLU6njSXzqzl0rJPSYh9L5lexY18rA68cwXsGq6SmKaxZNoMjx7sIBtzMmjE+PH3J/GqeeO4AR090URT2sHJxHY89u5+g38WGtU2UFnnZsuMkPo+Dhroitu1upqNrkFOtfaxYVMvDT+9DVQQ3rJ9La3sEEPi9jgvSOOi6SkNDCQcOnB45Fokk6OocxOdzkkplaS7w9gyjoiKAz3f5MtuGvS42LmrE67QzszxMwO2gL5qg9gwn+DOhqYKZ5XlK/2K/m5riAKV+N0PJNCCx6RrXLWjA53LgddpZXF/OtmNtrJ1Tx7P7juN12Hn1SAsA2ZzF4fYeBhNpirwaIFlSX8Hyhnya84A7//zZs/iECAElFf68EPXKcVatm8VQLMVV183G4TRob+3H6bIxe0ElnacjRAcS3PqWZTzw7RdIp7MoisKb374KoQhUVSEQcpNK5vkyQmEPmXSOLS8eYflVjTTOLmPpmgYqqoM88D8vYrfr9HVH2bXlBIf2tvHOP1rP9//ruZG2ZbMmP/neyyxcWsvml46STmVZv3EucxdWTViwz/ysEok0zz+5nyOHOpBSMn9RNeuum4NuaHl/igPtvPD0AaLRBKGwh403L6CyOsRDP9tKKOxh1/ZTXHv9XPbtaSWTznH3O1bhcBjs393K5peOMDiQoKjEy423LaK41DeuPYpQ8eoBclYmT4ImNPxGEUsC17AyeD2GMjnDa2llgFzWpO1kDxU14ZGHEuR9Gy9mQ/Z7gWMKFFcEee+n7pj03Ix5oyFIN7xt9cjfvpCbO953zYTyG9+6csIxIQS+oJvb75tYfun6OSxdP2fC8cXrmli8rmnCccOus+6Opay7Y+m44w6Xndveu27SZ7hUSOW66Io/WaD9nR6n/4XgxL4Wtjy2m67mXoQiKK0pmpZ9FSBrDjCUOQKAKpzU+/4QuzaqSsyTrGloytQq1iuBgG0JK8t/hCmTOLQylAtIEz1swsv/PVEYCwfd3HHDQgwjb+K78+ZFI6GP4aCbe+9YhiUluqYSCriYM6scTVNQhOCm9XPJ5UxUVUFRBLeMcf5UFMF9b1uDouTLrl8zk2zWRFEVVEXwjjtXIKWcwLIqhGDF4loWz69CKezc+iIJ4vG8H4DP6+CeO5ZhWRa6rlIS9lBTmRfeNU3BFnTznreuRoi8KfG26xeAlKiaiqoIZtQWoSgCRRG86caFCAFvunHhBe3chBDMaiqDh0aPZbM5TpzsoXFmKb09MXp7xyfSapxZOmJuuRxw2Axsw/ULke/DScoNJ6kcPqeI/MJs5Uy0wjsbu3NWFWWcqdllMxhKZZASYskMDsOirW9w5Pxb1ywYbQfgd52fkNV8vJuDu1uZObeCwf44FdVBNty6kCd/vRPD0Fi9vonm4908+MCrbLh1IcMSo5QgLYmijNnhFx7Ssixig0meeXQPG25dyO6tJ/PfiapgFcxeiqJQVVfE0tUNuD12Du1tQwgxLhzYNC02PX+YY0c6ufG2RfR2x/i///wwf/NPd1NbP94kdGbfp1M5IpE4K69qJJ3K8r3/9zwut51VV89kcCDB1770MLfduYzS8hm0NveSzeQ1Uru3nyIQcuP3O/nXzz3EPe9awzNP7GPWnHKWr27gdFs/1XVhQmEPzzy+j299/Uk+/dm7UbXRdjtVDx+o+zuSZpyczKIJHbfmw1DsZxUakvE0A5E4n/7gd6isDY/kudF1jQ/99a0UT6G1nw5+L3D8HheFaHo/WSuKplzezLQzFtTwto/fTs3sChRVyU/i0xS0s1aMnDUEgKGGsGtTJ4l7LSGEgl2bnk37QqAoCisW1WIY2siEOnYxFEKM+62qYtzCLETehDEMbQzh1ZnXCiGmLHsmhBAj/hRD8TR7DrSxdGEN3oK5RtOG6dbzODNz69jfNkOb8pw2Yna5cAFgxoxibDaNdDpvnpQSjhzu4MYb59Pc3EsqNSp0C5HPEHs5MVWvioJAEU/lMyVbUnKyq3/Minj2wZPO5ujoj1IZ8pGzLE51R1hcX46iCOpLg+iqwkduWTMiQJ5PorPJECr2oqgK7a39VNWF6eoYYNOzh/D6nPiDLvbvauHk0S7qZ5ZSXVdEy4keHv7pVlasnUnjnHKe/s1ufvnDzSy/qoFMOkdXxwA7XjnO1RvnUFoR4OCeVupmlgCCuYuq2PTsIVaaM7nu5vm8+PQB2pr7WH/jPBYuq+M3P92KL+BCH/MtSeD6Wxay6uqZSEuyb3czWzYdmyBwnAl/wMm9776KVDJDNmPy6pyjtJzqZdXVMxlmY06ns9TUFbFoWd04zduS5fWUVwXZ8spxrtk4l5ZTvfQVBNobbl1IJp0jncpiScl3vvksmUwWx5h8VEIInJoHp3Z+oc0Ol40737VmgtlRUcR55705E78XOH6PC4aUkv7UFibYZi8DhBA0Lq4d+ft8YMnMSAisIgzEBWgOfhegCMH82RXnLvgawu2ycd3VE7V4rxeUlPgIBt3jcqUcP5FnFj1ytGsc181rSfhlaCpLZ1Tw3We3E02m6YrEONTWTUV48hQOZ0JTFX7wwk6aewZo6xukrW+Qj715HQK49+qF/O0PHudLv3iO+tIgfbEEdl3nvg3LLri9Pr+Tt/7BVeOOjf29bE0Dy9Y0jPy+9ubxodW33D1eu9s4Z1TQu+PeFePO1c8spX7m6KbjrneOaqmXX93I8qsnmo5VVcHnLxD7KRAq8hLpGzrrM0kpaW/r50f3v0RiKI1uaBw73EFNbZ6vxutz8Jf/53Ye+tk2nn3iJ8xdUMW977kqfx9FYLPrqKrAZtdQNSWvmbHyAQAP/Xwre3Y0Y9h0kol0ISjgrM2ZNnwBF1dtnEs2k2MwkkAoAp/fOUIoeTF4Y868BeQdHnNkzAg5axCJRBUODDWIKpzn3blSWuRknIzZjyVTCDR01Yeu+BGc38uSUmKRIWdGyVpRpMwhhIqmuNEVH4o4u1rszHqkNBGohQV3eFdikbOGyFj9WDKNgoGu+tAU71nbO+womrUGiKR2jBw3ZYqclZhQPp90Tr8gE8G4eqbrJIok/18OKXMFHwY5ctaUKbAm2l6FMM7ZxvxuMUXWGiBnDRWSlunoigdd9SHQp/9eZKbgcDsRZ76rK4l829KFZxMF9tCpTRATyxuTmnPGllOENq6vpLTIWlGyZgSLPHuqrvjRFQ/TTfw2+fjzoyu+8x5/U8HlslFdHRoncLS3DzAwkODoGSnpw2EvxWdxNL9YlAbc3Lh45ogWSlUE1y+aSVmBrOsDG1dQFfbT3B2hvjTE37x1A8c6+1BVhesXNeJ32jEtyYaFDSiKYE5VCZaUuGwGf3DdMpbNqOTZvcewGxr//J5bqA77EULQUBri3+67jWf3Hae1d5Cg28mappqRdi1vqMJpO3skW87KsaXvRdzn2H2X2MuZ5XntHLmHYZoWA/3x/NwnJX09MWY0nltT+sB3X8bttvPhv7gJw6bxb//063Hn6xtK+Ognb6GnK8q3vvYkv/75Nt71/oIZXIz7ZwRHDnXw6IM7+cyX7qW03M++3a381/99/BI8ZR5SSo7sO839X3+SroLfU0VNiPv+/AZqG0p+78NxvlCEhiWz9CSepy32E2KZw2QLi5Iq7Ni0EoqdG6jy3ItNLTpnB0tpEcscoi32M/pSr5Ixe7FkGoGGpnjwGrOp8NxF2LH2rIvI8CIUyxykO/EskdRWkrnT5Kz4iMChCgd2rZSQ4yoqPXfj0CY6Lo2HxcG+fyKS3IrXNpv5Rf8MUiOZa6Ul+kN6ki+QyfVikc1P0IoXt9FAvf+PCNiXjmtbyuwkktpGLHOYocwxEtlTJHJtQJ5DYnvnBxCTfVJC0BT8JEXOif4qlxJSSqKZ/XTGHyWd6yFt9pIx+8laESyZz4GRyLbyavs7RrKcjmkkM4Mfo8S1YdJ6TRlnILWL7sSzDKR3kc51kZMJwCq8ZxcOrYpi1wbK3XdgKMGzs2lisr/3/zCY3jfp+YB9KXPCn5m8Py8zTJlkZ9dHSOU6URUHC4u/gkuvmbK8JMfenr8mljmMEBrziz6PzzaR3Msiw56eTzKUOULIsZrZof+DlDCUPUZL9Pv0JTeTMfuR5FDQ0VUfHqOJhsCf4DEmph8Yub+0iGYO0hb7Kf2pLWTMvpHxpytePLbZVLjvIuy8GoWLE+IURTBzVhmvvnp85FgsmuTYsS5aW8cTWl1uwq/a4iD3bRh10tZVlT+4dnTMuh027l49/j3MK+SMes+Ycu+6ZgkAV82uHTn29rWLAGgsn+hELYSgIuQbue5M3DRJqogzkZUZHuv85TnLrQhezSzPvHOWu+yQksd+vRO7Q6evJ8bxo1287T15DUwsmiQaTRKNJtB1jfa2fjxeB26PHcPQGBxI0NbSR/OJHo4eaqe2Lq/h6OoYYMumY9TUFeWjtTI5nK5zZ2zVNAXTtOg4HaGvN8bjv96JvIRK5qFokm9/5TE23L6YBcvrkJZkywuH+faXH+dv/u3tOJxTp2g4Z9svXTN/e6AInWORr9Mc/d5I5EJejszvwLKZQYYyR+hNvMCC4n/FqU1NEmTJDC3RBzgx8E2y1sCYMwLIYJoJepJd9CZfpsx9C7OCn8hrPCapT2JyqP/ztA/9GkumzjgrQGYwZZJMpp9o5gCd8UeZX/R5/LalUwsxSNK5bhK5ZoRQMGWKWOYw+3v+lkSu+YzSaUwzTjrZQ43vPRPq6o4/xaH+LzLRNQrAIpk7PcnxfNtzVnyKc+cPKeVISoEzn3sgtZNTg/879bVkSeZaJ2+jnFxFmrNi7O7+S/pTW5Gc6Rg7+p7TZg8D6Z10xZ9gQdE/n1MYTJt9JHNtYxhPR/vVYZ5fboRLi/y7TObaUIUTeU5n4Lwwmsg1I9AwrfQUxSSpXAeJXDNGJogls/SlNnGg97Okza4zWpAmlxsiY/Yzw//hqVsqM7REf8CJgW+RtQbHnBl9L6lEJ32Jlyl138qs4MfzGo8LFDqEEMyaVYqiiBHzSTZr8tKLR4hExn/jTbPLrvjOXEpJ2spiU6anaXstYSi2kaSIU0GfIrHZlYamq6xZ18SWTcdIp7L8yV/dPOK/sWPLCV59+SjpdJYUWb7/7RdYsaaBazbO5W1/cDUP/nQLv/rJFhpnlXHfB68bqdPhNBiIxDm4rw1FVVh5VSMbbloAwKw5FQQCLhxOG3MXVqMoCrX1RQRDbmbMLOUd963l2Sf24fE6uOXNS9i9vfmShbB2tPbj8TnZcPuiEX+nW966nK0vHiHSG8NxEYlM35ACR1f8KQbT+xBCIexYS9C+AkMNkbOi9KW20Jd8GUumiWb2c7T/yywo/hcEEz98KU1aoj/kaP9XscigCichxyoC9qXoSoCcFWcwvZue5AvkrCjtQw9hyRzzwp9FFRO9uAUqLr0OS6ZRhQOXXo/PtgCXXoemuMlaUQZSO+hNvoQpEyRzbRzq+yLLSr+Nrp7bNps1o0TT+9nf+/ckc6dx6XX4bAuwa+VIaZLMtRJNHwDAa8yecL3PvpCGwJ+N/DatOC3RH2HKOIqwUeN9F+okzqMCgceYec72TYVhNeboAdj21F6Wbpg3ISzWb19EQ+Cj445lcj20xn6MxMRQglR534Y4IyOsYPJnBtAUF3atBEkWTfHgMWbhM+bh0KtRhY202Udf8hUiqW1Isgymd3M08n+ZX/RFBJPvcAUqc8J/SzrXS9YaIGsNMpDayemhc+/6fheQMfuJpLaxv/fvyZoR3PpMfLb52LUSLJkhnm0mljmArgRwTqFdkdKkefB7HI18DUm2MP5WF8afn5w1NGb8xWgf+hVS5pgb/gdUceHObzU1YZxOG0NjUh4888x+MplR85iqKsyceWECx3RJrtpTPZTZwxMW7Z50hHJHEcqYal5vwoddcXBf3Z8SMM6+eDnU1zZybBhSQm19ETe/afHIseE+XbdhDus2TIwqBAgXeXj/hydqTQG8Pifv/sB4re9wpNBbx/iV/MEfrQdg480LRspsvHnByG+AeQsvHZW/YdMLTq65ESEmlcyQzeYmOGyfL96QAsdAeie64mN26G8pcW0csSVLKanyvo222E851PclJFl6ky8RyxzFZ5s7rg4pJYPpPRwf+CYWGWxqEXPD/0jIsWbEXpyfON5GJLWdvT1/TcrspCv+GCHHaircd06M4RaCMtetmFaSsHMtbn0GSmFiHK6v2vsOuuJPsL/37zBlgljmMJH0DoocEylqz0TOinGw7x/JmhFmBv+SCvdd6IqXUSuhJGdFSeY60RX/hLb5bQvw20Y/8nSuh/ahBzHNvMBR7X3XuHDTS4VUPM0PvvjgiLQtyROjLbluvKpVCIHPNn+COj+aPkjb0M+R0kRXA9T67kNTpk+oBQrV3nfj0uspcq7HqVeNCBLD76XG+y5ORe/neOTfkZj0Jl8ikW3FbUyeEVIIgUuvG8dqaighTg/9isk1SL9bSJs9HOj7LFKazA79HaXum9DEWGHVypOXmf2TCudSSgbSuzgx+C0kWWxqCfPCnyXoWH3G+Hs7/alt7O35a9JmF53xRwk51lDuvuOCF+Fg0EVJqZehY6MCx1hhA/KEX1UXSAHdn4nySt8eVKGyIjiXLf37cWtOGt1V7Bo4gkO10eCp4udtz7I2vIhiW4B9g8fxGR5mearZFTlCiT3I8z27ycocZfYQC/wTHSFfSwghKLKXUmS7MmnRLxUm+2YuRlt2PscvxT2ng/LqIF6/ky//7S9YuLwe07LY/vJRGmaXEyy6OJ+kK5OT9nUHQZ3v/ZS6bhrnUyFE3uGtwn33yMJqyiSD6d0Tdh0Sk1OD95OzoghUGgJ/WvDR0MbVJ4RKwL6cOv8HAIHEpC32Y0w5PqfEMAw1TL3/Q/hs81AVR6GOse3TKHHdQNi5bqQd0fT+aT21RYZEtoWGwJ9S6/0DDNVPPhmYKPyvoKt+vLamszoJXmkIRbD2zct516ffXPj/TpbfsOCCyJsu6P5C4DFmUet7H25jxsg3M/a9qIqdau87cBv5iT1nDRHPHj9btW9omDJB2uxidujTVHruRlc8Y77D/Lgx1BAeo3EK82OOU4PfIWfFEKg0Bv6MkOPqScdf0L6COt/7yI+/HK2xByYxWU4fhqEz4xzhkBdD+JUy03g0F0HDx+lkDzlpsia8gFOJDmZ6qslJE00o1DrLWOBrYOfAEZJWmvZkDx4t7+xuSclgdogVwbm0JCYmp/w9pg9NVbh6fRP+adCc/y5ANzT++K9vY/bCKnZvPcHBXS2suW4O7/7IxhEG4AvFG1LDYVOLKXPfPuWiqggbfvsSIuntACSzbRPKJHOnRxJlObQKip0bziqxhh1r0RUvWWuQocwxkrnWSR3hpiXdohKwLaYr/hgAGXP62Rc9RhMVnjsnjSJ4vcLmMJi5dDShmpSShetmo1xi2t2zYTrvRRNuvMYcYplDgCRj9l/+hv0WI2BfntcwXoBwm8y20Z/aCoBDr6LYed3Zx59zHdrAv5OzYgxljpLIteExLmzXLwTMairniScmd/gFmHmRhF8n4qfx6x5WhuYymI2hIKh2lrAzkiew8+ludEXjQPQkjZ4qTgydptxRRF8mSk86wql4O17dhU3RcZ4jQdrvcXbohsbb/uDq1+TeeYd1OWHDqxbI2i4HhBB4/U7ufPdVvPmdcsRXTsqL51t5QwocHmMWhnp226FtzPkztRFSyhHCKwC30YimeJBy8hBHAF3xoit+stYgpkwTzzaf1fP+bBBCjDGFSCw5/fTNIcdq1PNICPZ6gJSSgZ4olimHD/DqY7u46Q+mR21+JaEro7405/Ne3ogocqyb1DfqXJBSMpjZN0LZ7tFnoiquaY2/nBXDlCkS2ZaLEDgEjQ0l6Lo6Ln332PNNF0P4JQSzPDUsC85GFxrFtrxppsweJlzqR0FBFQrXl6zEwkIXGrXOMhShIIC3VV2PIlQa3FWoQmFd0eKz328MhknClDEavLHnCr7arzufkN9VmFLyhVef58RAP9FMCpduYFM1PrliHQ2BC3fenA6EyGdMh/y7f/RnW1i+dtbvmUbPF3kb/LkWqtFdl5zEph7PnmDY1j6Q3s22zveftTYpTdJmd+GXRc4cnFJazEuzkpyMk851kTZ7yJgRTJnAtFJYMs1gei8XYut36fW/dZNFIpriJ//28Eg+Ggl0t/ZeMqKb6SL/XvJ8EanCe8lag5hWAkumMWWagfTuK9uo31IMO0hf6LcYzxxndPztnOb46yn8svK8OxfxAZWXB/D5nBOozAHsdo36GRdO+BU2fHg0J4aS9xPSxmgjjTHOzvnj+XM2dVRw05Tx07p2HtrMaDbF3+94hL9ZdCNF9vEmBFNKvrL/Wa4vn8Wi0GsZRXVpkNceDCELMaWa4n7daX5VIfizJatJ53L85XOP8KGFK2gKFuGx2fIMsIMRSlxuTgz249QMZviDCCCZy3FioB9FCGb4gxhq/rmGshmOD/STNnMIoMrjo8ztLTjmjzDGT4pDe9qYv7Ru6gLTwBtS4NAV70UvumPNGBmzl4zZe5bSE2FNQfgkZY6B9F7ah35Ff2or6Vx3nqiqkJDrYnF+zpKvD9hdBvf85a0ESka1B8d2N4/Ld3A5MUye1pd8hY6hhxhI7ymQS2W4VO/ljQj1InLXpMeYq9JmzxhhYno4mzZkOnB77FRWBiYVOMJhz0URftlUY5wAcSWRtSz2RTrImBO1cwI4GevjwEDn74TAYck0R/q+RCx7mJw1xJKS/8KhV73WzRqHvCO8naxuoqsqPpudoCM/bqKZNH/38lM0BYsQAuyqzkeXriaVM/n8q8/i0g2S2Ry6qvDplevJWhZ/8+ITNAbCNEcHODkY4QvrbqCMPLHZ/371CZZe1UhRiY/vfuOpcay5ACcOd/DW+9Ze1PO8IQUOzqndODfGJiqza+U4tfMLS5osmsO0UpwY+CbN0R9gynxMvyJsOLQyDDWMrvhQFQeqsJPMto34mJwffru0G5DPkhss9TPQE2XrE3tYtnE+ngL97+WGlJKsNcCh/i/SNfQ4FnkCMVU4cWqVGGoRuuJBVRwowkY0vY+h7LHL3q7fDVz4+xvLh+LQKnBo57dQ2C4yZ42mKTTOLGXXrpYJ52ovM+HXawEpJTlpEc9lMC8Ry5QlTcxpmB2VS8QSO6FeYWNW6G+IZQ6xu/vPpmT9fd1CQiSV5E0Ns1lQVDpi7nry9HHSpsn75y8gY5r87ctPcXywH0NViWbSfGjhClpiA3zuleeo9QaAPKHdnEXVFJX6iEYSDMVSrB8TdguSgXNQuU8Hb1CB4+IxdndW7LyWWcFPnNf1Z5p0pJS0xh7g5OC3kZgowk6F+82Uu9+EU68pZDJVCgyZgrbYz4ikd/BG2V1LKXnxl1tIJTJEugfZ8+Ihbv+jDZfdh0OS40j/V+gY+g0g0ZUA1d53UOLaiF0rRxW2wrvMZ2k91PdPbziBQ8rLmyl4Mqhi7PjbwMzgx87r+nObVM+NWbPKxoTfjqKpqfy3zmzZmYjyi+bdxLJpBjNJvnP0VTzGGK4SCa3xCAcHOvnTORefgTptpvhB87cwzkHsJVB4c8XbqXCO52LJm0EkY2nvh02ew2MxD4usNYgls4WUELbx0WXCnjel/BZuxAA8ho1KT57IbvgJmqMDNEcH+O7+nQA0BcLYVJUSpxuHpvPN3VvoTyVYXV6FXsi4rSgKV23MUz8cibexZPUMbnjzknF9e2hP20XvV38vcFwgHNqoU1gq11GI/b/wqImsNUBr9IGClC2Y4f8Qtb73TZoDYjgHzBtF2BiG3WUj0h3l4Jbjef+XK6DhiGdP0Bl/FJAowsbc8Gcodm4AJneqs3jjOYpaMj3iwHmlcCnH3803L2TxovELWtPsszt9CiFYsKCaP/rgtSOpzoePr7nq3CR3Pp+D++5bRy43uqsWiqDsIhzyLgY2VUMTCgcGOkiYWV7sOo6ujMn+C7h1G38x91oWBS8+AaCFxcn40XOWEygkzIn5mSKprbTFfsyc8GdH+FssmeJA799T5r6NkGMtOTnEicg36E9tLjxjmBmBj+I1XvvcLJcKQkyUAcpdHpqCRfz9mg2oQoxoPkwpCTtczPAHuSnQOKLdOBMzZpdT21g6oY9uvHMpwfD5ZZ49E78XOC4AQgi8xhwEOpJsIRfLAIZ6YUQ/AMlcO6kCvbOhBChz337WRGKpXMcF3+vSYuxHefkEICEEa9+8gj0vHSKbzrJg7ewrMmnEModHzFtufQZhx9VnWdgsUrnfBc4DMZLDRWKN5KGZCimz+4qGAAsh8NrmItCQ5IhmDpG1BjHUySfQc9W1fn2eYTYvyGeRMocijMLvDFJaKMKeF/ILvh9C2AiF3Nxzz8oLegaPx8Fb3rri3AWvEAI2J384aw1vqVvMe1/4Pl9eeSflzvHsxZpQxgkh5wuBoNxedV7aBIHAPklYr0uvI5Y+wGB6N0HHGpAQzRxgML2zwDQsaR78X6Lp/cwv+ld0NUDH0IMc7P0Mi0v/C5s6MUfM6x3T7bVrqup4svkY//jKs4QcDpK5HH+6eBVCCDrjMX5yeC9O3aDa4+NDi1bgt43vX1VVJtCkCyFoWnDx/i2/FzguEB6jCZdey1D2KMlcB13xJ6n03HPBi6ApkyPe0qrinJRdcRg5OURfctMF3edSQgh1JAmalGbBufXyQErJ4e0nWHTNbDRdY/cLB1l4zeUXOswx2W81xctUqe2llCRzp4lmDlzW9lwJCJHPckwur73Ih3BP3tdSSvoKVPtXEl5jNk69hnj2OKlcO92Jp6lw332R34OkM/qdfIg7FkHnTfTGfwXSIuC8kaHMTiwrgV2vx2N7/QgLlwpCCLy6nWXhajy6Had2aR1XVaFyb/X7Jo36OxuUSfgpDTVM0LGazqFHCdrzNOBd8cfx25dg10rJyTjd8Seo9/8xLn1GPuGc5620x35JJLmFUvctl+SZrhRUofCRxauo8owKgQ5d42PLrsZtjE/45rfZ+ed1N7Kvt4t4NkutL4Bd0/np4b3MLyrl7sa5SCT/uWsLL7Y1c/uMpnHXRwcS9HQOUj9rVMthmRYnjnRSM6MY3bhwseH1Qyf5WwZN8eRzcqACFscH/pP+1KsjQsOZyIcdWaTNXtK5iR71huJHKYS8ZcwI6VznpGF7lszQPPg9oplDl/R5LgSqcKCrfiAvMA2kJjKyXkqc3NdKNmNiWRbH97QgrctvUjLUMMN7i2SunZwVm8g6W8gmeyzyjfOOVno9QsEYk/tG0j70q0kFCillIdPrD69sA8kLf1WeewEVicmxyDeIpLaee/zlJh9/Y0oSdN2GaUWJZ/aRybUjyZIxO7CsJF771a9bYUNKi3i2G+siInBUIfjUwusptl96Vs08U7KCKtTz+n9yIVJQ6rqFgdS2Qnj6AP3Jlyl13ZZPUmnFyVpR7NqoP40mnBhqaIrkja9vKEKwtKQCr23Ur0ZXVFaUVY2EvA5DCIHbsLGqvJoNNTNGQmUjqWSBiiEfHtuXjFPkmBgp1nqyh0d+umXcMdO0+OF/PUtfd/SinuP3Go4LhBCCcvcd9CU30514krTZze7uv6DMfTvFzmuxa+UoQseSaTJmP/HsSSKp7URS26jzfYAq773j6rNr5biNGQym92LKOEciX2VW8K9waJUIoWEVyIpaoj+iY+jXaIq7YDd/7fw4FGEjYF9eYNa0OD7w72iKC799EQoGEjOffdcaxK6VoysXZ/9rWFTLT778GxRVYcb86ivCNOo1ZmNTw6TNHpK5No5F/p06/wcKKlmBaSWIZY5wcvDb9CVfRld8Z2QtnYhh5zaJhZQ5rIIaf+x1lsyQMftQhA1F6Ai0gokt7xA3dhIe5m0Zrk+SxZK5fKr3gnAksUibfUiskfqE0EackM+c1Euc19M+9CCWzNCXfJmDfZ+jxvvu/ASOIGtF6U9t4eTgt0nlulCFa8T0dKEYTKZ4ePchEuksqqpw55I5+J2Ta/ryO9Y76U9tpjvxDGmzi13df065+w6KnOtxaGWIseMvc4JIejuR1Hbq/R+k0vOWSes1rSix1FYkEptWjaGV4jLm49Rnks615vvsdWD/l1ISSR/BrVdgqHnhIGsleKX7n1hb+lls00jmOBmEEOhTcFFIKclKC01cPpbL6WLYrKarAfqTm1AVF4qw47MvIv89awjUMdnAKcxHGZSzaI9/VyGE4J6m+fzw4B6+sXMzhqpyZ+NclpWOhjdLKZGWxLIsLEvmfZMK7zmdyjIUTWKaFxeh9HuB4yKgCidzQn8LSLoTz5C1BmmJfp/W6AMFb2il4MGfGRfGN5qOfGxdDmp972Nfz6cxZZLe5AsMdOzGUYiEyFoxUrkOTJnAqdcyK/hx9vf8HRlr+rTmlxpCKFR57qE7/hQps4Nk7jS7u/8SQw3mbd4yUzAVmSwu+QZBx/KLuJdg7upGZiyoxrIkDrf9ikz8dq2MKu/bOR75BhKT1tiP6Uo8hV0tRQiVrBkhZXZiyQwB+3KqPPeyt+dTk6SxH0XWinCg7x9J5bqwZBLTSmHKFKYVZ4TMKrWTV9rfgirsKMKOKuyoioMS5w1Ue985rj6JyeH+LxFN78eUKSyZKtSZwJT5ULaM2ceWjnejCgeqYivU6cBra2JW8JPjstoKIQg4llPmupXTQ79CYtE+9CBd8SfQ1QAChawVJWfl665w34kidFpjD1xUXx9s76Yi4GVhVRkCgdt+dpV+fvz9HQDdiefIWgM0R79LS/SHY8afiSWz48ffWcI6VcWHroYotr0NTQkQdN6CaUVRFCd+x3pU5cL4NfJasFR+ESSHKgxyVgpdcRbaKcnJBFLKwjGBJS1MmUYRGjkrhaY4UApTdtaKc2DgR8z234ubMvRClmZTprFkjrQZRRU21DG5oi4WppR8cfeTvL1+CY2+iwsrvhRQhIMS1410xZ9AU1wUOzeMOJDqihe30Uh/agsB+wpAkMy2kTa78NnySR8n5scaPfZ6ECovNQI2Bx9ZNN7naOxzplNZvvvvT7F/ZzO9XYN8umV0bUnG0/iCLoJFv3cafc0ghMBQQ8wv+gKnh35Fa/QBEtlmJLl8fPm471lBV3z4bQvx2xZOWleJcyNmKMHxgf8oqO8HiWVGd72KsFHkWM/M4Mdw6lW4jHoyqddO4IA8c+n8oi9yuP9LxDKHkeTGMKrmoQj72SnspgkhBA73hacVv7B7KtR63wvSoiX6QzJW/wSiN024KXPfQWPgT0Eo2NQwKXNqp15Tpokkt5Kxpna0lOQmzZEzNrvsKCwG07sL7LNT15i1ImSJMJZuwJLp/AJ8xutRMJgV/ASa4qF96MECJX8SMzdK868rASo9b6Xe/wG64k/SGvvxWe5/JiZ+D16HjV9sP0bfUAJdVVnfVI/Hbpvk2kINQmCoRcwv+iKnY7+kNfZjEtmWs48/+yJ8tgVT1YjbthCnMRtF5IUdm1YB5KMyFHXqtkwH+yPfJ2vFGcw0U2SfR09qL/MC76HIsZCjg7+kM5nn1Smyz2OW/x4SuW6293wNhxYiZUZQhY3lRX+BlBYHBn5IV3I7lsygK27mBt6FXQ1iWml29/0/MlYUU2ZYFv4oHuPSkHRZ0uLQYCdJ88qGQE8FIQRFzmtpjf4AiaTO/8HRkFd06vx/xMHez2BZSWxaCd3xJwk71uEtCBxDmcN0JR4jmW0na8U4OfBN7Gopxa7r8Z6RHfx3AecSomx2nXvev45Xnj3IpqcPcMtblo/M24ZNo2F2OXbHxfn1CHk5je7AF77wBT796U/z0Y9+lK9+9atAXor8h3/4B771rW8RiURYuXIl3/jGN5g7d/Qlp9Np/uqv/oof/ehHJJNJNmzYwH/8x39QWTm9wRONRvH5fAwODuL1eommD5HIngTyuU/cRsO48mMl22Q6y1D2FCZ5PgWHXo1qNWDoGsYUvA+mZdE31I2qnyKWOUgy14kl06jCjk0rxqXX49EbsWnFBXX25C9fSkna7CaS2laIfomhChsOrRynNg9dNOBzeMjkTA51vkzAE8PnqMVrzB1XZ18sgaYqeB0GkfQOMrkeQOC3L8aulTAQT6IqCm779HdAUkp6Y3Echo57zEIgpSRnxfKLXmZ/wUYu0RQPDq0cl14/kv02a5r0DyUp9rqu2C4ia0bpS20GaaIpboKO1WeNALIsSWvfADnTotjnxuOwIaVFItdCJLWVocwJLJlCVZw4tRr89kV5yviCP09f6lVyZhSPbTYuvWZC/aaVpC/5yjh173Th0KsmvGspLfpTr5I1B867Pk31EbKvnJLSWUqTRLaFSHoH8exJTCuOadmIDIXwG0tx6JUoQqXImyWR2wVCELQvnzRiS0qz0M5BEApB+4pxkSVD6QydA/nwWomkOujHpk9vT5T/BqNEMweJZg6SGhl/DmxaMW69HrfRiE0tnjTU/HJDSsmWnn+h1LGcgcwxBCo+o5bBzEkqXGvY3ff/uKr0bxFobO7+AjN9d+LUinn69J+zvvxLePQqNnd/gRr3BipdV2PKFM+2f4KVxR/HrVcUtE5xHm19P8uK/pxS51L29d+PpjiZG3jnWdvWnYzRlhg45zNkLZO/3/EIX1r+JhZcgtDYS4Hhb0pKc8K4llISzx6lK/4kOSuKz7aIIud6FJHXjiazbZMK6V7bXJz6+RE5XipYUtIZiyGBco/nkn2nUkp6EwlCDuc5GZp7uwZ54fF93PnuNdO6/5lr7dlwWTUcW7du5Vvf+hYLFozfUXzpS1/iy1/+Mt/5zneYOXMmn/vc57j++us5fPgwHk9eZfPnf/7n/PrXv+aBBx4gFArxsY99jNtuu43t27ejqucfmuW1NeG1NU16TkpJz2CcnmicpsoiDrR2kUhrrG66EbXwcnaeaKcy5KPI5yrk8Mj7WisF4p9oIsUjW9v4g+tWEnKsGle3aeUddZRCxj1EXkBRhMjTxw6fy1eLJooodd2CZq6nKxajsaoYRQh6onGO9QywdIaHnGnx0h6dm5euxucP5Sdc00JV8vb4H2/aTYnfw90r5xG0L5vwzI/uOkzI7eT6BeeXwOr/Pb2VFY1VbJg3KrAJIdBVL2HnWsLOs1Pfdg0M8T/PbuVTb74W/QokXusciPHIziO8e+0GdE1FSslz+0+gKIJ1syfP5ZGzLF4+3MwjOw/xrrWLuWnRLIRQcOm1uPTac9xRJexYc/YSioNi13UX/lBnQAiFkGP1JatvfN0qLqMOlzGqWTnZ088nfvkgs8s7UEQnhqbyJxtXU+6/6Zx1habom6xpYtc0KoN534P9p7voiyco90/PhJH/Bn2EHKvGjb/XEwQqDi1E0uxBV1zoigtTZohkjuMzajEKif+Ctln0pQ/h1Ipx6+V49SoUYeDUishaQ3mSJ6kUyJ5UlDHCok31EbTNQhUGLr2MoczETNdn4rG2g/zL3qfRlLP7REnyQsdrDSklfb1D5LI5bDadYHD1pOM47zw5E7cxOS+KQ6/EoZ97A5tMZhiMxAFBMOTGsF2+ZfNIby8/37uftXU1lLndl0zgsKTkf7ft4COrV+Iyzq6lCBV7ueMdl2cMXbaeGxoa4p3vfCf//d//zec+97mR41JKvvrVr/I3f/M33HXXXQDcf//9lJSU8MMf/pAPfvCDDA4O8u1vf5vvfe97bNy4EYDvf//7VFVV8dRTT3HjjTdOuF86nSadHt0xRqPT96bN5Ex+s+0g7f1Rblyc/zhfPHCSA61drJ83g2K/i02HmnnTyjkAPLbjMPF0Bo/dxtq5dfxs014syyKZHq9qlFLy8sFTHO/oI5ZMc/uKORxo7WLDggYe2nKQGxY38vC2Q0QTKe5aPY+2vkEOtHRj01WuXzSTR7Yfork7wo3pmSydUckrh5qxF3Z8TptORcg3kjL45YPNHOvoJexxcsuyJnKWlXf+GdbcMJxiOJ+k564V80aEk+G2jra7QCgz5tzw2WzBoWjc8TFJf4ZJZs78exilfg+fuOMatGk6fJ55j7HMjvKMY8NtHHtPl83g+QPHuW7eDGqLAuQsi5+/upd3rVsyWv+Y9ucXLoW3X7WQ5p7IuHwCY7Nljn2+qf4d164z+nQsMjkTIUA/iyAtpSSWTKOpCg5Dn/ZElC0QS00m3I195+czsUmg2Ovmn+6+YUQDcVHBqFKy6Wgz6ZzJrpZ2HIZO52CMD1zz+owGuRiIERbM0R7ThZPcmIzUWSuBS8/7SAihwqS8L2O/wrFHlXE8MdNRX5vS4pqyBj7UdPYU7Fkrx6e3/WYaNV5emDmLJ36zix1bT+DzO/n0P96Nql4+jVXrqV5+9ZMt7Nvdwif+/s3MW3hu7cdQOs1zJ04SS6epCwZZUVVJezTK8ydPEXY6uW5GPV1DQxzt7eN0NMqKqkpchsHP9u5nKJ1GVRQksKm5hWN9fSwpL2duSTHbTp9mKJ2hPRrj5lmNvNraxlA6g0PXqPT5aCou4pljxxlIpdgwYwZhl5NnT5ykL55gIJmc1veQy5q0nOihtrFkpF9TyQytJ3qY0VR2Uc76l03g+MhHPsKtt97Kxo0bxwkcJ0+epLOzkxtuuGHkmM1m45prrmHTpk188IMfZPv27WSz2XFlysvLmTdvHps2bZpU4PjCF77AP/zDP1xQWw1NZXF9ObXFAZY1VLL1aBuL6sqYXVXCjuOnuatiHlVhH+lsnkWyMxJjw8IGqor8HDndg89pY9WsGh58df+4ek3LYueJdt5//XK+/eRWUtkc/bEElpT0DA6hCEGJ303PYJzm7gixVIbKsJe1c+sRwOL6csoDHlY05glXFtdXsOXIxNwN6WyOx3ccZlF9OTtOtLN+/gwATnT38/lfPkMsmeamRbNYP6eenGnx7We3cvB0N3cun8v6ufmym4+2cLSjl55onM7BGCsbqnnz8rkoQvDM/mM8uecYJX43kaHEyLM9tO0AW4+3YVqSVY1V3LRoFv/99BbuW7+MHSdP8+qxVv7y1rX8bPNeltZX0BuL85vtB3HaDD7xpmvOusACpDJZHtp+gG3HTyOl5IaFM9k4v4H+oQQ/fGkXbf2DVIX8vOPqRUgJP960m1gqTZnfQzKbI5pI8eEbVzO/uowtx1qpCfvpiMSIJtPMqSgmnTP55ZZ97D7Vgddp457VC5hREppy8d10pJm2vkHuWb0ACfznE69w/fxGtp04TSZncqqnn5UN1bxw8CTvuHoh86pK2dfaxS+37ieZzrCqsZpbljShFMx2Nl1DVRVaeiJ4HXaKfC4yOZOsaeIwdBQhSKSzmJaF02Zw6HQ3rb2D3LVqHlJKEukshq6iKePpnTM5k5xpYdM19rV0YloWc6pKcBg6piVJZXM4DZ2cZfHSgZMsbajE47BhmhaZnInTppM1LXKmiaooGNrkJojJWA4vBEII1s2qo30gysr6KrwOG0e6enEZv1v5SKZCsWMhx6MP0zL0DIow6EsfoMF726TO5cMQQsWm+GhLvEzYnIvPqL3g+2uKQoO3iHmBsrOWy5g5ArYLT7h3qaBqCm9/79VU1YR48pE9E86f6SVwJv38ZJusySjqh8s1NpXx0b++lU/92Q/GscqeDYlslmdPnORja6/mf7Ztozbg5/7tO7mlaSabmlsIOByoiuCVlhbuW7oUj83Apmksr6wglk6zpLyc5oEBtrS28baF8/mfbTuo8HnZ0nqamoCfDQ0z0FWVbW2nKfG40VUXL51qpnNoiP5kkvpgkO/t3MWb5jSxt6OTu+fP5eXm5mm1vaOtn2/+88N89hvvxuHMm84z6Rz/9aWH+dS/vo1Q0YUnJrwsAscDDzzA9u3b2bZt24RznZ15JsaSkvHJy0pKSmgudEhnZyeGYRAIBCaUGb7+THzqU5/iL//yL0d+R6NRqqqmx4wmhEBVFFKZHDnTQghwO2zoqoJV2AFbVt5kAaCpCi67gSIEmqqSyuRIpDMj2oSRegv7mUQ6SzqbQ1UUEukskaEkiUyWzUdaMC1JkddFwbKC12EfCTlTFYVUNt8mTVUwTQvTklhS5qlqLavQXkHA7WBZQyWrm2pw2vIT9eH2Hj5953VE4gm++vBLLK4tx+e08551S/jG46/QEx0NY+yLJfj5ln384z03YDd0/uGnT7KkLm+nvf/57XzqzddiWZK/eeDxkT6rKw6ytL6SdC7HZ3/2NItqy+mJxumODrHzZDtH2nsYiCfZ3dzOutl11BYFcNkNvvboy+dMLS+l5Odb9rHrVDt/uGElqiKwaRqmJfn6Y5uYURLiLavm8/S+Y3zj8Ve4b/0yXjp0io/fsY7P//JZPnLjah7ecYhT3f2sm13HA5t2c9eKeWw70cbcqhLcDhs/27yXQ6d7+JOb1nCqp59//fUL/PM7b8HnnNwxtS+WoLWv4MQr4VhnH6saqznU3s2cihJcNoMtx1pZM6uGR3cdocTn4T+feIUPXb8Kv8vOv/z6BUIeF0PJNPFUhnnVpdSVBNhytJVFdeW4HQbffGwzFSEfQbeDqrCfXSfbOdnVz0duWUNdcZCWnvz9tx1v40RnP5aUvHXNArTCTsSSkvuf2UbI60IRgrKAh81HWth5op1bljax5WgrlpSEPE4ay8I8vecYmqqwpL6CX287iKYo1JUEae6OkDFN4qk0716/dIIvRVtkkE/99HEUReB3Ovirm9biuAgBQQhB2O1CKWjdakJ+tAswnb6eUeJYgkMLEaABVdjQFRdFzMeuBlle9Bc0Dz2DxGRp+KO49QrS5gBVrmtGyPWK7QuwayEgr8lYGPojTsWepCOxBbdeiq54qPFchyryi4TfqMM+DfbVmyrnTJi7JoMiFJaFq3DrF+c8e7EQo+rICecsS7J/dwvPPrmPTDrH8tUNXLW+iVQyy/3fepZ733M14UKkxeED7Wx+6Qjvev+6fK6mZw6yY8sJDJvGxpsXMHteZd5sJYZn8vNDidtFqceNz25nMJWmLRplW9tpFCFwGQapXJbGcJhSz6jpxKnnNwIOXac/kaTU46bE7cZl6AxlMhiqwpziIko9bpLZLD67nVK3m2K3m9PRKKcHo3TEoqRyOWr8PiLJFKVeD+VeLyHn9ITFeCyF02XDGEPwZXfoqKpKYihNqOi8u2IEl5zIoLW1lY9+9KP84Ac/wG6fOqJgsjwU51Lrnq2MzWbD6/WO+/98UFcSJJpIsedUB2GvixK/B6fNoLY4QHN3hP5Ygj2nOhhMpJhRGhqZgGuK/HgcNvac6mRO1XghSlEE1y1o4Ondx0hmsgRcdsqCXl453MK86hLmVJUQiSVw2nWKfC5KAx6CntGPoqbYTyKdYdfJdoZSGXaeOE00keJ4Rx+nuiNEhpLsPtVOMpPllmVNvHK4maPteedQgHWz65hREmReVSm6phJPZxBC4LQZI6aZsVhUU8786lIaSkKU+D1E4gkOtXczoyREU0UxcypLmDv8jDK/uD226zAP7zhENJkins5QVxzgeGcf/fEEs8qLONrZS9a0CLod6JqK22ab1uA1LYtNh5t525qFNJaGmFESojLkI5ZKc7Sjj5sXz6Is4OWmhbM43N7DUCpN0O1gVnkRJX4PsyuKCXtdxNNZmiqKGYgn6RiI8sqRZq6ZU59X4x9p5pYls6gIelnVWI2mKJzsPn+KbkUIZlUUUVsUoKEsRF1RgEQ6w8HT3bT0DvDLLfv5znPb6Y/l+7PE5yaeyqCpCrqqUlccJGdaSAkBt4NbljbREYkRS6ZHTGeuM0JEXz3cQs6y6IslRjRvI+1RFG5Z2kRvNI5pSVbPqmFOVQnNPQNEEyluWzab4519FPvc1JUEWdNUy1Aqg6Gq3LRkFgdau8hZFtfNb8Bh6KSyE/PDFHlc/OE1y/nQtat495rFUzpTTxdSSna2tNNScNZ95XgrXYNXNj/L5YQQghrPtbj1ckociwnb5+Azaqh0XY0QAo9Rybzge5gfvI+ALc+MadcCzPLfhVIgv6p0ryVsnzNSn9eoYkHofSwIvQ+HFkZTbDT570FX8jwTYftcKl1XnbNtRXY3JY5zhzuqQvDRueupc4curjMuE6SUHD5wmv/3H0+zdOUMrrtxPg/9bCsvPXsIh9NgMJJg2yvH8jmPLMlTj+7BbtdRVYXHf7Ob557cz8ZbFjJ/UQ3f+NfHaDl1cSR+R3r7+OX+A8TSGSp9Xq6urcGmaYRdeUFEQaCK8Rw4ihAjG86GUJDWgUF+sf8AlpQUuVyoijIyfwpAVfJkaooQqEJhdXUVLt0g4HBQGwxQHwxwtLePhw4cJJJMTktscnnsRAfixIfSI/0aG0ySTGYuOkrlkms4tm/fTnd3N0uXLh05ZpomL7zwAv/+7//O4cOHgbwWo6xsVIXX3d09ovUoLS0lk8kQiUTGaTm6u7tZs+bsDnkXCo/DxtvWLZpwfFgAeH/pqD35qjm1I3/rmsqty2dPWqcQgjnVJcyuKuY7T29DVRVuO6PsZPcchttu4961o+fvWjN/3Pn60tGB73c5aKocHxvvtBkMZxEUcE6twrBmhBG/iPw1SqEOWXBuBTjS0cPXHn2Zj958FcU+N/ta85qnhtIwrx5twWHozK8uZfPRFoJu57SjDYYxHBOvTObINlaVL0Z9K1QlT2KlCJHfKRdKeewGsyuKeWbfcSJDSeZUFI/cZFT4ETDs1Hu2dhUKWAXTBRQ0ZAX7gqYohTbly1SH8yafYc/wgMtBbzRORcjH7pPtlAe9tPdHcdp0qsL+gvkiX6ff5eClg6dY0ViFaUna+gbpGRxiMJGioSyMqgjmVZdiP4NqeDCeZOvRVnRNRdcUNEXFtCR2XUMRgq3H2vA58ypdTVE42NZNTZGfoVSa7cfbKPa5iacz+clsCkdCm6ZRXxyaVHC9EAwkUjxz8DiWlAScDhCwrPb1EQnxRsK5ghaV13lW1Wef2MeceZU0NuXXlsUr6nnxmQOsvW426zbM4fHf7GLDzQuID6U4uK+NT/z9m8lmTJ56dA933L2M8soAZRV+go+72f7qcaprwxfsuDmrKMzi8jKub5iBU9e5d/48TkejCCHw2e3MKi6iLjg+mmtReRlmwW/MZ7fzwZXL6YnHuXlmIzZV5U1zZuMuOH0amsa9C+ZjqHmzan0wQMjppNjtYiCVotTtxmUYfGT1SoYyGa6urcWunXu8llYGKSr187XP/oqrNs5FWpLnHt1D3cwSAuGLY6C95ALHhg0b2Lt3fKjRfffdR1NTE5/85Cepr6+ntLSUJ598ksWLFwOQyWR4/vnn+ed//mcAli5diq7rPPnkk9xzzz0AdHR0sG/fPr70pS9d6iZfEdy6bPa4UNIrATHJL9OySGdzZHImqWyORCZ71o9wZnmYH2/azfGuPqSEQ6e7uWZOPQOJFHZdozLkp6V3gM5IfjdaWxTgW0+9yu1LZzOzLMz3XtjB7cvyu7J0Nkcyk8G0LBLpDAIDTVUmHdCaorB8RhU/37yXoMuBpipYlqQs4KWxNMSTe46xcX4DT+87Rn1J6Kx8DQDr5tTxxV89x+qZNbgdNgSwZlYNj+8+Qk2Rn1M9A6QyWWqLA6N9ZOb7KJnJ+1uEPE5OdPfTOTBERyTKia6za0NmVxQTT2fpicaZURqiLxZHESJvsgnD6lnVIGFOdQkCsOkqNyyaicPQuWnxTF46eIqrZtdyoKWL6iI/XqeddfPqsaRkw4IGWnoHRoSIsfC7HRT73CyqK8+fE6OCY2N5mM6BGMtmVCCE4E0r5xIZSuCyG9y+Yg6RWJKqIj+xZAqv0871Cxtx2Sbuai51VKnfac9rSlSNgMuOqlwaNstELkPazKIrGhkrx97Iaeo9RVS5AuQsE1VM/v1dKAYzSXpSMRq8xeOOZawcQcPFS93HqPcUUeLw8ELnURYGKwnb3LQnB/HpjgnmCktKdve3sjBYdUXYPeO5DP9+4AXiuckT9ilC8Iez1lDp8l/2tlwIerqjtLX00XwyT1+fy5lU1xYhpWT+4hoe+O7LtLf209LcS7jYS0VVkHQqS6RviF//fBtPPZr3CUmns9jsF24iNFSVGcEgdYHAKLW6qlIzZgOtKQpOffw9xkaQCCHw2u14x1gKxppFFCEIu1wjv52Fa8Mu17jjIadz2uYUAF1X+eNP3cZvHtjME7/Mc8MsWFbHrfeunJDU7XxxyQUOj8fDvHnzxh1zuVyEQqGR43/+53/O5z//eRobG2lsbOTzn/88TqeTd7zjHQD4fD7e//7387GPfYxQKEQwGOSv/uqvmD9//kjUym8ThBAU+y99boKzodQ/ap4RQjCjJIihqbT0DvC9F3bQOTBEc+8ALb0DvO/aZQRcDsoDo2aomrAfl92gvjjIPWsW8J9PbKbU72HjgkZ8TjvzqkqYXVHMv/76eWqKAty2dDZOQ6fI66Iy5GN+dSmlfg+VIR9zK0vIWRbffWEHxzp7EULwb795katm1XDjwslD1oQQ3LNmAT99ZQ9ffeQlhBDcuHAmlSEff3LjGr734g6+8OCzlPu9/OlNa1AUQW1xIP9vUQBNVSkPenAVeEbmVJRQXxxk4/yGkQiSO5bN4Wev7OFfHnoBt93gL25di99p50hHLw9s2k1HJEZkKMnhjh4+cN0KltRVsLu5g3956HlqigPctGgmLptBZdCH06YTcjuxpMRp6FSFfBT73HzstrX8/NV9DLySJOxx8YENKyjzeyjxj6qwZ4/RTDkLi3uRz83C2jIOne6hvjREqd8zIdJkRulE1bYQgkV15TSWhaecHDyO0UUt4HYQcOdV8EG3k6A7/82EPPkJK+x1Tbi+1Ofhr25ai3EJqeWFEDh0HQrROi19AxR73RflFwLQkRykLR4hbHcTy6bwGQ66klHCNhe/advLwkAlVa4gkUyCrJWjxOGlLR4haHPh0my0xiMEbE4cqk57YoAyp49kLovfcDKQSZC1TBJmhnKHn3guzbFYN0PZ9IjAIaXklZ4TdKdivLt+JV49f/9Kpx+bqtGfTuA3nESzKYKGk5xl0hKP4DccODWDtniEHf2tLAxWcmlcdM8OU1o0x/uJZUYj/kwsBtNJWuMDLApVnJfgk2dQtehKDHEqFqE9HmUom0EAHt1GudtLnSdAkcM9wbxwISgu8VFTV8Q77ls7qrsUAlVV8PoczF9UzSsvHaHlZA9rr52NqiroukYo7OHe91zFkuX58G9JPmvqhbbHZ7dz59w5F/UsrxWEEARCbt714Q0jUXrDGtqLfT+XnfgLYP369SxatGgC8dd//dd/jSP+GiuopFIpPv7xj/PDH/5wHPHXdB1Bz4eMZCpIKbEwL2tCsskw7KSUD3G7sBc8jt9D5h1NhycK84ykZ6oyzAEy6iMzXF6MuX7E/CBGwz8tS+Y/xjGhpWPvdebfY7tSFNp3tmccvjcwrj1j733mMw7/O+zzI844f2YekuFnGzZlWAUb75l9NFyPecYzj9xv+LnOeO5h80r+3r+btMmXApuONeNz2JlTXsyT+48xu6yIqpD/ouo8Hu2hNRGhyOYmlkvh0mykzRxz/GX8z9GXuaFiDg5V5/HTB7imdCYBw8mW3lO0JwZYEqpmX+Q0a0sa2dHfQpnDR2s8giktbqucz8Nt++hORVkYrGQom6EnFaPE4UEguLkyP5dlLZP/PfoyppS8e8YqTgz1kDFNloVr2NR9nJDNzQxPmF+17GZlUR2nhvo4Eeshlk1R7QriNRzs7Gvho3OuQ5k0PPbSYng8nDnjpcwsL3Qe5/vHt/KVlXdNy+cja5ls6mjme4d3srOnnYFMclzdgnwWVL/NwfLiCt49awkrSqrOyQeSTmXp6Y7y6stH2fTCYf7kYzfh9TsJhtwcP9LJ1770CNfdOJ+yigA9XYNU14ZZsKQWKSUH97Xxn195HKEI/v6L9xAKe5Ay78/x+G92ccubluBwGrS39nPV+tmUlPno640xEEnw5X96iDe9dQVzF1RRXOLFsJ2fMJwPwZeYOQtpWSNz4fCcoKgKykUIOZcKuaxJf2+McInvnCRh8Doi/hrGc889N+63EILPfOYzfOYzn5nyGrvdzte//nW+/vWvX97GnQUWFj9v+zbd6dNX9L4qKoZix6cHKHPUUO1spMRegX4eeRHGfigjPgYFaJPErIt8wdE2iKmvH3uNoo4KIZNdO9Xf08Vk9x72S1HUyds4/K+YzjNMclwRYlzdZ5bXznjmkfuNKTe+/y6P7duyLMzc2UInQZ0ipPVSQcp8kqczBbSxUFRlWqrYqqCPB3ce5GhXL239g6xuyPMdWKZ11qRRQghUbfKJ2qZq9KRiZK0cxXYvKTNL2sxhUzVCdjd+w0nazFHjDtLoLebZjsNY0iKey1DjDtGfjrM70kbKzFLu9HMsllfVd6WiJMwMYbuHef4Knu44hBBQbPfSmx4auX93MopdM3CqBsdjPaStHBkrR86ySJk5UmYWEDg0nZSZJZZN4tQMGr3FnE4MUObwckDNL2zxaILBnqkdaYUQBMv82C7CsW+qceJWbFxfMYufntzJK90neXPNVPTweSSyGb6y+yW+f3gnSXOi0zHkNyw5adGbivNoyxGebz/J+2Yv40/mr8auTb2Yd3UM8KufbiWTzlJc4uVXP93CjMZSbr97GTNmlvLnn7qN55/az4mjXYSLPSxeXj/ybDMaS1m4pJZQkYdA0D1y/Lob5xMMudmy6SjpVI7qujBujx0p4YWnD9B8ooeauiL27mrmyMF27n77KsorJ7LpjjxbQbiIDybpONHFyf1ttBw8TVdLL4M9UeLRJNl0DpBohobdacMTdBEs8VPeUEr1rHKqm8pH3ueVFELaTvXw3//2GH/31XdelFlpMvw+l8pZIelINtOaPP6atsJQbJQ7alkd3Mg83woMxfaaS8G/x5VDyswSy6Qpcow3y+14ah/f+cxPp9TAVc+u4C+/+YfoxuUb5lLC9z73C7Y+vnvKMje9dz23f/DcptDKgI+7l82jNxZnfVM97oJ5afPDO/nBF381pddzw6Ja/vRr96HpEyNlypw+alxBMpZJvSfMjr6WvMOvmWNVOK9RmOktYZa3FIDZ/jKORbtZXzqTtJlFVRQWB6twqDoHBjvZWNZEysxyOjHAynAdmqLg0gyWhWtImzn603Hm+Ead4VVF5ZaKedhVnbZEhIFMnodnIJNAIolmkwxkEuiKSm9qiKuLG9gTOY1XtzOzdBb7B9pZWVQHCH78L7/mwf98csr+E0Lwp197L9e9bXqU1BcCIfI+KWeDKS3+a/8W/ufgNkwp0YRCrTfA/FApNR4/Ht2GBAYzKU5FI+zr66RlaIBELss3972KUzP40LyVU5puqmrD/OnHb56kbfnydTOKqZsxeXI5m13n/R/ZMK485M0nS1bUs2RF/YT67rx3fMKzsyEvZCTYt+kImx7cxr5NR+g53UcmeX75ZxRVwemxUz6jhPlrm1h50yIaF9fh8Fz+pJWZdA5dV1G1S69R+73AcQ68dsnfR5Gx0pyKH6YlfpQdAy9xe/m7KbFVvm6FjmH2zlQyQ39vjJ6uKP29MQYHEqRTWcychaIqGIaG023D63MQCLnxB1z4Aq5CzHf+Y3+9PuOVxIloH0+ePsxH510z7nhsIM6xXc1TChyKopw7NOmiIelq7uXYruYpS/R1Dkyrpv54kgc272ZmaZh0NkdjSRif085gX4xju05NORgdbvuUfaAKhRVFdSO/rykd9Rmq84Sp84QB8Bt5P5ZSh5dSx6hauNzpH/m7yJ43IwghqPeMJyOY4ZmcnGBsXU2+Upp8pSO/N5SNplq4oXzU3n91yWjagOH2JqJJtjy2m1T87Pl3Nj20jfVvXYV6gWHKOcvkeKyXnDVeo2RKybbeFvZFOnhf49lpr09GI3z38A5MKSlxuvnk4mvYWNWAZxL+jmHB4/GWI/zbzhfpScX5n4NbuaVmFrXewMTKOfeccKHnz/f4WEgpGeyN8eyPX+Hx+5+n5VA7Zu7CaeAt02JoIMGR7Sc5sv0kD/3Hk1Q1lXPdvWtY95aVFFeGRqIJLzXKa0LYHAanT/VSVV88wUH8Yu75e4HjtwgWFodju+k52cG9VX9MvWv262ZBHp7wI31D7N52ii0vHeHooQ76emOkkpm8yn2KBUOIvERvt+t4fU7KKgM0NJUzZ0ElDbPKCIbdl9S2KaUFMgXCPo4GeuryWfIpVi+PZimZy3Is2jOlcHtooOt1k6HzcuJoVy/zq0oZSqXpGUpQ4ktPScJ2pSGl5NjQLkrs1Xj1K8tDIaXkxN4WTh+bnPRwLPa/cpS+jgGKqy6sjdFsio9s+imRTOKMRuSjKu6ons+yorNTe2/qaCaSTmJTVf4/e+8dZ8dVn/+/z7Tby/betCuteu+ymm25N2xseg+BkJBASCCQ8PviFCeQEEggEFoCwaHG2Lh3W7Zkyeq9a7Xa3u+W2+/MnN8fd4tW2iqtJLfn9dJLd2fOnDlz78yZz/mU5/m75TewqaRq9Jc5adn091TNx6c7+PyWx+mIR9neWjeqwfFGgpSSVCLFq7/bya//5THqjjVdlpy/VNKk5kAdNQfreOQ/nuHGj67nnj+7GY9/6plfY5EkiiL42mcfpHxG3iABmKarfOzPbiA7L3DRfb9jcLwJ0ZVs45d1/8FHyr9AsWtkAbIrCSklbS09PPm73bz0zEHaW3rGjOlfeHxaHyESThAJJ2huDLHn9bTAWiDDTfXsIlZtmMmSlVVk506FgmIKGX8YYawDbQJJyHYnMv44wv0xYOrZL2vDnfzxaw+R6xq5kimcSrA2v3LKz/tGw7ScTH75+n6au/uYnp/NxpnTxj/oEiClpDF2iqSdDhEUOKeRkgmaYqfJdZSiCJWORCOG4kRXHPSk2olZffi0TMo8swgl24hZYRJ2jHLPbJpjNfSZ3ZS6q0nZSULJVlJ2gnLvHGxpUxc5ilcPUuCcNul7+PWn9pGMj290drf3cnDLsYsOq/h0J99c8a4LPByKEGQ5PBS6/ajjGOk1vely8apANtcUlk9oHEIINhRNo8KfyfHudk73TJ6A70pDSklbXSf/9dVfs+X3uzCTI+eqTO1JoaMpxEu/3sYdn9oEF88yPipUTWH+0grmLSkfvl1V3njEX28lCBRWZG5kZmrBFT2vhUXE7KU90UxrvIGoFb6gTXeqg4cb/4tPVHwRtzp1MsaTRSpp8vKzh3jwRy/T0tg9pX3btiTUGWH7qyd4fctJqqrzeeA/PoQ/MDGrXppnkckdIHSEPgeZOgHCgXCsB6UASCHtEDKxBZQMhD47/VnNS9NJ63OQyf0IYwWgAxKZOow0TyL0hQi1bEoIKaSEG4ur+Yt5IyvI7u9q4uWmk5d8njc6cnwePrVhBZFEEqeujVutcKmQSI70bkcTOl4tSMyK0BQ7TYm7mm2dT1DsqiJmhYlYvahCw6G4cCoeWuNnMRQnTfEaDMVBiat6sKosZcc51PMaHi1AX6oLt+rjTPgQnclmfFoGp0L78WQHCBjZEx5nLBxn17MXaoaMeE22ZNvje9hw36qLEjTTFZUFlyg9b8m0sZLn8uKYBD29U9XIdXk43t0+2McbFVJKjr5+in//7H9z5lD9FT//hvtWEcgZv1LoYpCZ7ePmdy+7LH2/Y3CMAYFgZdbV4/2wpElXsp1doc1s63ye2HmGR330FFs7nmFT3ruv+NiklMRiSX72vRd54qFdpFKXV7ZaSkn59Dy83om72KXd2f8hhR17AsVYgZQhsIYku2ViK1hNSLMG7E6ENh20KmTs4fRn8zgYAyyzFnbsMYRWgkzuBlfZlNSeFHuCvKdiEQ515Mcx3+Wj0j/xF9SbDVJK+uIJ4ubQCnH76Tpm5GdTkhm8rOd2Kh58egY+LYPeVCd9ZgjTTlDhmYMlLbIdRegpB1GrD0Wo5DpLcaY8hM1uBIJCZyWZjnwiZi8n+naTYeSRsGP4yKDIVYWm6HQkGulOtuFWvZS4Z6ArEycAlFJy5lA9DSebJ3zM4ddO0NXcTc4YVRRjnc+Schgnhi0lvak4AH7dOchjMxpKvGmXe8RMpsMLE3xILGkTTiWH9fFGhJSS3c8f5Fuf/jEdTaGL6iP99fWXzTN6uHkkBLJ9XPe+y8O4DUPh8UQ8dZ5YncDp1kdlH54I3jE4xsDVDlVoQifHUcBN+e9huncev6n/T0Kp9sH9EsnrXS+yNHMDmcYlKOpcBFJJi//6zvM88dCuSYVPBr7SyYY5NV3l2hvnISZQFz50Lg2p+AGJoBBpnQFpgq6DVYfERqjFSNmHUOchhBuZOoiQKVD8yMQrIMNgNSLtFoTVhNCqQLgQ+sxxzz9R+A0nfmO4ITXw0AshKPEEKXmDMjtOFX694wCKogyWZDaEeqjMvfy5EpqiowoNRag4VQ/Frhkk7Dg+LQNFqChCRRU6mki3O963i6QdZ0nGdcQiYRSh9HNXWJgyRdyOogl98FiBgiYMpnnn051sw6MF0JXJuaV3TDCcMoDuth4ObT3GhvtWTXoOi1op/mHfM3y4ajkzg3nYUvJ/tfv4wbEtSAkfqlrGh6uWj1niviq/DI9mcKa3i9ZomEKPf0I6WXXhHs70deHVDZbnTYxv6UpDSsm+l4/wL5/8IaHWngkf5wm4KZ1VyPSF5RRPLyAzP4jT48AybaJ9MToau6g/3sSZQ/U0nW4l0hcb1QhZddtiCqflXbb3k21JHnnwNV559iCJeApFUbBMi4xsH1/4+3vIznuDqcW+g6nDAAlYlXcO95b8IT8/+y1i1lBCV08qxOGenVyTffMVM5CklDz9+z089fDuMY0Nr89JeWUuldX5FJZkkZHlwek0QICZtOjtjdHZ3ktzY4iG2k5am0L09sRG5Fwon5bDzHmTrMzRZqa9FAAo6URR1HRYxXlLepuSgdDK+rd7Bz8LMRtkL3AtIFHcHwXhRrjuBLsHlMsTxpJS0hYPs72tFr/uZH1BFR3xMH7dOSY3wZsdty6YSX7AN7gYbgj14HVcXikAgWBJxvVp0iUUJBJFaMTMPnTF6DcYBDZ2P4mcgiXTL36n4mF2YCVxs4Fw6hRevYprcu4CQBXaMOK+bEchqtBoiW4n6JiHJiZucMQjCXZOMJwyANuWvPbYHta9e+WkwyoNkW5ebT3NJ2asAqCmr4N/O/wyNxbNIs/l479ObGdlbjmzgvmj9jEzI4e7K+fwvyf28f3Dr/PlxRtwa/qoz4uUklAixrf2baEnEecDMxZRHXzjefSklJw5WM+3P/OTCRkbQgiKpuez6YPXsPr2JeSX56I7tMF95/ctJaTiSdrqO9m/+ShbH93F0ddPEQvHB9s5PQ5u+uiGSS28JouWphAvPL6Pj3z2erY+f5gFyyvp64nS3tJDMMtD3OrkbPhFAArcKxBMPLn3HYPjTQIhBFXeuazMvJ6X2h89Z4/kcO9uVmXdgCauzM/Z3BDi1z/dgjkK6VRGloeb37WEjTfOI78oA10fnXxq4EEzTYueUJS6M20c2F3L3p1nOHu6nXgs7WJdt2kOLvfkVobi/IldnPMCU8+p0xcZo3w+d4V9TrxUvXyTYWO0h7/c8ShSSjIdbtYVVPKr03uZ5s/ittI5l+28VxNCCAqDflKWxWunzpLt9ZDldY+o4TLV53Worgu2e/Uglh2nJfIUEhNdCeIzZhCK78apFeJ3zKY58jiqcKGrAbpiO+nVDpPn2UQovouE1UGOez0d0VeRWGQ4liCEimU14VJXETMbCcV34NYrsGWCaKoORWjkuK/FUIPDxlJ7uIH6E00jjl936FimdZ7bO43Drx0n1NJNdtHkwipdiQhezUGuy4uUkkfrDpLr9PK5ORtwqhpbWk9zMNQ8psGhCYU/X7iWnkScX5/cz+meTu6qmMPczDyCDieaoiKRJC2L9liEfR1NPFJzmMOhNjYWVfKJ2UsJJWKjekENVSVgXH4+inMxUPb6nc/9lJba9nHbezM83PWZG7jtk9cRzB3fwyP6WYgdbgcl1YUUzyjgho+so/ZQPc/87BVefXgHPR19zF87i6qFZZf12ntDEYorsll6zQyOH2wgtzDI2hvn8o2/+g2hjjBqRjtBo5IMx3Q0xUUkPjYvy7l4x+C4ApBScjJcR22kkevzVg6jKJZScqS3hhJ3Pn7dg5SS+mgLB3tOcmP+ajRl6CdShMKKrOvYGXqZsNk7uL0lXkfY7CFoXH4XtJSSZx/bS0db74j7K6vz+fxX76BqRsGErPCBB80wNHLy/OTk+Vm8opL3J0zqajvYvvkY+3adYc3G2Vc9xHUl8ELTCdbmTWNDQRU/OPYaAijxBjne08ZtvDUNjgEcbmyltqObjr4oPqeD2UW5FGdcnVi+xMSSMWyZwJYmfeHj6Iqf7vhuLBnDqRUQdMynJ3EInzEdiUU0VY8lE8TMRiLJWuJWKwWeWwjF91DgvQ3T7kv3bPdi2hEMNUgovpe071yQsFqHGRxSSnY8vW9U0qgF62ZSd6yJtvrOC/aFWns4tPU46+9dOannRuufm2wpCSWjPNt4jPsqFuPTHdhI/LqTSGpsLpDj3R3819GdnO7twrIl21rq2N5Sh6FquDQNXVGRUpKwLBKWSdLuV10GTvR08JHnf0vCMrmQYD2NVfllfPua2yZ8TVMBy7T55dd/z9Ht4/U4fwABAABJREFU4ydvl1QX8tl/+yjz1lZfdL6DEALDoTNjyTSqFpZz52c28ej3n2PFrYvQLiORH6Tl6SN9cSzTIqcgwJF9ZymrzCUWSZBKmrjVAM3RnXQnayh0rwQm/oy+Y3BMEWwpaYq1EbXilLkLEQLORpoJ6F5yHBmUewrZ1rEfCUTNOEk7iUdz053spTbSRNJOke0IUuzKo8idy+b2XVjSRpWSrmQPnckeSt35ZBg5lLlncLh31+C5Y1aErmTbFTE4opEEW18+NuK+rBwff/H/7qJi+qXFF4UQOJw6VdX5VFXnc99HrrnMbJlpfYORmCqvNKJmijyXD7V/opKkk+8cylv/UTU0Dcu2aeruxalrLK24uvL0inD0h0UUnFoeTjUfp5aHaUeJpM5gKGlvmK4EMWWYhNVGLFWPrvgAia74UYQLkKTsXlJ2L0krhEPNxmNMoy3yEg4tG4SGQL+AvyEeSYzJ4Lr4urlohjaiwWHbktce38Pae1ZMKqxS6s0kZVv87+ldtMfDJC2Lm4rTfD+mZdGZiFygaHs+TnS385tTwxXDJZCwTBKj0JwPtGkIjx+q6EnEx20zlUjnbRzm6Z9uHjf3rHJhGV/6r09TPGP0ENL5sO0oYKIoI+dGKKpCSXUhn/rnTajq5cvdGEBeYQYz5xWTTJgsWlHJ33/hl7z0xH5yC4Jk5vhB9KEKB7Y0UYTOZOqJ3vqz2BVCV7KbF1pfZ0FGNaY02dq+F5/mYV/3MTbmLifDGIr5N8XaaI53MCdQyWud+5FS0pEIcbLvLGuyF1Loyh30goTNKE+3bKXQlcvR3hruKNxAuad6mMFhSYtQquOKXGdTfRetjSNnZt9y95JLNjbOxUA/U83nfz5CrT1s+f0u7pgA/fblxsqcMv798CvELZPeZJwXGk/w+7OH+OuFV39slxvV+dmkLIuznd3MLcojw31huONKQRFOsl1r0onFCDTFTyRVgyKcBBzTUBUXEhOPPq0/z8NEEQZOLQ9QcKp5uPQiDDVAlms1lh0l27UGU0bQFR+a8FDovQPZP10LBKoy/HrPHm2k7tgo4RRDY+byKmxLsv2JvSO2ObT1OKHWHrILJx5jz3F6+aNZ1/CDY1tRhODzczdS0M+W2hbroysRpTowMm34ALKcbpblFk/4nJPFjIwrm98R7Yvx4AOPjMvyWliZxxd//ClKZ2ZjWS2ARMqBY1TABmmDcAIJ0iaWEykjCNR+gzOFlCZisI0K6EgZI5l8Frfn/Vzu17bh0PjAH12HEGlvx9/86/tpbQxRPj0Pp0unM9FKpnMGmnASTjXhpmr8TvvxjsExRQjoPso8hZzoraXUlU9Hopu1OUuwsWlPdJFhDK+ZlshBgR9N0ZgbqKIh1kZbIkSha+iBDiV7aU+EyDQCZBh+JJDrKGRIrzWNsDnxjOlLQUNdJ4nEhasUp8tg9fqZYxobiViSQ6+dIJDto/ZwA5ULSimfnU4ENZMmR3ecouVsBxVzS5g2rwRFUWg5206kJ0oyYdJwopmZS6dRPCOtVdFa18HRHaexUhbVS6dRPD0fKdMT9en9tWQVZjJn1XR0Q+PojtP4MjzUHmkACQs3zMYbdNNwsoWXfrONQ6+dQHfoZBUEWXbDfCzT5tS+WupPNOP2uViwbiaefv6P5jNtHNt5mng0iRCCuatnUDw9n75QhANbjmEmTeatmUlmfmDSxtf8rELeV7mYX5zeTUusj5+f2sUnqlcwL7NwUv28GdEViZHvT+cOHGtuoyQzgD4JHoephCK0fuNhCAHHkJq1z5hx/iEA6Eb10Od+VqaBftz60EvYUMfOrZBSsvOZ/ST6c5jORzAvQFFVPkIIdIdOKnFh2CXU0s3h146z7p4VExd9FIJ3lS3gusJqBP1lsP3HZjk9fH/1eyj1jm3ArMovY0Xe2Gykl4IrGViVUvLq73ZyfOfYelpun4vP/OuHKJtdjGXVEo+/iMt1J9HIg4CNohZgW60oSgDDsQbLqsNMncDlfjfJ5A4UJRddn0Ek8nN0fSaqWkoisQWQGPoCUqmjmGbtZb3OloYQ2Xl+VE3BtuSgIGJ+UQb5RUO/edCooC68GYlNiWctcXPiJYeXX+/4bYKYlcCtph/OrmQPha5cXu88QEO0lTxHFvXRFrqSPdRFmvFqbs5GmtnVdRhL2kgke7uPcaqvjnxnNk2xdjoTPdRGmsgw/OQ5sshxZFDiykcRArfqRTnvp0vZI09MU43OtpHVKoMZbnLGobyNheP855f+l1cf3kkynuR7f/EgNQfrkbbksR+9wCsP70RKyYMPPMzu5w8hpeT0gTp+8Fe/ZNdzB4j2xQj1546cPlDHNz/9Y9rqOgh3R2iqaQXgwCtH+eU/P4ptS1753Q5+952nkVLy0m+38b2/+Dm9nWEOvnac//7ab7FtiZmysG2JbmgEsn2DVMHxSIJdzx9ESsnBrcf46f0PIW1JqLWH//jCz9F0jeaaNl57fDfegJtoX/raWmrbCbX28G+f/W+620fOcxkLqlDYVFTNj9a+l4eu/zg/Wfc+biyaOS6741sBp1o7qe0Ise10HeF4ktaeCwnvLhVSSk6HjxIxR1ddHevYs5FTWPLyM0omokl2PD16OKVyfim+DA8l1QXkloxsvAxUq0ymbB3SRkfQcBEwXMMMFbdmUOnPRlfGNgIVIdAU5bL9U5UrJ+Ee6Y3x2A+eGzExdwBCCG7/9PUsvm4eAKo6EAq0ULViVLUIKftQlAC6sRgzdRjLakbKGNLuRVXLQSZA2qhKNg7H9VhmLVLGEMJLyjyBw7kWVR09UfdSYaYsfvDPT9LR1kvN8RZ+/ZPNI7ezY4BCvnsp2c7Z9KZG11AaCe94OKYILtVBvjOLEnceec4syj1FtMQ7WBCsJqj7SNhJbi9cj0M1yHVmsik/LYDkUhwIoRCz4ggEOY4M2hMhbi1ci0Mx8GgubitcR1eyh0wjCNBf4y84dx6RV4iZLzHCSgrA6TYmlANhOHXu/PT1ZOQFiPTG2P7UXvJKs9j80Ovc9snr8Gd4KZ5RwCsP72DJ9ekH2ON38b6/vH2YINULv9zK+ntWcOsnNg5uk7bk6f95hfLZxQSz/UxfWMbT//MKd356E0hYftNCbvn4BtrqO/nmp39MKpGiYk4xrWfb6e3sY/Vtiwf78gRc3PLxjTSfaUNRBM/8z6tYpk2orQfDobP69sXkl+fQVNOKP8vLvs1H6WruZt270iRhWx/dzfHdNay8edG430lXIspT9Uexx/gNZwXzxtWweDNASpO0Ls2FktvFmX5+s+Mg182uoiscRb9IAbILzymJWRFa4g0E9Exa440k7Th+PZMCZwldyTZiVhSfFsClummK1xPUM3GqbkLJDhJ2jCJXOXErhinTcvLpMGgLfWYPRa6yEatdLmW8dcebqDvaOGqbBetmoagKHr+bWSum03iqdcR2h7Yeo7uth6yCiYdVpJSEzSSne9sJJWPMzSggx+nFkjYp28KhaG+LBG4pJXtfPDQuk2jprELe9Sc3oqppTpZU6hDS7sWyGlDVQsBC2G5SyX2Q0nAYq0gkd6CoBSA0zNRRpB1F06ejqmkvmG4sxba7UdRMNK2SRGIrQvFwuXwEUkI8msS2bOKxJJ1tvSNqwkTNdhJWD6HEKRDg0fKZTC3ZOwbHFEFXNEo9Q7LUioBi95BLtsA1nJgr3zk8DunXPYOfc52Z5DK0avHpHnzn7LekhX3ezaBeoZJYfRSjwjJtbHt8o8fpduBwpV82Gbl+Tu0/SyySINobo72hk+72XoI5fuasnD7oOs0uzEDVhkprpS3pbu9lyXVzh018lmXR3d5LRq6fuv5Swps/un7QNZhdmIEQYshwGWXhJ6Xk6I5T/OqfH2fxdXPSMXrbBiSFlXnoTp3vf/F/SUSTXPueVSiqQndbD6mkSUO/wNbKWxdROC1v5BOch4Rlcrq3Y3BC39ZWS6U/m3yXj85ElJreDr68cNOE+nqjQ8peUvHnUZQMVH0uQskbFNArzgjw2etXo6sKpm1PGbW5jc3Wjmep9M4hncCZJGZFqY/W4FRcvNr+DAuCKwDBzq5XyXUWsju0hVJ3JSf7DpPvKiac6qXKN5tjvfspcVUQMrs50LOD6b65l0VReucz+4lHR84ZcLodzFvbL9yopJNHX/jF1hFfEF0tPRx+7QRr714+YdXTQ6Fm/nbf05zsaSNpW/z7yndzfVE19eEQf7/vGf5uya0UuN+4TKBTBcu0eP7BLVijlP9DOqHzXX9yE8GcoYRPXV+Erg9faEjZg5QmLtddALi1IW0kl6ts8LPhSM8ZipKJy33f4Ha3e0jx+HJA0xVKKrL5t/sfwe1x0FTXyXf//tHhbTSV935yAxlZOWQ5ZyKRpOwoycgkzjPF437TIE3ha6OKsd1z57YDSPW7UzWhDitvHe9cA5iKlUHcimCflxs8lSusseALjHye3u4o0XACzzjU471dYbpae3B5nZw92kRBRS6+oIfM/CCLN85lxpIKLLOfaGmgrPYCfWQoqsrn6M7TLNwwB0UV2JaNqqmUzCigeEYBN38kLeVupqxzyHZGHpOqqSTjKWxbDrbZ8+Jh5l1TzZ2f3sTBLcd56f+2p9uqKooi2HjvSvLKcgYnmsLKvDQpz0fW4/G7SCXMCVe95Lt8fHXRDQA81XCUYk+QP5y5ClUo2FLy81O76E1e2cz8ywUh3ChqEVbqALbVjqpVoTmW9+8TGP3G4FTmbqRZQE3KPdMRCHTFoNwzA1vaJO0Ebs1LmacKgULUClPuqaI90UTcilHkLqfQWcrZ6CmciguH6kQCfakechwFlLimXmAuGUux4+l9o+4vmp5P8fS0e10IweyV0/FleujtvDAEZVs22x7fwzV3LUNMoFqlL5Xg/r1PUewJ8sez1vJPB54b3Jft9NIc6+VgqGlMg6Mx3MOe9pGTXSeKpblFFHjGZ7RMz63psuKp9ro017RxaNuJMduUzChgzZ1LB889+hj8uJw3jdPm6kEIwYf/5Hp2vHqCo/vq6O6KUFCSybkZM6qqoOkKPck6HKofgULc6kJn4tVkbxuDY8BwgHScPG4naIi2UOUtQ0qJKS1Aooo0KY0tJZpQsZGcCp+l0ltKyk7xWNNLTPeVUeYuJNMIYkoLpZ+p0JLWIGuhjT3YhyVtjvaeZqa/Ao1Lc0dKKfsrUs5dzQg82uUR8jkfuflBFFW5IKbZ1xfn1PFmsvPGJrlRVIXffvtJhCLoae/lrj/ahMNtcO/nbuHBf3yEYI6fVDLFDR9cy+Jr56IoYlgoZQA3fXgd//mlX/CNT/4A3dCYs2oGN390PXd95gZ+8tXfcHjbCUAwY1E5d356E6qmDNbEC8EwY6B8dhEPfSfEdz73MyrnlXDrJ65l3ppqfvGNR+lq7SERTeDPSHuYon0x+kIRfvH1R1F1FV+Gl0/+/XuoWljOrOVVfPPTP8YbTOeBfOLv7iOYPf6kee73daavkyyHZ9AQVoCA4eRU7/hkQ28GSBlHUTLRPB8HBNK6/NelCZ18ZzFbO56l0FWKS/WgCg2n6kJTNLyaH/q5QSs81WzvfAlVaGQZufSZvf1t3dTHauhOdnIqfJhyzwzOdJ1gW+cLzAksIaBPnZR6/Ykmag83jLp/0cbZOD1Dpak5RZlULSxnzwuHRmx/cMsxQm29ZBUExz13TV8H3ckY3119L5mGG5c65DB3qBpZDg/N0bFzk/a0N/Fnrz427rnGwvc33DWiwZE2MNJzdRo2ZmI7mmPdJZ1vpPPsfekw4e6xl+8b7l2JL8MzZhsg7cUTV6/qajwIIfAF3Fx320Iqpufx7CN7ePdH114wl1syybHuXVh2AkP1UuRePSkP39vG4OhIhHitcy85jgxWZC2gJtxAQyxtcJyJNHCsr4a2eCfX5a1iS8dunIqDRRmz8Wpu9ncfG8zJCKV6kRJ6UmGa4+3URZspdRdQ7ilmR+d+esww1+au5KnmV/BqbgpdueQ4MnmudSsxK87ijDlo4tJWb63x4bFdBYWANnmhpotBYUkmHo+Dvt7h7HK2ZfPc4/tZuqpqTM4MX4aHD375LhLRBJkFQdy+dGLa4uvmMn1xBaG2Hpxux2DMef7aWcxYPNydKIQgqzCDv/zhJ2lvCiFtOVj6Vzgtl7/80SfpaAyhqILsggwQ8O4/u3lwkg5k+/nsv30Ew5Uut80uyuQrP/0jQu296clDwPxrZlJYmUc8kiC7MINwTxRN13jiJy+x/p4VrLt7OdKW/Pirv+boztOsvm0x7/viHXQ2hYhF4gSyfASyJm8ELsku4Z/2P0/CNilyB2iJ9fHQmf18fu6GSff1RoOUEmm1ARrS7sM2awa9G5cTQggWBldhyhRK/7OnoDDbvwiBIDMrB6WfhrzKO5tyzwzU/nYFSAQKGUYWtpTcUVSSLpMVOutzbsGWFpqYurJtKSU7nz0wagmmZqgsvWG4erWqqyy7ccGoBkdnczdHtp9IeznGWezELRNDVfFoF0bmbSnT+8fhhJGAfZGBJk0oeA1jVCFDsEiEv8eQwSGRMj7lBodt2mmF3jEuw+13seqOJVfVY9HdFyOeSOF06AS847OvhqMJwtEEuqaSGXCP2L6gJJOb7lk64vGqMKj034qCitZfxh2OR0dsOxLeNgaHItIeCJ/uRSAo8xRSG0mvItoTXeQ4MkjZJqpQyTYymOmvpDbSwDXZS3BrzjTVtBGg3F2EpqjErQTHes9we+FGDEWnz4zg1lycjTbRm4qgKxobclfwYus25gdmUuYpZFnmvEu+DkuaNMVrh21zqi4CxpUxOLJyfJRX5XJwz4XZyTu2nuTVF46w8aZ5Y9743oCb3JLhJGVCCPyZXvyZ3mHbPX4XHv+FKwMhBA63g+KqCzO3XR4nJTMKhm07N2lO01UKyodKj4UQ+LN8+M81EER65TjYpzd9DzhcOrVHGiiuyifU1kNzTRtFf5iOu6qqcsF1TRbLckr583kbefTsIV5sOkmWw8Nn56xjTd7ljeFeGdhYqYPYVhNCzUYzVozasiscxeXQcelT8zIXQqCfT3UvFdJipuqg5zjd7sJzClTSEb6hKVNFHTRMRsIAbX+634m50pPxFDue2jfq/tySbCoXDKe2FkKwaOMcXD4nsb4LQ2+2ZbPtsT2suWPpuGGVEk+QhGWyo/0sa/LS4SIJWLbNltbTNEa7mZtRMGYfczPz+OrSa8dsI4FIKklDpIeDnS2c7ulESvjMvJW8u3IeBZ7RjHWB7rweRRsoS7YxkzvGPNfFoKezj1P7x67AqJxfSlHl5ascGQ9SSvYcrefZbccI+tx86WPXjXvMybp2Hn/lMJ3dEb7x+TsxRgj7utwOyipzSaUsLPNcFXCBw6kRSbWgK25UO0rEbMVJ+YTH/LYxOByKzrzADHZ2HaTSU0pPso8+M0LUipFpBNjRdZDFGbPTbVUDpf+Bjlgx+lIRulO9uNSh/AQhBC7VwZlIA5lGkLpoI3Er2T8BSQxFR2Egrge2tGmJt5PnzEZcQiV5r9lNe3x4fDTTyMWrXZkkLl1XWXvdbA7tPXsB614qafKDbz2D2+tg+Zrp/bTlQ9fqcBtc+57VaI43520nhODWT1zLtif3su+Vo7h9Lj75wPsonTl1HBmqUFibN421edOwkefcQ2+8uO/koaC7biP9ujFIExuNjJ21DVTn51CePbnqip5wnOb2XhyGSlFeEIc++r12ur6D3z63Dyklf/6hjTgdU0swF0uk+NmjOzjb3MUfvGsVVaXjKzo3nGwesypi3jXVeIMXuvALK/Mon13M0ddPjXjcgVeP0d3eS2Z+cMzzF7gDfKByKV/b+xQLMotoifXyyNn9/P7sAXZ21HFX2XxmBcdOhp4WyGRaYHyekQFEzCTP15/iH3a/xIPH97Iop3AMeXoFRZsFpJ8JKWW6rHQKIaWk/ngzPeOUtS/cMGcwP+xqQAjBxmXTMXSNF3eMnWsygIXVRQS8Lr714EuM5r6xLZtnHtnNC4/uJXkO55JuaPzlA+/GneumOboDRWhkOWZPasxvzpn/YiAECTvJupxlOFWDmB2n2ldB2IxxJtLAbH8Vh3pOsjZnKbP9VXg0Fw6/QcSMMstfSdSKk2kEWZQxC6fiQBGCMnchZyKNmNJkTmA6tZFGyj1FZBkZLM2Yh6EYLMuch4LC2pylhFMTdz2NhDQPwAmi1vDksErv7AtXb5cJQgiuuW42j/zqdZrquy7Y390V4RtffZi7P7CS2+9djj8wVMvv8ji55WMbrsg4LxdcXifX3rfqsp5j4PtSryjF0RWADCNlH7bZgCQJMoHuTK/KGkM9HG4cKu083NhKdf74L+hzse9YI//1yHbysn1EY0nuuX4hS2aPLnNeXpTFB25Zyj/8+FmsCVRYTRYuh86HblvGAz9+lr5xWCoh/XzvevbAMHXQc6GoCstvXDhi8rPh1Fm6af6oBkdnc4gj208OS3Ac8RxC8KGq5VT4snm4dj9ZDg+n+zopcPn4y3nXcWvJnCnhhDl3DF7dwZ0VszGlzZdee5p/2r2ZhVmFZDhHynmQmMnXkPbAHGhjm7U4vH90yWM6F6f212KmrFH3q5rKnFUzrvpCIK0mPsn24xzQ3Bji9/+7jff+wXryziH8UhRBRrYPXQ/gN8pxKD78RhnR5Pj39gDeNgaHV3MzNzDEDljlTZciSSkpdhfQFGulyJVLthEcFEwb8GjknVPCmneeUuicwBCt6yz/UKmTW0sfW9DPGprvzIGxCzjGhURytG9vWt+hf5tDdbIgeHlfgOcjM8vLez56Dd/5x8dHVIyNhOM8+MPNbH3pKO963ypWra/G67uy6o6ThS0tGqOHCRoF+PTJvegGkLLjhM1OMoyrqwHyxoWKtHuQJBHCg5RDE7pT18nxDYXTrp3lJT/gHamTERGLJ/nxw9v48O3LWDanDMu2x73fNFXB4x7yZg4gkTR54fUTHD/bRnFugJuvmY2mKvz6mT3cfd0CfB4niaTJr57ew50b5+FzO3ht/xn2HK0n6HNz69rZZAU9CCFwu4wJ84kk4yleHyOckpEbYOaKyhGvSwjBkk3z+M03Hx+RnXQgrLL69iXjhlV0RWVDfhXr8itJWRYWEoeijlvRdykQQnBdcRVFHj+nejrY2dbADaXTR2hpY5tnUfW5g39Lu23Kx1NzoG7M/b4MD8XVY4eW3qzo64lSOi2XtTfOQ1UvNC5DidO0xnaT7ZyLmYjjZOLh3reNwQFp42KAv0Lpd/cLIZjlm8YsXzpeebEPlJRD2obnT2BTiXXZt7AycyhWpyk6Ra6KK/oyF0Jw7U3zOLK/nmcf2zuioJGUkpoTrXzr73/Pw7/IZdPtC1mzcRY5/VUskxlvmoiok4jZiRAqQb2AlB2nJ9VCtqOclB0jbHahCJVsRwV9qTYiZhc5zkqiZoio1YOhuPDpOSSsMA7VS8KK4FJ9tCVq0IWLLEcppkzSnqjFq2UTt/roTNaRZZSiK07aEqfRhZNsRxk9qVYSdgSn4iNgDLmX41aYE71bKHHPI9dZiS0t2hNn8Ot5GIqbnlQzKTtBnrMKUybpSNSSYRThVoNvaGNsqiAUN4qYjkJVv37EUKVFltdNltd90X03d/RhmhYLZhSBGHq+pZSTvtceeekAXT1Rbl07m5d3nuLnj+/kD+9ZTVN7L/tPNLFmYQU1DR0cPt3M+25ezLb9Z3hl92nu2bSAI6db+M4vX+Vv/vCGSROXNZ5qoebg6C+6mcsrycgdPXRaNquIoqr8Ufs48OpRejr6yBiDEXhgHhOkw3uqduUYbn26g0KPn7pwN4e7WkcxOFQM972ADjIMwkDRyqd0HKmkSdPpkYnUBpBTknVBvtlbBXkFQVIpk/aWHnILApxbGitEmvZfSkln/Bil3skl676tDI6anhA/3r+LSCrJP6zbhM9IT3hTNdk/UXMcJNxeNXNK+jsfilAoclXQnYjjNxyDiqJXA7qh8Qd/toloJMGWF4+OSDoEYFuSmpOt/PBbz/Db/9nK0lVVbLhhLtVzi/F4J/79n43sJWJ2ogiNbr2JnmQLRe45HO19EV04EUKhL9WOIjRqwjvIc07nZN8WImaITKOEM/EdVPlW05k4S55zBq3xU0hsXKoflxFAIHCqXuJWHxKbA91PkekoYX/3kyzOvBMpbY6HX8Gt3cGRnhco8czHM0JlUMzqJWr1UBPeQczqI9NRwtHeFyl2z6M2vIugUYgpE7THzxAw8qkL7WNl9vvSiYtvA9hWPbbViJU6iKovRHdMjXcunkhh6BqapvDSjpM8tvkQy+eW8r6bl0yqn5RpsXnXKSqKsnh1z2m6+2LUNHRgWjbrl1axedcpVi0o59U9NaxeWIGmqry06xQp02Lr3hpi8RQn69roiyTIDEzcgJJSsvv5gyMmfUJ6ol9+4wKUEVacA3B5nSy6ds6oBkdHUzqssnqMyor2eJgfHN/KJ2asovAqkHsNLNa6k7ER96fHbWAm95OMPYTuuB5kFM1545SNIRFN0tk0skDlAAoqcq9q/sblhGlaxKNJvvLJ/6KiugBH/3VqusqHP3s9WTklTA/ciZQWXr2A3vjEJQjemt/YKCj3B/nskpX86QtPYPbHbM8n5RrtxTkRtEbCSDky0df5/Y62fbw2tpT8++5tfHbJKjIczlHHfblXzEIIfH4Xn/vr2wlmenj6kT2kxoh5SgldHWGefWwfLz51kKLSTFauq2btdbMpr8xF09Uxx6wKjYBRgCYMYmYPQijkOqtoiB7EoXvIdU7HljYxswen4iXPWcmh7tPoipN81wy6U01IaWNLG0umkNhEzW4qPEtxqsMz4m1p02e249dzyHaU0ZGopSNxFtNOYskUhuIi11GFQ73whRLQ88h1VnImvIO4FSHfOZ32+GlMO0G2o4KAkU9PsoXeVCtuLUC2o/yif4M3I4RwY6UOozs2IO2pExz0e5zEkyniCZNV88sJRxOcODt5V7ttS0zLZt70QnL7V7Aux1w0TWFeVQG/fnoPDS3dHD7dzO0bNgGSRNJkVkUes/qZZdctrcLrHlvC/XykEiavP7lv1P3eoId5a8cWRwRYduMCfv/95zCTF+q9DJCArbpt8ahhlbPhLp5pOMonZlzZMC2kSceaIulETbc2dgKvbZ5BM1YjZQRpj+2NmCzC3RGifSMbPAPIL8+56l5JKdP3aspK60ElUxa6liYmHK29ZdkkU0PtVUVBUYZ7nFVV5Zrr51zwTlFUhaioQyQ0WmK7UIWBBLT4xBiV4W1mcKiKglsbHrONmil+tH8XH5u3mIDDScxM8YP9O3nPzHk8c+YUUTNFjstN3DSJmEk+Pm8Jz5w5iSoUDra3IgR8YPYCirxpkprmSC//umsrPYkEd1TNZEleITaSLQ1neamuBrdmcE/1HKYF0sk4TeE+HjpxmMZwLwUeH5+Yv4SdLY0kLZMby9Muxc31Z4iaKZbkFfHgkX08feYk4VQSr2HwRwuXk+Py0BIJ89vjh+iIRVheUMJNFVVo44gsDcC07cHvxJb2hI8TQuD1u/jU529k5txiHvzhyzSPIl0/7Hymxdmads7WtPPob3Ywa34JN9y+kKWrqkbN9XConrSEtzBQdQ3NcnKo+1nynDOQpLkQnKoXv55Ld6qJoz0vUuSeS2+qBQUVp+rHrWUQjuwhGukm0ygh013M0d4XCRoFFLnm0hw7TsqOkeecToVnKWGzE6+Wg4KKKRM4VDeK0HCpgRFZZhWhErV6ONG7hVLPQpJ2lEPdz+JQPHi0TCQSTRg4VR/TfCvoTjbh1jMQl0kfwbYliX4G1csFaacnsYlCKAEc7veD8DAmycEkkZflIyvg4bntx7l+xQy0MTwBMFSyaln24MRt2xJD15hZnkdXT4S1i6dhWZKUlSb387odzJqWz+9e2E9upo/cTC9CCBbMKKSuOcTt69NEddF4El1TBid4W0os28bqf87Ov7+llDSdbuH0gdHLMCsXlI1bci2EoGpBGXmlWaNqq+x/5Sg9nX1jhmZcqo5LndqKnbEgpSRl2/zm5AHqw90IYJp/7GvVHCtIRH4BMobhvmdKxxPujo6q0juA7KIrQ0MwFsLRJD999HXqW0L0huN8839e5Ja1s1lYXTxie9Oy+d8ndnGqrp14IsW3HnyZ1QvKuXb5cOXjzBwft75neMm6lLKfiVnSa9YxzXczDjUDKU2ORJ6a8JjfVgbHSHBpOp3xKNua6rixfDqHOtqo6Q6hKyqPnz7GnyxeyTd3buUPFyxl6+mz1JX1cKSznZruLj63dDW7W5r4xuuv8s2NNwOwu6WJ/2/1RrriMf5l5xZ+fOO7ONbVzv8c2sufLV1NezTC3297mX/deDOGqvLVLc+zrricTXMX052I4VBVCj0+/nnnq6wvqUBTFP7vxGE+MmcRQaeT2ypn8mrDWT46dxEZThcZDhcJy+Lrr7/CDeVV3FBexb/v2YZb09hYOm1CVvierloqfbloQuVQdwNrckeKnY4O3dC47pb5zF1UysO/2M4LTx2gr2fsFcIAYtEke7afZv/OM5RNy+GWu5eyftMcfIHhSpXlngHXuAAkAoElLVShIbERKPj0HAQKcwI3IKWFIjTynGnK6ln+DQgUlmbd09+LkhbLc1b0/6UwP3gzIFGEzjTvCqx+oiiBQrajAkUo6b4CG0c0EtxqkFXZ70NKidKvbVPgrB4km8owihGD/wuKXfMmTI9/Mag71sjn1t8/blb6paJjHPfzubCtZqQdQtXnwRSGkXRd5TPvWctPHt7G5l3pSo2Ny0a/jyXwxKuH2XesgWg8yXd/+SrL5pSyaVU1H75jOT/9/ev8v+89haoqbFpZzXUr0hUJG5ZW8fX/fp5P3r160Hi4Ze0c/veJnfzdD59Oc2LMLOY9Ny7meG0rj79ymKa2Hh56fj97jzXwoduWjVh+u/v5Q0R7R39mlt4wH20MQr0BeIJu5q+dNarB0dHYxbEdp1h56+IR54ZKfzYBw8WJ3jaWZ5dd1Cq+LRbmaNfEvEu2lLTHI7zcWMMLDaexpCTL6WZZ7sgvzQFImcLp/RQIHdscO8Fzsoj0RsesUBnQgbraHg6v2+AP3716mN0+lqGtqQrvv2XJsJw7dRRvyEh47JfbWXXtLLLzi2iL78evW+iKh0LPygn38bY3OARwe+VMfnFkP9eVVvJs7SluKK9CUxQCDidL8orI93hZll/MzuZGwsm05bu+pJxZmTkUeHw8cvIIPYl4//YKFucVEkkl+cmB3UTNJJvrz7CxbBrzsvOQwCMnj3K0sx2/w0HKtnn/7AUY52hHVGZk4tYMDne0keV0E0mlmJOdh0PVKPB4cagq+R4fWa60S7++u4sD7S3kebwc7mwjnEyyp7WJjaUT03kQQrC36yyqUCbs3Ripj7yCIJ/6/I3cdOdinvjdLra+eJSurvCEFrKWZVNzspX/+OcneeJ3u7jvw2tYs3EWhkPrL/26cFxa/8t6YN/Q/wJG2aeed8urDE3+2nmlxef+fS6b5Gj5FulxaufmWKEOO274/yMxVPYkY4RTCQrdAaJWipeaTpLhcLMip2zSYmbJeIr645emaTHVEMJHKvksVuoImrEEVZ81ZX2X5Af56qduIpkyURVlRFKjwXEAm1ZVD1vdDUzWWQE3n//QBpJJM00wd86LfkZZLv/xlXtxGEMSBW6nzh/cs5pEfxjDoWsIAdNLc/jMe9aec+0M62sAZtJk+5N7Rx2r0+Ng0cY5E3rBCSFYfvNCnvmfV0aUVB8Iq6y4ZdGI/QUNN3806xr+/fBm7iqbT6Uve3gZrIDp/hzcIzCRDuD11no+N0FqcwnDhCg1ofCRmYsp9Y2dP2IldyEc1yBEEDO5FUOrGrP9ZBDpiY4dWheMyIVypSGEGJNnZqT2xijtBzwYA+GYC65fwqljTSxeVUV3sobO+DFMO46ueHArE//u3zE4hGBeTh6RVJL97S2cDHXw6YVpumVVUVBEOltbEaL/TZH+IQYewoFQhNX/A/kMR/+DnG4vJaQsC0MZePGBrigkLYuUZaErygVVLZpQuGXaDJ6sOUGxz8+aolJc2ug/Vcq28DscXFdWia4oXF9WSa574g/EwoxSjvQ0YkmbWYGLJ7ESQiBUQXlVLp/5y5u590Nr2PrSUTY/f5iaEy3DSGRGg7QlZ0628s37H2HLi0f4+J9cT1Fp1lVfTZyL8fJ8LmWsLzSd4GxfiD+bu56fndjB9rZaYlaKz8/dwOq3ANuoUAKo+jxUtRSUqZ20hRBoqkBTx+ekEULgNEYPG6hC4HJe2I+iCNznbR/gQnCd57nQNBVtnEoVKSVNNW2cHoPVsqS6kOLpEyvBFEIwc1klWQVB2hsu5MkB2L/5KL2d4WEKpwPoScb4zpFXOBvu4mCoCU2owzxkmlD5r7XvZ84YbKNp3arJhcsUBHluLx+ZuZiPzlwyrudP0SpJRn+ZrlJRy8ZsO1nEI4kxF0mKquBwXzzvkWVaREdJDp4sXF7nhEUix4Jl2fzg60+wfN1McgsC/Phfnx4eipVQX9vOfR9bh1PNIGWH6Ygfpsp/G3L8aX0QbxuDY6AkNmVbgzHDgZiqU02HH/5z3w6mZ2ST6XQNeixGw47mBm6eNoMD7S14DYOAY3SSjaUFxTxx+jibyqsIxWO0RMJMz8jCoWn0JRPsamlkbnYu4VSSLKcbXVVZVVjCr48d5GSog7+95vohMqj+VW57NIJL03FqGoVePx7dIGGZzM4qoDeZwKs7JvTiS9lpqftKby5J2+RwdyNLsy7txTZQ9ppXGORd71/JLXcv4fSJFra8cITtr56gpTE0bl6BadpsfekYZ0628dkv38qi5RMLD10J1PR18puafeS4vLx32iJ2d9TzYtNJVuaWc2PxzEui62qI9FDpz6Y7GeOVltN8Y/kd7O1sYEd73VvC4LCtOuzUUZBxQKA4N17tIV117HnhIJHe0UkBF183d1IvuECOn9krZ7C5X+H4fLQ3dHJsx6kRvRw+3cEDS2/HtEcOKQgEFb6x8ytmBHP47LzVExqrEODRDSp8GczLKiDP7Z0QrYCqz0dRiwEToWRP6dyQSprIMSwORVHQJuFZOB9njzbytXu/hZkcPWwzEai6ypf++4+Yu3rG+I3HgaIorFg/k6KybLra+wC48V3DK7we/9XrALi1XOZmfgSQaMJNX7xvwud52xgcAI+eOsZrTXUkLJNvvP4KywuKubd6bjo2W1rBjw7s4lMLl/XXoAvy3emksDyPF01RyHa5B0WFNEXh/q0vEjNTfHbxKhyqSsDhHFz9KkJQ6PGhKQrrisup7+3mr199DlUIPjF/CYXedGXEF5Zdw4OH9xGzTLJdbv5qxToyVBcBh5N5OXmc7u6i5Bz3okvTuWfGHP5l5xYynS7+cvlasl1uvrRiHf99cA8/O7QXj27w2cUr8TvGz5Svj3Ryoq+VtngvAvBprks2OM6FEAKny2DOglJmzyvhvR9by94dNTz3xH4O760jNk5yVlNDF9/4/x7mS393NwuXXVm+kdFQ4cuixBtkSXYxHs1gdV4F29pqWZdfecncoH7dSWusjxeaTlDhy6LIE+BIqIXUKC+ANxuEko3ExEzuw3DfdbWHc9VhJk22P7F31BW17tBYumn+pPpUFMGKmxfyyu9eR45g2FtmOqyy/OaFFzxPmqIyO3hp+iAzM3KYmXFx5HkTRdqbemm6RaPBHoHMcPi5QRmHPG0sWCmLzubuESuJJgNVU0klUpfUxwAURbD0mrThEu6LsWhVFWtvmDusUnLf66fTjnsh0MXFcea8rQyOWyurualiKJHs3HhVJJViWiCDuVl56ZJPw8HfrN6Aoaj89ar1GIrKHy1ckU6yOQ0rC0u5tXIGAoHe73V41/RZg/OGS9P4x3U3YKjpcs+Pzl3M+2YtQBHp9gM/5IqCYpbkF2LaNppQBuP0tpSEk0lur5yJes6koAjBvdVzuaNqFgIG+5+Xncc/b7iJlG0N62c0SGlhySQV3hwyHV68mhOQtMSnrlTxfAhFEMjwsP6GuazZOIvTJ1p46uE9bH3p6AXqs+ci1Bnmu19/kge+80HyCoOXbXwThSJE/78BCfn036oyOUKzkbChoIov73qcpGVy/5KbURCc6uug3Hv1s+KnBNJE1apQ9ZkI5a3J1DgZNNe2c2pf7aj788pymDavZFL3lRCCuWtm4M/yjaoHsm/zEfq6wgSyLwyrvN3xBljTXFVUVhdQMT3/gnvulnuXk5V7affL28bgEEKkEzPV4fGuaCrFL4/uZ3tTA/fOnIezP1dCCDHozRj431DVNHMh/Qlg50konys7L4TAcU7ehRBisO/zx6ULFb0/x0NKyY7mBp6tPUVnPMra4vILfviR+hJCoAkx4cTCvlQNhzq/ydLcr+PX0zdRyrYIpybOi3+xEEKgGxrVc4qYMauQu963gt/97zZeef4w8djIFnvD2Q5+/bMt/PEXbxmRbvdKYlAFdIBzRdLPv8KkmS3PR5k3gx+suQ9bSgJGOkx3d9l8AsZIuhLj40pMnpMJ1wsliKIWkoz+BtVYhu64ZsrHE0+aGLpKMmWhqQrhWPqe9rkcg/eOlJK+WALLsnE7DSzbJpE0MXQNt0O/Ip40KSV7XzhEuGf0cMqCdbPw+Ce/mswqzKR6yTR2PL1vxP3t9V0c23F6RC/HGx1S2sClG/ejQdHU/lq40c6fJjR8q0JRFc6vHRBCUDUrnd8XNTtQhIZTDU6677eNwTEadFVhQW4Ba4rLmB6cWHLifTPnjUpME+mLc/D10yxeO4MdLx1l+YZZGM50Wykl+7edoq0xRHl1AVVzi0ckaSny+tlUVkl1ZjaeKZLnPh+WnSCcOsvLrUdpiCZRhELKtshyeJkZuDIrz8Ek08pc/uyvb2ft9XP4wb8+Q8PZjhHbv/LcYe64bzll064u6c6Zvk5O9rQRNhMUeQLs7qinIx7m5eZTl5zDAek4uintwTBKttNzUeWzRVV5/ME/vm/cxMVLgZTwf99+kgOvHJ1YezuEmTqAZlyDqk9OaXKieHb3cdbPr+SVAzVML8rmhb0nqS7JZVFVIbFECltK8jP9/OyZXUwvzmZueT5bD9XiMDQqC7OYW35lJMfNlMW2McIpqqaw7MYFXMwNpWoKy29ewI5n9o3Yv2VabHtiD8tuGlkMbioxkETak4zTHosQNdNhVI9mkO3yEDCcqCPwk4wGM/FCmvSLIUNsKucDw6HDGCaHbduYqUsLh7yZkbC6SVg9BB3T0MXkEr/fMTgUlaX5ExfbEkJQ0U/aNRIivTFeeHg3xdNyee7/drJgZdWgwQFwfF8dS9ZVs2fLCTRNZdrs4VUhQgiKfH6KfFfG1Vnly2V9XimaUEhJi9rwyC/7ywkhBJqmsmx1FXkFAf7+S7+l7kz7Be36emO89vIxyqZNLj4spaQ7/jqR1Bl0NUCO+4ZBnozzEU2dIRTbDkIl130junpheV65L4u/WXQDIFCF4Jr8aazJq0AwOeXGkRA2k/zw2Gsc6Goalul/U/FMPli1dFJ9efxulm2ajz7FsuvnwrZtXv7Ntgm1lVIilAwM192AhW01oypTnwjbG4nzyoEaTjS0U5GfiWXbOHWN9p4IWw6eIeBxMrcin4RpYWgqTkMnYZp4XAZux5VRXQZoPdvOyb1nRt2fmR+keunFJUsLIViwfjYev5vIKB6UfS8PhFV8I+6/VEgpSVgWrzaf4aHThzjQ0UwoGSdpWYPh4KDDybzMfN5VOZf1hRU4VW3c67VSJ7BSR0GkPYCKVo7u2DRlRofT4xjL3sC2bJLxqcmdeDPCofrpiB8mYraS61oATPz+edsbHJcDvqCbk4fqyRpBJElRFLLyA8xfUUnNsaYLDI4rjSJ3Bknb5OmWo1jSZmPexHRgpJSkTAtD17Cl5HRdB1Wlw7PFkymTxtYeKoqzME0LIcSY4RAhBKUVOXzq8zfyt1/8NYkRHup9O2u498Nr0CdVCiZpifye5vDv8OgzyHZthFEMjp7EAY533Y8iDIKOxSMaHOn8jaHzq4iLWoWOhGcajnEk1MIfVK/EeQ7bY57r8rwUriSk3YFt1mKm9iNQEWomqjb1BoeuqcwqzSXUl37RFmT6mVmaS3ckRkGmn7xML93hOD6XwczSPLwuA0NTmVWaR17GlRHkklKy98XDhLsjo7YpnlFAtC+WLtO8mHPYkvzynFFLbtvqOjm+6zTLblww5R5DKSUt0TD/sOtFnq0/SXKEpGfTtImaKZoifbzYeJpriyr56rLrKPKMTaolFD+aYx1CpH8rIabWSPT406SDo1aqSIiOUVU0LoRIl7KOE4uUpD1RU0jIOyVQhRNFaJh2dHLxVN4xOC4LcgoCnNhfT27RKJ4QCb2hCB7fJerVj4JoqomO+C7GulOjqcZBefB9XXVU+/PRFZXdXbVcXzBnqF08SU1DJzkZXjL8Lk7Vd+BzO0iZFq8fPMvGZdPRNRXTsrBsSXtXHzkZHjq6I5iWjRBgWhYvvH4Cp0NnTmU+qqqgqQqWLQn6hucmCCFYsLScuQtL2b399AXjbqrvIhqOE8i4+sQ7lwMtsV7uKJvLNXlvnDLgqYJQslF1B6peDcLAtlouy3mKswMUZPmpLMzC53ZQWZhFdsBDbzTOqaYO4skU1y6azqnGDrYeOsOSGcUU5wQpyPRdwLFxuWClrDGrUwAOvHKMP1711Us6z1grccu02Pb4HpbesGBKwypSSjriUT6/5TG2t9YD4FI1ir0BijyBftFMSU8yQWO4h8ZIL3HL5Jn6k3TGo3xv/V3kuDyj3v+66zaE8CPE5QkVuv0uNF0lOQplv5SSns6JC5adj5IZBXzjma+My+djpSy++Yc/ovHU5XlOLha9yTpsaWGofuJWCAcT98a/Y3BMMYQiyCnMoK8nRmaO74IH2ZaSF3+/h0QsyR0fnvqEOUgnhB7r+t647RxqJgKFfFeAbe2nEEKwNKt8WJt4IkVLRy+7DtdRUZSFw9DIDnoGWek8LgNFEew+Uk9VaQ7bDpxhVkUe3X0xKoqy2Hm4jpKCDEzLxu9J66S8tu8MTofGzIq8CwwOSKsSLl5ROaLBEYkk6O2JvWUNjsVZxTzfdIL1BVV4NGOInVSI4YyPb0KkRQYhFX8GKU00Y9FlOc/qOeXD/i/NDQJpDpsl04tZMze9/YPXLx48piL/ylYBtdZ1cHx3zZhtLNNKr3AvI/a9dJhwKIw/a+o8aLaUfPfga2xvrUcVCjeXzeDjs5YyI5iNS9NREIPtomaKY93t/OTITp6rP8mu9ka+e3Ab/2/ZdcOq886Foowe0p4KeAJuHC5jTGMt1NJ90QniTo+D6iXjs0CnEqlLIhi7XPDpRRiqj+bodrIcs2AS0aV3DI4pRmaun7W3LGDNjfNQFHFB/Py2D64mlUjh6beiLwdyXMvZUPyrCbQU6IqPPJfBnSWLgQsfoH3HG7Fsm2TKxLJtdE1FVRQCXmeaCnrgJWJaJFMWZQWZbN51ivfevJh4wiSeSGFZNhkBNxKJ35s2OupbutmwdHSti6LSTBRFXEAQZqasEUMtbxX0puI813icba215Di9gwbrjUUzeX/V5KTW34iw7Q6EkoGmL0YoF1fLPx5GewkUZQfIz/Rddc+RlDKdPxG6+FXyVKG1rpPju2pYesP8KfteavtC/L7mCADvm76Av166ccTcDLWffmBpThFzrsnjb3c+z69OHuCx2qN8bNYSKvxXpxTcG/Tg8rnoC40e7mpv6Ep7p95aTshxYUsTTXGjKW7KvJtIWKFJSU++Y3BMMVRVGTVPQQiRDqNcZCjFsm1a2nvRVAW3yyASTZJ/Hj1xJJYg1BMlM+DB5Ry/vC9lm7zccozp/rTEcFO0m+sKhqoHFs0spq4lxPTSXAqy/Zw420ZfNEFJfpBZ0/IJR+KYlk11edqrMbsyH7dTx+9x0dbZTnlhJuFokvnTCzlV307KtMjN9BLwOkeVURZC4Bgc+3CDI12S+gYLak4hZgXy+Kelt12wvdAztrbEmwHpFaEb26zDttvR9CWo+qWzJE4UWn8o72pjoELkjRCbHwirLNk0b8oMjh2t9XQn42Q7PXxqznJc40jNCyFwazqfnrOSZ+tOEkrE2N3WeNUMDofLIDM/QFvd6An0zbVt2LaNepHaU29WnOl7hpQdRSBI2VGCjkr8TDyJ/7IYHI2NjXzpS1/iqaeeIhaLMWPGDH7yk5+wZEl6hSal5P777+eHP/whoVCIFStW8B//8R/MmTOUO5BIJPiLv/gLfvnLXxKLxbjuuuv43ve+R3Hx2CqCb2VEokme3XIUv9dF0O/Ctm0cDo2gb0hZdf/RRkK9UfoiCe64dh5u18guOdOOETUbUZUiQskIx3qa8WgOFmUO1yXI8LvJOIcHYEH1UEXP7GlD5YMl+UNuzln922eU5w7ra2F1Md19MTq6I6xbUjnqBCelJB5LjWhYaJqK4Xjr2sllvkzKfMMnWtO2SdlvhTK8BGbilXTCrh3lbbc87EdbfSfHd44dTrmS2PvSYcKhKP6sqUmYPdXTCcA0fyb5nomHago9fsr9GXS1xzjdO7IOzJWAbmjkl+dybMeFId0BtNV1EgvH3xAiblcCUkr27zxDYeV8cjILkUgsmSBh9WFPTBgcYFLekAkhFAqxZs0adF3nqaee4siRI3zzm98kGAwOtvnGN77Bv/7rv/Ld736XnTt3kp+fz6ZNm+jrG+Jk/9znPsfDDz/Mr371K7Zs2UI4HOa2227Dst4aFM8XB4ktGUy6PF3XwXNbj9HS0XtOC8nsqgIKcwM0j8IyCBBOnWFn6xfQRJx3ly3jtuKFrMqpIsO4vA9QwOvkxtUzLxC6Oh+N9Z0j6q04XQZe/8WRYL1ZUdPXyc9P7b7aw5gCGGjOG9Fdd6A5VmKZo0/ob1VIKdnfX476RkFrXQcnxsknmQxiVto49hrGhHRRBqAKgadfhTZmXp6wqSWTdMWPEUm1EjXb6UocJ5JqxrRjdMaPEje7QED5nLEXtqHWHrpaui/LGN+oePnJ/cS7HUTMNk70/I7Dof8lYXVPqo8pXyp+/etfp6SkhP/+7/8e3FZeXj74WUrJt7/9bf76r/+au+++G4Cf/exn5OXl8Ytf/IJPfepT9PT08JOf/ISf//znXH/99QA8+OCDlJSU8Pzzz3PjjTdOyVgHVtBT5Uq0pSSSTOLSdVQhSFhpYTSXNn5t+UThNDTWLJ5GvJ9D3+VMh1bORSKZojMUYea0vFH7kdLGkunjjnQ34tIMXm07waKMMlbmVE7JWEfCRL4H07TZt2NkfoLc/ADeS6jusWWMnsReFDGyzkwsVcuV9nVbtk1HIkK200PcTBE9b7JtiHQTSlxCGd4bBinMxKtIGUegoTnWjn/IWwyWabPtiT1jhgWdHseUs+mapkUiOrJukZVKh3iWXD8PMUqYczII9jPkdsWjmLY94WtJ2hZd/ff5AMvuVKM1ugsQtMf3AwKvXkRrcie64sWSKZrt7czJ+AiV80tRVAV7lEqVeCTBmUP1lFQXXvWcoKmAZdlsefbQ6BITEs6eagXApWZR5r2WvlQTKTvKZFh+ptzgePTRR7nxxhu599572bx5M0VFRXzmM5/hk5/8JABnzpyhpaWFG264YfAYh8PB+vXree211/jUpz7F7t27SaVSw9oUFhYyd+5cXnvttRENjkQiQSIxVK/e23vh6l5KScqykUgMVaW+p4dwMsn0rCy0fsl4tV8u3rTSvBFpjYzhD4xl2yQta5C6PGlZGKqKadv8/uhR5uTmsbAgn9pQiJdrzvCHy5dNifNY1zUWzCwiO8NDT1+MovwguqoOC5vkZfk5cqqZytJssjMn6iIVbGk7yca8WTRGQ1Mw0ouHlJLjhxo4vL9uxP2z5hdjGBd/28bMeva1fmKsEVx03xeLpmgvX9zxe/5lxV08WneIR2oPDFLdA8SsFNcWjp5g+2aBEA4M14X5KW8ndDR2jumq9wTcfO23nyevNHtKz1tzqI4HPvjdUSsv9r6U5gTxTXjOGB0zM3IQwOmeTk52dzAnM2/cl7KUkqOhNs70hlCEYHZm7pjtLxY2FoaSvkZFaGQ4ZhBONWLLFA7VR6ajGhCUzizEG3TTO0r5q5SSg1uOs+7uFW+JyKBpWjz0P1vJLQyij8BMLJH0dqeNwbjdTWt0D4rQKHAvI3E15elramr4/ve/z5//+Z/zla98hR07dvCnf/qnOBwOPvzhD9PSkq4pzssbvvrOy8vj7Nk0QU1LSwuGYZCRkXFBm4Hjz8c//uM/cv/99485trZIhEePHqPQ7+PaadN4saaGrlgMh6phSpttdXUIBIsKC3ixpgZVCMqCGdw+s3rwgUmYJr85dAinqrG2vJyj7W009PQScDq5fWY1lZmZmHbaWCnPyEBVatOrmSmwgl0Onbkz0kRhQb+b4AgaC1VlOVSWZpN+cY6VYDm0fWFmKWXeLDyagyL36CVnlmVj2zaapl4Wq15KSagzzH9993liI6zGDENj9fqJEZONBoGGoWYz2ixhyRim3X1J55gsCt1+vr3qbrIdHhKWyefnbWBR1pBL91BXM7s66q/omN7B1ENKyf7NR0d9iQFULihj5vLKfnrtqYM3w0NhZR61hxtG3N9a286JvWdYfO3cS362l+YWk+f20RLt45/2vMw/r76FfPfo1UFSShrCPfzj7peJminKfRksyZk4+/NkkO9aRlfiKAXuFShCx1B85LuX41KzCCVO4OjXB8nMz6B4egFHOk+O2tehrceJheO43wIhXgHkFgT4/P3vwjVSKa6Eb33tYQBSVpgc1zxUYRBONaMzcfLKKTc4bNtm6dKlPPDAAwAsWrSIw4cP8/3vf58Pf/jDg+3Ov/kmUtM8Vpsvf/nL/Pmf//ng3729vZSUlAxrY/QLt7l0HUNVmZ2bi2XbVGZl8l+7d2Pbkq5YjPZIhGkZGZi2TU88PqyPtkgEh6rx7rlzsGybzWdqqc7J5nRXJ6Y9tqzxlUJ34jA1Pf87Zpuk3YOUadP0RG8LTzYeQBWCVTlVrMqpGvGY+toOfvKd51izYRaLlk8jO9eHoipTYnxIKWms6+Q/vvEkh/eP/HKdvaCE6rnFl3Q+l17GwryfoIiRXbZtkac40TW24TrVUBVlkEl0dV45ZZ7MYcyivd44teGrl0T3DqYGtpWWhR8rnLLipoXol+DBGw1un5NF184d1eAwUxbbH9/L4mvnXvK58t0+PjhjIf+6fwtbms/y4ed/w3unL2BVfim5Li+6qoKEpG3SEg2ztfksvzq5n9q+ELqi8Kk5y8lyXp6SaU1xkusazv8SMMoByHMPlZ3rDo3562ZxZPvoBkfjqRZqDtYxd031ZRnrlYSmq3z0TzfhchsoIwiASimZv7QCt9eBpJeO2CFUxcClTk5mYsrv7IKCAmbPHi7KNGvWLB566CEA8vPTFQwtLS0UFAyJhLW1tQ16PfLz80kmk4RCoWFejra2NlavXj3ieR0OBw7HyHH5AahCsKSokFfO1LKksBC3rnO4tY3q7BjlwSDhZIolRUVIJHHTHLHM2msYdEajHG5ro9jvpyIjg5JAgEUFBdhS0hoOoykKCdOkPRyhKxajKxYj2+2+YrE+iY1FcszogCpc5LrXoAidUDLC/IwSnKo2KKw0ElJJk707zrBz60kCGR5mzStm8YpK5iwsJb8wiMttDF7jRK5VSoltSzraennlucM8+psdtLX0jNjW5TZ4z0evwXGJFSoCFV0Joiojr0pUxcPV9JEuyy69YNs0fxal3stLdvQOLj86Grs4+vqpUfe7vE4WX3/pHobRsPymBTz2n89hpkZOvN/z4iHC3VF8l0iqpwjBR2ct4VRPJ4/WHuVkTyd/t+tFXKqG33AOlslGzCR9yQTx/iRTXVH42Myl3F15+b6DiUIIwdJN83jo354kNUrMIBlPsfn/tjN71fQRX9JvJiiKQnH56MaDEILr70gbahIvlkxiS5MMRxXR1OjvjPMx5QbHmjVrOH78+LBtJ06coKwsXW5ZUVFBfn4+zz33HIsWpS8gmUyyefNmvv71rwOwZMkSdF3nueee47777gOgubmZQ4cO8Y1vfOOixzYg3X7n7Fn4HQ6qs9NxUkvarC0v52RnJ6oQ5Pt8FAcCIOUFXoug08mds2amDQtV5Z65czjV2YnHMDBtm+JAAEG6lDFumayvqCCaurJEVRmOeSzL/ecJthYszCglaVvs6jzDvIzxy46lhO6uCNs2H2fb5uM4XTrZuX7KpuVSUZVLUVkWufkBfH4XTpeBpqmDJF6ppEk0kqCzvY/a020c3l/HsUONdHeFR6XlVxTBne9ZwYKlFVd9IrrcGOn6VDE6t8s7eHNASsmBV47R09E3apvyOcUUVV0epVohBFULy8ktzabpdOuIbVpq02JyizbOueTnzKMZ/N2KGyj1BXnw+F66EjFilkksdmE4SZAuif3UnBW8Z/p8jDcIt8W0+WUUzyjgzMHRw5mvPbabd3/+1inPubmakFJimTZdHX2kzjFOhYBAjoKu62jCRUqG6UwcxcXEiwym3OD4/Oc/z+rVq3nggQe477772LFjBz/84Q/54Q9/2D9owec+9zkeeOABpk+fzvTp03nggQdwu928//3vByAQCPCJT3yCL3zhC2RlZZGZmclf/MVfMG/evMGqlYuB2zBYXDgUb9JVlbnn5JLMzh0/UUkIQaHfT6F/iHBr4TmemqVFQ7HH6VlZTM/KuujxXiwsGSdhdeDWihCj0GHb0sSWCSQOHKqGIhSWZ0/jdF8bBa7gpM4Xj6VoONtJw9lOtr50NJ1sqwoMQ0M3NFRVQYj0jWyaNsmESSppjlj2ej4URXD9rQt478eueVu9dC1p05WIkO3wvuWNrLcDJhJOWXbjgmHK0lMNb9DDgvWzRjU4zKTJ9if2smjjnBH3TwZCCLyGg88tWMOdFbN5tv4kO1rraQj3ELNMBODWDMr9GazJL+P6kioKxsjzuBpw+5xcc+eyMQ2OjqYQz/xsMx/667unpMLnjYBUyuIHX3+CAzvPkIinMBwasWiSorIs/vjv1uHOShJONSFQMJTJUeJPucGxbNkyHn74Yb785S/zt3/7t1RUVPDtb3+bD3zgA4NtvvjFLxKLxfjMZz4zSPz17LPP4vMNDf5b3/oWmqZx3333DRJ//fSnP0VV3xjW7xsZ7bHtHA/9J6sLfogxgtopQF/yFAc7/4VM919QF03RGkuHMvy6iyXn6alMFmkLWRIzkyMmf04UhkPjtnuW8qFPbcQ5CoHZGw22tHml9SRJ22RVTiU7O86QsC1W5UxjZ0ctzbFuKrzZtMX7MBSNBZnFHAw1EjTcOBSNlngPmYYHn+7kiYYD3FGykFmBgjfURPwOJo/OptCY+QAOt8HSG+Zf1jEIAStuXsQzP3tl1HLPPS8cJNITnRJCKwEIoVAZyOLT/kw+OXs5Sdsi2R9CcagahqKiCPGGvL+FEKx/9wp+//1nR0/0lfDkT15i3d0rKJtddFWuoynSi64o5LjS1TcJy+T1tjqKPQGm+Se+4O1LJWiPhVHbTE4fa+ZvvvV+nvztDpavq8a2bHa8eoKCnGkomkmmYwYCFUsmiIUnXqZyWSgbb7vtNm67bfTyNyEEX/va1/ja1742ahun08l3vvMdvvOd71yGEQ5BSkl38gyG6sOjjR7DStlRWmMHkdjkOufiUCdm2VkyRVfiFFmO6SijSKJPNboTh3FphejK6CVuDjWLmNlEgdMk3zUNn55OomyOdY/esRBXJLtBCCguy+aDf7iBazbOumyaM5cDEuhORvFoDhqj3ezuPIvfcJFpuOlORlGFQm8qnYhsSotH6/fjVg3ORjrJNDyszJnGq60nubloHjP8eVQHLo+L/R1cOUgpObDlGN0doxPxlVYXUjrz8nI6CCGYuaySrIIM2hs6R2zTfKadk3trWbhh9pSORQiBJgSaouAeh+r8jYTCynxW3baEZ362edQ2odYe/vv//Ya/+ulncHkvD3/IWNjf2YjPcJLl9CBIh2BTlsX21rNM82el5SD62w78oiP93RrtY0vLGVbE88grDFJcno0v4EJVFRYsn8azj+yhs60XR3Y7quLEr5eiCRcwepjwfLx9fNRj4GjPw7RE947ZRkqbqNnOrvbv05M8O+G+U3aUmt7nMe3E+I2nCCk7jEPNZKyfVxEGQugcCJ3i0YY9/PT0q/y8ZiudidFL9gqKMnjfx9dSUZV3WTLpFVWhpDybj37mOr7xnx9h/aY5bypjA9Ivlxynj/pIF4oQ5LsCTPflUe7NojnWTbk3G5eq49OdeDQH5d5svLqDxZllBAwXPt2JU9Vxqhq9qThnwyO/GN7BmweD4ZQxQohLNs3H6R476X0qEMj2MWf16Po1A2GVN4LOy6UikTQ5UddGOHbxc6+iCu749PV4x0mk3fH0fn79zccxk1degkACm5tO851DWzja3YoqBHn94SkpJa2xMD88uo3/PLKN2r4QzdFefnBkGz84so36cDeNkR6+e2gLj9cdxbJtApkeekJRkokUhaVZvL75GM11XXR3hkGCqjip7XuO072PEU41Tmqsb11RijGQjqNKLJlECHXYw5W2Bi0smUIVBoJ02aeheqny30RteDMTfRptaaIKncXZn+i3BPsrM2QKIVRsaQISVTgGVxNSpsclsVGFjmDynBcuLZfW6FZsmUQdgVFTSknCCmHaERYEp2ELnSJ3BoaiURNuH7Vfr8/J+z6xjrvet5La020c3HOWowfqqT/bQagzQiKRwjKtUZM/z4eqKjhdOnkFQWbOLWbF2hnMXlCCz+96Q7pYJwJVKMwNFjEvowif5qTYnUHSNqmPhCh0Z3Cyt5V1eTModAcH20fNJKoQaIqKoajcWjwfl6rz7rIlb9rv4R0MoaulmyPbRg+nGE6d5TcuuCK/tVAEK29ZyOb/2z6qAbTnhYNEei8+rHJunsrluKZYIkVrZx+ZATe2LfG6DHqjCTxOg95InHgyRU7Qy4u7TtLRHeG2a2bTHk8RS6QoygmQsixaOvrI8LtwOnRaOnrJCnrwOI0LxiuEYNq8UjZ9cC0Pf/fpUad+27L5v289icvr5O4/uRHNmDp26YlgQVYhi7OL+NWpfcwMDue4erbhOKvzyslwuHn4zEHcmsH6wkrcms5jZ4/g1gw2FlaRtC32dTSSmx/k+jsWArB4VRXPP7qXr/7xz1i8qorsPD9oTqqD70YgUIROjKscUnmjw8bkUOhXtMb241KziZkd5LnmIaWkM3Gcw6HfkLQjONUgC7M+ilfLv6ibpz1+hKPdDxMzu7iu8B8w1HSIY1/XT1GFQShZQ9IKU+Jdw6zAuwA43vMYDZHtSCxcWjbLsz8zeNxEkeNayanuB6nte4hy3z393owhg8aUYU73/AxDCRIwyqnypXix5Si2lKzLG7umXAiB2+Ng9vwSZs0rxrYl8ViS3u4one19dHWG6e6K0NsTJRpJkoinjRBbSvR+4TV/0E1Glpe8giC5BQEys3w4nPqo6rFTAYGGwEAR4yhXoqAIA0UYXEx5rBCCgDFUcuvWDNwYGIpK0jZxqBqlnky0czLxz20/cAyAV7/y7tl3MPU4tPUEobaRy70BCivzKJ9bMur+qYQQgjmrZxDM8RNqHXlMTTVtnNp3loUbZo+4fzyEEjF+feoAC7IKmJuVh093TOnLd8u+GhJJk0XVRew93siqeeW8tPskS2aV8Nz246xeUEGm30MklqAoJ4DLaXDoVDMHTjWxal45x8+2UZjjxzBUXtlzmlgiRTSR4kO3LEUdYZxCEdzzpzez85n9NJxoHnVcqUSKn//tQ3Q1d/P+L9+JP/PKJXwnLJOEZfVr10gs28aWEhuJrqgkLItk/35dUUlaJqoQqEr6X9K2SNnpihRVU7ju9kUIIXC6DP7mm++nrzdKRpYPTVdoiR3GUHwIoWDaMZxUTHicbzuDQ0pJW+wgTZGdrCv4KrZM8ULTXwNgyhi7O37E/MwPkOmo4lTv0+zv/B/W5P0lF/PyyXXOxZOdy0vN/w95jmkcNTuwZIpVOX9O1Ork1ZYHKPduQBMOTvU+xYrcPyOglxC3etBG4YsYC36jmsrA+zkW+h7tsW3kudfhUvOQWIRTdTRHXiSSOsv87K+gKz6K3fDBitVIGPGBGw1CCFRV4PE68XidFBRfHTnp8SEoD/4xxf4PogjHqDoqAFmu9Swt+D9A4NKnTpnYrTlYklU2fsN38JaCZdlse3z32OGU6+bhvgR9oMkiqyCDmcsq2fb4nhH3m0mT15/cy4J1sy6q8mJ/ZzP/svdVVCH42xWbeE/V1CXDSilZPLOYbQdqqWnsRAIpyyIaTyEllOZnMLcyXTVYkB2gINtPyrQ4draNgNdJXzRBXzTBgulF6JpKc2cvsyvyCXidjJahJoQguyiDj91/L9/4xH+OqkkDaa6i33/vWY6+fpL3/9VdLNo4G8N1oedkItc5UU9xkTvAwa5mnq4/xu3lc2iJhtnedpbeZIJ9HU3cVFLNo7VHSNkWd1XMw6VqPHb2CJa0ubN8LgqCR2oP4dcdTAtkDV7zwP9urwOXx6C5votgtotwqhFTJnCqGRS4lpKcBOvD287gAOhMnCTbORO3mq6dznKkY5qRVDuhxGkOhX6FQCUlo2jC0R8amXyVhBDKKImigmLPShxqAFVxoAkHph3HqQep8F3Hno4fk+OcTaV/E+Ii0mwEClXBj+DRy6jt/Q3Hur6PTfoh0YSboGMOszL/hGznkMt+MobGmxHRHi8Z42g6WJbNrteayc0LUDnjnWTNNwv6uiLsfHb/FatgK56eT2Hl+PogAKHWbg69dmLU/ZqhsfzmhVM4uvGhqAorbl7I9if2jPpS2/38QSJ9MbyByTN+Hulqw5I2TlVnYfbUJ8I2tvWQsix8Hie5mT627juDw9BwOXSyM4a8wUGfC5dDx9BVvC4Dy5ZkBtzMn17Ik68dZe60fNYtquRYbStupzGm+oQQgpW3Luauz9zAb//1iTFL+qWUHN9Vw9+//9+ZubySDfeuYv66WeQUZ+Jwj2J8yLSeSSwcp7MpxJnD9RzaepyWM6OHuAcwP6uA+VkFw7b94ayVw/7+8Iwlw/7+yIylY7YfCb/7+VbueN9Kyss30Z2oQWIx2YX429LgUIU+qJQK9OdSpMV8XFomK3I+i9FfhSJQx3XDTxYCkc4PEWJYTFCgMDt4DxW+jdRHtvFqywNsKPgaXn1yLz8hBAKdQs/15HvWk7RCpOw+BCqGGkBX/BeVG/JGgpSSrs4whw/Uk18QpLQ8m727a3G7DapnF3Fw31mikQTVs4owTYv/+8U2rtkwiwVLyjh+pIlwX5zyaTkYhsahA/UUl2ZRUZlLdo6f5sbQBQZHMmmyb1ctHe29LF1ZSU8oSk9PlGDQTWFxJvt21+IPuKicnk9DXScl5dnU13akw3QdfQSCHmbNvTplc2911B5p4P77vn3FzveRr97D+/7qznHbSSk5/NqJUUMXAPnlOVQuKBtsD5cn7+FcCCGYv24W3qCHvlBkxDZNNa2c3n+W+WtnTno8LdF01UKu20uhZ3I8DeNDMK+qgLlVBYOvuhmlQ9WF+VlD55szbegZvmvDvGG9LJg+xMdUXTYxoThNV3nvX95B85l2Xvnd6+Om8qWSJge3HOfg1uO4fS7ySrMpqMgluygTT8CNqiuYSYtob4zu9h46m0J0NIXo6egjEU2OydlyLqZKWqL2ZCuZOT4MQ6P+TPt5xqiktbEbJPQm64iYLXj1yRuTb0uDI881n1O9T9MY3YGUFp2JExR7VuDRc8hwTON4z+OUeteQtMIYqodc53ySVoS4FcK0Y0TMdiKpdlxaJooYeVUlpSRudRNOtWDJJOFUM7Y0cfaLA42ElB2hPrKNgFGCT08/EOcaRpOFEAIVA5eWh4vRperfrHjxmUOsWV+NP+Bmz84zeLwO2lp70XWNfbtqueHWBWx79Tg33r6QzCwvs/p1WF7fepLb3rWEQNDNk4/uZfmqKl579Tj5BUE0TRnRaG9q6KK3J0pfbwzD0Ni76wyLl02jsDiDHa+dIrcgQO3pNjRN5eSxZnLy/Bw91EAqZTFvYSl7dp6hrCIbz1Uom3tb4ApWVUz0VNKWbHtsz6icFwCLNszGG3AjkbzYcpT1eTPRR5lTphK5pdlULSpn74uHR9yfSpi8/sRe5q+dvFjiwOPj1QwMZWpfMen328TK80d7GSZTJqZt43ZM3mvt8jn54299mEQsyY6n9k4s7CEh2hvjzKF6zhx6Y4owWqbNr3+ymWuun0Nmjo9/+MIvCZ6jHCyBUD9LriIMepN12NLCqWYAE88xfNsZHEIIMoxpLM76JPWRrXj1fBZkfgivXoCCzoqcP+V03/Oc7n0WQ/FS4bsOgLb4QRoir+PTC2mO7iGUqGFuxnvHSOi0qQ2/RHfyLJmOKk70PkHQKGdm4E5yXHPw6mkDQEGlyLMcXXGjCI2Y1Ulrz35U4WBR1sfxT2EewVsJUoJlWviDbpxOnWTCJL8wSF9vnGQiRVa2j+wcH7YtMfQ046nDmb7dvX4XWTk+VEXBNC0CQTeqoqTVcKVE2hcKBQYzPJw9007ljHy8PicOp05uvh+3x0EikcLvd+Fw6pimlXaNRpOYpo2iCHx+F5qmYllvgVrDdzBhhNp6OLj1+Kj7VU1lxS2LaE30UhNu42hPEyuzqzgYqkdXVGYHimiOdVMb6aDKl0eG4eZAdwMe1cHMQEF/guDFQdNVlt+0cFSDA2DX8wf5QO9deCYZVinypskGo5ZJyrZwvoFeM1JKYkmTlGnhNPTB0IgiBLaUCJH+bNo2aj8hmdXfxrZtzrR0UVmYzRd+8Ad8/y8eZPP/vT6mQflmgaopfO5r70LTVY4fbOCaTXP52J/dMKzNv93/CABePR+vXoDfKEEVDiZz9W+cO+EKQgiFQvdSCt1Lz9sucKj+wYqRc7cXuVdQ5F5xwfbRz6Ey87x+Bo6Z4R8iRVMVgwWZHxnsa07wPRM+x2Rwpdy1k4GUMWyrBUUtB9mLlDEU9cLwkbTDWKl9KFo1Sr86oRCwdFUVLz17iLKKHBYuLee1V45jGBrzF5URi6VQNYWCogxUTaGkNIttr55gxZrpFBVnpr8HActXVbH5+cMUl2WhagonjjbT2xOjo72PnNwh+vpQZxiHQ6ezvY+mhhD5hUE0Lb0SXbqyku1bTuByO6iqLqCpoYs9O2ooKMqgqbGL7VtOkJPnx+u7/DwL7+CNASklh7edpKule9Q2OSWZVC4u57f1e1iTO52+VJzXO04jkUTMJDaSHR1nqPbnowqFl1qPETOTNERDeHUHpZ6Ll00QQrDo2jm4fU6iffER2zSdbuH0gbPMu2ZyYZXluSW4NJ3WaB9NkV6qjckpil5OSAl7TjYQ8Liob+9m98kGDE0lJ+ilNxJHVRQ2LKjk9WNnsSUsmFbA9qN1lOdl4HYaPLH9KHeumUN1cQ5/9t2PUzw9n4f+/WmivbErfzFTOJUPVKQA5BdlsPGWBcPYnaWUlE7LRTc0epN1xKwudNOHaSdwM7K6+Eh4WxocMJ6xMEJp1EW8qEc7ZqRa78mc5/zY3gDBy5jHWPVIGUfRpo87nonGDoeOZ8IZ1cPH1IkZewrD+0dIGUXaYVDzLzy/0LDNGpBJFPXawTFXTs+jcvpQqOjmO4Zkp1dek77OVWtnIIRgzYYh1/Ca9dWDfZRV5FBWMTQh3nT7whHH2tMdJSvHRyKeQkrJ8lVDD1lmlpdb7lw8+PemWxYMfn7uyQOsWF2FP3h55LbfwRsT0pZse3z3mKvf+Wtn4c5wI0OSSm8ugX422gWZJfQmY3Qno9xWvIAtbSewpE17vBdVKFT6cvBol268Fk7Lo3xOyaiU66mEyetP7mPeNZMLq8zJzOPm0hk8XHOYX57cz98s3TisDPxqQggozc2gJdSLqigUZqUXFY3tPSyfWcLppk7OtHQCgtqWTgxNZemMYiryM+mLJaguyaG6OD1fuLxO3vdXdzFndTU//7uHOLrj9BXxdghFkJkXZNG1cyisnPpQeWaOj8ycC3Nv3v3Ra1A1lZiVImn10WEdpipwO3ISXGdvW4PjzQ2JGX8K2zyNok1Hc96IlXgVK7UXoRajOa7BSu5Bc95EKvYbNMe1JCP/jZQxNOd1aI71pGKPI61GVGMhqnHNMKMj3ddBEA5AoOpzEMKNos8kFf0dmutGzOgjSBlFc25E0apIxX6HtFpQjRWo+hyS0d+C7ENz3oZQMjBjjyJJoOpLULRyUtHf9J/NBBkmFfs9qj4XmI6020jFHgaZRHffh6LmI9RCzjfpJ2METtT4Gw3zF5cxbXoeqqrg9jgmZCRKKVl33WwM482doPsOJo/u9l4Ovjp6OEVRFVbesgiHqlHly+Ph+t04VZ3l2dPY3HoMgFuK5rOz8wxxK4VHc7A+byavtB4nYZm41UvXFjKcOstunD+mxsuu5w7wgS/fhds/8fJ8XVH4q8Ub6IhH+PWpA+S7fXyweiGefn6Zq/Es2JZNc1M3mTk+jje0EeqLUVmYRYbXDUi6+qLsOtFAwONEU1WSpkVu0MvMklx2HKujoyfCgspCUpbFsfo2ZpakE01VVWHhhtnMWFLB1kd28fiPX6Rm/1lSU8w4ajh1coozmbViOstuXMCc1TPIyg9OmWCclJKO1l7Mc9Rhz4cQkJ2XDpdlOWeR6ajGo+XTNwlq83cMjjcphJqPgoWZeBHVWIaZeBmH7wsgNKTVhm3VARLbPI1w3YlqrEAIA9WxHts8gZV4BdVYQSr6O1RjGTCUzGhbTSj6TOzUYUBFKFmY8afQEEASK7EdoRaiGUtIRn6E5rwBaYcxvJ8GBEgTRavANk9iJbeiOa/Hts7i8H0RhE4q9jtUYxFCeDETL4HwouqLsa3GtHdDGChaJVZyL1ZyP4rr8pao2lKSsiw0VUFhZCEpRVHwTzKWLYTAeRnVPz1+F2WzirBHcS/lV+QOZNldVmQVZlA6q2jU/cEc/6j7JgJv0EPZrKKL8qJdDgSyx668kDJF7bEtODz1FM3woKoFnGssW1YT3gzJ9KUCSHFd/uzB/AGB4H0V6RJFBcH1BXOQUqL2qz6fu+9SIYRg+U0L2fLIrlFfkJqu0VrfQcWciROT2Ug8usFXllzLP+15mX/Z+wpPnj3GusIKKvyZOFVt3NtycU4R+e7JVbjEokkSiRTBEWjI+/ri/OsDj/GX/9+d3LCkGpAoYihBXNdUvE4HM4pzEALmVRT0i8pBcU76JasIwd3XzLvgmxdC4PG72fShtay9eznHdp7mtcd2c/DVY7ScbScRTU7Y86FqCpqh4cvwkFWYSfnsYqYvLmfGkmkUTsvDE0izME+10ZZKWXzvgcdoqu9EIEgkUsSjSTx+J0iI9MXJKwzylW++j+z8LDxWHqd6HqXYuxaDiecZvmNwTAIDIji2lEhkP7Wr6FdFvHJWu7TbMWOPobvuAbYyPG9eAgrIGMgI0u4BRNoQkUMMLULJQTUWoRpLgPNWS0JBCC9C8SNlHKFmg3CRij2C7vkAdurEeec7VwpIYiY2I+0eFLUQabUPng9x/ipJOacPABuQpKKPoKiFKEouYCGlDdJCirSmTfq7nprv25aSnx3ay0MnDrGxdBp/tmQ12pvEG7Fk03wWrB+dDVJRxGXXohFC8NH/924+9Dd3j9pG1S5tDKtvX8zymxaM3/AKYbzrsWWYkrmv8tXfh9C1TLIz7+dcXaNw5H+JJV4gIf4Q03oIXSsfxoOjct7nc25HdSoD90Dl/DK+/fL/N6YxN1ndpK3NZ7l/x/P0pRL0JhOY0uZAZwsHOlvSc+V41yDg++vvIr904gaHlJLXt54kHI5z27uWXLDf53fxV/e/i8wsL6p6IbfRnLJ8FEUMsh1r6jm/gRj58wXDFgKX18mijXNYuH428WiC9oZOGk620Hymjc6mEH2hCMl4CiHSibu6Q8cbcOPN8JCRFyAzL0hWYQbBHD+egDv93YvL/37RdZXP3f8uLMsmHk3y3//2LNfetpCqWelqyWMH6tm/o4ZgppeY2UFn/Ch57sUEjHJik/DmvGNwjIO09onkTE+IVxtq2dfWQnOkj6Rl4dI0Cr1+5uXksbqwlGnBTFRlaO2xramOF8/WYKgqH5u3hGzX5OP4L56tYVtTHW5d5xPzluB3OBHCj1CLsFJ7UPW5CCWA5lhHMvJjhFqC7rwFhJ9k9DcoWiWgoOqzSUV/jZlQ0RzrUPRZmPFnUPRZF+R1KEo+Qgki1CKETCEw0IyVJKMPoqilKEouqdhDpKK/RnfdiaJVYadOkgz/J6qxHEWbgRl/CjBRtHLAiaKluQaEEGiOjaSiv0EoPhRtGtJqwEpuR8ooduogqrEAK/EaQvEh1Dxs81Q6xINAUUtRtelIwbDEkYt9IOOmya+PHeBYVwft0SgfnbuYrIv4na4GVFVB7U/sGimv50pACIFmaJd1IlE19ZKNlisJRQTJzvonDMcPSSR3Yzj1tGZTPwznR7GsG2jpeDdXWyVNKALDeenhmXPRnYhzurdrxH3p5ck41ywn963EY0lefPYQzz6xH4dDp7kxRFa2j9vvWYqmKRw+2MCOrSdRNYW737sCn29I1yrUFWHr5mN0dYSZObeIxcumoesqp0+20tIUQiiCE0ebKCzKZO3GWbjcE/uuhJI2PkpnFlFSXTj+AQPHXaXFjhCCQL9n6NTRJhRFsHxd9aBxFsz08Pyje+ls7yWvKIeqwJ2DOmMxRldBPh/vGBxjQEpJRyzK9/a+zsMnj9CdGDmb+6ETh/EbDh5Yt4lbK4cSrA60tfCjA7vw6AZ3T599UQbHjpYGfnRgF5lOF++ZOQ+/wwnCieH5g2HtVMcGVMeGwb8Nz8eH7RdKAYb3c4N/664LK2iG+loLgKKlGVil3Y6V3Inuug1QQXjQ3R8e6hvQ3e8d1ofh/ZNhf2vOW88ZSw6G94/Pa//Z4WPQFw372+H7wvBBSsnWxjr2tDbx0bmL8TsuLolOVxRK/UFOhDopDwRxvYmks8+FJSW/PLofh6rx7uq5U7wOHhtSSlLmKVQlC9OqR9emYds92HYvuj4DIVSktLCsZkyrFSEc6FoFQnj6E54tUqljaHolltWGZbWhqjloaklar8FsBKGiCDcp8zSgoetVKMLVTwEdIWWeAez+fn3YsgfLakXXZqT3p46j67MRwkHKPI6mlqIoY4uTSWlj2x2YZgMIUNUiVCV3MEk7va8eobjRtQrAOM/dPVbe0OSTw6ca4yWbdyTCeDQHLnViz8RgpV1mLl9ZsvGSxlYdzJ5wW0VRKCnLJpjhITfPz/JVVTjdBmq/t6KoOJN5C0v5z397lptuXzRocPT1xviXv3uUGbMKKK/M5anf76W+toN73reShrpOfvzd59l4w1wqp+fx5O/3EOoKc98HV0/aKHiz5W8ZhkZLY4jm+k7yizKRSOpq2gh19KFp6qjcUxPBOwbHKJBS0hju5fMvPsmulkYkkOF0sTy/mNlZObh0na54jCMdbRzsaMWpaizILbgiE/2VYCI8FxIT1ViEos8bPfnyEvq/GNi2zYNH9rGzuYF7q+detMGhKQr/sHYTH5y9kBmZWbi0N+cj0RWL8t09rzM7K4e7Z8y5JI6GycMm1PMPKIqPlFmDphYACqnUcYL+L+Jx30Ik9jh94Z+gKFnYdhdCeMjJ/C6qmoWUCTq7v4jLeR3xxHZAoqoFZGf8C2AQjv4W02oYNGKkjJEZfACHMRfTPE1n91+TdtQLJCaZwb9FSpNQz9+Rl/1z4omtdIQ+T27WTzH02XSGvkxO5nfGNDiktAhHfkVv5L9QlSBS2mhaMdkZ30RKnVj8eXr6/h1FycS2e9C1CjKDf4sQU8OsaUmbl1uPEbeSLMmsYGdnDQLByuxKtrSfwKs5mRUoZEdnDX7NiU930RgL4dEczA+WsKOjhjyXH5/mpCbcTpE7g7AZZ0lmOXu6zrImZ8iruS9Ux+lwG9fkTGdfKE1MNTdYxGMNe8l1BtiQN5MdHTWkpMWq7Eq2tp/EpznJcvjIc/mpi3QyO1CEr19ssDKQRWXg4kt2JwvDoTF3QQkvP3+YopJMFiwpH7Y/I9PDjFmFF4SG9u85i6IIPvDxdWiaQvm0HL5+/++58baFAGRme3n/R6/B0Z+HtfmFI9i2RFXfXAbEZFFYmsWilVXc/6cPkpHtS3uCOsLcdM9SskaoXpkM3pyz6xVAOJXkb159np0tjQjgutJp/OWKtVQFswYJYaSUmLZNQ7iX5nAfRd5LS457o0JRC0GduFvwSqA7Eedge+sl9yOEIMftIcd9cVLcbxQc7WqnMxa9aueXMobTuB6/95O0dX6MvOxfEou/SDy5HbfrFtzO63A516MIH7bdQ2vHe0kk9+F2pYn1bLsX02ohN+tHCOFGygQwsLKWxONbyc36EbpejZRJhHAgpUl37zcxjPkE/V9AIOjp+yGhnn8iK+MbSBnFsntIJPfjMJaSTB5AVbIRQkVRxl5Bp8yT9PR9h8yMB3A51vRfYxzQse0uunv/mYzAV3A6rsG2e2nr/AjR2FN43PdOiUHdl4rTmQhzd8lSjvc2k+nwgpScCreRtC025s3i5dajLAiWcKC7nrZ4Hyuyp/F6Zw0diT5URWF/qJ6Z/nymeXOYGShga/spXmk7QUAfyqWykfSmYsTMJDXhdtrivdxbugyHqjPNm8v8jBI6E2GO9jYR1N20xntJ2hYb8mbRlQzzWvsp4laKpVkVl3zNVxod7X1k5fjQtHRoIBB0Y5kWkXACgKxsH4YjLTNvOHSstwDB10Sgagof/My1rL9pHg1nO1CEoGRaDkVl2Sgj5L9MBu8YHCNASslvjx/ilYZaAK4tq+SbG24m4LiwHFJXVSoCGVQEMq7SaK88Btywdn8S7WQTZweSbwf+F/19MME+pJScCHXQFg3jN64+mdZAns/FXMu5fZz7nUzmO5VSsr2pHlNe2oQ40u8iJjwOgaaVoChBVCUTTc1HUYJI81S6b2zi8ddImSew7V5suwcpw+ccr+Bx3ZLOTxICcZ5+kcNYgK7PQgh1cJ9l95BIHSTb+3EUkV5du12bCEf+N10ppWRimmdJmSfxuG4lntiOppX3h2pGv2+klGnjRC3A5Vgz2Hbg/5RZg2k1EIk+RjT2XPrq7B6SqcN4uHdiX/Y4cGsGUko2tx6l0pfHoe4GAFZkV9KXiqMIQbk3hz1dZ5FIcp0+PJoDj+agIdqFJW28mgOnauDVnShCYV6wmH8/9hx/OvP/Z++8w+uo7vT/OVNub7rqvVm23HvBNhiM6b0mQHrvfVM2bbObnk3Cbvom7A+SAAkESAjVgKm2AfdeZEuWrN5vL9N+f1zpSrIkdydkw/s8fnx1Z+bMmXNn5rznW97vJdnf0zBNWmJ92GUVm6QQUF2okoIkBLl2D1v7m1kQrKTYGaDA7iXP7iVocw9t99KfjjLNV3xWsmbOFEKAYVjjVIInQ2GRn80bD6HrBooiM9gfQ1Yk3J6h3/sspZz+I0IIQVVdIdVnuYjlm4RjAoRSSe7buwPTsihwufnXZavGkY1/FliWxUMH99A42M9VtdOYnlvAvr5uHj20nz29mdVWqcfHxZU1rK6owamoE47TsDWoMTTAxvYWdg4F32qGicdmo8qfw/lllZxXUoFTUca1YZgmHbEILeEQDQO9rD1yCM00iesaP9/+Gh51bDCXS1F51+wFeCcgJLt6Onmy8eC4wLRSr4+31s9BkU7M4i3LwrAsdvd2sbapgb19PUS1ND6bndn5hVxeXcfUYF42nXE0BpNJ7tmzDVkI3jVrAYok8UrrEZ5pPkxzeBDTtChyezivtILLquvIsTvGjUdC12iNhGkODbC/v5fHDmc0Hw6H+vnP118et39NIMhNk7haLMuiJx5jXUsjmzrbaI+G0UwTt6pS4vExK6+QxUWlVAdyUCcVcBLA8DaJ0VkZlpWgr//TCMmJ23kNkhQYcp2MhoQQruPopbgY77jLZDWJMT5lCYbokqpMJZXeimUlsduXEov/hVR6OzZ15gRtHTsm2hCxmehe0BHCgd2+EElkLGMO+1IU5eyt8lUhc2PFItKmjlO2UezMpGaqkkKpK7O4qfHkU+IMZEW1ZCFxeclsJCTSpo4qSdlMOsuy6ElGmB0oG2PhUCWZWyuXYA2dc05OeTYTY0GwkqSh4ZBt3FS+CN0yccgKqwozcWphLYFDUpkVKHtDvBurqvN54dm95OS6cbvtLFxaixCC5qYeOtsHSMTT7N/dSiQUp6q2gDnzK3n6se389tcvUlVTwIvP7WH1pbPx/IPVO8rEMYXIKHAJhORHTFil/OTQ0xnioXte4T2fuizrTjpbeJNwHAPLstje3cmR8CAAV9ZMo9qf84Z4oP4esIAnGg+yrqURm6ywq6eL773+MgPJxFASbAZ/PbSfiytr+eb5a8hzjp84UobBV155hqebGoikRwrSZds42sS9e7ezuqKWb19wCUGHc0wbzeFBbn/sAXrj8TEr+YSu87s928f1O8fh5Nb62RMSjoaBPn69cwu6aYwhHQsLS7hl2iyUCSeZUWNiWcS0NHdu2cgf9u0kqqXHXMu6lkbu2b2ND85dzHvmLMQuj33Mwukk/7trC2nDYHFxKQ/s382jh/ahmeaYMX3s8AEePLCbH190JRU+/5jxePTQfv5jw/PEdW2MDkdLOMQvd2wa1+cLy6u5aeoMjp1oraHg26+vf47Gwf6sZYNR/QAIOpzcdfkNzC88ddeaafaR0nZRmHcPqjIdw+zCtE4+sn0ySMKDqkwlmdqITZ0HQCq9CVkuQZKD2GyziMUfQpFLUOQShHCQSm/B7/3YCZWGVbUePfITNK0BVZ0+tEUDVBS5Ckm4UeQKHPblMKRPw1DUPljj0kxHr7qPDdScaEUuhEAVcpbg2UcFbo4O2nMqY4m2bWiiUaSx32e0PASXFM8ccwtkyjmMtC2PuvclIeEaUjS1yUo2eV4SwwsIg1WF9XiVsRO0bhokDR27rByHoE6OyQJZT/SbrbliDnanjZYjvVRWZdRATdNk1/Zm+nqjXLB6Oo2HuunuClNSHsTtsfOZf72a9S8eoKNtgGtuXMS8RdUgoLwyl+UXTMues7Qsh5UXTj/teSBzTQackyrdKWLhb6FrezDNPvzBu1Gy9+ypo78nQkdLP7JyZu6TifAm4ZgAW7ra0E0TRUhcXFnzBjAWvjHwSMNeBpMJanNy+eSC8yjz+gilUjzReIAXjjbx9JEG3DaV715wGTZ57IvGJstDVgjBitIKlhSXURvIxS7LHI2EeOTgXnb1drH2SAO1OUE+t3jlmHHPcTj56PylaGaGbKxva+G55sO4VJUPzFk8LmjUISt4bROnsF1YUcO9V99COJVkMJXkNzs3s7+/96THQTNNvvvay9y3bwc2SeaqmmlcWFFNwO6gIxbhsUMH2NzZxo82r0eVZd4ze+GEloWkrvHvG57nYH8vC4tKuapmKsVuL/3JBE80HuTl1iNs7Wrn+6+/zJ2rr0QdNaaz8wr57OIVWRfIPXu20RIOMSWQy1unzx53vjKvf0L9g85YlC+//AzN4UFq/DncMHUmdUPp3T3xGLt7u9jc2YZdUagNBE96jEZDkoLY1GkMhL6PTZ2OpjchiZOvMDk5FAK+T9E/+GU0rQGEQjq9ixz/lxHYsSlTGUjvwOW7DFBR1Vqi8T8PZZQcH3bbbNyua+gZ+Bg2NVPaXCCTm/NdZLkQn/djDIS+garWI1AwjC4C/i9ht80mld5JKr2FZOoVdP0o4ehvUJUqnI41mFaUeOIJdL0F0wwRjd2HIlficl6KLJ9cmfTTgRCCGu/49g3TzFhBTtF9IIQgzzFxAOGL7U38x6Z1fGTWMm6ZMnmg+USwLIvGcD+PH9nPgcFehIA6fx5ryqdQn5M/ocVwGA6njUuumDPu+2tvWjzpMf6Ae0xZgmHUTCmkZsqIbHhFdT4V1adfE8Y0WknG/4jL+xnOahEUAOx4/P+BoR8i1Pc2MsTm9JGT5wEBqYSG4j276ehvEo5jYAGHBjI55F6b7Z/aunEsmsODXFhezY9XX0lgyMxvWRZX1EzlPzY+z/37dvLE4YPcNHUmy0sqxsa7AB+at5Tbps+l2p+TMfeOWvFdWTOVdz/5MPv6eljb1MCH5y0ZY53IcTh5+8yRVNmUofNc82GcssJb6mdT7Dn56Omgw8mS4rLsuZ9uajhpwmFZFutaGnngwC5kIfjisgu4Y/pclKHrsSyL66ZM5/MvPM3TRxr45fbXuaiiZsLJ2gL29Hbz1vo5fOW8VbhVW7aNK2um8dkXnuTppgZebj1CSyQ0po0ZeQXMyMtMIIZp8nRTAy3hEOVeX9ZNczLY2tXO0XAIj2rjR6uvZG5+0ZjfzRyy5gymkhNaizKQ8Hs/hKrWIQl3JoBT2HHYl6AqtQjhIi/nv0imXwNLw+N+K6YZQpICAAhhI+D//KREwOW4FNOKMZG0vU2dQ37ub0ilt4Jl4Pd+EkXOmPgVpZpg4JvY7UsQQuBxvQWbbT6yfOKJQwgbAd/ncTmvQdMPIZBR1XpAHWrrFhy2xaS13VgYqEo1NnXa8NEI4cLlvHJUi/LQFjK6NkolOf6vDX0njbu2c4FMKq+VPZUkBM3t/eR4XQR8zqFKyRayLGWtLqZlIQlBU2sfPo+DoN89FCthIsnShEQ6pqU5Ehlg70A3ALppkjIy4lB2WckG3U/Uv5fam/jCxqfojI+Vy/7ffZv5+JzlvKt+wVmvy5KxPiQxzX6wTITkQwgvYojcWJaJZYWwzEhGG0gERr27TBiql2qavZnYITkXGHk/gomW3oSu7QA0LEuQcdXJQ/sMtyFjWYND5/EgRM6YNiyzPyPEKOVkU8ph2PLjGMqQOnOrhC/gpmZaMb/47mMsPn9qNrtHkiTmLK7G5T79uLk3CccxMCyTgWSm8p9LteGz/WP5884lbJLM++cuypINyNzsLlXlg3MX83RTA/3JBI8dPsDykooxxwohKHJ7KHKPX9kKISh0ebiqZhr7+nrojscIHXeC+/tBG0rHTRsGy0rKeUv97DGWByEEPpudD8xdxAtHm+hNxFl75BAfmrt4wpdssdvDxxcuwzPqWoUQeGw2bp02i2ePHCKSTtE02H/aFobjIa5rWFjIkjRhAK4kBF6b/bi/hRACp2NV9m+XM1PWWlVqUJUaAGQ5F/eYCXj08Qpu5xWTtm+zzTzuuRW5CGWCtiXJidt1bfZvVZ2Cqp58ZUshVOy2Odht41fNQkioag2qWjNu22THZI7z43HfdNJ9OJsIR5M88txOLNMi4HNyyfJ6Nm5v4oJFU1AUmQee2orbaaO+ppCBUJwFM8p5becR5k8v57EXd5Mf9LJm2VQ6esLsb+oi4HOxZtm0Sa0jh0J9PNy4h8eP7OdodBAQVHkDXF8zkzXlU8a5GvtTCb65+Xk64xEkIQjanciSxEAyQSid5IfbXqLM7eOyiqlnbRFoWSZa6iXi0f/CzKoie/Hm/BRFqcWyNJKx35GM/wELHYGKw/0OHK63IIRCOvU86eQTCOEinXoNrASSXIo38F0kuRJDbyAe/QVa+lUsM0So762AQLWvxOX5NAC6to1k/A+otuUkYr8ZUmkuwhe8CyH8WFaUeOTHpFMvkolZ8uL2fRbVdv45WQz3dAzSeLCDdFLnyYc2Z6mwalOomVb0JuE4m7As0MyMSUqVpKx4zJuAXKeL+mD+hDd5qdfH9Nx81re1sKO7k6Shn5KIlhCCUm8mrVi3zKzr5I2GrliU3UPpuBeWV+OQxz9CQgiqA0FynU7aoxG2dbVjDvnQj8WCwlKKXBO7F0q9PlRZJqnrk4rOnSnqg3k4FZVQKsm3X32Rzy5eQV1O3qSr0DfxjwvdMAl4nWiajmlaqIpMaUGAdFrHME0cdoVLltfz/OsHkSUJwzAZCMex2xXqKguYM7WE3ICbPz65lYriIAeburhgYS0O+8TP+audLWzsbMEYFXPVEOrlhfYm3j5tPl9YsGoM6djU3crhcB8Sgg/NXMo76xeiShJbetr4xqbnaI2G+NWe17mgpBqXenbUUQ29gUjo8zicb8HhugWEiml0IMulmWyl5Drisd/gDXwfRZ2Jnt5JJPSvyHIZqv0CLHOQZPxhnJ4PEMj9PZaVIDzwCRKxu3H7vo4kF+PyfIBEzIauH8Tj/xaZwM4RCQXLjJBKPAFYeAM/Rkh+LLMfIbxYlkkidhdaehO+nJ8hSQWkkk8QHfwK/tzfIitVZ2UcRqO8Jp+v3XnHuO8FvJkWe7YhBFlztG6ZkxbG+mdErtOJe5IHXRESVf4c1re10JuIEU2nxxGO4WCwmKbREYvQGYswmEyS0DVShsG27vbRO5+z6zgTHI2EiA4FvR7s7+U3OzdPuF/aMEgbGeLaE4+hW+aYgLxhTMkJTirSpUpyNu7iXN2H9bn5vHX6HH67ZxvPNh/m9Y5WVpRWcl1dPUuKyyfMkHkTbxxYlkVfOoYiJPyq84S/lSJLWJaMaVmkNZ1QNIEnbCfH78JhU7PWCpsq09jaR1t3CACHTaGtO0TQ76Yoz0dRvo/ptUXY1MmnEN3KBEEXOj3kO92YlkV7PMxgKsnvDmxlZrCQG2tmZvu8t78L07LIdbh427T5FA4R8TVlU9BNk0+8/Ff2DnRzYLCX+flnrgtkWRap5JNIUhEuz4cRUkYJOlNsLyP+lkw8hM2xGtW2PGPVsp+Pzb6SZOJB1CFFZiEFcLrfhSQXYFkWNvv5aNo2wESSvEjSdCQpDyHakJX6rKvmWDjd70NW6jLjIWfiR0wzQirxKC7PB5GVTBCrw3UzyfgDpJJrcbrff9afTyHEhPVmzgbeJBzHQBYSfnvGjZLQNKLp9BvStP/3gFNRj6tgOTxuacMgqY8t6GNZFp2xKPft28HaI4dojYRJ6lqGV4hR2SpvcAymEtksmYcb9sLklb2z0E1zUv7ktf19060VIfEvS1ZSlxPkrp1baQz182TTQdYeaaDSF+DaKdO5tX4WxW7vm8TjDYr7ml4l3+7lrVVLjrufx2Vn/owyLDOjs6LrJgXBTOyTqigsmVOJ22lj6ewq/F4HB4/0cPnK6TjtKotnV3KgqQtNN7ji/BnsP9KNJGWqqR6L4XtdlWQ+NHMpt0+dR9DhxLKgLRbih9tf5snmA9x7cBtXVU7DMbQwGUhlXNlBuwv/KFe2EIKVxVXU+HI4MNjLzr4O5uUVn4X70cLQm1CUKSAmcp0bmMZRVNtShgNfhBDISjWpxONA5h0nSQEk4ctuF8IG1qkFbgrJO0RKjs0ii2Ka/Uhy5ahtNmSlDEM/fErnOFlYlsXh/R28/uJ+EvGRjELVpnDt7csIBE8/4PtNwnEMBFDpCwAQSadpj4ZPKSDx/zJOuMqeZLtlWRwa7OcTzz3Gvr4e7LLMrLxC5hUUU+Hz47M5cCgKmzvbuGvXlnPQ87MHc+gSBXB+WRWFE8SkHIsyr2/SKpN/b8EkIQROReWt9XO4rKqOdS2N/OXQPrZ1ddAYGuDOLRt4pGEv/7psFZdUTZlUxyMcSnCkqYeiIj+FxYHjnrOluRen00Z+wVhl3s6OQdpbByivzCUv//gER9cN9u5qZfa8TKzQ3t1t6LrB3PmVxGMpBgfjlJSevBhfRlfFHBJcE9mASQsr+xsNZwRJQmAOfW8O0WSJEReUaZnAyGdJSFnxNMuyMIfSZke7rUYqUZsjVahHbcscY43p33Cfb69aNi4rbHR7ksgEd9ptCsVDpdaH+7Z0blW2b94h33x5cWbcFs0aicNSFZmFM0f+Xjhj8nL1rbGMVWRFcSUfm3PeGLdJjS/IVxatZltPO4dD/XTGo1T5Muczht4fdlkel43iUW1MzyngwGAvjaGJC8OdDgQyFserdqrAqO2WRUbvQsiMBPqO/nz6PZm4DWkoqHgsgbEsHSGdm7pPof4YP/76w9TWl9Da1ENZdT69nSGKy4LYJ3GfnSzeJBwTYG5BEZIQpE2DDe1HWVBY8ubqjkz0ecYfO3GU+HCcgU2Wx9Qk0U2TH216hX19PXhtdr51/hourarDfkyw5bCexRsZPpsdeWgyetuMuVxSdfJBiG9kCCEIOl3cNHUm106ZTsNALw8e2M0jDXtpDg/yry+tpczrZ2be+NRKXTN4+okdLFpSg6LKHD7URSKepmZKAf19UXTNpLwyl472QRKJNIMDMZIJjWRCo6wimH22Duxrx+NxsO6ZPVx9/QJaW/ooLPITj6eJRZMUFQeIx9MEcz10d4XYt7cdh1Olsjqf4pIAWzY1ZgSuesI4HBmlzq7OEOFQguqa/AnLrFuWRUhL8PvGjTREuvCrTm6vXsY0XxEHwh3c3/Qan5txOR7VwR+PvIZuWdxevZRfHHieEmeArf3NxPQUN1Qs5PyCjDn8L0e3Y5NkDkW6ORjuYn6wgvdMWZnJwug6yBNtu9BMnWX5tdxQsQBVyPSnY9x9eD3N0T5kIVhdNJ2ry+YCsKmviUdathLVU/hVJ++ru4AqTx4RPclP9z9HU7SXGyoWcGXpnOw1Ncf6+H3jRnqSEcrdQd5es5wCh5cXOvfTFO2lPx2lJdZPlTuP99ddgM/mHDc2p4vhDJPzCiuwHZNRIoSgwOlhaiCPDZ3N9KfiVDGeGE70ui31ZMhSTzJ2lnoqkNWZJOP3YpmDII3OCgFQUNTZQ9klBsPkQ9N2oqgzmew9OPGp5KE2Ts2OK0l+JKUSXdsx5NYBywpj6IewOy4+pbZOFl3tg+QXBfj4V6/l9z9fx7KLplNakctP/uMvaJrBmdwp58ZR8w8MIQTzC0qylV0fPbSP/mTinFdu/EdAfzJBOJWacJtumjSFBgDId7lxj9LA6E8m2NzZBsCaylquqpmGY0hNdPifZVn0JxLn/iLOEBU+P27VhkWmfgkw5jqO9+9vgTO9S4UQ2GSZGbkFfHX5Rdy5+io8qo2+ZIInGw9M+BzE42mcThvVtQUEcz3YbAp7drXS3RnmmSd38cK6vezc3sKW1xtx2FUs0yKRSPPaxkNjTLaGYbJvTxt5eV5eeG4v+/e28+Rft/P8s3tIxNM8/+weXl3fQDyWYsumpiHyEmfrpqYhGerMGOuayf697UTCCda/dCCjljjJ+JtY/PLg89gkhS/MvJLl+VP47u4niOhJ6ryFeFUnv2vayPb+Fp7p2MslxTMQCBqjPbzS08D76i7g1qol/HT/c7QnBgHoSoS4t+lVFgYr+ZeZl7O6aDoCwZ7Bdu5repV3T1nBx+vX8ELnAZ7v3A/A4607iespvjT7Sj4ybTXT/BlJ6aSh8YsDL3BZySz+dfbV3FS5kBxb5t3kVRx8cvolVHvy6EuNyMTH9TTf2f04MwOlfGHWlRQ4fPxw71NopkF/OsafmjexoqCOf5l5OU3RHtZ27DnDu2Yshi0VjkmCxgWZ9FjTsjCGgsMtyzph3NawmvCx7trThRACu/NKQCES+jzp1DOkky+QjP0/TKMNEDjdb0NP7yYR/RVaehOJ6C8wtH04XXdwKlYNRanD0BpIJ59CS29B1yZ+lsbDjsv9XpKxP5BK/Il06nVi4e8ghBebfQ1CCAyjk1TiKVLJp7CsBKnks6QST6Lrjac1b0nyiIXN63fS3T6Ay2PHNEzCA2dG9t4kHBOg2OPhsupMNcVDA338YvvrpM0zE1P5v4D+ZIJdvV0T3sSt0TAHhrQs5uUXj8neSBo6cV0DoNTjm9AsnzYNNra3nHRflCG1Rd2ysllFfwsUe7zMyssEdD3ddOicZY+cKoa1CVKGflbIsRACWUgsKymn0h8AMiJhE8HptBGLpWht6SccSrB3dyvzFlSiKBKKIlE/owSv14GiyjicKpIsUTulEI/XMaYglqLI1NUXo2k6umbg9TmZM79iaGJQMxOUYdLeNkA6pSHLEnaHim6YxGMpEvEUumYgSYJkIk06bSDLEk6nOunUENGSbOw5jG4ZvNC1n45EiI7EIO3xQRRJ5n1TzmdH/1G+s/tx3jflAgodQ24gCy4qqqfSncuSvGoKnT72hTqy7c7NKWdFQR1VnjxqvBndj5e7DyIJiW39LbzaexhFktjU2wRAtSePg+EuXuo6iEd1MMVbmFEblWRqvHk83raTxkgPU31F+IakyYUQuBU7Nmms5eZIrJe4nubyklmUuAJcWz6P5lgfncmMq2N2ThlL82oodwVZkFtJa/zsuSgAcu0ZQtQY7puQAKcMnbZYGIEgaRhZ909EyyxmMq6r8cfpQ+TkbJJ3SSrCF/wlslxMPPpzYpEfoWu7QShD8RrT8eZkvouGvomuH8SbcyeyMn1oey0O53UwSkpcUedid1zGaEJis1+Mw/02ErHfEAt/Gy09Iu0vyaU4XDcjJogjEUJgc1yO2/cFUom/Eot8B4SCL+e/EVImTd40OtDSGzCNVuyum7DMPrT0Rgy98bTGpLAkB8M0iUdTTJ9bwZ9/v5G7//sZujtDuH1nZgl706UyAQSC985eyItHm2gJh7hn91Y0w+AD8xZT5PZk/bXDRbsSusZAMkmpd+LJFDKs3zhBqqd0gpWweaI2xFhf8tmGbpr8z45NzM0vysqXW5ZF0tD5nx2b6E8mcMgKV9VOG3OcS1Hx2uzENI0D/T1opoFtiJBYloVumfzpwJ5TIhwlHi+SEETTKbZ1dVDu9f9NrAg2Seads+azpauN/X09/OemV/jc4pVjtEmGX6AxLU3jYD9Th1JPzxWEEJR4M3FGhwf7aYuGqfQFTjgelmVxYKCXoMNJrsM17v6zLIvGwX46ohkTebnPP2E7qk1mzWWzONLUiyxL5OZ5SSTSlJYHWX7+NOLxFOUVuVgWdHWGqKjMxem04XCqOJwj4zJteoaYdHWFyAl6ONLYjd/vQlVkopEUF1w0nUQsTV9fhCXLppBMaiTiaeYvrKK1pZ/CIj+RSJJ4PE1O0I3doTB3fiWdHYP4Ay6UCUzgmmmgmyZO2YZdUrFLKh+eehEFQyqabsVO0O6mLT6QrWEyDIeUEQETFjhklaShZbcFhqwQoxHVkjjlzDkALiysp9KTKeO+omAK+Q4vj7fu5PNbHuDmykVcWzYPWUh8dsblrO9u4OGWLfy+cQNfmn0VFe7Jy78nDA2bNBIHYZNkJERWfMurOrPvCUlIZz0hbGawAEkInm45yM21s5kZLMzWczEti6ePNtAw2Itumdy54xVyh8oYbOvNELaYliZl6jiOmZ6GXTUB+9nTRspkZFTj9n2DkVgNhdFBooq6EG/OfIalyUck7EG1zUO1zRvTps2xClg15jshuXB5Pgmejw59MyJxrqh1KOpnj9NHBZvjSmyOy8gIhGX6N9KH+ai2+ZMef6rw+p186t9uwONzMG12GVfcvJj9O1t4zycvJRA8s6rabxKOCSCEoNIX4JsrL+FzLzxJdzzGPXu28fSRBhYXlVEbCOJUFAZTSZrDgxzs7yXP6ea3V92UnUhHI6lrfH39Otzq5JPOlECQzy5ZiSom9gtG0im++OJaHMrkP9ns/CI+tmAp8jkKRMxzutjV08V7nnyYG6bOoMoXIJxO8XjjQdY1Z9j0VbXTWFRUOmbiynE4WV5awcMH9/Li0SN8+9WXuKx6Ci5FpTMW5ammBp5uaqAuJ/ekFT/nFxZT5PbQHo3w7VdfoC0apj6Yh0mm+F5S17hp6qxx49WfiNMUGiCmacT1NJF0mqORTF2PnniMhw7sIeBw4lZVXIpKscdLqcc3RuhsdUUN75q1gLt2buG+vTvZ0tnGqvJqKn0BLKA/GadxcIDdvV3ENY2Hrr/93BIO4OKKWv7SsI/ueIxPr3uC26bPId/lJm0Y9Cfj5DndrKmsHUsogP+3aysvtx5hfkEJcwuKqPD5scsKcU1jT183fz20n/5kggKXmyuqJxZcEkKQl+8jLz+z+i8pG5mYPXUjk0PdtLGVJ73HrJYKizKEpromEycyb0EVlmVRWZ3H3PkZiwlBKC0fL4BWP2MkTTKYOxLI6/Uef0XmVR0UOf3UePM5v6AOEGimjk1SsCyLJ9p2opsGd9Qs4xcHn+frc67FLqtYWBwMd3Jx8XRiepqOxOA4QnIspvmL6UpGuLJ0NnZZxbTMrAVAM02m+gqZOuNSNvYc5tcNL3JF6WwUIaMIiTXFM1hVOI1v7XqMV7obuK0qOCmhLHUFiOtpupNhSl05HI0NZH4je2ZczjUtX1RQRqUnQFNkgPc//xBXVNYzLZCHaVls623nqeYDpE2DKf5cdvd38Zan70eWJAZTmfpMXfEI+wd6WFJQll3UhNMptnRn3LK1vsnJ1ukgM44CmDjlP7Nd5pRiNiZt5/TeA5lj/3bTdSCYUTKVJLjkuvlcct38s7Kge5NwTAIhBOeXVfKrS6/j+6+/zJbOdjpjUf56eP+E++c6J6pmmYFhWSdcvQ+cIE5EM01eaWs+bhuGZWbTTM8F5uQXsby0gv/espF/3/D8mFRWWUhcVlXHl5ZegHqMrLYsBJ9csJzDA/3s7Onk7t1b+f3e7chCoJkmshBcXVvPxxYs4x2P/ymbHnc8FLu9fG7xSv59w/N0xWN8//WXkRBk8goymSFX19aPIxxrmw/x9VeeQzfNrK95GC2REP/68jNAxtokC8Gt9bP55so1Y/ZTJIlPL1pOjsOZrcMyEVGShKA+mD9uPM42hBBcVFHDrfWzeWD/LrZ1d7CtuyOTTTF0jTfWzWBNZe3Y4yBL+h5vPMDjjQeyGQvDxwmg2p/DV8+7kLqcs/uiP1ksXlZ74p1OE3ZJ4QN1q/jlwed5tmMvAA5J4XMzr6A51sfDLVv5xtzrKHEF2DvYziNHt/KWqiVIQrB94Cjf3f0E3ckI1Z58pvsz+g0TxYuIoUDQzb1NfGHrg+TZvQxqcd5Rs5y5OeX84chrNIS78NtcHIn2sDx/CoqQiWhJvrP7cXxqhrg1x/p4y1D666FwNxt6DrFrsJWmaGb7qoJplLmDXF+xgG/teoxKTx6HI93cVrWUgM017tVwLl4VuQ4Xn5i7gi+/+jSd8Sj/b994rZoyt587V17NE80HuGvfJlKagSpJXF89k+daD/HNTev48qKLmBrII6Fr3LVvMwdDvdhlhSWFZeeg1387xKJJ2lv6qZlWNE7vQtczbsC/Z5JCIp7m1ef3sfLSWdhsGddSJJzg1ef3ceGVc1CPo71yIrxJOI4DIQTzCoq56/Ib2drVzittzTQM9DKYTCIAj81OicfLzLxCzispHzexzC0o5oNzJy8cNBoZd8z4iWlpcdlJ++RrA5OLSJ0NJHSNt8+Yx+KiUh49tJ99fT2kTZ1Sj581lbWsrqzBNUF5eiEEFT4/d11+A48e3s/Gthb6kglsskylL8DFlbVcUFaFKkl8eN4SOuPRrKbHZBBCcH3dDKbk5PLXob7EtDQORaHI7WVeQXE2U2b0+JV6vdxcPxOPMrm2SlhLIgsJt2JjTn7RuO1CCOyywgfmLuay6jqeaz7Mtq52uuKZgCq/3U6VL4dFRaUsLCoh6Bi7yvbZ7Lxr1nySus7s/MJx7Q8jYHfw3tkL0UyDacHj1/+wyzJfPe8iLiir4tmhMve6aeK12Sjz+rmkcuJsmk8sPI+lxWVs7mqjORRiMJVAM00cikKpx8fiolIuqqihwOX+u7wEz/U5hRAsyaum1ptPU7QXSQgq3LnYJBmXrPKVOVdT5ckD4NMzLqU9Pph1md1cuYhSZwDdMpnmK8I+FEtxZemcCSdyj2LnK3OuoTHaQyidINfuoWrIpXJ9+Xwao70kDY3ry+dT5cnLyMqrDj4y7SI6EiEkBO+ru4B8eyZl2K3aqfXmU+sdMd87FRuSENxcuYileTV0JcPcUb2MUlcmA2NFQR3zgiPprWuKZ5z1GCghBNdUTUcWgp/t2khTeCAbA+eQFRYWlPL5+auYGSxkaiCfZUUV7OnvotaXy8riSiQh+OOhnbzzuQcJ2BykTYPBVAILOK+oglnBwrN2X8T0TFyLW5nYXQhDGkLJwxQ6apCEhGladLcPYJgWRaU5dHcMoigyuQVeBvpixKNJ8gv9JBJpErEUXr8TRVXo7hikoMiPoshseuUgZVV5KKpEx9EB3B47Hp+T5x7fTu3UYmrri4mEE8QiSYrLgqdUuVUzDVKj3HsjEEgC5KEqxMOLi2PR2drPUw9tZsWakZICsiR46qHNzFlcQ2FJ4KT7Mq4H1v/R9ItwOIzf7ycUCuHz+U58wHGQyYM3kZAycRSWgSSGfzCG/paG/KEWhqWjiPET7z8iTMvifU89wrqWRpYUlfH7q2/JEqthC0FGG+DkJodhP+7wTXcqxx6vzbRpYFoWAlBlGcvK6AyokkxMT7NzoI1FuRVs7T+KaVksyq1AlWQsMg/o8AOoWQavdB0m1+5mbvDkVlKjtRVgSAJ4lAvmb4kR/YURC8XJ9GXs75Ixk52N3+b/IkzL4nNb/sg1ZXO5qOj0y4D/X8ewK+TgYA/t8QhiqJZKXSAPh6xMeF9ZlkVrLMzHX/oLO3o7su8JAUzPKeC/zr+GKf7cSY9NmjHSZhKH5MLCImnE8Km5pM0kCSOCV8klZcYwLAOPEmAg3YlL8SMhoQgV3dKQhEJcD2GTHdgkJ2Gtj33hDSzNvQZZKBza186h/R3UTitGCDi0vwMtrTN/WS3P/GUbi1bWUT2lkMce2ETdjBKqphTw8rN7kCSBoZtcf/t5PPqHV7n0+oXousHWDYc4fKCDW951Pg//fgOLV9RRUhHk0ftfw+ZQqJ9dzrwl42v2TIbHW3fw3/ufG/e9ICPG5lOdVLiDLM2r4YLCaeTYXGPGc9+OFu7/nxf42n/dgaIMBaOnNL764Xv4+Fevo/yYqrmnMte+aeE4SWzse5F5gcUoQmFfeBfzApliXA2RfRyM7mO2bz7lripe6V2HbmosDq7Aq54e0bEsi/50H07ZiUs5syCds4nswz8c7HQaE5EYclWcTZhY/PbQa4S1JE5F5ZKS6WzobkQzDZYXVNOZiLC2bV+WkLzUdYhtfa1cUTaDXQPthNNJCp1epvjyebZ9Pz3JKFeWTV4wbMJrGpZLPUNYloVmmvTF4ngddtzqqRFXMUQSTtXSdezvYlkWjQMDlPv940Sl3gTk2tw45BGf/+h125sELQMhBH67g8WFk4uETXRMmdvHry+6iceO7GNnbycWFnPyirmqsp4C5/EtbbsGXyBoKybPXsauwZeQJYVCexXdqRZKnLWYlsme0MuAxUz/BXQnm/GqQSShoJkpBtIduJUAvalW0maSAnsFJiYxfTB7jv7eKJU1+dRMK2L7a4eprCkgHIoT6o/hz3EzY24FkiRwulRmzKvAZpMZ6I0yd3E1voBrJAvHsji4py2zQDBMVLtCbr6Xsqo8kok0hmkyfXY5xRWn5socjimCjKt79GhlFiN97Bps5cm2XUz1FfJvc69nun9EuTUnz8tAb4SutkFKKjLxUm3NfSTiaTxvZqmcO1iWRUu8iaOJZtoSLcz2z6cx2pBVF+xKdrC+70UK7IW4FQ/7I7vZFdrGgpyl2CQ7h6IHaE+0UuOeQp69gAORPcT1GFXuKbgUN7tD23HJLup9s9gT2kHKTBK05VPiLGNt118JqDnM9i+g1Fn+5kvseLCGMjVcfgI2J5t7m2mM9FLhyWHvYCcXFE6hIx5iRUENG3uaOK+gBp/qYPdAB12JMO+uO49fHXiF/nScC4umcjjSw7kPrZsYmmnyv5u34HM4qA3msKRsrJXFtCxCySQORcGuZII73apKNJ3GriikdR3dNPE5HBimiWaYJHUdv8OOBYSTSTx2O6okkdB1EpqGz25HkSTCqRSWZeFzOEjpOq2hEKVeH5ZkkTIM4pqG325HN03SRia7w+9wnJEbz7IsDN0kFkni9jqQlb+v//pkIIDPzbwc+ZgA7/1bmiipLiCZSFFY9veJd/m/ACEE+U4376pfOOG240EWKuWujNUpaUYos9fjUnyIFBQ6qonqA+hWmmJHLQ7ZhVPxoVsaJY4qNvc/iVv2oZtpZKFQ7KglZgxS6pxGX6ote4762WW88uwe+noizF5YxcYX9iNLErMWVBIejGdDeApLc5BlCUmWWLaqnubDXbg9Dtpb+oiGE+zdcZRgnoeutgGKSoPIkqC6rpDXXz7A8oumM2VaMV0dg5RVH9+dOhmcso3vLLhpJJWbjK5La3yA5zr28Ur3QfaHO/nu7if4xbK34x5yM+cX+VmwvI5vffY+Zs6vxDQt9mxt5sKr5uLPeTNL5ZxBtzS2DLzKRQWX0xo/gkCiwlXFhr6XAMi15VPurGSqdzoBWxCX4qbEUcYc/wKSZpzX+l5hum82L/U+y+VF17EvvJurim/AJtl5tvsJcm35HIoewCE72RfZzdXFN/F891NUuWsotBdR551OkePMixT9M0AWAmXIrRW0uyh0epkdKKHMnYMqyQymExyNDyIQOGQFWQjscsalsrO/DZukUOjwsi/USXs8RJHzzNxwp4vWUAhVlrmgqpK4NtYPa1kWLzY1cXQwxGAyydvmzeORvXuZnp9PeyRMZSCH5xsb8dntLCkrQ5YEzx1upDYY5MKaatY2HCI9RBzeOmc2/7tlKyVeL0vLy9AMkycOHqTM5+OyqXUMJhK82HSE+cUlmJbJPdu247XbCDpdOFWFza3t2BWZVdXVzC0eH+dysrAsi7UPb0ZWZAzd4PKbFyPk0yMcGZN6nNb4YbqSLaTMJE7ZRZGjilJnDTbp7NStycTwHJNtYMHh3a0IIQj1RXB7nbi9ziFBsv+7ME0rO8GebaJ4Ou0VO2uRhYosFGb6zyes9eJT8yh31XMktpMK10xq3HNJmykEgvhQDIdAUOqsw6fm45K9HIntwi67KHbW0hrfT4lzypDEeCZt9IqbFmXPedn1C7Kfl11Yn/289IJp2euon1NG/ZyRxcMdH7oo+7mqbiSOa8a8CmYMyfWvvOTkrawTQRaCOm8h5e6xWV0LgpVcVjKL7+5+nIdbtrI31EZDuCsb2yNJgjs+dBEz5lWwf+dREPC+z13O3MU12eJ+p4s3CcdxYFomQgh8qh+XkkkpU6QRESFFUlAlFZtkzwTiCBuypGCX7CS0OJKQ8CpezstdhYREji2IR/FhYZEwErhkN3MDi8ix5RJQc/CrAVTJhkCgSCqqZEMW8ht+xff3hiQEa0rqkYWEKknYJIXp/iK6kxHcig2v6uCSknqSusY0fyGCzMNY6gqwKLeSI9E+bq2aj1u1s3ewk2n+Qkr+ToQjpRu4VJWUbvDgrt18YdUFWdeVaVm80NhEqc9HLK2R0DRWVFbwg5de4ftXXEZDbx/zi4upL8jn2UOHmVVYQH1+HldMnUpc01jf3MKcokL6EwlMyyLodJLUdTw2G4aZcTfZFRlVkijx+chzZfzgreEIQaeTG2bM4Gevvsq0/DxWVlXgtdtp6h84I8KRTuqEB+Lc8r4LeOA3L5JKajjdp14s0bIsmmJ7ebzjHjoSzZijak/IQqHCNZVrS95DkaPyjJ+nYffJmHYEBPK9HNp1FNM0iYV3s/Ka+djOsPbE6fRrXN/OIY70DrCtqZ0ZZQXUFASxKZO/ryYKFzyb/RRCUOIcCY4ucdZR4swIOI4OCq3yzMl+nuFfkf1c6Z6V/TzNtzT7ebp/OTAUHzXRb3+SfXujYDjo/fKS2fzl6HbSpkFHYpB5VGS3qzaFJRdMY9HKqQBDhfreTIs9K7AsHaw4Qho7ydgkO0WOUtZ1P4VuauiWxv7BDfSle2iI7qPOMx2X7MqaVoUQeBQvIMixBSlzVtASP0K+vZA8WwFuZTgPXrAgsISG6D7skpM8e8HQceBRvAgEJc4ytgy8ylz/QspclUM3usVkpY0ty8CyIkhS4KyPjyJJ2GQZ2zkqWXymEEJQ7h6rgeC3OanwjDD7qf7xNUCGkesYMRPODZae/Q6eAkp8Xv66fz+ziwpR5bGKKpIQVOXkMLOwgKDTSa7bxYtHmlheWcH29g5cNpXD/f1IkiDXlUnTtg8F59lkmaqcAOdVVGBXZByKwnkV5ezs7OK1o62cV1HBpXVTeGz/AWYXFhFwOoil0wwkEvgdDvricQ729eKyqSiShCrLZyUjSrUrON12Nq7bh92hYrOf3iupN9XOA0d/yqDWM26bYek0xfby4NGf8e7qL+NVA6fdX00zuO/xzZQX53DRkroxL2FZlohHEmhpPUM0/obh+JZl8ezGA3T2hbntioXZYL9zjYrcAJFEij9v2kOu183KaZXMKBubeWVZEI0nee7Vg+xr7EQ3TCpLgtx86Txcjom1L95osCyLl7cc5lBLD2+7ZjG2M0gNfSNAkLHSZVLnR5SbIXOtkVCcJx/azN5tLQhJMHdxNZdcvwDPCXRtToR/7FE7SWQm6xSWGcnIwVrxbIVAIfxYZhemOYAsZgIGltmPEE4QHpbkzMEw48hSHoIU8zwBFgUvQRIKljXIPP90ZMmHZYYRVpIL8lZlrRIr8i7CsHQkDLBCLAsuAUwss59qVxnlzhIsK4YiyZyftxJhxVgZnIciQa27mgpnKbKQsawkptGGoR1CtZ8HwotlDSKQQXjBSmCa3ejJF7B73oVlWQymE1k5cchMVgUOD/JQholpmYTSSZKGjlPOKIGmDJ2krpNjzyj/6aZJXyrGV867kM8sWoFDUYhoSfS0SY7NmcnsECPqmpppMJhOYFqZ1E+nrGaFewbSCRQh4VXtI2I+WpKolkYIcMk2fDYHIjNC9CSiGJaFKskEbI7suSzLIpROEtNHanA4ZIWgfUT5NKKliOtpvKpjTJrucDbLYDqBQBCwO1GFhGYa9A4VhFIlGf/Q96OPC2spDCtz3cPniWopwloqIxkkywRszqy6Y28yht/myArBhdKJbNXQtGmMaSdl6ET0FHl2Nz67nVtnz2JPdzdXTJ06ZlIXQnDzrJlsam1DN0yKvF5mFhQyvSCfPV3dJHRtiKQI1tTWEk2nSBvDljmJ2+bOYUdHJ4WeDMFqDYUz7pfyMtKGQWP/AMsrKij2eWno7aMuL4/mwUGWlZdzcW0NLaEQt8yaRUzTsMsKiizhOo6Y3clAkgSX37yI3u4wi1ZORToNUmtZFpsGnpuQbIxGe/IIe8KvsTR46Wmv1pJpjbUb9zOztogLF9eNkdxYeNEMCstz6e8OM3vZFNTTJE+joekG+xo7mV5ThHoCErF+WyNH2vu5ac28vxnhaOkbpD8a54NrluKyqew+2jVuH9M0+fkfXmbdqwdZNrcKl9NGV2/4DbHqNwyTvYc7mVpVgH2C4n6j8erOI2zbd5SbLp33D084LMtif6gDzTTwqU5qvSMLMi2t84vvPo4AVqyZgWlYvP7yAVqP9PLhL119RvfWP/aonTR0UrF7EcKFkHIw9SYsqx8hPKjOa7GMDgy9GVmZiZ56GdNoRVZnIitT0GJ3IynTkOwXYFkRhPY6qmMZpt6Ilt4AloFwXEwqdg+KOhMLC8V1K8DQBCORjv0eIRcgq7PQ9YNYZgjLDCMptRjpTRgIZKUaTT+CrFSTNgeRbXOQLB0TsJAwzV4MbQ+yOgWsdvTUBiwrgc11I+nEnxEiB8vK+CMt4Ac7n2dbXxs5Q1UgvTYH31l8FTk2J2Etyc/3ruf1nqPYJBndMvnw9OWkDJ3n2g/yn0uvyyj+JSJ8dP1D3H3hbRS6Pfxi73pe7DyMKsnkOdx8ed4llLgyVqFdAx38ZPfL9KcTyELgVe18b8k15DncpEydT238M0VOL99ZclVWCfWX+zayrr2BfIeHpKGxuqSO99cvI6KleNeL9+O3OREio1/wkRkrmJ+bsT683NnIc+0Heb2nhXm5paworOb22gWYlsXjLXu5u2ETipAygmOzLmBJfsZUeCDUww93Pc9gKoGJxbKCKj47exUHQj18eP2fqPLkoJkmeQ43X5p3MWXuAJAhQP+xbS29yRi/WnlLttz2fYe38mDTDopdPuK6RpUnhy/NW4NHtfGpV//MF+asZk5uJgbnf/ZvJMfmYm5uCf+1+2V+tuJG/EO/zV0HXyOSTvH5uauzVoyqnIlVK712O6trR1Lkht0Z80uK2dLWTn1+HisqKwFw2UbIgBCCQo+HS+tGTM4X1lSPafvyqXXZz9ML8pleMBKsNi0/n2n5mb9He4SDzjNb8WTqpNgorcw77TZ0S6Mxuvck9rQ4FN3FkuAliNMMCva47HzvM9fhctjG6Xttfm4PRw91oWs63a39XHzLEuxnuILv6Anx/bue5adfuZXACVaXH79jFam0jtPxt3PjpDWdOZXFBD0uLMtiYc14C2EkluTVHUe4atVMPnb7KoTIWD3eAHyD3sEY3/3NM/z4CzdSkOs97r7vv3k5sUQan/vsSaufa5hY2RR5yCw0E4bGtv5m7j78CrKQuLlyUVZiHzIZKZFQnK/86PZM4UNgxZqZ/Men76W/O0LBGehwnHXCoes6//Zv/8a9995LZ2cnxcXFvOtd7+IrX/kK0tDq2rIsvvGNb/A///M/DAwMsHTpUn72s58xc+ZIkEwqleJzn/sc999/P4lEgosvvpif//znlJWdusqcZYYxtb3ItjlgRRHCgZBqEZIPy4wgKTUYekYJVFJqMfQGLDMKwokkV2IZnYCJkAoRkgewMLT9KLYVmGYPpt6IJBeiOq4gFf/9MSdPYJHG5rgKAC3xJHb3O0gnHsIy+5HV+qE+DiKEE9VxOanYXVjWcFEwC7AhK1MAC1mpJR1/ENMaRKBiGl0IbKjOy0jHHxwZP0PnjtoF3FSdKXEtGKnQ+F+7X+ZobJAfL7uOfIeHUDqBW7XxQvthEqMqMVpYxPU0lgUvdhzmufYGfnze9eQ73Pxy30b+e8/LfHvRlXQno3x50xNcXzWbG6tmo0gyfckYgaEJ9UhkgIFUnFA6QV8yRoHTm+3j1RUzeN+0ZbREB/jYhoc5v6gmS2K+tfhKChwenmk7yNe2PMkvVtxCmdvP1RUzWFlUzW3rfsfn56ym0pOZnI/GBvnvPS/z5XlrWJRfzgsdh/n+jnXcdcFbkYTg37Y+xeqSOt5SMw/DylybQGBaJrl2Fz9bcROWBd/a/iz3HtrC5+esRghBbzLGoVCm9kNztD/rnkmbBquL6/jMnFWE00k+//pj/PnILt42ZSFxXcOwRurepAyDtGkwN1hC0O5kbesBbq6eS3s8zLNtB/nB0mvP2EUxp6jwb2nFf8MgbSaJjkpbPB4G072YQ7o5kHkXxZNp2rtDaLpJQdBD0O9GiBG/u2lm9hl+b/s9TpQJAlvPu2IuS02L3oEovYMxjnaHKC3w47CPT222LItwLElXbwRNN3A7beQHPUNEJmP5SmsG2/e3EY4licVTWeuk3SajKiMWv0RKwzAsbKqCc5KYkeH4g56BGH2DUew2lZICPw6bMuo6TRJJDYdDJZHUaOsexDItCvN8BLzOCS0Summy4cARSoN+phTm4nM5suczLQtNM+gPx0mkNHJ8LmKJjGXSpspZi0LmN9Cw2zLWuc7eMIORBG6njZICP6qiDJGUzLV290WIJdI4bApFeT5cTtuE4xuNp+jsjZDSdFwOlYKgF7dzZHw13WB3QzsD4TixRJpILJXtm00dGd9kSkc3TBRZJsc3vkbOyPhC32CMnoEoNlWmpMCPc9Rvb5oWiVQah00lmdZp6x7EMEwKgl6CftdZt/gkDI2vbnt4TIBzxmodpScVId/h5VPTL+HWysWMTp7VNAO7Q0VRRyzYNruCosro+pmJxJ11wvG9732PX/7yl9xzzz3MnDmTzZs38+53vxu/388nP/lJAL7//e/zox/9iLvvvpupU6fyzW9+k0suuYQDBw7gHSpC9alPfYq//vWv/OEPfyA3N5fPfvazXH311WzZsgX5FHUBhORFUuuR5GIkuRo9/RpCKAgUMuThAKbRgmX2gJVAkssx9IMotgUIyYdptGOaA0APptGBoR9GVuvQ06+BlUKxr8LUm8lM68cMqXAAEnrqWSRlKpJSjZZ8BstKIskVWNawjLeMZfajJZ/JEB2pAC35LFhJFMf5CMmDqR/B0JuQ1RlYVgxJrkRSqtBT69GT68AaezOokjyuhkdHPMSLHYf56YobqfTkDCkWnmgVZvF8xyEuLp1KrTcjunNj1Ww+vuFhBtIJnmtrIM/h4W1TFmZX/141E/hnWRavdDayvLCajniYLb2tXF42EsmtCAmnolLtDRKwORhMJ4YIh8AmyfhsDq6rnMXz7Q0823aQd0/LyDoPr1CFGCmkt7W3lRKXj+WF1dhkmdUlU/jfA6+xP9SNbhokdI3baxfgGepb0D7y8pCGAqnsksKMnEJ293dmJm/LYkvPUaq9QfIcbl7ubKLON7LylyUJu6SQ7/AwP7eU1ljouCOpSjLvnraUH+xYxyWl03iwaQcrCqup8Z55GqV6lvQyjCHZd1X6+6aoNvUP8FrLUfwOB5dMnYIyiUS8hYVpndyL0LQMsvJmlsXWvUf5+R9epqsvUxjMpsjcdOk8br18QdaF0TMQ5Ws/eYxQJIlpmWi6yey6Yr7+0Suz2iVCCBIpjd/+5TWefHkvhmlhmiblRTl86h0XMa2qIDuWmm7w6LpdPPD0VgbDCYYlXBbMKOffPnoVqiLxl3W7WLt+H01tfURiST7+7QezC7bbr1rIDRdnFhKGafHDu9exu6GdtGZQVRrke5+5Hps69l5IpDTufuQ1nt6wD9M0MU2LypIgn3jbhdm+tfeE+dKPH+XmS+fx6PO76B2IktYMvG47H73tAi5YNGXc/VAa9JOeZBJ6dN0unnhpD/3hOJFoknsf38xfnt8FwLUXzebt12S0jJIpnc9+/2Fuvmw+Bxq7WLthH8m0jiQEX/vwFSybW539rX5y30v0DkSRhEDTDQrzvHzmHauZPbUk2zfdMHjy5b3c//gW+gZj2fGdUVvMtz91DQ67ytPr9/HXF3ZzpK2PUCTBZ77/cFZm/PrVc7jj6kVD9wj87P6X2LS7GU03KMrz8cPP3ziO2KXSOvc+tpnHXtyNrmdECEsLAnzsjguYXZfpW18oxud+8AjXrZ7D2vX76OgJkdYMXA4bH7h1BZcurz+rz5thmWwfODrhtny7lwsLp7E8f0o2zmsYxWVBIoMJnnpoM3OX1GCaFq+9sB+bXSW34PhWoBPhrBOOjRs3ct1113HVVZkVfVVVFffffz+bN2f09C3L4s477+TLX/4yN954IwD33HMPhYWF3HfffXzwgx8kFApx11138bvf/Y41azJ1LH7/+99TXl7Os88+y2WXXXaKvVKxu+7AMvsQUi425zWAlPknJCyjH0mpRAgnQnaBcKHaV4GwI6vTkdU5CCkPy+zH7n53Zj8pH1XKB2SEFECV80E4sbluHnNmIRTs7rdjGb0IKRfJUYpldiOEj0wxoMzDaqGTjt2PbJuLKhWAcGBz+Yba9wJ2bK5bQNgRoiqzDwZC+LC734FlxUCMTKAW8NCRnWzry+SPl3ty+ED9MjriYRyykiUbx2LPQCdf2pTx38X0NElDx7QsOuJhluRXZI/JdbjRTJNQOsGBUDdzg8XYpPETXto0eLmzkQ9NX057PMS69gYuLZuWZdQD6QSHw71s7W3FAqb5x+ecy0IwPVBIQ7gHy7ImfSg74mGKXb6sEqpdVsixO+mIh4lpKcrcAVyKjaiWojcZQxYSJe6MNSVtGDRHBghrSZ5ra+DWmnnZeJLn2hs4v6iGQpeXX+9/lbdPWYg6dK2GZZI2DfpSMbb0tnJNxczs9z/ft55ceyZeYntfG9dWzkIIweycYmp9efy/g6/zanczP1p23TmVpD9VbGlt56XGI3x21YoT73wO4bPbcakqv9uynYtqayYlHLJQUKWTM3M7ZDfSUIDc0c4BvvU/T7N0dhVf+/AV2FSZ519v4P898ipFeT5WL80Uq8sNuPnGx64ildZJpDR+fM86BsKJMUGhlmXx4FNbefylPXzybRcyq66YUCTJT+59ke/+Zi3/9cWb8XudWJbFky/v5Wd/eInLV87gmgtn4XU56O6PYJgm6pCE9aJZFdRW5PH4C7t5acsh/uXda/AMZe8UjjL9y5Lgw29ZSTia5Bd/fJnuvgjHRquapsX9j2/hsRd38fE7VjF/ejmRWJL/eXAD//GLJ/nxF2+iIOjFMEzaugf59Z828P6bl7NkThXRWIof3bOOX/7xFeZPL8fnGTvOA7EEGw42Y1oWeV531sIBsGxuFVMq8+kPxfnWL5/iipXTWb0skyqaFxgpsJexvET57V9eY9aUYr77mevwuOy0dQ1SX12YdcEUBL1cvWomc6eV4vc46egN851fr+XXD23gR/9yI6oqY1kWz7/ewJ2/fYGLltRxw5q5+L1OegeiJFJa1qoyZ1oppYUB1r16kMde3M2n33EROf7M+zM/Z6RvQsB7blzGTZfM4/89spH9R7rHZdtYlsUjz+3ggae38uG3nM+yOVXEkmnufuRV/uMXT3HnF2+itDCAaZh09ob59YPrefcNyzh/YS2JlMZP7n2RXz3wCotmVpAbOHtCj3ZJ4SPTVmffQRagmwbtiUFe62nkd40beaRlK++qXck7apdn32ken4P3fe5yfvez5/jLvRsRAqqnFvH+z15xxllXZ51wrFy5kl/+8pccPHiQqVOnsmPHDl555RXuvPNOAJqamujs7OTSSy/NHmO321m1ahUbNmzggx/8IFu2bEHTtDH7lJSUMGvWLDZs2DAh4UilUqRSqezf4XA4+1kIAcKFkCY2hwllrN9RlkbdcHLJqM+5QO6ov0cmRyECY/4f1XqGoCjlo46bQFvDslDs5yPJZQihDO03Nt1QyAWjPo+amIUXwXjmOTOniPOLMv5+v82BLDJFuTJqlBNPcAVOD5eWTUMAfckYewY6R13JxDAtK7v6OhYt0QGaowO0x8PE9DTb+9rpT8XJG3oInmtrYEdfOz3JKD9bcRP5Dg/9qfi4djJi28eflK0JHQpD5kxG1De39bXxsz2v0JuK8aeL3wVAZyLCt7Y/Q0Oolw/Un8cV5ZnVRn8ixo7+dubmlmLFIzRH+mmJDVI7ZJF46uh+9g50kTZ1FuaVc2V5RnRIQrA0v5KaocqWA+mRgnSKJPH2ukW868X7eVfd4qwL6XRgWRaHo7voTXeM+d6nBpnuXThpVtPxkNA0emPxrIUnnEyxt7sbVZKZWVSAQ1EIJZO0hsLMLMzck3u7eij2eclxOjjY00u+x0PzwCAJTWNuSRGyEBzq68drt9M8MEh5wE9VTgCAUDLFwZ5ekrpObW6QEl+mVkiu28WC0hL+tHPPcftrkxzk2grpO2YMJkKpswaJTAmCp17Zh0Dw/luWE/Rn7scbL5nLc68e4ImX9rBqcR2KLFBkiaK8zG9kmCZet4NUWh/Tbiia5NHnd3HFyhlZolIQ9PL2a5fw+f/8MzsPtrFyQWaCeeiZ7cyuK+ETd6zCMfQCLysKjCHTZYUBygoDbNrVjKrITK8pJDCBOV8IQV6Oh9yAG7/XOUQ4xmIwEufxF3dzyfLpXLZiBpIkKMz18tHbzueD3/gDz792kFsvH9KSsGDZnCquXjULWZawci2uWz2b79/1LD0D0XGEoy8SY2pxPom0RjQ58v4VQlCc76c4309XbxhZlijO9zO7bnJdIUWW+ehtF+B22bNjMLq9sqIAZUXzsmOUH/Rw0ZI6nnx5L8m0hqrKpDWDh9Zup7Y8j0+/8yLczpG2Ro9vSb6fknw/+w53osgS06oLxxC50ecN+t3k+Fzk+CcmA9F4ir+s28UFC2u55sKhcbMsPnzb+Xzg6/fz9Pp9vPuGZdnxnTe9jBvXzEVRMgTphovn8rWfPk5Hb3hSwpE2k+wKvYpmpsZ8X+OeSYFj4jADVZJZUzxjjA7HMFl6z5TzuavhJf730Cv84uDzlLlzuLR4ZnZ86maU8rU77yAaSWayL32Os1JU7qwTji984QuEQiHq6+uRZRnDMPjWt77FbbfdBkBnZ2YCKywcmzpVWFhIc3Nzdh+bzUbOMYFzhYWF2eOPxXe+8x2+8Y1vnO3LmRAnU37mdPK0FdusE+94su0B9f4CVpfUjfm+wOkloafpTkSp8ATG9TPf4eGi4ilIQtAaG+TX+19FEoJCp4fWWCj70A6mEqiShE91UOnNYWdfO4ZljZE7tyyLV7qayLE72drbCmSsFdt627ikNJPffUPVbG6fsoCPrX+Ipkg/9ROkrxqWxb7BLhbnH19xtcjpZXPPUXTLRBUyaSOTkVLo9OK3OXi0OUza0FleWEW5O8AHXn4gS1LK3QF+uvwm7j20lR39bdxuLciYcftaUYTEgcFuAAJ2J+s7m7KE44LiWj48fTluxYbPZkcgSBk6QggW5pUxPy/zMtjQdWRMXys9ORQ5vSzIKzujh1iz0jzVeS+ticNjvq9xz6Leu+CM9VL74wm+vvY5anKDJDSNR/fs50sXX8Ch3n7u3baD/7z6coQQ3LN5KzfMnsGyinJ+t3UHlmURdLkwTJPKnAAC+JfHnmZJeSmFHg8/W/8a/37ZxUzNz+X5Q4009g9gl2V+tXET37v6Msr8J0/CJCRm+ZfREN2JhTnpfg7ZzdxARlPBNC32Hu7AME0eeGpbVtDIsiwisRSJpIamGygnmTXT0ROidyBGc3s/v/7Thuz3A+E4hmnS1pVxtfUNxujoDnHZiunjsiLOlfuqoydMfzjOnKklY0S6ivJ8FOX52N3QwS2XDetLwIwpxdnxEELg8ziGYkr0cW3PKCukPxpn25F2SnLOTLtmRm0RLueIe3ei8egZiHKwqZuO3jDxZJo9hzoxzZHAyFA0wdHOAa5bPWdcyu25Gt+e/ijd/RFmT100ZtzyczyUFQbYc6gDwxyZM6bXjlSJHR5fYByJHYaFRUeimUdaf4VujRUDvLH0Q5MSjokwPAZuxc47alfwTMdemmN9/OXoNi4umo4iZFoOd/PcY9tZuWYmVXWFqLaJ696cDs464fjjH//I73//e+677z5mzpzJ9u3b+dSnPkVJSQnvfOc7s/tNFORzoos63j5f+tKX+MxnPpP9OxwOU15+8hr+JzqvYVkMpGMcifZyONJNW3yA3lSUmJ7GsEwUScKt2MmxuSh2Bqh051LhyaXQ4ctWkfxb+8ONoTRQGIouERKlLj/TA4X8av8GPjP7QryqnbShn8D/Lzi/qJa7DrzKDVWzybE7efzoXmbkFJFjd7G6eAp/PLydp1v3c1HJFGQhkdA1nIrKix2H+eiMlVw8RHx+f2gL69obuLg087csBDk2J++rX8ZP97yScdsAYGFYJjEtxVOtB2iK9PHFuRdPSPaGv5ufW8Yv9m1gW28bc3JL2Nh9BMMyqQ8UZNNP17Yd4JLSaeOsIUJkUlvfWjuP97/8AM93HOKS0qk8197AHVMWcseUhQjgufYG7j20hdtqMytCr2qnxOU77d/2TG+JwXQPvamJVvZnJ3z0+cONlPn9fOr85RimyWf/+iS7OrrGuYBGn003TKYX5vOOhfOy33WEI0gCPrpiKfluN3FNY1dnJ1Pzc7lqxjR6ojFCySS7O7to7h84JcIhhGBOYDn7I1vYG97MRNdukxxcUngrJc6aoZgfk2g8TVozaGztHbNvVWmQ/BzPKf02yZSGbpj0DkbHZAUAnDevmqK8oUDptI5mmH/TTIdESsOyrHHBlYosYbcpxEYFxAK4HJPU75ngljrSkxH+8jhspPSJJ8yTheM4acSmZfHUy3u56+GN+D0OplTk4/c4Ma2xBDOtGaQ1Y5wl5lwimdIwTSsbkDoMWRI47OpQwPFIZcfJx3eSZ9aCI7F948jGmcKrOihz5dAc66M1NkDa1FEkGX/QjWmY/Pe//wVvwMX5l8xk0cqp5BX6sjFzp4uzTjj+5V/+hS9+8Yu89a1vBWD27Nk0Nzfzne98h3e+850UFWXcBMMZLMPo7u7OWj2KiopIp9MMDAyMsXJ0d3ezfPnyCc9rt9ux209dofB4yOhHxNnQ08Az7XvZPdjGQDqGbk2+ihqGJARu2U75UFW+C4vqme4vxi6dPbZ4PCiSxL2HtrC27QCQmRi/sfBycmxOvjjvYr63Yx3vf/mPeFUHhmXy+TmrkSSR9eNBxoVhGxKfurikju19bXxsw8M4ZQWHovK1+ZciC0GNL48vzl3Nr/Zv5LcNm7HJMgUOD++vX0Y4nWRebmn2ms8rrOLPR3YRSidRJQllKDBxZWE1f23ewx8Ob+O22vnolslXNz+JbpnYJYV/W3A5Ze6MWuDTrQd4oeMQA+kEd+56keWF1dxcPYcqb5D3T1vGt7c/i0e1kTINPjNrVTY1+PNzV3Pnrhe5//A2TMsi3+lBGdL3sA2RwoDNyXunLeXug68z1ZfPoVAvH6w/LzvBzsst4Wd7X6E9HkIWEsokLgubNFYYS5HG7jus3SGdoQ3iaLyBpJk48Y6ngNGvvY5whFK/L1M5VpLId7vpjEQp8Y01P48mgpKAqpzx1rMcpxOvPaPD4lRV0oaBZpj86KX1xDWN6mAOoWQqW4X4VGCXnNxc9hE29D3FrsENhPR+DFPDJjsocVSzMv9q6jxzstkpQgj8HgdCwL9//KpxGheCU1sguJw2VFXihovncvn5M8ZtH27LaVexKTJ9odgpX+Ppwud2IEsSoUhizKItrRvE4mnKCsb/VieLlKaT73NTkRfAfcbv38n70DcQ41cPrGfRzHI+867VOB02BHDXQxtpaR/I7uewKdhtCv2D492y5woetwNFlhgMjx1fTTeJxpPkBjzHEPRTG2sTk8bY8d2KpwPLskiZw3pUI/3y57h572cuJxJKsGfrEV5au5snHtxE9bQiLrx8DtPnVeB0jc8MOhmcdcIRj8fH+fNlWcY0M5N0dXU1RUVFPPPMM8yfPx+AdDrNiy++yPe+9z0AFi5ciKqqPPPMM9x6a0bToqOjg927d/P973//bHd5HDLiUUn+2rqdPx7ZREusL1uw7WRhWhYRPcneUDt7Q+3c3/Qas3JKeUfNclYVTjunpEMAn551IREtmf1OFhK+IdGtUpefHy69jp5klKSh4VHt5Nnd1HiDLMorzz4OXkPhwlftqCtg38v7ucTI5z0rl5A2DQqcnqywlwDWlE5lWWEVfckYFpBrd6FIEv913g1jskGqPUF+dN71dO5uZ9p+wYU3ZaLtVUnm6wsuI6qn8Nsc/Pr8W9FNE4ecyQAZjqS2LIsFeaXU+nJ577SM/LBbyZhOJSG4pWYeF5dOJZxOErS78Nsc2bFeWVjNnGAxfck4iiSRa3fjUlSCEZmZj8e5Z+0fuP2LN7KmdCr1gULy7C5+fN71lLlGZJGDdjf/fd6N5DlcvLVm/oT3hU1W+M+l15I/pGCqazq5awfobNzP/nfnU79kCook84Ml15LnOP0gMcsyORzbzdmwZpimmXnrWHB0MESOKyPCVhEIsKuzC8M00U2TzkiUK3xeVFkiqWUCinXDoCM8NnZgovt7+F4Zje5olK1t7fzmlutxKCobj7ScVv+FELgULxcX3MzKvKuI6WEMS8cmOfAofmQxluhLkmDBjHJ++5fXOdLaz7TqkSyS4RTHU3lGSwsClBYEWL+tkTXn1Y9Jq7SsEQKTG3BTUZLD+q2N3LBmLl7XiBDe6GsZhqrI6IaJbpx4kTMZSgr8lBb6eW3nEdYsm5aNHWg82ktXX5i3XLHgtC1tZUE/Td0DNHT2UhQ4swyG4yEcTRCOJZlbX5Z1laQ1g72NY13sfq+TmvI8Xt3ZxG1XLcym8x5vfA3TPKN0z/ygh+qyXF7f3cw1F83CpipYlsXRzgGOdg6yZln9GdUgiekh2hNHTvv4iWBZFl3JMEeiGeteqSsnG/Q/PD5ev5O5S2tRbAqPP/A6e7c103KoG7tT5e0fvZhZC6pOeR4764Tjmmuu4Vvf+hYVFRXMnDmTbdu28aMf/Yj3vOc92Yv51Kc+xbe//W3q6uqoq6vj29/+Ni6Xi9tvvx0Av9/Pe9/7Xj772c+Sm5tLMBjkc5/7HLNnz85mrZwrmJbFjoGj/Hjv0+wcaD1lojEZkqbG5r4jLAxWsqpw2llpczIIIShyeSmaIJB0eLtNlil1+8d877U58NpGTJFW2qTjxSbMTxg07WnBMiyWXjZv0ja9qj2bDjsMl2esH1WWJCo9ObQHUkytKiXH7sweH7A7CQz9XT1JmqgQggKnN6vlcSwkIchzuCecyIUQ+G3OrODWMAqLc3nXB67hRx/4Fal4Cm+Om2pvMDsmx7Zf7gkA4FQmTicevQ+ArMjc9LaLufvfHqD9cCf1S6aM2+d0kDQTHI03nFEbkHn5PHXgEK+2HMUwTY4OhvjKmgtBCC6sreaVI818d91LJHWdQq+HWcWFJDWNlK7zvedfzvRFN8amKk9wnrGqqRkLWsDpJOBw8IuNr4MFkVQ6kx1kWaxvamZHRyedkSgP7NjFvNJi5pygbosQAofswiFPHCA+er/LV85g3WsH+eavnuLWy+dTnO8nGk+xr7GL2XUlnL+w9qTH0O208fZrl/Cju9fxg//3LBcurkNVZDp7wzQe7eW9N52Hz+PEblO446rFfOt/nubff/4kV5w/A6/bQe9AlIFwfEw6LkBtRR7xRJo/rd3OygU1mVTQXB8lBZlnt28wxuGjPcQSadq6QoRjKZ5/vQG/x0FRno/KkiBup407rl7Mnb97gd88tJHz5lbRH07w27+8xpSKfFZNkO56suiLxpEkQVLTCcWT5LjPTAhuMgQDbvJzPDz36gFqy/MQwNqN+2lq7RuznyJL3H7lIr7+s8f5+k+f4OoLZ5HjddIXitHdF+EtVywcEztTXZaLrps8uHYbFy+dhm6Y5OW4KS/KWNYHIwkOHukmnkzT3N5PPJHmxU0NBLwuCoIeasrzcNgU3nbNEr7767X88o+vcMGiKURiSX73102U5Pu55AzSXS0rE78RGyoydyYYJl0W0JeK8pP9z9KbiiIhuLhoRlYl2TQtujsG2bhuL+uf3Yuiylx4xWw+8dXrcLhsvP7ifu7+r2f495+/A/cpuq7OOuH4yU9+wle/+lU+8pGP0N3dTUlJCR/84Af52te+lt3n85//PIlEgo985CNZ4a+1a9dmNTgAfvzjH6MoCrfeemtW+Ovuu+8+ZQ2OU4FuGvy1dTs/3vcMg+kTm+QyRdYkBBkGrVvGcelJocPH9RUL/uaxHBMhFo6zZe1OOo90k1eWy7KrFuDyOjENk12v7KdhayNlU4vHHBMNxXn6nheIhxMsvXI+xTUZF1hnUzebnt6OJEssvXIBeaWZybrtUCdb1u5AS+lMXVTDrJWZB+/1p7bTtLOZKfOrs21blsVAV4jXHt9KKpFm0aVzKK0rJhFNsunp7fhzfTRsa6RqRjkL1sxGnkRet+doH0f2HqW7pZfpS+to2NpE+bQSpi+rQ0tpbHlmJ60NHUyZV82cC6YjKzKqTaGgPBflmCA+0zA5sPkwezYcILckyNIr5+McesB6WvvY/PQOIgNRaudWsWDNbPa/fgghBNOXZs71wgMbWXnDEpweBzlFATzHRKBblkVPax+vP7kN0zBZcsV8CivzT+r+sCyL3lQHg+neE+57MlhRXUGxL5OdVRXMIeDIWDh8DjvfuHQ1h/r6USSJ2twgNlnGLsv85zWXc6R/kKDLyTsXzcfnyJDN9y5ZSNA1dsLPdbv4wkXnZ2OFrps5PRP3ZFP57lWX0dQ/QNDl5B2L5uMckkvP87hZXFbKorJSBOB3nF2/fNDv4j8+cTW/+8vr/PbRTcQTaew2hfKiHM5fcPJkAzIEZs2yadhtCg88tZXv3fUMpmnh9zhZPKsiSyKEEJy/qJavypfzwJNbufN3z2MYFh6XjZULascRtYUzKrj96sWsXb+PJ17ag8Ou8v5blmcJR0NzN7999PWsJaUw18ufn9uBQLBkTiXvvG5ppm/n1SMJwR+f2soTL+1BVWXm15fxnpvOy8Y72G0Ks6eWjhO38rkdzJ5aitM5nmCndQOPw0ZaM9CNia0Eqiozq66YvFHppqMhSYLpNUWUFEwetxPwOvnU2y/kNw9t4F//6684bQoLZ1XwlQ9exiPP7cymTAshWDK7km989Cruf2IzP733RXTDxOW0sXR25ThLzswpxbz7hmU89uJu1r16ELtN4e3XLskSjub2Pu7586uYQ+NbVhjg0ed3AYK500p4f9kKZEli5YIavvDeS7jv8c08u/EAiiIxu66E9950HsGhdFtVlZk1pZi8Y0q8u5125kwtweOa2CXVGNuDeZxg6MmQNnXua3ptzAJLNw06EyG29jfTFs+4olYW1HFZyUiGypGGTv7zKw9RW1/MOz52MdNml2Ozj1gIl15Yz9N/3kIqoZ0y4RDWyaRc/AMiHA7j9/sJhUL4fCcOQNNNg/uPvMZP9j9H0pg4OEcA+Q4vc3LKmZtTTpU7D5/NiSIk0qZBSIvTEutnf6idPYPttCcG0cyRh/D9dav46LTVbwjNha7mHjb+dQsltYW88sjrlE8r4ebPXM3Ol/Zx/3ce4ZoPXcK+1w+x8a+bufOlf2ftb1/k2d+9zE2fvopIX4TNa3fy1Qc+Tbg3wi8+cw8X3HIe8XCc157Yxuf/30eQZIlv3nYnq9+6AqfHQSqhceFbzkMIQc/RPp677xUGukN8+IfvQAhBLBTnh+//JXMvnIkv6OHZe1/mwz96Jw63nc9e9A0ueutypi6o4ZGfPMnbvnozc1eN95MD7Nl4gHu+/gBLLp/Pi3/ayGXvvJDXntjGV+7/JA//95P0tfez6NK5vPTQq8y/eDZr7jgfIQTJWJKvXPd9vnjPx8grDWYyVJ7bxTO/fZELb13O3lcPoqV03vfdO+jvGOAH7/k5iy+fR2FlPliw8sYlPHTnE8iyxI2fvJJ4OMHXbvwB//r7jxMsysGyLH79xXuZMq+K1betBGCwO8R/f+wull+7CNMwefHBjXzufz9CToF/wmsbDcuyWN/7OI913D3h9hr3TN5X87Ws5sTZQlTrIK53UeCcd0rHaWacQ6FHKXGfh99WiWlp9CX3k+eY9Xcl4MMKnJkAUh1FkXE7bSiTpAAahsnnf/hnNN3gx1+8Kav+Obo9TTeIxlOYloXTruK0Z2TQR7c3Zj/Twm5TcDltmViZY/azrEzqZVrTUVUZj9OezXII9UeJDMQoqszL3MfxFCBwDPnYR583GopjCkgbJooi43XZx1QBtSwLwzDpbu3H43PiC3qy35uWNa5vANFkikNdfThVlbqi3AnT44ePF0JM+O6zLAvTtGhL9lDuKhjnAhmNZEojlkijKjIet32o+Jg1Ybu7B46wu+cIawoWYVdV3E7bhK4N07I42NdGvpKDqsi4XXbkoXHRTJ2uxADFjozFtS8dJm1qFDtys+M7Gqm0TjSRRpEEXrdj3PhONA7HG1/NTPPrxn+jJX5wwvG4sfRDLMkda/V/4MgmvrnrrxPuPxoexc6lJbP42LSLybW7s+eOhBNEQ3EKSnImHi/T4sjBTiqnFKKo8inNtf8ktVSOD9OyeKx1x3HJRoU7yFurlrKmeAb5Di8SE0frWpaFRaaw1/5wB0+37+aFzgPIQnBjxYI3BNkAyCsNMvfCGXQ0dpFT6Kd5byZt9bXHt3LhW5az/LrF1C2oYdu63dlj5l88i4tvX0k8kmD9XzYRD8XZ8uxOdN1AT2nIikx3Sy+tB9qpmlWBalPp7xzkgpuWUVCRl41wLqjIo3RKEQPdI2bChm1NKKrM1R+8BEkSdLf0svHRzVx02wrcfifXf+xy/Hk+mvYcpXnv0UkJB0BxTSGrbjmP7S/s4aK3ruC1J7cx2BNm89odfPG3HyO/LJeCijzu+tf7ufCW81AnELOxLIvn7n2FnMIAkYEo/jwfz977MvFwnC3P7KRqZjk3feqqMXL9p4pdr+wnOhjHNDM5M6G+KI07m1m4Zs4Jj7UYjt/420IzY3QndqGbKQqcc0gZYQbSDfjUCjxqKX3JPehWknzHXNJmiIHUIQK2KbiUfNxqMZoRGSrAN1JCPpRuJqn3IYRCnmMm4fQR4noP+c7ZqNLZE0KaCMP35GRZDSPxHJm/I/EUXX0R6irzJ9SFEUJgUxWC/uO/Wk9lPyHI9s+yLOKRJNHBOMFCH4ZmsO5Pr3H7p68EWdDe2E0gz4fTbScyECOVSOPP8yDLEs0HOiifUkhujpt0UqOnrR9/rgdFkenvDuPxu3B6HHQe6SXUH+GiG5dk+yBP8t462JGJ3Sg+TvzG8Y4fRnOikweOruOC/HksCk7j1d49pC2d6d5MXaDtgw0UOXIpdeaxJXEQwzK5wD6X7tQAhyKt1HnLkIXMgUgLspBZlT+PKf4S9seOkBtwE9biPNu9A7tsY2HONF7u2YFhmczNmUJCT/Fo78tcVDCfee6pvNq3m4F0hAsK5tEQOcpLPTu4uHAhM3xV7AwdotJdhCQJ9oSbaIl1Ue+rRDN1GmPtAKwuWIBdHm8Nmmwcjjc+Ia2PnlTbccfuWFR5crm2bN6E24QQuGQblZ5cFgarqPXmI4ux5NrhVHnthWYeuOsl0qNSdRVF5h0fW0NugY/a6ZPrqRwP//SEwxqO2di3dkKyoQiJq8vm8uFpqylyHD/9MWVoWEPHHIn1Ue8rZk5OOQuDVbgUG8XOAL3JCD7Vma0iOgzTsmiLD1Dmysky/P5UDM0ycMk2vKpj3LmThkYonaDA4T2lVaJlWTx51zp2r9/P8msX4/K56G3rx7IsYuE43hxP5oXotGWL9wDkFPoz7FySENJQxde+SKZAlQBZkbj501dTUJmP3WXjkz9/Hy/8cQM/+cT/Mn/1LG74xJXIE9SgAIiF4rh8riyj9uV6aW/MVJ50eV3YnZngOkWVMU8QQGdz2BCyQLUrCCkzLWgpHdMwsQ+ZLd1+F8l4CkM3JiYcpkVkIEpBee5Qfzzc9sXrsTtsRPqj5BRNFtk/Ipt9on6G+6PYhsZXkgTXfeQyyqed3IMc0yO0J5pOat+zCwvDSmJaGq2x9eQ5ZiILO4fCf6U+cAutsfWUuc/HQufA4EPkOWZxMPQQc3PfP2aCtssBjkZfpMAxl9bYKwRs1fQnDyIJhaPRF/DbamiKrKXOd/3f1QISiaX41QOv4PNkMj227W+lbzDGJ9924RmnNJ8O4pEkj9/9ElXTS3B67PhzPTjdjsxdZ1o07mmlrLYQb46b+370BPULq0jF01x08xL2b2nEl+PG5XPyxG9fpqgyj+rppciKzKGdLbQe6uLmj15CQVmQ8ED0pPrjsqn8ZfNegh4nF0yvOS7xOB5KnXlUuApZEswI5x2KtnFrxWqcsp3BdJQiRy7bBxtwKw4UIVHizONwtI2IHkeVFPLtORyMtJBn8xM3krTEuyh3jWj6qJJMsTOXV/v2UuspZVCLsqpgPtsHGrioYD5V7iIWBjOxdfn2AJ3JPlpinVS5i2lP9DLLX4OEoMSZx6AWJW1q7A41cmXxcp7o2EihI4diRy5dyX56UyFKXeMVk08VlmXRGj9M0ji1jJsleTUsyas58Y6T4GhjD3+5dyPXv205Lrcjm1QjSQKn+8wykU5dhvD/GMJagh/ueYqBCWI2bJLCh6ZexJdnX3NCsmFZFus69/Nsx14kIdGbjNIaH0CVZAzLosaTj4VFYojUmJZFWEugmTqGZRJKx3mxa8RsZmJxINzJ3Yc30JEIoVkGYS2RKYhkGoTScfpTMV7vbSKqp05phW2aFtuf38Pq289nxfWLUYYkgYUQlE0tpmFbI4Zu0NXcQ2RwJH1vohVd9exKTNNk+bWLWX3bSs67ZiGBAh+mYeJw27n+Y5fz4R++k/V/3kQymsyasC2sTN65lRm7sqnFdLf0Eh2Ioad1Dm45TO2cyuETnzFcPie+XC8t+1oxDZOGrY0UVeVjc9iyq9jhvliWhSRL1M6pxO6yc+Gty7noLStYdMlcVIdK5cwy9r9+iNhgHEM3SA4VfXJ5HPR3hjB0g84j3Qz2ZNRuraHrzHweOUfVjDIsy2LZVQtYffv5LL9uEbklwUmuYASZCPMWItrgmQ/MKUPgUgrx2SpIGWGOxl4ibUTRzQR2OYdyzyo64q8R13tJGgMYVop8x2yGf8Thu1SV3AghAxaKcJBjr8Op5JE0BkibMWShkmM7tTiKcwFFkfC47Bxq6WXv4U6qS3P53meuY+HMir8LERrsCRMs8rN4zSy8x8QCKKpMUWXekJyDRX5JgGWXziEaimN32CgYchWm4mkM3WTZZXMorMils6WXeCTJQE8E4xSzYaoKgsyvKqGmIJc8z/EDdSdDxsWQmYrSpoaFhVtx4JRsSAjWdW9BCJEthuhXPThkGyYmC3KmkmPz8lLPdiwgZWpopoEsJHRTRzcNdMvk9b59RLRE9tnzqW6csg0LC1lImJZF2tTpSPSzc/AwilAy+koiU01bN3UswLCM7GcQpMz0kMaRjE91Y5PVs5ZoABaHY7snUVA+d8jJ81I9tZj8Ij8VtflU1hZQWVtARU0Bqu3MbBT/1BYOy7J4qGULuwbHm6xkIXhX7QrePWUlijixpKthmfQmo1hDglXDBcJkkREEswDNNHi+cz9Xls6hKdrLoUgXAkGew0NMS9GfGpncZSExP7eS5lgftd58Hm7ZSto0mOYrpCnaR9DuotSVw4FwJ2EtwQWFU8dI2B4PkiRYft0i/vzTJ9n46CYUm5INaFz91hX8/NP38IP3/Bxv0ENeaRAhBKpNzaY2AzhcDoQkmHfhDA68fojvv+tnqHYVX56H93/vbSSjSX71L79HkgSpRJqlV87H4baTiCZ59Bdr2f9aAwNdIf7fV//Ape9cRdnUEpZdvZA7P/xrZEUmtzjA0qsWkIgkcAylDgKoNnVccOeY302WsQ0J69iHjrO77NgcKrd98Xoe+OGjPP7r59BSGm//2s0ISbD56R1sfmYn/R0D3PedR5i+tI41bzufaz98Kf/7lT/w7bf9BEkS1C+dws2fupq5q2ayZ/0Bvvuun2J32imdUsQ7vn4LCy6Zw08/8b/84L2/wOVxUDjkRupq7uGp/32evRsP0nqwg86mbq798KVMW1TL3FUz+M/3/QKb3YbT6+CDP3j7uODSidAY25t1SfwtoQgHSaOPo9EXKfOcT29yLylzEK9ahmZE6EvuRZYc2CQv5Z4LiWqt+NQKEnofA6kGFMmFRy2hN7mbpNFPT3I3DiWIJFQccgC/rYqk3k/C6Mdnq/qbX9+xcNpVPvSWlUMy7yOulb+X1SWnwEd/V4iNT+5g+uIaQn1Retr6ad7fTklNAc3725EkidLaAmwOGwiBalMI90c5eqgLXTfILw2i2mReeWwbNTNK6WjqQVZlbHYFPW3QuOcobYczhDmQf3yf/L62blK6TjKt09TTz9Ti01vZK0Jmpr+a3aEm5ufUUe+rzI7x3MAUOhJ9zM+pI9fmwyU7cMg2vIqT1ngPg+ko8wJ1dCX76Uj2UeLIo8xVwN5QE07ZTnOsg3pfJfvCR5gdqMWnuqn1lOKQbNR6SrFJKlO95ewLHaHeV0m+I4AqZAodQbyqkyJHkEPRNqrcxXQlB9Atg6SRZklwOjsHD7Eyfy6aqeFT3FiuQrzK6RGvY5EyU7TED5yVtk4FkiToah/gp9/6K16/M7vQVG0yn/rGDRSW5JyghcnxTx002pEY5F3r76IjMT7l6KKier4z/yac8skJnLTFB/hzyzaEEFxdNpeO+CBu1c5MfwnrOvdT682n0p3LE227WJRbxbrOfShCJmBz0pkMc1nJTB47upN3T1mRPV/C0Phzy1auL5/Pf+9/jpmBEoqdAfYMtvHWqiX0pWNs62umyOlHlWRm55y8xK1pmoR6M/50b8BNMp7KTnSpRJroQAxv0EMylsz8Hx1axfucmKZFqCeML9eDrGRcHOG+CLpm4Am4sm6LWChOIpJEtSv4cr0ISWAaJv2dg5jm8BoB/Hle7C47pmkS6YtiGAa+XB+yIg21HSWQ70NIglg4nvFDeidOv9NSGsl4CpfXmbmGXC/hvgi+3IybKBFNEg8n8ATc2F0ZP2t0MEY8MqJZYnOo2RetrhmEeyMIAd5cD4qqDI2fRaQvgpbW8QTcOIZMjdn2c9yk4mk8OW4MTWewO5xdp0iSIKcwkHEPmSaR/ijppIbH78LhGe86Oxa6qXFX03/QFNs76T7nKmjUGjIFWVgIpFGfBSCwMLOfgVF/k5UdF8hDn61R+wqGK+aMHPf3rVb7RoRlWSTjaeLRJP6gh0Q0STKewuaw4fI6CPVm9FD8uR60tIHDbScZSyKrMuG+GEIS5OT7MAyDyEAMj9+Vea5CCWxOFYfTxmBvBNOw8Oa4cbiOX0n6QHsPO5o7MC2LFdMqKc8N/A1GYWLsGSIYNZ7Tiy94o6E90cQvD3+F9DH1U0ZjoqDRM0XTwU7u/u+1fOobN+I85ve32dVxgaRvBo2eBCzL4sm2XXROQDby7B4+Ub/mpMkGQFxPc8NQUGhbfJDW+ECmbLndS08ykolYl1UG0nH2hzo4v2AqW/ubCdo9VLhz2djTSKl7LHOUhaDKnYddVlldVE9XMkyJ049mGqxt38P0QAml7hz8qjObQ32ykCRpTDbE6DgGh8uOY4g02IdS4Vw+56hjBTmFI8dKskRggswKT8A9brUuKzL5ZRNrbEiShP+YFZWsyGPO5Z6ggNVoqHY1ey3DbY1epbm8znFkxZvjwTtJyp5qU8idgNHLspjwmke3PzyGsmyjoCJvwvYlScKfd2o1KMJ6P13JictOn2tknofRzrWxjjbBsYqdo5VrpUn3G/72+NvfhBAZP/qwL92b4x7jWskbda8OPwfD92N+6cjkISsSuUWB7N+2gpHnf/T3J0Kh38N5UyswLYuA69xocJwspvsqOSv+1zcALMuiOXbguGTjXMGfk8lYuetHT5FX6MsGxsuKxFW3LiUQPP1A7n9awhHT0zzZtmtC79gtlYup9pycHsIwpnhHApQKHT4WBCuyf7+lanH28x3VS7OfS12B7OepvoymxRgVPCGzLD9T+2FRblX2+yLnyaVNmpjE9TD96W4G0t2EtD4SRgzd0pCQsMkOvEqAgC2fXFshPiWIKtnH9eONiuHVtmamiRtRwlo/YX2AiDZA3IiQMpOYVsbtkClhbscpu3DLfryqH68SxKP4sctOpH+A1fSwMbI1fpiEcXJBfW/i/x6GY6DSZpKwNsCg1kNI6yOqh0gacQxLRyBQJTsu2YNPDRJQ8wjY8nDJ3nGqq2eC/e09lAX9JDWNIz0DzK44vjDb2cLws5A2k4T1AQbS3QxqvUS1ECkzMWYMnLIbn5qDX80joObhVnwoYpJ6Jm8AZN7dBoejf/sstOHzz182ZVxcoCRLkwb9nyz+aQnHgXAHTdGecd/n2T1cUz7vlNNXz8bNq5kpXut9hoQxcZ2FMlct9d6Fk55reAIe1Po4ENnKvvDmjEqdkZF5nrTvSNglB0FbATWemczwLaHMNQVVnJ5e/rnC8AOQMhP0pNppiR+kJX6QruRRwlo/aTN50gWOJGRUyYZb8ZJrK6bCNZVazyyKnVU4pIwV5e917SOKgBZpM0VUH6Q/3UVX8iidyRaaYntPGEg2kO7m2a4HJwz0PROokp2luZfglM9Nuqpmpnm9/1ni+vgy62cKVbKxLPeyE6qQvhExTDLCWh+NsT0cjOygLdE4dN+njlslF0ARKg7ZTZ69mBr3TKZ551HsrEIV9jO6zyvyAjy94yBCCK5ZUH/cfU3LYMvAC5OK1eXai5gXOD8bQDoRLMsiacY4EtvPvvAWWuIHGEj3kjaTJxwDWSg4JBe59iKq3NOp9y6gzFmLKp3ZGJwuhp9zwzJImXFCWj+9qXY6ky10Jps5FN11wjb2hjcR0vpOuN+povqqcmb7zzvr4/JPSTgsy+LVnsPZSqqjcV7+FEpOwoJwLqCZadb3PsGA1j3h9mne+Uz1zkeewNxsWRb96S429j3FjsH1RPRBTrbGhoVJ0ozTnjxCe/IIr/atpcxZy/K8K6n3Lfy7Eo/hhzJhxDgaP8je8GYaY3sYSPegW+nTbtfEIGUmSKUT9Ke7aYju4IWeR8i1FTHLv5T5OavIsxXBJHorZwOjVxCGpZM044TSfXSn2uhKttCZbKEv3UlEGyB1Ei/U0RjQeljX/aez3meX7GVuYMU5IxyGpbGh90n60hNVwD0zOGUP83Mu+IciHMOr3db4YV7vf5aDkW1E9dApZy7olkZUHySqD3Ikto+Xeh6l2FnJopzVzPIvwyV7Tus+97sc1BQESRvGhKJfo2FaJpv719E8SSBkoaOcmb6l2OXxmiiWZRE3ImwbeIlN/c/Rk2o/5aBpw9KJGWFi8TAt8YNs6H2CYkcVS3MvYZZ/GXbJeU6e9dELCN1KE9PDDKR7hhYQzXSnWulPdxPXo2hWmlOpjbQ/soX9kS1nvc+z/ecxy7/srC9Y/ikJh26ZbOsfXyRKQnBRUf1ZH+Szhb5UJ5qZQj7mhamZabYMPM/z3Y8Q0s5c6lq3NI7E93P06CHqPHO4tOh2ih2Vf1PSkVHfM+hKHWXH4Hr2hjfRl+o8p5kZhqXTnWplXXcrr/c/y+LgGlbkXYlbPv3y88dD2kyydfAl2hONdCdbGdB6iOtRDEv7m6fCvYk3HizLoit1lBe6H2FveBNpM3nig04SupXmaLyB1vghNvY9xar865nlX3rKrobdRztp6RvEoar0hmNnVEslog0QM0LjCIdhGRyIbOWZzj/SmWw+a8+GbmkcTTTQ1nqYzf3ruKz4Dipd045rYTlVDP+Gu0Ov0plsoTfVQVjrJ2nE/y5ZZn9v/FMSjoiWoCXWP+57n83JdH/xG8qNMBpRPUREH8yu0IZZ/xMdv2Pb4EvZeIWzBcPS2R/ZSnuiiSuK386cwArks5z1cCwsy0Kz0jRG9/B6/zMcju4mdZbLr58MonqI57sfpiGyg+tK30eZs/as3xcRfZCnOn7/d7m+N/HGxfAzsKn/WV7ofmTIWnmOzoVFZ7KZP7X+jP3hzVxefAcB9eTj14r8Xpw2lVcbWrCpZ/ZuSBoJBtLdBG2ZeDbLyrgUX+h5hPW9j52zAEoTkyPx/fzuyPe4pOitLAmuQRZnb2o8GNnOs10PnLX2/pHxT0k4elNRBrXxQl+lzgC59omzFd4ISJtJ+lOd5NkyRdUi+gB/OvpzDka3n9PzhvUBHm79FWGtn5X5VyMJ+ZxagV7peYznuh88btzJ3wYWrYlD/L75B9xa/nFq3DPPMul404rxJsbCsiyieojHO+5h5+CGv9kq2LB0doTW05ls4YayD1LpmnZS97oqy1TnB6kvKUCVz8wyYGLQlTxKjTtTXydlJnis/W62DLxwSu7E00XciPJ4+z2kjATn519zFknHm8/5MP4plUa7EuExRdWGUe4OYpfeuBzMxKQzlUmHTBhRHm795TknG8PQrBTPdP2R9b1PYFnn9uGv8cw855aUU0FI6+NPrT+nK3X0tGqmvIk3cTKwLIsBrZv7Wn7E9sGX/y4m967UUe5r/hEN0R0nda/3RGIc7uojkkihnaJK6UToTGZc3ZqZ5qnOe9ky8PzfhGwMQ7c0nut6kG0DL735rJ8D/NMRDsuy6EtFszK5o1HsDPztO3SK6Ew0o1saT3fez4HItpM6RkJGESqqsKEKWyYt7jQsFLql8WzXH9k5uOGcPYxCCMqctdS4Z51ROxISilBRhq5ZESrSGWg7DKS7ebz9nrPqR38T4yEJmSr3NMqcteTbS/CruThlz6j79v/mK8uyLAa1Xv7Q8l/HFXSbHAJZKNnnXDmD5zys9/Pg0Z/RFNtzwuc81+OisbufjQ3NDMbP3DXYnWxFtzRe73+WTf3PnnS8xvDzro563k/3XtGsNE933kdH8sibpOMs4427nD+HCGsTTxq59nNbmfJsoCt1lE39z7J5YN2kD6MqbOTbS6lwT6XEUU3Alo9L9qBKGeGflJkgrA3QkThCY2wPbYnGk55I02aKJzp+R4Gj/JwFkspCYVnupTREd5zQrSIQ2CQHfjWXQkc5+fZS8uxFeJTA0ESlIoSEbmrEjQiDWi/tiSaaY/vpTrWddBotwOHoLnYMrmdx8OKzct2qZKfaPf2UfdMD6W4GtPEp3aPhkNwUOyvPuuvLIbtQxPhid2cLqrBzU9mHMS0Tw9LRrDSamSZtJkkYsaF/UeJ6hJgRIa6HiRtRBtI9tCYOndK5LMti68AhelPjxf8y95VCwOahyBEk1+5FEfI5y2KIGxEebv3lpGXIJ4Jb9lLirKbcVUehoxyvEsQhO5GFMpRqmSCiDdCVbKEl3kBbopG4cXLpxhF9gIdaf8U7q75Avr30uNd9+dyppHQDTT9zi0x/uosDkW2s6/oTxnFi0iRkgrYCyl11lLmmkGsrxK34sUl2rCFtnpgeoifVQUv8AM2xA0T0gZMmMBF9kGe7HuS2ik+hiuOrrZ4IfjWPGvfMUzrGwqQ13ohmHf/dkGcvwaecvtT4ZCh0lJ/1NuGflHAkjInTKU9FWfTvhY5EM08kfzfhRGyXHMzyL2NxcA3FjipsJ8gvn+lbgmHpdCab2dD3FLsGN57wBofMCujJjt/xtsrPYZfPvrqgEIIaz0zKnXUcie8bt11Cxq/mUuWuZ4pnDuWuKfjV3Ew+/UmksWaC0ZK0Jg6zofdJDkS2nhTxMDHZ2PcUswPnnZW0UJ8S5O1Vnz/l457tepDnux867j4lzkre/f/Ze884OY7r3PtfnSaHndmcAxY558ScM0UqUTlajrKvJEfZfuVrWbZkOV3pXkfZsnK2JJJiziAIgsg5p81xZieH7q73w+wusMBiE3ZBgMTD3xIz3dXV1T3VXadOPec5DZ+fdmlz4JI8ReNBCIFARREqGjoOxu5fQ9ozJ5IH+MaJ/409Cfe7RPLD0y+ytX/0ME0BqELFozmZ7avmgep1rAnPnXbDw5ImT3d+n6OJPRMoLSh2VLA6dAsL/GsIGsUojN0eKddhYxHJ9bAn+ipb+58lOoFotr5cB4+2/yfvr/vcqKHEmVyeJ3YfJuByYto2q5qqKQ1cGgcuZkb5Ucv/uagRrgqNWd5FrAndTr1nLi7VgxgjqmQuYMu7iZsR9kQ382rvr4iOY6wP4Uh8JyeTB2j2Lrmk37sQYrpm/ILnIG9n+X/HPk93tnXMchuL72VV6OYpt+1iEIP/TTfelgbHaMspgkIK4ysdEhtzlPaXO+u4t+LDNHgXTFg1UwiBJnSqXE08XP3rzPev4rH2b07ogZzu2f750EVBYOpM6vDgICLwaQGavUtYGFxHrbsZj+pjKjoZQggcqotGzwLq3HPYM/Aqv+r4Ngnzwpnu+ejKtHAycYB5/pWXfN1CCNQpPILKhFzFBRf7TBgcVxKGpNYndk/Ghkd1Dgv+ScC0TbJ2noF8kjf6D7M7epyHazby0cY7MKbJyyOlZHd0E9siLzAeuVAXDtaGb+e6kvvxaUEQo2dwllISy+0nY3ZQ6r51uJ+FjXJuKn2YJcGNPNn5XfYNvD4uP+JYYi+v9T3JjSUPXjCwG7rGhtl1uB0GPpeDommRNpcXNTZCRhl3lD/CfP/qSYXvKkIhoIfZWHwv8/wr+GXbf06I+2bKPK/3PUOTd9Go2kcTQcGAFkyWvWAJi4nItCso0xpRM9O4elo6jRhNRbSQevjykZOmE/Xuuby79tMUTSKc7VwMvZAW+FcT0MP84Mw/0pfrHPMYG5tXeh9lvn8lXj04xZaP3aY5vuVUuBoAWFF0I/P8Kwno4Ql5MSZ6Dk3oLAvegEcL8MMz/2dcl7ONxf7YVub5V/BWydtwDeBQdP5y8YepchVy3tjYJM0MJxKdPNW5jZ2R4+Rskx+feYVadxl3Vly6wVkQ6+vm2a4fjbt06FK93Ff5UZYENw4bV5adIm22YaghDCU8oj1uvY7e1CuUum9hqJ8O7Q8ZZbyz+rfw6yFe631iTK+QRPJq7+PM96+i1FE94hyKEPicDl44cAJVEdy0oInKosnlBZooalzNvLPmNy9ow2QghCBsVPDu2t/hRy1f58gEOHAnk/uJ5LopdlRM6ZxXO4Y4LEP3/FxOy1R+h7cmA2scOJTRZyc52xqTJJSIpentjJKMZ0jGM3S1RbBMi1gkSWdrP5ZpMdCfoLdzAMuyifYl6GqLEB9Ikc+ZpBIZspk8PR1RYtHktBCSio0K3lnzm1M2Ns7FEGHzoepfx636xi3fm21n98DUCKRSSmxbIqXkZHsfpnXheq1L9fD+us/wycYvsC58J0VGCYqY/pwnQghme5dwa9m7JzRTPpM6QnYMzotl21i2/bYinJmWxaaDJ9l7ZmxD9VzEUhlOdF2oh/NmQAhB2OGnzFVEmauICleYWb4qbitfzhcXfYQHqtYhAFNa/Lx1Mxl76iq3Q5DYvNzzi3H5OIbi5P7Kj7MseB3qOcs5HYnHiecOkbNG3kMhBAo6XGSpoeDhc3JH+SMsCq4ft50Jc6AQnTaKYdIVS7C0roJ7ls2lxD8zHLgKZz3vrf3dSzI2hiCEwKP6ub/yYxTppeOWT1lJTiTGJ8++VSHtHvLZl865fkku8wRSTi31wNvS4PBojlG3D4yizXEuXnpsFycOdhAfSPH4917j1af2snvLcZ768RucONhOf0+cx7+/hWd+uo0TB9t59Dub6esaoP1UL/u3n+K1Z/az9/XjvPz4bn75rc1kMxMnLI4GTejcUf4+wsb0iZUJIWj0zOeGkgfGXcOTSLb3vzAl4ap4Kstz244QTaTZcbiVjr44mWyedDZPJJ4ikcqSy1tYSQ8aDjI5k95oAsueGS+UEAorim6k1j173LID+b6L5oMAONkX4b9f38nW060kstmr8mUlpcSybUyrYIRf/HvBsFIUhYDHxetHC2GN9qDBNVRutONNu5CifuT5rixDTQiBUzV4X93NFDsKKQ9aUt10ZaKXVK+Ukvb0KXZHN419fgQbi+9lSXD9BUsaYdc68laMVP5C1eSJQBcO7ix/P2Fj/IRr+wa20Ju9UG4+7HWzt6WT5/Yfpy8+9vtzKvCofh6s+iQho2xa33Fho5zrSu6bAE9Bcjy5j7erloaZP0A+99o5WwRm7jUsc3IE7SG8/ZZUBAQNFwJxAWO5NzN2Bk5NV5m/oh5VU4hFksxbVkdJRZCiYh87Xj1CIOQhm84ze1E1Hp+T4rIA85bVkcuaPP7d1/D4nZimjaopzFpYhXqJQjlN3oXM9V88mdtUIYTCqtCt7BnYTFv6xJhlu7ItnE4dZrZ36aTaMZDIcPBUF801JSRSWQ6c6CSVyeF1O7Asm7n1ZWw7eAbblhT53fREEgghaKouZtW8mhnhjRiKk1WhWzidOjwmmz1vZ+nPdVLuqh11f1NxiIDTyS/2HuTnew6yobGW2+c2Y2hXD58ib9n8/I399AwkWVhbRlUowOM7DmJoKvUlIW5a0MjPtu6nP5FiVVM1q2fVEPK6hpcrtxxtwedy0FQW4n+27ufuZXP50Wu7UYTCLYsKrvdf7ThEkddFY1mY/kSKH722F11VuHPpHKrDb04+o9EghKDI8FLvKaMnO0DGzhPNJcBTNuU6JZLX+58mY489SFe5mthYfO+oXJyU2YIiDPJWZGTd0iaa3UXGbCeW24/fWDjq8yKEIKgXs6H4bh5t/68x+3zKirM7+iq3lr0bIUSBeG1aVIb83LNsLpFkmngmSznje0YnCoFgQ/E91LqbZ8SruTi4jk29j9Gf6xqzbGf6NDk7OyME+asDcsTngg7T1Aywt52HQyAodvjQRnE3tqWj2GPcyKb5VRgODafL4Mb7loEQuH1OIn1xqupLaJhTwcrr56BqKr6Am1kLqwAwHBpzltSwaHUjS9Y1UVEbxu1xXJLBoaCyJnT7jIUoulQP68J3jjsDsKTJvoEtTLYDFgc9VIT9VJYE8HkcrF1YT24wrG7p7CqqSwJ09MYo8rsJ+d10ReKUBL2E/DOXeEsIQZN3IR5t7HVoSWHt/WIv6FP9Ef5nzwFmlYT4g1uvw23odMSmP/vpTKMs4KXE72HrsRZS2RwBl5MPXr+cfS2d2BLKg16KPC7eOH4hk35WeZjXDp9mX0sXQY8LiSSVzTO7spjyoA+HrrGmuZZYukAQzFs2mXyeeVWlFPuuvORqihA41MHwyEEPzaUgkuvmwMAbY58TletL7r9oRFSRYwXlnjup9L3jvD2CgGMhzUX/C4/eOOY5hBAsCqwjqJeM2+YDsa0jvJktfQPsPNnOk7uP8NLBE8O/5XSh2FHJ6vCtzBRXyqMWSOjjIWZGJhxOfCXBsmz6euMX7avtbRHe2HJ8zL6s6XMxc7vIpf8HM7ebbPon2NYJVLVhSm162xkcACVOH07twoG6PRUhbV58bXbWgioMR4EdPWtBFRtuX0i41M/yDbNZe8t83F4ni1Y3svaW+fiCbpoXFtYchRAsWNlAZV0xLreDNTfPZ/GaJpRLMDjCjnIaPPNmLIxXCMFc/wqKjPHXOU8k9pO2kiO2WXYa65zZm2knsM8JPXXoGiUhOHKmg1nVJTgMldm1JdSWF+FxGqiqwp3r5iEllIV83L56LhJJwOOc0dBlrxak2FE5brmEOXBRGyvgdPL+lUu4YVbhodzQWEdVcGbIdDOFox29HGztprmimKH3UdDjQlNVFCHYc6aDM71RmsrCg6nTIWdamIPLJsV+Dw5d45k9R1nVVI3HYfDeDUvojMZ56cAJJJC3LEyrsIwSdDt5z7olHOvq4/VjLW/mpY8K07bozxYGHUPR8OlTn+1KKTkQe4OkFRuzXLmzltm+0T2HQghUxYGu+lGENqKMEAJN8WKoQTTFM+7z4tUCNPvGH3h7sh10Zc6q7TaVhVhUW8671i7iveuWMKssPG4dk8HKoptnLHHiEJq8i8adVOXsDLF8ZMwyVyJyWZPXXj1KOp2juytGb0+cSH+StpZ+ksksxcU+Ws70MZbtLJQyPP7Pk8+9Rir+95i57bj9f4pQpqb98bY0OIoM96g5U7rSMTrT44dGXglo8i7EOUMpwofgUX3M9i0dt1w033tBvHgqf4pIZis5qx8pLVL5U9gyg5QWGbODnN3OvOZW6qtTzG8M4NA1ls2uZk5tKb5Bo6K5poTb18yhujTIgsZybls9h5Kimc11owqNkgkYHBdzhVu2zY7WDk71R4imMzy2/zCKEGjjpO6+0lBbHCTgdtLSG2VlUxVFXje1JUFUIVhYU05zeTG6qtITS7CkvpKBVIbXj7aQMy22nWhDAEvqK3DqGsU+D4lMjuf3HSdnWiyuq6QvnmTHyXbi6Sx7znQQTWV4bt8xNEVhXtX4Ru7lhJSSU8kuTqcKrvdiZ5Ay59TFlkyZZ39s67jlFgTW4FAuhxtf0OxdPO7Aa8rcsArq0ETK4zBQFQWnoRNwX5hWfqpwqz4WBFbPqLEhhKDUWYWujM7pG4IlTZITCJm/EiGl5PDBDnZsO0E6nePJx3fRcqaPl547gKIKhDL2/RVCoOqL8QS+jC/0DTyBv0bV5k/5d3n7cTgAl2bQ5C3lVGIk8S9t5dgdaaHJV3pFC4AJBE2ehTMelSmEwhzfMrb2PTNm6JwlTU4nj1DnnnvOfbNJ5U+QNlso9zxAIncYXSkiI9uIZfdh2jE0xUcyf5RYdjcV3oe5UsJMA/r4MzXTHp3wm87n2dfexd72ToIuJw3hEOpVZmwA+FwOHtm4dMS2mkFexR1LC8Ta91+3bMT+9244O0s+0xtly9Ez3Ll0DooiCPvcF5T/wHnfP3j98ulq/rRgyHPTnu7j/x17lKSZQQA3lS7Bq03dEIjkuulMnx6zjC6Mi3o3phtCCCpcdTgU17ickjOpI0jkjCZvBKhxz6LIGH+Z51Lh04I4Ffe4Ssspa2x+35WGdCpHb28cVVEQwKzmcqprQng8DhYuruG5Z/Zh5i3MvIVlWijGxU2BIa2bIf9EPrcDRSlC1Sa/rPK2NDgUBMvDtTzXOTJngQRe7DrEAzXL0K5gwSRDcVHuqp3xhx4KIWluzTeuKFZr+th5LyKB37GErNmJxERXAkhMVOEmZ/USdt9AKnecoGM1vennuZJY4BOZVRZCBCXnG0kew+Aja5djqCouXcOy5RViRl1euA2du5bOoaY4+GY3ZUKwpc3e6Knh6JO8bdKXi3Eo1sLWvsPD8ufzA3W8o3rDlM8jpeRM6iiZcSK7Anr4smo/eLUAHi1AJje2wdGTbSNnZ0ZVHp1ONHkXzaii7RA0oeNUPcTMscOzxwqDvxLR2xPn1Mke1m5sJp+zMAYNivkLqzEcGvMXVNHeFiFY5KGrc4Dq2pGTLClNwAZUOE992sztQNPnXzM4JgohBCvD9bhUnbQ1cqa6ve80x+M9zPZPXxjWdMOnBfHNgH7+aPBqAUJG2bgGR0+2HdPOYagFt6qhFiPJoykepLSwZJqMWVh2cWgVRDPbCDiWoipufMY8rhTvhhBiQuqco5lHQ6GeXsMga5mk8nleO3mGG2Y1oKtXrgE7Eyj2eyjmys9NNIScbfLVQz8e7oXn/76qUFhR1MzvznkHRYb3kt4Np1OHRjnDSJQ5a3Ao07dEMR504cCnB+nLXRj6ei4SZoyUGZ9Rg0MVGjWuWZfl/asIZTjH1FgYT5jtSkNNXZiaugs9tbNmF0Kgm+cUjNnGWaNHWuWzL2GZJ9D0+aRifwvnBCfYVife4Jen1K63pcEB0OAtYY6/gl2RkTHsCTPLj06/wZ8svAf1CjU4gkYYY5x1x+mCKjRKHdXjJpWK5/tJ28lhg8OhjVyHL/feh5SStHka007g1MvxGQsQQsHvWDxj7Z8KLuVXP9DZTTKbY+vpNtyGTlc8wfVN9dPVtGuYQegjcqQIdEUloHto8lZwU9lS1obnXXK+JVPm6RhnOQWg1Fl9WTPjCqEMpgoYGzk7Q8KKEWLqIcHjwal6CDlmrv5zIRCoE/JmXzke2MsB3ViLZizHzG7FcD2A4bpjeF829eMp1/u2NTgcisY91YvZHWm5ILzxibY93FW5kBXh+ivSyxHUiy/ry2giURtZO0s8Hx2T/yCEwK3X49brp7F1VxYWV5bTk0iypKoCl6Gzr70LZYzkUlcbpJRY0kY9R/G1sE2iCDFq2oCrAQ5F508XvJ8KVwgoeDQcqo5Xc+HRnCjTJKeftpIMTCBxWsgov6zvnqGsy+PBlvaMEyh9WnBakiNODFdnf51pCMWDwINqLEJlEap6dgzQ9GVTjlJ52xocQghuKZ/Ht09s5kxy5Ppdwszy1QNP8X9Wv48Sh++KMzp8euiynasgelRM4cG8uJVvyTwJM3q5mnVRSORgMwtmpC0tLGlhY2FLC1vaSAqpz01pYtn5wr+y8K8p83RmphaWOdRPSrxnX5Z+p4MrrPtcEmwkf7/vBR5pWkGNp/DSkcD/O/gKd9fMZ5Z/5ol+MwEhBLWeEuouQcxrIkiYUdLWeIqcgv5c17g6HdMJiSRujh/6KZEXhMBPN/xa0YzpC10qCiq5MMTfEuLCnCLDZaREKNNjqL5ZONfQGILu2MhUDbW3rcEBEHZ4eaR+LX+7/4kLBL8ODLTzxT2P8oUlD1JkuK+oTjMR1+d0wqsVjarMei4kckLZVqcThSiCQqr5uBklmuuhL9dFJNdNLN9PwhwgY6XIySymncOS5vDfkOFhIwfrsc/+O0X3qZSS106eoTOWGLbPTvRF+PQNa6/KSJXRIBCkrTydqRjV7iBQuO6jsR5c6pU5SFxJiOUjE+ADSF7o/ullac/kIclfJJvrdMGnBy8LIX4qsG3JD7+1CU1TSaVyPPTeNfgDI/kse3acZv+eFrLZPPMX1bB6/eXho8wEbKsPyKOoBe6HlBLbakNRwiAmz+N5WxscQgjur1nKc50H2NZ36oL9L3Ud5g+2/4g/XHg3s3ylw8dMFpeaYe98OFTXZe3ATtWFKjRMOXbCqplW4xu6j3k7S0+2nZPJg5xOHaQz00I8HyFrZ8ZNtz3TGEhnWFpdMby0kLcnlmb6aoEAKtx+OlIxdvS18lLnUT45Zz0SiU+/PLyiqxlxM/Km99FLhT3DWbVdqpcr9ZmRUtJ6pp9f+/RtbH7pMCePd7Nkef2IMtFIkqKQh7XXzeZH397MyrVNqOqVeT3jwcxtw7b7cXoeGd6WTf8E3XEDujH5MPa3tcEB4NUcfHb+HXx66/foyY4cMCWwte8kv77lW7y3YTX3Vi2h1OWf0Hru0Fp3PJ/hRKKX3ZEz3FG5kCr3pUWXCMS4QjXTDV0YqELFHGfin7Emn8RtIpCy4Ivoybaxb2ALB2Jv0JNpJy9ndqY1Fdw+rxllUBRJSknA5US7xJw5VxKEENR4ijgZ7+N0sp8DkU7akgNoQsGpjc/2fztDSknKvPokss/HVD2AE8VEuCRvJrw+J26PA5fbwLIuNL6EIigu9eNw6Fftcmohm3fH4N8AVr6QrE2Sx8ofxnDcPKV63/YGhxCC+YFK/nDhXfzF7l8SNy+Mt+7Jxvn6oef44amtrA43srqkkVm+UsIODw6lIHVuS5uMlSeSTdKWjnIk1sWhgQ6Ox7vpycYRCFYXN1LpChLtTZBJZUe0obgiOGGjXr0M8ekjzif0CREf83YhM+p0el9sadGWPsGrvb/icHzHjK8fXyoypokiBLFM4fd97eQZ7p4/56pK3DYeKlx+NnedxJI2a0rr2dZ7Bq/uGDU/0TWMxFQyK7/doAn9il6C8AdcCMDp0nGMIpjldOo4HAW5eZ//ak34JjGzb5BNP460+zFz2wa3CzRjCao+Z0q1vu0NDigM+LdWzCdnW3x5368YyF/4UpBAdybOY227eaxtN4ai4VJ1nKqOKhRMaZE282Rtk7xtXjAHMJSzt/rUoXYObDtBf9cAtc3lnDnayQd//x6MKydB5ggoQplQVIwlrWk7p5QFEtuL3T9nR+TFcRUQrxSc7ovSl0qxv6Mbn9NBSyTK3fPHT3l/NaHE6eN0op95wXLWlzbwTwdeYkGw/Ap1gl9ZyNtjL0tew/QsO88UVFXh3R/cgKarrFo3Ojdj+erGgp6PInj4fetQxpEPvzIhMFz3o2iVWOYZHK77ztk3dc/NNYNjEIpQuLtqMcUOL1/e/wTH491jls/ZJjnbHNU4GQtCCJZunI0QAsu0mLeigZd+sZ1cJo8RuNpJd9PjapVScip1iF+2fYOOzKlpqfNiEAgEyrBRpQgFU+anJPQjhGBeeQmxTJbVtdUYmsrx3v63DGF0CH7DQSSXYkFROfW+MJFsilLn5SUyX62wmT6j/BouP4QQw6qd2kW8ludu13WVjJ0HKXFeoobL5cRQOzV9Mao2F4HOdKwPXTM4zoEiBGuKG/mXNR/kv49v5tHWXZM2KC6GITV6KPyYzYtrePbHWzm4/SSVDSWESgPkmNgsfqy8JjMBOfjfeBDT4FKXUnIw9gY/a/u3KYfZKqg4VCce1Y9XD+LXivBoftyqF6fqxlBcGIoDQ3GiKwaa0Af/NdAUnVd7H2dL31NTOnchi2kElSYAAOlCSURBVKfg53sPEstkWFFTddVqU1wMbs3gs3NuZmFxBW5V58+X3kmpa2z1zVgiQzyVobIkMKKclBJ7UMNDCEEmm8eWErfzcvBBBJXuMLNylThVY4QXcubO+NbqC9cwMihgNByNt/F632E+0XjHBeWvdAPEyh8in9uM4bgNRasDtEtq8zWD4zwUMgj6+eyCO3hH7XIea93Ni12HaEtFyNmTm52oQsGvO5ntL+em8rnUec6KYhlOnbKaEPNW1BMs8RU64QR+R8nll9m1pYmcADP9UtdepZQcS+zlp63/Mm7q7nMhEPi0IFXuJho886h0NhBylOFWfeiKgSjQfAtlJ0D2dSqXJtu8v6Ob6qCfuWVN/HzPARZVll310ua2bdMbTaJrKl63g6KMGyc6tpTUGkVkUiamYZPLmQwk0oQCHnJ5E7fTIJ3NY9k2T2w6yMceXEveNOkbSOH3OFGE4LnXD7N8fg1lYR+tXVHcLgOHrjGQyJA3LYqDHrJ5k8hACqdTJ+SfnjB1Afx28wPDxvTlyJ+kTkBfQhcGt5c/glud2czIU4Ogxj3rzW7EFYVYPsVrfYfIWHnWFc8laWbYETlOhbOItcVzmeOrZmtfQak5a+V5qXsvCTPD9aULCRtXns7TuVDUKkCQjP0lQvFhOG9HN9YjlNCUJpjXDI5RIIRARdDsL+P35t3Gx2ddx7F4N3ujrRyJddKRHiCaS5G28ljSRkFgKBpuzSCguyh1+an3FNPsL6PJV0KJ03eebDIc2X2GjtO9xCJJXK39zF5ah698IksqMx8Hfz7ydn5CruBLkVuXUhLJd/OL9v+YsLGhCo069xxWhG5ilncRPi1YMC7epAd4SIdjZ2sH0XSGw129JLO5q97DIaVk+8FWeiMJ6itDNFYXs+9YB2UhH5Zt871fbWfl/FpcDp3HXt5PY3UYoQg27zrJDStmsXXfaW5fPxeno9C/+wdS7DjYQiSW4u6NCzh8upuG6jClRV5Od0QI+Jw4dI3v/mobtRVFNFSFOXq6B1VV8Hsc3Lx6ejgxQojLnqRxIvlRFKEwz79y2pK3FSIOJMo0iVAVhK2mlxx+NSNt5Tid7OZDDbegCoXH29/gHdXreLpzJ92ZKCHj7HLjgdgZTia7CBk+NvXs54GqtW9iy8eHohbj9HwKp/vDmOYBsqmfkI5/Hd2xDofrYVR94aTqu2ZwjAMhBH7DxfJwHctCtQCY0sa0LSxpD+cLLcg6K2hCHZGD5WIPpeHQMfMWXWf6MJw6S9Y3M1EORNZOX9YHPmdnJuRVuRQ5YhuL57t+Qm+2fULlw0Y5t5c/wjz/SnRx5ayNzq8ooyEcIpbNYloWTv3KZtxPFO09A6xdVE9pqDDrLg56C145CWVhHysX1DCQyGDoKqsX1ZHN5jFNm7xpkctbw+qvINl3rAO3w+B0op+gz0l5sZ/ZdaWoqkJ5sY9UJo+UkoaqMAuaKmjtihT6OzCvoZwrVaNhInBNwGthS3vcdOmjQUpJIpnF63GM6HMDA2meeX4/D9y7bJh/cCloa4+QTGaZM/vyZbO90lHs8ONU9MKYICUORUcXKqa0Bnt9ATnbJGT4WFbUSNC4Ej1YI1FY/slimvvJpR/HttowXHeiqvWk4v8wqM8xcaPpmsExCQw9xLpQ0ZVLmxk1LajCMi06TvXQvKQOX5GHtJWY0LGXO5Y/ZSUmJPbj0fxTPkdb6gR7Bl6bUNk691zeWfObFBsVV9RgLoQg6HLSMRDjl3sPkc7nKfa6+Y2Na6aFcPVmYsnsSl7efpzaiiBNNcW0dUcRAlYtqCUcLBiaPrcDj8vg8Zf3s3pRHS6nzubdJwn6XBw53U00lubQyW68bgddfXFKQz4QgrKQj1d3nmDVwloOn+oml7coC/sIBdw4DQ230yCXt1AUhTOdESpK/FyNRocQYlhFcyxOlCWtMZ9x07TYvbcgv19VWYSuq8RiaQxD49HHd7Fu7SzqasLsP9hGRXmAhvoSDF3DtiWdXQMcO97FrKYybMvm8NEuisNe3G6Dzq4B5s6pIBJJUlrqJxZLF/7iGZYtqcUx6KHKZPLs3ddKPJFl3twK9u1rxeNxEAi4aWuL4PYYNNSVsHd/K6UlPpoaS6+o53S6oSvasBdDFQqrwrP5edsW/JqLUkeQzb0HGcgl2dZ/lIWBOlpSveyInGBteA7Fjqm/My8HLPMQqdiXEcKF4boHl+/TCBEEQNEayKV/DuKawXHFI9Ibp7giiGVaHNt7hvLa8ITfobHLmLNESkks3zcuaVRBxatNLa5XSpttkRcmNKsrc9Tw7prfIWTM3EvsUoWNBjJZbmxuoDUaI5nNYUt5mZVTphdCCOoqQtSUFxXIz0LwoftWFzx7iuC6ZU0w+PnODfOG3ff3XLcAiRwWQWuuK0WIgjfQtgvbBXDzmtnIwWPuv3HRcF3VpUGEgIDPxeFT3ZSFfURiV0d49MUQ0MMoQh3TY2hjMZDvv+h+07LJZvLsO9hOKpWjpNjH6ZY+li2uJRTy0NxUyiuvHmXO7HK27zhFZcVgzhsp2bT5KOvXzmLza8fQdZWioJt4IsPBwx2sXtnAps1HURWBw6Fz6nQvvX1xys4n+gLBoIfe3jgvvjRAZWURZ1r6yZ/opqYmzNGjXZw63Us2a3LwUDt1tWF0/a071IQMLzeUFvqtEIJFgToWBGpRBl/o15cu5LqSBYVQWQQPVReUeZWrwGgWih+3/w9QtVkUwmHPtlnVGnG43klqEs64SbM+Xn75Ze677z4qKysRQvDzn/98xH4pJV/4wheorKzE5XJx4403sn///hFlstksv/M7v0NxcTEej4f777+f1tbWEWUikQgf/OAHCQQCBAIBPvjBDxKNRifb3CsWpw910Haimz2vHSUVz9DXGZ3wsQP5vssqj9yfGztEGEBTdHza1FRUk1aco/Hd459DGNxZ8f4ZNTaAS+bILKooY25ZCWGPm6aSENpbICy2EH2joCgFjoymKqiqMqw3IMTZv3O3q4qCMnispiqog8erqjJ8nHLOMZpaKKecU6/bqXPP9QtoqinmljVTExy6UuDTiiZESu7Jtl00+qGra4C2jii6puByGZw81UNbWwRNV1FVha7uGD6fg7b2CAhIprL0R5L09iXwuA1aWvtxOnU8Hgd9kSSzGkvRNIW29ggBv4tkKsehwx3YtqS5qYxTZ3rpj5wV3BNCEI0mSSSzhMNeenvjZDJ53G4HJcU+HE6doN+Nx+1g1YoG1KucMD0ehvrw0DtJCDGcTXnos6aow9uUc/Zf6VCUEEIJMmRsSCmxzJNImUdRAmjGoknVN2mzM5lMsmTJEj760Y/y8MMPX7D/K1/5Cn//93/PN7/5TWbPns0Xv/hFbrvtNg4fPozPV3A7/d7v/R6PPvooP/jBDwiHw3z2s5/l3nvvZfv27cOd833vex+tra08+eSTAPzar/0aH/zgB3n00Ucn2+QrEuV1YZ787mY23L2Evq4Y+iTWVmP5fnJ2Fqd6adEUE4FE0pNtG7ecS/VMeUmlK9NCzLz4jG4I9Z65zPIunvEHNXkJOWGklLgNHSnhuqY6drS0Y9r2VR+l8mZCCEHQ5yLou1pVG8/CrfkI6KFxidEdmVPY2KOqCldXhdA0FcPQCPhd9PTGWb6sHr/fxS03zSebzbNqRSNd3QMsXlSDlJIbrpuDw9C46YZ59PTGWbigiief3kuoyMMb209y2y0LGBhIUVYWIB5Lk8ma+H1O4okMN90wl9KSs8THmqoivB4HiiIIh710d8dwOHQMQ8XQNTaub8bjdtDdE7uq5b2vAczcHnKZp3H7/3RwiySd+A+cng+g6fMmXd+kDY677rqLu+66a9R9Ukr+8R//kc9//vM89NBDAPz3f/83ZWVlfO973+NTn/oUAwMDfOMb3+Db3/42t956KwDf+c53qKmp4dlnn+WOO+7g4MGDPPnkk2zZsoU1a9YA8O///u+sW7eOw4cPM2fO1T3LASipLOLBT96EpqmUVofwF3nITlCHI56PkjRjl8XgyNkZeiZA5AzqJTiUyQ8IUko6M6cnREpdFFg742mrLWkxkO+b0rFSSna1FWaGr5w4jaGq9CSSLKkqn+ZWXsPVCl0YVLjqaR9H0K4r00LaSoy6TKmqClWVZ72J534OnpO5tLoqNPzZf46xVlMdQkrJ7OZyBgZSLF5Ug9fjwOctRNCEQmfJjF7vhVE1DodOednZdlWUB0fsHyKmntuua7g6IWUcoZxLbhUI4UDaE5ctOBfT6us9efIknZ2d3H777cPbHA4HN9xwA5s3bwZg+/bt5PP5EWUqKytZuHDhcJnXXnuNQCAwbGwArF27lkAgMFzmfGSzWWKx2Ii/KxmdZ/p47iev86vvbOK//vqXJAYmLjCWtdN0j+FynU5Ecz0TGoArXHWoYmrrtH3ZrnHL6MKgxt08496NjJ0kMoElpIthcWU5YY+bD6xcwifWreTm2Y1Xhet0CFJKMlaetlSEk4meEX+tyQj2Zehzb3U0eOYzHmErlo/Qnj45Y8+4EIJFC6rZuH42NdWhq6qPXk2QUhLpidHTHhlM7W4Tj17Z+aDOhaLWYOZ2YltnkHYa2zqJZR4eTlc/WUwrk6ezsxOAsrKyEdvLyso4ffr0cBnDMCgqKrqgzNDxnZ2dlJaWXlB/aWnpcJnz8dd//df8xV/8xSVfw+VCVUMJD3z8RgBe+sUOMukc+gSlzSU2p5MHmeubfHrgyUBKyenU4QmQOQU17uYpnydhDoxbxqG6p0xKnQx6sm0Tas9oKKzXCgxNpSuewOtwsKGx7k2jhk12qJJScirRy1/tfYwTiZ4LjItaT4h/W/cRnOrVLsH/5kEIQZ17Di7VPWYiQhuL/QOv0+xdzNUYkXMNZ2HmLF59cjcPfOwG8jmTZCyDN+DGsmykLdF0FduykRJU7cridqjaLAznzSSivwtoIC0c7nehqDVTqm9GqMPn37CJaEacX2a08mPV88d//Md85jOfGf4ei8WoqZnaTbkcaDnWxcuP7gDA7XUSDHuxmDhZ8XhiH3mZwxAzl6rexuJgbPu45RyKk2rX6ImMJgJTjp/QakiCfCYhpeRwfNclK7l6HQZ72jp59cQZqoN+7pw3vZ6ZidRVkL+fnMkhgW+d2IwiBF9e/i78umvEUKer2mWR/36ro8gopcrVxLHEnjHLHYxt58bShwjqxVfUIHQNE4cQAn/IM5xf5fSRDlqPdeHxO3n8vzfh9jlZtG4WB7efIp/Nc/19yykq9Q9rO42HmVadFkLF4f4Qhut+pB1HKH6ECEw5jcW0vj3Kywtuls7OTioqzorCdHd3D3s9ysvLyeVyRCKREV6O7u5u1q9fP1ymq+tCN3tPT88F3pMhOBwOHI6ZG3ynG7Wzy3nf/7qrEGY4mE0wbU3c4OjMtNCZOU2te+YykfZmOzmdOjxuuTJnDSHjQo/URDGRTLSXAykrzv6B1y+5Hk1R8DgKuUCSufw0pbQ7C12Mn2ckZ2WwpDWpZS4pJWeSfXygcT0rw/UzMshJeTboeCjE9u0GVWgsDqzneGLvmCHYMbOfbf3Pc2vZuy9j665hOnFufweoaijlxP42LNOmqMxPw9xKDu88TevxLiobSsikhyZfYkITrLG8ZNOBgqpsAjP7BpbVhqrVohtrkXim9OxO65u+oaGB8vJynnnmmeFtuVyOl156adiYWLFiBbqujyjT0dHBvn37hsusW7eOgYEBtm7dOlzm9ddfZ2BgYLjM1Y7h0ED1bPjUZJCXWXZGXp6QINdUIKVkZ+SlCYmRzfEtvyTvg0MdX+45b2cxZX7K5xgPUkr2RDdPWOl0LPQlUzhUjfetXMw7ly6Y9myxE1GrTJgDk1arFEJQ4QrSl52YAN1kYUubF9tO8Pc7X+Efdm5iU/uptyUnRAjBXP8KgkbJuGVf73+GrsyZy8LXuoaZwfG9LUR6YnSc6uXI7jP0dQ4Q6YlTXB7E5XVSN7uCxvlVeP1u/KGCiJ4iFBwTCAroz3XNbN+QCZIDf0Yu+wxSRsmlHyMZ+wIweSVcmIKHI5FIcOzYseHvJ0+eZNeuXYRCIWpra/m93/s9vvSlL9Hc3ExzczNf+tKXcLvdvO997wMgEAjw8Y9/nM9+9rOEw2FCoRCf+9znWLRo0XDUyrx587jzzjv55Cc/yb/+678ChbDYe++99y0RoTJd2BPdzJrw7ZQ5aqZ1piilpC/XwY7Ii+OWdSpu5vtXXdL5JqLfkbFSxPIR/Hpo3LJTQX+ui1d6H71k0S+A6mCA6mBgxmbvfj00rlplyorTm+2YFO9FAO+sW8lX9j+BIgTzA5UjFHV1RaXaHZpybpiTsQinYhE+sWAVtpT85Ng+an1B6vxvv2gGnxZkRdGNPNv1ozHLJcwov+r4No/U/a9LSh1wDW8e5q1oYO7yBoQiKK8Ns3hdM0IR1M+pGKbnzFleD1IOe7sVVHxacNy6OzKnZ3Rp3czvRVHLcPv+kIJ/wiQ58AWs/FE0Y/Gk65u0wbFt2zZuuumm4e9DvIkPf/jDfPOb3+QP/uAPSKfT/OZv/iaRSIQ1a9bw9NNPD2twAPzDP/wDmqbx7ne/m3Q6zS233MI3v/nNEQIx3/3ud/n0pz89HM1y//338/Wvf33SF/hWRtKK8VzXj3lXzW9Pa4ezpMnzXT8lZkbGLdvoXUCps+qSBtewMT7j2ZR5zqQOU+Wa3qgPKSVZO80THd+mPzd+tMxEcH76dUlhPVZKSVt/jKqQ/6LXMDRbGesaA3oYXXGM6cEwZZ7D8R3UuedM+H4JIdgXbaMl2c9X9j+BLgpiRUO4VNJobzqFRLK3r3CfFSHoSSfflgaHEIKVRTezI/LSuP3uaGI3T3Z8l3sqP4QxgeRv042J9MlrGB1CCIR67n0b/R4Wbu1IDuNEkvf1ZNvozrRQ5Wqaod9nKFsYg8JfgkshMU/a4LjxxhvHdOEIIfjCF77AF77whYuWcTqdfO1rX+NrX/vaRcuEQiG+853vTLZ5lw1SSg7ubSXSn2TpqgaOH+5kIJJk2epGDuxpwbYl9U0l5HMWuZxJJp2noz2CrqusXt+Myz3+OvxEsH9gKxXOx7ih9EHUach8aUubrf3Psnvg1XHLakJnTeg2lEsQ7hZCUO6sRRP6uEsmu6ObWVF084SWYCYCKSU5O8OTnd9lf+yNSR+fMy3SuSy6quI0NKLJDG6HjlPXhlX5oqkMu061s7KxGk1VsGx7+Nh4OkvA7SSdy5O3LPwuBwfbelAVwazyYvKmRdY0CXpcI7wKAT2MVwvQnxvbrbkruok1odsJGsUTvqa7qhaxrqRp1H26cmmk0aZAiL5MikSuwFWq8vipfxsaG0MI6GGuL3mAX7Z9Y8xszBLJ1v5nsbG5q/z9uFTvZRn8pZRk7BSnkgfxayGq3I0zfs5rOItKZz0CZUxV6ZydYWv/szxQ1TCqSNylQtUXY6e+T3Lgj1DUSmzzDAgHqj61qMRrlPNLQF9vHNuWpFM5trxymFCxj7aWPlpO9XLPwyvp7higtydGKpklmciQz1lkFUFsIDVtBoeNxfPdP0URChuK70ETU89OakmLnZGXeKrzexNiPzd6F9LoXXjJL79iRwUBvZi+XMeY5VpSR9kVfYXVoVsv+ZxSSuJmhMc7/ps90demJBW/42Q7Z3qjZPImdyyZzfYTbfQnUrx/49Lh9nVF4+w+3UFTWRiPw+CZvUf58A0r+OW2A+RMi5DXxZGOXmqLg5QFvJzuieJ26FQU+fnZ6/toKC1iw5x6HOfkonCqbqpcjePOjCO5bp7v/gn3VX4MXZlYfws7vIQdM5PFMmXmORTppjMVx2848WgGC8Ojk8DfDhBCsLzoeg7Hd3Awtm3MshKbN/qfozfbzp3l76fGPQvB9IZQDk0k8zJLV6aVg7FtHIi9QU+2lYeqfv2awXGZUeGqx616x1Wl3RXdxBzfcub7V027ISqEF0/gr8hnX8O2OjBcS9CNNcDUJn3XDI5LQElZgAN7WkglMpRVBKmoKqK8sohTx7txODQ8Pge7t/eTiGcoqwgMKvBNniA6HkyZ4+nOH9CZOcMtpe8cdMVN/DxSSlJWnE29j7Gp53HycvxoGYfi4qbSh6YlVNWlemj2LqKvf2yDw8bi6c7vE9BDzPEtYyr3UkqJJU2OJvbwdOf36MicnnK7LdtmVnkxRzt62dfSiS0l/YkUtpQoDJIwi3zUhINUFvkRAhyahmnZnO6NML+qjJDXTanfy6qmag60dlFbHCDoceN3OVg9q4adp9pJ5/IjDA6BYJ5/BfsGtozLOdnW/wJOxc3NZe/EobjeVLd4jTfA7y3dyKMnD7IoXE69v+htrzChCwd3V3yI7kwrfbnRNYbOQnIyeYD/OvlXLA6uZ1Xo1mHvIExuyUMih6OmLWmSMKN0Zlo4ntjLieR+ujNtE3oPXMPMwa+HqHHP4lB8x5jlcnaGn7f9OwLBXP/yaTdEQaBq9ahaQWbCsk6hqvUgJs8pumZwXAKqakKUVwbxB9yUlAdIp3J4fU6uu3k+AKGwl+tvnY8QjMiWaEwib8qFKGTYPH+gsbHYFX2F44m9LA5uYHFgPWXOGgzFiRhlYJZSYmMTz0c5HN/Blr6n6MycniBpUrA6dBt17tnT0rGFUFhadD07oi+RGydxWtKK8cOW/8N1xfezKnQzXi04oTZIaQ+6hw+xtf9Zjsb3XFT/I6CHSZmJCb1wD7Z2UR0OUlsc4HB7L4tqK0a0x+Nw4HMaHOvsQ1UEEjjdE+GupXM42R2h2OdBEQKPw6AqFCDs8/DG8RbKAh56YklK/Z4RxkbhfglmeZcQ1EuI5MdWRbWxeKX3MVrTx9lYch8Nnrk4FPeofeLsvZKDx9rY0iJv58jYKVJmHImkeorrxe3JGI+dOsSJgX6ORHoIOJzcWz+PSu/EcvAMtUtiI5HDfdi086SsxLg9VyJJmjEMxYkqNJTBF3PhvwJX5XIbZEIIio0KHqj6BD8480+kJpDHJ2On2Nr/LLuim6h0NdDsXUyNezZhowyX6kVXDIauauh5ltjk7Tx5O0vKShDL99Ob66Azc4auTAt92Q7SVmJQv+UargQoqCwNXsfh+K5xPbBxM8IPW/6J5UU3sip0KyWOynG93QV+mURiY0mLrJUmY6dImAMU6SUEjWKk3UMi+hlAwJBhi4LL9zk0Ze6kr+ltZXBIKUmksiRSWfxeF27nxJYfpJS09wzQH02xsLliOIzV5z+bn8DlMnC5Cm5rt+csgTMQnN58J5WuBmZ5F7Kp57FRXw5xM8qrvY/zet8zFBkllDlrKDYq8OtFg7lOBFk7TTTfQ2fmDB3p0yTM6KSiM+rdc7ix9EGUaeCMDKHa1cQc3wr2DowuXX8u0laSZ7p+wLbI88zxLaPRu5ASowKX5h3WnbClRc7OkjCjdGfbOJM8wunUIfpzXVjy4uvlRXop76v7DM90/oAjiV1jtsNl6GyYW09DaSFyprEsfEEZTVW4fclZrZTmirN8ivnVZYPHFY4Pegr96d7lhaRINy8cnUsBg1EOofGjHKAw2JxI7ud06hBFRhlVrkZKHVV4tSC6oiOlxJR5cnaWjJUibSVIWXGSZpykGSNtJcnaKXJ2libvIj5c/4eIKawXl7i8PNS0YMS2gOEiacbI2hnydpasnSFnpQv/2hkyVoqMnSr8a6XI2unC3zllTDtP1k6P+1LOWCn+6+RfDYrIGRiKE4fixFBdOBQnDsWFU3XjVN3Dnx2KE2Pwz6E40RUnhmLg1aYufnQ+hBA0exfzQNXH+Z/WfydjT0xbIWdnOJU8yKnkQRRUDMWJS/XgVF0YihNFqNjSwpIWeTtLzs6Sk1lyVhpLmteMiyscQgjm+JdT6aqnLX1i3PJZO8NrfU+yI/ISZc4aKl0NhAaNUHWwL+TtHFk7Q8ZKkhp+zmMkzdjw82XKPA9V/TorQjdi5vej6vNx+z7HSBWNqb3731YGB8Azmw+hqSqdvTE+9MBqnI6C1WbbkvbuKFVlQTp6YoSCbk639Rdmk7XFeF0Ont50iPlN5UTjKZwOjXQmj9tlkErn6OiJMau2GJdzergZF4OC4IaSB4nlI+yKbuJiapKmzNGTbZtQptfJIGSU8UDVJ3GrvvELTwKq0Li59GFOJQ8Sn0B0jETSn+vitb4n2dL3FJrQMRQnmlL4PS1pkrdzmDI/YTU+nxbk4ZrfoNrVRL1n3rgGx5K6CpRpGnQmCyEEa0K3sTe6ha7smQkdY0mL3mz7JWmNyEvQfTFUlRLXSH6ILW1+2vINDsd2YkkLiY0t7WEvxvRCEjejkzpiyPshhEBBQREqYaOcTzZ9YVrDVIVQWBRYDwh+2fYfk85YbGORsZMFY2Xm5Gqu4TLDqbi5qfRhfnDmnyakyAyFXFtnUkc4kzpyCWcueBAV5VwZgkufYF4ZEo+XGfObylFVgWmNfHlu3nWS/oEUL2w9gm1LsnmTV3ecoLM3jttpoOuFG77vWAcd3TF2HWqltTPKL57fS3d/nKdePTTjAj1pK4kqNO6r/Chzfctm9Fznw6+HeLj6Nyh31s4AOakQrXJn+fsmpKR5LiSSvMyRtGIM5PsYyPeRMAfI2ulJGBtFvLP6N2nyLASgzjNnXJVOVREoypvHQvBqQe6u/CBOZeazBs8k0oNejLwsiLvZWDNgbEwNgw7nggErc2TtdGH5Zgaec0UoLA6s5721/4tiY/yQyGt460OIAl9rdeiWwcX0y4N8bgvJgT8lk/o++czTxPs/QXLg8yQH/pRk7M+wrZNTqvdtZ3DkTYtdh1rZuLwJj+vswCYENNeV8uIbR6kqDdLTn+DIyW6yeZNMbuSUQQC2lOTyFplsnp5IAsuyqS4Lznj7h1zPbtXHO6t/i0WBdZelI4aNct5b87s0ehbM2Dq3EIKlRddza9m70SZpdFwKio0KHqn9PWb7lg0vl5U6qi9LsrhLQcEVv4S7Kz74pugzXMP0o8DPWcRHGv6E+f7VlxRyfg1vDSio3Fb+XhZepnc9gKJWYThvwHDejNv/Jzg9H8Bw3ljY5rgBIYJTqvdtt6QSDnpYPr+WUGDkrFAIQXNdCS+9cZTrVjSRzuTJ5k2choauqew/3kF3X5yDJzqpLg/y6o4TJNM5Fs+uZMmcKjJZk4DXOeOkM9MuzLJ8ogiP5ufh6t8gbJSzue+JSUtZTwQCQZN3IfdVfoxSR/WMX58qVDaW3ItTdfNU5/cnRKKbKgQKzd7F3Fv5UUoclSOuza35KHfWMpDvm7HzTwcUobAydDOaYvCrjm+TmOSSwTVceRBCFAz82k+zK7KJl3p+PoEIlpmBglrggTkq35TzX0OhPzgVN++o+jVcqpvtkRdnPGmbqtZgOG8a9OSZ2FYb0o4hlCCKWsk1DscEcePq2agXcYN7XAa/9b7r0dSC4+dddyxDEQJFUSgL+5jbUIaiKOiaQnVZcDgfSmVpkLxpoWsz7zAyZZ7soGEhhMCpurm9/L00eOfzbNePaEsdnzYymF8Lsb74LtaEb8epuC8bg18VGqtDt1LmrOWpzu9xOnlo2gluAT3MhuJ7WB26ddRwUQWFOvdcDsd3Tut5ZwKKUFkWvJ5SRzVPd32f44l9M/5CuoaZhRACQzhZFbqFOf7lbO9/ge2RFwq5M2Z4uUkg8GpBGr0LWBLYQKN3Po6rfNnuaocQArfm5b7Kj1Hrns0L3T+jL9fFZDNCTxoyRTL2V1jmYYTwIGUCTV+O2//7wOTVrd9WBocQAk29+KAphEDXzlpuxrmhrOcpLJ67DwGOSwp1nThsaZG1RnoyFKEy27uUOvds9g9sZWv/s7SnT5KfIMnoXAgUiowSFgfWsyp0CyGjEElx+cMFFercc/hI/R+zP7aVrX3P0JY+MaVrGoIqNEJGGYsD61kRupEivXTwXBdemxCCes/cQQXUCwfvy7meOhEIIahyNfKBut/naHw3W/uf4XTyMBk7NS31a0LHo/kpc9ZwKdLGo6FwL2fyfp6bn/bSIc759c/lcgz1o9G2TflcQuDXirip9CFWh2/lSHwXe6KbaUkdJWXFp834MBQnAT1MnXs2zb6l1Lvn4tOLxgyfnjzEuL+14PI/WxNp08z2z4lDVwxWFN3EbN9SdkReZlf0ZXqy7dMywRAIDMVBQC/GpxcUgM38bsDGF/omQjiRMkly4M+x8oenlEtFyLdoGsJYLEYgEGBgYAC/f2Jx/m82Umacrx39wzG1FQSCD9X/EfP8K0bdL2WBQNmRPs3RxC5OJQ/Sm+0gZSUKoXDyLCFPQUEVGobiJGgUU+1qKrxsPHPxqP5C6PUV8KANXVNn+jRHErs5lTxIX7aTlBUvkAzPuaahqAJFqOiKjkf1EzLKqHbPotG7gCpnA051YqmVc3aWltTRUTPy+vWiy7LENBUUxM0s+nIdnEjs52TyAN3ZVmL5CHk7OxwNcuE9K9w3h+LCrfkI6CFKHJWUOWopd9YSchRC7JRpFBaSUtKROUXSnLmlszOp/RyL7+T60unhBumKQY17FqrQGMj30p46ylz/2uF7krMzHI1vY75/w7T3j4L2iEUs309r6jinU4fpSJ8iku8hZcYxh5/xsX9fj+YjoIcpc9RQ7qqjwllPkVGCQ3EyE+KEhbbbtKVPkLbGNoLDjnJCRum0n3802INtyozTpmJHBUWD2X3PnO4lEHBPWvLAtiWJRAaf79KX3oeG7aydpi19guOJfZxJHaE/1zXYDwrvxXM9wwJR6AOoqELDqXrwan6KjFJKHdWUu2opdVQT0MPDXt98bjv57CZc3t9hkL1IKvbXONwPo2oFHY54PD7hsfZt5eF4q2CsnCMFV6yDOs9sat3NhXA5KzUca12I3LAQCHTFgVvz4tUCBcGgwZfxlTaIDl1TrWc2NcPXlB6OIc9aqWEvhCJUDMXAobjxaD6cqqegSTCFQdJQHDR5F87EJc0ohBBoQqPMWUOpo5o14dsHxbuSw7oaOTuLLU1AFIwzYeBQnThVD07FjaE40RV9xgWxhBBUuhqmfLyUNgkzSl5mcSge3KqPvMwSy/fi1YpwKG4avfOxZY4mzwIUoZK107hVP2krDghydgZVqJgyT0AvIWenSZgR/HoxunCQtAYKL29p4dWKSFtxIrku/HqYvJ2hL9dOX65t+HwJM0qJo2awfZKUNUDKjOPTw0hsslYSTTGwpY1PC03q3gohUNEoMkopMkpZGFiLTcHrOSTOlrFT5O0strQHBxkVTWg4BjVGLufvO7LtCuXOBvZGW1lSVHtB1uGCMSVRLuMkRxEKNe5ZkzrmxIkespk8pWV+Fi+upbWtn/a2CAsXViOlZP/+NoqLfTQ2lXLsaCfxeIa6+hL6euO88NwBbrx5HnPnVV7SPR861qm6afIupNGzABubrJUmbSVIWjGyVpq8ncPGHpxcquiKY1BrxoNDceFQHChCu6gnS1FC5LMvYVutKEopltWCZR5HCAeIX6FpC4F1E273NYPjasQEnVIH+3oIOlxU+vx4tJGW50A2gyYUPMalz/gypsnJaIS54eIxH6Kj/X1UeH14L+GcQy9cj+bDo/kouUZmGxNDSpoO1YlDLbjNr1SYlk1Xb4wz7RHiyQyKIgj63VSWBigL+1DVCzlSpjR5puu/afauoD19jPXF72B75ClCRgU92RbWFz84KHhXQF7meKP/V2wsfidv9D9BubOBM6kDJMwoPi3EPP86DsW2UOKsZd/AJtYXv4OXu39EmbMevx7GkiYv9/yIRu8S9g10Mt+/gfb0MbxaEb3ZVm4qez/xfB+HYq9ze/lHydkZXu75MVWu2ZgyT0f6OAP5XlLWALri4MbSRzDE1COMhp4Hl+pBmA4yCQfVATcOQ7uiJg5DxkTGyvNsx0EWBauRCGwpUUXBxEiaWV7pPsotFfPQB0mJ5qDRpIrp9bpIWdCZsCyJABRVQYgLDa9CGRspQRkMg7dMC7fHwYnj3QSLPDz/zD6aZ5fz/HMHuPmW+fh9Ll5+8SBVVUW8+PxB7ntgOV6vA9uyCRa5qamd/mew0A9U3JoXt+YlzPgZuCcGHYfrXcPfFLUa3ThrYAglOKnarhkcbyFIKXmjo42uRIISj4d4LstrrS1U+fxcV1PHKy0F6fL11bX8YP8eVKHwwOx5tMQHOBWNsrqyimORfgYyGWoCAZaVnZXpTuVzvHT6FJqiUB8MsqerC11VWFRaTn86RSKXY264mH09XRzr72NFRRVSSrZ3tjM7VExtIMD2jjbuappNMpfjhdMncWoai0vL2NzagpSSmxsaCTjGf/lGcwl6shFmeS//kkZ/LsaR+BkMRWNRYBb6JWRPnQ70ZqMkzBR17opR70V/LkbSTFPtKr2iBqDzEY2l+JcfbOKlrUdJJLNYdsGo1lSFytIA//cL7yEcHE1oS+JSfcwPrCdpRunOnsaWFosC17Ot/wmiuS7KnPXDpZ2KB7fq51RyL0IouDU/la5merOthB2V9GTP4NECLApcz0s9PyRlDqAJnQWBjTgUF5FcJ8WOahYFbuCZzm+St7NUuWezKHg9z3Z+C6RNmbOeY4P5L3TFoMo1m2iui1JHLQAN3kV0Zk5i2RMXpRsPpmXzt//xLJu2H+e2DXP5zEdvRh2Dr3a5Ec2n+O6JLThUjXg+jSUlv2rdTVsqQrkrwP3VS3mifR/Pduwnkk1yf81SOtMDPNd5kISZ5QMNaylzTU+YupSSo4c7+dmPt9LW0o+qKmy4fg4Pv2cN5z4i2Uyex3+5ky2vHiWVylIU8vKp374VTVeprQ2RzeTJpHOk03kcDp35C6rY9sYJFEUhl7OwpSQQdFNWHkBVFfJ5C6dTx+2ePNnyzYKilqPq87CtVhhSaBYC3ViPUAYNp+zEl0Pfdjocb3Uc7utlfkkpu7s6SOfzzAkXE8mkebX1DJqi4NENDvf1Uh8sYm1VDW5DZ1t7G+ura3jm5HH293SxvKKSHR3t2Od4UrZ1tHOwt4edXR3s7uokZ1skcnmO9PVSFyiiLV7odCciEUDgNQza4nFS+TxFTide3UBVFNJmnu2d7ZS4PWQtk51dHQxkM5R5vRzq7ZnQNZ5MtvE/bS++KeJQtrTpyUb4xolfkrKmPwx5stg3cJwnO1676P6WVBd7B45dxhZNHpZt8x8/3syjz+0lkcwyq66E2zbM5bYNc1k8t4p5TeX4vRc3ROP5Pk4k9hDN9xA2KpFITiR3MZDvxaeF6M91kDSj9GRbsbFp8i7njf4nafAsGs45UlhaEHi1EAkzyonkbkw7V+CsCHWEy7krc5rjiZ2FpQrFQB2ctwkEFha92VYSZpT+XAd5O4dXCxI0SjmR3D3scVJQGBrdpJRkcybZnDllQbFc3uTg8U4SqSwHj3deIGr4ZmNH32ma/WU8XLsSVSgoQrAyXM/akiZ29Z9BCLi+dDaLi2p4pGENHs1BuSvAxtLZuFWDo/GxcwZNBslEln/48uN0tke5+/5l3H7XYhoaSzjfHn/5xYP89zdeZs68Sh58eBUrVzfi9zsJBj04nQZFIQ/FxT6WLqujuzuGpikUhbzEYmnKKwpGRllZYLhel8tA01R27jg1arsSiQxbXzuGbV85v52Z30k6/rfY5ilsu6PwZ3UgyQ5rFk0G1zwcbzFYtk1XMoEtQVdVil1uelJJHKpKbzqFJhSaikJkNJOedJLaQAAhBB2JBE6t0B2CTieKECOGc49uUBMIsKC4lL50imgmg6TA/4/nssRzWTKmydKycnZ2dfB6WwvLyyvJWibPnDzOe+cvIpHLEclkcGk6vakk8WyWCq+PYpcbj26QyE0uO6UpLWw7j6EYKEJgSxtTWigomNLEUPRxk5TlbBNNUcnZeQzlbEKvQn4RC1NaGIqOMlhPsSPIDSXLeKF7+3A9trTJ2SYORR8+Nmfn0RQVa5BwqqAwlHZMH1QwlUiydh5NqGhCPedYE13RyNl5FCHQhYY5yLuxsZFSFq7tnN/IlBambRXawBB5MU+zt4a5vvoR92DoHDY2utBQhTKYX0ZgSQtd0cnbeXRFuyzS7X2RJC9uPYoE7r15Eb/zgRtwOodSDtiYpj0cqj4afHoIh+JidfgeAnoJ68L3051tYVX4btxagHimn0XBGwa9CTZeLYBfD1PubMCSeYJ6KeXOBnTFga44KHXW0p/rYF3x/RiKi6VFN6MrZ5cBw0YFhuJiffGD6IoDh38NCirLQrchULCxWRi8bpAbomEoLgK6xmzfKrJ2GkM4COglSGwMxYll2fzdN55DKII/+MStU/JMuBw6D962mJe2HuO+mxdh6FeWYFghg3JhaUQRCp3pAX54aivXlc7GkjaSgv1lD30GfnBqK3XeMDZyxOTnUtHTHaOtLcIf//kDrN3QPLz9/Gdk984z1NUX88GPXofh0IaNwcVLCvyc0rLCMnVxiQ8ph+1HFi+pHf58483zhuvUNIV771920RXxA3tb+dH3trBsZQPKFeIKUJQSVG02mrEScU52WEVMzdt0zeB4i8FQVbKmyT2zZuPQNFyajtcwKHK5OBWNYkubecUlZEyT/T2FWcO9s+ZwJhbl3llz6E2ncKoaN9Y3jCB1LSkrx1AVspbF7HAxln32xdCbSjEnXEwsmyVnWZR7vMwrLiGRy+FQVe5saiaZz9MYLCKdz7OotGzYy1Lj9xPLZnHrOuYkLPvebIR/PvZT+nMx5vrreWf1zbSlu/lJy/N4NBddmX7qPOU8UnsHTnV0zkgsn+T/Hv8JFc4wLakuArqXjzTci1/zcDB+il+0vUTeNgk7gjxSezshY3QGdtLM8PWjP+JTsx4iZPhJmGm+dvSHvLf2dn7R9hIScCg6uqLRk43wO83vxpaS7595ip5sFF3RuK/yOhb4G0mYKf7txM9p8FSyb+A4Ps3Nb8x6Jy/37OBMqouBfIKBfILripdyS9kqANrSPXzt6I+I5uPUuyv4QP1d6ELj+e5tvNa3l9m+Wj5QdxdQeJEWtu/BlpKg7uUTjQ/yau9uTibbaUl1sSTYzIHYSZYEm7m/8voZX4rp6IkRi2fQVIU7Ns7DdU5SRUVV0dSLD54CgV8vpto9Z9g4cmt+6rWzSeIqXGeT4CXNAbb3P808/xo0YaArjgs0jJyqB/85XJdiR/XwZ1VoBI0yat3zhttoGAXvS8lguVr3PM5Ftfts8j7nYP4VF2dzEfXE4ry26yQNNeEp++wUReHddy3n4TuWoSozE2VyKVgeruM7J16jNRUh7PDgUnVUoXA03kWlOzj4O7oQCL574jUeqltBqdPPyXgvCgKvNvYyhJSSZDLLof1t9PbGCYd9zFtQhcfrGDbk0+kc8ViGUyd7sCybRDzD6VO9CKC0PIDLZWBZNgMDKZKJLH09cQTQ2tKPogqcTp2y8sDwvbVtSXtrP0cOd2BZkqZZpdQ1lIzgGklZMJrb2/o5frSLdDpHIOCmobGE8sogAPm8xUA0xeZNR0kms5w51YuqFTgl5RVBHIP5vt4MSJnCzO1E2gMwHOElcHk/gap4xzx2NFwzON5iaAgWsbC0DJ9x9gH1OwqfF5ScDTXzGAarq6oH9zup8BVegL7Bso3Bc5P2gKYU+BqjodJ3diAuw8sswsP1nrvvhrqz0QhLys7W5T2nraadI2VF8GghVHHxBy2WT/LZObdhKAZfPfxtFgWacCgGB+On+MKCTxLUvfzTkR+wM3KYdcWLRq3DwuZo/Az3VWzkPTW38Z3TT/BM51buqljHt0/9ig/U3Umjt5qnOl/jJy3P8YnGBy9g1gN4NBclziK29R/gtrI1HIidxKk68GpuWtJdfHb2+/nq4e/w8cYHeK7rDc6kunij/wAhI8BHGu6jJdXFf518lD+Z9xFsJAcGTrCiaC6fnfN+8oOek6SZ4Uyqk8/N+QCxfJK/P/xdFgcLs7NILsZvN78bh6LzpYP/xZlUF02eKu4oX4uuaByLtw63NWebPNu1lffX3UmTt5qEmcapGiTMNA7F4I7ytTzd9Tofqb+X75x+grsrNgx7ZGYKyVQWW0ochoZ/kmq9qtBZG75vwuHbbtXP+uIHUcXUSJV+vZglwRsnfdzFIKXk6OkeorEUcGlkwvF0ht5MhAwPvzXn5uFJiioUfmfuLYPfC54PTSj8+uybsKWNrqjcW70E07YKpNIxLktKSVtrhL//m8fo7YlTFPLS1xuntMzP5/7kPioGB/af/nArm146RDyWIZ8z+c9/fRHDoaGqCp/743uZv6ia7q4YX/3So0QjSbq7Y0hb8hef/wkA8xdW8dk/vhdNU7Ftm8d/sZMffGcz/oAbIaCvN8H9D63gPe9fhzao55TPm3z/W6/y+C924nDquN0G8XiG+Qur+OM/fxBFFfzgO5vZsukoba39mKbNX3z+J4XfUlP40798iIbGyxMifDHojrU43O9DCINhVRKlaEp1XTM4RkHBdTb0N32aAzMNIQRrq2re7GZcEvqyJ3ms7Qs8UPMlih0XD5esdZdT4igIEzV6qjmVbGeOr54KZzEVzmJUoTDX38CJZNtFDQ6AoO6lwVOJW3OyJNjMi9076M1GsaRNs68WQ9FZHpzL14/9uLBMM4oRJIAbS5bz3TNPcn3JMl7r28N1JUtRhMCneQg5AhQZfsocITyai5SZ4Wi8hY813IdLddDgqUQRCt3ZCMWOIF7dzbKiOXg014jzzPbV4tPceDUXQcNHZ6a3sN1fR6mjCAkUGX6SZnqYK6CeR9MyFI1bylbxgzPPMMtbzS1lq4YH6zJnaLidQcOLHMwYOZ0Yqs+yJfl8gbfQP5Ac1uaKJTL0RUemZ/d7nSME+XJ5k3gyiwACPheqeuFrTEpJPJklb1oYuorX7Ti75myr9MdSaKoyzA1JpLK0dkaJJTLomkpZsY/SsA9NHfn8F+6resG5MlmT7v44fZHk8DmL/G6Ki7y4XcaICIiz98AmmcqxZefJwfth0R9NXhCN43LoI7w+59+H83Hu9Y6HoSiMnkiCzp44ubyJ1+2gqjx40VQNUkrS2XwhW7ZTx+nQsaWkL5KkvXuAbM7E4zKoLAsS9LtQBu+7Jkbet/O/F7YJhqiFAjBG+W3PRz5v8e//7zlUVeGrX/sAwSIPPd0x/vef/pRvfeNlfv9P7kNRBQ+/ezX3vWMFx4508oU//jGf/tydzFtYjQA8nsKkp7TMz59/8WFsKfnHr/yKRDzD5//iHSiqgqYpqKqClJLDBzv41n++woc+dh233rkIIQTPP72Pf//n51mwsJoly+sAePG5A/z0R1v5wEc2csfdS3A4dZKJDKZpowwahw+/Zw33v2MF//cfn6azI8oXvvROVE0ttGsM7tLlgY2ZP4Q58GeDBgeAgsv3GTR9zqRru2ZwjAJp95GJ/z221YbD8zF05w1vdpMmjEsxjs4fXEYLEbvUc401gAlR4Cjk7fS4adBzdh6JRCDI2Tn0wbT0OTuPjY2KQtbOXaAQez7y0sKUBV5EdpDHoSsaUtqFteUhPsYgcfBi7a7zVGAoOtv6D9KXHWC+v4G0lS1wP2AEl0QIgaHoZO18IVxQ2li2NfwCVoU6qhZB1iqorNpSkrdNtEHPgzFJD8QtpatYWTSPbZGD/OOR7/NHcz8MMOy9KbRz5ozsl7Ye48dP7mAgniGezJBIFjwc6UyeP/jKz0dk4FUUwZd//0EWzT4b/rz7UBt//k+PY+gqX//zd1NTceFsS0r4u/98jtd3n2LD8kY+/xt3DN//lo4Iv/vFH1NW7Ofv/ughXtp6lO8/vp32rih500IRAo/bwYoFtXzqvRuoqSi6+MCbyfPkKwd47IV9tHREyGTzBb6CouDQVcJFXu66fj4fenD1cB39Aym+/YutHD/dQ3v3AL2RBAD7jnbwoT/41gXneeTelXzowdUXbN95oJX//fUnsM5birxh1Sz+6FO3j/s7SCk5cqqbb/18Kzv3txBPZbFtG11TKQl5ufO6+bzrrmX4PBcaHv/zzG6+/fOtPHz7Uh6+cyn/9dMtvLDlCLFEBsu20VSVcNDDPTct5JF7V+B2zlwyxrbWfvbsPM1n/uheSkoLHtXKqiI2XD+Hx3+xk2g0RbjYi9vjwA14Bw0pr9dJ8DzxLlVVCATd2LZE11U0TSUQdJ+3TCJ56fkDFIU83HL7wmG+0cYb5/L9b2/mtc1HWbK8Dsu0ee6pfcyZW8GDD69CNzSEYLj8EDweB9JtYBgaqqbgD7iHM5O/2VCUCjyBv0RRSxgZYzI10+GawTEKhFKE0//7pAf+DNueWOTE1QopJS2pnWjCQcYa4Fj8FSxpUu1ewtzArYU1bgS2NDmV2MqJxGvY0iTsqEcROobiYo7/ZjRl7DVWy85zPPEqXq2EfdHHKXPNodq9lJ39P8GrF7M89G4M4RqzjnNxOtXJlr59OFUHRxOt3Ft5HRkrR0e6l009uyh2BNkVPcInGh4Ys554Psnz3W8wz9/A813buLlsJSWOIipcJTzRsZkFgUae6NjM2vBCNKESyyfpykTI2Xm6MxEA/JoHTahsLF7Kj1qeZX3xYtyqk7Q1OglWFQobS5bwq45X0YTK0cQZ/LqHcmeYjH1x6fZd0aPsjh4lmo+TtfPUuMvozkZGLWtJi0guTiQfJ2ml6cr0E9QLa65b+/dT5gxT6ihCQWAOhbtdJiRSGQbihQgfn8dZiF7K5hFCEPS7RqQNUM5LNwCFENBYPI1haNj2xQ3YVDpHLJEhlR55Ty3bZiCRIZM1+a+fbeF/nt6F22kwf1YFTodGR0+M1o4IL7x+hM7eAf72Dx+6INmjlJKBeJqv/PuzvLztGLYtcbsMqsuLcDo00tk8fdEkbZ1RdE0dMWDHkxl2H2wlb9q4nDoOQydvZjG0wiB9/uDudo6+tBgOelizpJ5oPEUskeFkax/pTJ5U5uLCgOe2f+ue0/zVPz9JbySJ3+tkwawKPG6Dnv4EZ9r7+c+fvsb+Yx386W/cSVFgZC6lbNYklsiw40ALh052sXX3KcpLAsyqK8GybE619dPZG+O/fvoa2WyeTz2yEXWGmJCd7VHS6Rw/+9FWnn5iz9ntHVFSySypVJYwk+cbXAxSSk6d7KG/L8GX/uLn53A6bGIDKXq7CxF72WyejvYIG66fg26oYy4LXamwrNOkY19G0ZpwuO5G05eCmJhS82h4yxsc+czLSN9dCKEW3Ie5NxBqCYpaj221YuX3g8yi6nNRtGaEUBBCBYIFNbVzIO0UZu5VNMcNCGEg7Thm7nU0x42AipQxrNw2pEyj6UsRatVVsRxzJPYCrandBPRy6r1ryVgxtvT+Nzk7xfLQuwDJ8cRmNnX/GyvDj+BRQ+yM/IxYvoMVofcwkdmwKbO83vttQo5aQkYdr/d+m1POrVS6F7I38ijFjkZm+a6bUHtDhp8P1t1Nb3aAzkwfH66/h2pXKccSrdR6ykhZWTb37eVd1bfQ7Bt7iSnsCODVXLzUs4PrSpayLrwITah8vPF+nut6gxe6trMkOJsNxYuRFAbr44k2Znmreb77DRo8ldxathpFKCwMNPG9M0+yLlxYwnEqBkuKZqMKlcXBZhyKwWxfDSEjwOLALJyKgxd7thMy/Hyq6SEMRceSNqtC80fV91gQaORg/BQpM8NvND2ET3NT7gwztB4hgEWBWYQMP0kzwxMdm4nlk+hC49H2V7i5dCU17jJi+RT7Bo6jKzrvr7uLMmeIWnc5DlUnqPuY66vDoegsDc6ekSiVO6+bz63r5w5/f23XSf7sHx/DaWj85e/dS13lSP7QTEVcJFJZfvLEDtYubeC3P3ADlWUBFCFIZXL8+Imd/NfPtnDoRBcvbDnCQ7cvGfEsW7bk33+0mZe2HkVVFe65eQHvunM5laUBdE0llzfpjSTZd7SdVYvqRhxbWxHin//ivUDhl/vSPz/Fc68dZt6scr78uQcuWFK5WIROU20xf/qbdxYiqiyb3//y/7Bt35kJXXtHT4yvfuM5eiNJViys4Xc/dBN1lSEURZDLm2zdc5q//6/n2bLrFP/6g0187hO3XmD4Aew53I5DV/nkuzdw/y2L8XocICWdvXG+8h/PsG3vGR59YR/33bxoVE/UdMA0bYQQNDWXES4+a1jMX1iFpqn4AxOfyEwEUoKZt/EHXMxfWD3CkFi4uGZY2KtAGJXDfI6rEZq+FG/onzFz28imf0E68R/oxgp05+2oWiOTNSHe8gZHJvF17NAiVK0OZJJ0/G9w+b8Aap5c6tsUKOoa2cQ/4wr+NZqx7KJ1STtCJvZ3eItXgzCw7V4y8X/Aa6xDkiMd/aNC6l7hJpv8Ju7AX6Joc68Ko8OUWW4u/z38egUgydlJTia2sDT0DhQ0TsRfo8K1gIWBuyjkWlB4sev/0OTbiKZMzF1qY9HoXUez7wZOJV+nxDmLlaH30J05Ql/29IQNjjpPBXWeilH36ULjzvJ1aMrEHnKBYEPxEm4vXztie0D38lD1TReUv7VsNbeWjdw2lLvkWKKFBk8lVYMiW17dzYNVheW4B6quB+D6kuXDx20sWcLGkiUj6nJrTh6pHd0dHtS9vPe8ffP89czz1w9/v7dy4/DnD9bfPWo991RuuGDbitBZA6DKXTLY5ulfSiyQ4dQRL2Fj+LPAoWs4LyMrv6zYz+c+fgulYd/wc+rzOHnPPct5ZdsxDp/sZvu+M7zjtiXDA4uUkqOnunlq00EkcM+NC/m9j9w0IoGjrqt43A7qqkIXnFNRxPA1SimHs1crisDh0McMAT4XBU4KFJ7HiS9xSin55XN7aeuKUlzk5fc/cRs15cHh412qwfWrZpFK5/jSvz7NM5sPc89NC1k8p2rUum7dMJf33bdyxG9aVRbg4+9cz97D7cQSaQ6d6KL6nHNMJ4pLfGi6yqo1jaxeN2vG37eKIiivCJBKZXno3asvWCIZgmFoFIU8tLb0YdtyYuHOV1hmMyEUoAjdcROKWkM29X2y6Z+Tz72Golbh9n0WmHhOmSsk2nfmoGqLMLMvFWYB+T0I4UbVZwM6Tt/v4/T+Ng7vR1GNxVj53VMmyeUzT4Nw4PD+Bg7PR9H0xeRSP53ei5lBhB0N+PQhNUqBTy8jZ6eGuRS64iQ3mAAOIGPFUNAG9SUmBoHArYURQsVQPPj1UkCgCyemnJwGx2hQhYJHc03YdVkIt3NfcoK6mJnkH458n8faN/HO6ltQZ8Ar4FB1nBM07K5h4rhuZdMIY2MIbqdBU23B8OqNJC7gSWzafpxUOoff6+S996644nQvxkI6k+fVHccBWLesgeqyCw0BIQQbVjRRWRIgk83z0tajo74bdU3l7hsWXOCVEUJQVxXC73UiJfT0J2bseuoaSmiaVcYv/2c70UgK25bYdiEMtq83Pu3EZ4DrbppHR3uUV144SD5vDZNvI/1J0qnCEp5uqKzbOJvdO07zxuvHMU1rcByyiMfSF7TL43UQi6VJJbPD0utvdm5VaSfJZR4jEfldUvG/RdXm4Q9/D1/oG2j6UjLJ70yqvre8h0N33UE+8y0M97vJZ55Ad94OOECmyCT/BTt/HKF4MXN7ULTmcesbiaFIFrDNY1i5XaSinyvskRk0Y9Xg/ivfw6EL53Aip9GwMHg3T7b/NU+0fxG3GqQjc5CloXfgVH0XPeZ8DCssDn8/5yU9Dc9Vrbuc35z1zgkbQX7dw+fmfACXemlSwz7Nza81vgNd0XAqxozMsG4pXXWlTX6ueghgbuPood5CCFyDM1fLtkdwRaSUHDrRBUB9VZiKEv9V4cUcQl80SVdvgWewYFb5RQ10j8ugoSZMS2eEg8e7sCz7guUBn9dB1SgGCxSWgoYMsbw5czwhl0vn13/nNr76pUf57O98m/qGAo+kq3OA+Qur+e3/dcfU+ROjHCeEYPnKBh54eCX/9v+e46lf7aEo5CE2kKK7O8YffP5+5i0oeIPufWA5Rw518JUvPsqs2WX4/S4i/UmCRR7+6M8fGCaHCiFYt3E2zz21j7/8s59SU1tMLmfyoY9fT1n59Ei6TwVmfj9mbitO70fR9EXA2egn3bGeXOZpmIQw6lve4ND0+WBmMHM7sPL7cHg+iRCCfGYTVvYN3KF/Rggf6YE/G7+ywZmrxAIpkXYcOZi5VYgiNMf1uAJ/xtleqnA1GBswdhp6IQQ+rRSfVkKVaxFBo5ploXcSNKoGXW5XBjRFRVMmvl6rCAWfPrkU0xerx6+Pludj+uC4iHjZNVwChKDI7xrXWDh/kpk3bSIDhXTmpWHvqNyGKxnxZIZsLo8QEC7yXvT6FUUM56+JxlLk8tYFBofT0C9Kar1cEEIwZ14Ff/MPj7Bl87GCcJaqsHZ9M8tW1o8wNqSUVFYH+KM/v5/a+uJR65NSIoTJw+9ZjmkqI6KmhqBpCh/4yEZWrm5kxxsnicXS1NYXM3d+JY2zSofb5fM7+cM/vZ+d209yYF8bmUye6uoQS5fXoWkj351LltXyhb9+J29sOU4mk6eqJoTbc+FkSEo5PI8dS0V5qA3nI5vOIQGna/x3imasQDNWwjlRdnJQlVhR63B6Pk4+nhq3nuH6JlzyaoXwoDmuJ5v4NxS1DkUdXIcUGpIs0urEsnZi5rZhaI1AwY0k5QDSTiHtfmyrE6GEEMIHipt8+nFUfQm51PcYMu905+2kop8hn34URWvCtjpQtWZUfbJekysT/bkzRHKtrC7+AB4thEAhb6cxlKkzlsdCzk6SsWLD3xWhF7wwV9FM8hreXEzEHT1aBtqJ1Du0xHK1GRvAcPZTEMP8kYth6P7Y9ujy4ooiEOPUcTkghKC4xM+9Dywft6zL1cW6jdUoysUmGxaJ5PdpmDUXh7Fq1HfOEBdp4eIaFi6+ODFdCIHLbbD+ujms2zibVDzD0T1ncKqCZDyDmTNxe50k4wXtnPkLqqipKkI3NDRDIxVPk7Bt3F4n0d44DpeBlJI9m4+yaO0sDJdBJplF01VUXSURTREs9tJ5po/ejijzVjQgJaTiaYIlPlKJLEd3n8HldTB3Wf0E7uuF/TuffQ5FKUczFjNZVsZb3uAQQqC77sbKH8Bwv4uhG6Q51qObx8kk/hVVa8Dp+91hYRMz9zr5zK8ACyu3i4x5HIfn4yhaMy7/n5FL/QArvw/NcVMhY55QUbQmXIEvkU//lHz2RRSlHFVf+OZd+CQgCqbyBduGvBdSSnTFiSIUnmj/IgoaIHGoHtaXfJx6z5oJGQLiHI+PGFaoYDAyaGg7WNLkqfa/GaE02uBdx3Wlv8bV4jEaD1JKBnIZstbUs4UGDNdw/puZhmXb9GVSU06YpwiFsNM9qlLrTEAiyeZnxo2vKgpOo9A3E6nc4Iz46umXbpeBqipYtkkyffEwbCkLKrAADod+VRpX50PKNNn8blzqTVhWD+nsq+haA4oSJJvbjqHNRpInm9+Lw1hBLr+XvHkMp7EK02rHtiOoaiV58xggMLTZGMaCcc8LkM+aPPuTrQBUNZTw1Pc2Y1s25XXFnDnSgaKqNC2oJtobJ58zKa4I0tcZxcxbLL1uDtueP8CKG+fhcBkc399K06Iajh9oo7c9yoLVjdi2ZPemw1TWl2CaFl2t/TTMr+KlX2zHtiRNC6o4cbAdpKR5ce2YbbXtKNLqHXWfmduN7phamPFb3uAAUNQG3EX/F+Ccgc2Jw/PJUctrjpvQHBdGKAghUPWluAJLh7fpzjvO2bcAVZ9Y57uSsDz8buxBN9kQmn3XU+VejCp04mY3z3R8lVXh91PtXooiFCyZZ1f/z9jW90Nq3SvGlCEH0BUXt1X8PkGjCgWV60t/HZcWBGBl6L0og8eHjDoerPlrhkgd23adRlEEC6sXA4WcCFt3nCRU5KX5TZb8vRTYSP7i9ed4vvX4lOv46sa7ua328njQOlJx3vfUDxjITi1Dbpnby0/ufj9+49KVE8Xw/7iAzDmEbM4cXvaYbqiaQkWpn71H2mntjJDO5PFcRSnHiwJugj4XXX1xTrf3X9RgMi2Ltq4oUIg60bUrZ/l0qhDCBSgFLzZZbKsXoc8hnXkOt+tukqlf4vW8G0Ofh6Y3EU/8Fx73g6TTzyDJ43beicQseL8xyeUPTdzgyJvoukpFfTGpRJbEQJo5y+oKWWVrwiAEfV0DVDWU0NMeIZPMMm9lA0d3txAIealsLOHEgTbW3r6IkooiwmUB2k92M3tpLeW1YZ778VZ0h04smqK2uQwhBE6XQX/XAHOW1eP2u9ANlfLa4nHnbbn0Y2RTP0AoF/JHbKsN3XFhpNtE8LYwOEadfYipxSYMi7xIC1uaqKJAEiyERuZRxYUSxFcyhBAUGdUXbPPqJXj1Aks/kmshayWo967GrQ7F0ks8ejHd2WMTmvUqQqXMdVYKt9jZOPy5yHHWJWmobqrcZ6XIHzsaRVMVitbUFJRIpeTI8S7qasyr2uBAQsrMMZCbeor7/GVMY21LSSyXmXJ7XZp+0SyZk67LqaMqCqZl0xdJ0lAdHvHMSSlp7YzS2TMwPSc8DwJYsaCWZ149RGtnlJ0HW9mwvHHKz70yuGxhmvZliUoIeF0saK6gqy/O1t2neOTelbjOC0WWUtLSEeVEax9CcIGWyNUKKRNYVht5swhda0JVy8hk30BVyshm30BRvAh0hHAi0FEUP9nsNhS1BNuOoSiBwX/9SOxJRbi5PE4qG0pIDKRoWliDN+Aik8xSUV9MsLhAvvcEXJw50km4PEhxRRC3z0nd3Apy2TxmzqS6qRSHS6e4Mkjr8S5Kq0J4/AXeWlVTKZGeGJX1JZTVhGg93k0qkWHD3Uvpbo1QXB4kXl84f1VDydiNFRpu/58MBj6MRCY1uciUc/G2MDhmAj2Z4+wbeIqbyn4LgcCUWV7o/DobSj+GR7sw9v5qRpFRg644eKX7X6hxL0di05s5zsnk66wOf2Bc78ZkMCQX3R9JFkSEzkEuZ9LRPcDGNc2EQ54Ljksks0QHUqiqQlHQjdNxNl18MpUlEk3hcTsIBtwoihgWTIpEkmSyJn6fk8A5JELLsumPJkmn87hdOsGgZ1gjwbYLg102axIq8oya6+IaZgZlxX58XieRgRTPbj7EknlVw2qeQ/3n+49tm5Di5lQghCiEk5YX0dIR4Z+/9wplYR9NtSUjCIZSSvKmRTZn4vNc3LNTGiq4p9u6ovRFkpQVXximO51QFMEDtyxm884THDjWya9e3M8Dty4e7ttSSpLpHP/9P1tIJLNUlQXZuKLpLdG/hTDwuO4HoaEoARzGChQliBAGlt2LqgQBA4/rPkDB634Yy46iKsVImSnIKqhOXM5bJn1uRREs3Xh20lVRNzpptbJ+pDEQGpRrL6k8K5y28qb5Fxw3b8XI3FMb71kKQFGJf3gJ5dzzjwXDeTdCGIhR3u26sbbAZ5wCrhkcU4Qpc6TNCEOuf00YrCv5MC71zQthmin4tFLuqfr/OBJ/iZbUTgQKfr2cOyv/hDLnnGl7EUkp6eqJ8Xf/9xlsKXE7dRKpLAvnFoi+sXiaX/xqF9t2neZdD6zgvjuWDB934HAH//7tV3A5dbJZk/raML/18ZtQFNi1r4Vv/3ALDodGIpnljpsXcPetiwDJt37wGgcOt6PrKv2RJB95ZD3rVjUV0sf/dCvbd5/G6dRJprK896HVrF/VRD5v8f2fbmXn3jPD8tq/9fEbqasJT+peiEEv29UQ7lpIqXVlDDglRV7WLqnniZcP8OQrB7El3LB6Fm6XQVdvnKc3HWTPoTbKS/x09sTGr3AKCAc9fOo9G/jrf32ak619fOavf8b1q2Yxf1Y5LqdBMpXlTEeEA0c7mNdUzm9/8OIiaqsW1fHDX+2gpz/B3/zb0zx46xKCfhfZnMlAPE19dZjZ9SO9eelMjtauKOl0Qco8lckOJ73r7I3x0tajuJxGIfGbS6eqNIh7MCpBCMGy+dU8fPtSvv/4dv7vd1/m6OluNixvwusu3MMnXj7A9n1ncDl1fu09GygumtkorMsFIRxo2lmPrnJOgkRNLT+n3NCA6hzeLsQQb0FBzHAG5TcbiuK/6D5Nnzflet/ad20QeTvDqcQb9GRPDOb+uBGvVkJP9jhnkjvI2xkqXPOp9SxDESqtqb2oQmMg10Ek10qDdy1lzmaydpIjsRfJWIlBL0bhBTyQ6+TgwLMALAs9iEMtdMykGeFE/DXi+W78RjnNvuswBpnR/bkznExsJWclKXU10+Rd96bcm4mgsOxSy5rwB0fddy5GcwlPZhD++a92UV7q57c+cRPpdJ4/+eLPhveFQ15++xM385WvPYlljTzPpi1HmTurnI+9f8Nw9k5FESRTOb7xnU188N3rWL6kltMtfXzxq4+zfHEtFWUB3nHvMt738Go0XeWxp3bz+NN7WbuyiUwmz0ubj/DpT93CvOZy0pn8MGlu174Wtu0+xRf+4H68Xgc/+eV2vvXD1/j8Z+6ZmJoghRwhn1iwihuqGolm00QyafqzaSLZNLFchkQuSzyfI57LXtKyy3Qh7PLwV+vuoDudIJLNEMmmiGTSRLMZ4vks8VyWRD5LNJshcwlE2IlAUQSfeNd62roG2Hukncdf3McTL+9HEQLLsnE6dT7wwCochsbXv/PyjLRBCMGNa5oRQvCvP9hES2eE/3lmN//zzO7zysGs+ou7r4UQLJ5bxUO3L+UnT+1k657TbNt7BkUpLB/atuR3P3TjBQbHvqMd/NFXf4FpWliDQldD2H+0gz/5+0dRFIGqFLKc/u9P38OGFU3DZVRV4WPvXI+mqfzkqZ388rm9PPb8PhSlcA8lUBr28an3buDmtbOndVIRzR0nZRZyVBU5ZuHWxnbvZ6wofZmDADjVICHHherN8VwrsXwLAD69Gp9ePa1tTpjtxHIF2XhD8VHsnH9FSAIUkkvGiGSPEc2dIG32IbFxKH58Rg1Fjll4tDIE6hXhoXrLGxy2tNjS822SVoRm33VkrcQw52Ag10lAr0AVBq/3fhe3FqDU2UxX+ggnE1uY7b+RYkcDilCRSLb0fhuAes9K9kWfxKbAgndrQeq8K3mh8+ssCN4xbHAMhXVWe5ZwaOAFUmaUVeH30Jc9xXOd/4e5gZspMqoH45ovP6Zjvfj8OlLpHLsPtrJueSMHj3Uyp7GMsXI2nfsQ2Lbk8NFOHrxnGQ5Dw2FozJtdMaLsxdq8Yc0s/t9/vsg//suz3Hz9PBbPL3hFuntitHdG2XOglcPHOjFNm0QyQ1tHlIqyANKWbN15ip7eOCdP95JKF6IOnE6d69Y18y//+SJrVjZy08Y5VFUWFULS9reSz1s89nQhUVRHZ5STZ/rI5szhWeR4EEKwsrSaFSUj5aIlBSJk3rbI2za7etv55HM/I2e/OX1kCG5N5676ORfcfxuJOdRey+bvdr7Mdw7vmlTd1RVFfPjBNWiaQsA3vo6KEILyEj9f/v0HeHHrUXbsb6E3kkBTVeqrQ9y0ZjaLZlfS0hkhkcpRXxUa0c+K/G4++MBqbFtSXnLxmdzaJfV43Q5KQt5Rw2cVReHGNc0snlvFll0n2X2ojc7eGOZgUraKEj8LmitYvah+zOvRNZVPvXcDyxfUsGnbMVq7BrAsG5/HQXV5kOULLgy7LC/28567V0zoGVaEoKosOGKbEAKnQ+MT71rP9atm8eLWoxw91UMmm6fI72Lh7EpuWN18UVGzJfOq+PA71hDwuS4avWLoKg/dvpRYIsPiOWez/R6IfI8T8V8BCuvL/pQm/+gS/EPozxzmhfbPIrGpcq/nxsq/HSkaCJyMP8Xu/v8AJItDH2dx6BPj3peJQ7K77985GX8SALdWxl0138Ctjb4kcjlQMDTiHB34Bcdjj5HIt2FzvqEvcCh+Sl1LWRj6MGHHvDfd6HjLGxxpK0Zrai/3Vf9/F3ArqtyL6MocJmVGUYRGLN9NqbPA+i92NLIoePfwD5SxEnSmD3F31Z/g00qxZJ4DA88ABdnvsFGLJs4ONhJJQK8g60gwkO/EUFxEcq0AHE+8Rr13JYuD9w6XfzP6QSyR4dlNhxACSsIFF+KapfW8vvMUVeVB9hxqo6LUz4LmSl7aehSnQ2fdsga27DxJIpXl1g1z2bTtOFJKlsyr5sSZXjp6BjBNm8beGPuPdjCnsYzt+84wu6GMfUfakVLS3hlF01SuWzWL4tDI8KpCam8xbFxMRCdBCMGCuZX81ecfZMv2k3z3x1vYVBPmtz5xE/ZgHSVh73Cui0988DrqasJ098T53199lBVL6pjbXE4mm6e9MwoUQh/f/841bFwzixc2HeYvvvIoH3v/RtatasSybLweJyXhQttLwl7WrWqaUkrpCySlAUVV0dVCXUHHxKXaLwfOb6+KQFUVHKqG1CRubfICZXWVIT75nsmx3oUQBHwu7r95EffdtKgw8AqGw26FENRXhfm1UeoNBz184l3rxz3HhhVNI7wCF2tHOOjh7hsWcNcNC0aIMp3blvFg6BrrlzWwflnDsLdirPwoNRVFo17bZCCEQFUF85rKmdtYVtDZkGdztFzs3EIIViyoZcWCsUMrDV3jkXtXjtg20kCa6IRHDk8Sxyaoz8ziZMaK0JXeOfw9bfbQk95DrfemN2UAl1ISz7ewpftvBts1lLxRHY72s2UeiUXWHqA1uYl6362EHVNfCpkuvOUNDksW0l4bykhFwbQ5wFPtX6HWs4xiZ2NhqeOc/urWRsr12oOKoppwDNbnYczYIinZ0vsdslacBu9aPHqYbDYBSLJWgqBRmNmeew5DcXJ7+fvJ2hd3oQugzFlPzj5rzSoI1HO0LCaKXN7E0FWyeYv+aBKv28GuA61k8ybb9p7m9uvm8dTLBzBNm/JiH0vm15DO5MibFqfb+onGUnR0D/Cue5YjEJxq6+OWdXPYtO04pWE/pmlhS0lXb5z6qvCwoeF0FmL6u/vjIwwORRE01ZewZ38ra1c2ks9ZHDvRzcJ5FyaNAjkczlcghebwep3ccdN8ZjWU8sW/e4x0OkdpsY9wkZfqyiKWLqqFQVKhx22wbddpTNPmfQ8XZtfHT/UMvxAtyyadyVNXE+bDj6xHVQWvbz/BulWNLJhbyYHD7axd2Yjf58KybPJ5a8JJt65h+nBuArM3vR2FD5dUBzDhZbnphBAC9UqybK8QSCnpyewlPbgEBAKJTUvyZWq9N3K5+52UkpTZw6bOL9CXPQCArnio895CrfdGvFoFCEjmu+hMb6cl8RKqMKhwT0wraabxljc4XKoPTThpTe2l1rMMW5ooQiVp9pOzUywM3oUtTbLW+cmFRv44huLBUNz0Zk9SpS6kK3MEOagyKqUctsEl9mCIrEln+iDrSz5KmbN5sHxhMCt1NnMs/irNvo3oigtTZnEoXpJmnv88foBoLjnOVe0d8W1RsI7PzXtwCl1fYBhaYdBGsnBOJf/5o8185J3r2HeknYPHOpESwkUeDh7rxOtxDkeDOAwNSSFE0dC1Qal3ydHTPVi2TTSWIhpL09ufwO00OHCsg87eGHVVYRyGVhicR5mQPHj3Ur7ytaf4i688iqEXjJOhB+X1bSfYubeFQ0c66eqO0dMb5/r1s2luLOMHP9vK8ZM9eL0OevsSbFzTjMftQFEEH33fBv77B6/xs8d2FpZLHDq//9u301BbjK6rfPlrT2LoKoqiDGd+jMbS/O3XnsTp0FEUQVdPnE98YCNCCFYtq2f/4Xb+v7/5JQG/i3Qmz7pVTTx077JJ/wLXcA3XcCVD0pJ4GYmNofhxa6VEc8foSu8kY0VwaeHL2hobk119/zJsbLi1UtaW/jEV7tUo56iCBowGKtxrmB98HymrB0OZWlTJdOMtb3Bowsn6kg/xRt8P2RN9DIHC6uL3EnbUU2RU80zH3+NQvRQ5qlGVwu3QFAMhR85WVaGzIvwutvX9iH3RJ/BoYdxqEICj8Zc5k9xJ2oryWs+3KHU2s7joXmb7bxjkhhTh1oKD5QVNvnX0Zk/yRPuXUYVGkVHDxtKPYUmLk4lu+nLxSV1j2OFnKknigj4Xq5fUDxpMoCqC2soQpWEfN6xpprUjyvzmCnweJz6PE9OyqCgN4nTo6LpKSZGXm9fNGZRHFtx900IG4mnmNJYSTaRZt6IRy5Y0NZaQz5rMqi/FOWjgCFFwuZ4LIQTVlSE++rHryCbzNFYXYxgq+UHFyOqqIhxOnQ1rZ4GEnliCUJEHIeCRh1fT0TVANmvi9zupKA0ML82sXl7PnOYyOrtiKALKSv24XAYul8EX/+RBjp7qpi+V5rqljfT1JVAUQVHAzWd/83Z6B7NclpX6KQoUCL+6rvLx92+kqztGNFYItS0vfetFJ13DNbzdkbGidKV3ABAw6qlwrybaf4y02UN3Zg+1nhsvm+dASkl3ejenE88BoAoHq0o+Q6V77UXl151aEU6t6IJ9kznnUF3nfj9322Twljc4hBBUuOZzT9XnydlpFKHhUNyA4JaKT5O1kuiKc1DApXAD5wduG7WeWvcyKpxzsTHRFTemnUWgUOdZSZV78XBZVWgoqCwK3s1s/w2AwFCcmHZBRlhTHGwo+QhZO4ktLQzFjUDBozn5zNz7ydoj9QN2Rk7waNs2NKHyiaZbKXWOHNyKHf4ppVjXdXV4ELVtm9d3neLGtbML7HZVo7H2LCmqqjw4/Lm++qxVf+6SSFHAjd/n5Odb9qMogoayEA6XxpmeKMubqoinsyQyORQhKAl4aO+P0ZdMEfS4UBVBzrRwGTp5JKYDykp89AwkSVp5TMtmIJ/jTDLGxvkNGLpG4pRJUdCNZdt0x5OEir04dI3+RIrOaILKsL/wqwqBx+2gtMJPwO0kkkiTzObpisSpCvtZNK+Kb72wA0VVqB28NiGgpNhHSfGFM4Ohte/KiiCVFcEL9l/DNbxVURhwJBkrwkDuJPF8G3k7CQgM1YdXq8CnV+HSwgi0K8KNP1VIKenN7B+OqClzLaPCvZp9kW9hyxytiVeo9RTe75elPdgcG/gllizIzVd7rqPKs2FG77G0OwtS5s47Bs8jyaV/ju68GSGCk67vLW9wwGCiHeFAU0YKSanouAfltc+Frowu0iOEwFDPJvxR1cLtc6geHIwWpy5GpG831HNutxAXpHZ3qDo3ly/ifJi2xWNt21CFwnWl82n0lo3avkuBoiisW944fsFx0B9PkzMt3ntdQSOjeyDBrpPtLG+qYuvRFlLZPIvrytl7upOWnijNlcW09cXwuQza+mLMrynj/2fvvcPjuM6z79/07RW9EgAB9k6RFEX1XixLLnJc4yRvEsdJHNckTpzEdt7Ejp04eW1/jktcYluRu1xkSVYXJVEixd47AKLXxfYyO3O+PwZYAgTATpWY93XxInbnzNkz9TznKfcd8bnpH3O8PJ1DMXZ19LGyuRbTshjL5BAIJGBXRx8rmmvYcqSLgmnRF0vQWBGmYyCGJMEtK9qoDDnnuGjZ/Gb7YdbNa+Bw7zAjyTQNZSF2dfRx77pFeF2X1Vgv4+whhCAdzyAE+EKe1/XEerYQQpC1Rtgf+x86U0+SLQ6Ph5UnVr0SEjKGEiBstNIWfBP13mtfx+dG0J3eiMBCRqXacwUhvRm/VkO80MFAdvsrGlbJWaMlb4uMytzAG8Z1rS4diuZBiubOkoQHSBTNnchqI7K+6pz7+63PchPjte6nKy8TwlFKnFCJdNQWzy0j2h5ntXwlqItfTaiKTN4sYlo2thCEvG50VUHgZO0vaqhkTmWE4USa1poyWmvKkCXHu5HOFyblwkA6V2DviX4iPjeZfIHKkI/qsJ+wz4PH0PC5dISA4USaxY1VuHWNXKHI4sYqaqNB0pOYJl26is+ts3FfOwvqKsibRVY015LI5ErXduLf2UAIQdY0Z9XyuIz//fjNdzfy6/968tUexisCx9gYZmPf33Bg7H/IFAeQkDCUIB61ArcSRZVcCGxyVoy+zJYSb8XrFXkrTn9mGwBerYqw0Yome6h0OxNtpjjEUG7vKzIWR+yxnZwVA5zcjchFJF2cHQpCFDlpVAqEMDlfr85vhYfjVDgTi+M2t4XgWPcwrfXlJyeciYs4/mcmZzIST1NbHuThF/ZTGfWzoKkKn1sv9TNlt4nvgJ7BMWrLQ6SyeR7ddIB7rlsyrW799bsCmI6g10VLdZSfbtrN4sYqCkWLZDbPkd4hogEvXsPxJCxvquHpPcfoiyVZWF/JM3uOYtlO1cnB7kGS2TzzasoJedxYwiYa8BL1e9mS6uJ4/wiyJJHM5tnV0ceatgae299OyOumoTyEqsgosoRnkj6EJEksb6rh+f0d1EYCLG2s5uFtB1k1t44TQ2NOX+19rG1rOOtCg5FMhojHg1uSJq3xpmbTzPb9ZEx8/7/pPrgUEEIQy2RxqSpuXZsSV84UTPLFImGP+6zP48Tz7uQUSTN+RnBS3Ew6yQUjbMGNb79q1v4mx74nj7NUNjsOSZZeN9f98NjPGMo53DPVnrUsCr+TgNaAIrsQokjOGiOWP0pfZjOx/NFXrWz0YmE4v590cQCACveK8cRLiVrveo7Ef47Aoju1kXrv1a8ICVi80IEY537y6/WvSCKoqi0gl/oK+cz3UdRWiuYBbOsEinp+3vBzNjg2btzI5z//ebZt20ZfXx8PPvgg99xzDwCmafKJT3yChx9+mOPHjxMMBrnpppv47Gc/S03NSeKXfD7PRz/6UR544AGy2Sw33ngjX/nKV6irO0k5G4vF+MAHPsAvf/lLAO6++26+9KUvEQqFzutAJyCE4GjXMAc7Blgxvw5VkTnUMcjcujJe3t9FR+8ILXVltPeOoikya5fMYWAkQcG0CHhdHO0aJhL0ksrkeWHncVyGxhUL69my7wT5QpGGqjAHOwbwuQ0WtlTxo8d2cNv6hSxsrsTQVWwheHF3B4tbqtlzrJf1S5vOPOjXEWRJYsOCOVO+W9k8vaw16vfwlvUnw0f3bVhW+rt2zUmdgHvWTVVifOtVJ3Nl3nfbutLfk/uaDXXRYCnUs7KllpUtJ8c1ua+zQbZY5Jn2dm5rbeXp48fpTSTw6jpuTcO0LCp8PjyaRlc8ztxIhLFcjr5kkrayMkYyGVbV1LB3cJCMaTKazbKhoYGGC7y3/7fDFoJ/eehZoj4PH7vjmtL3AvjiY5sYTWf4zFtvQz3LslIh4Luf/inr37CKtlXNmHmTb3z8B7zlQ3dQUR/l+J4T/Pq/niI+lMQf8fGWv7idurZqzLzJA//yS47v6WLDPau56Z0bADDzJv/9qZ8yZ1Ed25/ahwS84Y9vYv4ah8tj+5N72fizLaRiaTKJLIuuauNtH30Dmn5+676iNYose7DtJIocmqJ7IYQgW9iJW19Wmgxzhb3oWiuyZCCERaF4HF2de1ZGgY1Jf9ZZ7RtykLXlH8On1U7Z162WEdJbaPLfQsFOoctnkjAXdKWeJWX2nrZV0uzmlRYAEMKmO/UcAgsJmVrPlYBjHEaNBXjUctLFfvqz28lbY7heAf2stNlf+tunViO9AgEKSS7DE/wk+cwDmPkXkJUavIFPIUnnlyR/znd6Op1m2bJl/N7v/R5vfvObp2zLZDJs376dv/u7v2PZsmXEYjE++MEPcvfdd7N169ZSuw9+8IP86le/4gc/+AHRaJSPfOQj3HXXXWzbtg1lnPDoHe94B93d3Tz6qMPu9kd/9Ee8+93v5le/+tV5HehkuA2NouWERqqiASfUAQzFUngMncqon47eUZa01tAzOEZDVZh9x/vxunUaq8PYts3ASAJJkrhmZQtjiQxm0eJ4zwgBr4tFzVUc7Bx0Vvt1ZSxompxzIRHwudi44xh1FaELPpZXGxMrubxlEctnGMymGcikGMtnyRZNLCFQJRm3qhLQXZS5vURdHiIuNx5VL9X+X9LEp/ExmrbNaC5DbzpBXybJWD5L3rJQJAmfZlDh8VLjDVDp8eNVtdOOy62qRDwe8pZFtlgk6HKhyDLdiQRvW7yYXx48SG0gwLKqKhpCIb67YwdvXbyYXx08iEfXea6zk9pAgCePHWNuNEp/KnXZ4DgDZElidVMd33thO++7YS0Bt5NrlczmeeFIB++5auV4xdRZQgg69vew5Or5ANiW4NiuDvKZArZl8z+f+QVrbl/O8msXMtg1jG9cT0QzNN76oTv58X88zEDncKk72xJse3IvZqHIu/7mHvY8f4jvfPLH/OODHyGTzPH9f36Q9//be9B0lc//4de45k0Opf75IpPfjEtbQKawFa9xFbbIocphJNmNWewmk38Jl9ZGodiLJGlkC3tQlSpsklBKkheYxX5skUVT65DHyQuFEBTtQYSdQVMbQIAtxrl/JAlJUmZ01znPi4ShzM7gOhld6WfpSj973ufgUiFvJ+jPOnOWSwlT5lpcehe4lBAV7mW0J/vJFAcZyu2jzrvhkntzCvbJ6kVjBs2uCUIw085M2yZLKkF9DvI5asBIkoSizsMT+CTnUwl5Ks7Z4Lj99tu5/fbbZ9wWDAZ5/PHHp3z3pS99iTVr1nDixAkaGhqIx+N885vf5Hvf+x433XQTAN///vepr6/niSee4NZbb+XAgQM8+uijvPTSS6xduxaAb3zjG1x55ZUcOnSIefPOTvFuNpiWhaYqjMadCzMUS9E7FKdYtECSiCdzhAMeXLqKpiq094zQOxQnlcnj97jwuHSiQS8dfTE27WqnpjxIOlMg6HPhdml43AZ+jwtVVZAVmUOdg5SFvAyOpujsHaW5NsozW49y3aqzW128FiGEIFHIs3O4l2e6j7N9qJfuVJxkIU9R2KVS2wlMhAxkScKjaoQNN02BCEvLqlhdUcfCSAVhlxuZi+dinsi96UyO8XjXEZ7pPs7R+Ahj+RyWbWNPGqEEpbHVeAOsqazntjnzWFleg0uZnm0/lsvROTaGKsv4dB15nPjpxNgYTxw/TrXfT8Aw8Oo6qixTFwjw6JEjtEajlHm9PHz4MLfMncuJsTEUWb5sbJwFJEliXUs9X3nyJQ72DbGm2aH8PtA3SCpXYN3chot278iyzLzVzTz/4BY0XWXljYsJjlcsSZKE2+/C5dEx81PppFVN4ZZ3X01NSyWaofHwN58ilymQTeZAQE1LJaoq4/G5xkOv5z9egUki+2tMqw+wkaUAKasHVY4gSW4se5RU7lmEKGALp7w7kf01XmMDiuwnmXuCiPc9xFLfwaUvxrS68bkmPEcmY+kf4tIWoaq1yJJK2JjLSH4/eSvOzpGvsiz6x/jUqgsKJ8iojvFyuuMUNjaXRvl35t8TjOQOlDwKZa5FpySGStR61tOefMwJq6Q3Uue9iktdrWKJSWSPMxgOAostQ//GwHjeyWS41Ch31H/rvBJcT96jzv9mfjOSHEHVWs+5r0uewxGPx5EkqRQK2bZtG6Zpcsstt5Ta1NTUsHjxYjZt2sStt97Kiy++SDAYLBkbAOvWrSMYDLJp06YZDY58Pk8+ny99TiRmV4lsqApTUxZE1xSKls177ryiFGt1uzTyZtExBmSJqjLHA7JsniOBff0VrUjjtMXV5UFs20ZTFeom8T5ISNSUBZBliTuuWogQAlmSePcdq5FlxwBZ3laL9yx1N15LcErF0jx4bD8/PbqH44lRzLNInBScNAAShTyJQp7O5BjP9BxHlWQqPT6urG7gQ8s3UOu7cE4LIQQdiRjf3L+VhzsOMprPnnF8lhAkzQKHxoY5NDbMj47uZkV5LX+8eC0bahpRJ7G5BgyD965Y4VRATRKLiWWz3NjSQtjtLsXzZUniltZWTMtCH/fgve+KK1BlmTcuWEDRtktU5pdxelSF/CyoKWfjwXauaHJCsM8dbGdBTQXVoXOMaZ+SaGPbNlbRuZclWeJNH7iNJVfP59mfbObhbz3N+z73TuYun3PaLlVVwe1zOdd9wtsiIFoTpra1im994ge4vC5qWiqpmkWe/OyHr+J330o2vxXLTuAylmBaPVh2DI9rAXnzALLkpmD143VdRTq3CUskkSQVWfI6+SkUUdVaXPoycoXJCZAqPtf1pHPP4daXochR2oL30p1+npw1SnvyNwxkt1PvvZ4m/82EjVaUcRbmc8HS6B9S7736tG2Gcrt5afBfeCXDKt3p58a1SSRqvFdOCV9IkkS5eykuJUTOitGf2UbejuNSzp/v4mww2ciwxcwCiUJYM2iqzN5+NghRACxARYip786iuRNVWwK8xgyOXC7HX//1X/OOd7yDQMBxsfX396PrOuHw1ItTWVlJf39/qU1FRcW0/ioqKkptTsVnPvMZPvWpT51xTBMUvoru3ECaqqCpCkII7tiwELNoOeySEw+O5CguzgRVkWCczvpUEquJt9nkeLKiyAghaGsoR1XPnYr81YQQAtO2eaTzEF/c9QLH46MX7fEvCpuedILnejv48IrTv3zOBgXL4sFje/mPnS/Qlzk3ErXJyFsWL/WfYOdQL2+Zu4QPrdhAxHCSEhVZxn3KfSGE4MaWFkIul3P/TLq+siRhqCfvkQkDQznN/XUZ06HKMjcsbOGBF3eRKZgIAS8d6+Lt65ZNMfzODhLegJu+9kGKZpHO/T2M9DlVALZtkxhN0bKskZaljXzj4w+w+7mDzF0+52Ti53hCqTNxn/5pUHUFX9BD48I62lY1UdtShX6BCw5Dm4eqlOHSl6PIIXLmHrzGWlSlgmxhJx5jDUVrECSVbGEvHmMtqlKFaXVj2UlUpYyiNYhHX4kihzC0yQs5G8uO4dIXIcuOgFvEmM+Gqk+yffjLjOaPkikOcSj+I44mfkHYmMsc3000+K7Ho1acpddDwqOWEzJOn4CYKQ5e0Hk6VxTsJH2ZlwGn0Hcwu4uU2TOljS2skhGSLg4wnNtHrefScmJMThIt2KcyY4OETFvwXmq9jk5Q0c6xf+z+cZ6Uc4OZ34hVPIaiLSCT+Bck6SSlhG0N4gt97jyO4BIaHKZp8ju/8zvYts1XvvKVM7YvZYKPY6YLd2qbyfj4xz/Ohz/84dLnRCJBff10lcXZIElSyfi4lJAkqSQi9nqBU5KV41+3P8ePjuy+ZMql19c2U+U5/8xrR2fA5As7nud7B7dftHHmrCL3H9rBsfgIn7vqdup8wVmZ/aIezww9vPZgC8thlz2DO/u1BkmSWNtSz38+uZmjAyOO3Hkmx9qW+nN+2UsS3Pbea/nOJ3/Ctif2ECoPUD+vxpFoNy2+++mfEuuPIysySHDPnzpe2a5Dvfzqa09ydFcHtiVIjCS55T3XUD+vBpfPhSSfzEtyvB1gmRaj/WMc3dnBlkd24g26ueuPbmLe6ubznqQMzUlGVXTHI6ipVaVtfvctTkw/+wgyNrLkxdActVBVcRIc3friKf0p8sm8C0lSJ4VXJr6TqHJfwU21X6Ij+STHEr8ilj+KJfIM5/YxnNvP/rEHaA28kXmht6DLMyvNvpZxMpzS53zGLqnEzroPFl2p56j1rOdShlW86slFuGOETc2pkCSZRv+Npc95K8Hh+IOYnLvBoRkb0PS1mIVNuDxvR3edTKPIZ354XuOHS2RwmKbJfffdR3t7O0899VTJuwFQVVVFoVAgFotN8XIMDg6yfv36UpuBgYFp/Q4NDVFZOTPplWEYGIYx47bLOH84D2CGv970KE92HT1rr4YE44JyzmNh22JKzsSpMBSFNzYvvKDHNWcV+eetT/ODw7uwTsOnoUoyHk3Dp+mosoJl26TMApliYdbwkABe7D/Bh557iC9f+0YqPb7X3ct0Mnqy3WStLM3eFhRJxcZGwtHUEcJmIiNfQqIoiqiSikBgCxtZkpF59Tx01cEA86vLeOFwBzYwv7qc6tDZJSlOhiRJLL5qHp/6yYfJZ/L4I15ymQIevxtFlfmTz7+LVDwDAnxhL/q4zk5lYzn3feROJm4xSQJ/2Ifh0vmrb78Pf9ipzghVBPjr77wfb9DDkw+8QKQqxDs+fg+KIrN302F+9G8P8bf3//klFWvzu28DbGDmJM9zhSQ53BttwXtpDtzKcG4fHckn6ElvImuNkCkOsmv0v+jPbmdD1T/gVspfd89Jd/r5UlhCkYzTVoMURQ4Q9Ge3krcTuMblLi4FAno9EgoCi6TZQ1Fk0aSZCCcvHJLkAsmFqq0ATSArJ3M/VH0Fknx+ZGcX3eCYMDaOHDnC008/TTQ6dWCrVq1C0zQef/xx7rvvPgD6+vrYu3cvn/uc46a58soricfjbNmyhTVr1gCwefNm4vF4ySi5jFcGKbPAJ1567IzGhibL1PmCLCurZlG0klpvkKBuoCsqRdsmUcjRm05wZGyYA7Eh2hOjJPL5khEyP1zBsrLq8345FW2b/9zz0qzGhixJtAQj3NrQxrqqBhr8IbyajirJWMImUzTpSsZ5sb+TRzoOcSw+OqOBtHWwh09teYJ/3XAnXu31l4MzAVOY7I3vpDN9nIXBJQznB6ly1dCdOcFAvg9b2ESNcurdjRxLHSasR0hbaQpWHkmS2FB2/XnR6V8MKLLEDQvn8uC2fdi24M1XLD636pRJkCQJX8iDL+R4pvRJjLOGx8DwTF/EGG6d8rqZX7jhSZo6iqoQrnQ+j/bHsW2BqqlYZpH+9kHK6yInQ7eXABMVI5eC31GSJDTJS7VnDVXu1aSLg7Qnf8PBsR+Rs0YYyG5jz+i3WVP+UeD140VzwilbANAkD9dUfwafVjNjW4HN5sHPMZDdRtrsZyS3nxrPlZfEwJIkiaDejK74yVtjpM0+kmYPEaPtov/WZMjK9NQGVT83CoEp+57rDqlUiqNHj5Y+t7e3s3PnTiKRCDU1NbzlLW9h+/btPPTQQ1iWVcq5iEQi6LpOMBjkD/7gD/jIRz5CNBolEonw0Y9+lCVLlpSqVhYsWMBtt93GH/7hH/K1r30NcMpi77rrrguuULmMs8fEJP5Y55FZjQ1Nlllf3ci7569kdUUtAd1Vkuk+9bGbXEI7kEmyfaiXJ7qO8vJAF3c3LcCtaqd2f1YQQvBU9zH+a9/LMxobEcPN+5as461zlxAyXDO+ECJAnS/Iuqp63rtgFd8/uIOv7dtC2ixMa/vYiSP88Mhu3rtg1SWdMC4lJCTa/AsQCEYLI2StLKZdIGtlCGtRTGFStE0G8/3oikFfrheP4mFZaCXbx16mKEx06dXxKE6EVf6/J14EOK9wyiuN23/vWh759jP88F9/haLKzFlUzw1vW/9Kq5tfEkiSjE+rYnH4PZS5FvJs319j2ml60i+SjyYv6ar/YkIgGM0fKuVrhIxWKt3LUeSZ73MhBA2+axnIbnPCKumN1HjWcakuqkctI2rMpzfzEkWRpTP5FGF97iUlHRPColh4EbOwBcREpZCE4fkdFLXhnPs7Z4Nj69atXH/99aXPE3kTv/u7v8snP/nJElHX8uXLp+z39NNPc9111wHw7//+76iqyn333Vci/vrOd75T4uAAuP/++/nABz5Qqma5++67+fKXv3yuw72M84QQgi0DXfz3we2zhkLK3V4+tvIa7m5agDFD6eipKNWxqyqNgTAN/hB3Ny1gIJvCr517hvsEhnMZ/nX7RjLF6aVzVR4f/7bhTq6sbjwrNk9Jkoi4PPzp0iup9QX5u5cem9avJQTf2LuFG+tbaPRf2sz0SwVFUjBkg6IoossGvdlu0sUUbsWDJmtIQkZgM2bG8ChedFlHlw0USUWTdF7tmbIq6OfWpW1I43+/1uGP+LjvI3dN+e61biSdKyRJosK1lIDWwEj+AKadwrJzrx8Hh5gaTqnzri/xkswEJ6dlNZrsxbTT9Ge2UrCTM3JkXAxIqDQHbqcv8zICi2OJh5jjv4mQ3nLJ7iWreIhM8t8x3HcjSe7SSCRpZr2xM+GcDY7rrrvujLojZ4LL5eJLX/oSX/rSl2ZtE4lE+P73v3+uw7uMi4ScVeTLu1+ccYUPUO3x8+/X3MXayvNfXU5UDNV4zz3+PgEhBD84vIsjY8PTtnlUjU+tvZn11Y3nPEZFlnlj80KOxkf46p6XpplcfZkkPzy8m4+uvOZ16eWocTklpQKBLMnUuusQQqDIk18JTlJa0TZRZcf7pEoqayLr0aTz80ZdLCiyVGIbfT2c/de7cVG085h2EpcSYSK/51Q4eiujZK0RADTZjyq7p7V7rcK0U6Vwiiq5Z5V9nwy/VkfYaGUwu5OU2c9wbv9Z7Xc+kCSJWu8Gyt1LGMzuJGsN89LgZ7my4m8J6nNKbeDs5uGzgW31oxs3Ynjec1GO6fVVLnEZrwiEELzYf4KtA90zbveqOp9ed/MFGRsXC4PZND86sntGH8y9LYu4sf78ydVUWea9C1bx6/aDnEiNTdv+UMdB/mDhaqLu6YlbjtCfQHmNamWo8tRHX1Fmnxh0eeoqz1Be/eRsaYaQ3WVcOqSL/TzT+5dEXQuo8awlbLTiUsIokgEITDtNLH+UfWP3l8pYa73rXhG9j1Mxmj/MscRDZ2zn06qpdK8qPZ+j+cPjNOoQMloI6I1n7EOWNGo9VzGY3YmgSHf6OWo8a7lUZrAmeVgZ/TOe7fsrstYIw7m9PNn7FzT7b6PKsxq3EkVgky2OlLxMFwJFbaWQ+zVW8TCyHGXiuCQ5MIVK/2xx2eC4jGmwhOAnR/fMWlb61tYlXF936dx4ZwshBE93H6M7FZ+2Lai7eM/8lRfMcVHh9nJrYyvf2PfytG09qTjbh3q5aRaj5pEdB7lmYTNBz/m5H3/bYI8TwynSuRtpE6Ry8nnsexlnA0GmOEQi2Ul78jeokjHuwdAdjh6RoWAlS+JiZa5FLAr/Lq+G/6k7/Rzd6efO2K7Bd0NJ+VUI4YRTxvMUaj3rx42p00OSJGq8a9kz+i2KIktf5uVLG1aRJMpci1hX8XE2D32OTHGQTHGQvbHvsi92P7KkjJMsWqVrAed/FWx7mKK5j1Tsz5FkHxNJyN7gP6Bqi8+0+zRcNjheB6hwBVlXNg9NUvAol74yoj+TZEt/14zbyt1e3rtgVUkD5dVEUThEZDN5N1ZX1tESjFyU1901tU18e/82imJqyawlBC/0dXJT/VzAeWkd6BnkUO8QC2orGEqmeXz3EUJeF1fPb2LT4U7G0lmuXdjMvq4B4tkcIY+b1S11PH+wnd7RBGtaG1Akib1d/cyvrYDXbyHMOcEWgp8c3ku2aHLv3IUEjHMz0gTwwKHdvG3eErQL4BYRQjCafYZcsZsa/zvOSLs9gXyxn57k/QhhIqFSG3gXxiRejAsZz0jmCQrWENX+t531eHLFHnqTDyBEEUnSqAu8B10pP+9xGEqIOt8G+jNbyVtxiiJH0coxaU5DQsGjltPgu4FF4XfhVspm5qsZ13E5ex+VhISTUzT7PhMVOWePyX2ZIkN/5mVAQpVc1HrPvtokoDUQMloYzu0jXRxgJH+IavcVl8zwdUIrV3GD9gX2jv43vZmXKNgpBBaWmGxkKGiyl6DeSL3vWrQziulNh6otJhD9MVNZXqVJ+Rzn2N957XUZryjWRFtZEz13GtnzgRCCnUO9s1KB31DXQoM/9JpYRQ5kUuwZmc7XIgHX1jShXITsbUmSaA5E8OsGsRnOyZ6Rfgq2haGo5MwiT+87xjs3rEBXVTYeaGdJQxWbDncSS2epCPjoH0uyo72X3Sf6eOu6pfxq2wHCXjexdA5dVZAl+OnmvVwxt45fbt3PjWvnXvAxvNYhhGDrQA9PnDjGG+cuwFBVdgz20pEYY21VHQXLQpFlPKrGQCZF2iwwnM2gyjLX1TdxaHSYY/FRDseGuRih63juZeL5rc4Ef5YZj7Lkwq3WkyocoD/1AOXe2y+KwQEQy71EunCIKv99Zz2lypILl1pHKr+PwfSvqPTefWEGhxzkqsp/IFscJml2kTR7yVtjWCKPhIyhBPFr9YSMZtyK43qf7R2xKPJumgN3AJRyD06HqGsBN9V+0RmHEpyRF6M5cDsV7mXTvj8dJlORK6isqfgYtigiSxoh4+yfO0UyuLLyb8kVRwFHOv5SQ5IkQnoLV1X9Aymzd7y6pg9L5FEkA5cSwqtV49dqcSvR0ya/nh4qwh4hn/kJttWDrDZguN+CpJy78eL0dhmvebzSk/vWwR7sGd7ciiRzS0PrayJ2LoTg4OgQ8RmMAE1WWFJWddHOW1B3ETbcMxocvakEKbOAoajjiVoOY60iS7h1jYqAF5+h0zkcY3dnPwG3i6Jt43MZRP2OQGDY66ZjcJQFtRVUhfyAwK1p3LqsDfFbwno+L1xGUzDMuup6xnI5Xug9wV1N8/jJkX0sjFbgUTXK3B72jQzSkYhxY30Lm/u7aAyE+HX7Id7WtoRNvSfO67fPNsFucrtT7y1NCVHtv49EfjcDqV+c1zgu5nh0JUqN/3cY07YymP71Of120bRQNWUa87OEglerxKtVcr6mlMMnMeesDI0JGEqAKs+q07bxadX4tOrzHBUosnHOBssEnMm/CfQmAF4+0YNXH2Jh1XQOCzh53c7l/SSEYGtXD5V+H/WhYEn7S0IloDcQ0M+9RBWgULR47NARrpvbhG8G4kxhD5OOfwrddS2qvgKreIxM4lN4Q/+KJIXO+fcuGxyXMQVFYXMwNrN2QdhwsTBS8ZrwbgDsGx2YkXfDrxtUXwBF+qlQZQW/PnM8N2XmiedzRF0e3LrG2tZ6Htp2gMUNVbRURtE1lcbyMDXhAF3DcXRVoSEawqWpKLLM3Koow8k0XpdOLJ1lf/cgd69eyN6uARrLQhjnKCf9eoQkOSq9LkUloBn05BMEdYMaX4CCZWELgSVs8lYRgcCjajQFwxwZGyZjmhiKQq0/QPA8mIaFsEnkdzGUeRhb5Im4r0Fgn9JGkCt2MZj+NbniCQylhnLv7Xi0i5/H5IxnO0PpRxGYRNzXcapomRCCbLGTofSvyRW7cal1lHvvwK3OueDxDPfH+a/PPcwHPv0mvP7f3tyjXNapznOdh97NE4ePUh3wz2hwCCE4ODhMKp9ndX3tOV2vjcc6WFlXQ33o4uWH5ItF/uvFbSyvrZ7R4Cia+1D15Rie30WSJIS4gYw9iFU8hqyf3gicCf/r32aWbWPb4qRy4ymYSDab4Gh4pSfT01m7QojS2F+pcWVMk97UzIJntb4gEddrRyvkaHxkxu8l4KX+E7jOk0jsVBRte9by4LxlkSk62yRJYnVzHaub66a0WTPXcbG+Jbqk9N0CnJfR1fOb2NHRS9DjCL65NJWFdZUsrHMo/HcN912UY3itQ5IcQxEJqn1+TNvm+wd2sqisgtZQlJ8c2YtLUWkKhvHrBvK4kRI0XAQNNw8c3I1li3PyvgkhiOe3cmDow/iNpXi1NnoS3yVvDaKN64oIIciYRzkw9CFcah0+fSGpwn4G0r9gQfkX8OtLLtqzKYQgltvEweG/JGiswqM10534FvniAPo446MQgnThAAeGP4pHa8KrzSOR38VA6pcsLP93vPqCCxqPP+jhpntWYbhe3bLnVxNCCDY+vJtgxMva6xectl0inydvFgm6XejKJK+QgHg2R8GyCLvdqOPCncl8nkf2H8bvMqgLBdEVhYjHyYco2jbxbA5biCn9FS2b4XSa+5YvIeJ1l36jaNkk83m8usZYNoehqgRcxrhh4Mxr8WwOSwjCbnepYs65hwpkCuYZk+ol2Y9t9YHIIHAhRBrbGkaSLodUZsQj2w4i6y7etmHZjA/icCLND1/YTVt1GTctbyWTK6BfJBE3Rzwpj8+lI89yYfedGEDXFNpqpsdX+8eS/OC5nbxxzSKaq86Pu/5ckTTzJAq5Gbc1+INo8snzcn613pMFh2b720HeGkSVvSiSd9q1M22b/vTMhtFwLsMHnztzWdzFgC0EeevCROKWN1Yzr9pJsHNNUx3+7YAiybx74XJUyRFKe8/CFeStIm5VQwL+dNk6ZElCkSVsIdBlhVvntKHKEu9esJyCVUSR5XNSjBVYdMe/hVefz4Kyf0OWXBSsIXb1v2tSK4sT8f/Eo7Uwr+xfkCUDW+TYN/hndMW/zsLy/+BivUYFJt3xbxEwljO/7PPIkkHe6psyHkGRzvhX8OmLmFf2f5HQsUWGvYPvoyvxTeaXfY7zZdrat72DHS8cwe11sWxtM2gKVtHm+cf2YBgaY6Mp2pbUs+25w2y4dTHl1SGe/tUOGlur2PniUQIhDxtuW1LyjDz36B6a51Wzf0cnIwMJ1t24gDltVdi2YP/2TvZubScQ8rD+5kWEoj5OHB3k+ME+rrtzGZIsUcib/OYnW7nmjqUEQh76u2Nsfmo/hXyR1dfMo2leFbHhJAd2nCA+mqa6IUIhX2S4P86N96zEcGkkxzK8+OR+RgYTLFzRyJIrmlFUmS3PHCQQ8nD8YB/xWJqVV7XStqSOfNbkuUf38OsHXqKiNsyh3V20LKhh/c2LpryDbFvw4J79PLTvILqioKsqH77uKuZEQgBs7uxie08vY5kc8yvL+PB1V1GwbL76wss8cfgofsNgX/8ALdEIf7phHQWryGeffI6esQS2sHFrGp+8/UbKvB7iuRzffGkbmzpO8GdXr+P2BQ6deU88zicffYqaYICRdIZYJssfrr+CG1ubyRctvrppC/v6BhBAXTDAR67fgM/Q2dXbzxeefgGPrhH2uMkXZ5euV7XFFOTfkBj9A2TZj20n0Y0NKGrLed1j/+sjxGta60lk84AzQQ6MpTjUM0TOLJLOFXhm73FcmsrixioyuQI/eH4nmw51MhSfXr88MJaiUCxi2Ta9owls26ZreIxj/SMULZvRZIaekTiHe4coFC1iqSzffnIrO9p7SWRyZPIFBuMpDvUMkszmyeZNLCEoDzg8DrYt6Boe40D3INm8SVXIT2NFhEzBKdUyLYujfcN0j8RnzLG4GEgW8uRnKYctd/ummASmHaM7+WOGMk+RLXbTk/oZA5nHGMo+Q0/qQYYyz5Ao7KM39QvG8juI53fRk/op8fxORnOb6Un9nJzVz3D2ObqTPyVZOMCJxP10J39I2mynO/kT+lIPUxTTr0XRthibJbH1lYYlZhZ8O1tIkoTH0HHr2msmXPVKwxEFU0teRlWW8Wp6qczVo2m4VBVNVkrtdEVBlhwjw6PpZ8V2OxlFO0GqsJ+I+2pkyTXeZxkB42Qs37TjxHNbcWuNpAsHSeZ3kS4cxFArSBUOUjwP6e/ZYFpjpM1DRNzXIkvG+DmpwjdJ1dW0Rknkd+DWGknlD4yP5zC6UkGqsB9LnP8zUdtYRvOCGp55aCeFgjMJ2bbNwz/YTNfxQZ57ZA8//eZGctkCD37neYpFi4f+5yUe+p8XqWsq4/Cebr7zhUexLYEQ8MJje/n2Fx4lny0QrfRjFZ3nZNNje/nhV5+mdk4Z6WSO//eJn5FKZDHcGr/6/ibiMeecHj/Yx6bH92G4NIb6xvjS3/8MzVCJVPj5yqd/QfuhfsZG0jzwn08hhOCr//Qr2g/2sXXjIfZu7SCfM/nKP/6S4f44DS0V/PRbG3n+sT0IIdj+whG++k+/QlFkAiEPX/z7nzHUN4asSNTMieL1u2iaV8XyK+fSMHe6YOjx0VH+Z9su/v7WG/jim+/i6uZG/t/GTRRtG4SzfPqnO27mP+69g/39Q2zu7MZv6Hz0hg2sa6znvhVL+MI9d/CnV69DkkBXVd63fg1ffPOdfPHNd2EJwdYTDidIxOPm4zdfy8LKCorWyXeNLQSHh0a4ua2FL77pTn53zQoe2LaLom3zzNHjnIiN8W/33MF/3HsnY7kcDx84TNG2+crzm7lnyQL+35vu5M6FbcRzMy8wHeh4/B/DF/onXN4/whf6F1y+P+F8jdrfquVU90icn7+0j+qIn5cOdfLGtYtI5wvYQmAWLfJFi77RJNVhJ3Z8Kna29xL2uakI+nhufzuLGyrZerQbQ1M53DPEWCZHKpvH0FQ6BmIsaqikL5YgnStQtGxODI/x85f2ceX8BgIeF0GPi+3HusnkC1w5r5GXj3axs72Xlqoo5QEvbkM7uf4Xgoe3HiRnFukfS3LL8jYW1M2clHQhyI0bVDMhqE/VIbFEHlkyKPdcT1/6IUwrjmnHUSQ35Z5rGUj/BiTw6XMJ6As4EvsibrWGtNmJR2tECAtb5BjOPodXayZtdiBJMkFjGbliHz59LkF9MeoM7rviuODaZVzG+cIWWSyRQZ+iaCqhKVGyxU4AinaSop1iIPVzhjOPl/YVQmAolcCFGZtTx5PBsrPoU8pJJXQlgmmNjo8nQdFO0Z/8CUOTkkGFsDHUCxtPKOqjZUENijp1HaooMutvWYxpWvj8bhZfMYcf/OfTCNsxLG67bw0LljfQuriOT73/u8RjKUJRx8BYsb6VO9++ttSXVbR54ufbuee9V7FqQxu2ZXNodxf7tnZwxXXzqWksY8+W42y4bQmbHt/HmuvmY7g0Nj91gEDYy8IVDhlXVX2EzU8fYO31CyirDHDD3St47tE9XH37UiRZYqQ/zvGDffR3jfKm37saTVdZvm4uzzy0i6tvXQJCsOKqVm55y2osy2bz0wfo74pRURNm4YpGQlEfjXMrWbqmecZztb9/iIZwkIZwEEWWuaq5ke9v20Uy5yxuV9RV4zOc/I/F1RUcGBjimpY5J0P3MEVqwbJtjo2MsKWzm3ShQFdsjPT4QlOSJBCCmWzpqNfDyvoadFVlTiRMquDMZ1tO9HB8JManf/MUAJ2jY1T6fKTyBfoSSVY31GKoKourqwh7Zi9xFSKJsEeRlebz9mpMxm+VwXG0b5ihRAq/x8DQVPxug9bqMgpFi8aKMEIIaqNBls2ppjYyPTFnVUstP31xDyGvmzWt9bx0+ATxTI6wzw2So0h69cImDE1l08FOaiIBqsJ+VrXU4XXp9I4mWFBfwQ1LThJFNZaHSzlhB7oHuWV5G02VkWm/bQvB9uM91EWDGKqKWbwwN/5sMIU1q/fEUKZatTIquhIGJAL6QmL2NtxqHZniCYYyG9HkMKrkQ5V9gEzYtZKCFcOvz8MSWQQWphUnqC8BScKnt5A2O1BkN4pwoeBmNPcyld6bUU+RYbZsccGehcv47YaEioSCLabm5whx0pCVUZEkmcbQByj33jatB+U8+QhmHI+kIUnytPHYojipjTPmpvBHiHqun7o/ErJ08XOsZFlG11UURcZwO2OcCKcqqozX7yxEPD4XCEE+NzFRQkXN1BJ6y7JJJbKEy/xIkoSsyAQjXmIjKWRZ4urbl/D0r3aydG0zB3ae4EP/9BYARoeSdLcP8eB3nnc6EoLKWqesVTM0ZEVG0xU0XUVWZCd/YTRNbDjJr+5/EWfOFsxdVDtxIimvCo7/KaGqCpZ19u8T2bEBSiiFlydSOCZtswUzGguT932po4svP/cSH7n+KmoCAUbSZ+epUmUZdTzMfepvrG2s401LF5U+h9yuaW3OxF5SLOzALGzC4//rsxrPGcd7UXp5DeNo/wgDY0lODI3RXBVlT2c/TRURIn73uLt26oUKuA22HOlirSRRE5mq8RHxe1Bkic6hGPeuW0w6V2D78R5aqqI0lofZerQbRZbH3cLOPoaq8uKhTla11IIEqiKXHsCRZIaOoRiGqjKvrpzW6jKe2H2EtupyFtRXOOx3I3EkSaKhLMTyphpsIYj4PNSVXSqBoNlxqhmiK1Gi7vUAeLUW3KpDdV5IjRBxr8Eo1f07bvEy99XYIj9OiSsI6AuRJYOgsQRbFJAlHa/WgoSMR61nwpCZrYZ8tqCSKsv4NP0VkU9XZdnJO7iM1x1U2Y+uVpEq7EeIu52JlCIZs73URlMiuNR6UoW9VPnuLRFvnU9p45nHEyiFRso9tzkJfphkzY5SG10pw6XWkCrspcJ7JxNKoZdiPGcDs1Ckv2uUhpYKhvvjyIoyqbpFmjbBaZpCVV2EzsMDNM+vJp8zGeiOce0dTo7dopVz+Om3nuOFx/dRXh0qGRV1zeUM9Mb4s0/ei6Yr2JYNkkTnkYFZn/LK2jBlVUH+z1/eQSDsQdhOEr40UUAgTZyv6W8SWZYpFIqzlh4vrq7kv7fsoH0kRm0owMZjHbREwwTGKz22dvXwO7klmJbN3r4B3r/hpJfHo2v0J1MlL7quKHSNxakJ+llWU81IJkP7yCgbmh1vjhCi9M/mZJHD6bCusY4Htu/Gb+iE3G6S+bwTltRUaoMBNnd2UeHzsaevn1hm9pCKJPvHeU+m59idD/7XGxwhr5u7Vi9AAI1lId62YRkDY6mSB2NRQ9WUh/X2VfM53j+CPkPSqATcu3YxObOIpsgsb66hLOAlkclRHvBy3eJmfC4DSYKbljpEXW+/Zjldw2OoikJTRWScZ8GBEIJVzeMWt4B18xqoiQRI5wr4XQbxTI6rFzaVbvS7rlhA+8Aoti3wuS6NnoUqK44Y2Qyzee6U5CJJkqeQ8ExQAUc9V6HJgWmsiJIkT10Rlrj4ldL3p97SyiyqhIoszTrRLyur5gtX3/mKGAISElH3q1e5k4xn2frSMdZfNw/DOHNlgWXZHNrfy/xFtbNWbv22QJbcVHhupyf5fUKutXi1NsZym0gVDuDW6kttagPv5vjo53GpjUTcVzlaFeYJFMlFxHMNQgjyVh+mFSNdOIjAIl04CDj8HIZSc1aGgCJ5KffcSn/qZwSN1Xi0Jkazz5E2j+DVW8fb+KgJvJOO2JdwqXWEXGvHx9OBKvsJu68aH08vpjVGpnAYgUWqcABbFNCUMIZSPW08VtHmxSf30XG4n9hQkkd+uJnGtiqWrW05+VCO7zN5V0WReewnW9m3rYOj+3q47q5l+ALjz8MMhyzJEve+dwPf/rdHOXagl9hwkprGKPOXOzwS3oCLxavn8OB3nuf3PnwbsuIsVtZdv4Adm47yb3/9I8JlfhKxNG/5P9ee8jvSlI8NcytYsb6VL3z8x1Q3REknsqy9fgEbblsyfWV/ylgXXzGHhx94ic7DA7QurmX9zYumbG8Ih/i9tav4zBPPOhVTus6HrluPIst4DZ2maJi/e/hJ4tkcK+qquaKhtlQhcseCNj775Eb29g2wrKaKP9mwlg3NjTx5+Bh/8eCv8Rs6S2ur0Mc9ys8cbec3B4+wf2CI/mSKlzt7+P11K1EkGb+hl66HIsn4dAMJievmNtEZG+Ovf/UYsiShKjIfvX4D8yrKeP+GtXzh6Rd44tAx6sNB2iqiswpQKkoDeWuAXOoryGoTEwyxqr4GWTn3QgZJXCxZudcYEokEwWCQeDxOIHD+aqQTmOk0zabMdybFvokb70zfXejvnK7dbC/Ag7FB3vTr78+YH/Ge+Sv51NqbXhOJjRmzwBt//V2OjE0vjV1RXsMPbns7hnJ29nTSTJK2MlS5pieHvdrYNdzHfY/cP2MlzFeuu4fbGtr45U9e5sbbljAWSxMKe0kmsqRTeUaGkqiqTHVdhIHeMfJ5k4VL6vnFj7bQMq+K1vnVyLLEof29NM2tIJnIEY+lkRWZ+YtqObC3G11XWbKiYdYqq8kQQvCZrc/w9X1bpm2r8vj5zRt/n+A5UpZPwLQsfn74APFcjpDLxd1tC0ov5AtB0U7SHvs3RjLPIEsaPn0hIdcakoW9tEY/jSxp2MJkIPVzepP3j+dSSGhKiPrgH1HhvRMhbNrHvkAitx0bEyEsJElBRsNvLKE5/JdnTUluWnGOxz5PLPs8sqTjN5YQMJaRLhylNfoPSJITAupP/pTe5AMU7TFARlNCNAbfT5n3FoSwOB77HMn8nknjUZFRCRgraQp/uOQZmYBt2ezf0Uk2nS+tZf0hD62L6ji6v4emtiqGBxNomoLX76a3c5i65nL+9ve+yf/56zsx80U8foM5bVWoqoIQgmP7eymrChKKTs3BEkIwNpyi8+gAHp+LOW2VaLpaegeOjaRoP9TPwhWNuDx6aZ9CvkjnkQGS8QzRigB1TeXksgX6u0Zpnl/N0f09NLZWMTqYYGAoweJlDUhAd/swwwNxfAE3jXMrcXl0Nj17kEze5MabnYTco/t6qKgNEww7oduiadF+qI/kWIaaOWVU1obp64/j97nwj3twnPJSk3yxiN8w6O8fY2goydx5VbgNjXyxSNGyCbiMKeWnE2Wp2UIRj6FhyAoDgwki5T7SBROvfjJ3z6VppRLWyQi6XMiyRDKXHw+VSBQti2S+UPpsC0EqX6BgFXFrGh5NK53jrGmSNYsEXAaZgonP0GcskS2ah8hnHsDhsD+ZV+TyvhdFdYjOzmWu/V/v4bgYEEIwFE/z8JaDdA6O4jF07r1qMXNrysjkCzy69RD7OweoCPm4+8pFVIacB+zBTXtpqY6y81gvnQMxNixu4vplLRQtmxf2tbNpfycuXeX2K+Yzr66cTL7AA8/spK22nE37O9BVlXuvWsycyjBFy+aJHUfYeawXWwhWt9Vx4/JWVEWmezjOiwc6qSsL8syuY/g9Bu+95Qr2dfTTO5rg3vWLkSSJTN7km7/ZwjuvX0E0MF3hFCCguTAUdUaDYyCTwkagvAa4RlVZIWx4gOkGRyyXpWBZZzQ4bGFzPNVOX24AQzHQJI2uTDc1bmcF6JZdCAR5u0CZ8cqUJZ8rZNlZvYCzSt2zo5ORoRShiIeR4RQIGB5KMjqcYsmKBrZvOU6xaFFdG2bLC0fI54usu7qVF54+iKLKFE0Ll0cnUuYjlzXZ+uJRmlsr8QdeXZlx07b46rYtHB+LMTcc4baWtoticCiSj7mRT9AQfD9goSlRJFSqsZnIxJcljSrfWyj33k7RTgASqhxAKeVLSDSFPoiYwS0ojYtdnS1UOUBr9JOY1ggg0JQIEipOMqjTT3vHGMHgXSyvfgNFOw7IaHIQedxLuO9gP/HEm1iz6sMoytTflk5Z25tFi1zWxO93MX95A109MeY0RKcsKuYtdbw9NQ0nn4G5i2rJ50wE4PO7qF8+NYFdkqST+RKnnhNJIlzuJ1w+nZxPkiTCZX68ATeWZVMoOJN2Pm8ibEFDWyWpVA5ZkjAti00vH2fp4jpMy6a8PkIynSdSGSAnROkYXEEXcysDSBJoLpVkKsfyK5p45PE9ACSTOfzlfnwBN4lkllzOJBj00LrY4dMRQjAaS7PvQA+NDVEMo4yiZaPIEtlEHlWTMaUiTz1zgPVr5yJboCAhCjYKMDycwu93oWkKIyMpvF6DoaEE/YMJli+pJ1nIIcsSLlXFzBVJxXOEgm4SyRwJK0tZ1I9XnzmsPDnhU1WUKZ9lSSLgMoCp3nBp3CPjGe8z6J79OVLUNjyBf5h1+7nissFxFkjnCnzq+4/RUl3GbavnE0/ncOkqti349m9eZiie5p71i9jXOcA/P/Ak//R7t+Nz6ew+3seTO45wxxULaKstx+9xLvzTu47y4At7+d2bVxNP5/jcj57h7955EyGvi1++uI/VbfW8Ye1CXj7cxb/99Fm+8EdvACBvFrlpRSuFosWXf/k81ZEAS5uqiaez/M9TO7h5VRs3rmglky+gKQqVYT9f/fWL3LB8LkGPi70d/RzuGsLnnj0c49cNgoZrRhrvE8kxCpaFW331cxY0WabWO7M1PVbIMpbPzsoOOoGR/CjH0x0EtAC2sJAkCU3WeHFkM6vDKzmWakdCos5TcykO4aKgWLQoFIrk80VqG6K8uPEQwZAHf8CNVbQROKyJQoiSlyIU8VJeEXDi2eNxbAHouorX50LTFQ7v70XTVQyXdp58K68POJOSiqGeWvElT2t3MgF65j4uhhk+QVftVJxMHU+xaPHiy8fpODHMovk1ZDJ+CgWNYMDNvoNdREJe6mrDPPnsAdZf0cLx9hg11SHaO4awBYyMpKipDhGNeNm9r5u5zRUMDiXZf7CXO25ZQjZn0j8Qp7E+ys49J4iNZViysJade7qQJYl1a5rxeoxJY4VIuQ9Fu3DD71SkM3m27+gkEHSDgIOH+7BtQWNDlKHhJLYt2HBlK+0dQ7Q0lZPJFNi6vZ0VyxrxeHRe3HyUyvIV7NrbTT5v0tRYxq49XVx/7QI2Pn+Im29YhDzu5TnRPcre/d0sW1zPth2dLFxQg9ulY+jO9Dg0nOS5Fw6TSuVxGRrxeJbYWJrGhjK2bD3OyuWN1FaHyeVMFFXmxS1HWbO6mac3HiSXM6mtDjGWyOLzGhi6StOcMgaHkgwMJDDnW6TTebbu6OTm6xfy2JP7CPhduN06R48NEgl7Wbm8kfq66YUErxRsuxfLPAJMLEIlVH0lknTuY7pscJwFDnQNks0X+ZO7rsSlnzxliUyOF/Z38M+/dzuNFREWNlbxwr4O9nX0s3Z+g5Oj0VrHHWvml/axbcEjLx/kzRuWsGaes3LY19nP07uOcu/6xaiyzDuuX0FLdZSqiJ8ndx4lVyji9xjctKKVrqExkpk8AY+L/tEkS5sc/QBDU3j3DStLRg1AfXmImmiArYe6uGF5K0/uOMINy+fOmJ8yAbeqUecL0pGITdvWm04wkEkxJxC+4HN6MTA/PLMYVapQoDM5Rp0veNrwT87O4Vd9lBtlDOWH2B7bSUgLkrcLVLjK2TnmrIBWhZdfiuFfFIwOpwgEPfScGCEc9hKO+pg7r4pA0EOkzFlBppI5hvoTJOIZVl/ZQl9PDMOlsXBpPaGwh0P7e7nq2nkO98I4uZZuqLQfHWTZqqbfatbJ1xJGY2kK+SL1NRG8HoO9+3sAWL+2hVgsTTTiIxT00DKnnEULa3l5ewfhkIeOEyNIksTK5Q1s33mCjhMyq1bMIRr2Issylm1TXuYnlzPZe6CHXM6kq2eURfMdYyOdydNQF6GvP87c5pOGmaarfPRzb0M3Lv40Egx4yGQLjMbSLF/agGlazG2uQNNVFrRV0z+YQNdVysr8VFUGGRiM0zSnnLktTrK9x61TLNqMjWVYvLCWsqiPYtEmkciSzZoULRvLssjlTfYf6MHQHc+Hx6OzdHEd6qR3ZDqdJxLx4fUa1NaG2ba9A1VVaKyPkkhkOXS4n3mt1VRWBGmoi3Ls+CCJRJZkMkfA72LFsgYee2o/8USWq9bNJRjwkM8XsSwbr9dAkp0wRy5vYugqdTURjrUPMqexjHDYSzqTv+jn92xhW92kxv4CRWkE6WQysKI2g3zZ4LgkGEtlCfvd6KcIGuUKRSeB0+0kiqqKjM9tEEud9A5UhvxTy8Jsi2QmT8TvKcXTon4PA2MOuZWmKQS9TgxuIpFHIOgYiPH5Hz9DS02U6rCfTN6csvL0e1y4jKnEUYoMt18xn1+9tJ8lTdUc7hni929dc9pJWJEkFkcqeb63Y9q2ZCHPjqFeGl8jarFLyqrQZBnzFN6QorDZMtDFVdWNp92/wqjgYOIw8eRRGrz1CAGpYooyI4oiKZQZESxho1yA3PmlRkVVkJvuWIoQgs7jQ8iyRGNzBdqkVWcqmSMxlmHthlYkSSqFR+bOcyS4yipm9hRV1bw2DMvLcOBx64wlMs7k21KBJIHXa6DrKlVVQQ4d6WPhvGqnhFWWCAXd7NrbRSKZo7IigM/ruPWjER/79vfQ1lqJ16MzMJhgLJ5hLJ5leDhJJltAkiSOHBugujLI6JiM2zXdpS9J0nlpjZwNZFli2ZJ6EsksTXPKiCeymGaRupowuq7idut4PToL5lVz+Gg/9XVRjPH33+BQEk1T6DgxwtrVTeze100ub7J0cR3Hjg/S1lrFiRMjuFw6w8MpmuaUYxYtamvC+LyuaflKdbURevvjKIpENOIlFPJQWRGgYBbJZAq0zq1EliXmtVUhyxJLF9dz8HAf89qqCPhc6LrK/LZqyqJe9h/opWlOGVWVQbq6RxkZTTM4lEDXFEzToqE+ykgsxdormkmn87hcOuqr6FG2ikfQjA24fR/kcpXKK4TKsJ+BWJJkJk/I5y5N9D63gUvX6B9NEvV7yOZNhhNpaqKTXuCnXCNVUaiJBmgfGGV5i1Pm2j4QY0F9RWmHmco5n9/XTnXEz4fuvYaibbNxb/uU7TPVU0uSxIqWWr73xHZ+tXk/TVURKkIz525MxprKOr6x7+VpPBc2goc7DnJX03y0V3kSliSJeeFyKj1+ulPxaduf7j7OHy9ei1eb/YWoyxo3Vl7n9MdJ405CIlaIMWbGWRe54jVhXJ0NGprKaWgqnzZer89g7VWtr9KoLuNiwes1uPXGxU55p3BItxYvqMUwVOa3VrF8Sb3DZbG+DV1XWbyglmR9FE1TUGQZXVe4doOzLZnI4XJpGIbK9VfPx+XSUFWFO29dis9ncPP1C8nni/i8BqZpObkgr/Bj0FB/Mmdk9co5U7ZVjhvJC+dPD3dWVgS487aTbLHXXX3Swzy35WSoav48xzs8OVxRO4ORrWkKV61z5Or7B+Lk8ybzWqswDI1rr55XajcxlqrKIFWVU2kLFi2oGR/bye+v2TCvNN4li+pK+5YwswP3FYEQNmAjK1WIfBwh0khTOGcuM41eMsyrK6e1tpxPfu8xlrXUkMzkWb9oDqvm1vLWa5bynw9t4qqFczjSO8ycyjDz62dnAJUkuO/aZfzHg88RT+dIZvIMjqX40zesP+0YGivCPLbtMD/ftJeu4TFiycxZjd3r0rlq0RweeHoHf/+um884eUqSxJKyaqo8PnrSiWnbX+w/wd6RAZaXTS+te6URNtxcVd3ID4/snrbtUGyIzf1dXF/XPOs4nXj51G0Tn92qh/XRtfjU8xMpeqUxmftlpm2vgTzfi4ZXgl/ltQhJkvB5nZBpoVBk/doWggFHzCs8aSHhHg+BKYpEKDi1ZHvCUxEKnfw+OO7xMnQVv+9kFZHLmOjn1c/Zeq2gotzP7bcs/V9fUm7mnyaXeQCwscxDmIVtyEoFICMh4fZ/BFWbf6ZupuGywXEGCCFQZZmPveVadrf30TU0Rk0kQEt1BEmSuHXVPJoqIxzoGuDqBU0srC0v5UjcsWYBleGpE5YkSSxsqOTv33kzO471UBsN8K4bVxL2ucmbFr9/yxV4x92Ufo/B799yBS5dY/3CObgNjcOdg1yzuJlbVrbhHX95VEcCvP36FTM+BJIksay5mse3H2Zp09kZCVGXh+vqmrn/0M5p21JmgS/t2sSXr70bz2m8B68EZEninuaF/Pz4fvLWVI6Qgm3x1b2buaKy7ozJozPBrbhA+e2V534tw1FPhoJVZO/QINv6euhPpdAVhdZIGetq66j2+c/qXp9Q/Nw12M++oUGGM2kUWaYxEGJldQ1zwxFUWZ61r4F0il0D/RiKwpV1DWiyTDyfZ1tfD/uGBonlsrhUjaZQmNXVNTQGQ2dU6JwY13A2w47+Pg4MDxHP5XCpKs3hMKuqa2kIBEvGxqVCrljkxe4TyJLElXUNmJbFY+1H2Tc0SK0/wG0trVR5nfdbZ3yMR44dYTSbYX60nJuaWggYxrTxTXiHk4UCR2MjHBgeojuRIFs0cakqVV4/C8vLWVhWgVc7vbaQZdts6e0mUcgzP1pOQ8DxDiQKebb19bJ3aICxXA63qtIYDLOkopK54QjaDNVNGdPkpZ4uLNtmdU0tYZfjyR5Ip9nS283h0WEypknAMJgbjrKkopL6QHBW/gohBLlikf3Dg+wa6KcvlUQAVV4fy6uqWVRWgUudqv0jhODw6DAdY2N4NZ21dXXTxDJ3D/bTn0qBBIvLK6n1Tw2HxnJZtvY6uT1X1NQScp1fdZmqLcfjm4UmQAJFqT+/fs9rr98SFPImzzy6F8u2nYfuuvm40zZVtWHCPmeF8NIzB7niqlZGjoywcF4Vj/9yB29+z3psWzAnEKCiIjhjln9dWXAaW6ihKdyyylECFELg1rXSZ4DVrXWMHRphXlUZHt/JSTQa8HLD8rnTfsOybYqWzTO7j3Pj8taSgXImSMBb5y7h58f3zyjL/mzPcb61fyvvW7LunNQ5LwVWlNeytrKejb3t07ZtHezmG/u28IFl60v0v5fx+oeuKAyl03xh8yaeaD9KdhIhnQRU+fy8f9Ua3rZwyYyTywRMy+KRY4f5z21bOBobdYS3JsGn69wwp5kPrVlPY3DmvKWd/X28/9Ff4dN0fn7fO+lJJvjMC89yaGQY65TnPuJy887Fy3jfqjV4tJkTccW4+vAP9+/hWzu30Z1MTJMaCLtcvLFtAX+2eh0R96UzOsZyWf7yyd9g2hY/fvPb+a8dW/npwX2l4/rZwX189fY3MprL8ue/eYjO+BjgLASubWjiP265ncApvCvD2Qzf272TR48f4UR8bEZ+GV1RWFhWzseuvJora+tnPT7Ttvm/zz/L/uFBPrjmSj5wxZVs6e3mn154lv1DQ9NCwmVuDz9409toCU9PdhzOpPnQ4w+TKhT41l33clV9Iz8/tJ8vvvwS3Yn4lIJnCVhcUcn/3HMfvhnKVW0heLm3m3/fsomd/X3TjtFQFFZV1/LhtVexoqp6itHyQtcJ/vH5ZyjzePjVfe+iyneydLhgWXz6uafZ3t8HwAeuuJIPrrlyCs/SS91d/NlvHsKn6/zire88b4NDVqLIShQhCuPhlFAp51DYQ5MSSM8Nlw2O0+D4kQGCYQ9XbGjj8L4e2o8OcOL4EPPG67PBqRKwLZvYcBKf34XbayAE7Hq5g10vH+e2e1bS2x0jncwxd0E1iViGjmODXLGhlYN7urGKNivXtbB10xGsos3cBdVYlsC2bDLpPD0nRlA1heVXNLH9pWN0d46w/vqzc2Vt3H2cn76wB4+h8bs3rTrr45YkiUXRSm5taOVnx/ZN224JwZd3v4iuKPzuglXosnLBL70J2l55nAb9bGEoCn+yZC3bBrtJn8IdYgvB1/duIaAbvGf+SrSLNM6isOlKxqny+vGolys4Xmnki0X+5unHeamni3KPl0XlFRiKSl8qyYlEnL5Ukn98/hkKlsV7l62ccRVq2hZf2/4yX976EnnLQlcU5oajVHq9FCyLrkScgXSKXx4+yIGhIf7j1jtYEJ2eHzOBtFng54f28z/7djOazVLl9VEXCKJIEr2pJN2JOKO5LF/ZthlFlvnzK9bNOK68ZfHZTRu5f6+j+unXdeYEwwRdLlKFAh3xGLFcjv/evYNjsVG+cPMdRC+h0SFwqr7+e/cOHm8/xoqqGkayGdrHYuwdGuTrO17maGyURD7H2po6epIJupMJnj3RzmPHj/Lm+VNl3UezWb67ZwfxfB5Nlqn2+ajyOjwTyXyejniMeD7PzoF+Pvz4I3z7DW9ifrTsNMfnmAL9qRQv9XTxwcceZjibIWS4HAZgyTGcYtkcFV4vVb7ThEiF887oSyX5wb7d/PMLz2LaNhVeH0HDhSVsRjIZEoU8bZHojEajEIJHjx3mE888QSyXQ5EkGgJBavwBJCjdC5u6T3B4ZJh/vv5mbmpqYUIleUFZOaosk8jn6U0mpxgcw9kMHeNGHcDuwX4sIVAnnZuDI8PYQlDl9VHuOXO+3plQNPdQyD2Kx/83pZOUTX0Jw/NuVK3ttPvOhMsGx2lQNC10l4YkOQl5jzy4jWDYg3FKGZgtHI7+idCyBDQ0lZHPFaibU8aeHSdYd00bgZCH7o5h8jmT7o5hNF2lkM8x2D+GYWhE6vwc2N1NZU0Is1AkncxR11jG6FCSnVvamb+kDrNw9qJta+c3sKCxkpDXhaGdm3S3Kiu8f8mVvNh3gr5Mctr2nFXk89s3sn90kD9deiXNgchZuYonY2I1dyI1xvO9HRSsIn+8eO2Zd5wESZK4orKet89bzjf3vTyNeilnFfncto0cGRvh/UvWUe8PzeoGPd04i7bNQDbF5v4uHuk8xP7RAR649e00vkZKhH+bcGR0lHY5xu8vX8XvL1tJucfrENuZBX599DCf3bSRRD7Pl7e+xNraehaVT82pEkLw+PFj/H/bNpO3LJpDYf7mqmtZW1uHS3V4R0ayGX64fy9f276FI7ER/ubpx/nmXffOSmNvCcF/btuCrqh87MoNvHneIofxEYlkPs9PDu7jC5tfIFcscv/eXbxp/kLqA8Fp43pg327u37sLy7a5qamFD61dT3PICevYwqYrkeDfN7/Aw0cP83xXJ1/e+hKf2HDdlEnnYsMSgl8cOsBnbriZW5pbGc5k+IOHHuTgyBA/OrCXoOHia3e8keWV1XTGx3j3L35CfzrFs50dvGn+oikZNy3hCPfOW0jRtrmtpZV50TIChgtZkrBsm474GP/0/DM819XJQDrF/Xt38elrbzxj1s7uwQG29vWgKQqfvvZGrm1oIuxyVuHJQp4Dw0NkTPOsFgiPHDvCnsF+2iJl/MnqNayorMGna1hCEMtm2dHfVzIgJkMIwYGRIT618WliuRwRl5uPrtvArS2tJY2VZCHPE+3H+NyLzzGcyfD3zz5JfSDIvHGjak7Q0WMZzWY5FhtlZXVNqe+joyPEczkaAkEG0imOxUZJ5vOE3Y4XQyA4ODIEQGskinsWL9q5QNijSFMEASVAR9jTaRPOBpcNjtOgqbWS3/x8B7GRFKuvnIuqKcyZOzWuVT+njMd/tROP12B4IMHwQILO40NUVocY6k/Q2zWKz+/CMDSELejvHcNwaeiGSrFok0xkMQyN+FiGsViaBUvr2b2tg3zWpL6pDF/ARS5boDIQYt+OE6SSubM2HDwuHc9ZhlFOhQS0BCP85apr+fimR8mdkiMBjkvz58f3s7G3nRvr5nJrYxsLwxWEXe5xb4KT4CdwMuqLtk26WGA4m+ZofIQdQ71sG+zh6NgwKbPAHXPmTR/IWUCVZf506ZUcGB3khb7OadsLtsUPj+zmmZ7j3NbYxi0NbbSGogR1F6okl5IthXDWS0XbJlMsMJrL0pEYZddIP9sHezgYGyKWy2Ij8Gr6rOJx5wshHK7KifMlECWBp5lg2hamZVGSu5ZOplNe6oTeiTChmDRue9z7M2N7BAWriGlbTh2WdLIe61zHKhBcP6eFj67bgEs9+QoLGC7etnAJsVyWf33xeWK5HA/s282nr71xipGZLBT4yrbN5IpFgoaLz914KyurpuqdVPn8/OnqtVjC5ssvv8TugX5+uH8Pf7Jy9rJyyxa8f+0a/nD56inGd9jt5r1LV7BvaIBfHD7IcCbDzv4+6vyBKX31pZL8146tFG2bZRVVfPaGW04xcGSaQ2E+fe2NHB+LcWB4iJ8f2s/bFy1lXrTsnM7huaIlHOGmphZ0RaHa5+P2llYOjgyRKxa5d14zq6prkSWJplCYZZXV9B8/QmfCIQqcfI0USeLjV12LKsvTDH9VlmmLRPn7q6/nvp/9kFguy/a+XnLF4qwhqAnsHx6kyuvjq3e8kaUVlVPOq1fXqfSeffL3xhMdrKyq4f+77Q1Uer1T+vLrRslQnKZHIwRf3/4yg5k0qizz8auu4U3zF005zrDLzVvmL8KtqnzkiUfpT6f4yrbN/NvNt6NJCmG3mzp/kNFsloMjQ4hJjKk7B/qwhOCmprk83n6UoXSarmS8ZHBkzSLtMccQWFJReVFSq2WlBivzQ4Q9AnIIYY9gFY8hK+d3v102OE4Dj9fg7t9Z43g6DI0737waWZmaQLb8iiYWLK1D01Vsy+bt/+caVFVG01XueqvTvrImVMr0fsNbr0AIR9bZKlosX9OErqvUNEQRtkDTFRqaykCSxpPjJJpaK5FlmdaFNQ6V9SVg9psJkiTxhqb5dKfifHHXJkx75slvNJflx0f38LNjzmqn0u2nwuPFpxkokoRp26TMPKO5LLG88y9XLM5IBX2+COkuPrP+Nv7s2V+we7h/xjYDmRT/fWA7/3NoJxGXhyqPnzK3F4/qaBcULIukmWcsn2Ms77CVZq3itBj6hWAkl+F4fIRM0SRlFkgW8s4/M0/KLJAqOP8nzTxps0Asn53V6Pjctmf59v6teDUdn6bj04zS337dwK8Z+HQDn6bjUTWiLg+tobKz9vAIITgaH2E4myZTNEma42MtFEiZ42MuFJxxj493phJlgJFshnc9/iP8mj4+RmN8zM7ffn3ifwOvquPRNOb4w5S7vdNe7Iok8eb5izBmyM+QJYl72hbwnV07GMqkeaGrk0Q+T8h1Uv9iR38vh0aGAbipqZnllTMnU6uyzDsWLeUnB/bSl0rxi0MHeffi5fiNmZOQa/x+3rpg8YyePlWWub6xmV8ePujw6sSnrhCFEDzd2U5fKokEvGPxUiIzxN8lSSLscnNbS6uTTJrP83xXJ22R6CU1MlsjUfRxqQBJkmgJR0oT2sqqmtLfsiSVwhapQmGawSFJ0mkp6SVJoiEYpDkUZlt/ltFclrx1ZoMD4N1Llk8zNib3e7bQFYW/WHPlNGPjTH31JBNsPOEseBaUlXN7S9uMz5okSdzU1MLyymq29Haz8UQHJ+JxWsIRDEVhfrSM3YP9HBkdwRI2qqRgCcHOgX5kSWJNTS3HYiN0JeLsHxpiaYXDpzOczTCYSaFIMgvLKi7K/aCobSjaIpKxP0SS/Ag7ge66BVk5PcfRbPitNziEEFgiixAmiuxG4mRmtCRJqKpSYp2TZ0g8zNm9WEoSQ25DUVS0SUyk+inqnUIIVE0qCTnJsiBvDQJVU4iaTt1vAq8G46Miyfzx4jUAfGX3i2Rn8HRMwBKC0Zzzkjhwfh6384YkSdT7gnzxmrv5qxceYctA16zmjGnbDGRSDGRSr+gYAZ7sOsonXnwM07Yv2ODqSSdmLF0+FRIgSzLLy6v5n1t/56xF7Swh+MeXn2JTbyeWsC9otEVhcyg2dFZtJSRUWeKvVl3HHyxcPW27V9dLLuiZUO7x0hqJMpRJM5BO0ZdKlgwOgJd7eyjaNhJwTcOc0xpg5R4vSyqq6Esd5URijM74GIsrZs7eX1JRNaORAM79WT4+gQkhSBWmJmPbQvBi9wkE4NE0VlQ5HBGz0cq3hqNIOB6m/cODs47/YqHc452yYvbqesmjVuXzTXlnThgYRds+o7E+0/E5qqeOZ7YUrj4DPKrG9XNmL4E/F9T6AyyvrDqnvoQQ7BsaJJ53pN7X1daf1kgyFJWr6hqcKpt8np0DfaVk1kXlFXAATiTi45UxCol8jiOjw3g1jbmRKIvKK3j2RAe7Bvp420JHK+tEfIxUoUDAMJgTulihXhW37wMY7rcg7BiSHEFWqjkXfaCpvV0GnfH/RJUDmFaMxuAfoyknY6uOu9hRXJQlA5CwRR5JUhxRJSHoTf6EuZGPgdARWAhRHG8LgmLpc9GOE8ttJuq+FllyUbRTpAqHMdxV2KII2AhhI0vTy8nOBxMP84X05eiLKPzJknU0+kN8bvuzdKfOPMm9GpAkiUZ/iK9c90a+sPN5fnp074yhoFcTlrAxbeuih2NOBzHxu5bFuTlrBKZlzRomuVQQCExbTKsymIBP10+rOqvIcsntXbAsBtIpFpSVj/cNx8dGAdAUZdbqkwnI46t5gHzROq3B0Rg8fX6QMinkdeplMG2b9jHHSjcti09tfBpDnf31PJLJlPqIZbMlhddLBa8+tURVnmRgnDqxnlIIO60vIQSmbdGVSHBoZIiO+BgjmQxp0yRXLJIrmuwdOjcjym/oVHgvPEkSoNrnO6+S/46xGLYQTjg6dHrab0mSmBtxiM0EcHR0pBQ+WVBWgSbLjGQyDGUyBAwXHfExhjIZ6vwBKrxeFpdXIksS+4YHyVtFDEUtVUbV+AOUzZJrdK5wrrmCotYD51cKOxmXDQ4AZGr8b6Mv+RPyVv8Ug8O0Y/Qk7kdVApR7biZf7GcsvxVbmNT6fwdDrUKRnYtriRQ9yR8ihIXfWIhHa6Y/9XNU2Ue552bGctsYzjyBQFDuuYl4fjupwkGi7qsZzjxFqnAQgUW552YCxuILOiIhBD84upNlZTUsDF+Y7LojXCXxhqYFLC2r5qt7NvNw50EShYvH8a9IMiHjwhVJJUki4vLwyTU3cV1tM1/Z8xJ7hvsv2qQpSxJVHj+3N7YRdV2ch/oyzg0uxaHung0STFkhpyd5E2whSvetJitnnlgkqWTcCATxfG5KXH0y/OOr/vNBwSqSNp0qK9O2eaH7xFnvawnhLC4uYUhltvJ3CceQOltYts3zXZ18c9c2dvb3kzYLJS+IPCkXybLP7XnVFRVVujgl+m5VOy/jbWzcuyFJ0owcJKfCr+sokuQko+ZOymE0BIMEXS5i2SwdYzGaQ2F2DwxQsCzmRqJ4VI3W8SqZ7kS8ZIgcGHY8iG2RstMaq68mXpujeoVRtBP0JO4HZNzqVCtOQkYgMJRKVDnIifS30ZUyTCtGxuwkYCwttU3m95Mxj+HRmonndpAv9hNxbyCgO21CrtUUrCEqvbcDEHStIllwyk4tO0XEvR5ZcpEuHL5wgwN4uvcYYcN9wQbHBCRJYk4gzP+98hbePX8FDx7fx1Ndx+hOxSnMkt9xOmiyQoXby6qKWm5vnMf6M2ifnMs4NUXhpvq5rKtq4Nme4/zs2D62D/WSyOc41+CALitUeHysKK/hxroWrqxupNztPedqF3DCBYosvyoKrOdaRcT4WM9lQrmYkC/Wml069eM59HsO1+lCPIlCnPRIejWN21pazzr01XqJ8zccXHj/thDcv3cXn3vxOdKmia4oLKusYmVVDU2hMCHDhUfT0BSFz734HHsGBy7CuF85XMgZmnyXhQwXDYEgw5kMR2OjXD+nmZ0DvQAsr6waz5PxU+31c3xslGOxUco9Xo7FHM/dxUoYvRS4bHAAquyj2vdmdCXKqbEpWTKo9t3LcPZp4rltGGoFQWM5ulKOoVRgiyy2KGDZWVTZj0drosJzO5KkksjvJlfsxa3Wokg+JBSKdhrTSqDKPmzb2dcWOUelU/LAeFXHxYRT1pnApogiuVDlC3M9qrLMwkgFCyMV/PnS9RweG2bnUA+7R47Rl7YYy+dJFwuYlo0kOd4Ll6ri03QihocGf4jWUJSFkUqagxFChuuc+Tdmgy2K2CKPIjnieH7d4M4587m1sY3edIJdQ33sGu7jyNgIQ9k0STNP3ioihHNcblXFpxmEDJs6n5v54RqWRFuYE3BeiNI5jnPi3KuyD0lyjKB5s6jcnn2fNpbIjF/Hsx+LR9VOm7B3KhRJ4pNrbiQ5A/nbK4Ea78yicrli8bQrYAEk844XQ5akKXo6yvjqE5wqn5mI7U7FWG585YpTCXMpJnddUUpljG5N4y+vvPqi8Ci8lnBkdIT/2LKJtGkSdrn49LU3cWNTM65Jyajg5H4EzoMd+NXGBMmWEKf3hE0gWciXSNTCk3J/dEVhXrSc7f19HBkdJls0OTw6girLpQRRj6Yxr6yMI7ER9g4OsKisgt5UEk2WnfDhq7RIOBMuGxxA2LUWVQmWkjknwxZ5YrnNqHKAgLEMv7GE0exGcsU+yjzXE89tx1DKGctvI+LagGmPEcu9SMBYTtR9DSPZZxjOPEuZ5zp0JYJPbyOWe4moewPx/HY0OUQivxuv1oo+Xmrk08+uPPTsV8k2PamfM5R5hrBrNXPDf3q2p2ZWTDxIQcPFFZV1LC8Psmvgv5gf/b8ghaYkjDkhGRlVltEVpbRyPd8XtxAWBSuGrkxf2SXy++hPP8K8yMeYEBiSJAlNUmj0h2nwhXhD0wJsIchbRUzbLuUKTIxTk2WGs48ymH4UVfGxpOyz5z1WmwJ7h/+WeZG/xKM1UOb2Uua+sIkkbXbSPvZdFkT/DkW+NC/momVRMC1agtHxzzaqMjvFtxCCXKGIqsho6tkbNUIIh8l3hjLJ2ZAsFIjlcrOyKFq2TVfCqZbRFaVEvz2B1rBzTKbl5GQsq5g9QdAWopTzoStKiT77YmOi70MjwyTzefpSKSrOoZTztQ4hBBtPdBAbN97uW7iEO+bOXMVh2XYpvPS6wXiujyxJ2EJwLHb6rHmHV2O09LklHJlyDy4ud7wUJ+Jx+lMp+pJO4nOpnRAsq6jioSOH2Ds0yLXpJMlCnqDhcvKSLtVxXiB+6w0OSZKIuDfMul1TQtT43zLluyrfG0t/Rz3XEuXa0ueIe6oIW4X3tlM+3zrp79tn/E1DnV38bQJCCP770DZ2jfTOvB3YM9rPm5oWAzKNgXcjSzrZYs8Z+z4vCEFRJFFlCZd6aVcn2WIfJxLfZ17kLzl1hR8wFuLVmpgti3rioVYkCY88c/xeCEGt7y5caoSuxA8vbLBCYNpJBBcv8dKj1jEv8jFk6cK1bIQQDMVSlId9U154yUyeXz67l7ffuhJNVejsG6W5tmzWhdPwWJonthzmulUtVJedflIWQjA0lqYs6EWSoG84QVnIh3uW6qxTkTYLHBgeYs4sCZ9DmTRHYyMAVHp9U9gaAdbW1qFvVyhYFhtPdHDX3Hmzho2GMpmSa78uEKQxFDqrMZ4rJvRKHm8/Rt6yeLrj+Kwlnq9X9CadZHOJ07v9hzLpksH4eoGEU10SdXsYyqTZ3NNFxjTxzkB9Dg6j7KbxPB2/rrNs3HMBzjtqflkZmqLQn045Rmghz8qqGiLjyaCSJLGkohJNlkthlXyxyPxo2ayVUq8F/NYbHK9nRF0e6nyzv9zrfUtoCUx4AaYro6YKxxnOPk9j4J1IkoJpJehMfJ86/5sYzDyFLQookhdV9pIyj9IYeA+5Yh/JwiEskSFtdlDm3kDZJINtNPsiicJ+NDlIrf8tGEo5giKDmaeJ5baiy2FqfHfjUh0GPdOO0Zd+hHThGKrso87/FiRJpS/1MHOCv4ssaVh2lo74d6gPvI1Efj89qZ+TKOzHHjHRlTBNwT9ElnT6048Sy23FozXSGHgXE8aILYqMZDcxkn0RgUnEtZYKz41IsySZlUr8ZjBaLDtLf/pREoX9uJRqavxvRJcjDGWfBaDCcx1C2JxI3E+ZZwMupbq0rxAWfemHkdGo9N6CLQoMZB4nnt+NoVRS63sjuhKhO/kTJEmlYI0QMBYzknmeusB9eLU5DGeeZyj7LJocojn0x06lFI4R1p/6NdliL4ZaQa3vHlSpnGe3HUNRZBqrwiiKTCZXwG1o7G/vJxr0UlcR4nsPb+WGK1qpjgbYebiH2oogy9pq8bgccrOB0SSHTwzRVBvlSNcwhzsHWdRSzZxqJxO/aFls2t1OPJUlX7DYe6yPoM/FSDxD10AMWZLZsLyJrQe6kJCYP6eC+x/dxvqlTSxrrWHn4R6uXTmX0XiaHYec38/mTcaSWarLAixvq51yDWwh+PGBvVzX2DStQsIWgl8cPsBwxlFTvqq+sRRCmbi2SyuqWFJRyba+Xp5sP87Ogb5pxF/Otbb54f7d9Kccpt075rZdMle/JEnc3NTCN3ZspS+V5IF9u7lhTrMzMZ/Gq2TaNtppxOVeS5hI0BXAWDY3Y5uibfPAvt2MZs9ODfu1hCqvj5uaWnhg324OjAzx8LHDvPkU4i9wrttTHc59B04J7allrPX+IGGXm0Q+z8u93VhCsLSiCm1SHtacUJiwy81QOs2O/j4EMD9aflr9oFcbl3WHX6eQJIm7Ghfw4aXXnPbf3ODsjHCGEmUw8xSZYjdCCEZzL5Mx25GQ6Un+DJdaTXfyR+SsfvLFIUayL5Kz+jk+9jUMpZxyz7UcH/sqicJeAEwrQaJwgCrvHZh2nPb4NwBBb+qX9Kcfocp7G4Zawf6Rf3RySkSBAyP/RNbspsp7G0FjCbJkoMkhRnObSRWOjMdD9xLP70GRvfj0ViKuNXjURhoCb6fGdzey5Ew6UfeVhFzLiOW2lo5RCEF/+hE64t8m4l5DhedGNDnE+aR4CWHTkfhvUuYxanxvQGBxePTzCIqkCkdIFQ5PtGQ0t5mCNTJxtRDCoiv5I2K5bUTc6wCJruQDxPN7qPa9AVlSOTj6WSyRYyD9OEIUied3M5h+Ak0J05N8ECEEQdcyytzXMJrbjOBkoq5t53Cp1dT678WyMxwf+7qjhJrJIcsSIb+bHYe62XO0D7ehkczkURWZspCXOTURlrfV8vL+E6xd3MihzkEK5sm+K8J+Eukcti3Yur+La1a0UF8RKm1XZJn5cyodI8Wt0zMUZzSRoXtgDFVR8HsMdh7uwbJsrl7RTEXET2NVmNUL6vG6dXRNJVcosmXfyd8/3jPCyvl1HOqcXh4pAc93dfIvmzbSk0xQtG0s2yZVKPDTg/v42naH4j7kcvH2RUumvfA9msafr16HT9eJ53P81VOP8eyJDtJmwRE8tG2GM2m+vmMrX9+xFQG0RaK8Y9HSSzqx1/oDvG/lFWiyzGAmzZ/95iF+fGAffakkGdMkXyySKhQYSKd4ubebL738Ev/w7JOY51jR8WpAkiSWVlaWPEk/Pri3JEw3EVYbyqT58ssv8e1d21EuUsXJKwlZkvjDFauoDwQp2jaffWEjPz6wl7FcDmv8Hk3k8/zy8EE+/dxT5C2LiMvNn6xaO8WQAAi6XDQEg2TMApu6u5CA5VVTCerCLjdzQmGShTybe7sBx3N0PsnsrxQuezguEc6WA8Oy0xTtBIZajW3nMO0YunJ2pDMX+vJT5QBl7vUMpB9nTvC9DKR/Q5X3NiRJGd92FQPpx4i41qJILkx7FEWuwafPpcJzAyATc21lNLsFj38OimxQH3g7Xq0Rgc3xsa9hC5OB9OM0BX+fkLGCoLGUwcxTJAr7MZRKssUeFpZ9ElX2TUnVrvTcRF/6Efz6PAYyv6HCexMyOi61EpdajSr78GrNU7wUuhLCUCqmeHIEFgPp3zAn+F7K3NcwHv48r3NniSyD6ScIGssYymzEtJOM5Xdj2qfnJZGQ6Uk9SL44yMKyv0eRvNgiT3/6Mfx6G8OZjRTtNIn8PgpWDElSibqvJG+N4FZr8Gj19KZ+CQg02Y9brWaywSSEwFArUIsnGMvtomhnyBZ7sIVNWdBLe+8Iy9tqEULgMlRcukZZ0MvBjkEWtzgvsUOdg9SUB3l5/wlcukYskWZgNMmJvhget85gLEXPYJyykJfNezuZN6eC+kpnVSZJEpqqoGsKHpfGcCzFcCxFWchL0OdGUWQMTWXf8T62Hehixbw6DN353FxXRu9QnJDPTXVZoPT7iiLjdem49OmvqBvmNJPI5/neHkd1tDkUwaU64m3HY6OYto2uKPzpqrUsKJsenpQkiQ31jXxs3Qb+5cXnOBYb5X0P/4KmUJgqnx/TsuiIj9GXSmILQZ0/wD9dd/M50WOfDyRJ4m2LljCYSfNfO7bSlYjz8acfI+J2U+72osoyuWKRWC5LPJ/HtC2WVVa9KhVP54MraxtYWVXDy3097Bro5x0P/ogVVTUEDYPhbIZ9Q4P0JBMsq6hiWWUV39m949Ue8jlhQgvl/153Ex978lEG02n+9unH+dr2l0s09j3JBJ3xsVJi7N9uuJZlM5CMabLMgmg5L/f2OIRfus6CsrJpbRaXV7Clt5vDI8OlZNPXMi4bHBcBMz3wRTtGrtiNT19y2n2zxS4SuS1U+9+NJXLkit3oStW0ficYCifjQg0OSZKo8t7G/uFPUeZeT87qJ+xajaA4nkArI6EgozK5esbxKDi/LcsGliiMf2+gSE78UEJhXGnDCc3I44qWQkaWdCyRxxZ5ZDRkdMdImHQ45Z7r2TP0V6QKR0jkD9IU/MPzPF6BJfLjVSITyarndboQwkIgCBqLMRTnwa703OAYS6U2AoHAFieT3iyRoWCNkrcGyVvDeFTvOEGcRUBfPG5AQLnnWjQlOF4JoyJJ8qRzfbpJxebw6BeQJY0K702osodssRtNUVjaWsvK+XXI4273lfPq8Xp0Vs6vx6WraKrC3VcvomjZeFyO58Nt6Fi2zdtvXYmuOZwX77xtFS5dpb4y5LQ5hfW2oSpMXUUITZW557ql2EKgq0rpXMuyzNz6MsyijaYp3HblAvJmEZeu8sZrFqMoMj6PQWr8921ho6sqt165YMrvSMDtc9tYV1vPPz//LE91HOelnq4p2yu9Pv5k1RrevmjprKs9RZZ55+JlVPn8/L8tL3J4dJiDI86/CbhVjavqG/jw2qvOoFh68aDLCn9xxZXMj5bzte1bODQyzHAmUwoRTUCVZer8Aa5raDqPcudXB35d5zM33MLfPfsEL/f20D2uLDsBl6pyW0srH19/Lb2pBPfv3X0WvV66a3K+xIlX1zfy9TveyL++9Dwv9/bQPhYrkbqBYyisqKrmg2vWs6G+cVb688XjeS4Cx/tV5fVPa7essrrUJuRyXbKk5ouFywbHRYCgwEDqQUwrRti9HrfWTE/iv8kVOwm7r6bcexdD6Yco976RZH4HqhxCkVwMpR9CYKHIzop3OP0w6jjpmBAWI5knyZrH8BlLCbnWk8i/7JTmKhWU++5G4uyS7JxJ0CpNcrYwkVCQJBm3Wotba+D42DcIG6scxlV79LT9JQuHyRS7UGUfY7md1PvfNmtbSVIJu1YwmHkajzaHXLGPfHEQnzYXTfYjsBnOPkfEtQZL5FBkN5rsx1DKCBpLOBb/On69rTTBAyiSgWmPUbSTSJJWMnImWF4FNjYmstCQUAkaS+lL/RqP2oAkadgi73hCThMbn+gLbAQmCBVV9uLX51GwY5R7rgdsinYaGR1dCRHLbacoUmTNHtJme6k/WTJoCv4fUuZRDo1+jkVln0aXwwSMRRSsESq9NwGCop1CkU6fI+CU/ZqAGD9WFVsUSZlHaAm9n4C+gFhuKwJH1C3oc0irYokMC5uqqC4PIEtOiGUCrknJmkHfxPfKlCTOySKAk/edgKrIE0VBeN0zJ8qpysnvDV3FGPdeRIInX0OTfx8ojUFXVP7u6uvJmCbrausJu1x84ebb2TM4wJbebvrTKXRFoS0S5cq6Bmr9gTO6lhVZ5uamFtbV1rG9v4/dA/0MZdJo4xUjK6trmBcpQ1eUWe+VZZVVfPGWO534edns4UuAuZEo/+/WOxECWsIzU09PcMjcObeNaxvnsH9okN2DA/QmExQsC6+mU+P30xYtY16kjLDbfclc6CGXi89cfzN5yyoxtU5gQbScL95yp8PuGwxN2fbGtgUsKq/Eo2lTiNUkSaI5FOYbd9zD1r4etvf3MZLNoMkytf4AK6trWFRWga4ohN0uvnTbnSiSVCJxOxWaLPPX668mns+P/9b5Sz+UeTx87sZbMW2bSq8XgeC5gXY2VDafk0mzN9ZPldvP0ooqvn7nPewbHGRbf28pYbbK52d5ZRVLKqrwatppjZnrGpv48m13YQso93imqb86nroGvnzbG7CFwK/rJSG3s4Vl2w7h2mnehUXLkQFQz6H6bDZI4vXijztHJBIJgsEgo7EYm0YHyBeLLK+opnmccnY4m+apE8dRJIl5kXIGMylShQJX181h20AvuaLJ/Eg5u4f60RWFW+a0zsphULCGOTH2Rap8b8OlNaBIPuK5F8kVu6nw3QsI2kf/habIXzGcfhhdqSSR30bEfT15q4+s2UFt4A/IFjsYTj9KffB9ZIsd9CW+R6XvzfQmv0tT+OP0Jr+HV5uH31iKrpx9BnvW7KE9/k3SZge2yOPVmqnzv5WQaylCCGK5l9k99DFWVv4nfn0Bph3n0Oi/sDD6DxyJ/Qd1/vtI5PcisNGUIJ3x7+JW68lbAwT0hTSH/hhBkT1Df8PCsn/AUKIk8gfoTHyPxWX/iGknOT72dTJmB5KkUuu7l3LPtYDEWH4nnfH/pijSyJJOS+h9BA3HK5TIH2DbwPtYVv55wq4rSsdr2gkOjXyevDWEV5tDW+TDWCLPsdh/kjE7yFuD+PQ2Kj03UeG9gYI1xvGxr5MyjyAhE3GtYU7w92ZNGjWtBMfHvkr6lL7KPdeTtwY4PvY1ssVeQKbMfSUNgXdRsEY5NPp5TDuBW63BFnnqA2/Dp7exd+hvaQ1/ELdaTVfyh+SLQ7SE3485Pq5M8QQgEXFdQWPw3ewf/jRzw3/OQOYJ3EoNhlrOQPpxWkJ/Qnv8v0gVjpApnsCvzyPiWkuN7x760g/Rl3oITQ7i19vIFvtYEP3bWY/x9Yp8cQBZ0tCU01NHX2rksgXSqRyRMv95ez5ylokuq69azF0IQVdmBxWuVlyKf8r3pp1FkXVkFDrT26hxL0RXpjPr2sLmaPJ5dNlNo3c1kiQxnGtHk10E9eopbYUQdKS3UrAztPmvmXbehBB0Z3YRK3TTGrgGtzIzD8tMsIWFaecwFKfkvGBlGMgdoc5zbnk3w7kUxxIjzPFHeLBjNyujdbSFKogXsgzn0lS5AyiSTM4yUWSZbNEkWywwP1TJofggO0a6ubZqLnP8r+z9KcZzYYQAWZaYIJ6dmN0FYoqS9MT2oyeGqKkI4jb0kjdyQgGa8b72Humjo3eEN1w3s7d+Yq6Nx+MEAqe/Zv/rPRw2ghOJMe5snsfW/p6SwZEqFBBCkLdtnu/uZCCToszt4ejYCKZtsX9kEFWWCblcjGazxPO5WYl4NDlCjf89jGSfxDCrqPDdjSRpOCEJFUGRifCCJXLO/3YGTSlDYJEzT+AIISml/APLTmHaMVKF/QSM1ciSTo3/PcSyz9GT+A6Nob8orezPBJdaRVvkI5x0y0tTSioFFgF9IT597rh2SpCF0X9Algxawx9ElnQ8msPAOpx9HkOtZGHZJ7CFQyTmuDUNlpb/S0lDxq+3sTD694CMJgeZF/kolsghSYoTQhm/u0PGcoIVi7FFwQnfTGjQjHsZfFoTAWPxlJeGKvlZWPYPjqYNKhIaqqSO84uctJ8njnHi922RRyDGvQizv4RU2UfLDH1JkoShVLIg+gkskUdCKunr6EqUxeX/hC0K479rj4eVZBaX/eO4Po5Mvf9t4/uq6EoZ86Mfd87LpL4WRD+BLOnU+986fg9J+LRWZElnTvD3YVKJrYSKJElUe++i0nNT6do6XpDXRvJY1uxgLLcJTSnDpy8mnttcGmPUcyNj2Rco2ikinuvJFA7hN5aRKzrl3hnzCJadQVfK8BtL6Ul8C1lyEfXciE9f8qpVZxTyRX79wy28/Y+umyLYKIQgk84jSRJuz+mpzjcNtjOQTXJr7XzC+snJ/GLpKCWLQ6TMIcpczZh2lkxxDEsUKHfNpWjnGcl30pPZR1hvoGjnSZgDRI05gGBH7BeUGXOodS9mKH8MWVJwK0HKjDnk7RQj+ROE9VrcSogK11zaU1to9K7GHO+n3NXinAsrRqzQTVCrxqeWUelqY/fYQzOOd6zQw77448wLXIsiaYwVeglq1YwVenCrAVLmCAU7Q7lrLoqkMpLvxLRzlLta6M8eoDuzh1b/BqJGI6OFLuRxXiVLFBnOtaPKOmG9nnihl7ydwlD8hLSp1UnbhrtJmjkafWGyloksSTzWfZB0scDCUBU/79xNUHeTKOTwqDqDuSQuRaMnEydTLDiMsa+oUpIDs2jx0DN78XoMVi2sZ9/RPha2VHO8e5hMrkA6W6C5royegTE2rGzmuW3HWLt0Dpt3d3LntYvo6OnH7dKIJ7NEgl7au0foG45z24aFzKmNcOTExREI/F9vcACEDTdeTUdTTq72ZEkioLuwhI0mK2iKTJ0viEtR6UnGcasaqiwTdXnIFU8vAGbaI8RyLyCEXaoc0JVKhtIPo2S8RD03oSll9Ca+S9bsxKPNJehaQ1/yfiRkdKWcgjVCLPssGfMoifw2fPoC3FozRTuBpoSQJJVY5kmKdmzcKDkXymUFVZpuLBWsGInCAU7Ev0et/82lEI0kSeOGBKX/p5aICmeSP4XHYrIBJEkKyhQiNQlVmr5CcgwtrVRp4pzPJIn8PrqSP6LGd/c0w8rZR0WWJt++0ozHONEepLM20CRJPkNfyszHMm1MDk49L1P3nX5eTp7zyQyZzrmc6XcnxjX5d84UmnmlIIRAlly41TkMpX+NjIFlp0gXuzDUGobTDyNLHnzGIgZTD2KLAh69jVzR4SiIZZ+lMfQX9Ca+j99YiltrxqM149Xnv6rH5Q+68fmnC8gN9I7x3GN7MQtFbn/zasJl0+PuE7i2ai77Y/18fs+T1HiChHQ39zWtPGtK89MhZyXYE3uYqNFAX/YAHjVMuhhDkVSKdoHB3BHCRj0Jc4CCneZwYiO1nsXsGXuYxaHbMe0suuxBllRMO0emOEZ3ZjeabHAw/jRRYw7Hky+xvvx3p9zzsiSTLA5hmH58ahl5K0XByrIz9cvxticXVadCkTU0ycCrRinaeQ4nNrI6+lYOJJ6gzrOME+kdRI0GUsVhDMVHvNBPuasFsLGFhQRo8kQOmURvdh817kV0pLZg2jlyVhLTzrF37FHm+tdzJPEca8vfhS6dZAhdGK5i82Ane2J9lBk+Gv0RjiQcjZKisKhyBziaGKbM5SVieEiYOZaEqwkbbg7Hh14VYwPGQ3GaUvJexBIZCmaRRCpHOltg/YomysM+4qks2/b//+3de2wU5d4H8O/c9trttNuy3W63LS2Xl0sp1IIg8goiARREJa8CQsGYk4gRaNFUSDDBGJX6jwc1AoEQEoMGYigE0QhFsZbTSpOWSgGRi+VWaBdK291e9zK/949tB5a2COf0NnueT9LEzjzdPl/qzv5m5nnmuYaAoiAywgCrbILfH0D8kEgUlV2C1+fHzMlWNLW0w93UhrqGZsTF9Pz/8KMK+4JD5HgsGD4KelHErOTh6nZHRGTIFQsiQpvfj0i9AU6LDJHnIfECeI7DSGssdN0sTd9J4mNgMz8PAqlTLg1iIpKjshH8cBbhlP8Bv+IGzxmCZ8sQYdGng+N04MAHZyaY5iDGNBs8pwfPmZAovwG/0gieM4GDBKvpaShKCwTeAp7rebXMh+VTGnGn9Tc4LC9iiGnGQ51ZGUUnYo1P/se/+0ECShPqWktgM86APWKuJp4xwPSEUNuUD4s+DRwnAghAEmIRUFogchZ4lduw6JKgE2wIKE3gOD2IAggoLcHxPMIQ6AQ7hI7H8QffG3pwePD974FyveoWAoEA4hOt4B6wwBwAXPbcQVHtJUy3D0dGjBMiJ0B6wHHmUTQH6tHsr0OkFIdIyY4AeeE0jYNCATT769AW8MBpSkdd+xW0BhphFGQ4Tem43nIKIifBLFph1SVCx5sg8QYkmSdAIT9a/A2o91YjQopBtN7Z5QNW4CSYxZiO76jj9fTwBppBD1hAkeM4RIixMInRsOqc8JMXwWsFBKXj5xzGMbDqk3G1uRwt/gYMjZgIWQo+z8ciDYHHPwSyLjjgPkKKBd8xDqjBexMjI59Ck+82Grw3YBJlOE3j4Wq71LFK9z39AJBqicGwyFi4vW2IlAyYET8CChFutzXh2UQnbra4YRIlmEQd0tsdaPS2YqRsg16QoBAhzth7H9APi4gQGx2B85ddGDPMDndzO8rOXusYKyVAEoPFyOiUOGz/9l9Y9GwmPM3tuHnbjarqO8gY7URTSzusshk+fwANnlbopGB5cOXGHdTe9qCuoRkxUf/hshi9EXYwCy6fHDxTNIp3z9JFnu+yAmJnu+guT2p78EGA4/gu95SDg7+i7n4Pnfro8k73/8z9TxgN/szdwVoiFwHwvTc1r3P8w6Ow6EbAohvRa33ojkGMx0jr2j79HUx/4SAJVrT4LoHnjOA5EwARoiBD4CMQpRuJhtZ/wdNegWjTDAQUD2qa9oLIhyjDVEh8cHClyEcB4GGShqGuY8XlSP34AUlERLh++TZuu9w4f7oaYyYkqcVF6v/E48bVOggCD2MPg2c7eRU/XknJQIze3OvFk0UcgkgpDiYxChbJhgbvdfAcD4ICnhMRIQ3BRc9x1HuvY5hlKqqVM7jgLoJJiIbASTDwEbjSXI6UiEnqLDWO46HjTbAZhkHPR8AgRIJAcLVdhNtXA4/fBYkzoL79GlqEO7DqnPD4bsFmCJ7oKQjgVttFeHwuNHirEaVL6JKb53gEr/rp0K4046LnONoDno6TMr7j8YU8hhiG45KnBFZ9EhKMadDxJjR4b6K29Txi9ENxq+0S3L5auH01sBmG4a+m3+BTWjHUPAkN3uqOW5ihx3WO4+A0R8FpjgIAyLrgSV28KTguIcEcHNA/LPLucVzW3f2sGB3VO4tk/jtEQcDwxFiMGhqHqEgjXpyZDp8/AKNBCk6H1wWvIMsWI/7xf1MhW4zw+QJ4dtoYiAIPgefwwsx0CAIPg07Es/87BjzPwWzUwd3UhgUzx3U7Rf1Rhf2g0YcZyMIwTN8hCoDIB3CiejmdoHT8N99xG1JRbyERtQOcgOBKzYo6DqrzqapEXoATur191T95CAG/Ar8/AJ7nIenuzmLp3KcoFLJ9IProVZrR7K+HWYwGIXj1IThNPQCBk+Dx34LEGWAUZfiVdrT462GRbBB4CQHFC7fPBYsUC5/SDoNggVdpgcjpARDcPhf0QgQMHbc2FARgEqIgcBKa/LcAcIiUbAiQD22BJuh4IwyCBY2+WgQUHwxCBMxi6FpIwTEfDTAJMgAOrYFGeJUWSLwheKuECAIvwau0wsBHoMl/GwHyIVKyg0PwVg4HDiYxGm5vDQLkh1GMhEmIgsd3Czwnwixa0RKoh0mIRmugEQbB0qXwYB7No3zWhm3B0djYiKioKFy7do0VHAzDMAzTB9xuNxITE9HQ0ABZfvBzQML2lkpdXfCx0omJiQPcE4ZhGIYJbx6P57+34LBag+Mjrl69+rf/CFrRWUmG01Ublkkbwi1TuOUBWCatCLdMRASPxwOHw/G3bcO24OA7BoTKshwWf9R7RUZGskwawDINfuGWB2CZtCKcMj3sSX14PYaQYRiGYZhBiRUcDMMwDMP0ubAtOPR6PTZu3Ai9fnA8cbE3sEzawDINfuGWB2CZtCIcMz2ssJ0WyzAMwzDM4BG2VzgYhmEYhhk8WMHBMAzDMEyfYwUHwzAMwzB9jhUcDMMwDMP0OVZwMAzDMAzT58K24NiyZQtSUlJgMBiQmZmJoqKige5StzZt2oRJkybBYrHAZrPhxRdfxJ9//hnShojw/vvvw+FwwGg0YsaMGThz5kxIm/b2dqxevRqxsbEwm81YsGABrl+/3p9RurVp0yZwHIecnBx1mxbzVFdXY9myZYiJiYHJZMKECRNQVlam7tdaJr/fj/feew8pKSkwGo1ITU3FBx98AEVR1DaDPdOvv/6K559/Hg6HAxzH4cCBAyH7e6v/9fX1yMrKgizLkGUZWVlZaGho6PdMPp8P69atw7hx42A2m+FwOLB8+XLcuHFDs5nu98Ybb4DjOGzevDlkuxYz/fHHH1iwYAFkWYbFYsGUKVNw9erVQZupX1AY2rNnD0mSRDt27KCzZ89SdnY2mc1munLlykB3rYs5c+bQrl276PTp01RRUUHz5s2jpKQkampqUtvk5eWRxWKhffv2UWVlJS1atIji4+PJ7XarbVauXEkJCQlUUFBA5eXl9PTTT9P48ePJ7/cPRCwiIiotLaWhQ4dSeno6ZWdnq9u1lufOnTuUnJxMr732Gp04cYKqqqro6NGjdPHiRc1m+vDDDykmJoYOHTpEVVVV9O2331JERARt3rxZM5l++OEH2rBhA+3bt48A0P79+0P291b/586dS2lpaVRcXEzFxcWUlpZG8+fP7/dMDQ0NNGvWLNq7dy+dO3eOSkpKaPLkyZSZmRnyGlrKdK/9+/fT+PHjyeFw0D//+U9NZ7p48SJZrVbKzc2l8vJyunTpEh06dIhqa2sHbab+EJYFx+OPP04rV64M2TZq1Chav379APXo4blcLgJAhYWFRESkKArZ7XbKy8tT27S1tZEsy7Rt2zYiCh6IJEmiPXv2qG2qq6uJ53n68ccf+zdAB4/HQyNGjKCCggKaPn26WnBoMc+6deto2rRpPe7XYqZ58+bR66+/HrJt4cKFtGzZMiLSXqb7D/q91f+zZ88SAPrtt9/UNiUlJQSAzp0716+ZulNaWkoA1JMprWa6fv06JSQk0OnTpyk5OTmk4NBipkWLFqnvpe4M9kx9JexuqXi9XpSVlWH27Nkh22fPno3i4uIB6tXDa2xsBHB3tduqqirU1NSE5NHr9Zg+fbqap6ysDD6fL6SNw+FAWlragGV+6623MG/ePMyaNStkuxbzHDx4EBMnTsTLL78Mm82GjIwM7NixQ92vxUzTpk3DTz/9hPPnzwMAfv/9dxw/fhzPPfccAG1muldv9b+kpASyLGPy5MlqmylTpkCW5QHPCASPFxzHISoqCoA2MymKgqysLOTm5mLs2LFd9mstk6Io+P777zFy5EjMmTMHNpsNkydPDrntorVMvSXsCo7bt28jEAggLi4uZHtcXBxqamoGqFcPh4jw9ttvY9q0aUhLSwMAtc8PylNTUwOdTofo6Oge2/SnPXv2oKysDJs2beqyT4t5/vrrL2zduhUjRozA4cOHsXLlSqxZswZfffWV2t/O/vXU38GWad26dViyZAlGjRoFSZKQkZGBnJwcLFmyRO1vZ/966u9gy3Sv3up/TU0NbDZbl9e32WwDnrGtrQ3r16/Hq6++qq46qsVMn3zyCURRxJo1a7rdr7VMLpcLTU1NyMvLw9y5c3HkyBG89NJLWLhwIQoLC9X+ailTbwnb5ek5jgv5noi6bBtsVq1ahVOnTuH48eNd9v07eQYi87Vr15CdnY0jR47AYDD02E4reYDgGcvEiRPx8ccfAwAyMjJw5swZbN26FcuXL1fbaSnT3r17sXv3bnzzzTcYO3YsKioqkJOTA4fDgRUrVqjttJSpO73R/+7aD3RGn8+HxYsXQ1EUbNmy5W/bD9ZMZWVl+Oyzz1BeXv7Iv3uwZuoceP3CCy9g7dq1AIAJEyaguLgY27Ztw/Tp03v82cGaqbeE3RWO2NhYCILQpQJ0uVxdznYGk9WrV+PgwYM4duwYnE6nut1utwPAA/PY7XZ4vV7U19f32Ka/lJWVweVyITMzE6IoQhRFFBYW4vPPP4coimp/tJIHAOLj4zFmzJiQbaNHj1ZHnGvtbwQAubm5WL9+PRYvXoxx48YhKysLa9euVa9KaTHTvXqr/3a7HbW1tV1e/9atWwOW0efz4ZVXXkFVVRUKCgrUqxuA9jIVFRXB5XIhKSlJPV5cuXIF77zzDoYOHar2V0uZYmNjIYri3x4ztJSpt4RdwaHT6ZCZmYmCgoKQ7QUFBZg6deoA9apnRIRVq1YhPz8fP//8M1JSUkL2p6SkwG63h+Txer0oLCxU82RmZkKSpJA2N2/exOnTp/s98zPPPIPKykpUVFSoXxMnTsTSpUtRUVGB1NRUTeUBgCeffLLLVOXz588jOTkZgPb+RgDQ0tICng99+wuCoJ6daTHTvXqr/0888QQaGxtRWlqqtjlx4gQaGxsHJGNnsXHhwgUcPXoUMTExIfu1likrKwunTp0KOV44HA7k5ubi8OHDmsyk0+kwadKkBx4ztJap1/TvGNX+0TktdufOnXT27FnKyckhs9lMly9fHuiudfHmm2+SLMv0yy+/0M2bN9WvlpYWtU1eXh7Jskz5+flUWVlJS5Ys6XZ6n9PppKNHj1J5eTnNnDlzwKfFdrp3lgqR9vKUlpaSKIr00Ucf0YULF+jrr78mk8lEu3fv1mymFStWUEJCgjotNj8/n2JjY+ndd9/VTCaPx0MnT56kkydPEgD69NNP6eTJk+qMjd7q/9y5cyk9PZ1KSkqopKSExo0b12dTEx+Uyefz0YIFC8jpdFJFRUXI8aK9vV2Tmbpz/ywVLWbKz88nSZJo+/btdOHCBfriiy9IEAQqKioatJn6Q1gWHEREX375JSUnJ5NOp6PHHntMnWY62ADo9mvXrl1qG0VRaOPGjWS320mv19NTTz1FlZWVIa/T2tpKq1atIqvVSkajkebPn09Xr17t5zTdu7/g0GKe7777jtLS0kiv19OoUaNo+/btIfu1lsntdlN2djYlJSWRwWCg1NRU2rBhQ8gH12DPdOzYsW7fOytWrOjV/tfV1dHSpUvJYrGQxWKhpUuXUn19fb9nqqqq6vF4cezYMU1m6k53BYcWM+3cuZOGDx9OBoOBxo8fTwcOHBjUmfoDR0TUt9dQGIZhGIb5bxd2YzgYhmEYhhl8WMHBMAzDMEyfYwUHwzAMwzB9jhUcDMMwDMP0OVZwMAzDMAzT51jBwTAMwzBMn2MFB8MwDMMwfY4VHAzDMAzD9DlWcDAMwzAM0+dYwcEwDMMwTJ9jBQfDMAzDMH3u/wG6cTSfP5YuqwAAAABJRU5ErkJggg==\n",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# wordcloud\n",
    "from wordcloud import WordCloud\n",
    "import matplotlib.pyplot as plt\n",
    "wordcloud_ip = WordCloud(\n",
    "                      background_color='White',\n",
    "                      width=1800,\n",
    "                      height=1400\n",
    "                     ).generate(merged_text)\n",
    "\n",
    "plt.imshow(wordcloud_ip)\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "5c6a5608",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# remove stop words and clean text\n",
    "from wordcloud import WordCloud, STOPWORDS\n",
    "other_stopwords_to_remove = ['\\\\n', '\\\\t', '\\\\r']\n",
    "STOPWORDS = STOPWORDS.union(set(other_stopwords_to_remove))\n",
    "stopwords = set(STOPWORDS)\n",
    "wordcloud = WordCloud(width = 1800, height = 1800, \n",
    "                background_color ='white', \n",
    "                max_words=200,\n",
    "                stopwords = stopwords, \n",
    "                min_font_size = 10).generate(merged_text)\n",
    "plt.imshow(wordcloud, interpolation='bilinear')\n",
    "plt.axis(\"off\")\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "165e901b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Haematologia, \n",
       "<mark class=\"entity\" style=\"background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Vol\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DRUG</span>\n",
       "</mark>\n",
       ". 30, No. 1, pp. 27–30 (2000)</br>(cid:211) VSP 2000.</br></br>Serum L-selectin and P-selectin levels in lymphomas</br></br>Short communication</br></br>I. C. HAZNEDARO ˇGLU, M. \n",
       "<mark class=\"entity\" style=\"background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BENEKLI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DRUG</span>\n",
       "</mark>\n",
       "</br>I. H. GÜLLÜ, S. V. DÜNDAR and ¸S. KIRAZLI</br>Department of Internal Medicine, Hematology and Oncology Division, Hacettepe University</br>Medical School, Ankara, Turkey</br></br>, O. OZCEBE, M. C. SAVA ¸S,</br></br>(cid:3)</br></br>Abstract—The migration of normal and malignant lymphoid cells is governed by speciﬁc adhesion</br>molecules. Selectins comprise a family of adhesion receptors expressed by leukocytes, platelets and</br>endothelial cells. In this study, the serum levels of soluble L-selectin and P-selectin were measured in</br>patients with non-Hodgkin’s lymphoma and Hodgkin’s disease and found to be signiﬁcantly elevated</br>in both patient groups compared to healthy controls. This result provides evidence that alterations in</br>the expression and function of adhesion molecules may play an important role in the progression of</br>lymphomas. Further studies are awaited to establish the exact roles of these adhesion molecules in</br>distinct patterns of growth and spread of lymphomas.</br></br>Key words: L-selectin; P-selectin; Hodgkin’s disease; non-Hodgkin’s lymphoma.</br></br>INTRODUCTION</br></br>Adhesion of lymphocytes to endothelium is essential in lymphocyte trafﬁcking</br>[1, 2]. Lymphocytes migrate from the circulation by selective attachment to spe-</br>cialized endothelial cells lining the postcapillary high endothelial venules (HEV)</br>in organized lymphoid tissues, lymph nodes and Peyer’s patches. Selectins com-</br>prise a family of adhesion molecules which have been demonstrated to participate in</br>the initial tetherting/ rolling of leukocytes on activated endothelium [3]. L-selectin</br>(CD62L, LAM-1, LECAM-1) mediates the binding of lymphocytes to HEV of</br>peripheral lymph nodes through interactions with corresponding endothelial lig-</br>and and therefore also known as the lymphocyte homing receptor [4]. P-selectin</br>(CD62P, PADGEM, GMP-140) is stored both in the alpha granules in platelets and</br>\n",
       "<mark class=\"entity\" style=\"background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Weibel\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DRUG</span>\n",
       "</mark>\n",
       "-Palade bodies of endothelial cells [5] and involved in the stabilization of</br></br>(cid:3)</br></br>To whom correspondence should be addressed. M. Benekli, 14. Sokak, 43/ 8. Bahçelievler,</br></br>Ankara, Turkey.</br></br>\f",
       "28</br></br>I. C. Haznedaroˇglu et al.</br></br>platelet aggregates and in the interaction of leukocytes with activated platelets or</br>endothelial cells [6].</br></br>Lymphoma cells represent immortalized counterparts of normal lymphocytes. A</br>similar adhesion mechanism is also utilized by malignant lymphoid cells during</br>dissemination [7, 8]. Altered expression patterns of adhesion molecules appear</br>to be involved in the spread of lymphoid malignancies and Hodgkin’s disease</br>(HD) [7–10]. In this study, serum levels of soluble L-selectin and P-selectin were</br>determined in patients with HD and non-Hodgkin’s lymphoma (NHL) and in normal</br>healthy individuals.</br></br>PATIENTS AND METHODS</br></br>The study group consisted of 17 patients (10 NHL, 7 HD; 11 men, 6 women; median</br>age 35 years, range 19– 70) and 15 healthy volunteers (11 men, 4 women; median</br>age 49 years, range 36– 67). Out of 10 NHL patients, 5 were classiﬁed as low-</br>grade, 1 intermediate, and 4 high-grade according to the Working Formulation.</br>Four patients out of 7 with HD had mixed cellularity, 1 nodular sclerosis, and</br>2 lymphocyte predominance type. Staging was performed according to the Ann</br>Arbor system.</br>In NHL, 2 patients had stage III and 8 patients had stage IV</br>disease, and in HD 1 patient had stage II, 2 stage III, and the remaining 4 stage IV</br>disease. All patients with HD and 3 out of 10 with NHL had B-symptoms. Serum</br>L-selectin and P-selectin levels were determined using a commercially available</br>ELISA kit (Bender MedSystems, Vienna, Austria) according to the manufacturer’s</br>instructions. Data are presented as mean (cid:6) SD. Mann–Whitney U test was used</br>for statistical analysis.</br></br>RESULTS</br>Adhesion molecule levels were signiﬁcantly higher in lymphoma patients compared</br>to healthy controls (Table 1) (Fig. 1). Serum levels of sL-Selectin (1137 (cid:6)</br>428 ng/ml vs 625 (cid:6) 159 ng/ml; p D 0:0023 and sP-Selectin (610 (cid:6) 211 ng/ml</br>vs 178 (cid:6) 48 ng/ ml; p D 0:0001) were signiﬁcantly increased in patients with</br>non-Hodgkin’s lymphoma compared to the control group. In HD, serum soluble</br>L-selectin (1140 (cid:6) 498 ng/ml; p D 0:0082) and P-selectin (875 (cid:6) 370 ng/ ml;</br>p D 0:0002) concentrations were signiﬁcantly elevated also compared to healthy</br>controls (625 (cid:6) 159 ng/ ml and 178 (cid:6) 48 ng/ml for L-selectin and P-selectin,</br>respectively).</br></br>DISCUSSION</br></br>Disseminating malignant lymphoma cells and lymphocytes share several character-</br>istics, including migration and extravasation involving adhesive \n",
       "<mark class=\"entity\" style=\"background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    interactions\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DRUG</span>\n",
       "</mark>\n",
       " [7, 8].</br></br>\f",
       "Adhesion molecules in lymphomas</br></br>29</br></br>Table 1.</br>Serum soluble P-selectin and L-selectin levels in the study group</br></br>Patients</br></br>HD</br>HNL</br>Controls</br></br>P-selectin (ng/ml)</br>875 (cid:6) 370</br>610 (cid:6) 211</br>178 (cid:6) 48</br></br>* Compared with healthy controls.</br></br>(cid:3)</br></br>p</br></br>0.0002</br>0.0001</br></br>L-selectin (ng/ml)</br>1140 (cid:6) 498</br>1137 (cid:6) 428</br>625 (cid:6) 159</br></br>(cid:3)</br></br>p</br></br>0.0082</br>0.0023</br></br>Figure 1. Circulating soluble P-selectin and L-selectin levels in the study group.</br></br>Emerging evidence indicates that the adhesion molecules governing the homing</br>of normal lymphocytes also mediate the dissemination of their neoplastic counter-</br>parts. Adhesion molecules have also been demonstrated to function in the spread</br>of HD [9, 10]. Therefore, we determined serum levels of soluble adhesion mole-</br>cules, L-selectin and P-selectin as indicators of distinctive clinical and biological</br>behaviour of lymphoid malignancies.</br>In this report we demonstrated that serum</br>concentrations of these adhesion receptors are increased in patients with HD and</br>NHL. Our results conﬁrm and extend data published previously on the role of dis-</br>tinct adhesion molecules in lymphomas. Elevated levels of circulating intercellular</br>adhesion molecule-1 were reported in various hematologic malignancies including</br>HD [9, 10], acute lymphoblastic leukemia [10], chronic lymphocytic leukemia [11]</br>and NHL [12, 13], and non-hematologic malignancies [10, 13]. To our knowledge,</br></br>\f",
       "30</br></br>I. C. Haznedaroˇglu et al.</br></br>this report is the ﬁrst investigating the levels of circulating L-selectin and P-selectin</br>in NHL and HD.</br></br>Differential expression of these adhesion molecules may account for diverse</br>patterns of growth and dissemination of lymphomas. The study of adhesion</br>molecule expression and function may allow a better understanding of the malignant</br>behavior of lymphoid cells. Our data need to be validated and extended in a</br>more homogenous patient series in order to elucidate the clinical and prognostic</br>signiﬁcance of L-selectin and P-selectin in lymphomas.</br></br>REFERENCES</br></br>1. \n",
       "<mark class=\"entity\" style=\"background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Shimizu\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DRUG</span>\n",
       "</mark>\n",
       ", Y., Newman, W., Tanaka, Y., Shaw, S., Lymphocyte interactions with endothelial cells,</br></br>Immunol. Today 13, 106 (1992).</br></br>2. Stoolman, L. M., Adhesion molecules controlling lymphocyte migration, Cell 56, 907 (1989).</br>3. Bevilacqua, M. P., Nelson, R. M., Selectins, J. Clin. Invest. 91, 379 (1993).</br>4. Gallatin, W. M., Weissman, I. L., Butcher, E. C., A cell-surface molecule involved in organ-</br></br>speciﬁc homing of lymphocytes, Nature 304, 30 (1983).</br></br>5. Bonfanti, R., Furie, B. C., Furie, B., Wagner, D. D., PADGEM (GMP 140) is a component of</br></br>Weibel-Palade bodies of human endothelial cells, Blood 73, 1109 (1989).</br></br>6. De Bruijne-Admiraal, L. G., \n",
       "<mark class=\"entity\" style=\"background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Modderman\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DRUG</span>\n",
       "</mark>\n",
       ", P. W., Von dem Borne, A. E. G. Kr., Sonnenberg, A.,</br>-dependent adhesion of activated platelet to many different types of</br></br>C</br>P-selectin mediates Ca2</br>leukocytes: Detection by ﬂow cytometry, Blood 80, 134 (1992).</br></br>7. Pals, S. T., Horst, E., Scheper, R. J., Meijer, C. J. L. M., Mechanisms of human lymphocyte</br></br>migration and their role in the pathogenesis of disease, Immunol. Rev. 108, 111 (1989).</br></br>8. Pals, S. T., Drillenburg, P., Radaszkiewicz, T., Manten-Horst, E., Adhesion molecules in the</br></br>dissemination of non-Hodgkin’s lymphomas, Acta Haematol. 97, 73 (1997).</br></br>9. Gruss, H.-J., Dölken, G., Brach, M. A., Mertelsmann, R., Herrmann, F., Serum levels of</br></br>circulating ICAM-1 are increased in Hodgkin’s disease, Leukemia 8, 1245 (1993).</br></br>10. Pui C.-H., Luo, X., Evans, W., Martin, S., Rugg, A., Wilimas, J., Crist, W. M., Hudson, M.,</br></br>Serum intercellular adhesion molecule-1 in childhood malignancy, Blood 82, 895 (1993).</br></br>11. Christiansen, I., Gidlöf, C., Wallgren, A. C., Simonsson, B., Tötterman, T. H., Serum levels of</br>soluble intercellular adhesion molecule-1 are increased in chronic B-lymphocytic leukemia and</br>correlate with clinical stage and prognostic markers, Blood 84, 3010 (1994).</br></br>12. Christiansen, I., Gidlöf, C., Kalkner, K.-M., Hagberg, H., Bennmarker, H., \n",
       "<mark class=\"entity\" style=\"background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Tötterman\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DRUG</span>\n",
       "</mark>\n",
       ", T.,</br>Elevated serum levels of soluble ICAM-1 in non-Hodgkin’s lymphomas correlate with tumour</br>burden, disease activity and other prognostic markers, Br. J. Haematol. 92, 639 (1996).</br></br>13. Benekli, M., Güllü, I. H., Tekuzman, G., Sava¸s, M. C., Hayran, M., Hasçelik, G., Fırat, D.,</br>Circulating intercellular adhesion molecule-1 and E-selectin in gastric cancer, Br. J. Cancer 78,</br>267 (1998).</br></br>\f",
       "\f",
       "</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": [
       "[('Vol', 'DRUG'),\n",
       " ('BENEKLI', 'DRUG'),\n",
       " ('Weibel', 'DRUG'),\n",
       " ('interactions', 'DRUG'),\n",
       " ('Shimizu', 'DRUG'),\n",
       " ('Modderman', 'DRUG'),\n",
       " ('Tötterman', 'DRUG'),\n",
       " ('Jaroslav Stanicek', 'DRUG'),\n",
       " ('Ladislav', 'DRUG'),\n",
       " ('M.D.‡', 'FREQUENCY'),\n",
       " ('dobutamine', 'DRUG'),\n",
       " ('dobutamine', 'DRUG'),\n",
       " ('Dobutamine', 'DRUG'),\n",
       " ('5 µg/kg per min', 'STRENGTH'),\n",
       " ('20 µg/kg', 'STRENGTH'),\n",
       " ('dobutamine', 'DRUG'),\n",
       " ('dobutamine', 'DRUG'),\n",
       " ('Sseptal', 'DRUG'),\n",
       " ('Santerior', 'DRUG'),\n",
       " ('Sinferior', 'DRUG'),\n",
       " ('sestamibi', 'DRUG'),\n",
       " ('at rest', 'FREQUENCY'),\n",
       " ('sestamibi', 'DRUG'),\n",
       " ('midazolam', 'DRUG'),\n",
       " ('albumin', 'DRUG'),\n",
       " ('5,000', 'STRENGTH'),\n",
       " ('heparin', 'DRUG'),\n",
       " ('cen-', 'DRUG'),\n",
       " ('trifuged', 'DRUG'),\n",
       " ('240 g', 'STRENGTH'),\n",
       " ('1,200 g', 'STRENGTH'),\n",
       " ('Histopaque', 'DRUG'),\n",
       " ('human albumin', 'DRUG'),\n",
       " ('1,000', 'STRENGTH'),\n",
       " ('heparin', 'DRUG'),\n",
       " ('daily', 'FREQUENCY'),\n",
       " ('75 mg', 'STRENGTH'),\n",
       " ('clopidogrel', 'DRUG'),\n",
       " ('100 mg', 'STRENGTH'),\n",
       " ('aspirin', 'DRUG'),\n",
       " ('bolus', 'DOSAGE'),\n",
       " ('heparin', 'DRUG'),\n",
       " ('fects', 'DRUG'),\n",
       " ('Dobutamine', 'DRUG'),\n",
       " ('Aspirin', 'DRUG'),\n",
       " ('Clopidogrel', 'DRUG'),\n",
       " ('ACE inhibitor', 'DRUG'),\n",
       " ('Beta blocker', 'DRUG'),\n",
       " ('Statin', 'DRUG'),\n",
       " ('high-doses group signiﬁcantly\\nimproved the regional systolic function (Sinfarct)',\n",
       "  'DOSAGE'),\n",
       " ('ESV', 'DRUG'),\n",
       " ('−0.2', 'DRUG'),\n",
       " ('0.625', 'STRENGTH'),\n",
       " ('0.432', 'STRENGTH'),\n",
       " ('0.342', 'STRENGTH'),\n",
       " ('0.798', 'FREQUENCY'),\n",
       " ('pretransplant', 'DRUG'),\n",
       " ('dobutamine', 'DRUG'),\n",
       " ('signiﬁcance', 'DRUG'),\n",
       " ('diac', 'DRUG'),\n",
       " ('diac', 'DRUG'),\n",
       " ('Hamano K', 'DRUG'),\n",
       " ('Cardiol', 'DRUG'),\n",
       " ('Cardiol', 'DRUG'),\n",
       " ('Hamano K', 'DRUG'),\n",
       " ('Cardiol', 'DRUG'),\n",
       " ('2004;44:1690–1699', 'FREQUENCY'),\n",
       " ('Meyer GP', 'DRUG'),\n",
       " ('Meyer GP, Wollert KC', 'DRUG'),\n",
       " ('Cardiol', 'DRUG'),\n",
       " ('Italy', 'DRUG'),\n",
       " ('Italy', 'DRUG'),\n",
       " ('6Department', 'DOSAGE'),\n",
       " ('December', 'DRUG'),\n",
       " ('acteristics', 'DRUG'),\n",
       " ('Helsinki', 'DRUG'),\n",
       " ('lyzed', 'DRUG'),\n",
       " ('gories', 'DRUG'),\n",
       " ('Spearman', 'DRUG'),\n",
       " ('n=9', 'DRUG'),\n",
       " ('CD4+/CD25high', 'DRUG'),\n",
       " ('Spearman', 'DRUG'),\n",
       " ('coefficient (rho)', 'DOSAGE'),\n",
       " ('IL-2', 'DRUG'),\n",
       " ('P=0.021', 'DRUG'),\n",
       " ('Cancro', 'DRUG'),\n",
       " ('Fondazione', 'DRUG'),\n",
       " ('Gorgun', 'DRUG'),\n",
       " ('thalidomide', 'DRUG'),\n",
       " ('Baricordi', 'DRUG'),\n",
       " ('methotrexate', 'DRUG'),\n",
       " ('Lindhard', 'DRUG'),\n",
       " ('Baricordi', 'DRUG'),\n",
       " ('Guilloux', 'DRUG'),\n",
       " ('Guilloux', 'DRUG'),\n",
       " ('Bilgi', 'DRUG'),\n",
       " ('Bergui', 'DRUG'),\n",
       " ('Baricordi', 'DRUG'),\n",
       " ('Rotola', 'DRUG'),\n",
       " ('2012;73(11):1140', 'DRUG'),\n",
       " ('Rebmann', 'DRUG'),\n",
       " ('Tregs', 'DRUG'),\n",
       " ('Zeevi', 'DRUG'),\n",
       " ('Daefler S', 'DRUG'),\n",
       " ('exosomes', 'DRUG'),\n",
       " ('Radanne', 'DRUG'),\n",
       " ('Hindawi', 'DRUG'),\n",
       " ('Narváez', 'DRUG'),\n",
       " ('Zuilma', 'DRUG'),\n",
       " ('12.5 mg', 'STRENGTH'),\n",
       " ('a day', 'FREQUENCY'),\n",
       " ('diuretics', 'DRUG'),\n",
       " ('receptor blockers', 'DRUG'),\n",
       " ('digitalis', 'DRUG'),\n",
       " ('12.5 mg', 'STRENGTH'),\n",
       " ('oral', 'ROUTE'),\n",
       " ('ivabradine', 'DRUG'),\n",
       " ('diuretic', 'DRUG'),\n",
       " ('mineralocorticoid', 'DRUG'),\n",
       " ('Postischemic', 'DRUG'),\n",
       " ('nitric oxide', 'DRUG'),\n",
       " ('spironolactone', 'DRUG'),\n",
       " ('aliskiren', 'DRUG'),\n",
       " ('predicts', 'DRUG'),\n",
       " ('Riccioni', 'DRUG'),\n",
       " ('Sarullo', 'DRUG'),\n",
       " ('Microvascular', 'DRUG'),\n",
       " ('captopril', 'DRUG'),\n",
       " ('postinfarct rat hearts', 'DRUG'),\n",
       " ('MacCarthy', 'DRUG'),\n",
       " ('Ouzounian', 'DRUG'),\n",
       " ('Metra', 'DRUG'),\n",
       " ('Melenovsky', 'DRUG'),\n",
       " ('Brutsaert', 'DRUG')]"
      ]
     },
     "execution_count": 38,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# using med 7 library on merged data to get features\n",
    "import spacy\n",
    "\n",
    "med7 = spacy.load(\"en_core_med7_lg\")\n",
    "\n",
    "# create distinct colours for labels\n",
    "col_dict = {}\n",
    "seven_colours = ['#e6194B', '#3cb44b', '#ffe119', '#ffd8b1', '#f58231', '#f032e6', '#42d4f4']\n",
    "for label, colour in zip(med7.pipe_labels['ner'], seven_colours):\n",
    "    col_dict[label] = colour\n",
    "\n",
    "options = {'ents': med7.pipe_labels['ner'], 'colors':col_dict}\n",
    "\n",
    "final_doc = med7(merged_text)\n",
    "\n",
    "spacy.displacy.render(doc, style='ent', jupyter=True, options=options)\n",
    "\n",
    "[(ent.text, ent.label_) for ent in final_doc.ents]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "id": "40095e01",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[['Vol', 'DRUG'],\n",
       " ['BENEKLI', 'DRUG'],\n",
       " ['Weibel', 'DRUG'],\n",
       " ['interactions', 'DRUG'],\n",
       " ['Shimizu', 'DRUG'],\n",
       " ['Modderman', 'DRUG'],\n",
       " ['Tötterman', 'DRUG'],\n",
       " ['Jaroslav Stanicek', 'DRUG'],\n",
       " ['Ladislav', 'DRUG'],\n",
       " ['M.D.‡', 'FREQUENCY'],\n",
       " ['dobutamine', 'DRUG'],\n",
       " ['dobutamine', 'DRUG'],\n",
       " ['Dobutamine', 'DRUG'],\n",
       " ['5 µg/kg per min', 'STRENGTH'],\n",
       " ['20 µg/kg', 'STRENGTH'],\n",
       " ['dobutamine', 'DRUG'],\n",
       " ['dobutamine', 'DRUG'],\n",
       " ['Sseptal', 'DRUG'],\n",
       " ['Santerior', 'DRUG'],\n",
       " ['Sinferior', 'DRUG'],\n",
       " ['sestamibi', 'DRUG'],\n",
       " ['at rest', 'FREQUENCY'],\n",
       " ['sestamibi', 'DRUG'],\n",
       " ['midazolam', 'DRUG'],\n",
       " ['albumin', 'DRUG'],\n",
       " ['5,000', 'STRENGTH'],\n",
       " ['heparin', 'DRUG'],\n",
       " ['cen-', 'DRUG'],\n",
       " ['trifuged', 'DRUG'],\n",
       " ['240 g', 'STRENGTH'],\n",
       " ['1,200 g', 'STRENGTH'],\n",
       " ['Histopaque', 'DRUG'],\n",
       " ['human albumin', 'DRUG'],\n",
       " ['1,000', 'STRENGTH'],\n",
       " ['heparin', 'DRUG'],\n",
       " ['daily', 'FREQUENCY'],\n",
       " ['75 mg', 'STRENGTH'],\n",
       " ['clopidogrel', 'DRUG'],\n",
       " ['100 mg', 'STRENGTH'],\n",
       " ['aspirin', 'DRUG'],\n",
       " ['bolus', 'DOSAGE'],\n",
       " ['heparin', 'DRUG'],\n",
       " ['fects', 'DRUG'],\n",
       " ['Dobutamine', 'DRUG'],\n",
       " ['Aspirin', 'DRUG'],\n",
       " ['Clopidogrel', 'DRUG'],\n",
       " ['ACE inhibitor', 'DRUG'],\n",
       " ['Beta blocker', 'DRUG'],\n",
       " ['Statin', 'DRUG'],\n",
       " ['high-doses group signiﬁcantly\\nimproved the regional systolic function (Sinfarct)',\n",
       "  'DOSAGE'],\n",
       " ['ESV', 'DRUG'],\n",
       " ['−0.2', 'DRUG'],\n",
       " ['0.625', 'STRENGTH'],\n",
       " ['0.432', 'STRENGTH'],\n",
       " ['0.342', 'STRENGTH'],\n",
       " ['0.798', 'FREQUENCY'],\n",
       " ['pretransplant', 'DRUG'],\n",
       " ['dobutamine', 'DRUG'],\n",
       " ['signiﬁcance', 'DRUG'],\n",
       " ['diac', 'DRUG'],\n",
       " ['diac', 'DRUG'],\n",
       " ['Hamano K', 'DRUG'],\n",
       " ['Cardiol', 'DRUG'],\n",
       " ['Cardiol', 'DRUG'],\n",
       " ['Hamano K', 'DRUG'],\n",
       " ['Cardiol', 'DRUG'],\n",
       " ['2004;44:1690–1699', 'FREQUENCY'],\n",
       " ['Meyer GP', 'DRUG'],\n",
       " ['Meyer GP, Wollert KC', 'DRUG'],\n",
       " ['Cardiol', 'DRUG'],\n",
       " ['Italy', 'DRUG'],\n",
       " ['Italy', 'DRUG'],\n",
       " ['6Department', 'DOSAGE'],\n",
       " ['December', 'DRUG'],\n",
       " ['acteristics', 'DRUG'],\n",
       " ['Helsinki', 'DRUG'],\n",
       " ['lyzed', 'DRUG'],\n",
       " ['gories', 'DRUG'],\n",
       " ['Spearman', 'DRUG'],\n",
       " ['n=9', 'DRUG'],\n",
       " ['CD4+/CD25high', 'DRUG'],\n",
       " ['Spearman', 'DRUG'],\n",
       " ['coefficient (rho)', 'DOSAGE'],\n",
       " ['IL-2', 'DRUG'],\n",
       " ['P=0.021', 'DRUG'],\n",
       " ['Cancro', 'DRUG'],\n",
       " ['Fondazione', 'DRUG'],\n",
       " ['Gorgun', 'DRUG'],\n",
       " ['thalidomide', 'DRUG'],\n",
       " ['Baricordi', 'DRUG'],\n",
       " ['methotrexate', 'DRUG'],\n",
       " ['Lindhard', 'DRUG'],\n",
       " ['Baricordi', 'DRUG'],\n",
       " ['Guilloux', 'DRUG'],\n",
       " ['Guilloux', 'DRUG'],\n",
       " ['Bilgi', 'DRUG'],\n",
       " ['Bergui', 'DRUG'],\n",
       " ['Baricordi', 'DRUG'],\n",
       " ['Rotola', 'DRUG'],\n",
       " ['2012;73(11):1140', 'DRUG'],\n",
       " ['Rebmann', 'DRUG'],\n",
       " ['Tregs', 'DRUG'],\n",
       " ['Zeevi', 'DRUG'],\n",
       " ['Daefler S', 'DRUG'],\n",
       " ['exosomes', 'DRUG'],\n",
       " ['Radanne', 'DRUG'],\n",
       " ['Hindawi', 'DRUG'],\n",
       " ['Narváez', 'DRUG'],\n",
       " ['Zuilma', 'DRUG'],\n",
       " ['12.5 mg', 'STRENGTH'],\n",
       " ['a day', 'FREQUENCY'],\n",
       " ['diuretics', 'DRUG'],\n",
       " ['receptor blockers', 'DRUG'],\n",
       " ['digitalis', 'DRUG'],\n",
       " ['12.5 mg', 'STRENGTH'],\n",
       " ['oral', 'ROUTE'],\n",
       " ['ivabradine', 'DRUG'],\n",
       " ['diuretic', 'DRUG'],\n",
       " ['mineralocorticoid', 'DRUG'],\n",
       " ['Postischemic', 'DRUG'],\n",
       " ['nitric oxide', 'DRUG'],\n",
       " ['spironolactone', 'DRUG'],\n",
       " ['aliskiren', 'DRUG'],\n",
       " ['predicts', 'DRUG'],\n",
       " ['Riccioni', 'DRUG'],\n",
       " ['Sarullo', 'DRUG'],\n",
       " ['Microvascular', 'DRUG'],\n",
       " ['captopril', 'DRUG'],\n",
       " ['postinfarct rat hearts', 'DRUG'],\n",
       " ['MacCarthy', 'DRUG'],\n",
       " ['Ouzounian', 'DRUG'],\n",
       " ['Metra', 'DRUG'],\n",
       " ['Melenovsky', 'DRUG'],\n",
       " ['Brutsaert', 'DRUG']]"
      ]
     },
     "execution_count": 39,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "features = [[ent.text, ent.label_] for ent in final_doc.ents]\n",
    "features"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "00e28890",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Name</th>\n",
       "      <th>Category</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Vol</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>BENEKLI</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Weibel</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>interactions</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Shimizu</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>129</th>\n",
       "      <td>MacCarthy</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>130</th>\n",
       "      <td>Ouzounian</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>131</th>\n",
       "      <td>Metra</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>132</th>\n",
       "      <td>Melenovsky</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>133</th>\n",
       "      <td>Brutsaert</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>134 rows × 2 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "             Name Category\n",
       "0             Vol     DRUG\n",
       "1         BENEKLI     DRUG\n",
       "2          Weibel     DRUG\n",
       "3    interactions     DRUG\n",
       "4         Shimizu     DRUG\n",
       "..            ...      ...\n",
       "129     MacCarthy     DRUG\n",
       "130     Ouzounian     DRUG\n",
       "131         Metra     DRUG\n",
       "132    Melenovsky     DRUG\n",
       "133     Brutsaert     DRUG\n",
       "\n",
       "[134 rows x 2 columns]"
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "df_final = pd.DataFrame(features)\n",
    "df_final.columns = [\"Name\",\"Category\"]\n",
    "df_final"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "id": "c5688388",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Name</th>\n",
       "      <th>Category</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Vol</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>BENEKLI</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Weibel</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>interactions</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Shimizu</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Modderman</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Tötterman</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Jaroslav Stanicek</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Ladislav</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>M.D.‡</td>\n",
       "      <td>FREQUENCY</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>dobutamine</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>dobutamine</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Dobutamine</td>\n",
       "      <td>DRUG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>5 µg/kg per min</td>\n",
       "      <td>STRENGTH</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>20 µg/kg</td>\n",
       "      <td>STRENGTH</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                 Name   Category\n",
       "0                 Vol       DRUG\n",
       "1             BENEKLI       DRUG\n",
       "2              Weibel       DRUG\n",
       "3        interactions       DRUG\n",
       "4             Shimizu       DRUG\n",
       "5           Modderman       DRUG\n",
       "6           Tötterman       DRUG\n",
       "7   Jaroslav Stanicek       DRUG\n",
       "8            Ladislav       DRUG\n",
       "9               M.D.‡  FREQUENCY\n",
       "10         dobutamine       DRUG\n",
       "11         dobutamine       DRUG\n",
       "12         Dobutamine       DRUG\n",
       "13    5 µg/kg per min   STRENGTH\n",
       "14           20 µg/kg   STRENGTH"
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_final.head(15)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "id": "41de958d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>entities</th>\n",
       "      <th>labels</th>\n",
       "      <th>pos_start</th>\n",
       "      <th>pos_end</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>(Vol)</td>\n",
       "      <td>DRUG</td>\n",
       "      <td>14</td>\n",
       "      <td>17</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>(BENEKLI)</td>\n",
       "      <td>DRUG</td>\n",
       "      <td>167</td>\n",
       "      <td>174</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>(Weibel)</td>\n",
       "      <td>DRUG</td>\n",
       "      <td>2018</td>\n",
       "      <td>2024</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>(interactions)</td>\n",
       "      <td>DRUG</td>\n",
       "      <td>4691</td>\n",
       "      <td>4703</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>(Shimizu)</td>\n",
       "      <td>DRUG</td>\n",
       "      <td>6732</td>\n",
       "      <td>6739</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>129</th>\n",
       "      <td>(MacCarthy)</td>\n",
       "      <td>DRUG</td>\n",
       "      <td>121081</td>\n",
       "      <td>121090</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>130</th>\n",
       "      <td>(Ouzounian)</td>\n",
       "      <td>DRUG</td>\n",
       "      <td>123345</td>\n",
       "      <td>123354</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>131</th>\n",
       "      <td>(Metra)</td>\n",
       "      <td>DRUG</td>\n",
       "      <td>124512</td>\n",
       "      <td>124517</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>132</th>\n",
       "      <td>(Melenovsky)</td>\n",
       "      <td>DRUG</td>\n",
       "      <td>124771</td>\n",
       "      <td>124781</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>133</th>\n",
       "      <td>(Brutsaert)</td>\n",
       "      <td>DRUG</td>\n",
       "      <td>125314</td>\n",
       "      <td>125323</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>134 rows × 4 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "           entities labels  pos_start  pos_end\n",
       "0             (Vol)   DRUG         14       17\n",
       "1         (BENEKLI)   DRUG        167      174\n",
       "2          (Weibel)   DRUG       2018     2024\n",
       "3    (interactions)   DRUG       4691     4703\n",
       "4         (Shimizu)   DRUG       6732     6739\n",
       "..              ...    ...        ...      ...\n",
       "129     (MacCarthy)   DRUG     121081   121090\n",
       "130     (Ouzounian)   DRUG     123345   123354\n",
       "131         (Metra)   DRUG     124512   124517\n",
       "132    (Melenovsky)   DRUG     124771   124781\n",
       "133     (Brutsaert)   DRUG     125314   125323\n",
       "\n",
       "[134 rows x 4 columns]"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "entities=[]\n",
    "labels=[]\n",
    "pos_start=[]\n",
    "pos_end=[]\n",
    "for ent in final_doc.ents:\n",
    "    entities.append(ent)\n",
    "    labels.append(ent.label_)\n",
    "    pos_start.append(ent.start_char)\n",
    "    pos_end.append(ent.end_char)\n",
    "df=pd.DataFrame({\"entities\":entities, \"labels\":labels, \"pos_start\":pos_start, \"pos_end\":pos_end})\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "c7e81b22",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Collecting mysql.connector\n",
      "  Downloading mysql-connector-2.2.9.tar.gz (11.9 MB)\n",
      "Building wheels for collected packages: mysql.connector\n",
      "  Building wheel for mysql.connector (setup.py): started\n",
      "  Building wheel for mysql.connector (setup.py): finished with status 'done'\n",
      "  Created wheel for mysql.connector: filename=mysql_connector-2.2.9-cp38-cp38-win_amd64.whl size=247962 sha256=31e07fc9f566dc352093038424ab9cdabe91ce802525f7f30080b40dd56e1cbb\n",
      "  Stored in directory: c:\\users\\zaid\\appdata\\local\\pip\\cache\\wheels\\57\\e4\\98\\5feafb5c393dd2540e44b064a6f95832990d543e5b4f53ea8f\n",
      "Successfully built mysql.connector\n",
      "Installing collected packages: mysql.connector\n",
      "Successfully installed mysql.connector\n"
     ]
    }
   ],
   "source": [
    "!pip install mysql.connector"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "3ca41d22",
   "metadata": {},
   "outputs": [],
   "source": [
    "import mysql.connector as sql"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "9f116ced",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<mysql.connector.connection.MySQLConnection object at 0x0000017D4AD16400>\n"
     ]
    }
   ],
   "source": [
    "mydb = sql.connect(user='Project', host='localhost',password='abcd1234',database='project',auth_plugin='mysql_native_password')\n",
    "print(mydb)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "dea42704",
   "metadata": {},
   "outputs": [],
   "source": [
    "mycursor = mydb.cursor()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "id": "1ce98ba4",
   "metadata": {},
   "outputs": [],
   "source": [
    "mycursor.execute(\"DROP TABLE IF EXISTS DF_FINAL\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "id": "4d1698dc",
   "metadata": {},
   "outputs": [],
   "source": [
    "mycursor.execute(\"\"\"\n",
    "CREATE TABLE DF_FINAL (\n",
    "    name VARCHAR(100) NOT NULL,\n",
    "    category VARCHAR(20),\n",
    "    pos_start INT,\n",
    "    pos_end INT\n",
    "    )\n",
    "\"\"\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "id": "3120deb7",
   "metadata": {},
   "outputs": [],
   "source": [
    "SQL_Insert = \"INSERT INTO DF_FINAL(name, category, pos_start, pos_end) \\\n",
    "                VALUES (%s,%s,%s,%s)\"\n",
    "                \n",
    "SQL_Insert_values = [(ent.text, ent.label_,ent.start_char,ent.end_char) for ent in final_doc.ents]\n",
    "                \n",
    "mycursor.executemany(SQL_Insert, SQL_Insert_values)\n",
    "\n",
    "mydb.commit()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "b806af4d",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.11"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
